TY - JOUR T1 - A Randomized Controlled Trial of a Patient-Centered Approach to Improve Screening for the Metabolic Side Effects of Antipsychotic Medications AN - 1865323175 AB - Adherence to recommendations for monitoring of metabolic side effects of antipsychotic medications has been historically low. This randomized controlled trial tested whether a computerized, patient-centered intervention that educated Veterans with serious mental illness about these side effects and encouraged them to advocate for receipt of monitoring would increase rates of monitoring compared to enhanced treatment as usual. The mean proportion of days adherent to monitoring guidelines over the 1-year study was similarly high and did not differ between the intervention (range 0.81-0.98) and comparison (range 0.76-0.96) groups. Many individuals in both groups had persistent abnormal metabolic parameter values despite high rates of monitoring, contact with medical providers, and receipt of cardiometabolic medications. Participants exposed to the intervention were interested in receiving personalized information about their cardiometabolic status, demonstrating the preliminary feasibility of brief interventions for enhancing involvement of individuals with serious mental illness in health care decision making. JF - Community Mental Health Journal AU - Kreyenbuhl, Julie AU - Dixon, Lisa B AU - Brown, Clayton H AU - Medoff, Deborah R AU - Klingaman, Elizabeth A AU - Fang, Li Juan AU - Tapscott, Stephanie AU - Walsh, Mary Brighid AD - U.S. Department of Veterans Affairs Capitol Healthcare Network (VISN 5), Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, MD, USA; Division of Psychiatric Services Research, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA ; Department of Psychiatry, Center for Practice Innovations, New York State Psychiatric Institute, Columbia University, New York, NY, USA ; U.S. Department of Veterans Affairs Capitol Healthcare Network (VISN 5), Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, MD, USA; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA ; U.S. Department of Veterans Affairs Capitol Healthcare Network (VISN 5), Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, MD, USA ; Division of Psychiatric Services Research, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA ; Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, USA ; U.S. Department of Veterans Affairs Capitol Healthcare Network (VISN 5), Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, MD, USA; Division of Psychiatric Services Research, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA Y1 - 2017/02// PY - 2017 DA - Feb 2017 SP - 163 EP - 175 CY - New York PB - Springer Science & Business Media VL - 53 IS - 2 SN - 0010-3853 KW - Psychology KW - Antipsychotic medications KW - Metabolic side effects KW - Monitoring KW - Randomized controlled trial KW - Intervention KW - Patient centredness KW - Veterans KW - Health Problems KW - Side effects KW - Interventions KW - Medications KW - Mental health services KW - Mental illness KW - Screening KW - Mental Health KW - Health care KW - Feasibility KW - Antipsychotic drugs KW - Mentally ill people KW - Medical Decision Making KW - Decision making KW - Randomized controlled trials KW - Medicine KW - Tests KW - Individualized KW - Brief interventions KW - Mental Illness KW - Computerization KW - Decision Making KW - Health Care Services UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1865323175?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Community+Mental+Health+Journal&rft.atitle=A+Randomized+Controlled+Trial+of+a+Patient-Centered+Approach+to+Improve+Screening+for+the+Metabolic+Side+Effects+of+Antipsychotic+Medications&rft.au=Kreyenbuhl%2C+Julie%3BDixon%2C+Lisa+B%3BBrown%2C+Clayton+H%3BMedoff%2C+Deborah+R%3BKlingaman%2C+Elizabeth+A%3BFang%2C+Li+Juan%3BTapscott%2C+Stephanie%3BWalsh%2C+Mary+Brighid&rft.aulast=Kreyenbuhl&rft.aufirst=Julie&rft.date=2017-02-01&rft.volume=53&rft.issue=2&rft.spage=163&rft.isbn=&rft.btitle=&rft.title=Community+Mental+Health+Journal&rft.issn=00103853&rft_id=info:doi/10.1007%2Fs10597-016-0007-5 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA); Social Services Abstracts N1 - Copyright - Community Mental Health Journal is a copyright of Springer, 2017. N1 - Last updated - 2017-02-06 DO - http://dx.doi.org/10.1007/s10597-016-0007-5 ER - TY - JOUR T1 - The safety and efficacy of Diphoterine for ocular and cutaneous burns in humans. AN - 1826739956; 27486965 AB - Diphoterine, developed by the French company Prevor, is a polyvalent, chelating, amphoteric and slightly hypertonic solution used in the management of chemical cutaneous and ocular burns. While used extensively in Europe and Canada, it is has not been approved by the United States Occupational Safety and Health Administration (OSHA) as an alternative to the water-rinse method due to a lack of evidence of its safety and efficacy on human subjects. An unbiased and extensive systematic review was undertaken in order to better understand Diphoterine's safety and efficaciousness on humans. Review the safety and efficacy of Diphoterine for treating chemical burns of the skin and eyes in humans. Data sources: Information sources included Pubmed, the National Library of Medicine's Medline Database and the "Publications" sections of the Prevor website. Search terms included Diphoterine, chemical burn, ocular burn and cutaneous burn. Any study type published through a peer-reviewed journal up to May 2016 was considered eligible. Published data must have included Diphoterine in the treatment of chemical burns on the skin or eyes as well as meet other specified criteria. Acceptable studies had to use either a quantitative (e.g. number of work days lost) or qualitative (e.g. level of erythema) approach when measuring cutaneous or ocular lesion outcomes. Independent assessment of article inclusion by two authors using predefined criteria. Diphoterine is safe and highly effective in improving healing time, healing sequelae and pain management of chemical burns on the skin and eyes of humans. Outcomes are significantly improved when compared to water or a physiologic solution equivalent. We recommend that this product be readily available to emergency responders and companies that expose their employees to hazardous chemical substances in order to improve healing sequelae, pain management and lost work days from these types of burns. JF - Cutaneous and ocular toxicology AU - Lynn, Darren D AU - Zukin, Leonid M AU - Dellavalle, Robert AD - a Department of Dermatology and. ; b Department of Opthamology , Denver School of Medicine, University of Colorado , Aurora , CO , USA , and. ; c U.S. Department of Veterans Affairs, Eastern Colorado Health Care System, Dermatology Service , Denver , CO , USA. Y1 - 2017/01/17/ PY - 2017 DA - 2017 Jan 17 SP - 1 EP - 8 KW - amphoteric KW - chemical burn KW - acid burn KW - Prevor KW - alkaloid burn UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1826739956?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cutaneous+and+ocular+toxicology&rft.atitle=The+safety+and+efficacy+of+Diphoterine+for+ocular+and+cutaneous+burns+in+humans.&rft.au=Lynn%2C+Darren+D%3BZukin%2C+Leonid+M%3BDellavalle%2C+Robert&rft.aulast=Lynn&rft.aufirst=Darren&rft.date=2017-01-17&rft.volume=&rft.issue=&rft.spage=1&rft.isbn=&rft.btitle=&rft.title=Cutaneous+and+ocular+toxicology&rft.issn=1556-9535&rft_id=info:doi/10.1080%2F15569527.2016.1217423 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-08-03 N1 - Date revised - 2017-01-24 N1 - Last updated - 2017-01-25 DO - http://dx.doi.org/10.1080/15569527.2016.1217423 ER - TY - JOUR T1 - Acrolein Can Cause Cardiovascular Disease: A Review. AN - 1861461235; 28084565 AB - Acrolein is a highly reactive unsaturated aldehyde that is formed during the burning of gasoline and diesel fuels, cigarettes, woods and plastics. In addition, acrolein is generated during the cooking or frying of food with fats or oils. Acrolein is also used in the synthesis of many organic chemicals and as a biocide in agricultural and industrial water supply systems. The total emissions of acrolein in the United States from all sources are estimated to be 62,660 tons/year. Acrolein is classified by the Environmental Protection Agency as a high-priority air and water toxicant. Acrolein can exert toxic effects following inhalation, ingestion, and dermal exposures that are dose dependent. Cardiovascular tissues are particularly sensitive to the toxic effects of acrolein based primarily on in vitro and in vivo studies. Acrolein can generate free oxygen radical stress in the heart, decrease endothelial nitric oxide synthase phosphorylation and nitric oxide formation, form cytoplasmic and nuclear protein adducts with myocyte and vascular endothelial cell proteins and cause vasospasm. In this manner, chronic exposure to acrolein can cause myocyte dysfunction, myocyte necrosis and apoptosis and ultimately lead to cardiomyopathy and cardiac failure. Epidemiological studies of acrolein exposure and toxicity should be developed and treatment strategies devised that prevent or significantly limit acrolein cardiovascular toxicity. JF - Cardiovascular toxicology AU - Henning, Robert J AU - Johnson, Giffe T AU - Coyle, Jayme P AU - Harbison, Raymond D AD - Department of Environmental and Occupational Health, College of Public Health, University of South Florida, The James A. Haley Hospital, 13201 Bruce B. Downs Blvd, Tampa, FL, 33612-3805, USA. robert.henning@va.gov. ; Department of Environmental and Occupational Health, College of Public Health, University of South Florida, The James A. Haley Hospital, 13201 Bruce B. Downs Blvd, Tampa, FL, 33612-3805, USA. Y1 - 2017/01/13/ PY - 2017 DA - 2017 Jan 13 KW - Protein adducts KW - Free oxygen radicals KW - Unsaturated aldehydes KW - Glutathione depletion UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1861461235?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cardiovascular+toxicology&rft.atitle=Acrolein+Can+Cause+Cardiovascular+Disease%3A+A+Review.&rft.au=Henning%2C+Robert+J%3BJohnson%2C+Giffe+T%3BCoyle%2C+Jayme+P%3BHarbison%2C+Raymond+D&rft.aulast=Henning&rft.aufirst=Robert&rft.date=2017-01-13&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=Cardiovascular+toxicology&rft.issn=1559-0259&rft_id=info:doi/10.1007%2Fs12012-016-9396-5 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2017-01-13 N1 - Date revised - 2017-01-24 N1 - Last updated - 2017-01-25 DO - http://dx.doi.org/10.1007/s12012-016-9396-5 ER - TY - JOUR T1 - Impact of a Pharmacy-Cardiology Collaborative Practice on Dofetilide Safety Monitoring AN - 1859498261; PQ0003971117 AB - Background: Limited studies have been published examining dofetilide's postmarketing use and its recommended monitoring. Objective: To evaluate the impact of a collaborative pharmacy-cardiology antiarrhythmic drug (AAD) monitoring program on dofetilide monitoring. Methods: This retrospective cohort study was performed to assess if a novel monitoring program improved compliance with dofetilide-specific monitoring parameters based on the Food and Drug Administration's Risk Evaluation and Mitigation Strategy. Results: A total of 30 patients were included in the analysis. The monitoring parameters evaluated included electrocardiogram, serum potassium, serum magnesium, and kidney function. The primary outcome evaluated was the composite of these dofetilide monitoring parameters obtained in each cohort. In the standard cohort, 245 of 352 (69.6%) monitoring parameters were completed versus 134 of 136 (98.5%) in the intervention group ( P < 0.05). Conclusion: A collaborative pharmacy-cardiology AAD monitoring program was associated with a significant improvement in dofetilide monitoring. This improvement could potentially translate into enhanced patient safety outcomes, such as prevention of adverse drug reactions and decreased hospitalizations. JF - Annals of Pharmacotherapy AU - Quffa, Lieth H AU - Panna, Mark Jr AU - Kaufmann, Michael R AU - McKillop, Matthew AU - Dietrich, Nicole Maltese AU - Franck, Andrew J AD - 1 .North Florida/South Georgia Veterans Health System, Gainesville, FL, USA, Lieth.quffa@va.gov Y1 - 2017/01// PY - 2017 DA - January 2017 SP - 39 EP - 43 PB - Sage Publications, Inc. VL - 51 IS - 1 SN - 1060-0280, 1060-0280 KW - Toxicology Abstracts KW - pharmaceutical care KW - cardiology KW - antiarrhythmics KW - drug monitoring and drug safety UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1859498261?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Annals+of+Pharmacotherapy&rft.atitle=Impact+of+a+Pharmacy-Cardiology+Collaborative+Practice+on+Dofetilide+Safety+Monitoring&rft.au=Quffa%2C+Lieth+H%3BPanna%2C+Mark+Jr%3BKaufmann%2C+Michael+R%3BMcKillop%2C+Matthew%3BDietrich%2C+Nicole+Maltese%3BFranck%2C+Andrew+J&rft.aulast=Quffa&rft.aufirst=Lieth&rft.date=2017-01-01&rft.volume=51&rft.issue=1&rft.spage=39&rft.isbn=&rft.btitle=&rft.title=Annals+of+Pharmacotherapy&rft.issn=10600280&rft_id=info:doi/10.1177%2F1060028016669962 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2017-01-01 N1 - Number of references - 15 N1 - Last updated - 2017-01-18 DO - http://dx.doi.org/10.1177/1060028016669962 ER - TY - JOUR T1 - Post-training Beliefs, Intentions, and Use of Prolonged Exposure Therapy by Clinicians in the Veterans Health Administration AN - 1857276463 AB - To examine how changes in beliefs during the training process predict adoption of prolonged exposure therapy (PE) by veterans health administration clinicians who received intensive training in this evidence-based treatment. Participants completed a 4-day PE workshop and received expert consultation as they used PE with two or more training cases. Participants were surveyed prior to the workshop, after the workshop, after case consultation (n = 1.034), and 6 months after training (n = 810). Hierarchical regression was used to assess how pre-training factors, and changes in beliefs during different stages of training incrementally predicted post-training intent to use PE and how many patients clinicians were treating with PE 6 months after training. Post-training intent to use PE was high (mean = 6.2, SD = 0.81 on a 1-7 scale), yet most participants treated only 1 or 2 patients at a time with PE. Pre-training factors predicted intent to use and actual use of PE. Changes in beliefs during the workshop had statistically significant yet modest effects on intent and use of PE. Changes in beliefs during case consultation had substantial effects on intent and actual use of PE. Pre-training factors and changes in beliefs during training (especially during case consultation) influence clinicians' adoption of PE. Use of PE was influenced not only by its perceived clinical advantages/disadvantages, but also by contextual factors (working in a PTSD specialty clinic, perceived control over one's schedule, and ability to promote PE to patients and colleagues). JF - Administration and Policy in Mental Health and Mental Health Services Research AU - Ruzek, J I AU - Eftekhari, A AU - Crowley, J AU - Kuhn, E AU - Karlin, B E AU - Rosen, C S AD - Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, USA; Palo Alto University, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA ; Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, USA ; Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA ; Education Development Center Inc., New York, NY, USA; Bloomberg School of Public Health, Johns Hopkins University (Previously affiliated with Mental Health Services, U.S. Department of Veterans Affairs Central Office, Washington, DC), Baltimore, MD, USA ; Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, Menlo Park, CA, USA; Palo Alto University, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA Y1 - 2017/01// PY - 2017 DA - Jan 2017 SP - 123 EP - 132 CY - New York PB - Springer Science & Business Media VL - 44 IS - 1 SN - 0894-587X KW - Public Health And Safety KW - Post-training beliefs KW - Intentions KW - Use of prolonged exposure therapy by clinicians in the veterans health administration KW - Posttraumatic stress disorder KW - Training KW - Implementation KW - Veterans KW - Intensive training KW - Military hospitals KW - Contextual factors KW - Evidence based medicine KW - Change agents KW - Exposure therapy KW - Perceived control KW - Consultation KW - Beliefs UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1857276463?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Administration+and+Policy+in+Mental+Health+and+Mental+Health+Services+Research&rft.atitle=Post-training+Beliefs%2C+Intentions%2C+and+Use+of+Prolonged+Exposure+Therapy+by+Clinicians+in+the+Veterans+Health+Administration&rft.au=Ruzek%2C+J+I%3BEftekhari%2C+A%3BCrowley%2C+J%3BKuhn%2C+E%3BKarlin%2C+B+E%3BRosen%2C+C+S&rft.aulast=Ruzek&rft.aufirst=J&rft.date=2017-01-01&rft.volume=44&rft.issue=1&rft.spage=123&rft.isbn=&rft.btitle=&rft.title=Administration+and+Policy+in+Mental+Health+and+Mental+Health+Services+Research&rft.issn=0894587X&rft_id=info:doi/10.1007%2Fs10488-015-0689-y LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Administration and Policy in Mental Health and Mental Health Services Research is a copyright of Springer, 2017. N1 - Last updated - 2017-01-16 DO - http://dx.doi.org/10.1007/s10488-015-0689-y ER - TY - JOUR T1 - Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer. AN - 1835352360; 27697581 AB - This phase I trial was conducted to determine the safety, maximum tolerated dose (MTD)/recommended phase II dose, and efficacy of crizotinib plus erlotinib in patients with advanced NSCLC. Patients with NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 2 after failure of one or two prior chemotherapy regimens were eligible. Erlotinib, 100 mg, was given continuously once daily starting between day -14 and -7; crizotinib, 200 mg twice daily (dose level 1) or 150 mg twice daily (dose level -1), was added continuously beginning on day 1 of treatment cycle 1. Potential pharmacokinetic interactions between crizotinib and erlotinib were evaluated. Twenty-seven patients received treatment; 26 received crizotinib plus erlotinib. Frequent adverse events were diarrhea, rash, decreased appetite, and fatigue. Dose-limiting toxicities were dehydration, diarrhea, dry eye, dysphagia, dyspepsia, esophagitis and vomiting. The MTD was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily. Crizotinib increased the erlotinib area under the concentration-time curve 1.5-fold (dose level -1) and 1.8-fold (dose level 1). The plasma level of crizotinib appeared to be unaffected by coadministration of erlotinib. Two patients whose tumors harbored activating EGFR mutations achieved confirmed partial responses, one at each crizotinib dose level. The MTD of the combination of crizotinib and erlotinib in patients with advanced NSCLC was crizotinib, 150 mg twice daily, with erlotinib, 100 mg once daily, which is less than the approved dose of either agent. The phase II portion of the study was not initiated. Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer AU - Ou, Sai-Hong Ignatius AU - Govindan, Ramaswamy AU - Eaton, Keith D AU - Otterson, Gregory A AU - Gutierrez, Martin E AU - Mita, Alain C AU - Argiris, Athanassios AU - Brega, Nicoletta M AU - Usari, Tiziana AU - Tan, Weiwei AU - Ho, Steffan N AU - Robert, Francisco AD - Chao Family Comprehensive Cancer Center, University of California at Irvine Medical Center, Orange, California. Electronic address: siou@uci.edu. ; Siteman Cancer Center, Washington University, St. Louis, Missouri. ; Seattle Cancer Care Alliance and the University of Washington, Seattle, Washington. ; Ohio State University Comprehensive Cancer Center and the James Cancer Hospital, Columbus, Ohio. ; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. ; Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Pfizer Oncology, Milan, Italy. ; Pfizer Oncology, San Diego, California. ; Birmingham Veterans Administration Hospital, Birmingham, Alabama; University of Alabama-Birmingham Comprehensive Cancer Center, Birmingham, Alabama. Y1 - 2017/01// PY - 2017 DA - January 2017 SP - 145 EP - 151 VL - 12 IS - 1 KW - Erlotinib KW - Phase I combination trial KW - EGFR inhibitor KW - MET inhibitor KW - Crizotinib UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1835352360?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.atitle=Phase+I+Results+from+a+Study+of+Crizotinib+in+Combination+with+Erlotinib+in+Patients+with+Advanced+Nonsquamous+Non-Small+Cell+Lung+Cancer.&rft.au=Ou%2C+Sai-Hong+Ignatius%3BGovindan%2C+Ramaswamy%3BEaton%2C+Keith+D%3BOtterson%2C+Gregory+A%3BGutierrez%2C+Martin+E%3BMita%2C+Alain+C%3BArgiris%2C+Athanassios%3BBrega%2C+Nicoletta+M%3BUsari%2C+Tiziana%3BTan%2C+Weiwei%3BHo%2C+Steffan+N%3BRobert%2C+Francisco&rft.aulast=Ou&rft.aufirst=Sai-Hong&rft.date=2017-01-01&rft.volume=12&rft.issue=1&rft.spage=145&rft.isbn=&rft.btitle=&rft.title=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.issn=1556-1380&rft_id=info:doi/10.1016%2Fj.jtho.2016.09.131 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-10-04 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.jtho.2016.09.131 ER - TY - JOUR T1 - Automatic Classification of Ultrasound Screening Examinations of the Abdominal Aorta AN - 1850783532; PQ0003893062 AB - Our work facilitates the identification of veterans who may be at risk for abdominal aortic aneurysms (AAA) based on the 2007 mandate to screen all veteran patients that meet the screening criteria. The main research objective is to automatically index three clinical conditions: pertinent negative AAA, pertinent positive AAA, and visually unacceptable image exams. We developed and evaluated a ConText-based algorithm with the GATE (General Architecture for Text Engineering) development system to automatically classify 1402 ultrasound radiology reports for AAA screening. Using the results from JAPE (Java Annotation Pattern Engine) transducer rules, we developed a feature vector to classify the radiology reports with a decision table classifier. We found that ConText performed optimally on precision and recall for pertinent negative (0.99 (0.98-0.99), 0.99 (0.99-1.00)) and pertinent positive AAA detection (0.98 (0.95-1.00), 0.97 (0.92-1.00)), and respectably for determination of non-diagnostic image studies (0.85 (0.77-0.91), 0.96 (0.91-0.99)). In addition, our algorithm can determine the AAA size measurements for further characterization of abnormality. We developed and evaluated a regular expression based algorithm using GATE for determining the three contextual conditions: pertinent negative, pertinent positive, and non-diagnostic from radiology reports obtained for evaluating the presence or absence of abdominal aortic aneurysm. ConText performed very well at identifying the contextual features. Our study also discovered contextual trigger terms to detect sub-standard ultrasound image quality. Limitations of performance included unknown dictionary terms, complex sentences, and vague findings that were difficult to classify and properly code. JF - Journal of Digital Imaging AU - Morioka, Craig AU - Meng, Frank AU - Taira, Ricky AU - Sayre, James AU - Zimmerman, Peter AU - Ishimitsu, David AU - Huang, Jimmy AU - Shen, Luyao AU - El-Saden, Suzie AD - Department of Radiology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA, Craig.Morioka@va.gov Y1 - 2016/12// PY - 2016 DA - December 2016 SP - 742 EP - 748 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 29 IS - 6 SN - 0897-1889, 0897-1889 KW - Biotechnology and Bioengineering Abstracts KW - Computer programs KW - Aneurysm KW - Classification KW - Aorta KW - Algorithms KW - Language KW - Radiology KW - Ultrasound KW - W 30910:Imaging UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1850783532?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Digital+Imaging&rft.atitle=Automatic+Classification+of+Ultrasound+Screening+Examinations+of+the+Abdominal+Aorta&rft.au=Morioka%2C+Craig%3BMeng%2C+Frank%3BTaira%2C+Ricky%3BSayre%2C+James%3BZimmerman%2C+Peter%3BIshimitsu%2C+David%3BHuang%2C+Jimmy%3BShen%2C+Luyao%3BEl-Saden%2C+Suzie&rft.aulast=Morioka&rft.aufirst=Craig&rft.date=2016-12-01&rft.volume=29&rft.issue=6&rft.spage=742&rft.isbn=&rft.btitle=&rft.title=Journal+of+Digital+Imaging&rft.issn=08971889&rft_id=info:doi/10.1007%2Fs10278-016-9889-6 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-12-01 N1 - Number of references - 23 N1 - Last updated - 2017-01-18 N1 - SubjectsTermNotLitGenreText - Computer programs; Classification; Aneurysm; Aorta; Algorithms; Language; Radiology; Ultrasound DO - http://dx.doi.org/10.1007/s10278-016-9889-6 ER - TY - JOUR T1 - An unusual case of underlying rilpivirine resistance in an antiretroviral-naive man with AIDS AN - 1846415999; PQ0003886022 AB - Primary resistance mutations to second generation HIV non-nucleoside reverse transcriptase inhibitors are rare in HIV-infected persons in the US (estimated at 1.8%). We report an antiretroviral treatment (ART)-naive patient with acquired immunodeficiency syndrome (AIDS) (CD4 cell count 20 cells/mm 3 , viral load 8439 copies/mL), who was infected with HIV-1 sub-type B virus containing a reverse transcriptase mutation, E138A, associated with rilpivirine resistance. Subsequently, he was initiated on a single tablet ART regimen containing an integrase inhibitor and developed immune reconstitution inflammatory syndrome (IRIS), presenting as Mycobacterium avium cervical adenitis. The patient went on to develop rifamycin-induced neutropenia during treatment of his opportunistic infection but later recovered his counts, and remains well on an integrase-based HIV regimen. His case illustrates the growing importance of archived resistance mutations including the less common E138A mutation, as well as the risk and rapid occurrence of IRIS in AIDS patients initiated on integrase inhibitors. JF - International Journal of STD & AIDS AU - Skalweit, Marion J Y1 - 2016/12// PY - 2016 DA - December 2016 SP - 1346 EP - 1349 PB - Sage Publications, Inc., 2455 Teller Road Thousand Oaks CA 91320 United States VL - 27 IS - 14 SN - 0956-4624, 0956-4624 KW - Health & Safety Science Abstracts; Virology & AIDS Abstracts KW - HIV KW - AIDS KW - rilpivirine KW - non-nucleoside reverse transcriptase inhibitors KW - primary resistance KW - treatment KW - immune reconstitution inflammatory syndrome KW - Mycobacterium avium cervical adenitis KW - Acquired immune deficiency syndrome KW - Lentivirus KW - Mycobacterium avium KW - Retroviridae KW - Viruses KW - Infection KW - Mutation KW - Antiretroviral agents KW - Sexually transmitted diseases KW - H 11000:Diseases/Injuries/Trauma UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1846415999?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+Journal+of+STD+%26+AIDS&rft.atitle=An+unusual+case+of+underlying+rilpivirine+resistance+in+an+antiretroviral-naive+man+with+AIDS&rft.au=Skalweit%2C+Marion+J&rft.aulast=Skalweit&rft.aufirst=Marion&rft.date=2016-12-01&rft.volume=27&rft.issue=14&rft.spage=1346&rft.isbn=&rft.btitle=&rft.title=International+Journal+of+STD+%26+AIDS&rft.issn=09564624&rft_id=info:doi/10.1177%2F0956462416643852 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-12-01 N1 - Number of references - 18 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Acquired immune deficiency syndrome; Viruses; Infection; Antiretroviral agents; Mutation; Sexually transmitted diseases; Mycobacterium avium; Lentivirus; Retroviridae DO - http://dx.doi.org/10.1177/0956462416643852 ER - TY - JOUR T1 - Effect of Clinical Pharmacist Intervention on Hemoglobin A1C Reduction in Veteran Patients With Type 2 Diabetes in a Rural Setting AN - 1846409057; PQ0003843908 AB - Background: Type 2 diabetes mellitus (T2DM), if left uncontrolled, is associated with significant morbidity and mortality. Patients in rural areas may not have access to adequate resources to successfully treat diabetes. Clinical pharmacists may be utilized to bridge this gap. Objective: To evaluate the impact of a clinical pharmacist on glycemic control in veterans with T2DM enrolled in a rural, outpatient clinic. Methods: Retrospective chart review was performed on veterans with T2DM referred to the pharmacist-managed therapeutic monitoring clinic at a community-based outpatient clinic located in rural Jackson, TN. Patients served as their own controls. Patients with hemoglobin A 1C (A1C) greater than or equal to 8% were included. The primary outcome was A1C change from baseline in patients managed by the clinical pharmacist. Secondary end points included blood pressure, cholesterol, and weight. Results: Of 111 veterans identified as having a A1C greater than or equal to 8% in the pharmacist-managed clinic, 86 met inclusion criteria. At baseline, mean plus or minus SD A1C was 10.5% plus or minus 2.0% (range = 8.7%-16.2%). By the end of the intervention period, mean A1C had decreased by 2.8 percentage points to 7.7% plus or minus 1.4% ( P 10% ( P < 0.001). Improvements in diastolic blood pressure ( P = 0.001), total cholesterol ( P = 0.001), and triglyceride levels ( P = 0.036) were also statistically significant when baseline and intervention period values were compared. Conclusion: Pharmacist interventions at a rural, outpatient clinic had a statistically significant impact on A1C reduction in veterans with T2DM. JF - Annals of Pharmacotherapy AU - Sullivan, Joshua AU - Jett, Bryan Paul AU - Cradick, Mark AU - Zuber, Jeffrey AD - 1 .VAMC Memphis, Clinical Pharmacy Specialist - Ambulatory Care, University of Tennessee College of Pharmacy, TN, USA, josh.sullivan@va.gov Y1 - 2016/12// PY - 2016 DA - December 2016 SP - 1023 EP - 1027 PB - Sage Publications, Inc. VL - 50 IS - 12 SN - 1060-0280, 1060-0280 KW - Toxicology Abstracts KW - ambulatory care KW - type 2 diabetes KW - therapeutic monitoring KW - clinical pharmacy KW - pharmaceutical care KW - Diabetes mellitus KW - Hemoglobin KW - Mortality KW - Triglycerides KW - Statistical analysis KW - Cholesterol KW - Blood pressure KW - Morbidity KW - X 24310:Pharmaceuticals UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1846409057?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Annals+of+Pharmacotherapy&rft.atitle=Effect+of+Clinical+Pharmacist+Intervention+on+Hemoglobin+A1C+Reduction+in+Veteran+Patients+With+Type+2+Diabetes+in+a+Rural+Setting&rft.au=Sullivan%2C+Joshua%3BJett%2C+Bryan+Paul%3BCradick%2C+Mark%3BZuber%2C+Jeffrey&rft.aulast=Sullivan&rft.aufirst=Joshua&rft.date=2016-12-01&rft.volume=50&rft.issue=12&rft.spage=1023&rft.isbn=&rft.btitle=&rft.title=Annals+of+Pharmacotherapy&rft.issn=10600280&rft_id=info:doi/10.1177%2F1060028016663564 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-12-01 N1 - Number of references - 11 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Hemoglobin; Diabetes mellitus; Mortality; Triglycerides; Statistical analysis; Cholesterol; Morbidity; Blood pressure DO - http://dx.doi.org/10.1177/1060028016663564 ER - TY - JOUR T1 - Is a Skilled Nursing Facility's Rehospitalization Rate a Valid Quality Measure? AN - 1844983424 AB - Objective To determine whether the observed differences in the risk-adjusted rehospitalization rates across skilled nursing facilities (SNFs) reflect true differences or merely differences in patient severity. Settings Elderly Medicare beneficiaries newly admitted to an SNF following hospitalization. Study Design We used 2009-2012 Medicare data to calculate SNFs' risk-adjusted rehospitalization rate. We then estimated the effect of these rehospitalization rates on the rehospitalization of incident patients in 2013, using an instrumental variable (IV) method and controlling for patient's demographic and clinical characteristics and residential zip code fixed effects. We used the number of empty beds in a patient's proximate SNFs during hospital discharge to create the IV. Principal Findings The risk-adjusted rehospitalization rate varies widely; about one-quarter of the SNFs have a rehospitalization rate lower than 17 percent, and for one-quarter, it is higher than 23 percent. All the IV models result in a robust finding that an increase in a SNF's rehospitalization rate of 1 percentage point over the period 2009-2012 leads to an increase in a patient's likelihood of rehospitalization by 0.8 percentage points in 2013. Conclusions Treatment in SNFs with historically low rehospitalization causally reduces a patient's likelihood of rehospitalization. Observed differences in rehospitalization rates reflect true differences and are not an artifact of selection. JF - Health Services Research AU - Rahman, Momotazur AU - Grabowski, David C AU - Mor, Vincent AU - Norton, Edward C AD - Department of Health Services Policy and Practice, Brown University, Providence, RI ; Department of Health Care Policy, Harvard Medical School, Boston, MA ; Department of Health Services Policy and Practice, Brown University, Providence, RI; Health Services Research Program, Providence Veterans Administration Medical Center, Providence, RI ; Department of Health Management and Policy and Department of Economics, University of Michigan, Ann Arbor, MI; National Bureau of Economic Research, Cambridge, MA ; Department of Health Services Policy and Practice, Brown University, Providence, RI Y1 - 2016/12// PY - 2016 DA - Dec 2016 SP - 2158 EP - 2175 CY - Chicago PB - Wiley Subscription Services, Inc. VL - 51 IS - 6 SN - 0017-9124 KW - Medical Sciences KW - Elderly people KW - Medicare KW - Demographic aspects KW - Hospital discharged KW - Immediate KW - Hospitalization KW - Severity KW - Beds KW - Empty KW - Nursing KW - Risk adjustment KW - Beneficiaries UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1844983424?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Health+Services+Research&rft.atitle=Is+a+Skilled+Nursing+Facility%27s+Rehospitalization+Rate+a+Valid+Quality+Measure%3F&rft.au=Rahman%2C+Momotazur%3BGrabowski%2C+David+C%3BMor%2C+Vincent%3BNorton%2C+Edward+C&rft.aulast=Rahman&rft.aufirst=Momotazur&rft.date=2016-12-01&rft.volume=51&rft.issue=6&rft.spage=2158&rft.isbn=&rft.btitle=&rft.title=Health+Services+Research&rft.issn=00179124&rft_id=info:doi/10.1111%2F1475-6773.12603 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © Health Research and Educational Trust N1 - Last updated - 2017-01-30 DO - http://dx.doi.org/10.1111/1475-6773.12603 ER - TY - JOUR T1 - Patient Perception of Enough Time Spent With Provider Is a Mechanism for Improving Women Veterans' Experiences With VA Outpatient Health Care AN - 1837050762 AB - We postulated that associations between two specific provider characteristics, class (nurse practitioner relative to physician) and primary care providers who are proficient and interested in women's health (designated women's provider relative to nondesignated) and overall satisfaction with provider, were mediated through women veterans' perception of enough time spent with the provider. A national patient experience survey was administered to 7,620 women veterans. Multivariable models of overall patient satisfaction with provider were compared with and without the proposed mediator. A structural equation model (SEM) of the mediation of the two provider characteristics was also evaluated. Without the mediator, associations of provider class and designation with overall patient satisfaction were significant. With the proposed mediator, these associations became nonsignificant. An SEM showed that the majority (>80%) of the positive associations between provider class and designation and the outcome were exerted through patient perception of enough time spent with provider. Higher ratings of overall satisfaction with provider exhibited by nurse practitioners and designated women's health providers were exerted through patient perception of enough time spent with provider. Future research should examine what elements of provider training can be developed to improve provider-patient communication and patient satisfaction with their health care. JF - Evaluation & the Health Professions AU - Trentalange, Mark AU - Bielawski, Mark AU - Murphy, Terrence E AU - Lessard, Katarzyna AU - Brandt, Cynthia AU - Bean-Mayberry, Bevanne AU - Maisel, Natalya C AU - Wright, Steven M AU - Allore, Heather AU - Skanderson, Melissa AU - Reyes-Harvey, Evelyn AU - Gaetano, Vera AU - Haskell, Sally AU - Bastian, Lori A AD - Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA ; VA Connecticut Healthcare System, Newington, CT, USA ; VA Connecticut Healthcare System, West Haven, CT, USA ; Veterans Health Administration Health Services Research & Development, Center for the Study of Healthcare Innovation, Implementation and Policy, VA Greater Los Angeles Healthcare System, Sepulveda, CA, USA ; Center for Innovation to Implementation, VA Palo Alto Health Care System, Menlo Park, CA, USA ; Office of Performance Measurement, VHA Office of Analytics & Business Intelligence, Department of Veterans Affairs, Providence, RI, USA ; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA ; Department of Veterans Affairs, Pittsburgh, PA, USA ; Office of Performance Measurement, VHA Office of Analytics & Business Intelligence, Durham, NC, USA ; VA Connecticut HSR&D Pain, Research, Informatics, Multimorbidities, and Education (Prime) Center, West Haven, CT, USA ; Women's Health Services, Patient Care Services, VA Central Office, VA Connecticut Healthcare System Yale School of Medicine, West Haven, CT, USA ; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA Y1 - 2016/12// PY - 2016 DA - Dec 2016 SP - 460 EP - 474 CY - Beverly Hills PB - SAGE PUBLICATIONS, INC. VL - 39 IS - 4 SN - 0163-2787 KW - Medical Sciences KW - women KW - veterans KW - experiences with health care KW - primary care KW - nurse practitioners KW - structural equation model KW - Patient satisfaction KW - Health care industry KW - Womens health KW - Nurse-Patient communication KW - Nurse practitioners KW - Health professionals KW - Primary health care KW - Veterans KW - Associations KW - Mediation KW - Women's issues UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837050762?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Evaluation+%26+the+Health+Professions&rft.atitle=Patient+Perception+of+Enough+Time+Spent+With+Provider+Is+a+Mechanism+for+Improving+Women+Veterans%27+Experiences+With+VA+Outpatient+Health+Care&rft.au=Trentalange%2C+Mark%3BBielawski%2C+Mark%3BMurphy%2C+Terrence+E%3BLessard%2C+Katarzyna%3BBrandt%2C+Cynthia%3BBean-Mayberry%2C+Bevanne%3BMaisel%2C+Natalya+C%3BWright%2C+Steven+M%3BAllore%2C+Heather%3BSkanderson%2C+Melissa%3BReyes-Harvey%2C+Evelyn%3BGaetano%2C+Vera%3BHaskell%2C+Sally%3BBastian%2C+Lori+A&rft.aulast=Trentalange&rft.aufirst=Mark&rft.date=2016-12-01&rft.volume=39&rft.issue=4&rft.spage=460&rft.isbn=&rft.btitle=&rft.title=Evaluation+%26+the+Health+Professions&rft.issn=01632787&rft_id=info:doi/10.1177%2F0163278716629523 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © The Author(s) 2016 N1 - Last updated - 2016-11-08 DO - http://dx.doi.org/10.1177/0163278716629523 ER - TY - JOUR T1 - Risk of Recidivism Among Justice-Involved Veterans AN - 1834159132 AB - Empirical research on recidivism risk among justice-involved veterans (JIVs) is limited. Using the risk-need-responsivity model, we conducted a systematic review of research on risk factors for recidivism among JIVs to identify the gaps in this literature and provide recommendations for future research. Substance abuse and indicators of antisociality were consistently linked to justice involvement in veterans; however, the evidence for negative family/marital circumstances and lack of positive school/work involvement was mixed. Several known risk factors for reoffending among civilian offenders (i.e., antisocial cognitions and associates; lack of prosocial activities) were marked by little to no empirical studies among veterans. Posttraumatic stress and traumatic brain injury, particularly when combined with anger and irritability issues, may be veteran-specific risk factors for violent offending. The implications of these findings for policy and practice and challenges to implementing risk assessments with JIVs are discussed. JF - Criminal Justice Policy Review AU - Blonigen, Daniel M AU - Bui, Leena AU - Elbogen, Eric B AU - Blodgett, Janet C AU - Maisel, Natalya C AU - Midboe, Amanda M AU - Asch, Steven M AU - McGuire, James F AU - Timko, Christine AD - VA Palo Alto Health Care System, Menlo Park, CA, USA ; Durham VA Medical Center, NC, USA; University of North Carolina at Chapel Hill, USA ; VA Palo Alto Health Care System, Menlo Park, CA, USA; Stanford University School of Medicine, CA, USA ; Veterans Health Administration, Washington, DC, USA ; VA Palo Alto Health Care System, Menlo Park, CA, USA Y1 - 2016/12// PY - 2016 DA - Dec 2016 SP - 812 EP - 837 CY - Thousand Oaks PB - SAGE PUBLICATIONS, INC. VL - 27 IS - 8 SN - 0887-4034 KW - Law--Criminal Law KW - recidivism KW - risk factors KW - assessment KW - veterans KW - risk-need-responsivity KW - Justice KW - Participation KW - Veterans KW - Recidivism KW - Family Work Relationship KW - Risk KW - Research KW - Substance Abuse KW - Empirical Methods KW - Offenders KW - Family School Relationship KW - Indexes (Measures) UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1834159132?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Apais&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Criminal+Justice+Policy+Review&rft.atitle=Risk+of+Recidivism+Among+Justice-Involved+Veterans&rft.au=Blonigen%2C+Daniel+M%3BBui%2C+Leena%3BElbogen%2C+Eric+B%3BBlodgett%2C+Janet+C%3BMaisel%2C+Natalya+C%3BMidboe%2C+Amanda+M%3BAsch%2C+Steven+M%3BMcGuire%2C+James+F%3BTimko%2C+Christine&rft.aulast=Blonigen&rft.aufirst=Daniel&rft.date=2016-12-01&rft.volume=27&rft.issue=8&rft.spage=812&rft.isbn=&rft.btitle=&rft.title=Criminal+Justice+Policy+Review&rft.issn=08874034&rft_id=info:doi/10.1177%2F0887403414562602 LA - English DB - PAIS Index N1 - Copyright - © 2014 SAGE Publications N1 - Last updated - 2016-11-01 DO - http://dx.doi.org/10.1177/0887403414562602 ER - TY - JOUR T1 - Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance AN - 1827917584; PQ0003688468 AB - Prediabetes is a major epidemic and is associated with adverse cardio-cerebrovascular outcomes. Early identification of patients who will develop rapid progression of atherosclerosis could be beneficial for improved risk stratification. In this paper, we investigate important factors impacting the prediction, using several machine learning methods, of rapid progression of carotid intima-media thickness in impaired glucose tolerance (IGT) participants. In the Actos Now for Prevention of Diabetes (ACT NOW) study, 382 participants with IGT underwent carotid intima-media thickness (CIMT) ultrasound evaluation at baseline and at 15-18 months, and were divided into rapid progressors (RP, n=39, 58 plus or minus 17.5 mu M change) and non-rapid progressors (NRP, n=343, 5.8 plus or minus 20 mu M change, p<0.001 versus RP). To deal with complex multi-modal data consisting of demographic, clinical, and laboratory variables, we propose a general data-driven framework to investigate the ACT NOW dataset. In particular, we first employed a Fisher Score-based feature selection method to identify the most effective variables and then proposed a probabilistic Bayes-based learning method for the prediction. Comparison of the methods and factors was conducted using area under the receiver operating characteristic curve (AUC) analyses and Brier score. The experimental results show that the proposed learning methods performed well in identifying or predicting RP. Among the methods, the performance of Naive Bayes was the best (AUC 0.797, Brier score 0.085) compared to multilayer perceptron (0.729, 0.086) and random forest (0.642, 0.10). The results also show that feature selection has a significant positive impact on the data prediction performance. By dealing with multi-modal data, the proposed learning methods show effectiveness in predicting prediabetics at risk for rapid atherosclerosis progression. The proposed framework demonstrated utility in outcome prediction in a typical multidimensional clinical dataset with a relatively small number of subjects, extending the potential utility of machine learning approaches beyond extremely large-scale datasets. JF - Eurasip Journal on Bioinformatics and Systems Biology AU - Hu, Xia AU - Reaven, Peter D AU - Saremi, Aramesh AU - Liu, Ninghao AU - Abbasi, Mohammad Ali AU - Liu, Huan AU - Migrino, Raymond Q AD - Arizona State University, Tempe, AZ, USA, raymond.migrino@va.gov Y1 - 2016/12// PY - 2016 DA - December 2016 SP - 1 EP - 7 PB - Springer-Verlag (Heidelberg), Tiergartenstrasse 17 Heidelberg 69121 Germany VL - 2016 IS - 1 KW - Biotechnology and Bioengineering Abstracts KW - Learning KW - Data processing KW - Epidemics KW - Bayesian analysis KW - Forests KW - Arteriosclerosis KW - Demography KW - Diabetes mellitus KW - Glucose tolerance KW - Learning algorithms KW - Bioinformatics KW - Ultrasound KW - W 30960:Bioinformatics & Computer Applications UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1827917584?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Eurasip+Journal+on+Bioinformatics+and+Systems+Biology&rft.atitle=Machine+learning+to+predict+rapid+progression+of+carotid+atherosclerosis+in+patients+with+impaired+glucose+tolerance&rft.au=Hu%2C+Xia%3BReaven%2C+Peter+D%3BSaremi%2C+Aramesh%3BLiu%2C+Ninghao%3BAbbasi%2C+Mohammad+Ali%3BLiu%2C+Huan%3BMigrino%2C+Raymond+Q&rft.aulast=Hu&rft.aufirst=Xia&rft.date=2016-12-01&rft.volume=2016&rft.issue=1&rft.spage=1&rft.isbn=&rft.btitle=&rft.title=Eurasip+Journal+on+Bioinformatics+and+Systems+Biology&rft.issn=1687-4153&rft_id=info:doi/10.1186%2Fs13637-016-0049-6 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-10-01 N1 - Number of references - 24 N1 - Last updated - 2016-10-12 N1 - SubjectsTermNotLitGenreText - Diabetes mellitus; Demography; Learning; Epidemics; Data processing; Bayesian analysis; Forests; Glucose tolerance; Bioinformatics; Arteriosclerosis; Learning algorithms; Ultrasound DO - http://dx.doi.org/10.1186/s13637-016-0049-6 ER - TY - JOUR T1 - Effects of Age, Sex, Body Weight, and Quantity of Alcohol Consumption on Occurrence and Severity of Alcoholic Hepatitis. AN - 1826704402; 27320325 AB - Only a minority of heavy drinking individuals develop alcoholic hepatitis (AH), for unclear reasons. We analyzed data from the Translational Research and Evolving Alcoholic Hepatitis Treatment cohort, consisting of subjects who drink heavily with normal results from liver tests (controls) and patients with AH. We examined risk factors for the development of AH including body mass index (BMI), drinking pattern and quantity, and sex. We compared data from 145 patients with AH and 124 controls based on BMI when they joined the cohort; groups were matched for sex and race. Drinking patterns were assessed using the timeline followback method, the Alcohol Use Disorders Identification Test, and the National Institute of Alcohol Abuse and Alcoholism 6-question survey. We performed univariable and multivariable analyses to assess the effects of these factors and their interaction in increasing the risk for AH. We also explored the association between PNPLA3 variants and AH. Cases with AH were older (47 vs 44 y; P = .03). For nearly all measures of quantity of alcohol consumed or frequency of binge drinking, controls drank more heavily than cases with AH. We did not find an association between BMI, sex, drinking patterns, and the presence of AH. Age and BMI were independent predictors for the severity of AH. When we analyzed cases and controls of European ancestry, the PNPLA3 single-nucleotide polymorphism rs738409 was associated with risk for AH (odds ratio, 1.89; P = .007). Compared with heavy drinkers without liver disease, subjects with AH consumed lower levels of alcohol and had less binge drinking, suggesting an increased sensitivity to the toxic effects of alcohol. The risk for AH may be associated with the PNPLA3 rs738409 polymorphism. Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved. JF - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association AU - Liangpunsakul, Suthat AU - Puri, Puneet AU - Shah, Vijay H AU - Kamath, Patrick AU - Sanyal, Arun AU - Urban, Thomas AU - Ren, Xiaowei AU - Katz, Barry AU - Radaeva, Svetlana AU - Chalasani, Naga AU - Crabb, David W AU - Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium AD - Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Department of Medicine, Roudebush Veterans Administration Medical Center, Indianapolis, Indiana. Electronic address: sliangpu@iupui.edu. ; Division of Gastroenterology and Hepatology, Department of Medicine, Virginia Commonwealth University, Richmond, Virginia. ; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. ; Division of Pharmacotherapy and Experimental Therapeutics, Center for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina. ; Department of Biostatistics, Richard M. Fairbanks School of Public Health, Indiana University School of Medicine, Indianapolis, Indiana. ; National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland. ; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. ; Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Eskenazi Health, Indianapolis, Indiana. ; Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium Y1 - 2016/12// PY - 2016 DA - December 2016 SP - 1831 EP - 1838.e3 VL - 14 IS - 12 KW - Body Weight KW - Gender KW - TLFB KW - Alcoholic Hepatitis KW - TREAT KW - Alcohol Intake UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1826704402?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Clinical+gastroenterology+and+hepatology+%3A+the+official+clinical+practice+journal+of+the+American+Gastroenterological+Association&rft.atitle=Effects+of+Age%2C+Sex%2C+Body+Weight%2C+and+Quantity+of+Alcohol+Consumption+on+Occurrence+and+Severity+of+Alcoholic+Hepatitis.&rft.au=Liangpunsakul%2C+Suthat%3BPuri%2C+Puneet%3BShah%2C+Vijay+H%3BKamath%2C+Patrick%3BSanyal%2C+Arun%3BUrban%2C+Thomas%3BRen%2C+Xiaowei%3BKatz%2C+Barry%3BRadaeva%2C+Svetlana%3BChalasani%2C+Naga%3BCrabb%2C+David+W%3BTranslational+Research+and+Evolving+Alcoholic+Hepatitis+Treatment+Consortium&rft.aulast=Liangpunsakul&rft.aufirst=Suthat&rft.date=2016-12-01&rft.volume=14&rft.issue=12&rft.spage=1831&rft.isbn=&rft.btitle=&rft.title=Clinical+gastroenterology+and+hepatology+%3A+the+official+clinical+practice+journal+of+the+American+Gastroenterological+Association&rft.issn=1542-7714&rft_id=info:doi/10.1016%2Fj.cgh.2016.05.041 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-08-11 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.cgh.2016.05.041 ER - TY - JOUR T1 - Identification of novel small molecules that bind to the loop2 region of sclerostin - an in silico computational analysis. AN - 1826722878; 27429110 AB - The goal of this study was to identify small molecular weight compounds that bind to sclerostin using in-silico methods because of the established importance of sclerostin-based therapies for the treatment of disease characterized by low bone mass. The zinc database (Zdb) revealed that nine potential molecules bind to the loop2 region (functional site) of sclerostin with ADME/T properties that are within an acceptable range defined for human use. Compounds 30160056 and 56871042 showed the highest docking score. Density functional theory (by HOMO, LUMO and MESP analysis) and MM/GBSA analysis showed that four compounds 30160056, 56871042, 72112226 and 43920281 exhibit high stability among the nine small molecules identified. Induced Docking Fit and Pymol software analyses revealed that the identified compounds differ in the interaction with amino acids in the loop2 region of sclerostin. Six compound exhibited interaction with Ile95 and 2 compounds with Asn93, an amino acid in the loop2 region known to be involved in sclerostin's inhibitory effect, suggesting that the identified compounds have the potential to bind and neutralize sclerostin function. Furthermore, compound 43920281 showed a low risk of toxicity and drug-like characteristic features compared to all nine identified compounds. In conclusion, in silico analysis identified a novel compound 43920281 as a potent anti-sclerostin therapeutic for drug development for the treatment of osteoporosis. JF - Physiological research AU - Muthusamy, K AU - Mohan, S AU - Nagamani, S AU - Kesavan, C AD - Department of Bioinformatics, Alagappa University, Karaikudi, India; Musculoskeletal Disease Center, VA Loma Linda Healthcare System, Research Service, Loma Linda, CA, USA. Chandrasekhar.Kesavan@va.gov. Y1 - 2016/11/23/ PY - 2016 DA - 2016 Nov 23 SP - 871 EP - 878 VL - 65 IS - 5 UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1826722878?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Physiological+research&rft.atitle=Identification+of+novel+small+molecules+that+bind+to+the+loop2+region+of+sclerostin+-+an+in+silico+computational+analysis.&rft.au=Muthusamy%2C+K%3BMohan%2C+S%3BNagamani%2C+S%3BKesavan%2C+C&rft.aulast=Muthusamy&rft.aufirst=K&rft.date=2016-11-23&rft.volume=65&rft.issue=5&rft.spage=871&rft.isbn=&rft.btitle=&rft.title=Physiological+research&rft.issn=1802-9973&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-07-18 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 ER - TY - JOUR T1 - Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin AN - 1837341539; PQ0003740510 AB - Objective: New regimens to treat hepatitis C virus infection have expanded the eligible patient population to include more patients receiving concurrent warfarin. The primary objective of this study was to assess whether a drug interaction occurs when these regimens are added to warfarin therapy. Methods: This was a retrospective cohort design using a nationwide database of the Veterans Affairs Health System. Patients on warfarin therapy treated with sofosbuvir or ombitasvir, paritaprevir-ritonavir, and dasabuvir (OBV-PTV/r-DSV) from March 2014 through October 2015 were identified. The warfarin dose response was calculated using a warfarin sensitivity index (WSI) defined as the steady-state INR divided by the mean daily warfarin dose. The primary outcome was the change in WSI from hepatitis C treatment initiation to completion. Results: The final sample consisted of 271 patients. The WSI decreased 23% from a mean baseline value of 0.53 to 0.39 (decrease of 0.14; 95% CI = 0.11 to 0.16; P < 0.001). OBV-PTV/r-DSV produced a significantly greater decrease than any sofosbuvir regimen. Concurrent ribavirin accounted for an additional decrease in warfarin sensitivity of -0.09 (95% CI = -0.06 to -0.12; P < 0.001). The percentage of subtherapeutic INR results increased from 26% prior to hepatitis C treatment to 58% during treatment. Conclusions: Results indicate a clinically significant reduction in warfarin dose-response when hepatitis C treatment regimens were added to warfarin. They were most profound with OBV-PTV/r-DSV. Ribavirin was associated with an additive effect. Clinicians should be aware of this potential drug interaction to closely monitor and minimize subtherapeutic levels of anticoagulation. JF - Annals of Pharmacotherapy AU - DeCarolis, Douglas D AU - Westanmo, Anders D AU - Chen, Yi-Chie AU - Boese, Amanda L AU - Walquist, Mary A AU - Rector, Thomas S AD - 1 .Minneapolis VA Health Care System, Minneapolis, MN, USA, douglas.decarolis@va.gov Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 909 EP - 917 PB - Sage Publications, Inc. VL - 50 IS - 11 SN - 1060-0280, 1060-0280 KW - Virology & AIDS Abstracts; Toxicology Abstracts KW - anticoagulants KW - anticoagulation KW - antivirals KW - cytochrome P-450 interactions KW - drug interactions KW - gastroenterology KW - hepatitis C KW - pharmacokinetics KW - therapeutic monitoring KW - warfarin KW - Drug interaction KW - Databases KW - Hepatitis C virus KW - Ribavirin KW - Warfarin KW - Hepatitis C KW - Infection KW - X 24330:Agrochemicals KW - V 22400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837341539?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Annals+of+Pharmacotherapy&rft.atitle=Evaluation+of+a+Potential+Interaction+Between+New+Regimens+to+Treat+Hepatitis+C+and+Warfarin&rft.au=DeCarolis%2C+Douglas+D%3BWestanmo%2C+Anders+D%3BChen%2C+Yi-Chie%3BBoese%2C+Amanda+L%3BWalquist%2C+Mary+A%3BRector%2C+Thomas+S&rft.aulast=DeCarolis&rft.aufirst=Douglas&rft.date=2016-11-01&rft.volume=50&rft.issue=11&rft.spage=909&rft.isbn=&rft.btitle=&rft.title=Annals+of+Pharmacotherapy&rft.issn=10600280&rft_id=info:doi/10.1177%2F1060028016660325 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Number of references - 44 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Databases; Drug interaction; Ribavirin; Hepatitis C; Warfarin; Infection; Hepatitis C virus DO - http://dx.doi.org/10.1177/1060028016660325 ER - TY - JOUR T1 - What Is the Critical Value of Glenoid Bone Loss at Which Soft Tissue Bankart Repair Does Not Restore Glenohumeral Translation, Restricts Range of Motion, and Leads to Abnormal Humeral Head Position? AN - 1837318707; PQ0003816088 AB - Background: A general consensus has been formed that glenoid bone loss greater than 20% to 25% is the critical amount at which bony augmentation procedures are needed; however, recent clinical results suggest that the critical levels must be reconsidered to lower values. Purpose: This study aimed to find the critical value of anterior glenoid bone loss when a soft tissue repair is not adequate to restore anterior-inferior glenohumeral translation, rotational range of motion, or humeral head position using a biomechanical anterior shoulder instability model. Study Design: Controlled laboratory study. Methods: Eight cadaveric shoulders were tested with a customized shoulder testing system. Range of motion, translation, and humeral head position were measured at 60 degree of glenohumeral abduction in the scapular plane under a total of 40-N rotator cuff muscle loading in the following 11 conditions: intact; soft tissue Bankart lesion and repair; Bankart lesion with 10%, 15%, 20%, and 25% glenoid bone defects based on the largest anteroposterior width of the glenoid; and soft tissue Bankart repair for each respective glenoid defect. Serial osteotomies for each percentage of bone loss were made parallel to the long axis of the glenoid. Results: There was significantly decreased external rotation (121.2 degree plus or minus 2.8 degree to 113.5 degree plus or minus 3.3 degree ; P = .004), increased anteroinferior translation with an externally applied load (3.0 plus or minus 1.2 mm to 7.5 plus or minus 1.1 mm at 20 N; P = .008), and increased posterior (0.2 plus or minus 0.6 mm to 2.7 plus or minus 0.8 mm; P = .049) and inferior shift (2.9 plus or minus 0.7 mm to 6.6 plus or minus 1.1 mm; P = .018) of the humeral head apex in the position of maximum external rotation after soft tissue Bankart repair of a 15% glenoid defect compared with the repair of a Bankart lesion without a glenoid defect, respectively. Conclusion: Glenoid defects of 15% or more of the largest anteroposterior glenoid width should be considered the critical bone loss amount at which soft tissue repair cannot restore glenohumeral translation, restricts rotational range of motion, and leads to abnormal humeral head position. Clinical Relevance: The critical level of anterior glenoid bone loss at which bony restorations should be considered is closer to 15% of the largest anteroposterior width of glenoid for defects perpendicular to the superoinferior glenoid axis, which is lower than the commonly accepted threshold of 20% to 25%. JF - American Journal of Sports Medicine AU - Shin, Sang-Jin AU - Koh, Yong Won AU - Bui, Christopher AU - Jeong, Woong Kyo AU - Akeda, Masaki AU - Cho, Nam Su AU - McGarry, Michelle H AU - Lee, Thay Q AD - * .Department of Orthopaedic Surgery, Ewha Womans University, Seoul, Korea, tqlee@med.va.gov Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 2784 EP - 2791 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 44 IS - 11 SN - 0363-5465, 0363-5465 KW - Physical Education Index KW - shoulder instability KW - Bankart lesion KW - Bankart repair KW - biomechanics KW - glenoid bone loss KW - Measurement KW - Bones KW - Flexibility KW - Muscles KW - Rotator cuff KW - Shoulders KW - Work load KW - Sports medicine KW - Biomechanics KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837318707?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+Journal+of+Sports+Medicine&rft.atitle=What+Is+the+Critical+Value+of+Glenoid+Bone+Loss+at+Which+Soft+Tissue+Bankart+Repair+Does+Not+Restore+Glenohumeral+Translation%2C+Restricts+Range+of+Motion%2C+and+Leads+to+Abnormal+Humeral+Head+Position%3F&rft.au=Shin%2C+Sang-Jin%3BKoh%2C+Yong+Won%3BBui%2C+Christopher%3BJeong%2C+Woong+Kyo%3BAkeda%2C+Masaki%3BCho%2C+Nam+Su%3BMcGarry%2C+Michelle+H%3BLee%2C+Thay+Q&rft.aulast=Shin&rft.aufirst=Sang-Jin&rft.date=2016-11-01&rft.volume=44&rft.issue=11&rft.spage=2784&rft.isbn=&rft.btitle=&rft.title=American+Journal+of+Sports+Medicine&rft.issn=03635465&rft_id=info:doi/10.1177%2F0363546516656367 LA - English DB - Physical Education Index N1 - Date revised - 2016-11-01 N1 - Number of references - 30 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Measurement; Bones; Flexibility; Muscles; Rotator cuff; Work load; Shoulders; Sports medicine; Biomechanics DO - http://dx.doi.org/10.1177/0363546516656367 ER - TY - JOUR T1 - Potential Role of DARC-Chemokine Interaction in the Recruitment of Osteoclast Precursors in Response to Bacterial Lipopolysaccharide Challenge AN - 1837317859; PQ0003740916 AB - Duffy antigen receptor for chemokines (DARC) binds to a number of pro-inflammatory chemokines, and since chemokines are known to regulate trafficking of osteoclast (OC) precursors, we predicted that DARC would regulate OC recruitment to sites of inflammation by modulating chemokine activity. To test this hypothesis, we evaluated the mRNA expression of Darc and the chemokines known to bind to DARC, in endothelial cells treated with bacterial lipopolysaccharide (LPS). The mRNA expression of Mcp-1, Rantes, Darc and Ccr5 was significantly increased in endothelial cells in response to LPS treatment. Blocking the function of DARC with neutralizing antibody partially abrogated the effect of LPS on the mRNA expression of Mcp-1 and Rantes. In vivo, mice with targeted disruption of Darc gene (Darc-KO) and control wild-type (WT) mice were used to assess the role of DARC in response to single LPS application on the top of parietal bones. Five hours post-LPS injection, local expression of Cd14 mRNA (a marker of inflammatory monocytes) was significantly increased in both lines of mice. However, the magnitude of increase was greater in WT mice compared with Darc-KO mice suggesting a role for DARC in mediating the recruitment of monocytes in response to LPS. Histological staining for tartrate-resistant acid phosphatase (TRAP) in calvaria sections taken from the injection sites revealed a significant reduction in TRAP-labeled surface per bone surface in response to LPS in Darc-KO mice compared with WT mice. Based on these findings, we concluded that DARC regulates recruitment of OC precursors at the inflammation site, probably through regulation of chemokines transcytosis across endothelial cell barrier. JF - Calcified Tissue International AU - Alemi, Fatemeh AU - Elgendy, Mohamed AU - Edderkaoui, Bouchra AD - Musculoskeletal Disease Center, Research Service, Jerry L Pettis Memorial Veterans Administration Medical Center, 11201 Benton St. (151), Loma Linda, CA, 92357, USA, Bouchra.Edderkaoui@va.gov Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 481 EP - 488 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 99 IS - 5 SN - 0171-967X, 0171-967X KW - Microbiology Abstracts B: Bacteriology; Calcium & Calcified Tissue Abstracts KW - Bacteria KW - Chemokines KW - Monocyte chemoattractant protein 1 KW - Osteoclasts KW - RANTES KW - CCR5 protein KW - Calvaria KW - CD14 antigen KW - Inflammation KW - Endothelial cells KW - Gene expression KW - Antibodies KW - Duffy antigen KW - Acid phosphatase (tartrate-resistant) KW - Osteoprogenitor cells KW - Lipopolysaccharides KW - Monocytes KW - parietal bone KW - J 02410:Animal Diseases KW - T 2025:Bone and Bone Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837317859?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Calcified+Tissue+International&rft.atitle=Potential+Role+of+DARC-Chemokine+Interaction+in+the+Recruitment+of+Osteoclast+Precursors+in+Response+to+Bacterial+Lipopolysaccharide+Challenge&rft.au=Alemi%2C+Fatemeh%3BElgendy%2C+Mohamed%3BEdderkaoui%2C+Bouchra&rft.aulast=Alemi&rft.aufirst=Fatemeh&rft.date=2016-11-01&rft.volume=99&rft.issue=5&rft.spage=481&rft.isbn=&rft.btitle=&rft.title=Calcified+Tissue+International&rft.issn=0171967X&rft_id=info:doi/10.1007%2Fs00223-016-0170-2 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Number of references - 20 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Chemokines; Monocyte chemoattractant protein 1; Osteoclasts; RANTES; CCR5 protein; CD14 antigen; Calvaria; Inflammation; Gene expression; Endothelial cells; Antibodies; Duffy antigen; Osteoprogenitor cells; Acid phosphatase (tartrate-resistant); Lipopolysaccharides; Monocytes; parietal bone; Bacteria DO - http://dx.doi.org/10.1007/s00223-016-0170-2 ER - TY - JOUR T1 - Coronary angiography and failure to rescue after postoperative myocardial infarction in patients with coronary stents undergoing noncardiac surgery AN - 1837317853; PQ0003764195 AB - Background We evaluated coronary angiography use among patients with coronary stents suffering postoperative myocardial infarction (MI) and the association with mortality. Methods Patients with prior coronary stenting who underwent inpatient noncardiac surgery in Veterans Affairs hospitals between 2000 and 2012 and experienced postoperative MI were identified. Predictors of 30-day post-MI mortality were evaluated. Results Following 12,096 operations, 353 (2.9%) patients had postoperative MI and 58 (16.4%) died. Post-MI coronary angiography was performed in 103 (29.2%) patients. Coronary angiography was not associated with 30-day mortality (odds ratio [OR]: .70, 95% CI: .35-1.42). Instead, 30-day mortality was predicted by revised cardiac risk index greater than or equal to 3 (OR 1.91, 95% CI: 1.04-3.50) and prior bare metal stent (OR 2.12, 95% CI: 1.04-4.33). Conclusions Less than one-third of patients with coronary stents suffering postoperative MI underwent coronary angiography. Significant predictors of mortality were higher revised cardiac risk index and prior bare metal stent. These findings highlight the importance of comorbidities in predicting mortality following postoperative MI. JF - American Journal of Surgery AU - Hollis, Robert H AU - Holcomb, Carla N AU - Valle, Javier A AU - Smith, Burke P AU - DeRussy, Aerin J AU - Graham, Laura A AU - Richman, Joshua S AU - Itani, Kamal MF AU - Maddox, Thomas M AU - Hawn, Mary T AD - Center for Surgical, Medical Acute Care Research and Transitions (C-SMART), Department of Surgery, Birmingham Veterans Administration Hospital, University of Alabama at Birmingham, Birmingham, AL, USA Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 814 EP - 822.e1 PB - Elsevier B.V., Radarweg 29 Amsterdam 1043 NX Netherlands VL - 212 IS - 5 SN - 0002-9610, 0002-9610 KW - Biotechnology and Bioengineering Abstracts KW - Postoperative myocardial infarction KW - Coronary stent KW - Coronary angiography KW - Postoperative mortality KW - Failure to rescue KW - Cardiac risk index KW - Heart KW - Mortality KW - Metals KW - Angiography KW - Implants KW - Surgery KW - Risk factors KW - Myocardial infarction KW - Hospitals KW - W 30910:Imaging UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837317853?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+Journal+of+Surgery&rft.atitle=Coronary+angiography+and+failure+to+rescue+after+postoperative+myocardial+infarction+in+patients+with+coronary+stents+undergoing+noncardiac+surgery&rft.au=Hollis%2C+Robert+H%3BHolcomb%2C+Carla+N%3BValle%2C+Javier+A%3BSmith%2C+Burke+P%3BDeRussy%2C+Aerin+J%3BGraham%2C+Laura+A%3BRichman%2C+Joshua+S%3BItani%2C+Kamal+MF%3BMaddox%2C+Thomas+M%3BHawn%2C+Mary+T&rft.aulast=Hollis&rft.aufirst=Robert&rft.date=2016-11-01&rft.volume=212&rft.issue=5&rft.spage=814&rft.isbn=&rft.btitle=&rft.title=American+Journal+of+Surgery&rft.issn=00029610&rft_id=info:doi/10.1016%2Fj.amjsurg.2016.07.023 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Number of references - 16 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Heart; Metals; Mortality; Angiography; Risk factors; Surgery; Implants; Myocardial infarction; Hospitals DO - http://dx.doi.org/10.1016/j.amjsurg.2016.07.023 ER - TY - JOUR T1 - Perspectives on expedited partner therapy for chlamydia: a survey of health care providers AN - 1837303961; PQ0003812314 AB - There is a lack of research on health care providers' use of and perspectives on expedited partner therapy in a state where expedited partner therapy is not prohibited or explicitly allowed. The aim of our study was to understand if and how health care providers use expedited partner therapy, if specific demographic factors and knowledge contribute to increased use of expedited partner therapy, and to describe barriers and facilitators to the use of expedited partner therapy in Pittsburgh, Pennsylvania. A convenience sample of 112 health care providers from diverse disciplines who treat young women at risk for chlamydia completed an online survey. About 11% of health care providers used expedited partner therapy consistently. Those who self-reported that they were knowledgeable about expedited partner therapy were more likely to use expedited partner therapy (73% vs. 49%, p =.009) as were those who said no or were unsure about their institution's guidelines for expedited partner therapy (35% vs. 22%, p =0.01) (62% vs. 57%, p =0.01). The most commonly reported facilitator of expedited partner therapy was having clear legal guidelines (86%). This study finds that in a setting where expedited partner therapy is not expressly permitted, health care providers still use the practice but also experience barriers that limit uptake. Legislation expressly endorsing expedited partner therapy in the state and in medical institutions is needed to increase expedited partner therapy use. JF - International Journal of STD & AIDS AU - Rosenfeld, E A AU - Marx, J AU - Terry, MA AU - Stall, R AU - Flatt, J AU - Borrero, S AU - Miller, E AD - 1 .VA Women's Health, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, Elian.rosenfeld@va.gov Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 1180 EP - 1186 PB - Sage Publications, Inc., 2455 Teller Road Thousand Oaks CA 91320 United States VL - 27 IS - 13 SN - 0956-4624, 0956-4624 KW - Microbiology Abstracts B: Bacteriology; Health & Safety Science Abstracts; Virology & AIDS Abstracts KW - Expedited partner therapy KW - providers KW - survey KW - sexually transmitted infection KW - treatment KW - Acquired immune deficiency syndrome KW - Guidelines KW - Demography KW - Health care KW - Risk factors KW - USA, Pennsylvania KW - Sexually transmitted diseases KW - Internet KW - Legislation KW - Chlamydia KW - V 22360:AIDS and HIV KW - J 02400:Human Diseases KW - H 0500:General UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837303961?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+Journal+of+STD+%26+AIDS&rft.atitle=Perspectives+on+expedited+partner+therapy+for+chlamydia%3A+a+survey+of+health+care+providers&rft.au=Rosenfeld%2C+E+A%3BMarx%2C+J%3BTerry%2C+MA%3BStall%2C+R%3BFlatt%2C+J%3BBorrero%2C+S%3BMiller%2C+E&rft.aulast=Rosenfeld&rft.aufirst=E&rft.date=2016-11-01&rft.volume=27&rft.issue=13&rft.spage=1180&rft.isbn=&rft.btitle=&rft.title=International+Journal+of+STD+%26+AIDS&rft.issn=09564624&rft_id=info:doi/10.1177%2F0956462415610689 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Number of references - 29 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Demography; Legislation; Internet; Acquired immune deficiency syndrome; Health care; Risk factors; Guidelines; Sexually transmitted diseases; Chlamydia; USA, Pennsylvania DO - http://dx.doi.org/10.1177/0956462415610689 ER - TY - JOUR T1 - The Scourge of the Spurge Family-An Imitator of Rhus Dermatitis. AN - 1835519592; 27775975 AB - The Euphorbiaceae family (commonly known as "spurge") is a large, diverse, and widely distributed family of plants that encompass around 300 genera and more than 8000 species. Their attractiveness and hearty nature have made them popular for both indoor ornamentation and outdoor landscaping. Despite their ubiquity, the potential to cause irritant contact dermatitis (ICD) is often overlooked in favor of more notorious causes of phytodermatitis, namely, Toxicodendron species and nettles. We examined case reports spanning 40 years and discovered that spurge-induced ICD tends to befall children and middle-aged adults who unwittingly encounter the plant through play or horticulture, respectively. Clinical presentation is pleomorphic. Erythema, edema, burning, vesicles, and pruritus of acute onset and rapid resolution are frequently observed. We present a classic case of ICD in a 12-year-old girl after exposure to Euphorbia myrsinites and review the literature on phytodermatitis caused by members of the Euphorbiaceae family. JF - Dermatitis : contact, atopic, occupational, drug AU - Huerth, Kimberly A AU - Hawkes, Jason E AU - Meyer, Laurence J AU - Powell, Douglas L AD - From the *University at Buffalo School of Medicine, New York, NY; †The University of Utah Department of Dermatology, Salt Lake City; and ‡Veterans Administration Hospital, Salt Lake City, UT. PY - 2016 SP - 372 EP - 381 VL - 27 IS - 6 UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1835519592?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Dermatitis+%3A+contact%2C+atopic%2C+occupational%2C+drug&rft.atitle=The+Scourge+of+the+Spurge+Family-An+Imitator+of+Rhus+Dermatitis.&rft.au=Huerth%2C+Kimberly+A%3BHawkes%2C+Jason+E%3BMeyer%2C+Laurence+J%3BPowell%2C+Douglas+L&rft.aulast=Huerth&rft.aufirst=Kimberly&rft.date=2016-11-01&rft.volume=27&rft.issue=6&rft.spage=372&rft.isbn=&rft.btitle=&rft.title=Dermatitis+%3A+contact%2C+atopic%2C+occupational%2C+drug&rft.issn=2162-5220&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-10-24 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 ER - TY - JOUR T1 - Restoring Retinoic Acid Attenuates Intestinal Inflammation and Tumorigenesis in APCMin/+ Mice. AN - 1835353279; 27638841 AB - Chronic intestinal inflammation accompanies familial adenomatous polyposis (FAP) and is a major risk factor for colorectal cancer in patients with this disease, but the cause of such inflammation is unknown. Because retinoic acid (RA) plays a critical role in maintaining immune homeostasis in the intestine, we hypothesized that altered RA metabolism contributes to inflammation and tumorigenesis in FAP. To assess this hypothesis, we analyzed RA metabolism in the intestines of patients with FAP as well as APCMin/+ mice, a model that recapitulates FAP in most respects. We also investigated the impact of intestinal RA repletion and depletion on tumorigenesis and inflammation in APCMin/+ mice. Tumors from both FAP patients and APCMin/+ mice displayed striking alterations in RA metabolism that resulted in reduced intestinal RA. APCMin/+ mice placed on a vitamin A-deficient diet exhibited further reductions in intestinal RA with concomitant increases in inflammation and tumor burden. Conversely, restoration of RA by pharmacologic blockade of the RA-catabolizing enzyme CYP26A1 attenuated inflammation and diminished tumor burden. To investigate the effect of RA deficiency on the gut immune system, we studied lamina propria dendritic cells (LPDC) because these cells play a central role in promoting tolerance. APCMin/+ LPDCs preferentially induced Th17 cells, but reverted to inducing Tregs following restoration of intestinal RA in vivo or direct treatment of LPDCs with RA in vitro These findings demonstrate the importance of intestinal RA deficiency in tumorigenesis and suggest that pharmacologic repletion of RA could reduce tumorigenesis in FAP patients. Cancer Immunol Res; 4(11); 917-26. ©2016 AACR. ©2016 American Association for Cancer Research. JF - Cancer immunology research AU - Penny, Hweixian Leong AU - Prestwood, Tyler R AU - Bhattacharya, Nupur AU - Sun, Fionna AU - Kenkel, Justin A AU - Davidson, Matthew G AU - Shen, Lei AU - Zuniga, Luis A AU - Seeley, E Scott AU - Pai, Reetesh AU - Choi, Okmi AU - Tolentino, Lorna AU - Wang, Jinshan AU - Napoli, Joseph L AU - Engleman, Edgar G AD - Department of Pathology, Stanford University School of Medicine (Blood Center), Palo Alto, California. ; Department of Immunology, Veterans Administration Hospital, Palo Alto, California. ; Department of Pathology, Stanford University, Stanford, California. ; Department of Nutritional Science and Toxicology, University of California, Berkeley, Berkeley, California. ; Department of Pathology, Stanford University School of Medicine (Blood Center), Palo Alto, California. edengleman@stanford.edu. Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 917 EP - 926 VL - 4 IS - 11 UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1835353279?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cancer+immunology+research&rft.atitle=Restoring+Retinoic+Acid+Attenuates+Intestinal+Inflammation+and+Tumorigenesis+in+APCMin%2F%2B+Mice.&rft.au=Penny%2C+Hweixian+Leong%3BPrestwood%2C+Tyler+R%3BBhattacharya%2C+Nupur%3BSun%2C+Fionna%3BKenkel%2C+Justin+A%3BDavidson%2C+Matthew+G%3BShen%2C+Lei%3BZuniga%2C+Luis+A%3BSeeley%2C+E+Scott%3BPai%2C+Reetesh%3BChoi%2C+Okmi%3BTolentino%2C+Lorna%3BWang%2C+Jinshan%3BNapoli%2C+Joseph+L%3BEngleman%2C+Edgar+G&rft.aulast=Penny&rft.aufirst=Hweixian&rft.date=2016-11-01&rft.volume=4&rft.issue=11&rft.spage=917&rft.isbn=&rft.btitle=&rft.title=Cancer+immunology+research&rft.issn=2326-6074&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-09-17 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 ER - TY - JOUR T1 - Delayed onset and long-lasting hemidiaphragmatic paralysis and cranial nerve deficit after interscalene nerve block for rotator cuff repair in beach chair position. AN - 1825220126; 27687453 AB - Hemidiaphragmatic paralysis is the most common adverse effect associated with interscalene block. In most cases, it resolves with the resolution of nerve blockade with only an estimated incidence of 0.048% persisting for longer duration. Occasionally, interscalene block is also associated with recurrent laryngeal nerve block and seldom with cranial nerve paresis. We present a case of delayed onset and prolonged hemidiaphragmatic paralysis that was associated with 3 cranial nerve deficits after interscalene nerve block for shoulder surgery performed under general anesthesia in the beach chair position. Etiology is unclear, but most likely multifactorial. JF - Journal of clinical anesthesia AU - Chiaghana, Chukwudi O AU - Awoniyi, Caleb A AD - Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL, USA. Electronic address: chuks.chiaghana@gmail.com. ; Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL, USA; North Florida/South Georgia Veterans Affairs Medical Center, Gainesville, FL, USA. Electronic address: caleb.awoniyi@va.gov. Y1 - 2016/11// PY - 2016 DA - November 2016 SP - 571 EP - 576 VL - 34 KW - Index Medicus KW - Interscalene nerve block KW - Cranial nerve deficit KW - Hemidiaphragmatic paralysis KW - Beach chair position KW - Intraneural injection KW - Local anesthetic toxicity UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1825220126?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+clinical+anesthesia&rft.atitle=Delayed+onset+and+long-lasting+hemidiaphragmatic+paralysis+and+cranial+nerve+deficit+after+interscalene+nerve+block+for+rotator+cuff+repair+in+beach+chair+position.&rft.au=Chiaghana%2C+Chukwudi+O%3BAwoniyi%2C+Caleb+A&rft.aulast=Chiaghana&rft.aufirst=Chukwudi&rft.date=2016-11-01&rft.volume=34&rft.issue=&rft.spage=571&rft.isbn=&rft.btitle=&rft.title=Journal+of+clinical+anesthesia&rft.issn=1873-4529&rft_id=info:doi/10.1016%2Fj.jclinane.2016.06.026 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-09-30 N1 - Date revised - 2017-02-09 N1 - Last updated - 2017-02-09 DO - http://dx.doi.org/10.1016/j.jclinane.2016.06.026 ER - TY - JOUR T1 - Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions AN - 1827914156; PQ0003723734 AB - Alcohol use is common among people living with human immunodeficiency virus (HIV). In this narrative review, we describe literature regarding alcohol's impact on transmission, care, coinfections, and comorbidities that are common among people living with HIV (PLWH), as well as literature regarding interventions to address alcohol use and its influences among PLWH. This narrative review identifies alcohol use as a risk factor for HIV transmission, as well as a factor impacting the clinical manifestations and management of HIV. Alcohol use appears to have additive and potentially synergistic effects on common HIV-related comorbidities. We find that interventions to modify drinking and improve HIV-related risks and outcomes have had limited success to date, and we recommend research in several areas. Consistent with Office of AIDS Research/National Institutes of Health priorities, we suggest research to better understand how and at what levels alcohol influences comorbid conditions among PLWH, to elucidate the mechanisms by which alcohol use is impacting comorbidities, and to understand whether decreases in alcohol use improve HIV-relevant outcomes. This should include studies regarding whether state-of-the-art medications used to treat common coinfections are safe for PLWH who drink alcohol. We recommend that future research among PLWH include validated self-report measures of alcohol use and/or biological measurements, ideally both. Additionally, subgroup variation in associations should be identified to ensure that the risks of particularly vulnerable populations are understood. This body of research should serve as a foundation for a next generation of intervention studies to address alcohol use from transmission to treatment of HIV. Intervention studies should inform implementation efforts to improve provision of alcohol-related interventions and treatments for PLWH in healthcare settings. By making further progress on understanding how alcohol use affects PLWH in the era of HIV as a chronic condition, this research should inform how we can mitigate transmission, achieve viral suppression, and avoid exacerbating common comorbidities of HIV and alcohol use and make progress toward the 90-90-90 goals for engagement in the HIV treatment cascade. This narrative review finds that alcohol use is associated with HIV acquisition and transmission, lack of viral suppression, common comorbid conditions (e.g., hepatitis C, tuberculosis, cardiovascular disease, frailty/falls, depression, trauma, and other substance use disorders), and ultimately mortality among people living with HIV (PLWH). Associations between alcohol use and HIV-related care and outcomes may disproportionately affect vulnerable subgroups of PLWH. Interventions to address drinking and subsequently improve HIV-related risks and outcomes have been tested with limited success to date. JF - Alcoholism: Clinical and Experimental Research AU - Williams, Emily C AU - Hahn, Judith A AU - Saitz, Richard AU - Bryant, Kendall AU - Lira, Marlene C AU - Samet, Jeffrey H AD - Veterans Health Administration (VA) Health Services Research and Development, Center of Innovation for Veteran-Centered and Value-Driven Care, Seattle, Washington. Y1 - 2016/10// PY - 2016 DA - October 2016 SP - 2056 EP - 2072 PB - Wiley-Blackwell, 111 River Street Hoboken NJ 07030-5774 United States VL - 40 IS - 10 SN - 0145-6008, 0145-6008 KW - Immunology Abstracts; Virology & AIDS Abstracts; Toxicology Abstracts KW - Mortality KW - Acquired immune deficiency syndrome KW - Beverages KW - Depression KW - Mycobacterium KW - Retroviridae KW - Infection KW - Drug abuse KW - Disease transmission KW - Trauma KW - Hepatitis C virus KW - Lentivirus KW - Human immunodeficiency virus KW - Risk factors KW - Reviews KW - Alcoholism KW - alcohols KW - Drinking behavior KW - Tuberculosis KW - Cardiovascular diseases KW - Hepatitis C KW - Ethanol KW - V 22360:AIDS and HIV KW - X 24380:Social Poisons & Drug Abuse UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1827914156?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Social+and+Clinical+Psychology&rft.atitle=Depressive+Symptoms+And+Affective+Reactivity+To+Maternal+Praise+And+Criticism&rft.au=Cuellar%2C+Amy+K%3BJohnson%2C+Sheri+L&rft.aulast=Cuellar&rft.aufirst=Amy&rft.date=2009-11-01&rft.volume=28&rft.issue=9&rft.spage=1173&rft.isbn=&rft.btitle=&rft.title=Journal+of+Social+and+Clinical+Psychology&rft.issn=07367236&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-10-01 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Mortality; Acquired immune deficiency syndrome; Depression; Beverages; Drug abuse; Infection; Trauma; Disease transmission; Reviews; Risk factors; Alcoholism; alcohols; Drinking behavior; Tuberculosis; Hepatitis C; Cardiovascular diseases; Ethanol; Lentivirus; Hepatitis C virus; Mycobacterium; Human immunodeficiency virus; Retroviridae DO - http://dx.doi.org/10.1111/acer.13204 ER - TY - JOUR T1 - Provider Opinions Regarding the Development of a Stigma-Reduction Intervention Tailored for Providers AN - 1827886858; PQ0003686222 AB - Interventions involving contact with a person who has recovered from mental illness are most effective at reducing stigma. This study sought input from health care providers to inform the design of a contact intervention intended to reduce provider stigma toward persons with serious mental illness. Using a purposive sampling strategy, data were collected from providers at five Veterans Affairs hospitals in the southeastern United States. Seven focus groups were conducted, and 83 health care providers participated. A semistructured interview guide was used to elicit providers' opinions about the target group of a contact intervention for providers, what providers would consider a credible contact, the preferred format for delivery, the usefulness of potentially tailoring the intervention to a specific facility, and how to measure change in clinical behaviors. Focus group data were analyzed using rapid data analysis techniques. Participants uniformly recommended a broad target audience for the stigma-reduction intervention, including all primary care and specialist providers. They suggested that the person providing the "lived experience" for the contact intervention should be either a health care provider or a patient with serious mental illness. Face-to-face presentation was favored, but video presentation was considered more feasible. Participants stated that information about local disparities in care rendered to patients with or without mental illness would convince providers of how stigma may be a contributing factor to these disparities. Multiple training opportunities were favored, while mandatory training was disliked. Standard stigma-reduction interventions with subgroups of the general public (e.g., providers) may need to be modified for optimum subgroup effectiveness. JF - Health Education & Behavior AU - Mittal, Dinesh AU - Corrigan, Patrick AU - Drummond, Karen L AU - Porchia, Sylvia AU - Sullivan, Greer AD - 1 .Central Arkansas Veterans Healthcare System, North Little Rock, AR, USA, Dinesh.Mittal@va.gov Y1 - 2016/10// PY - 2016 DA - October 2016 SP - 577 EP - 583 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 43 IS - 5 SN - 1090-1981, 1090-1981 KW - Physical Education Index KW - intervention KW - mental illness KW - provider stigma KW - schizophrenia KW - stigma KW - Mental illness KW - Health (care) KW - Videotape KW - Analysis KW - Strategy KW - Health (behavior) KW - Patients KW - Standards KW - Hospitals KW - PE 120:Sport: Psychology, Sociology & History UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1827886858?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Health+Education+%26+Behavior&rft.atitle=Provider+Opinions+Regarding+the+Development+of+a+Stigma-Reduction+Intervention+Tailored+for+Providers&rft.au=Mittal%2C+Dinesh%3BCorrigan%2C+Patrick%3BDrummond%2C+Karen+L%3BPorchia%2C+Sylvia%3BSullivan%2C+Greer&rft.aulast=Mittal&rft.aufirst=Dinesh&rft.date=2016-10-01&rft.volume=43&rft.issue=5&rft.spage=577&rft.isbn=&rft.btitle=&rft.title=Health+Education+%26+Behavior&rft.issn=10901981&rft_id=info:doi/10.1177%2F1090198115614316 LA - English DB - Physical Education Index N1 - Date revised - 2016-10-01 N1 - Number of references - 27 N1 - Last updated - 2016-10-12 N1 - SubjectsTermNotLitGenreText - Videotape; Health (care); Mental illness; Analysis; Strategy; Health (behavior); Standards; Patients; Hospitals DO - http://dx.doi.org/10.1177/1090198115614316 ER - TY - JOUR T1 - An Engagement Intervention for Young Adults with Serious Mental Health Conditions AN - 1826093038 AB - Young adults with serious mental health conditions (SMHCs) often do not engage continuously with mental health services, and there are few engagement interventions designed for them. This qualitative study presents a blueprint for conceptualizing and developing an engagement intervention designed for young adults with SMHCs. The blueprint includes the following activities: (1) establishing a strong theoretical basis, (2) designing an initial manual based on previous research and practice, (3) systematically examining feedback on the manual from stakeholders, and (4) examining the feasibility, acceptability, and implementation demands of the intervention. Interviews, group discussions, and journaling were utilized to collect information from young adult participant-researchers, intervention facilitators (i.e., recovery role models and clinicians), and additional stakeholders (e.g., clinic staff and administrators) (N=43). Analyses were performed with multiple coders using constant comparative methods. Results revealed critical information to improve the intervention, while also suggesting that the engagement intervention for young adults with SMHCs has promise. JF - Journal of Behavioral Health Services & Research AU - Munson, Michelle R, PhD AU - Cole, Andrea, MSW AU - Jaccard, James, PhD AU - Kranke, Derrick, PhD AU - Farkas, Kathleen, PhD AU - Frese, Fred J, III, PhD AD - New York University Silver School of Social Work, New York, NY, USA ; Veterans Administration, Veterans Emergency Management Evaluation Center (VEMEC), North Hills, CA, USA ; Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, USA ; Department of Psychiatry, Northeast Ohio Universities College of Medicine, Rootstown, OH, USA ; New York University Silver School of Social Work, New York, NY, USA Y1 - 2016/10// PY - 2016 DA - Oct 2016 SP - 542 EP - 563 CY - Gaithersburg PB - Springer Science & Business Media VL - 43 IS - 4 SN - 1094-3412 KW - Public Health And Safety KW - Interventions KW - Young adults KW - Feedback KW - Role models KW - Facilitators KW - Feasibility KW - Mental health services KW - Stakeholders KW - Recovery UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1826093038?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Behavioral+Health+Services+%26+Research&rft.atitle=An+Engagement+Intervention+for+Young+Adults+with+Serious+Mental+Health+Conditions&rft.au=Munson%2C+Michelle+R%2C+PhD%3BCole%2C+Andrea%2C+MSW%3BJaccard%2C+James%2C+PhD%3BKranke%2C+Derrick%2C+PhD%3BFarkas%2C+Kathleen%2C+PhD%3BFrese%2C+Fred+J%2C+III%2C+PhD&rft.aulast=Munson&rft.aufirst=Michelle&rft.date=2016-10-01&rft.volume=43&rft.issue=4&rft.spage=542&rft.isbn=&rft.btitle=&rft.title=Journal+of+Behavioral+Health+Services+%26+Research&rft.issn=10943412&rft_id=info:doi/10.1007%2Fs11414-014-9424-9 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - National Council for Behavioral Health 2016 N1 - Last updated - 2016-10-06 DO - http://dx.doi.org/10.1007/s11414-014-9424-9 ER - TY - JOUR T1 - Veteran Use of Health Care Systems in Rural States: Comparing VA and Non-VA Health Care Use Among Privately Insured Veterans Under Age 65 AN - 1825276940 AB - Objective To quantify use of VA and non-VA care among working-age veterans with private insurance by linking VA data to private health insurance plan (PHIP) data. Methods Demographics and utilization were compared between dual users of VA and non-VA systems versus single-system users for veterans < 65 living in 2 rural Midwestern states concurrently enrolled in VA health care and a PHIP for ≥ 1 complete federal fiscal year from 2000 to 2010. Chi-square and t-tests were used for univariate analyses. VA reliance was computed as the percentage of visits, admissions and prescriptions in VA. Multinomial logistic regression was used to compare characteristics by dual use versus non-VA only or VA only use. Results Of 16,330 eligible veterans, 54% used both VA and non-VA services, 39% used non-VA only, and 5% used VA only. Compared with single-system use, dual use was associated with older age, priority levels 1-4, service-connected conditions, rural residence, greater years of study eligibility, and enrollment in the PHIP before VA. VA reliance was 33% for outpatient care, 14% for inpatient, and 40% for pharmacy. PHIP data substantially underestimated VA use compared to VA data; 26% who used VA health care had no VA claims in the PHIP dataset. Conclusions Over half of working-age veterans enrolled in VA and private insurance used services in both systems. Care coordination efforts across systems should include veterans of all ages, particularly rural veterans more likely to be dual users, and better methods are needed to identify veterans with private insurance and their private providers. JF - The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association AU - Charlton, Mary E AU - Mengeling, Michelle A AU - Schlichting, Jennifer A AU - Jiang, Lan AU - Turvey, Carolyn AU - Trivedi, Amal N AU - Kizer, Kenneth W AU - West, Alan N AD - Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa ; VA Office of Rural Health, Rural Health Resource Center--Central Region, and the Comprehensive Access and Delivery Research and Evaluation (CADRE), Center at the Iowa City VA Healthcare System, Iowa City, Iowa ; VA Center of Innovation in Long-Term Services and Supports for Vulnerable Veterans, Providence VA Healthcare System, Providence, Rhode Island ; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa; VA Office of Rural Health, Rural Health Resource Center--Central Region, and the Comprehensive Access and Delivery Research and Evaluation (CADRE), Center at the Iowa City VA Healthcare System, Iowa City, Iowa; Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, Iowa ; VA Center of Innovation in Long-Term Services and Supports for Vulnerable Veterans, Providence VA Healthcare System, Providence, Rhode Island; Department of Health Services, Policy and Practice and Department of Medicine, Brown University, Providence, Rhode Island ; UC Davis School of Medicine, and Betty Irene Moore School of Nursing, Institute for Population Health Improvement, University of California (UC)-Davis Health System, Sacramento, California ; Research Service, VA Medical Center, White River Junction, Vermont; Office of Rural Health, Veterans Health Administration, Washington, DC ; Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa Y1 - 2016///Fall PY - 2016 DA - Fall 2016 SP - 407 EP - 417 CY - Washington PB - Wiley Subscription Services, Inc. VL - 32 IS - 4 SN - 0890-765X KW - Public Health And Safety KW - Age KW - Health care KW - Health insurance KW - Coordination KW - Veterans KW - Rural communities KW - Reliance KW - Hospitalization KW - Residence KW - Insurance KW - Pharmacy KW - Enrollment KW - Outpatient treatment KW - Prescriptions KW - Delivery Systems KW - Health Care Services KW - Rural Areas KW - Health Care Industry KW - Health Care Utilization KW - Methodology (Data Analysis) KW - Health Insurance UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1825276940?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+Rural+Health+%3A+Official+Journal+of+the+American+Rural+Health+Association+and+the+National+Rural+Health+Care+Association&rft.atitle=Veteran+Use+of+Health+Care+Systems+in+Rural+States%3A+Comparing+VA+and+Non-VA+Health+Care+Use+Among+Privately+Insured+Veterans+Under+Age+65&rft.au=Charlton%2C+Mary+E%3BMengeling%2C+Michelle+A%3BSchlichting%2C+Jennifer+A%3BJiang%2C+Lan%3BTurvey%2C+Carolyn%3BTrivedi%2C+Amal+N%3BKizer%2C+Kenneth+W%3BWest%2C+Alan+N&rft.aulast=Charlton&rft.aufirst=Mary&rft.date=2016-10-01&rft.volume=32&rft.issue=4&rft.spage=407&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+Rural+Health+%3A+Official+Journal+of+the+American+Rural+Health+Association+and+the+National+Rural+Health+Care+Association&rft.issn=0890765X&rft_id=info:doi/10.1111%2Fjrh.12206 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA); PAIS Index N1 - Copyright - © 2016 National Rural Health Association N1 - Last updated - 2016-10-03 DO - http://dx.doi.org/10.1111/jrh.12206 ER - TY - JOUR T1 - Insured Veterans' Use of VA and Non-VA Health Care in a Rural State AN - 1825276864 AB - Purpose To understand how working-age VA-enrolled veterans with commercial insurance use both VA and non-VA outpatient care, and how rural residence affects dual use, for common diagnoses and procedures. Methods We analyzed VA and non-VA outpatient treatment records for any months during 2005-2010 that New Hampshire veterans ages <65 were simultaneously enrolled in VA health care and commercial insurance (per NH's mandatory claims database). Controlling for covariates, we used analysis of variance to compare urban and rural VA users, non-VA users, and dual users on travel burden, diagnosis counts, duration in outpatient care, and visit frequencies, and logistic regressions to assess whether rural veterans were as likely to be seen for common conditions and procedures. Findings More than half of patients were non-VA users and another third were dual users; rural residents were slightly more likely than urban residents to be dual users. For nearly any common diagnosis or procedure, dual users were more likely to have it at some time during treatment than other patients in either VA or non-VA care, but they seldom had it listed in both care systems. Dual users also were seen most often overall, although within either care system they were seen less often than other patients, particularly if they were rural residents living far from care. Rural residence reduced chances of treatment for a wide variety of conditions, though it also was associated with more musculoskeletal and connective tissue diagnoses. It also reduced chances that patients had some diagnostic and treatment procedures but increased the odds of others that may require fewer visits. Conclusions Dual users living in rural areas may have less continuity in their health care. Ensuring that rural dual users are identified in primary care should improve access and care coordination. JF - The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association AU - West, Alan N AU - Charlton, Mary E AD - Research Service, VA Medical Center, White River Junction, Vermont; Office of Rural Health, Veterans Health Administration, Washington, DC ; Iowa City VA Health Care System, Comprehensive Access and Delivery Research and Evaluation (CADRE) Center, Iowa City, Iowa; Department of Epidemiology, The University of Iowa College of Public Health, Iowa City, Iowa ; Research Service, VA Medical Center, White River Junction, Vermont; Office of Rural Health, Veterans Health Administration, Washington, DC Y1 - 2016///Fall PY - 2016 DA - Fall 2016 SP - 387 EP - 396 CY - Washington PB - Wiley Subscription Services, Inc. VL - 32 IS - 4 SN - 0890-765X KW - Public Health And Safety KW - Rural areas KW - Health insurance KW - Databases KW - Coordination KW - Primary health care KW - Veterans KW - Insurance KW - Rural communities KW - Residence KW - Diagnosis KW - Outpatient treatment KW - Health Care Services KW - Rural Areas KW - Urban Population KW - Patients KW - Residents KW - Travel KW - Treatment KW - Variance (Statistics) KW - Health Insurance UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1825276864?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+Rural+Health+%3A+Official+Journal+of+the+American+Rural+Health+Association+and+the+National+Rural+Health+Care+Association&rft.atitle=Insured+Veterans%27+Use+of+VA+and+Non-VA+Health+Care+in+a+Rural+State&rft.au=West%2C+Alan+N%3BCharlton%2C+Mary+E&rft.aulast=West&rft.aufirst=Alan&rft.date=2016-10-01&rft.volume=32&rft.issue=4&rft.spage=387&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+Rural+Health+%3A+Official+Journal+of+the+American+Rural+Health+Association+and+the+National+Rural+Health+Care+Association&rft.issn=0890765X&rft_id=info:doi/10.1111%2Fjrh.12196 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA); PAIS Index N1 - Copyright - © 2016 National Rural Health Association N1 - Last updated - 2016-10-03 DO - http://dx.doi.org/10.1111/jrh.12196 ER - TY - JOUR T1 - Alcohol intake alters immune responses and promotes CNS viral persistence in mice. AN - 1808604639; 27269869 AB - Chronic hepatitis C virus (HCV) infection leads to progressive liver disease and is associated with a variety of extrahepatic effects, including central nervous system (CNS) damage and neuropsychiatric impairments. Alcohol abuse can exacerbate these adverse effects on brain and behavior, but the molecular mechanisms are not well understood. This study investigated the role of alcohol in regulating viral persistence and CNS immunopathology in mice infected with lymphocytic choriomeningitis virus (LCMV), a model for HCV infections in humans. Female and male BALB/c mice (n=94) were exposed to alcohol (ethanol; EtOH) and water (or water only) using a two-bottle choice paradigm, followed one week later by infection with either LCMV clone 13 (causes chronic infection similar to chronic HCV), LCMV Armstrong (causes acute infection), or vehicle. Mice were monitored for 60days post-infection and continued to receive 24-h access to EtOH and water. Animals infected with LCMV clone 13 drank more EtOH, as compared to those with an acute or no viral infection. Six weeks after infection with LCMV clone 13, mice with EtOH exposure evidenced higher serum viral titers, as compared to mice without EtOH exposure. EtOH intake was also associated with reductions in virus-specific CD8(+) T cell frequencies (particularly CD11a(hi) subsets) and evidence of persistent CNS viremia in chronically infected mice. These findings support the hypothesis that EtOH use and chronic viral infection can result in combined toxic effects accelerating CNS damage and neuropsychiatric dysfunction and suggest that examining the role of EtOH in regulating viral persistence and CNS immunopathology in mice infected with LCMV can lead to a more comprehensive understanding of comorbid alcohol use disorder and chronic viral infection. Published by Elsevier B.V. JF - Behavioural brain research AU - Loftis, Jennifer M AU - Taylor, Jonathan AU - Raué, Hans-Peter AU - Slifka, Mark K AU - Huang, Elaine AD - Research & Development Service, Veterans Affairs Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. Electronic address: jennifer.loftis2@va.gov. ; Research & Development Service, Veterans Affairs Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. Electronic address: taylorjo@ohsu.edu. ; Division of Neuroscience, Department of Molecular Microbiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA. Electronic address: raueh@ohsu.edu. ; Division of Neuroscience, Department of Molecular Microbiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA. Electronic address: slifkam@ohsu.edu. ; Research & Development Service, Veterans Affairs Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd., Portland, OR 97239, USA; Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239, USA. Electronic address: huange@ohsu.edu. Y1 - 2016/10/01/ PY - 2016 DA - 2016 Oct 01 SP - 1 EP - 8 VL - 312 KW - Index Medicus KW - Lymphocytic choriomeningitis virus KW - Blood brain barrier KW - T-cells KW - Hepatitis C virus KW - Neurotoxicity KW - Ethanol UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808604639?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Behavioural+brain+research&rft.atitle=Alcohol+intake+alters+immune+responses+and+promotes+CNS+viral+persistence+in+mice.&rft.au=Loftis%2C+Jennifer+M%3BTaylor%2C+Jonathan%3BRau%C3%A9%2C+Hans-Peter%3BSlifka%2C+Mark+K%3BHuang%2C+Elaine&rft.aulast=Loftis&rft.aufirst=Jennifer&rft.date=2016-10-01&rft.volume=312&rft.issue=&rft.spage=1&rft.isbn=&rft.btitle=&rft.title=Behavioural+brain+research&rft.issn=1872-7549&rft_id=info:doi/10.1016%2Fj.bbr.2016.06.006 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-08-02 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.bbr.2016.06.006 ER - TY - JOUR T1 - Intervention Efficacy in Engaging Black and White Veterans with Post-traumatic Stress Disorder into Treatment AN - 1807616170 AB - This study examined racial differences among Black and White Veterans who screened positive for post-traumatic stress disorder (PTSD) but were not in PTSD treatment and were participating in an intervention trial. Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) Veterans with PTSD but not yet engaged in treatment were recruited and randomly assigned to control or intervention conditions. Intervention participants received a cognitive-behavioral engagement intervention by phone. All participants received follow-up calls to assess symptoms and utilization of treatment. Black and White participants were compared to assess differences in treatment utilization. Intervention session notes were analyzed qualitatively for explanatory themes. Participants of both races who received the intervention had higher PTSD treatment initiation than their respective control groups (Blacks: 85% vs. 58% and Whites: 53% vs. 45%, respectively). However, Blacks completed fewer PTSD treatment sessions compared to Whites overall (M = 2.06 [SD = 2.3] vs. M = 3.77 [SD = 9.9]; p < .05). Within the intervention condition, Blacks were significantly more likely to initiate treatment (odds ratio = 2.3, p < .04), and had a greater reduction in PTSD symptom compared to Whites (PTSD Checklist - Military Version [PCL] scores: 12.75 vs. 9.68). Based on qualitative analysis of intervention session notes, themes emerged that may suggest cultural differences involving social connection, attitudes towards treatment, and the desire to appear "okay." Blacks had a higher initiation rate and greater reduction in PTSD severity but completed fewer treatment sessions than Whites. These are promising results with respect to other studies which demonstrate that Black Veterans are less likely to seek treatment for PTSD. JF - Social Work in Public Health AU - Stecker, Tracy AU - Adams, Leslie AU - Carpenter-Song, Elizabeth AU - Nicholson, Joanne AU - Streltzov, Nicholas AU - Xie, Haiyi AD - Psychiatric Research Center, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA; VA Health Services Research and Development, White River Junction Veterans Administration, White River Junction, Vermont, USA ; Psychiatric Research Center, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA ; Psychiatric Research Center, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA; VA Health Services Research and Development, White River Junction Veterans Administration, White River Junction, Vermont, USA Y1 - 2016/10// PY - 2016 DA - Oct 2016 SP - 481 EP - 489 CY - Abingdon PB - Taylor & Francis Ltd. VL - 31 IS - 6 SN - 1937-1918 KW - Social Services And Welfare KW - Treatment seeking KW - treatment engagement KW - OEF/OIF Veterans KW - PTSD KW - health disparities KW - Freedom KW - Armed Forces KW - Black White Differences KW - Racial Differences KW - Social Attitudes KW - Intervention KW - Crosscultural Differences KW - Posttraumatic Stress Disorder KW - Qualitative Methods KW - Symptoms KW - Trauma KW - Veterans KW - Iraq KW - 6140:illness & health care UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1807616170?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Social+Work+in+Public+Health&rft.atitle=Intervention+Efficacy+in+Engaging+Black+and+White+Veterans+with+Post-traumatic+Stress+Disorder+into+Treatment&rft.au=Stecker%2C+Tracy%3BAdams%2C+Leslie%3BCarpenter-Song%2C+Elizabeth%3BNicholson%2C+Joanne%3BStreltzov%2C+Nicholas%3BXie%2C+Haiyi&rft.aulast=Stecker&rft.aufirst=Tracy&rft.date=2016-10-01&rft.volume=31&rft.issue=6&rft.spage=481&rft.isbn=&rft.btitle=&rft.title=Social+Work+in+Public+Health&rft.issn=19371918&rft_id=info:doi/10.1080%2F19371918.2016.1160340 LA - English DB - Social Services Abstracts N1 - Copyright - © 2016 Taylor & Francis Group, LLC N1 - Last updated - 2016-10-25 N1 - SubjectsTermNotLitGenreText - Iraq DO - http://dx.doi.org/10.1080/19371918.2016.1160340 ER - TY - JOUR T1 - The Relation of Arm Exercise Peak Heart Rate to Stress Test Results and Outcome AN - 1827882325; PQ0003666796 AB - Purpose: Arm exercise is an alternative to pharmacologic stress testing for >50% of patients unable to perform treadmill exercise, but no data exist regarding the effect of attained peak arm exercise heart rate on test sensitivity. Thus, the purpose of this investigation was to characterize the relationship of peak arm exercise heart rate responses to abnormal stress test findings, coronary revascularization, and mortality in patients unable to perform leg exercise. Methods: From 1997 until 2002, arm cycle ergometer stress tests were performed in 443 consecutive veterans age 64.1 yr (11.0 yr) (mean (SD)), of whom 253 also underwent myocardial perfusion imaging (MPI). Patients were categorized by frequency distributions of quartiles of percentage age-predicted peak heart rate (APPHR), heart rate reserve (HRR), and peak heart rate-systolic blood pressure product (PRPP). Exercise-induced ST-segment depression, abnormal MPI findings, coronary revascularization, and 12.0-yr (1.3 yr) Kaplan-Meier all-cause and cardiovascular mortality plots were then characterized by quartiles of APPHR, HRR, and PRPP. Results: A reduced frequency of abnormal arm exercise ECG results was associated only with the lowest quartile of APPHR ([< or =]69%) and HRR ([< or =]43%), whereas higher frequency of abnormal MPI findings exhibited an inverse relationship trend with lower APPHR (P= 0.10) and HRR (P= 0.12). There was a strong inverse association of APPHR, HRR, and PRPP with all-cause (all P[< or =] 0.01) and cardiovascular (P< 0.05) mortality. The frequency of coronary revascularization was unrelated to APPHR or HRR. Conclusions: Arm exercise ECG stress test sensitivity is only reduced at [< or =]69% APPHR or [< or =]43% HRR, whereas arm exercise MPI sensitivity and referral for coronary revascularization after arm exercise stress testing are not adversely affected by even a severely blunted peak heart rate. However, both all-cause mortality and cardiovascular mortality are strongly and inversely related to APPHR and HRR. JF - Medicine & Science in Sports & Exercise AU - Hong, Xian AU - Weijian, Liu AU - Cynthia, Marshall AU - Pooja, Chandiramani AU - Emily, Bainter AU - Martin, Wade H AD - Division of Cardiology 111A/JC, St. Louis Veterans Administration Healthcare System, 915 North Grand, St. Louis, MO 63106, Wade.Martin@va.gov Y1 - 2016/09// PY - 2016 DA - September 2016 SP - 1648 EP - 1654 PB - Lippincott Williams & Wilkins, 530 Walnut Street Philadelphia PA 19106-3621 United States VL - 48 IS - 9 SN - 0195-9131, 0195-9131 KW - Physical Education Index KW - AGE-PREDICTED PEAK HEART RATE KW - CORONARY REVASCULARIZATION KW - HEART RATE RESERVE KW - MORTALITY KW - MYOCARDIAL PERFUSION IMAGING KW - STRESS TEST SENSITIVITY KW - Stress tests KW - Death KW - Heart rate (exercise effects) KW - Heart rate KW - Motor performance tests KW - Sport science KW - Cardiorespiratory KW - Patients KW - Electrocardiology KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1827882325?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Medicine+%26+Science+in+Sports+%26+Exercise&rft.atitle=The+Relation+of+Arm+Exercise+Peak+Heart+Rate+to+Stress+Test+Results+and+Outcome&rft.au=Hong%2C+Xian%3BWeijian%2C+Liu%3BCynthia%2C+Marshall%3BPooja%2C+Chandiramani%3BEmily%2C+Bainter%3BMartin%2C+Wade+H&rft.aulast=Hong&rft.aufirst=Xian&rft.date=2016-09-01&rft.volume=48&rft.issue=9&rft.spage=1648&rft.isbn=&rft.btitle=&rft.title=Medicine+%26+Science+in+Sports+%26+Exercise&rft.issn=01959131&rft_id=info:doi/10.1249%2FMSS.0000000000000971 LA - English DB - Physical Education Index N1 - Date revised - 2016-10-01 N1 - Last updated - 2016-10-12 N1 - SubjectsTermNotLitGenreText - Death; Stress tests; Heart rate (exercise effects); Heart rate; Sport science; Motor performance tests; Patients; Cardiorespiratory; Electrocardiology DO - http://dx.doi.org/10.1249/MSS.0000000000000971 ER - TY - JOUR T1 - Evaluation of safety climate and employee injury rates in healthcare AN - 1815709931; PQ0003596861 AB - ObjectivesSafety climates that support safety-related behaviour are associated with fewer work-related injuries, and prior research in industry suggests that safety knowledge and motivation are strongly related to safety performance behaviours; this relationship is not well studied in healthcare settings.MethodsWe performed analyses of survey results from a Veterans Health Administration (VHA) Safety Barometer employee perception survey, conducted among VHA employees in 2012. The employee perception survey assessed 6 safety programme categories, including management participation, supervisor participation, employee participation, safety support activities, safety support climate and organisational climate. We examined the relationship between safety climate from the survey results on VHA employee injury and illness rates.ResultsAmong VHA facilities in the VA New England Healthcare System, work-related injury rate was significantly and inversely related to overall employee perception of safety climate, and all 6 safety programme categories, including employee perception of employee participation, management participation, organisational climate, supervisor participation, safety support activities and safety support climate.ConclusionsPositive employee perceptions of safety climate in VHA facilities are associated with lower work-related injury and illness rates. Employee perception of employee participation, management participation, organisational climate, supervisor participation, safety support activities and safety support climate were all associated with lower work-related injury rates. Future implications include fostering a robust safety climate for patients and healthcare workers to reduce healthcare worker injuries. JF - Occupational and Environmental Medicine AU - Cook, Jacqueline M AU - Slade, Martin D AU - Cantley, Linda F AU - Sakr, Carine J AD - Veterans Administration Connecticut Healthcare System, Department of Veterans Affairs, Veterans Health Administration Y1 - 2016/09// PY - 2016 DA - September 2016 SP - 595 EP - 599 PB - B M J Publishing Group, B.M.A. House London WC1H 9JR United Kingdom VL - 73 IS - 9 SN - 1351-0711, 1351-0711 KW - Health & Safety Science Abstracts KW - Injuries KW - Health care KW - Perception KW - Safety KW - Climate KW - Barometers KW - Medical personnel KW - H 1000:Occupational Safety and Health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1815709931?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Occupational+and+Environmental+Medicine&rft.atitle=Evaluation+of+safety+climate+and+employee+injury+rates+in+healthcare&rft.au=Cook%2C+Jacqueline+M%3BSlade%2C+Martin+D%3BCantley%2C+Linda+F%3BSakr%2C+Carine+J&rft.aulast=Cook&rft.aufirst=Jacqueline&rft.date=2016-09-01&rft.volume=73&rft.issue=9&rft.spage=595&rft.isbn=&rft.btitle=&rft.title=Occupational+and+Environmental+Medicine&rft.issn=13510711&rft_id=info:doi/10.1136%2Foemed-2015-103218 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-08-01 N1 - Last updated - 2016-10-12 N1 - SubjectsTermNotLitGenreText - Health care; Injuries; Perception; Climate; Safety; Barometers; Medical personnel DO - http://dx.doi.org/10.1136/oemed-2015-103218 ER - TY - JOUR T1 - At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS) AN - 1815696785; PQ0003592073 AB - Effective management of patients using warfarin is resource-intensive, requiring frequent in-clinic testing of the international normalized ratio (INR). Patient self-testing (PST) using portable at-home INR monitoring devices has emerged as a convenient alternative. As revealed by The Home INR Study (THINRS), event rates for PST were not significantly different from those for in-clinic high-quality anticoagulation management (HQACM), and a cumulative gain in quality of life was observed for patients undergoing PST. To perform a cost-utility analysis of weekly PST versus monthly HQACM and to examine the sensitivity of these results to testing frequency. In this study, 2922 patients taking warfarin for atrial fibrillation or mechanical heart valve, and who demonstrated PST competence, were randomized to either weekly PST (n=1465) or monthly in-clinic testing (n=1457). In a sub-study, 234 additional patients were randomized to PST once every 4 weeks (n=116) or PST twice weekly (n=118). The endpoints were quality of life (measured by the Health Utilities Index), health care utilization, and costs over 2 years of follow-up. PST and HQACM participants were similar with regard to gender, age, and CHADS sub(2) score. The total cost per patient over 2 years of follow-up was $32,484 for HQACM and $33,460 for weekly PST, representing a difference of $976. The incremental cost per quality-adjusted life year gained with PST once weekly was $5566 (95 % CI, -$11,490 to $25,142). The incremental cost-effectiveness ratio (ICER) was sensitive to testing frequency: weekly PST dominated PST twice weekly and once every 4 weeks. Compared to HQACM, weekly PST was associated with statistically significant and clinically meaningful improvements in quality of life. The ICER for weekly PST versus HQACM was well within accepted standards for cost-effectiveness, and was preferred over more or less frequent PST. These results were robust to sensitivity analyses of key assumptions. Weekly PST is a cost-effective alternative to monthly HQACM and a preferred testing frequency compared to twice weekly or monthly PST. JF - Journal of General Internal Medicine AU - Phibbs, Ciaran S AU - Love, Sean R AU - Jacobson, Alan K AU - Edson, Robert AU - Su, Pon AU - Uyeda, Lauren AU - Matchar, David B AD - Health Economics Resource Center, VA Palo Alto Health Care System, Palo Alto, CA, USA, CiaranPhibbs@va.gov Y1 - 2016/09// PY - 2016 DA - September 2016 SP - 1061 EP - 1067 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 31 IS - 9 SN - 0884-8734, 0884-8734 KW - Biotechnology and Bioengineering Abstracts KW - Heart KW - Age KW - Fibrillation KW - Statistical analysis KW - Warfarin KW - Quality of life KW - W 30965:Miscellaneous, Reviews UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1815696785?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+General+Internal+Medicine&rft.atitle=At-Home+Versus+In-Clinic+INR+Monitoring%3A+A+Cost-Utility+Analysis+from+The+Home+INR+Study+%28THINRS%29&rft.au=Phibbs%2C+Ciaran+S%3BLove%2C+Sean+R%3BJacobson%2C+Alan+K%3BEdson%2C+Robert%3BSu%2C+Pon%3BUyeda%2C+Lauren%3BMatchar%2C+David+B&rft.aulast=Phibbs&rft.aufirst=Ciaran&rft.date=2016-09-01&rft.volume=31&rft.issue=9&rft.spage=1061&rft.isbn=&rft.btitle=&rft.title=Journal+of+General+Internal+Medicine&rft.issn=08848734&rft_id=info:doi/10.1007%2Fs11606-016-3700-8 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-08-01 N1 - Number of references - 29 N1 - Last updated - 2016-09-29 N1 - SubjectsTermNotLitGenreText - Heart; Age; Fibrillation; Statistical analysis; Warfarin; Quality of life DO - http://dx.doi.org/10.1007/s11606-016-3700-8 ER - TY - JOUR T1 - Clearance of apoptotic neutrophils and resolution of inflammation. AN - 1814658308; 27558346 AB - The engulfment of apoptotic cells by phagocytes, a process referred to as efferocytosis, is essential for maintenance of normal tissue homeostasis and a prerequisite for the resolution of inflammation. Neutrophils are the predominant circulating white blood cell in humans, and contain an arsenal of toxic substances that kill and degrade microbes. Neutrophils are short-lived and spontaneously die by apoptosis. This review will highlight how the engulfment of apoptotic neutrophils by human phagocytes occurs, how heterogeneity of phagocyte populations influences efferocytosis signaling, and downstream consequences of efferocytosis. The efferocytosis of apoptotic neutrophils by macrophages promotes anti-inflammatory signaling, prevents neutrophil lysis, and dampens immune responses. Given the immunomodulatory properties of efferocytosis, understanding pathways that regulate and enhance efferocytosis could be harnessed to combat infection and chronic inflammatory conditions. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. JF - Immunological reviews AU - Greenlee-Wacker, Mallary C AD - Inflammation Program, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine University of Iowa, Veterans Administration Medical Center, Iowa City, IA, USA. Y1 - 2016/09// PY - 2016 DA - September 2016 SP - 357 EP - 370 VL - 273 IS - 1 KW - Index Medicus KW - inflammation KW - apoptosis KW - infection KW - neutrophil KW - efferocytosis KW - macrophages UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1814658308?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Immunological+reviews&rft.atitle=Clearance+of+apoptotic+neutrophils+and+resolution+of+inflammation.&rft.au=Greenlee-Wacker%2C+Mallary+C&rft.aulast=Greenlee-Wacker&rft.aufirst=Mallary&rft.date=2016-09-01&rft.volume=273&rft.issue=1&rft.spage=357&rft.isbn=&rft.btitle=&rft.title=Immunological+reviews&rft.issn=1600-065X&rft_id=info:doi/10.1111%2Fimr.12453 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-08-25 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1111/imr.12453 ER - TY - JOUR T1 - The Utility of Exercise Testing in Patients with Lung Cancer. AN - 1814648042; 27156441 AB - The harm associated with lung cancer treatment include perioperative morbidity and mortality and therapy-induced toxicities in various organs, including the heart and lungs. Optimal treatment therefore entails a need for risk assessment to weigh the probabilities of benefits versus harm. Exercise testing offers an opportunity to evaluate a patient's physical fitness/exercise capacity objectively. In lung cancer, it is most often used to risk-stratify patients undergoing evaluation for lung cancer resection. In recent years, its use outside this context has been described, including in nonsurgical candidates and lung cancer survivors. In this article we review the physiology of exercise testing and lung cancer. Then, we assess the utility of exercise testing in patients with lung cancer in four contexts (preoperative evaluation for lung cancer resection, after lung cancer resection, lung cancer prognosis, and assessment of efficiency of exercise training programs) after systematically identifying original studies involving the most common forms of exercise tests in this patient population: laboratory cardiopulmonary exercise testing and simple field testing with the 6-minute walk test, shuttle walk test, and/or stair-climbing test. Lastly, we propose a conceptual framework for risk assessment of patients with lung cancer who are being considered for therapy and identify areas for further studies in this patient population. Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved. JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer AU - Ha, Duc AU - Mazzone, Peter J AU - Ries, Andrew L AU - Malhotra, Atul AU - Fuster, Mark AD - Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California. Electronic address: d5ha@ucsd.edu. ; Respiratory Institute, Cleveland Clinic, Cleveland, Ohio. ; Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California. ; Division of Pulmonary, Critical Care, and Sleep Medicine, University of California San Diego, La Jolla, California; Pulmonary and Critical Care Medicine Section, Veterans Administration San Diego Healthcare System, San Diego, California. Y1 - 2016/09// PY - 2016 DA - September 2016 SP - 1397 EP - 1410 VL - 11 IS - 9 KW - Index Medicus KW - Stair-climbing test KW - Shuttle walk test KW - Exercise testing KW - Cardiopulmonary exercise testing KW - Six-minute walk test KW - Lung cancer UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1814648042?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.atitle=The+Utility+of+Exercise+Testing+in+Patients+with+Lung+Cancer.&rft.au=Ha%2C+Duc%3BMazzone%2C+Peter+J%3BRies%2C+Andrew+L%3BMalhotra%2C+Atul%3BFuster%2C+Mark&rft.aulast=Ha&rft.aufirst=Duc&rft.date=2016-09-01&rft.volume=11&rft.issue=9&rft.spage=1397&rft.isbn=&rft.btitle=&rft.title=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.issn=1556-1380&rft_id=info:doi/10.1016%2Fj.jtho.2016.04.021 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-08-27 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.jtho.2016.04.021 ER - TY - JOUR T1 - "I'm Coming Home, Tell the World I'm Coming Home". The Long Homecoming and Mental Health Treatment of Iraq and Afghanistan War Veterans AN - 1811252332 AB - This study explored the journey of American armed forces personnel from their decision to join the service, through their service in an active military conflict and how these factors may be associated with potential resistance for mental healthcare. The data came from qualitative interviews with 46 OIF/OEF/OND active-duty military, reservists, and discharged veterans of the average age of 25 years, who presented for a new episode of mental health treatment to a large Veterans Affairs Hospital (VAH) in Northeastern United States in 2011-2012. Qualitative analysis of veterans' perceptions revealed several major themes describing how a mental health diagnosis would negatively impact both their sense of identity and pragmatic career-building goals: enlisting as a career-building avenue, 'noble superhero' identity, escaping from hardship, and mental illness as a career-killer. Findings suggest that factors making young veterans resist mental healthcare may be reduced by partnering VAH psychiatrists with career counselors, and by enhancing military leadership's awareness and understanding about how to support soldiers with emotional and mental health needs, with a goal to eliminating stigma. JF - Psychiatric Quarterly AU - Rozanova, Julia AU - Noulas, Paraskevi AU - Smart, Kathleen AU - Roy, Alicia AU - Southwick, Steven M AU - Davidson, Larry AU - Harpaz-rotem, Ilan AD - Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA ; VA Connecticut Healthcare System, West Haven, CT, USA ; VA Connecticut Healthcare System, West Haven, CT, USA; United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, West Haven, CT, USA ; United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, West Haven, CT, USA; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA ; United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, West Haven, CT, USA; Yale Program for Recovery and Community Health, New Haven, CT, USA ; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA Y1 - 2016/09// PY - 2016 DA - Sep 2016 SP - 427 EP - 443 CY - New York PB - Springer Science & Business Media VL - 87 IS - 3 SN - 0033-2720 KW - Medical Sciences--Psychiatry And Neurology KW - Young US veterans KW - Mental healthcare resistance KW - Qualitative interviews KW - Sense of identity KW - Pragmatic career-building goals KW - Leadership KW - Soldiers KW - Discharged KW - Veterans KW - Military forces KW - Personnel KW - Stigmatization KW - Resistance KW - Health needs KW - Psychiatrists KW - Mental health services KW - Military personnel KW - Qualitative analysis KW - Diagnosis KW - Identity KW - Mental illness KW - United States--US KW - Afghanistan KW - Iraq UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1811252332?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychiatric+Quarterly&rft.atitle=%22I%27m+Coming+Home%2C+Tell+the+World+I%27m+Coming+Home%22.+The+Long+Homecoming+and+Mental+Health+Treatment+of+Iraq+and+Afghanistan+War+Veterans&rft.au=Rozanova%2C+Julia%3BNoulas%2C+Paraskevi%3BSmart%2C+Kathleen%3BRoy%2C+Alicia%3BSouthwick%2C+Steven+M%3BDavidson%2C+Larry%3BHarpaz-rotem%2C+Ilan&rft.aulast=Rozanova&rft.aufirst=Julia&rft.date=2016-09-01&rft.volume=87&rft.issue=3&rft.spage=427&rft.isbn=&rft.btitle=&rft.title=Psychiatric+Quarterly&rft.issn=00332720&rft_id=info:doi/10.1007%2Fs11126-015-9398-7 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Springer Science+Business Media New York 2016 N1 - Last updated - 2016-08-24 N1 - SubjectsTermNotLitGenreText - Afghanistan; United States--US; Iraq DO - http://dx.doi.org/10.1007/s11126-015-9398-7 ER - TY - JOUR T1 - Practical Disadvantage, Socioeconomic Status, and Psychological Well-Being Within Families of Children with Severe Emotional Disturbance AN - 1810994965 AB - Although socioeconomic status (SES) has been associated with a myriad of physical and psychological health indicators, it is arguably one of the most elusive constructs in the psychological literature. Most researchers agree that SES is complex and multidimensional; however, the majority of empirical studies that focus on SES do not measure (or attempt to measure) multiple components of the construct, instead focusing on one or two indicators of SES, most commonly household income and/or levels of education. This paper explores relationships among indicators of SES, disadvantage, and psychological well-being in two independent samples of families with children with severe emotional disturbances. In addition to utilizing two common SES indicators (parental education and income), we incorporated measures reflecting resource-related challenges of living, such as adequate food and housing. Based on analyses, we argue that such variables may better capture the challenges experienced by many families than traditional SES indicators. Findings also suggest that income and education relate to different aspects of family well-being, and solely using one or both of these variables may mask relevant relationships. Moreover, assessing practical, day-to-day challenges may permit a more nuanced picture of the relationships between factors associated with SES and indicators of well-being and adjustment. JF - Journal of Child and Family Studies AU - Munsell, Eylin Palamaro AU - Kilmer, Ryan P AU - Vishnevsky, Tanya AU - Cook, James R AU - Markley, Lauren M AD - University of North Carolina Charlotte, Charlotte, NC, USA; Arizona State University Colleges at Lake Havasu City, Lake Havasu City, AZ, USA ; University of North Carolina Charlotte, Charlotte, NC, USA ; University of North Carolina Charlotte, Charlotte, NC, USA; Providence Behavioral Health Associates, Providence, RI, USA ; El Paso Veterans Administration Healthcare System, El Paso, TX, USA ; University of North Carolina Charlotte, Charlotte, NC, USA; Arizona State University Colleges at Lake Havasu City, Lake Havasu City, AZ, USA Y1 - 2016/09// PY - 2016 DA - Sep 2016 SP - 2832 EP - 2842 CY - New York PB - Springer Science & Business Media VL - 25 IS - 9 SN - 1062-1024 KW - Psychology KW - Socioeconomic status KW - Family wellbeing KW - Poverty KW - Education KW - Income KW - Emotional disturbance KW - Healthy food KW - Health status KW - Emotionally disturbed children KW - Health indicators KW - Mental health KW - Psychological wellbeing KW - Housing UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1810994965?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+Journal+of+Sports+Medicine&rft.atitle=Effect+of+Rotator+Cuff+Muscle+Imbalance+on+Forceful+Internal+Impingement+and+Peel-Back+of+the+Superior+Labrum.+A+Cadaveric+Study&rft.au=Mihata%2C+Teruhisa%3BGates%2C+Jeffrey%3BMcGarry%2C+Michelle+H%3BLee%2C+Jason%3BKinoshita%2C+Mitsuo%3BLee%2C+Thay+Q&rft.aulast=Mihata&rft.aufirst=Teruhisa&rft.date=2009-11-01&rft.volume=37&rft.issue=11&rft.spage=2222&rft.isbn=&rft.btitle=&rft.title=American+Journal+of+Sports+Medicine&rft.issn=03635465&rft_id=info:doi/10.1177%2F0363546509337450 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Springer Science+Business Media New York 2016 N1 - Last updated - 2016-10-12 DO - http://dx.doi.org/10.1007/s10826-016-0449-y ER - TY - JOUR T1 - A Lens Model Approach to the Communication of Pain AN - 1808612966; PQ0003266872 AB - Two studies examined the expression and detection of suppressed, genuine, and exaggerated pain. In Study 1, videotaped participants underwent an acute laboratory pain stressor and completed pain ratings. In Study 2, the lens model examined the cues encoders displayed while in pain (facial expressions of pain and viewers' global impressions), the cues decoders used to infer pain in the videotaped encoders, and decoders' accuracy in making judgments of pain. Results revealed expression differences between the suppressed, genuine, and exaggerated pain such that exaggerated expressions contained more tightened facial expressions while genuine expressions of pain contained more open facial expressions of pain. Decoders were accurate at detecting pain only in the exaggerated pain expressions. These results highlight the need for improving providers' accuracy in detecting pain intensity for suppressed, genuine, and exaggerated pain displays. Trainings should focus on teaching providers that patients who appear more agitated and less composed may be suppressing pain, while patients who appear more tense and determined may be exaggerating pain. Finally, patients who seem to not be in that much pain because they are not showing tightened facial expressions may actually be experiencing higher intensities of genuine pain. JF - Health Communication AU - Ruben, Mollie A AU - Hall, Judith A AD - Center for Healthcare Organization and Implementation Research, U.S. Department of Veterans Affairs Y1 - 2016/08/02/ PY - 2016 DA - 2016 Aug 02 SP - 934 EP - 945 PB - Taylor & Francis Group Ltd., 2 Park Square Oxford OX14 4RN United Kingdom VL - 31 IS - 8 SN - 1041-0236, 1041-0236 KW - Environment Abstracts KW - Communications KW - Training KW - Pain KW - ENA 04:Environmental Education UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808612966?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=2009+Conference+on+Australasian+Professional+Society+on+Alcohol+and+other+Drugs+%28APSAD+2009%29&rft.atitle=Odds+ratios+of+externalizing+and+internalizing+disorders%3A+An+approach+to+service+design+within+and+across+cultures&rft.au=Westermeyer%2C+Joe&rft.aulast=Westermeyer&rft.aufirst=Joe&rft.date=2009-11-01&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=2009+Conference+on+Australasian+Professional+Society+on+Alcohol+and+other+Drugs+%28APSAD+2009%29&rft.issn=&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Last updated - 2016-08-04 N1 - SubjectsTermNotLitGenreText - Communications; Training; Pain DO - http://dx.doi.org/10.1080/10410236.2015.1020261 ER - TY - JOUR T1 - Through Their Eyes AN - 1851151708 AB - In this methodological article, we examine participatory methods in depth to demonstrate how these methods can be adopted for quality improvement (QI) projects in health care. We draw on existing literature and our QI initiatives in the Department of Veterans Affairs to discuss the application of photovoice and guided tours in QI efforts. We highlight lessons learned and several benefits of using participatory methods in this area. Using participatory methods, evaluators can engage patients, providers, and other stakeholders as partners to enhance care. Participant involvement helps yield actionable data that can be translated into improved care practices. Use of these methods also helps generate key insights to inform improvements that truly resonate with stakeholders. Using participatory methods is a valuable strategy to harness participant engagement and drive improvements that address individual needs. In applying these innovative methodologies, evaluators can transcend traditional approaches to uniquely support evaluations and improvements in health care. JF - Qualitative Health Research AU - Balbale, Salva N AU - Locatelli, Sara M AU - LaVela, Sherri L AD - U.S. Department of Veterans Affairs, Hines, Illinois, USA ; U.S. Department of Veterans Affairs, Hines, Illinois, USA Y1 - 2016/08// PY - 2016 DA - Aug 2016 SP - 1382 EP - 1392 CY - Thousand Oaks PB - SAGE PUBLICATIONS, INC. VL - 26 IS - 10 SN - 1049-7323 KW - Medical Sciences KW - health care KW - guided tours KW - participatory action research (PAR) KW - photography KW - photovoice KW - qualitative KW - United States KW - Quality management KW - Veterans KW - Stakeholders KW - Photography KW - Health care KW - Health initiatives UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1851151708?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Qualitative+Health+Research&rft.atitle=Through+Their+Eyes&rft.au=Balbale%2C+Salva+N%3BLocatelli%2C+Sara+M%3BLaVela%2C+Sherri+L&rft.aulast=Balbale&rft.aufirst=Salva&rft.date=2016-08-01&rft.volume=26&rft.issue=10&rft.spage=1382&rft.isbn=&rft.btitle=&rft.title=Qualitative+Health+Research&rft.issn=10497323&rft_id=info:doi/10.1177%2F1049732315618386 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © The Author(s) 2015 N1 - Last updated - 2017-01-06 DO - http://dx.doi.org/10.1177/1049732315618386 ER - TY - JOUR T1 - Somatic mutations in histiocytic sarcoma identified by next generation sequencing AN - 1815709373; PQ0003589986 AB - Histiocytic sarcoma is a rare malignant neoplasm of presumed hematopoietic origin showing morphologic and immunophenotypic evidence of histiocytic differentiation. Somatic mutation importance in the pathogenesis or disease progression of histiocytic sarcoma was largely unknown. To identify somatic mutations in histiocytic sarcoma, we studied 5 histiocytic sarcomas [3 female and 2 male patients; mean age 54.8 (20-72), anatomic sites include lymph node, uterus, and pleura] and matched normal tissues from each patient as germ line controls. Somatic mutations in 50 "Hotspot" oncogenes and tumor suppressor genes were examined using next generation sequencing. Three (out of five) histiocytic sarcoma cases carried somatic mutations in BRAF. Among them, G464V [variant frequency (VF) of 43.6 %] and G466R (VF of 29.6 %) located at the P loop potentially interfere with the hydrophobic interaction between P and activating loops and ultimately activation of BRAF. Also detected was BRAF somatic mutation N581S (VF of 7.4 %), which was located at the catalytic loop of BRAF kinase domain: its role in modifying kinase activity was unclear. A similar mutational analysis was also performed on nine acute monocytic/monoblastic leukemia cases, which did not identify any BRAF somatic mutations. Our study detected several BRAF mutations in histiocytic sarcomas, which may be important in understanding the tumorigenesis of this rare neoplasm and providing mechanisms for potential therapeutical opportunities. JF - Virchows Archiv. A. Pathological Anatomy and Histology AU - Liu, Qingqing AU - Tomaszewicz, Keith AU - Hutchinson, Lloyd AU - Hornick, Jason L AU - Woda, Bruce AU - Yu, Hongbo AD - Department of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA, Hongbo.Yu@va.gov Y1 - 2016/08// PY - 2016 DA - August 2016 SP - 233 EP - 241 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 469 IS - 2 SN - 0945-6317, 0945-6317 KW - Biotechnology and Bioengineering Abstracts KW - Tumor suppressor genes KW - Uterus KW - Tumorigenesis KW - Hydrophobicity KW - Lymph nodes KW - Differentiation KW - Leukemia KW - Pleura KW - Oncogenes KW - Sarcoma KW - Hemopoiesis KW - Monocytes KW - Mutation KW - W 30965:Miscellaneous, Reviews UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1815709373?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Virchows+Archiv.+A.+Pathological+Anatomy+and+Histology&rft.atitle=Somatic+mutations+in+histiocytic+sarcoma+identified+by+next+generation+sequencing&rft.au=Liu%2C+Qingqing%3BTomaszewicz%2C+Keith%3BHutchinson%2C+Lloyd%3BHornick%2C+Jason+L%3BWoda%2C+Bruce%3BYu%2C+Hongbo&rft.aulast=Liu&rft.aufirst=Qingqing&rft.date=2016-08-01&rft.volume=469&rft.issue=2&rft.spage=233&rft.isbn=&rft.btitle=&rft.title=Virchows+Archiv.+A.+Pathological+Anatomy+and+Histology&rft.issn=09456317&rft_id=info:doi/10.1007%2Fs00428-016-1965-2 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-08-01 N1 - Number of references - 34 N1 - Last updated - 2016-09-29 N1 - SubjectsTermNotLitGenreText - Tumor suppressor genes; Uterus; Tumorigenesis; Hydrophobicity; Lymph nodes; Pleura; Leukemia; Differentiation; Oncogenes; Sarcoma; Hemopoiesis; Monocytes; Mutation DO - http://dx.doi.org/10.1007/s00428-016-1965-2 ER - TY - JOUR T1 - A randomized trial of a pain management intervention for adults receiving substance use disorder treatment AN - 1811905658; PQ0003466126 AB - Background and Aims Chronic pain is difficult to treat in individuals with substance use disorders and, when not resolved, can have a negative impact on substance use disorder treatment outcomes. This study tested the efficacy of a psychosocial pain management intervention, ImPAT (improving pain during addiction treatment), that combines pain management with content related to managing pain without substance use. Design Single-site, parallel-groups randomized controlled trial comparing ImPAT to a supportive psychoeducational control (SPC) condition; follow-up assessments occurred at 3, 6 and 12 months. Setting The Ann Arbor VA Substance Use Disorder treatment program, USA. Participants Veterans Health Administration patients {n = 129; mean [standard deviation (SD)], age = 51.7 (9.5); 115 of 129 (89%) male; ImPAT (n = 65); SPC (n = 64)}. Intervention ImPAT combines principles of cognitive-behavioral therapy and acceptance-based approaches to pain management with content related to avoiding the use of substances as a coping mechanism for pain. The SPC used a psychoeducational attention control treatment for alcoholism modified to cover other substances in addition to alcohol. Measurements Primary: Pain intensity over 12 months; secondary: pain-related functioning, frequency of alcohol and drug use over 12 months. Findings Primary: randomization to the ImPAT intervention versus SPC predicted significantly lower pain intensity { beta [standard error (SE)] = -0.71 (0.29); 95% confidence interval (CI) = -1.29, -0.12}; secondary: relative to the SPC condition, those who received ImPAT also reported improved pain-related functioning [ beta (SE) = 0.27 (0.11); 95% CI = 0.05, 0.49] and lower frequency of alcohol consumption [ beta (SE) = -0.77; 95% CI = -1.34, -0.20]. No differences were found between conditions on frequency of drug use over follow-up. Conclusions For adults with pain who are enrolled in addictions treatment, receipt of a psychological pain management intervention (improving pain during addiction treatment) reduced pain and alcohol use and improves pain-related functioning over 12 months relative to a matched-attention control condition. JF - Addiction AU - Ilgen, Mark A AU - Bohnert, Amy SB AU - Chermack, Stephen AU - Conran, Carly AU - Jannausch, Mary AU - Trafton, Jodie AU - Blow, Frederic C AD - VA Center for Clinical Management Research (CCMR), Veterans Health Administration, Ann Arbor, MI, USA. Y1 - 2016/08// PY - 2016 DA - August 2016 SP - 1385 EP - 1393 PB - Wiley-Blackwell, 111 River Street Hoboken NJ 07030-5774 United States VL - 111 IS - 8 SN - 0965-2140, 0965-2140 KW - Physical Education Index KW - Evaluation KW - Alcohol KW - Measurement KW - Objectives KW - Pain KW - Addiction KW - Adults KW - Drugs KW - Self efficacy KW - PE 140:Business, Marketing & Sports Equipment UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1811905658?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Addiction&rft.atitle=A+randomized+trial+of+a+pain+management+intervention+for+adults+receiving+substance+use+disorder+treatment&rft.au=Ilgen%2C+Mark+A%3BBohnert%2C+Amy+SB%3BChermack%2C+Stephen%3BConran%2C+Carly%3BJannausch%2C+Mary%3BTrafton%2C+Jodie%3BBlow%2C+Frederic+C&rft.aulast=Ilgen&rft.aufirst=Mark&rft.date=2016-08-01&rft.volume=111&rft.issue=8&rft.spage=1385&rft.isbn=&rft.btitle=&rft.title=Addiction&rft.issn=09652140&rft_id=info:doi/10.1111%2Fadd.13349 LA - English DB - Physical Education Index N1 - Date revised - 2016-08-01 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Evaluation; Measurement; Alcohol; Objectives; Pain; Adults; Addiction; Drugs; Self efficacy DO - http://dx.doi.org/10.1111/add.13349 ER - TY - JOUR T1 - Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis. AN - 1805767479; 27031380 AB - The mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway is an essential component of innate immunity necessary for mediating proinflammatory responses in the setting of sepsis. We previously demonstrated that the mitogen-activated protein kinase 1/2 inhibitor trametinib prevents endotoxin-induced renal injury in mice. We therefore assessed efficacy of trametinib in a more clinically relevant experimental model of sepsis. Controlled in vivo laboratory study. University animal research laboratory. Male C57BL/6 mice. Mice were subjected to cecal ligation and puncture to induce sepsis or underwent sham operation as controls. Six hours after cecal ligation and puncture, mice were randomized to four experimental groups as follows: 1) sham control; 2) sham control + trametinib (1 mg/kg, IP); 3) cecal ligation and puncture; and 4) cecal ligation and puncture + trametinib. All animals received buprenorphine (0.05 mg/kg, SC) and imipenem/cilastatin (14 mg/kg, SC) in 1.5 mL of warm saline (40 mL/kg) at the 6-hour time point. Mice were euthanized at 18 hours after induction of cecal ligation and puncture. Trametinib inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase signaling 6 hours after cecal ligation and puncture attenuated increases in circulating proinflammatory cytokines (tumor necrosis factor-α, interleukin-1β, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours. Trametinib also attenuated multiple organ injury as determined by serum creatinine, alanine aminotransferase, lactate dehydrogenase, and creatine kinase. At the organ level, trametinib completely restored peritubular capillary perfusion in the kidney. Restoration of microvascular perfusion was associated with reduced messenger RNA expression of well-characterized markers of proximal tubule injury. mitogen-activated protein kinase/extracellular signal-regulated kinase blockade attenuated cecal ligation and puncture-mediated up-regulation of cytokines (tumor necrosis factor-α, interleukin-1β) and restored interleukin-6 to control levels in the renal cortex, indicating the protective effects on the proximal tubule occur primarily through modulation of the proinflammatory response in sepsis. These data reveal that the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor trametinib attenuates systemic inflammation and multiple organ damage in a clinically relevant model of sepsis. Because trametinib has been safely used in humans, we propose that this drug might represent a translatable approach to limit organ injury in septic patients. JF - Critical care medicine AU - Smith, Joshua A AU - Mayeux, Philip R AU - Schnellmann, Rick G AD - 1Department of Medicine, University of Colorado Denver, Aurora, CO. 2Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR. 3Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC. Y1 - 2016/08// PY - 2016 DA - August 2016 SP - e711 EP - e720 VL - 44 IS - 8 KW - Abridged Index Medicus KW - Index Medicus UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1805767479?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Critical+care+medicine&rft.atitle=Delayed+Mitogen-Activated+Protein+Kinase%2FExtracellular+Signal-Regulated+Kinase+Inhibition+by+Trametinib+Attenuates+Systemic+Inflammatory+Responses+and+Multiple+Organ+Injury+in+Murine+Sepsis.&rft.au=Smith%2C+Joshua+A%3BMayeux%2C+Philip+R%3BSchnellmann%2C+Rick+G&rft.aulast=Smith&rft.aufirst=Joshua&rft.date=2016-08-01&rft.volume=44&rft.issue=8&rft.spage=e711&rft.isbn=&rft.btitle=&rft.title=Critical+care+medicine&rft.issn=1530-0293&rft_id=info:doi/10.1097%2FCCM.0000000000001672 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-07-19 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1097/CCM.0000000000001672 ER - TY - JOUR T1 - MicroRNA-19a/b mediates grape seed procyanidin extract-induced anti-neoplastic effects against lung cancer. AN - 1805483646; 27289489 AB - Oncomirs are microRNAs (miRNA) associated with carcinogenesis and malignant transformation. They have emerged as potential molecular targets for anti-cancer therapy. We hypothesize that grape seed procyanidin extract (GSE) exerts antineoplastic effects through modulations of oncomirs and their downstream targets. We found that GSE significantly down-regulated oncomirs miR-19a and -19b in a variety of lung neoplastic cells. GSE also increased mRNA and protein levels of insulin-like growth factor II receptor (IGF-2R) and phosphatase and tensin homolog (PTEN), both predicted targets of miR-19a and -19b. Furthermore, GSE significantly increased PTEN activity and decreased AKT phosphorylation in A549 cells. Transfection of miR-19a and -19b mimics reversed the up-regulations of IGF2R and PTEN gene expression and abrogated the GSE induced anti-proliferative response. Additionally, oral administration of leucoselect phytosome, comprised of standardized grape seed oligomeric procyanidins complexed with soy phospholipids, to athymic nude mice via gavage, significantly down-regulated miR-19a, -19b and the miR-17-92 cluster host gene (MIR17HG) expressions, increased IGF-2R, PTEN, decreased phosphorylated-AKT in A549 xenograft tumors, and markedly inhibited tumor growth. To confirm the absorption of orally administered GSE, plasma procyanidin B1 levels, between 60 and 90 min after gavage of leucoselect phytosome (400 mg/kg), were measured by LC/MS at week 2 and 8 of treatment; the estimated concentration that was associated with 50% growth inhibition (IC50) (1.3 μg/mL) in vitro was much higher than the IC50 (0.032-0.13 μg/ml) observed in vivo. Our findings reveal novel antineoplastic mechanisms by GSE and support the clinical translation of leucoselect phytosome as an anti-neoplastic and chemopreventive agent for lung cancer. Published by Elsevier Inc. JF - The Journal of nutritional biochemistry AU - Mao, Jenny T AU - Xue, Bingye AU - Smoake, Jane AU - Lu, Qing-Yi AU - Park, Heesung AU - Henning, Susanne M AU - Burns, Windie AU - Bernabei, Alvise AU - Elashoff, David AU - Serio, Kenneth J AU - Massie, Larry AD - Pulmonary, Critical Care, and Sleep Section, New Mexico Veterans Administration Health Care System, University of New, Mexico. Electronic address: jenny.mao@va.gov. ; Pulmonary, Critical Care, and Sleep Section, New Mexico Veterans Administration Health Care System, University of New, Mexico. ; UCLA Center for Human Nutrition, David Geffen School of Medicine at UCLA. ; Pathology and Clinical Laboratory Services, New Mexico Veterans Administration Health Care System, University of New, Mexico. ; Cardiothoracic Surgery Section, New Mexico Veterans Administration Health Care System, University of New, Mexico. ; Department of Biostatistics, Department of Medicine, David Geffen School of Medicine at UCLA. ; Pulmonary & Critical Care Medicine, Scripps Green Hospital. Y1 - 2016/08// PY - 2016 DA - August 2016 SP - 118 EP - 125 VL - 34 KW - Index Medicus KW - Grape seed procyanidin B1 bioavailability KW - MiRNA KW - IGF-2R KW - AKT KW - PTEN UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1805483646?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+nutritional+biochemistry&rft.atitle=MicroRNA-19a%2Fb+mediates+grape+seed+procyanidin+extract-induced+anti-neoplastic+effects+against+lung+cancer.&rft.au=Mao%2C+Jenny+T%3BXue%2C+Bingye%3BSmoake%2C+Jane%3BLu%2C+Qing-Yi%3BPark%2C+Heesung%3BHenning%2C+Susanne+M%3BBurns%2C+Windie%3BBernabei%2C+Alvise%3BElashoff%2C+David%3BSerio%2C+Kenneth+J%3BMassie%2C+Larry&rft.aulast=Mao&rft.aufirst=Jenny&rft.date=2016-08-01&rft.volume=34&rft.issue=&rft.spage=118&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+nutritional+biochemistry&rft.issn=1873-4847&rft_id=info:doi/10.1016%2Fj.jnutbio.2016.05.003 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-07-18 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.jnutbio.2016.05.003 ER - TY - JOUR T1 - Edentulism and transplant-associated complications in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. AN - 1799559262; 26984247 AB - Patients undergoing autologous hematopoietic stem cell transplantation (HSCT) are at risk for oral complications which may cause significant morbidity. The aim of this study was to compare the incidence of toxicities and complications in edentulous and dentate patients undergoing autologous HSCT for multiple myeloma. We conducted a retrospective case-control study to analyze the incidence of bacteremia, fever, and oral mucositis, between edentulous and dentate patients. All patients underwent dental evaluation, received dental treatment if indicated, and were cleared before transplantation. The two groups were matched for age, gender, ethnicity, disease stage, time from diagnosis to transplant, performance status, and conditioning regimen. A total of 45 edentulous and 90 dentate patients were enrolled. All patients were male with a median age of 60 years and a mean performance status by Karnofsky score of 90 %. Two thirds had stage III MM with a median time from diagnosis to transplantation of 12 months, and all received melphalan as part of the conditioning regimen. The incidence of bacteremia (p = 0.553), fever (p = 0.245), severity of oral mucositis (p = 0.465), and other post-transplant toxicities were similar between both groups. There were no significant differences in the incidence of bacteremia, fever, severity of oral mucositis, or other complications between edentulous and dentate patients with multiple myeloma after autologous HSCT. JF - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer AU - Toro, Juan Jose AU - Gushiken, Francisca Cecilia AU - Schneider, Deanna AU - Lee, Shuko AU - Haile, David Johannes AU - Freytes, Cesar Ovidio AD - Audie L. Murphy Memorial Veterans Hospital, South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX, 78229, USA. Juan.toro2@va.gov. ; Audie L. Murphy Memorial Veterans Hospital, South Texas Veterans Health Care System, 7400 Merton Minter Blvd., San Antonio, TX, 78229, USA. Y1 - 2016/08// PY - 2016 DA - August 2016 SP - 3411 EP - 3415 VL - 24 IS - 8 KW - Index Medicus KW - Post-transplant toxicities KW - Multiple myeloma KW - Oral complications KW - Autologous hematopoietic stem cell transplantation KW - Edentulous KW - Dentate UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1799559262?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Supportive+care+in+cancer+%3A+official+journal+of+the+Multinational+Association+of+Supportive+Care+in+Cancer&rft.atitle=Edentulism+and+transplant-associated+complications+in+patients+with+multiple+myeloma+undergoing+autologous+hematopoietic+stem+cell+transplantation.&rft.au=Toro%2C+Juan+Jose%3BGushiken%2C+Francisca+Cecilia%3BSchneider%2C+Deanna%3BLee%2C+Shuko%3BHaile%2C+David+Johannes%3BFreytes%2C+Cesar+Ovidio&rft.aulast=Toro&rft.aufirst=Juan&rft.date=2016-08-01&rft.volume=24&rft.issue=8&rft.spage=3411&rft.isbn=&rft.btitle=&rft.title=Supportive+care+in+cancer+%3A+official+journal+of+the+Multinational+Association+of+Supportive+Care+in+Cancer&rft.issn=1433-7339&rft_id=info:doi/10.1007%2Fs00520-016-3168-4 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-06-23 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1007/s00520-016-3168-4 ER - TY - JOUR T1 - Religious Well-Being and Suicide Ideation in Veterans - An Exploratory Study AN - 1798991861 AB - Religious well-being is a multi-faceted construct posited as a protective factor against suicidal thoughts and behaviors. This cross-sectional, exploratory study used religious practice data collected from n=5378 U.S. military veterans to create composite measures of private and public religious practice. These composite measures were subsequently used to determine the probability of being identified with a history of suicide ideation. Data analysis was conducted using logistic regression. Veterans with a history of suicide ideation made up 10.2 % (n=549) of the sample. Such veterans had significantly lower mean public and private religiosity scores compared to those without ideation. Differences between these two composite measures of religiosity were associated with a higher probability of being identified with a history of suicide ideation. The present study adds to the extant literature by presenting a framework for interpreting religious well-being in the context of religious practice. Quantitative differences in engagement between private and public practices may be indicative of a decreased sense of religious well-being, conferring less protection against suicidal behavior. JF - Pastoral Psychology AU - Kopacz, Marek S AU - Morley, Sybil W AU - Woniak, Barbara M AU - Simons, Kelsey V AU - Bishop, Todd M AU - Vance, C Garland AD - U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, USA ; Department of Medical Sociology, Jagiellonian University Medical College, Kraków, Poland ; U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, USA; University of Rochester Medical Center, Rochester, NY, USA ; U.S. Department of Veterans Affairs, Charles George VA Medical Center, Asheville, NC, USA Y1 - 2016/08// PY - 2016 DA - Aug 2016 SP - 481 EP - 491 CY - New York PB - Springer Science & Business Media VL - 65 IS - 4 SN - 0031-2789 KW - Religions And Theology KW - Veterans KW - Suicide ideation KW - Religious practice KW - Religious well-being KW - Protective factors KW - Religious aspects KW - Wellbeing KW - Suicidal behaviour KW - Suicidal ideation KW - Suicide KW - Religiosity KW - United States--US UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1798991861?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Pastoral+Psychology&rft.atitle=Religious+Well-Being+and+Suicide+Ideation+in+Veterans+-+An+Exploratory+Study&rft.au=Kopacz%2C+Marek+S%3BMorley%2C+Sybil+W%3BWoniak%2C+Barbara+M%3BSimons%2C+Kelsey+V%3BBishop%2C+Todd+M%3BVance%2C+C+Garland&rft.aulast=Kopacz&rft.aufirst=Marek&rft.date=2016-08-01&rft.volume=65&rft.issue=4&rft.spage=481&rft.isbn=&rft.btitle=&rft.title=Pastoral+Psychology&rft.issn=00312789&rft_id=info:doi/10.1007%2Fs11089-016-0699-z LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Springer Science+Business Media New York 2016 N1 - Last updated - 2016-06-29 N1 - SubjectsTermNotLitGenreText - United States--US DO - http://dx.doi.org/10.1007/s11089-016-0699-z ER - TY - JOUR T1 - Examining the differences in current regulatory processes for sunscreens and proposed safety assessment paradigm. AN - 1794469003; 27016397 AB - Skin cancers including malignant melanoma which are due to UV radiation constitute a serious public health problem. Recent studies have confirmed the importance of UVA radiation in the pathogenesis of skin cancer, as well as the protective effects of broad-spectrum sunscreen use. Barriers for effective protection of the US public include the lack of effective UV filters, especially in the UVA spectrum. The major reason for the paucity of UVA-effective filters in the US is due primarily to the FDA's reluctance to approve agents which have already been on the market in Europe and elsewhere in the world for more than a decade. The underlying reasons for these discrepancies in new sunscreen approval success between the US and abroad are complex, and include factors such as that the FDA considers UV filters as drugs, whereas they are regulated as cosmetics elsewhere. FDA has not as yet developed a consistent approach for the approval of new UV filters. We provide a paradigm for both non-clinical testing and human safety testing which includes parameters for a human maximum use test (MUsT) that is based upon both ethical and scientific concepts. These suggestions could form the basis of future regulatory guidelines for rational testing thus allowing us to reach the consensus goal of more efficient and timely approval of much-needed UV filters to provide protection for the US public. Copyright © 2016 Elsevier Inc. All rights reserved. JF - Regulatory toxicology and pharmacology : RTP AU - Sargent, Edward V AU - Travers, Jeffrey B AD - Rutgers University, School of Public Health, Piscataway, NJ, USA. Electronic address: evsargent@gmail.com. ; Wright State University, Dayton, OH, USA; Dayton Veterans Administration Medical Center, Dayton, OH, USA. Electronic address: Jeffrey.travers@wright.edu. Y1 - 2016/08// PY - 2016 DA - August 2016 SP - 125 EP - 141 VL - 79 KW - Index Medicus KW - Safety testing KW - Non-clinical KW - Human KW - UV filters KW - Sunscreens KW - Skin cancer UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1794469003?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.atitle=Examining+the+differences+in+current+regulatory+processes+for+sunscreens+and+proposed+safety+assessment+paradigm.&rft.au=Sargent%2C+Edward+V%3BTravers%2C+Jeffrey+B&rft.aulast=Sargent&rft.aufirst=Edward&rft.date=2016-08-01&rft.volume=79&rft.issue=&rft.spage=125&rft.isbn=&rft.btitle=&rft.title=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.issn=1096-0295&rft_id=info:doi/10.1016%2Fj.yrtph.2016.03.008 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-06-06 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.yrtph.2016.03.008 ER - TY - JOUR T1 - A Lens Model Approach to the Communication of Pain AN - 1792708495 AB - Two studies examined the expression and detection of suppressed, genuine, and exaggerated pain. In Study 1, videotaped participants underwent an acute laboratory pain stressor and completed pain ratings. In Study 2, the lens model examined the cues encoders displayed while in pain (facial expressions of pain and viewers' global impressions), the cues decoders used to infer pain in the videotaped encoders, and decoders' accuracy in making judgments of pain. Results revealed expression differences between the suppressed, genuine, and exaggerated pain such that exaggerated expressions contained more tightened facial expressions while genuine expressions of pain contained more open facial expressions of pain. Decoders were accurate at detecting pain only in the exaggerated pain expressions. These results highlight the need for improving providers' accuracy in detecting pain intensity for suppressed, genuine, and exaggerated pain displays. Trainings should focus on teaching providers that patients who appear more agitated and less composed may be suppressing pain, while patients who appear more tense and determined may be exaggerating pain. Finally, patients who seem to not be in that much pain because they are not showing tightened facial expressions may actually be experiencing higher intensities of genuine pain. JF - Health Communication AU - Ruben, Mollie A AU - Hall, Judith A AD - Center for Healthcare Organization and Implementation Research, U.S. Department of Veterans Affairs ; Department of Psychology, Northeastern University Y1 - 2016/08// PY - 2016 DA - Aug 2016 SP - 934 EP - 945 CY - Mahwah PB - Taylor & Francis Ltd. VL - 31 IS - 8 SN - 1041-0236 KW - Public Health And Safety KW - Pain KW - Accuracy KW - Cues KW - Detection KW - Displays KW - Facial expressions KW - Impressions KW - Judgments KW - Suppressed KW - Teaching KW - Viewers KW - Communication UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1792708495?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Health+Communication&rft.atitle=A+Lens+Model+Approach+to+the+Communication+of+Pain&rft.au=Ruben%2C+Mollie+A%3BHall%2C+Judith+A&rft.aulast=Ruben&rft.aufirst=Mollie&rft.date=2016-08-01&rft.volume=31&rft.issue=8&rft.spage=934&rft.isbn=&rft.btitle=&rft.title=Health+Communication&rft.issn=10410236&rft_id=info:doi/10.1080%2F10410236.2015.1020261 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © 2016 Taylor & Francis N1 - Last updated - 2016-06-01 DO - http://dx.doi.org/10.1080/10410236.2015.1020261 ER - TY - JOUR T1 - Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis. AN - 1804867546; 26927663 AB - The approaches aimed at inhibiting the ability of cancer cells to repair DNA strand breaks have emerged as promising targets for treating cancers. Here, we assessed the potential of imipramine blue (IB), a novel analogue of antidepressant imipramine, to suppress breast cancer growth and metastasis by inhibiting the ability of breast cancer cells to repair DNA strand breaks by homologous recombination (HR). The effect of IB on breast cancer growth and metastasis was assessed in vitro as well as in preclinical mouse models. Besides, the therapeutic efficacy and safety of IB was determined in ex vivo explants from breast cancer patients. The mechanism of action of IB was evaluated by performing gene-expression, drug-protein interaction, cell-cycle, and DNA repair studies. We show that the systemic delivery of IB using nanoparticle-based delivery approach suppressed breast cancer growth and metastasis without inducing toxicity in preclinical mouse models. Using ex vivo explants from breast cancer patients, we demonstrated that IB inhibited breast cancer growth without affecting normal mammary epithelial cells. Furthermore, our mechanistic studies revealed that IB may interact and inhibit the activity of proto-oncogene FoxM1 and associated signaling that play critical roles in HR-mediated DNA repair. These findings highlight the potential of IB to be applied as a safe regimen for treating breast cancer patients. Given that FoxM1 is an established therapeutic target for several cancers, the identification of a compound that inhibits FoxM1- and FoxM1-mediated DNA repair has immense translational potential for treating many aggressive cancers. Clin Cancer Res; 22(14); 3524-36. ©2016 AACR. ©2016 American Association for Cancer Research. JF - Clinical cancer research : an official journal of the American Association for Cancer Research AU - Rajamanickam, Subapriya AU - Panneerdoss, Subbarayalu AU - Gorthi, Aparna AU - Timilsina, Santosh AU - Onyeagucha, Benjamin AU - Kovalskyy, Dmytro AU - Ivanov, Dmitri AU - Hanes, Martha A AU - Vadlamudi, Ratna K AU - Chen, Yidong AU - Bishop, Alexander J AU - Arbiser, Jack L AU - Rao, Manjeet K AD - Department of Cell and Structure Biology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Department of Biochemistry, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Department of Laboratory Animal Resources, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Department of Obstetrics and Gynecology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. Department of Epidemiology and Statistics, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. ; Emory School of Medicine, Atlanta, Georgia. Veterans Administration Medical Center, Atlanta, Georgia. ; Department of Cell and Structure Biology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. Greehey Children's Cancer Research Institute, The University of Texas Health Science Center at San Antonio, San Antonio, Texas. raom@uthscsa.edu. Y1 - 2016/07/15/ PY - 2016 DA - 2016 Jul 15 SP - 3524 EP - 3536 VL - 22 IS - 14 SN - 1078-0432, 1078-0432 KW - Index Medicus UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1804867546?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Clinical+cancer+research+%3A+an+official+journal+of+the+American+Association+for+Cancer+Research&rft.atitle=Inhibition+of+FoxM1-Mediated+DNA+Repair+by+Imipramine+Blue+Suppresses+Breast+Cancer+Growth+and+Metastasis.&rft.au=Rajamanickam%2C+Subapriya%3BPanneerdoss%2C+Subbarayalu%3BGorthi%2C+Aparna%3BTimilsina%2C+Santosh%3BOnyeagucha%2C+Benjamin%3BKovalskyy%2C+Dmytro%3BIvanov%2C+Dmitri%3BHanes%2C+Martha+A%3BVadlamudi%2C+Ratna+K%3BChen%2C+Yidong%3BBishop%2C+Alexander+J%3BArbiser%2C+Jack+L%3BRao%2C+Manjeet+K&rft.aulast=Rajamanickam&rft.aufirst=Subapriya&rft.date=2016-07-15&rft.volume=22&rft.issue=14&rft.spage=3524&rft.isbn=&rft.btitle=&rft.title=Clinical+cancer+research+%3A+an+official+journal+of+the+American+Association+for+Cancer+Research&rft.issn=10780432&rft_id=info:doi/10.1158%2F1078-0432.CCR-15-2535 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-07-16 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1158/1078-0432.CCR-15-2535 ER - TY - JOUR T1 - Meeting the Treatment Needs of Veterans with Substance Use Disorders AN - 1808626944; PQ0003359735 AB - Substance use disorder (SUD) treatment staff from the Brooklyn Veterans Administration Hospital and Samaritan Village describe current practices and challenges in treating the increasing Veteran population with SUD. Article addresses best practices for treating Veterans with SUDs, posttraumatic stress disorder, and traumatic brain injury complications; military sexual trauma; combat versus noncombat status; significance of period served (WW II, Korea, Vietnam, Kuwait/Iraq I, Iraq II, Afghanistan); active service obligations; treatment interventions for trauma survivors; gender treatment differences; medically assisted treatments, especially for those with pain issues; family involvement; benefit seeking; self-help Step 1's "surrender" and "powerlessness" terms; access to treatment issues; returning home adjustment; and coordinating interdisciplinary treatment services. JF - Alcoholism AU - Carroll, Jerome FX AU - Hall, Charles E AU - Kearse, Roy AU - Mooney, Michael AU - Potestivo, Jo AU - Forman, Nancy AD - Psychology Department/Ambulatory Substance Abuse Program, Brooklyn Veterans Administration Hospital, Brooklyn, New York, USA Y1 - 2016/07/02/ PY - 2016 DA - 2016 Jul 02 SP - 354 EP - 364 PB - Taylor & Francis Group Ltd., 2 Park Square Oxford OX14 4RN United Kingdom VL - 34 IS - 3 SN - 0734-7324, 0734-7324 KW - Toxicology Abstracts KW - Alcoholism KW - Pain KW - Traumatic brain injury KW - Drug abuse KW - Post-traumatic stress disorder KW - Hospitals KW - X 24380:Social Poisons & Drug Abuse UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808626944?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Alcoholism&rft.atitle=Meeting+the+Treatment+Needs+of+Veterans+with+Substance+Use+Disorders&rft.au=Carroll%2C+Jerome+FX%3BHall%2C+Charles+E%3BKearse%2C+Roy%3BMooney%2C+Michael%3BPotestivo%2C+Jo%3BForman%2C+Nancy&rft.aulast=Carroll&rft.aufirst=Jerome&rft.date=2016-07-02&rft.volume=34&rft.issue=3&rft.spage=354&rft.isbn=&rft.btitle=&rft.title=Alcoholism&rft.issn=07347324&rft_id=info:doi/10.1080%2F07347324.2016.1182820 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Alcoholism; Pain; Drug abuse; Traumatic brain injury; Post-traumatic stress disorder; Hospitals DO - http://dx.doi.org/10.1080/07347324.2016.1182820 ER - TY - JOUR T1 - Periconceptional seafood intake and pregnancy complications AN - 1846409598; PQ0003835504 AB - To investigate associations of maternal periconceptional shellfish, lean fish and fatty fish intake with risk of pregnancy complications. In this prospective cohort study, we collected information on intake of seafood subtypes using FFQ. We categorized seafood intake into frequencies of 1 servings/week. We ascertained gestational hypertension, pre-eclampsia, gestational diabetes and preterm birth diagnoses from medical records. Using generalized linear models with a log link, the Poisson family and robust standard errors, we estimated risk ratios and 95 % confidence intervals across seafood intake categories. The Omega study, a study of risk factors for pregnancy complications among women recruited from prenatal clinics in Washington State, USA, 1996-2008. The current study included 3279 participants from the Omega study. Median (interquartile range) shellfish, lean fish and fatty fish intake was 0.3 (0-0.9), 0.5 (0-1.0) and 0.5 (0.1-1.0) servings/week, respectively. Lean fish intake of >1 servings/week (v. <0.2 servings/month) was associated with a 1.55-fold higher risk of preterm birth (95 % CI 1.04, 2.30) and was not associated with the other pregnancy complications. Higher intake of seafood (total or other subtypes) was not associated with pregnancy complications (separately or combined). Higher intake of lean fish, but not fatty fish or shellfish, was associated with a higher risk of preterm birth; these findings may have significance for preterm birth prevention. Studies of mechanisms and potential contributing factors (including seafood preparation and nutrient/contaminant content) are warranted. JF - Public Health Nutrition AU - Mohanty, April F AU - Siscovick, David S AU - Williams, Michelle A AU - Thompson, Mary Lou AU - Burbacher, Thomas M AU - Enquobahrie, Daniel A AD - Cardiovascular Health Research Unit, Department of Medicine and Department of Epidemiology, University of Washington, Seattle, WA, USA, april.mohanty@va.gov Y1 - 2016/07// PY - 2016 DA - July 2016 SP - 1795 EP - 1803 PB - Cambridge University Press, The Edinburgh Building, Cambridge CB2 2RU United Kingdom VL - 19 IS - 10 SN - 1368-9800, 1368-9800 KW - Health & Safety Science Abstracts; Calcium & Calcified Tissue Abstracts KW - Prenatal experience KW - Nutrients KW - INE, USA, Washington KW - Public health KW - Models KW - Risk factors KW - Pre-eclampsia KW - Seafood KW - Complications KW - medical records KW - Pregnancy KW - Birth KW - Diabetes mellitus KW - Nutrient content KW - Prevention KW - Pregnancy complications KW - Fish KW - Shellfish KW - Contaminants KW - Hypertension KW - H 11000:Diseases/Injuries/Trauma KW - T 2020:Nutrition and Metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1846409598?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Public+Health+Nutrition&rft.atitle=Periconceptional+seafood+intake+and+pregnancy+complications&rft.au=Mohanty%2C+April+F%3BSiscovick%2C+David+S%3BWilliams%2C+Michelle+A%3BThompson%2C+Mary+Lou%3BBurbacher%2C+Thomas+M%3BEnquobahrie%2C+Daniel+A&rft.aulast=Mohanty&rft.aufirst=April&rft.date=2016-07-01&rft.volume=19&rft.issue=10&rft.spage=1795&rft.isbn=&rft.btitle=&rft.title=Public+Health+Nutrition&rft.issn=13689800&rft_id=info:doi/10.1017%2FS136898001500316X LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-12-01 N1 - Number of references - 28 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Diabetes mellitus; Birth; Pregnancy complications; medical records; Risk factors; Pre-eclampsia; Nutrients; Seafood; Contaminants; Models; Hypertension; Public health; Nutrient content; Prevention; Prenatal experience; Complications; Shellfish; Fish; Pregnancy; INE, USA, Washington DO - http://dx.doi.org/10.1017/S136898001500316X ER - TY - JOUR T1 - Initial Assessment of the Molecular Epidemiology of blaNDM-1 in Colombia AN - 1808677721; PQ0003483856 AB - We report complete genome sequences of four blaNDM-1-harboring Gram-negative multidrug-resistant (MDR) isolates from Colombia. The blaNDM-1 genes were located on 193-kb Inc FIA, 178-kb Inc A/C2, and 47-kb (unknown Inc type) plasmids. Multilocus sequence typing (MLST) revealed that these isolates belong to sequence type 10 (ST10) (Escherichia coli), ST392 (Klebsiella pneumoniae), and ST322 and ST464 (Acinetobacter baumannii and Acinetobacter nosocomialis, respectively). Our analysis identified that the Inc A/C2 plasmid in E. coli contained a novel complex transposon (Tn125 and Tn5393 with three copies of blaNDM-1) and a recombination "hot spot" for the acquisition of new resistance determinants. JF - Antimicrobial Agents & Chemotherapy AU - Rojas, Laura J AU - Wright, Meredith S AU - La Cadena, Elsa De AU - Motoa, Gabriel AU - Hujer, Kristine M AU - Villegas, Maria V AU - Adams, Mark D AU - Bonomo, Robert A AD - << + $0, robert.bonomo@va.gov. Y1 - 2016/07// PY - 2016 DA - July 2016 SP - 4346 EP - 4350 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 60 IS - 7 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Genomes KW - Hot spots KW - Drug resistance KW - Plasmids KW - multilocus sequence typing KW - Transposons KW - Recombination KW - Acinetobacter KW - Acinetobacter baumannii KW - Epidemiology KW - Escherichia coli KW - Klebsiella pneumoniae KW - A 01380:Plant Protection, Fungicides & Seed Treatments UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808677721?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Initial+Assessment+of+the+Molecular+Epidemiology+of+blaNDM-1+in+Colombia&rft.au=Rojas%2C+Laura+J%3BWright%2C+Meredith+S%3BLa+Cadena%2C+Elsa+De%3BMotoa%2C+Gabriel%3BHujer%2C+Kristine+M%3BVillegas%2C+Maria+V%3BAdams%2C+Mark+D%3BBonomo%2C+Robert+A&rft.aulast=Rojas&rft.aufirst=Laura&rft.date=2016-07-01&rft.volume=60&rft.issue=7&rft.spage=4346&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.03072-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Number of references - 36 N1 - Last updated - 2016-08-17 N1 - SubjectsTermNotLitGenreText - Transposons; Genomes; Recombination; Epidemiology; Hot spots; Drug resistance; Plasmids; multilocus sequence typing; Acinetobacter baumannii; Acinetobacter; Escherichia coli; Klebsiella pneumoniae DO - http://dx.doi.org/10.1128/AAC.03072-15 ER - TY - JOUR T1 - Intimate partner violence, partner notification, and expedited partner therapy: a qualitative study AN - 1808616856; PQ0003281275 AB - Summary Over one-third of women experience intimate partner violence (IPV) in their lifetime. IPV increases the risk of infection and re-infection with sexually transmitted infections (STIs). The extent to which health care providers consider IPV when recommending partner notification and expedited partner therapy is unknown. The objective of this qualitative study was to understand health care providers' views on IPV and STIs when recommending partner treatment to patients with chlamydia. Using a purposive sampling strategy to include health care providers who treat young women at risk for chlamydia, 23 semi-structured, in-depth interviews were conducted. While some health care providers expressed concern for their patients' safety and believed assessing for IPV was needed before provision of expedited partner therapy, nearly a third had not considered the links between IPV and STIs. Strategies used by health care providers to assess for IPV did not include inquiry about specific behaviours related to IPV, STI risk, and sexual coercion. Many health care providers understand the risk for IPV in the setting of STI treatment, yet a significant portion of those interviewed failed to recognise the link between IPV and STIs. Provider education is necessary to increase knowledge and implement more effective inquiry and counselling about IPV to more safely recommend expedited partner therapy. JF - International Journal of STD & AIDS AU - Rosenfeld, Elian A AU - Marx, John AU - Terry, Martha A AU - Stall, Ronald AU - Pallatino, Chelsea AU - Borrero, Sonya AU - Miller, Elizabeth AD - 1 .VA Women's Health, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, elian.rosenfeld@va.gov Y1 - 2016/07// PY - 2016 DA - July 2016 SP - 656 EP - 661 PB - Sage Publications, Inc., 2455 Teller Road Thousand Oaks CA 91320 United States VL - 27 IS - 8 SN - 0956-4624, 0956-4624 KW - Health & Safety Science Abstracts; Virology & AIDS Abstracts KW - Intimate partner violence KW - sexually transmitted infections KW - treatment KW - sexual violence KW - partner notification KW - expedited partner therapy KW - Risk assessment KW - Acquired immune deficiency syndrome KW - Safety KW - Infection KW - Health risks KW - Health care KW - Infectious diseases KW - Coercion KW - Domestic violence KW - Sampling KW - Aggression KW - Sexually transmitted diseases KW - Chlamydia KW - V 22360:AIDS and HIV KW - H 11000:Diseases/Injuries/Trauma UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808616856?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+Journal+of+STD+%26+AIDS&rft.atitle=Intimate+partner+violence%2C+partner+notification%2C+and+expedited+partner+therapy%3A+a+qualitative+study&rft.au=Rosenfeld%2C+Elian+A%3BMarx%2C+John%3BTerry%2C+Martha+A%3BStall%2C+Ronald%3BPallatino%2C+Chelsea%3BBorrero%2C+Sonya%3BMiller%2C+Elizabeth&rft.aulast=Rosenfeld&rft.aufirst=Elian&rft.date=2016-07-01&rft.volume=27&rft.issue=8&rft.spage=656&rft.isbn=&rft.btitle=&rft.title=International+Journal+of+STD+%26+AIDS&rft.issn=09564624&rft_id=info:doi/10.1177%2F0956462415591938 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Number of references - 26 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Sampling; Aggression; Infection; Risk assessment; Health risks; Acquired immune deficiency syndrome; Infectious diseases; Health care; Safety; Coercion; Domestic violence; Sexually transmitted diseases; Chlamydia DO - http://dx.doi.org/10.1177/0956462415591938 ER - TY - JOUR T1 - Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells. AN - 1800702010; 27354582 AB - Head and neck squamous cell carcinomas (HNSCC) are known to evade the host immune response. How premalignant oral lesions modulate the immune response, however, has yet to be elucidated. A mouse model of oral carcinogenesis was used to determine how mediators from premalignant oral lesion cells vs. HNSCC cells impact on immune cytokine production and activation. Media conditioned by premalignant lesion cells elicited an increased production of T cell-associated cytokines and proinflammatory mediators from cervical lymph node cells compared to media conditioned by HNSCC cells or media alone. In the presence of premalignant lesion cell-conditioned media, CD4(+) T cell expression of the IL-2 receptor CD25 and CD8(+) T cell expression of the activation marker CD69 was greater, compared to what was induced in HNSCC cell-conditioned media or media alone. Premalignant lesion cells promote a proinflammatory environment and induce immune changes before HNSCC tumors are established. Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. JF - Anticancer research AU - Johnson, Sara D AU - Levingston, Corinne AU - Young, M Rita I AD - Research Service (151) Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, U.S.A. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, U.S.A. ; Research Service (151) Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, U.S.A. ; Research Service (151) Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, U.S.A. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, U.S.A. Department of Medicine, Medical University of South Carolina, Charleston, SC, U.S.A. rita.young@va.gov. Y1 - 2016/07// PY - 2016 DA - July 2016 SP - 3261 EP - 3270 VL - 36 IS - 7 KW - Cytokines KW - 0 KW - Interleukin-2 Receptor alpha Subunit KW - Interferon-gamma KW - 82115-62-6 KW - Index Medicus KW - cytokines KW - head and neck cancer KW - T cell activation KW - premalignant oral lesions KW - Lymphocyte Activation KW - Animals KW - Tumor Cells, Cultured KW - Mice, Inbred C57BL KW - Interferon-gamma -- biosynthesis KW - Disease Models, Animal KW - Mice KW - Interleukin-2 Receptor alpha Subunit -- immunology KW - Interferon-gamma -- immunology KW - Female KW - Interleukin-2 Receptor alpha Subunit -- biosynthesis KW - Carcinoma, Squamous Cell -- immunology KW - Mouth Neoplasms -- immunology KW - CD8-Positive T-Lymphocytes -- immunology KW - Cytokines -- biosynthesis KW - Cytokines -- immunology KW - CD4-Positive T-Lymphocytes -- immunology KW - Precancerous Conditions -- immunology KW - Head and Neck Neoplasms -- immunology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1800702010?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Anticancer+research&rft.atitle=Premalignant+Oral+Lesion+Cells+Elicit+Increased+Cytokine+Production+and+Activation+of+T-cells.&rft.au=Johnson%2C+Sara+D%3BLevingston%2C+Corinne%3BYoung%2C+M+Rita+I&rft.aulast=Johnson&rft.aufirst=Sara&rft.date=2016-07-01&rft.volume=36&rft.issue=7&rft.spage=3261&rft.isbn=&rft.btitle=&rft.title=Anticancer+research&rft.issn=1791-7530&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2017-01-06 N1 - Date created - 2016-06-29 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 ER - TY - JOUR T1 - Approach to the Treatment of Methanol Intoxication. AN - 1799836777; 27180631 AB - Methanol intoxication is an uncommon but serious poisoning. Its adverse effects are due primarily to the impact of its major metabolite formic acid and lactic acid resulting from cellular hypoxia. Symptoms including abdominal pain and loss of vision can appear a few hours to a few days after exposure, reflecting the time necessary for accumulation of the toxic byproducts. In addition to a history of exposure, increases in serum osmolal and anion gaps can be clues to its presence. However, increments in both parameters can be absent depending on the nature of the toxic alcohol, time of exposure, and coingestion of ethanol. Definitive diagnosis requires measurement with gas or liquid chromatography, which are laborious and expensive procedures. Tests under study to detect methanol or its metabolite formate might facilitate the diagnosis of this poisoning. Treatment can include administration of ethanol or fomepizole, both inhibitors of the enzyme alcohol dehydrogenase to prevent formation of its metabolites, and hemodialysis to remove methanol and formate. In this Acid-Base and Electrolyte Teaching Case, a patient with methanol intoxication due to ingestion of model airplane fuel is described, and the value and limitations of current and new diagnostic and treatment measures are discussed. Published by Elsevier Inc. JF - American journal of kidney diseases : the official journal of the National Kidney Foundation AU - Kraut, Jeffrey A AD - Medical and Research Services Veterans Administration Greater Los Angeles Healthcare System, UCLA Membrane Biology Laboratory, and Division of Nephrology, Veterans Administration Greater Los Angeles Healthcare System, and David Geffen School of Medicine, Los Angeles, CA. Electronic address: jkraut@ucla.edu. Y1 - 2016/07// PY - 2016 DA - July 2016 SP - 161 EP - 167 VL - 68 IS - 1 KW - Index Medicus KW - ethanol KW - methanol intoxication KW - fomepizole KW - serum osmolal gap KW - serum anion gap KW - hemodialysis KW - methanol KW - Toxic alcohols UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1799836777?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+journal+of+kidney+diseases+%3A+the+official+journal+of+the+National+Kidney+Foundation&rft.atitle=Approach+to+the+Treatment+of+Methanol+Intoxication.&rft.au=Kraut%2C+Jeffrey+A&rft.aulast=Kraut&rft.aufirst=Jeffrey&rft.date=2016-07-01&rft.volume=68&rft.issue=1&rft.spage=161&rft.isbn=&rft.btitle=&rft.title=American+journal+of+kidney+diseases+%3A+the+official+journal+of+the+National+Kidney+Foundation&rft.issn=1523-6838&rft_id=info:doi/10.1053%2Fj.ajkd.2016.02.058 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-06-26 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1053/j.ajkd.2016.02.058 ER - TY - JOUR T1 - Meeting the Treatment Needs of Veterans with Substance Use Disorders AN - 1798807318 AB - Substance use disorder (SUD) treatment staff from the Brooklyn Veterans Administration Hospital and Samaritan Village describe current practices and challenges in treating the increasing Veteran population with SUD. Article addresses best practices for treating Veterans with SUDs, posttraumatic stress disorder, and traumatic brain injury complications; military sexual trauma; combat versus noncombat status; significance of period served (WW II, Korea, Vietnam, Kuwait/Iraq I, Iraq II, Afghanistan); active service obligations; treatment interventions for trauma survivors; gender treatment differences; medically assisted treatments, especially for those with pain issues; family involvement; benefit seeking; self-help Step 1's "surrender" and "powerlessness" terms; access to treatment issues; returning home adjustment; and coordinating interdisciplinary treatment services. JF - Alcoholism Treatment Quarterly AU - Carroll, Jerome F X, PhD AU - Hall, Charles E, ThD AU - Kearse, Roy, LCSW, CASAC AU - Mooney, Michael, LCSW AU - Potestivo, Jo, LCSW-R, C-CATODSW AU - Forman, Nancy, MD AD - Psychology Department/Ambulatory Substance Abuse Program, Brooklyn Veterans Administration Hospital, Brooklyn, New York, USA ; Chaplain Services, Brooklyn Veterans Administration Hospital, Brooklyn, New York, USA ; Recovery and Community Partnerships for Samaritan Village, Queens, New York, USA ; Ambulatory Substance Abuse Program, Brooklyn Veterans Administration Hospital, Brooklyn, New York, USA ; Psychiatry/Ambulatory Substance Abuse Program, Brooklyn Veterans Administration Hospital, Brooklyn, New York, USA Y1 - 2016///Jul/Sep PY - 2016 DA - Jul/Sep 2016 SP - 354 EP - 364 CY - Abingdon PB - Taylor & Francis Ltd. VL - 34 IS - 3 SN - 0734-7324 KW - Drug Abuse And Alcoholism KW - Veterans KW - posttraumatic stress disorders KW - traumatic brain injuries KW - trauma-informed treatment KW - abstinence KW - harm reduction KW - evidence-based practices KW - ecological dysfunction model KW - medical model KW - integrated KW - holistic KW - comprehensive treatment KW - substitute therapies and other medically assisted treatments KW - surrender and powerlessness concepts KW - gender treatment differences KW - spirituality issues KW - Brain KW - Sex Differences KW - Adjustment KW - Treatment Methods KW - Sex KW - Management KW - Substance Abuse KW - Trauma KW - Self Help KW - Stress KW - Armed Forces KW - Posttraumatic Stress Disorder KW - Alienation KW - Injuries KW - Afghanistan KW - Kuwait KW - Iraq KW - Vietnam KW - 6129:addiction UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1798807318?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Alcoholism+Treatment+Quarterly&rft.atitle=Meeting+the+Treatment+Needs+of+Veterans+with+Substance+Use+Disorders&rft.au=Carroll%2C+Jerome+F+X%2C+PhD%3BHall%2C+Charles+E%2C+ThD%3BKearse%2C+Roy%2C+LCSW%2C+CASAC%3BMooney%2C+Michael%2C+LCSW%3BPotestivo%2C+Jo%2C+LCSW-R%2C+C-CATODSW%3BForman%2C+Nancy%2C+MD&rft.aulast=Carroll&rft.aufirst=Jerome+F&rft.date=2016-07-01&rft.volume=34&rft.issue=3&rft.spage=354&rft.isbn=&rft.btitle=&rft.title=Alcoholism+Treatment+Quarterly&rft.issn=07347324&rft_id=info:doi/10.1080%2F07347324.2016.1182820 LA - English DB - Social Services Abstracts N1 - Name - Department of Veterans Affairs N1 - Copyright - © 2016 Taylor & Francis N1 - Last updated - 2016-09-26 N1 - SubjectsTermNotLitGenreText - Afghanistan; Vietnam; Iraq; Kuwait DO - http://dx.doi.org/10.1080/07347324.2016.1182820 ER - TY - JOUR T1 - Intimate Partner Violence Screening in a Women Veterans' Health Clinic: Assessing Feasibility AN - 1794492397 AB - Women presenting for care within a suburban Department of Veterans Affairs Hospital (VA) were screened for intimate partner violence (IPV). This study aimed to explore the feasibility of screening for IPV within a VA women's health clinic, assess how well the screening measure captured women veterans' experiences of IPV, and compare clinical correlates of IPV in women veterans who have and have not experienced IPV. Of 96 eligible women, 93 (97 %) answered a self-report question regarding experience of lifetime IPV and 72 (75 %) participated in a standardized screening. Among participants, 42 (47 %) reported experiencing past or current IPV, and of those, 11 (25 %) reported that they were currently experiencing IPV, and 31 (70 %) reported that they had experienced IPV in their past. Screening for IPV among women veterans in a women's health clinic is feasible and identifies women who experience IPV, offering opportunities for referral and intervention. JF - Journal of Family Violence AU - Latta, Rachel E AU - Elwy, A Rani AU - Ngo, Tu A AU - Kelly, Megan M AD - Center for Social Innovation, Needham, MA, USA ; Center for Healthcare Organization and Implementation Research, VA Boston Healthcare System, Veterans Health Administration, Bedford, MA, USA; Boston University School of Public Health, Boston, MA, USA ; Edith Nourse Rogers Memorial VA Hospital, Department of Veterans Affairs, Veterans Health Administration, Bedford, MA, USA ; Edith Nourse Rogers Memorial VA Hospital, Department of Veterans Affairs, Veterans Health Administration, Bedford, MA, USA; Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA Y1 - 2016/07// PY - 2016 DA - Jul 2016 SP - 595 EP - 606 CY - New York PB - Springer Science & Business Media VL - 31 IS - 5 SN - 0885-7482 KW - Psychology KW - Domestic violence KW - Women's health KW - Primary care KW - Partner abuse KW - Female veterans KW - Intervention KW - Womens Health Care KW - Health Care Services KW - Health KW - Veterans KW - Diagnosis KW - Females KW - Partner Abuse KW - Tests KW - Screening KW - Violence KW - Selfreport KW - Abusive relationships KW - Feasibility KW - Women's issues KW - 2858:studies in violence; studies in violence KW - 2190:social problems and social welfare; victimology (rape, family violence, & child abuse) KW - 6143:child & family welfare UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1794492397?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Family+Violence&rft.atitle=Intimate+Partner+Violence+Screening+in+a+Women+Veterans%27+Health+Clinic%3A+Assessing+Feasibility&rft.au=Latta%2C+Rachel+E%3BElwy%2C+A+Rani%3BNgo%2C+Tu+A%3BKelly%2C+Megan+M&rft.aulast=Latta&rft.aufirst=Rachel&rft.date=2016-07-01&rft.volume=31&rft.issue=5&rft.spage=595&rft.isbn=&rft.btitle=&rft.title=Journal+of+Family+Violence&rft.issn=08857482&rft_id=info:doi/10.1007%2Fs10896-016-9798-y LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA); Social Services Abstracts; Sociological Abstracts N1 - Name - Department of Veterans Affairs N1 - Copyright - Springer Science+Business Media New York 2016 N1 - Last updated - 2016-09-26 DO - http://dx.doi.org/10.1007/s10896-016-9798-y ER - TY - JOUR T1 - The impact of proposed changes to ICD-11 on estimates of PTSD prevalence and comorbidity. AN - 1792772377; 27124207 AB - The World Health Organization's posttraumatic stress disorder (PTSD) work group has published a proposal for the forthcoming edition of the International Classification of Diseases (ICD-11) that would yield a very different diagnosis relative to DSM-5. This study examined the impact of the proposed ICD-11 changes on PTSD prevalence relative to the ICD-10 and DSM-5 definitions and also evaluated the extent to which these changes would accomplish the stated aim of reducing the comorbidity associated with PTSD. Diagnostic prevalence estimates were compared using a U.S. national community sample and two U.S. Department of Veterans Affairs clinical samples. The ICD-11 definition yielded prevalence estimates 10-30% lower than DSM-5 and 25% and 50% lower than ICD-10 with no reduction in the prevalence of common comorbidities. Findings suggest that by constraining the diagnosis to a narrower set of symptoms, the proposed ICD-11 criteria set would substantially reduce the number of individuals with the disorder. These findings raise doubt about the extent to which the ICD-11 proposal would achieve the aim of reducing comorbidity associated with PTSD and highlight the public health and policy implications of such a redefinition. Published by Elsevier Ireland Ltd. JF - Psychiatry research AU - Wisco, Blair E AU - Miller, Mark W AU - Wolf, Erika J AU - Kilpatrick, Dean AU - Resnick, Heidi S AU - Badour, Christal L AU - Marx, Brian P AU - Keane, Terence M AU - Rosen, Raymond C AU - Friedman, Matthew J AD - Department of Psychology, University of North Carolina at Greensboro, UNCG Psychology, PO Box 26170, Greensboro, NC 27402, USA. Electronic address: bewisco@uncg.edu. ; National Center for PTSD at VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, 150 South Huntington Avenue, Boston, MA 02130, USA. Electronic address: Mark.Miller5@va.gov. ; National Center for PTSD at VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, 150 South Huntington Avenue, Boston, MA 02130, USA. Electronic address: Erika.Wolf@va.gov. ; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina at Charleston, 67 President Stress, MSC 861, Charleston, SC 29425, USA. Electronic address: kilpatdg@musc.edu. ; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina at Charleston, 67 President Stress, MSC 861, Charleston, SC 29425, USA. Electronic address: resnickh@musc.edu. ; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina at Charleston, 67 President Stress, MSC 861, Charleston, SC 29425, USA. Electronic address: christal.badour@uky.edu. ; National Center for PTSD at VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, 150 South Huntington Avenue, Boston, MA 02130, USA. Electronic address: Brian.Marx@va.gov. ; National Center for PTSD at VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, 150 South Huntington Avenue, Boston, MA 02130, USA. Electronic address: Terry.Keane@va.gov. ; New England Research Institutes, 480 Pleasant Street, Watertown, MA 02472, USA. Electronic address: RRosen@neriscience.com. ; VA National Center for PTSD, Departments of Psychiatry and Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, National Center for PTSD, VA Medical Center (116D), 215 North Main Street, White River Junction, VT 05009, USA. Electronic address: matthew.friedman@va.gov. Y1 - 2016/06/30/ PY - 2016 DA - 2016 Jun 30 SP - 226 EP - 233 VL - 240 KW - Index Medicus KW - Diagnostic criteria KW - DSM-5 KW - Diagnosis KW - ICD-11 KW - Trauma KW - PTSD UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1792772377?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychiatry+research&rft.atitle=The+impact+of+proposed+changes+to+ICD-11+on+estimates+of+PTSD+prevalence+and+comorbidity.&rft.au=Wisco%2C+Blair+E%3BMiller%2C+Mark+W%3BWolf%2C+Erika+J%3BKilpatrick%2C+Dean%3BResnick%2C+Heidi+S%3BBadour%2C+Christal+L%3BMarx%2C+Brian+P%3BKeane%2C+Terence+M%3BRosen%2C+Raymond+C%3BFriedman%2C+Matthew+J&rft.aulast=Wisco&rft.aufirst=Blair&rft.date=2016-06-30&rft.volume=240&rft.issue=&rft.spage=226&rft.isbn=&rft.btitle=&rft.title=Psychiatry+research&rft.issn=1872-7123&rft_id=info:doi/10.1016%2Fj.psychres.2016.04.043 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-05-30 N1 - Date revised - 2017-02-02 N1 - SuppNotes - Cited By: Am J Psychiatry. 2001 Jan;158(1):134-6 [11136648] J Consult Clin Psychol. 1998 Dec;66(6):914-23 [9874904] J Trauma Stress. 2013 Oct;26(5):557-9 [24151002] J Trauma Stress. 2013 Oct;26(5):548-56 [24151001] J Trauma Stress. 2013 Oct;26(5):537-47 [24151000] Mol Psychiatry. 2013 Aug;18(8):937-42 [22869035] Lancet. 2013 May 11;381(9878):1683-5 [23583019] Arch Gen Psychiatry. 2012 Jul;69(7):698-705 [22752235] J Trauma Stress. 2009 Oct;22(5):384-90 [19774665] J Trauma Stress. 2009 Oct;22(5):366-73 [19743480] J Trauma Stress. 2010 Oct;23(5):631-8 [20839312] Behav Res Ther. 2010 Sep;48(9):909-14 [20541179] Am J Psychiatry. 2008 Jul;165(7):898-904 [18347001] Psychol Bull. 2007 Sep;133(5):725-46 [17723027] Biol Psychiatry. 2005 May 1;57(9):953-60 [15860334] J Abnorm Psychol. 2004 Nov;113(4):636-45 [15535795] J Trauma Stress. 1999 Apr;12(2):335-43 [10378170] Br J Psychiatry. 1999 Jan;174:3-5 [10211143] Psychol Assess. 2000 Jun;12(2):210-24 [10887767] J Trauma Stress. 2014 Dec;27(6):647-54 [25418442] J Trauma Stress. 1995 Jan;8(1):75-90 [7712061] Br J Psychiatry. 2014 Sep;205(3):230-5 [24809400] N1 - Last updated - 2017-02-02 DO - http://dx.doi.org/10.1016/j.psychres.2016.04.043 ER - TY - JOUR T1 - Prostacyclin reverses the cigarette smoke-induced decrease in pulmonary Frizzled 9 expression through miR-31. AN - 1799560952; 27339092 AB - Half of lung cancers are diagnosed in former smokers, leading to a significant treatment burden in this population. Chemoprevention in former smokers using the prostacyclin analogue iloprost reduces endobronchial dysplasia, a premalignant lung lesion. Iloprost requires the presence of the WNT receptor Frizzled 9 (Fzd9) for inhibition of transformed growth in vitro. To investigate the relationship between iloprost, cigarette smoke, and Fzd9 expression, we used human samples, mouse models, and in vitro studies. Fzd9 expression was low in human lung tumors and in progressive dysplasias. In mouse models and in vitro studies, tobacco smoke carcinogens reduced expression of Fzd9 while prostacyclin maintained or increased expression. Expression of miR-31 repressed Fzd9 expression, which was abrogated by prostacyclin. We propose a model where cigarette smoke exposure increases miR-31 expression, which leads to decreased Fzd9 expression and prevents response to iloprost. When smoke is removed miR-31 is reduced, prostacyclin can increase Fzd9 expression, and progression of dysplasia is inhibited. Fzd9 and miR-31 are candidate biomarkers for precision application of iloprost and monitoring of treatment progress. As we continue to investigate the mechanisms of prostacyclin chemoprevention and identify biomarkers for its use, we will facilitate clinical trials and speed implementation of this valuable prevention approach. JF - Scientific reports AU - Tennis, M A AU - New, M L AU - McArthur, D G AU - Merrick, D T AU - Dwyer-Nield, L D AU - Keith, R L AD - University of Colorado Denver, Aurora, Colorado, USA. ; Denver Veterans Administration Medical Center, Denver, Colorado, USA. Y1 - 2016/06/24/ PY - 2016 DA - 2016 Jun 24 SP - 28519 VL - 6 KW - Index Medicus UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1799560952?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Scientific+reports&rft.atitle=Prostacyclin+reverses+the+cigarette+smoke-induced+decrease+in+pulmonary+Frizzled+9+expression+through+miR-31.&rft.au=Tennis%2C+M+A%3BNew%2C+M+L%3BMcArthur%2C+D+G%3BMerrick%2C+D+T%3BDwyer-Nield%2C+L+D%3BKeith%2C+R+L&rft.aulast=Tennis&rft.aufirst=M&rft.date=2016-06-24&rft.volume=6&rft.issue=&rft.spage=28519&rft.isbn=&rft.btitle=&rft.title=Scientific+reports&rft.issn=2045-2322&rft_id=info:doi/10.1038%2Fsrep28519 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-06-24 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1038/srep28519 ER - TY - JOUR T1 - Electrical stimulation and blood flow restriction increase wrist extensor cross-sectional area and flow meditated dilatation following spinal cord injury AN - 1811886776; PQ0003176098 AB - To examine the effects of neuromuscular electrical stimulation (NMES) and blood flow restricted (BFR) exercise on wrist extensors cross-sectional area (CSA), torque and hand functions compared NMES only in individuals with incomplete tetraplegia. The acute effect of an acute bout of NMES with BFR on flow mediated dilation (FMD) was compared with BFR only. Nine men completed 6 weeks twice weekly of bilateral NMES training of the wrist extensor muscles. The right forearm received NMES + BFR (30 % above the resting systolic blood pressure), while the left forearm received NMES only. The CSA of the extensor carpi radialis longus (ECRL) and extensor digitorum communis (EDC) muscles was measured on ultrasound images. Torque was measured isometrically and hand function with grasp and release test. Another eight men with SCI received NMES+BFR to the right forearm, while the left forearm received BFR only. Immediately, the FMD of the brachial artery was measured. Following training, the ECRL CSA was 17 % greater in the NMES+BFR forearm (mean difference = 0.6 cm super(2), p = 0.003) compared with the NMES only. The NMES+BFR had a 15 % increase in ECRL CSA (mean increase = 0.58 cm super(2) , p = 0.048). FMD increased (p = 0.05) in the exercise arm (12 plus or minus 3 %) compared with the control arm (6.5 plus or minus 6 %). NMES training with BFR is a strategy that can increase skeletal muscle size. NMES with and without BFR can improve wrist strength and hand function. The acute effects of NMES+BFR may suggest that an increase in FMD may partially contribute to skeletal muscle hypertrophy. JF - European Journal of Applied Physiology AU - Gorgey, Ashraf S AU - Timmons, Mark K AU - Dolbow, David R AU - Bengel, Justin AU - Fugate-Laus, Kendall C AU - Michener, Lori A AU - Gater, David R AD - Department of Veterans Affairs, Hunter Holmes McGuire VA Medical Center, Spinal Cord Injury and Disorders Service, 1201 Broad Rock Boulevard, Richmond, VA, 23249, USA, ashraf.gorgey@va.gov Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 1231 EP - 1244 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 116 IS - 6 SN - 1439-6319, 1439-6319 KW - Physical Education Index KW - Hands KW - Force KW - Measurement KW - Blood flow KW - Men KW - Wrists KW - Muscles (growth) KW - Arms KW - Electrical stimulation KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1811886776?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=European+Journal+of+Applied+Physiology&rft.atitle=Electrical+stimulation+and+blood+flow+restriction+increase+wrist+extensor+cross-sectional+area+and+flow+meditated+dilatation+following+spinal+cord+injury&rft.au=Gorgey%2C+Ashraf+S%3BTimmons%2C+Mark+K%3BDolbow%2C+David+R%3BBengel%2C+Justin%3BFugate-Laus%2C+Kendall+C%3BMichener%2C+Lori+A%3BGater%2C+David+R&rft.aulast=Gorgey&rft.aufirst=Ashraf&rft.date=2016-06-01&rft.volume=116&rft.issue=6&rft.spage=1231&rft.isbn=&rft.btitle=&rft.title=European+Journal+of+Applied+Physiology&rft.issn=14396319&rft_id=info:doi/10.1007%2Fs00421-016-3385-z LA - English DB - Physical Education Index N1 - Date revised - 2016-08-01 N1 - Number of references - 43 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Force; Hands; Measurement; Men; Blood flow; Muscles (growth); Wrists; Electrical stimulation; Arms DO - http://dx.doi.org/10.1007/s00421-016-3385-z ER - TY - JOUR T1 - Diabetes Transition Care From an Inpatient to Outpatient Setting in a Veteran Population: Quality Improvement Pilot Study AN - 1811886682; PQ0003146622 AB - Purpose The purpose of the study was to evaluate a diabetes transition care program in a population of veterans with diabetes by calculating 30-day readmission rates and assessing glycemic control. Methods Hospitalized patients with poorly controlled diabetes were identified to participate in the diabetes transition care program. The program included follow-up through a postdischarge telephone call by the diabetes educator, with an opportunity for a face-to-face clinic visit. A retrospective before-and-after study design was used. Analysis included calculating the readmission rate and the pre- and postintervention A1C rates to evaluate the intervention. Results Of the 40 participants, 100% completed the intervention. All 40 participants received a postdischarge telephone call as follow-up, with 20% presenting for a face-to-face visit. The 30-day readmission rate for the cohort was 10%, in comparison to 14.3% for patients who did not receive the intervention but were otherwise comparable. For those who had repeat A1C measurements conducted 2 to 8 months after time of enrollment in the program (n= 33), average A1C declined -2.2%, from 11.3% (100mmol/mol) to 9.1% (76 mmol/mol). Conclusions Diabetes-specific transition of care for those with complex psychiatric, medical, and social needs was feasible, with good outcomes in hospital readmission rates and glycemic control, when executed by an adult nurse practitioner who was the inpatient diabetes educator. JF - Diabetes Educator AU - Brumm, Susan AU - Theisen, Kathleen AU - Falciglia, Mercedes Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 346 EP - 353 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 42 IS - 3 SN - 0145-7217, 0145-7217 KW - Physical Education Index KW - Measurement KW - Programs KW - Analysis KW - Patients KW - Adults KW - Diabetes KW - Hospitals KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1811886682?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Diabetes+Educator&rft.atitle=Diabetes+Transition+Care+From+an+Inpatient+to+Outpatient+Setting+in+a+Veteran+Population%3A+Quality+Improvement+Pilot+Study&rft.au=Brumm%2C+Susan%3BTheisen%2C+Kathleen%3BFalciglia%2C+Mercedes&rft.aulast=Brumm&rft.aufirst=Susan&rft.date=2016-06-01&rft.volume=42&rft.issue=3&rft.spage=346&rft.isbn=&rft.btitle=&rft.title=Diabetes+Educator&rft.issn=01457217&rft_id=info:doi/10.1177%2F0145721716642020 LA - English DB - Physical Education Index N1 - Date revised - 2016-08-01 N1 - Number of references - 25 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Measurement; Programs; Analysis; Patients; Adults; Hospitals; Diabetes DO - http://dx.doi.org/10.1177/0145721716642020 ER - TY - JOUR T1 - The effect of long and short head biceps loading on glenohumeral joint rotational range of motion and humeral head position AN - 1808729642; PQ0003235897 AB - Purpose: To evaluate the effect of loading the long and short heads of the biceps on glenohumeral range of motion and humeral head position. Methods: Eight cadaveric shoulders were tested in 60 degree abduction in the scapula and coronal plane. Muscle loading was applied based on cross-sectional area ratios. The short and long head of the biceps were loaded individually followed by combined loading. Range of motion was measured with 2.2 Nm torque, and the humeral head apex position was measured using a MicroScribe. A paired t test with Bonferroni correction was used for statistics. Results: Long head loading decreased internal rotation in both the scapular (17.9 %) and coronal planes (5.7 %) and external rotation in the scapular plane (2.6 %) (P < 0.04). With only short head loading, maximum internal rotation was significantly increased in the scapular and coronal plane. Long head and short head loading shifted the humeral head apex posteriorly in maximum internal rotation in both planes with the long head shift being significantly greater than the short head. Long head loading also shifted the humeral apex inferiorly in internal rotation and inferiorly posteriorly in neutral rotation in the scapular plane. With the long head unloaded, there was a significant superior shift with short head loading in both planes. Conclusion: Loading the long head of the biceps had a much greater effect on glenohumeral range of motion and humeral head shift than the short head of the biceps; however, in the absence of long head loading, with the short head loaded, maximum internal rotation increases and the humeral head shifts superiorly, which may contribute to impingement following tenodesis of the long head of the biceps. These small changes in rotational range of motion and humeral head position with biceps tenodesis may not lead to pathologic conditions in low-demand patients; however, in throwers, biceps tenodesis may lead to increased contact pressures in late-cocking and deceleration that will likely translate to decreased performance therefore every effort should be made to preserve the biceps-labral complex. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - McGarry, Michelle H AU - Nguyen, Michael L AU - Quigley, Ryan J AU - Hanypsiak, Bryan AU - Gupta, Ranjan AU - Lee, Thay Q AD - Orthopaedic Biomechanics Laboratory, VA Long Beach Healthcare System (09/151), 5901 East 7th. Street, Long Beach, CA, 90822, USA, tqlee@va.gov Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 1979 EP - 1987 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 6 SN - 0942-2056, 0942-2056 KW - Biotechnology and Bioengineering Abstracts; Physical Education Index KW - Measurement KW - Scapula KW - Statistics KW - Head KW - Humerus KW - Flexibility KW - Muscles KW - Sports KW - Knee KW - Joints KW - arthroscopy KW - Shoulder KW - Surgery KW - Cadavers KW - Shoulders KW - Performance KW - Pressure KW - PE 090:Sports Medicine & Exercise Sport Science KW - W 30965:Miscellaneous, Reviews UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808729642?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=The+effect+of+long+and+short+head+biceps+loading+on+glenohumeral+joint+rotational+range+of+motion+and+humeral+head+position&rft.au=McGarry%2C+Michelle+H%3BNguyen%2C+Michael+L%3BQuigley%2C+Ryan+J%3BHanypsiak%2C+Bryan%3BGupta%2C+Ranjan%3BLee%2C+Thay+Q&rft.aulast=McGarry&rft.aufirst=Michelle&rft.date=2016-06-01&rft.volume=24&rft.issue=6&rft.spage=1979&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-014-3318-5 LA - English DB - Physical Education Index; ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Number of references - 31 N1 - Last updated - 2016-08-17 N1 - SubjectsTermNotLitGenreText - Measurement; Statistics; Head; Surgery; Flexibility; Muscles; Shoulders; Performance; Sports; Scapula; arthroscopy; Shoulder; Humerus; Cadavers; Pressure; Knee; Joints DO - http://dx.doi.org/10.1007/s00167-014-3318-5 ER - TY - JOUR T1 - A biomechanical assessment of a novel double endobutton technique versus a coracoid cerclage sling for acromioclavicular and coracoclavicular injuries AN - 1808722987; PQ0003235876 AB - Purpose: Recently, many acromioclavicular-coracoclavicular (AC-CC) ligament reconstruction techniques address only the CC ligament. However, many of these techniques are costly, time-consuming, and require the use of allogenic grafts, making them prone to creep and failure or novel devices making them challenging for orthopaedic surgeons. The purpose of this study was to compare the biomechanical characteristics of a double endobutton technique using a standard endobutton CL with those of a coracoid cerclage sling (CS) for reconstruction of the CC ligaments. Methods: Anterior-posterior (AP) translation and superior-inferior (SI) translation were quantified for eight matched pairs of intact AC joints. One shoulder from each pair underwent a double endobutton repair, using an endobutton CL modified with an additional endobutton (Smith & Nephew, Memphis, Tenn) and placed through holes in the coracoid and clavicle. The contra-lateral shoulder received a coracoid sling reconstruction using an anterior tibialis tendon. Translation testing was repeated after reconstruction, followed by load-to-failure testing. Paired t tests were used for statistical analysis. Results: The CS technique demonstrated a greater SI and AP translation than the double endobutton technique (p < 0.05). Additionally, the double endobutton technique had a greater stiffness (40.2 plus or minus 11.0 vs. 20.3 plus or minus 6.4 N/mm, p = 0.005), yield load (168.5 plus or minus 11.0 vs. 86.8 plus or minus 22.9 N, p = 0.002), and ultimate load (504.4 plus or minus 199.7 vs. 213.2 plus or minus 103.4 N, p = 0.026) when compared to the CS technique. Conclusion: The double endobutton technique yielded less translation about the AC joint and displayed stronger load-to-failure characteristics than the CS reconstruction. As such, this technique may be better suited to restore native AC-CC biomechanics, reduce post-operative pain, and prevent recurrent subluxation and dislocation than an allogenic graft construct. The double endobutton technique may be a suitable option for addressing AC-CC injuries. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Grantham, Cori AU - Heckmann, Nathanael AU - Wang, Lawrence AU - Tibone, James E AU - Struhl, Steven AU - Lee, Thay Q AD - Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, tqlee@va.gov Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 1918 EP - 1924 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 6 SN - 0942-2056, 0942-2056 KW - Biotechnology and Bioengineering Abstracts; Physical Education Index KW - Translation KW - Injuries KW - Reconstruction KW - Dislocations KW - Statistical analysis KW - Techniques KW - Pain KW - arthroscopy KW - Shoulder KW - Surgery KW - Biomechanics (sports techniques) KW - Adenylate cyclase KW - Clavicle KW - Ligaments KW - Knee KW - Joints KW - Dislocation KW - Shoulders KW - Work load KW - Tendons KW - Biomechanics KW - PE 090:Sports Medicine & Exercise Sport Science KW - W 30900:Methods UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808722987?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=A+biomechanical+assessment+of+a+novel+double+endobutton+technique+versus+a+coracoid+cerclage+sling+for+acromioclavicular+and+coracoclavicular+injuries&rft.au=Grantham%2C+Cori%3BHeckmann%2C+Nathanael%3BWang%2C+Lawrence%3BTibone%2C+James+E%3BStruhl%2C+Steven%3BLee%2C+Thay+Q&rft.aulast=Grantham&rft.aufirst=Cori&rft.date=2016-06-01&rft.volume=24&rft.issue=6&rft.spage=1918&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-014-3198-8 LA - English DB - Physical Education Index; ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Number of references - 27 N1 - Last updated - 2016-08-17 N1 - SubjectsTermNotLitGenreText - Ligaments; Dislocations; Surgery; Techniques; Work load; Shoulders; Biomechanics (sports techniques); Biomechanics; Joints; Clavicle; Translation; Reconstruction; Injuries; Statistical analysis; Pain; Knee; Dislocation; arthroscopy; Shoulder; Tendons; Adenylate cyclase DO - http://dx.doi.org/10.1007/s00167-014-3198-8 ER - TY - JOUR T1 - Pitfalls and Pearls of Wisdom in 18F-FDG PET Imaging of Tumors AN - 1808718223; PQ0003241407 AB - 18F-FDG PET imaging of tumors has pitfalls and pearls of wisdom that begin at the point of scheduling and continue through the patient interview, the resting phase, the scan itself, and the image review. Interviewing the patient at the time of scheduling, followed by placing a reminder phone call shortly before the appointment, can save a nuclear medicine department the financial loss of wasted doses and missed appointment slots in the schedule. The pitfalls and pearls of wisdom in tumor imaging are ever changing, and the technologist is in a constant state of inquiry about the patient's disease process and ability to comply. Consideration of each item on the worksheets in this article affects every scan. On completing this article, the reader will be able to identify questions that should be asked in the scheduling and preinjection patient interviews, interpret the answers to those questions, determine how the images may be affected, and adapt the scan. JF - Journal of Nuclear Medicine Technology AU - Britton, Tracey AU - Robinson, Nicholas AD - Nuclear Medicine Service, Birmingham Veterans Administration Medical Center, Birmingham, Alabama; and Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 59 EP - 64 PB - Society of Nuclear Medicine VL - 44 IS - 2 SN - 0091-4916, 0091-4916 KW - Biotechnology and Bioengineering Abstracts KW - interview KW - question KW - review KW - adapt KW - assess KW - Pearls KW - Reviews KW - Positron emission tomography KW - Reminder KW - Nuclear medicine KW - Tumors KW - W 30910:Imaging UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808718223?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Nuclear+Medicine+Technology&rft.atitle=Pitfalls+and+Pearls+of+Wisdom+in+18F-FDG+PET+Imaging+of+Tumors&rft.au=Britton%2C+Tracey%3BRobinson%2C+Nicholas&rft.aulast=Britton&rft.aufirst=Tracey&rft.date=2016-06-01&rft.volume=44&rft.issue=2&rft.spage=59&rft.isbn=&rft.btitle=&rft.title=Journal+of+Nuclear+Medicine+Technology&rft.issn=00914916&rft_id=info:doi/10.2967%2Fjnmt.115.170803 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Last updated - 2016-08-04 N1 - SubjectsTermNotLitGenreText - Pearls; Reviews; Reminder; Positron emission tomography; Nuclear medicine; Tumors DO - http://dx.doi.org/10.2967/jnmt.115.170803 ER - TY - JOUR T1 - Associations between markers of colorectal cancer stem cells, mutation, microRNA and the clinical features of ulcerative colitis. AN - 1795865140; 27153478 AB - AIM Several factors have been implicated in the pathogenesis of colorectal cancer (CRC) associated with ulcerative colitis (UC). We investigated markers of cancer cell pluripotency, including CD44 and CD166, microRNA-21 (miR-21) and microRNA-215 (miR-215), and APC, K-ras and DCC mutations in biopsy specimens from patients with UC to evaluate any correlations with clinical risk factors. METHOD We observed 18 patients with UC and collected two biopsy specimens from each patient at diagnosis and at a follow-up end-point. We examined the expression of CD44, CD166, miR-21 and miR-215, and APC, K-ras and DCC mutations. We compared these markers at the two time points and assessed their associations with clinical characteristics, including the duration of colitis, histological alterations and the age of the patient at the onset of UC. RESULTS Most (16/18) patients had alleviation of mucosal inflammation or remained stable during follow-up; one patient developed dysplasia and one had severe aggravation of the lesion during follow-up. Enhanced expression of CD44, CD166 and miR-21 with miR-215 was found in the specimens obtained at follow-up, despite alleviation of mucosal lesions. Coherence of cancer stem cell markers and miRNAs was seen in patients who had significant worsening of inflammation, dysplasia and a long duration of colitis. APC mutation occurred in only one patient; this patient had the longest duration of UC (23 years). CONCLUSION Enhanced markers of CRC in follow-up colonic mucosal samples support the conclusion that the duration of UC plays the most important role in UC-related carcinogenesis. JF - Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland AU - Yang, L AU - Levi, E AU - Du, J H AU - Zhou, H H AU - Miller, R AU - Majumdar, A P N AD - Department of Gastroenterology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China. ; Division of Gastroenterology and Department of Internal Medicine, Veterans Administration Medical Center, Detroit, Michigan, USA. ; Department of Pathology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, China. Y1 - 2016/06// PY - 2016 DA - June 2016 SP - O185 EP - O193 VL - 18 IS - 6 KW - Index Medicus KW - APC mutation KW - miR-21 KW - carcinogenesis KW - Ulcerative colitis KW - colorectal cancer KW - cancer stem cells UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1795865140?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Colorectal+disease+%3A+the+official+journal+of+the+Association+of+Coloproctology+of+Great+Britain+and+Ireland&rft.atitle=Associations+between+markers+of+colorectal+cancer+stem+cells%2C+mutation%2C+microRNA+and+the+clinical+features+of+ulcerative+colitis.&rft.au=Yang%2C+L%3BLevi%2C+E%3BDu%2C+J+H%3BZhou%2C+H+H%3BMiller%2C+R%3BMajumdar%2C+A+P+N&rft.aulast=Yang&rft.aufirst=L&rft.date=2016-06-01&rft.volume=18&rft.issue=6&rft.spage=O185&rft.isbn=&rft.btitle=&rft.title=Colorectal+disease+%3A+the+official+journal+of+the+Association+of+Coloproctology+of+Great+Britain+and+Ireland&rft.issn=1463-1318&rft_id=info:doi/10.1111%2Fcodi.13371 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-06-09 N1 - Date revised - 2017-02-09 N1 - Last updated - 2017-02-09 DO - http://dx.doi.org/10.1111/codi.13371 ER - TY - JOUR T1 - Alcoholic Liver Disease in Asia, Europe, and North America. AN - 1793212934; 26924091 AB - Alcoholic liver diseases comprise a spectrum of clinical disorders and changes in liver tissue that can be detected by pathology analysis. These range from steatosis to more severe signs and symptoms of liver disease associated with inflammation, such as those observed in patients with alcoholic hepatitis or cirrhosis. Although the relationship between alcohol consumption and liver disease is well established, severe alcohol-related morbidities develop in only a minority of people who consume alcohol in excess. Inter-individual differences in susceptibility to the toxic effects of alcohol have been studied extensively-they include pattern of alcohol consumption, sex, environmental factors (such as diet), and genetic factors, which vary widely among different parts of the world. Alcoholic liver disease is becoming more common in many parts of Asia, but is decreasing in Western Europe. Treatment approaches, including availability of medications, models of care, and approach to transplantation, differ among regions. Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved. JF - Gastroenterology AU - Liangpunsakul, Suthat AU - Haber, Paul AU - McCaughan, Geoffrey W AD - Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; Roudebush Veterans Administration Medical Center, Indianapolis, Indiana. Electronic address: sliangpu@iupui.edu. ; Drug Health Services, Royal Prince Alfred Hospital, Sydney Medical School, University of Sydney, Australia. ; Centenary Research Institute, AW Morrow GE/Liver Center Australian Liver Transplant Unit Royal Prince Alfred Hospital, University of Sydney, Australia. Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 1786 EP - 1797 VL - 150 IS - 8 KW - Abridged Index Medicus KW - Index Medicus KW - North America KW - Clinical Profiles KW - Europe KW - Asia KW - Alcoholic Liver Disease UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1793212934?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Gastroenterology&rft.atitle=Alcoholic+Liver+Disease+in+Asia%2C+Europe%2C+and+North+America.&rft.au=Liangpunsakul%2C+Suthat%3BHaber%2C+Paul%3BMcCaughan%2C+Geoffrey+W&rft.aulast=Liangpunsakul&rft.aufirst=Suthat&rft.date=2016-06-01&rft.volume=150&rft.issue=8&rft.spage=1786&rft.isbn=&rft.btitle=&rft.title=Gastroenterology&rft.issn=1528-0012&rft_id=info:doi/10.1053%2Fj.gastro.2016.02.043 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-05-31 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Addiction. 2014 Jun;109(6):880-93 [24467748] Kaohsiung J Med Sci. 2014 Jun;30(6):291-8 [24835349] Lancet. 1995 Oct 14;346(8981):987-90 [7475591] Alcohol Alcohol Suppl. 1994;2:21-7 [8974312] Hepatology. 1997 Jan;25(1):108-11 [8985274] Gut. 1997 Dec;41(6):845-50 [9462221] Dig Dis Sci. 2014 Dec;59(12):2967-74 [25069572] Hepatology. 2014 Dec;60(6):2099-108 [25164003] Lancet. 2014 Nov 29;384(9958):1953-97 [25433429] Public Health. 2014 Nov;128(11):977-84 [25443132] Addiction. 2015 Jan;110(1):59-68 [25138287] Addiction. 2015 Jan;110 Suppl 1:68-78 [25533866] Alcohol Clin Exp Res. 2015 Mar;39(3):522-31 [25704494] Lancet Glob Health. 2015 Apr;3(4):e190-1 [25794669] J Hepatol. 2015 May;62(5):1061-7 [25634330] J Hepatol. 2015 Apr;62(1 Suppl):S38-46 [25920088] J Clin Gastroenterol. 2015 Jul;49(6):506-11 [25198164] Am J Public Health. 2015 Nov;105(11):2220-7 [26378848] Nat Genet. 2015 Dec;47(12):1443-8 [26482880] Clin Gastroenterol Hepatol. 2016 Feb;14(2):191-202.e1-4; quiz e20 [26256464] Alcohol Alcohol. 1998 Jul-Aug;33(4):381-92 [9719397] Pharmacogenetics. 1998 Aug;8(4):335-42 [9731720] Am J Respir Cell Mol Biol. 1999 May;20(5):976-83 [10226067] J Clin Invest. 1965 Jun;44:1009-21 [14322019] Alcohol Res Health. 2003;27(3):209-19 [15535449] Curr Gastroenterol Rep. 2005 Feb;7(1):32-6 [15701296] Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):12-7 [15730911] Addiction. 2005 Jun;100(6):737-41 [15918802] Liver Transpl. 2005 Nov;(11 Suppl 2):S21-4 [16237730] World J Gastroenterol. 2005 Oct 14;11(38):6043-8 [16273622] Clin Gastroenterol Hepatol. 2005 Dec;3(12):1260-8 [16361053] Lancet. 2006 Jan 7;367(9504):52-6 [16399153] Eur J Gastroenterol Hepatol. 2006 Jun;18(6):673-9 [16702858] Alcohol Alcohol. 2006 Jul-Aug;41(4):355-7 [16624839] Alcohol Res Health. 2007;30(1):22-7 [17718397] Hepatology. 2007 Dec;46(6):2032-9 [18046720] J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S2-8 [18336658] BMC Gastroenterol. 2008;8:3 [18261240] Alcohol Alcohol. 2008 Jul-Aug;43(4):416-22 [18385412] Arch Psychiatr Nurs. 2008 Aug;22(4):190-9 [18640538] Nat Genet. 2008 Dec;40(12):1461-5 [18820647] Lancet. 2009 Jun 13;373(9680):2041-53 [19524780] Lancet. 2009 Jun 27;373(9682):2201-14 [19560602] Alcohol Clin Exp Res. 2009 Dec;33(12):2057-66 [19740136] Nat Genet. 2010 Jan;42(1):21-3 [19946271] Alcohol Clin Exp Res. 2010 Feb;34(2):317-30 [19930235] BMJ. 2010;340:c1240 [20223873] Drug Alcohol Rev. 2010 Jul;29(4):437-45 [20636661] Alcohol. 2010 May;44(3):211-6 [20570082] Alcohol. 2010 May;44(3):217-21 [20682189] Semin Liver Dis. 2010 Nov;30(4):378-90 [20960377] Hepatology. 2011 Jan;53(1):86-95 [21254164] J Med Assoc Thai. 2010 Feb;93 Suppl 2:S87-91 [21299085] Omega (Westport). 2010-2011;62(3):269-83 [21495535] Alcohol Alcohol. 2011 Jul-Aug;46(4):416-23 [21467046] Hepatogastroenterology. 2012 Jan-Feb;59(113):204-7 [22251540] J Hepatol. 2012 Aug;57(2):399-420 [22633836] Alcohol Alcohol. 2012 Sep-Oct;47(5):563-70 [22683652] Gene. 2012 Nov 1;509(1):178-88 [22902304] World J Gastroenterol. 2012 Nov 14;18(42):6018-26 [23155331] J Korean Med Sci. 2013 Feb;28(2):181-9 [23400047] Bull World Health Organ. 2013 Apr 1;91(4):270-6 [23599550] J Hepatol. 2013 Jul;59(1):160-8 [23511777] J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:11-7 [23855290] Alcohol Clin Exp Res. 2013 Aug;37(8):1391-401 [23550892] Ann Hepatol. 2013 Nov-Dec;12(6):901-7 [24114820] Br J Gen Pract. 2013 Oct;63(615):e698-705 [24152485] Liver Transpl. 2014 Mar;20(3):298-310 [24470014] Alcohol Clin Exp Res. 2014 Apr;38(4):1035-41 [24428769] Gastroenterology. 2014 May;146(5):1231-9.e1-6 [24440674] World J Gastroenterol. 2014 May 28;20(20):6279-86 [24876748] Addiction. 2014 Jul;109(7):1081-90 [24716508] World J Gastroenterol. 2014 Jun 21;20(23):7217-22 [24966592] Am J Health Syst Pharm. 2014 Aug 1;71(15):1265-76 [25027533] Saudi Med J. 2014 Jul;35(7):753-6 [25028237] Aliment Pharmacol Ther. 2014 Sep;40(6):571-81 [25060292] Am J Gastroenterol. 2014 Sep;109(9):1417-23 [24935272] Dan Med J. 2014 Oct;61(10):B4755 [25283626] PLoS One. 2014;9(10):e108381 [25290313] Chem Immunol. 2000;74:61-82 [10608082] Chem Immunol. 2000;74:108-21 [10608084] Gut. 2000 Apr;46(4):540-5 [10716685] Hepatology. 2000 Apr;31(4):984-9 [10733556] Mol Pathol. 2000 Apr;53(2):88-93 [10889908] Hum Biol. 2000 Oct;72(5):801-20 [11126726] Hepatology. 2001 May;33(5):1148-53 [11343243] Alcohol Clin Exp Res. 2001 Jun;25(6 Suppl):19S-23S [11410736] Alcohol Clin Exp Res. 2001 Aug;25(8):1181-7 [11505049] J Korean Med Sci. 2001 Dec;16(6):745-50 [11748356] Hepatology. 2002 Apr;35(4):868-75 [11915033] Alcohol Alcohol. 2002 Nov-Dec;37(6):618-21 [12414558] Addiction. 2003 Sep;98(9):1267-76 [12930214] Eur Addict Res. 2003 Oct;9(4):147-56 [12970583] J Hepatol. 2004 Jul;41(1):25-30 [15246203] World J Gastroenterol. 2004 Aug 15;10(16):2423-6 [15285035] Am J Public Health Nations Health. 1967 Dec;57(12):2076-88 [6070248] Br J Addict Alcohol Other Drugs. 1978 Sep;73(3):237-46 [280347] Liver. 1988 Jun;8(3):132-7 [3393062] J Biochem. 1991 Oct;110(4):559-65 [1778977] J Biochem. 1994 Aug;116(2):321-6 [7529759] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1053/j.gastro.2016.02.043 ER - TY - JOUR T1 - Comparing the Health Care Experiences of Medicare Beneficiaries with and without Depressive Symptoms in Medicare Managed Care versus Fee-for-Service AN - 1790472904 AB - Objective To compare patient experiences and disparities for older adults with depressive symptoms in managed care (Medicare Advantage [MA]) versus Medicare Fee-for-Service (FFS). Data Sources Data came from the 2010 Medicare CAHPS survey, to which 220,040 MA and 135,874 FFS enrollees aged 65 and older responded. Study Design Multivariate linear regression was used to test whether case-mix-adjusted associations between depressive symptoms and patient experience differed for beneficiaries in MA versus FFS. Dependent measures included four measures of beneficiaries' experiences with doctors (e.g., reports of doctor communication) and seven measures of beneficiaries' experiences with plans (e.g., customer service). Principal Findings Beneficiaries with depressive symptoms reported worse experiences than those without depressive symptoms regardless of coverage type. For measures assessing interactions with the plan (but not for measures assessing interactions with doctors), the disadvantage for beneficiaries with versus without depressive symptoms was larger in MA than in FFS. Conclusions Disparities in care experienced by older Medicare beneficiaries with depressive symptoms tend to be more negative in managed care than in FFS. Efforts are needed to identify and address the barriers these beneficiaries encounter to help them better traverse the managed care environment. JF - Health Services Research AU - Martino, Steven C AU - Elliott, Marc N AU - Haviland, Amelia M AU - Saliba, Debra AU - Burkhart, Q AU - Kanouse, David E AD - RAND Corporation, Pittsburgh, PA ; RAND Corporation, Santa Monica, CA ; Heinz College, Carnegie Mellon University, Pittsburgh, PA ; UCLA, JH Borun Center and Los Angeles Veterans Administration Health System, Los Angeles, CA Y1 - 2016/06// PY - 2016 DA - Jun 2016 SP - 1002 EP - 1020 CY - Chicago PB - Wiley Subscription Services, Inc. VL - 51 IS - 3 SN - 0017-9124 KW - Medical Sciences KW - Beneficiaries KW - Coverage KW - Depression KW - Doctor-Patient communication KW - Health inequalities KW - In care KW - Managed care KW - Medicare KW - Older people KW - Quality of service UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1790472904?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Consumer+Health+on+the+Internet&rft.atitle=Influenza+A+%28H1N1%29+Virus+%28Swine+Influenza%29%3A+A+Webliography&rft.au=Taylor%2C+Mary+Virginia%3BStephenson%2C+Priscilla+L&rft.aulast=Taylor&rft.aufirst=Mary&rft.date=2009-10-01&rft.volume=13&rft.issue=4&rft.spage=374&rft.isbn=&rft.btitle=&rft.title=Journal+of+Consumer+Health+on+the+Internet&rft.issn=15398285&rft_id=info:doi/ LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © Health Research and Educational Trust N1 - Last updated - 2016-05-25 DO - http://dx.doi.org/10.1111/1475-6773.12359 ER - TY - JOUR T1 - Using Social Media, Online Social Networks, and Internet Search as Platforms for Public Health Interventions: A Pilot Study AN - 1790472853 AB - Objective To pilot public health interventions at women potentially interested in maternity care via campaigns on social media (Twitter), social networks (Facebook), and online search engines (Google Search). Data Sources/Study Setting Primary data from Twitter, Facebook, and Google Search on users of these platforms in Los Angeles between March and July 2014. Study Design Observational study measuring the responses of targeted users of Twitter, Facebook, and Google Search exposed to our sponsored messages soliciting them to start an engagement process by clicking through to a study website containing information on maternity care quality information for the Los Angeles market. Principal Findings Campaigns reached a little more than 140,000 consumers each day across the three platforms, with a little more than 400 engagements each day. Facebook and Google search had broader reach, better engagement rates, and lower costs than Twitter. Costs to reach 1,000 targeted users were approximately in the same range as less well-targeted radio and TV advertisements, while initial engagements--a user clicking through an advertisement--cost less than $1 each. Conclusions Our results suggest that commercially available online advertising platforms in wide use by other industries could play a role in targeted public health interventions. JF - Health Services Research AU - Huesch, Marco D AU - Galstyan, Aram AU - Ong, Michael K AU - Doctor, Jason N AD - USC Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA ; Information Sciences Institute, University of Southern California, Marina del Rey, CA; Department of Computer Science, Viterbi School of Engineering, University of Southern California, Marina del Rey, CA ; Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles, CA; Veterans Administration Los Angeles, Los Angeles, CA ; USC Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA; School of Pharmacy, University of Southern California, Los Angeles, CA Y1 - 2016/06// PY - 2016 DA - Jun 2016 SP - 1273 EP - 1290 CY - Chicago PB - Wiley Subscription Services, Inc. VL - 51 IS - S2 SN - 0017-9124 KW - Medical Sciences KW - Advertisements KW - Advertising KW - Campaigns KW - Consumers KW - Health costs KW - Health education KW - Health status KW - Interventions KW - Public health KW - Quality of care KW - Radio KW - Search engines KW - Social networks KW - Soliciting KW - Women's issues KW - Los Angeles California UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1790472853?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Health+Services+Research&rft.atitle=Using+Social+Media%2C+Online+Social+Networks%2C+and+Internet+Search+as+Platforms+for+Public+Health+Interventions%3A+A+Pilot+Study&rft.au=Huesch%2C+Marco+D%3BGalstyan%2C+Aram%3BOng%2C+Michael+K%3BDoctor%2C+Jason+N&rft.aulast=Huesch&rft.aufirst=Marco&rft.date=2016-06-01&rft.volume=51&rft.issue=S2&rft.spage=1273&rft.isbn=&rft.btitle=&rft.title=Health+Services+Research&rft.issn=00179124&rft_id=info:doi/10.1111%2F1475-6773.12496 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Name - Facebook Inc; Google Inc; Twitter Inc N1 - Copyright - © Health Research and Educational Trust N1 - Last updated - 2016-05-25 N1 - SubjectsTermNotLitGenreText - Los Angeles California DO - http://dx.doi.org/10.1111/1475-6773.12496 ER - TY - JOUR T1 - Prevalence and incidence of liver enzyme elevations in a pooled oncology clinical trial cohort. AN - 1790454585; 27025923 AB - Few epidemiologic studies describe longitudinal liver chemistry (LC) elevations in cancer patients. A population-based retrospective cohort was identified from 31 Phase 2-3 oncology trials (excluding targeted therapies) conducted from 1985 to 2005 to evaluate background rates of LC elevations in patients (n = 3998) with or without liver metastases. Patients with baseline liver metastases (29% of patients) presented with a 3% prevalence of alanine transaminase (ALT) ≥ 3x upper limits normal (ULN) and 0.2% prevalence of bilirubin ≥ 3xULN. During follow-up, the incidence (per 1000 person-months) of new onset ALT elevations ≥3xULN was 6.1 (95% CI: 4.5, 8.0) and 2.2 (95% CI: 0.9, 4.5) in patients without and with liver metastases, respectively. No new incident cases of ALT and bilirubin elevations suggestive of severe liver injury occurred among those with liver metastases; a single case occurred among those without metastasis. Regardless of the presence of liver metastases, LC elevations were rare in cancer patients during oncology trials, which may be due to enrollment criteria. Our study validates uniform thresholds for detection of LC elevations in oncology studies and serves as an empirical referent point for comparing liver enzyme abnormalities in oncology trials of novel targeted therapies. These data support uniform LC stopping criteria in oncology trials. Copyright © 2016 Elsevier Inc. All rights reserved. JF - Regulatory toxicology and pharmacology : RTP AU - Shantakumar, Sumitra AU - Landis, Sarah AU - Lawton, Andy AU - Hunt, Christine M AD - Worldwide Epidemiology, GlaxoSmithKline, Gateway West, Singapore. Electronic address: sumitra.y.shantakumar@gsk.com. ; Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom. Electronic address: sarah.h.landis@gsk.com. ; Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, United Kingdom. Electronic address: andy.m.lawton@gsk.com. ; Department of Veterans Affairs, Durham VA Medical Center, North Carolina, USA. Electronic address: christine.hunt@va.gov. Y1 - 2016/06// PY - 2016 DA - June 2016 SP - 257 EP - 262 VL - 77 KW - Index Medicus KW - Liver injury KW - Liver enzyme KW - Truncated robust multivariate outlier detection KW - Oncology KW - Bilirubin KW - Alanine aminotransferase KW - Hepatotoxicity KW - Metastasis KW - Clinical trial UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1790454585?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.atitle=Prevalence+and+incidence+of+liver+enzyme+elevations+in+a+pooled+oncology+clinical+trial+cohort.&rft.au=Shantakumar%2C+Sumitra%3BLandis%2C+Sarah%3BLawton%2C+Andy%3BHunt%2C+Christine+M&rft.aulast=Shantakumar&rft.aufirst=Sumitra&rft.date=2016-06-01&rft.volume=77&rft.issue=&rft.spage=257&rft.isbn=&rft.btitle=&rft.title=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.issn=1096-0295&rft_id=info:doi/10.1016%2Fj.yrtph.2016.03.019 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-05-19 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.yrtph.2016.03.019 ER - TY - JOUR T1 - Sleep Quality Improvement During Cognitive Behavioral Therapy for Anxiety Disorders AN - 1789436495 AB - Despite the ubiquity of sleep complaints among individuals with anxiety disorders, few prior studies have examined whether sleep quality improves during anxiety treatment. The current study examined pre- to posttreatment sleep quality improvement during cognitive behavioral therapy (CBT) for panic disorder (PD; [Formula omitted.] ) or generalized anxiety disorder (GAD; [Formula omitted.] ). Among sleep quality indices, only global sleep quality and sleep latency improved significantly (but modestly) during CBT. Sleep quality improvement was greater for treatment responders, but did not vary by diagnosis. Additionally, poor baseline sleep quality was independently associated with worse anxiety treatment outcome, as measured by higher intolerance of uncertainty. Additional intervention targeting sleep prior to or during CBT for anxiety may be beneficial for poor sleepers. JF - Behavioral Sleep Medicine AU - Ramsawh, Holly J AU - Bomyea, Jessica AU - Stein, Murray B AU - Cissell, Shadha H AU - Lang, Ariel J AD - Center for the Study of Traumatic Stress, Department of Psychiatry, Uniformed Services University of the Health Sciences ; San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology ; Department of Psychiatry, University of California San Diego; Department of Family & Preventive Medicine, University of California San Diego ; Department of Psychiatry, University of California San Diego ; Veterans Administration San Diego Health Care System, Center of Excellence for Stress and Mental Health; Department of Psychiatry, University of California San Diego Y1 - 2016///May/Jun PY - 2016 DA - May/Jun 2016 SP - 267 EP - 278 CY - Mahwah PB - Taylor & Francis Ltd. VL - 14 IS - 3 SN - 1540-2002 KW - Psychology KW - Sleep KW - Cognitive behaviour therapy KW - Generalized anxiety disorders KW - Quality management KW - Sleep problems KW - Anxieties KW - Insomnia KW - Behavior modification KW - Quality UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1789436495?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Behavioral+Sleep+Medicine&rft.atitle=Sleep+Quality+Improvement+During+Cognitive+Behavioral+Therapy+for+Anxiety+Disorders&rft.au=Ramsawh%2C+Holly+J%3BBomyea%2C+Jessica%3BStein%2C+Murray+B%3BCissell%2C+Shadha+H%3BLang%2C+Ariel+J&rft.aulast=Ramsawh&rft.aufirst=Holly&rft.date=2016-05-01&rft.volume=14&rft.issue=3&rft.spage=267&rft.isbn=&rft.btitle=&rft.title=Behavioral+Sleep+Medicine&rft.issn=15402002&rft_id=info:doi/10.1080%2F15402002.2014.981819 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Copyright © Taylor & Francis Group, LLC N1 - Last updated - 2016-05-19 DO - http://dx.doi.org/10.1080/15402002.2014.981819 ER - TY - JOUR T1 - Changes in Sleep with Auricular Point Acupressure for Chronic Low Back Pain AN - 1789436226 AB - The purpose of this study was to report sleep quality from 4 weeks of auricular point acupressure that was designed for chronic low back pain and determine the relationship between pain intensity and sleep quality. Participants were randomized into the APA group [Formula omitted.] or the sham-APA group [Formula omitted.] . At baseline assessment, 87% of the participants reported poor sleep quality. Participants who received APA had decreased daytime disturbance and improved global Pittsburgh Sleep Quality Index scores at end of intervention (EOI) and 1-month follow up compared to participants in the sham-APA group. For the APA group, both the sleep duration and wake after sleep onset decreased gradually during the 4-week APA (0.56% and 0.23% daily change, respectively). JF - Behavioral Sleep Medicine AU - Yeh, Chao Hsing AU - Suen, Lorna Kwai-Ping AU - Shen, Juan AU - Chien, Lung-Chang AU - Liang, Zhan AU - Glick, Ronald M AU - Morone, Natalia E AU - Chasens, Eileen R AD - School of Nursing, University of Pittsburgh ; School of Nursing, Hong Kong Polytechnic University ; School of Nursing, Suzhou Health College ; Department of Biostatistics, University of Texas School of Public Health at San Antonio Regional Campus; Research to Advance Community Health Center, University of Texas Health Science Center at San Antonio Regional Campus ; Departments of Psychiatry, Physical Medicine, and Rehabilitation, University of Pittsburgh, School of Medicine ; Department of Medicine, Division of General Internal Medicine, University of Pittsburgh, School of Medicine; Veterans Administration Pittsburgh Healthcare System, Geriatric Research, Education, and Clinical Center Y1 - 2016///May/Jun PY - 2016 DA - May/Jun 2016 SP - 279 EP - 294 CY - Mahwah PB - Taylor & Francis Ltd. VL - 14 IS - 3 SN - 1540-2002 KW - Psychology KW - Sleep KW - Acupressure KW - Chronic low back pain KW - Sleep problems KW - Insomnia KW - Back pain KW - Quality KW - Pittsburgh Pennsylvania UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1789436226?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Behavioral+Sleep+Medicine&rft.atitle=Changes+in+Sleep+with+Auricular+Point+Acupressure+for+Chronic+Low+Back+Pain&rft.au=Yeh%2C+Chao+Hsing%3BSuen%2C+Lorna+Kwai-Ping%3BShen%2C+Juan%3BChien%2C+Lung-Chang%3BLiang%2C+Zhan%3BGlick%2C+Ronald+M%3BMorone%2C+Natalia+E%3BChasens%2C+Eileen+R&rft.aulast=Yeh&rft.aufirst=Chao&rft.date=2016-05-01&rft.volume=14&rft.issue=3&rft.spage=279&rft.isbn=&rft.btitle=&rft.title=Behavioral+Sleep+Medicine&rft.issn=15402002&rft_id=info:doi/10.1080%2F15402002.2014.981820 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Copyright © Taylor & Francis Group, LLC N1 - Last updated - 2016-05-19 N1 - SubjectsTermNotLitGenreText - Pittsburgh Pennsylvania DO - http://dx.doi.org/10.1080/15402002.2014.981820 ER - TY - JOUR T1 - Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair via ERK MAPK signaling pathway. AN - 1788228790; 27084535 AB - The expression of kidney injury molecule-1 (KIM-1), a very promising sensitive and specific urinary biomarker for acute renal injury, is markedly upregulated in injured and regenerating renal proximal tubular epithelial cells following ischemic or toxic insults, suggesting a possible role for this molecule in renal repair process. In the present study, we report that expression of KIM-1 facilitates renal tubular epithelial cell repair by promoting cell migration and proliferation. KIM-1 expression also enhances ERK MAPK activation, and the modulatory effect of KIM-1 on cellular repair process is likely mediated via ERK MAPK signaling pathway. JF - Molecular and cellular biochemistry AU - Zhang, Zhiwei AU - Cai, Cindy X AD - Division of Nephrology, Department of Medicine, VA Loma Linda Healthcare System (111 N) and Loma Linda University School of Medicine, 11201 Benton Street, Loma Linda, CA, 92357, USA. zhiwei.zhang@va.gov. ; Division of Gastroenterology, Department of Medicine, VA Loma Linda Healthcare System and Loma Linda University School of Medicine, Loma Linda, CA, USA. Y1 - 2016/05// PY - 2016 DA - May 2016 SP - 109 EP - 116 VL - 416 IS - 1-2 KW - HAVCR1 protein, human KW - 0 KW - Hepatitis A Virus Cellular Receptor 1 KW - Index Medicus KW - ERK MAPK KW - Cellular repair KW - Cell migration KW - Cell proliferation KW - Kidney injury molecule-1 (KIM-1) KW - Humans KW - Cell Line KW - Epithelial Cells -- metabolism KW - Cell Movement KW - MAP Kinase Signaling System KW - Kidney Tubules, Proximal -- metabolism KW - Epithelial Cells -- pathology KW - Kidney Tubules, Proximal -- pathology KW - Hepatitis A Virus Cellular Receptor 1 -- genetics KW - Cell Proliferation KW - Hepatitis A Virus Cellular Receptor 1 -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1788228790?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Molecular+and+cellular+biochemistry&rft.atitle=Kidney+injury+molecule-1+%28KIM-1%29+mediates+renal+epithelial+cell+repair+via+ERK+MAPK+signaling+pathway.&rft.au=Zhang%2C+Zhiwei%3BCai%2C+Cindy+X&rft.aulast=Zhang&rft.aufirst=Zhiwei&rft.date=2016-05-01&rft.volume=416&rft.issue=1-2&rft.spage=109&rft.isbn=&rft.btitle=&rft.title=Molecular+and+cellular+biochemistry&rft.issn=1573-4919&rft_id=info:doi/10.1007%2Fs11010-016-2700-7 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2017-02-06 N1 - Date created - 2016-05-10 N1 - Date revised - 2017-02-08 N1 - SuppNotes - Cited By: Cell. 1996 Feb 9;84(3):359-69 [8608589] N Engl J Med. 1996 May 30;334(22):1448-60 [8618585] J Biol Chem. 1998 Feb 13;273(7):4135-42 [9461608] J Virol. 1998 Aug;72(8):6621-8 [9658108] J Clin Invest. 2005 Jul;115(7):1743-55 [16007251] Kidney Int. 2005 Oct;68(4):1613-7 [16164638] Kidney Int. 2005 Nov;68(5):1956-61 [16221175] J Am Soc Nephrol. 2007 Mar;18(3):904-12 [17267747] J Am Soc Nephrol. 2007 Oct;18(10):2704-14 [17898236] Kidney Int. 2008 Apr;73(7):863-9 [18059454] Cell Stem Cell. 2008 Mar 6;2(3):284-91 [18371453] Clin J Am Soc Nephrol. 2008 May;3(3):844-61 [18337550] J Clin Invest. 2008 May;118(5):1657-68 [18414680] Nat Biotechnol. 2010 May;28(5):478-85 [20458318] Kidney Int. 2010 Nov;78(9):838-48 [20703216] J Clin Invest. 2011 Nov;121(11):4210-21 [22045571] J Clin Invest. 2015 Apr;125(4):1620-36 [25751064] Am J Pathol. 2015 May;185(5):1207-15 [25759266] Am J Physiol Renal Physiol. 2005 Jul;289(1):F31-42 [15713913] Am J Physiol Renal Physiol. 2000 Oct;279(4):F593-604 [10997909] Nat Immunol. 2001 Dec;2(12):1109-16 [11725301] Cell Res. 2002 Mar;12(1):9-18 [11942415] Kidney Int. 2002 Jul;62(1):237-44 [12081583] J Biol Chem. 2002 Oct 18;277(42):39739-48 [12138159] J Am Soc Nephrol. 2003 May;14(5):1188-99 [12707389] J Am Soc Nephrol. 2003 Jun;14 Suppl 1:S55-61 [12761240] J Clin Invest. 2003 Jul;112(1):42-9 [12824456] Am J Physiol Renal Physiol. 2004 Mar;286(3):F552-63 [14600030] Curr Biol. 2004 Apr 20;14(8):731-5 [15084290] Mol Endocrinol. 1992 May;6(5):845-54 [1603090] Eur J Cell Biol. 1995 Sep;68(1):1-7 [8549585] N1 - Last updated - 2017-02-08 DO - http://dx.doi.org/10.1007/s11010-016-2700-7 ER - TY - JOUR T1 - Effectiveness of individualized, integrative outpatient treatment for females with anorexia nervosa and bulimia nervosa AN - 1786270411 AB - The effectiveness of an individualized outpatient program was investigated in the treatment of bulimia nervosa (BN) and anorexia nervosa (AN). Participants included 151 females who received outpatient eating disorder treatment in the partial hospitalization program, the intensive outpatient program, or a combination of the two programs. Outcome measures included the Eating Disorder Inventory (EDI-2), Beck Depression Inventory (BDI-II), frequency of binge eating and purging, and mean body weight. Findings included significant increases in weight for the AN group, reductions in binge eating frequency for the BN group, and reductions in EDI-2 and BDI-II scores and purging frequency for both groups. This study provides preliminary support for the efficacy of a multimodal program for the treatment of both anorexia nervosa and bulimia nervosa. JF - Eating Disorders : the Journal of Treatment & Prevention AU - Freudenberg, Cara AU - Jones, Rebecca A AU - Livingston, Genvieve AU - Goetsch, Virginia AU - Schaffner, Angela AU - Buchanan, Linda AD - U.S. Department of Veterans Affairs, Tennessee Valley Healthcare System, Murfreesboro, Tennessee, USA ; Georgia School of Professional Psychology, Argosy University, Atlanta, Georgia, USA ; Atlanta Center for Eating Disorders and School of Counseling, Richmont Graduate University, Atlanta, Georgia, USA ; Atlanta Center for Eating Disorders, Atlanta, Georgia, USA Y1 - 2016///May/Jun PY - 2016 DA - May/Jun 2016 SP - 240 EP - 254 CY - New York PB - Taylor & Francis Ltd. VL - 24 IS - 3 SN - 1064-0266 KW - Psychology KW - Anorexia nervosa KW - Binge eating KW - Body weight KW - Bulimia nervosa KW - Eating disorders KW - Efficacy KW - Hospitalization KW - Individualized KW - Outpatient treatment KW - Purging UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1786270411?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Eating+Disorders+%3A+the+Journal+of+Treatment+%26+Prevention&rft.atitle=Effectiveness+of+individualized%2C+integrative+outpatient+treatment+for+females+with+anorexia+nervosa+and+bulimia+nervosa&rft.au=Freudenberg%2C+Cara%3BJones%2C+Rebecca+A%3BLivingston%2C+Genvieve%3BGoetsch%2C+Virginia%3BSchaffner%2C+Angela%3BBuchanan%2C+Linda&rft.aulast=Freudenberg&rft.aufirst=Cara&rft.date=2016-05-01&rft.volume=24&rft.issue=3&rft.spage=240&rft.isbn=&rft.btitle=&rft.title=Eating+Disorders+%3A+the+Journal+of+Treatment+%26+Prevention&rft.issn=10640266&rft_id=info:doi/10.1080%2F10640266.2015.1090868 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © 2016 Taylor & Francis N1 - Last updated - 2016-08-17 DO - http://dx.doi.org/10.1080/10640266.2015.1090868 ER - TY - JOUR T1 - Identifying gaps for research prioritisation: Global burden of external causes of injury as reflected in the Cochrane Database of Systematic Reviews. AN - 1785748312; 26804937 AB - IMPORTANCE Burden of disease should impact research prioritisation. OBJECTIVE To analyse the Cochrane Database of Systematic Reviews (CDSR) and determine whether systematic reviews and protocols accurately represent disease burden, as measured by disability-adjusted life years (DALYs) from the Global Burden of Disease (GBD) 2010 Study. METHODS Two investigators collected GBD disability metrics for 12 external causes of injury in the GBD 2010 Study. These external causes were then assessed for systematic review and protocol representation in CDSR. Data was collected during the month of April 2015. There were no study participants aside from the researchers. Percentage of total 2010 DALYs, 2010 DALY rank, and median DALY percent change from 1990 to 2010 of the 12 external causes of injury were compared with CDSR representation of systematic reviews and protocols. Data were analysed for correlation using Spearman rank correlation. RESULTS Eleven of the 12 causes were represented by at least one systematic review or protocol in CDSR; the category collective violence and legal intervention had no representation in CDSR. Correlation testing revealed a strong positive correlation that was statistically significant. Representation of road injury; interpersonal violence; fire, heat, and hot substances; mechanical forces; poisonings, adverse effect of medical treatment, and animal contact was well aligned with respect to DALY. Representation of falls was greater compared to DALY, while self-harm, exposure to forces of nature, and other transport injury representation was lower compared to DALY. CONCLUSIONS AND RELEVANCE CDSR representation of external causes of injury strongly correlates with disease burden. The number of systematic reviews and protocols was well aligned for seven out of 12 causes of injury. These results provide high-quality and transparent data that may guide future prioritisation decisions. JF - Injury AU - Karimkhani, Chante AU - Trikha, Ritika AU - Aksut, Baran AU - Jones, Trevor AU - Boyers, Lindsay N AU - Schlichte, Megan AU - Pederson, Hannah AU - Okland, Tyler AU - DiGuiseppi, Carolyn AU - Nasser, Mona AU - Naghavi, Mohsen AU - Vos, Theo AU - Yoong, Sze Lin AU - Wolfenden, Luke AU - Murray, Christopher J L AU - Dellavalle, Robert P AD - Columbia University College of Physicians and Surgeons, New York, NY, USA. ; Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA. ; Columbia University Medical Center, New York, NY, USA. ; University of Arizona College of Medicine, Tucson, AZ, USA. ; Georgetown University School of Medicine, Washington DC, USA. ; Baylor College of Medicine, Houston, TX, USA. ; University of Colorado School of Medicine, Aurora, CO, USA. ; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, CO, USA. ; Peninsula Dental School, Plymouth University, Plymouth, UK. ; Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ; Hunter New England Population Health, NSW, Australia; The University of Newcastle, NSW, Australia. ; Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, CO, USA; Department of Dermatology, University of Colorado Anschutz Medical Campus, CO, USA; Department of Dermatology, Denver Veterans Administration Hospital, CO, USA. Electronic address: robert.dellavalle@ucdenver.edu. Y1 - 2016/05// PY - 2016 DA - May 2016 SP - 1151 EP - 1157 VL - 47 IS - 5 KW - Index Medicus KW - Injury KW - Epidemiology KW - DALY KW - Burden of disease KW - Disability KW - Systematic review KW - Cochrane KW - Trauma UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1785748312?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Injury&rft.atitle=Identifying+gaps+for+research+prioritisation%3A+Global+burden+of+external+causes+of+injury+as+reflected+in+the+Cochrane+Database+of+Systematic+Reviews.&rft.au=Karimkhani%2C+Chante%3BTrikha%2C+Ritika%3BAksut%2C+Baran%3BJones%2C+Trevor%3BBoyers%2C+Lindsay+N%3BSchlichte%2C+Megan%3BPederson%2C+Hannah%3BOkland%2C+Tyler%3BDiGuiseppi%2C+Carolyn%3BNasser%2C+Mona%3BNaghavi%2C+Mohsen%3BVos%2C+Theo%3BYoong%2C+Sze+Lin%3BWolfenden%2C+Luke%3BMurray%2C+Christopher+J+L%3BDellavalle%2C+Robert+P&rft.aulast=Karimkhani&rft.aufirst=Chante&rft.date=2016-05-01&rft.volume=47&rft.issue=5&rft.spage=1151&rft.isbn=&rft.btitle=&rft.title=Injury&rft.issn=1879-0267&rft_id=info:doi/10.1016%2Fj.injury.2015.12.019 LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-04-29 N1 - Date revised - 2017-02-09 N1 - SuppNotes - Cited By: Acad Emerg Med. 2003 Mar;10(3):251-60 [12615591] Health Policy Plan. 2003 Dec;18(4):351-6 [14654511] Am J Public Health. 2005 Jan;95(1):13-7 [15623852] PLoS One. 2011;6(2):e16837 [21383981] Implement Sci. 2012;7:50 [22651257] Lancet. 2012 Dec 15;380(9859):2163-96 [23245607] BMC Health Serv Res. 2012;12:454 [23234463] N Engl J Med. 2013 Aug 1;369(5):448-57 [23902484] JAMA Dermatol. 2014 Sep;150(9):945-51 [24807687] JAMA Ophthalmol. 2015 Jan;133(1):25-31 [25232930] JAMA Otolaryngol Head Neck Surg. 2015 Jan;141(1):67-72 [25356671] BMJ. 2015;350:h117 [25630558] J Epidemiol Community Health. 2015 Jul;69(7):708-14 [25888595] N1 - Last updated - 2017-02-09 DO - http://dx.doi.org/10.1016/j.injury.2015.12.019 ER - TY - JOUR T1 - Perceptions of Duchenne and non-Duchenne smiles: A meta-analysis AN - 1784151440 AB - A meta-analysis was conducted to compare perceptions of Duchenne smiles, smiles that include activation of the cheek raiser muscle that creates crow's feet around the eyes, with perceptions of non-Duchenne smiles, smiles without cheek raiser activation. In addition to testing the overall effect, moderator analyses were conducted to test how methodological, stimulus-specific and perceiver-specific differences between studies predicted the overall effect size. The meta-analysis found that, overall, Duchenne smiles and people producing Duchenne smiles are rated more positively (i.e., authentic, genuine, real, attractive, trustworthy) than non-Duchenne smiles and people producing non-Duchenne smiles. The difference between Duchenne and non-Duchenne smiles was greater when the stimuli were videos rather than photographs, when smiles were elicited naturally rather than through posing paradigms and when Duchenne and non-Duchenne smiles were not matched for intensity of the lip corner puller in addition to other perceiver and methodological moderators. JF - Cognition & Emotion AU - Gunnery, Sarah D AU - Ruben, Mollie A AD - Department of Occupational Therapy, Tufts University, Medford, MA, USA ; Center for Healthcare Organization and Implementation Research, United States Department of Veterans Affairs, Boston, MA, USA Y1 - 2016/04// PY - 2016 DA - Apr 2016 SP - 501 EP - 515 CY - Hove PB - Taylor & Francis Ltd. VL - 30 IS - 3 SN - 0269-9931 KW - Psychology KW - Duchenne smile KW - Non-Duchenne smile KW - Smile perceptions KW - Analysis KW - Feet KW - Models KW - Moderators KW - Perceptions KW - Photographs KW - Smiles KW - Stimulus KW - Videotapes UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1784151440?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cognition+%26+Emotion&rft.atitle=Perceptions+of+Duchenne+and+non-Duchenne+smiles%3A+A+meta-analysis&rft.au=Gunnery%2C+Sarah+D%3BRuben%2C+Mollie+A&rft.aulast=Gunnery&rft.aufirst=Sarah&rft.date=2016-04-01&rft.volume=30&rft.issue=3&rft.spage=501&rft.isbn=&rft.btitle=&rft.title=Cognition+%26+Emotion&rft.issn=02699931&rft_id=info:doi/10.1080%2F02699931.2015.1018817 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © 2015 Taylor & Francis N1 - Last updated - 2016-09-07 DO - http://dx.doi.org/10.1080/02699931.2015.1018817 ER - TY - JOUR T1 - Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. AN - 1777982542; 27034809 AB - Colorectal cancer (CRC) is a leading cause of cancer death in the United States. In recent years, therapeutic advances have prolonged the survival of patients with advanced disease. Along with the addition of new treatments, an increasing body of literature explores the potential benefit of using molecular testing to define tumor, circulating, or host biomarkers of benefit to specific treatment strategies. At present, testing for specific mutations in exons 2, 3, and 4 of KRAS and NRAS has become accepted practice to select patients for treatment with epidermal growth factor receptor (EGFR)-targeted agents. Additionally, testing for the BRAF V600E mutation is used to refine decisions based on patient prognosis. The presence of the uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *28 polymorphism is associated with toxicity from irinotecan, although it has not been universally applied. Nonetheless, molecular markers to predict response and toxicity of cytotoxic therapy are evolving. While the development of selection biomarkers for anti-angiogenic treatments has not proved fruitful to date, improved development strategies and novel targeted agents are anticipated to revolutionize the approach to treatment of advanced CRC in the near future. This review summarizes currently available data to select treatment strategies in patients with advanced CRC. JF - Journal of gastrointestinal oncology AU - Semrad, Thomas J AU - Kim, Edward J AD - 1 Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, California, USA ; 2 Veterans Administration Northern California Healthcare System, Mather, California, USA. Y1 - 2016/04// PY - 2016 DA - April 2016 SP - S11 EP - S20 VL - 7 SN - 2078-6891, 2078-6891 KW - biomarker KW - Colorectal cancer (CRC) KW - BRAF KW - RAS UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1777982542?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+gastrointestinal+oncology&rft.atitle=Molecular+testing+to+optimize+therapeutic+decision+making+in+advanced+colorectal+cancer.&rft.au=Semrad%2C+Thomas+J%3BKim%2C+Edward+J&rft.aulast=Semrad&rft.aufirst=Thomas&rft.date=2016-04-01&rft.volume=7&rft.issue=&rft.spage=S11&rft.isbn=&rft.btitle=&rft.title=Journal+of+gastrointestinal+oncology&rft.issn=20786891&rft_id=info:doi/10.3978%2Fj.issn.2078-6891.2015.094 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-04-01 N1 - Date created - 2016-04-01 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.3978/j.issn.2078-6891.2015.094 ER - TY - JOUR T1 - Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. AN - 1772143764; 26772189 AB - Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by CYP epoxygenases, and EETs are kidney protective in multiple pathologies. We determined the ability of an EET analogue, EET-A, to mitigate experimental radiation nephropathy. The kidney expression of the EET producing enzyme CYP2C11 was lower in rats that received total body irradiation (TBI rat) compared with non-irradiated control. At 12 weeks after TBI, the rats had higher systolic blood pressure and impaired renal afferent arteriolar function compared with control, and EET-A or captopril mitigated these abnormalities. The TBI rats had 3-fold higher blood urea nitrogen (BUN) compared with control, and EET-A or captopril decreased BUN by 40-60%. The urine albumin/creatinine ratio was increased 94-fold in TBI rats, and EET-A or captopril attenuated that increase by 60-90%. In TBI rats, nephrinuria was elevated 30-fold and EET-A or captopril decreased it by 50-90%. Renal interstitial fibrosis, tubular and glomerular injury were present in the TBI rats, and each was decreased by EET-A or captopril. We further demonstrated elevated renal parenchymal apoptosis in TBI rats, which was mitigated by EET-A or captopril. Additional studies revealed that captopril or EET-A mitigated renal apoptosis by acting on the p53/Fas/FasL (Fas ligand) apoptotic pathway. The present study demonstrates a novel EET analogue-based strategy for mitigation of experimental radiation nephropathy by improving renal afferent arteriolar function and by decreasing renal apoptosis. © 2016 Authors; published by Portland Press Limited. JF - Clinical science (London, England : 1979) AU - Hye Khan, Md Abdul AU - Fish, Brian AU - Wahl, Geneva AU - Sharma, Amit AU - Falck, John R AU - Paudyal, Mahesh P AU - Moulder, John E AU - Imig, John D AU - Cohen, Eric P AD - Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, U.S.A. ; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, U.S.A. ; Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, U.S.A. ; Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, U.S.A. Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, U.S.A. Eric.Cohen@va.gov. Y1 - 2016/04// PY - 2016 DA - April 2016 SP - 587 EP - 599 VL - 130 IS - 8 KW - Angiotensin-Converting Enzyme Inhibitors KW - 0 KW - Antigens, CD95 KW - Eicosanoids KW - Fas Ligand Protein KW - Radiation-Protective Agents KW - Tnfrsf6 protein, rat KW - Tnfsf6 protein, rat KW - Captopril KW - 9G64RSX1XD KW - Aryl Hydrocarbon Hydroxylases KW - EC 1.14.14.1 KW - CYP2C11 protein, rat KW - Cytochrome P450 Family 2 KW - Steroid 16-alpha-Hydroxylase KW - Index Medicus KW - afferent arteriole KW - Fas KW - apoptosis KW - novel small lipid molecule KW - radiotherapy KW - Animals KW - Renal Circulation -- drug effects KW - Hypertension -- physiopathology KW - Steroid 16-alpha-Hydroxylase -- metabolism KW - Fibrosis KW - Cytoprotection KW - Albuminuria -- prevention & control KW - Blood Urea Nitrogen KW - Angiotensin-Converting Enzyme Inhibitors -- pharmacology KW - Captopril -- pharmacology KW - Rats KW - Antigens, CD95 -- metabolism KW - Aryl Hydrocarbon Hydroxylases -- metabolism KW - Albuminuria -- metabolism KW - Hypertension -- prevention & control KW - Signal Transduction -- drug effects KW - Apoptosis -- drug effects KW - Blood Pressure -- drug effects KW - Male KW - Hypertension -- metabolism KW - Fas Ligand Protein -- metabolism KW - Kidney -- radiation effects KW - Radiation Injuries, Experimental -- pathology KW - Kidney -- metabolism KW - Radiation Injuries, Experimental -- metabolism KW - Kidney -- pathology KW - Kidney -- drug effects KW - Acute Kidney Injury -- prevention & control KW - Radiation-Protective Agents -- pharmacology KW - Acute Kidney Injury -- metabolism KW - Acute Kidney Injury -- pathology KW - Eicosanoids -- pharmacology KW - Acute Kidney Injury -- physiopathology KW - Kidney -- blood supply KW - Radiation Injuries, Experimental -- physiopathology KW - Radiation Injuries, Experimental -- prevention & control UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1772143764?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Clinical+science+%28London%2C+England+%3A+1979%29&rft.atitle=Epoxyeicosatrienoic+acid+analogue+mitigates+kidney+injury+in+a+rat+model+of+radiation+nephropathy.&rft.au=Hye+Khan%2C+Md+Abdul%3BFish%2C+Brian%3BWahl%2C+Geneva%3BSharma%2C+Amit%3BFalck%2C+John+R%3BPaudyal%2C+Mahesh+P%3BMoulder%2C+John+E%3BImig%2C+John+D%3BCohen%2C+Eric+P&rft.aulast=Hye+Khan&rft.aufirst=Md&rft.date=2016-04-01&rft.volume=130&rft.issue=8&rft.spage=587&rft.isbn=&rft.btitle=&rft.title=Clinical+science+%28London%2C+England+%3A+1979%29&rft.issn=1470-8736&rft_id=info:doi/10.1042%2FCS20150778 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-07-18 N1 - Date created - 2016-03-09 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1042/CS20150778 ER - TY - JOUR T1 - The human colonic thiamine pyrophosphate transporter (hTPPT) is a glycoprotein and N-linked glycosylation is important for its function. AN - 1771452116; 26828122 AB - The recently identified human thiamine pyrophosphate transporter (hTPPT; product of the SLC44A4 gene) is responsible for absorption of the microbiota-generated TPP in the large intestine. The hTPPT is highly expressed in the colon, but not in other regions of the intestinal tract and is localized exclusively at the apical membrane domain of epithelia. The hTPPT protein is predicted to have multiple TM domains with a number of putative N-glycosylation sites, but it is not known if the protein is actually glycosylated, and if so at which site, and their role in the functionality of the transporter. Using several approaches including inhibiting de novo N-glycosylation in human colonic epithelial NCM460 cells with tunicamycin as well as enzymatic de-glycosylation, we show that the hTPPT protein is, indeed, a glycoprotein. Glycosylation of hTPPT was shown, by mean of site-directed mutagenesis, to occur at Asn(69), Asn(155), Asn(197), Asn(393), and Asn(416). However, only N-glycosylation at Asn(69), Asn(155), and Asn(393) appeared to be important for transporter functionality possibly through an effect on protein conformation and/or interaction with its ligand (but not through changes in expression at the cell membrane as determined by live cell confocal imaging). Results of this study showed, for the first time, that the hTPPT is glycosylated and that N-linked glycosylation occurs at multiple sites with some of them being important for function. The results also provide an indirect support for a membrane topology for hTPPT with 10 transmembrane domains as predicted by the TMHMM transmembrane helixes prediction program. Published by Elsevier B.V. JF - Biochimica et biophysica acta AU - Nabokina, Svetlana M AU - Subramanian, Veedamali S AU - Said, Hamid M AD - Department of Medicine, University of California, Irvine, CA 92697, United States; Department of Physiology/Biophysics, University of California, Irvine, CA 92697, United States; Department of Veterans Affairs Medical Center, Long Beach, CA 90822, United States. ; Department of Medicine, University of California, Irvine, CA 92697, United States; Department of Physiology/Biophysics, University of California, Irvine, CA 92697, United States; Department of Veterans Affairs Medical Center, Long Beach, CA 90822, United States. Electronic address: hmsaid@uci.edu. Y1 - 2016/04// PY - 2016 DA - April 2016 SP - 866 EP - 871 VL - 1858 IS - 4 SN - 0006-3002, 0006-3002 KW - Glycoproteins KW - 0 KW - Membrane Transport Proteins KW - choline transporter-like protein 4, human KW - Index Medicus KW - Transport KW - Thiamine pyrophosphate KW - Uptake KW - Glycosylation KW - Mutation KW - Mutagenesis, Site-Directed KW - Epithelial Cells -- metabolism KW - Glycoproteins -- metabolism KW - Glycoproteins -- chemistry KW - Humans KW - Protein Structure, Secondary KW - Colon -- metabolism KW - Membrane Transport Proteins -- chemistry KW - Colon -- chemistry KW - Cell Membrane -- chemistry KW - Cell Membrane -- metabolism KW - Membrane Transport Proteins -- metabolism KW - Membrane Transport Proteins -- genetics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1771452116?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Biochimica+et+biophysica+acta&rft.atitle=The+human+colonic+thiamine+pyrophosphate+transporter+%28hTPPT%29+is+a+glycoprotein+and+N-linked+glycosylation+is+important+for+its+function.&rft.au=Nabokina%2C+Svetlana+M%3BSubramanian%2C+Veedamali+S%3BSaid%2C+Hamid+M&rft.aulast=Nabokina&rft.aufirst=Svetlana&rft.date=2016-04-01&rft.volume=1858&rft.issue=4&rft.spage=866&rft.isbn=&rft.btitle=&rft.title=Biochimica+et+biophysica+acta&rft.issn=00063002&rft_id=info:doi/10.1016%2Fj.bbamem.2016.01.028 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-06-17 N1 - Date created - 2016-03-07 N1 - Date revised - 2017-02-03 N1 - SuppNotes - Cited By: Gastroenterology. 2010 May;138(5):1802-9 [19879271] PLoS One. 2010;5(10):e13616 [21049048] Nature. 2011 May 12;473(7346):174-80 [21508958] Biochim Biophys Acta. 2011 Aug;1808(8):2073-80 [21570947] Biochem J. 2011 Aug 1;437(3):357-72 [21749321] Cent Nerv Syst Agents Med Chem. 2012 Jun;12(2):70-81 [22483272] Am J Physiol Gastrointest Liver Physiol. 2012 Aug 1;303(3):G389-95 [22628036] Mol Aspects Med. 2013 Apr-Jun;34(2-3):646-54 [23506897] Am J Physiol Gastrointest Liver Physiol. 2013 Nov;305(9):G601-10 [23989008] J Biol Chem. 2014 Feb 14;289(7):4405-16 [24379411] Metab Brain Dis. 2014 Dec;29(4):1069-82 [24590690] World Rev Nutr Diet. 2015;111:30-7 [25418386] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1835-40 [10677542] Proc Soc Exp Biol Med. 2000 Sep;224(4):246-55 [10964259] J Biol Chem. 2001 Jan 19;276(3):2168-73 [11036075] Am J Physiol Cell Physiol. 2001 Sep;281(3):C786-92 [11502555] Curr Mol Med. 2001 May;1(2):197-207 [11899071] J Biol Chem. 2003 Feb 7;278(6):3976-84 [12454006] Nat Med. 2003 Mar;9(3):294-9 [12592403] Diabetes. 2003 Aug;52(8):2110-20 [12882930] Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G491-8 [14615284] Anal Biochem. 1989 Aug 1;180(2):195-204 [2510544] J Neurochem. 1995 May;64(5):2013-21 [7722487] J Neuropathol Exp Neurol. 1999 Sep;58(9):946-58 [10499437] Am J Physiol. 1999 Oct;277(4 Pt 1):C645-51 [10516094] Mol Pharmacol. 2005 Mar;67(3):868-76 [15576633] Am J Physiol Cell Physiol. 2006 Jan;290(1):C1-C10 [16338974] Biochim Biophys Acta. 2008 Jun;1778(6):1407-14 [18405659] Biochem Biophys Res Commun. 2008 Sep 12;374(1):123-7 [18619416] Basic Clin Pharmacol Toxicol. 2008 Nov;103(5):482-6 [18715237] Am J Physiol Renal Physiol. 2009 Mar;296(3):F459-69 [18971212] Alcohol Alcohol. 2009 Mar-Apr;44(2):141-7 [19151161] FEBS J. 2009 Jun;276(11):2917-25 [19490098] N1 - Last updated - 2017-02-07 DO - http://dx.doi.org/10.1016/j.bbamem.2016.01.028 ER - TY - JOUR T1 - Important Complexities of the Antivirulence Target Paradigm: A Novel Ostensibly Resistance-Avoiding Approach for Treating Infections AN - 1785227593; PQ0002903385 AB - Use of antivirulence therapy has assumed that inhibition of bacterial fitness at the site of infection without directly affecting viability will minimize the development of resistance. However, selection for resistant strains is much more likely to occur at sites of colonization or in the environment following excretion of the therapeutic agent. Data are needed regarding whether the drug's target promotes fitness among bacteria in (drug-exposed) niches other than sites of infection. Furthermore, in vivo studies of resistance selection should assess off-target selection for resistance (eg, within the microbiome). Only when such data are available can the risk for development of resistance be gauged appropriately. JF - Journal of Infectious Diseases AU - Russo, Thomas A AU - Spellberg, Brad AU - Johnson, James R AD - Veterans Administration Western New York Healthcare System, trusso@buffalo.edu Y1 - 2016/03/15/ PY - 2016 DA - 2016 Mar 15 SP - 901 EP - 903 PB - Oxford University Press, Oxford Journals, Great Clarendon Street Oxford OX2 6DP United Kingdom VL - 213 IS - 6 SN - 0022-1899, 0022-1899 KW - Health & Safety Science Abstracts KW - antivirulence therapy KW - antimicrobial resistance KW - antimicrobial targets KW - virulence factors KW - microbiome KW - resistance selection KW - Risk assessment KW - Colonization KW - Infectious diseases KW - Niches KW - Excretion KW - Infection KW - H 0500:General UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1785227593?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Infectious+Diseases&rft.atitle=Important+Complexities+of+the+Antivirulence+Target+Paradigm%3A+A+Novel+Ostensibly+Resistance-Avoiding+Approach+for+Treating+Infections&rft.au=Russo%2C+Thomas+A%3BSpellberg%2C+Brad%3BJohnson%2C+James+R&rft.aulast=Russo&rft.aufirst=Thomas&rft.date=2016-03-15&rft.volume=213&rft.issue=6&rft.spage=901&rft.isbn=&rft.btitle=&rft.title=Journal+of+Infectious+Diseases&rft.issn=00221899&rft_id=info:doi/10.1093%2Finfdis%2Fjiv533 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-04-01 N1 - Last updated - 2016-08-03 N1 - SubjectsTermNotLitGenreText - Risk assessment; Colonization; Infectious diseases; Niches; Excretion; Infection DO - http://dx.doi.org/10.1093/infdis/jiv533 ER - TY - JOUR T1 - Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen AN - 1785248255; PQ0002867820 AB - Ceftolozane/tazobactam (C/T) is a novel antibiotic approved for complicated intra-abdominal and urinary tract infections caused by Gram-positive and Gram-negative organisms, including some MDR strains. Little is known about the use of this agent for treatment of bacteremia and even less so about the appropriateness of the renally defined regimens. We describe a case of a 66-year-old man with a history of chronic kidney disease (baseline Cr = 3-4 mg/dl) and recurrent nephrolithiasis with bilateral stents who had positive concurrent urine and blood cultures for MDR Pseudomonas aeruginosa (PSA), susceptible only to amikacin and colistin. Due to the MDR phenotype and his underlying kidney disease, the 375 mg (250 mg/125 mg) dose of C/T was given as monotherapy every 8 h for his bloodstream infection. Once steady state was anticipated, blood was obtained at the end of infusion (1 h), and at 3, 5 and 8 h for drug concentration determination using a validated high-performance liquid chromatography method at the Center for Anti-Infective Research and Development, Hartford Hospital, Hartford. The minimum inhibitory concentration (MIC) for the PSA was 2/4 for C/T, indicating susceptibility. Concentration of ceftolozane of 21.87 mu g/ml at 8 h indicated that serum concentrations were maintained above the MIC throughout the dosing interval. The patient was given 25 days of C/T and experienced a successful clinical outcome. Blood cultures obtained at 1 and 3 weeks after completion of treatment remained sterile. No adverse events were attributed to C/T. In this patient, the renally adjusted dose of C/T was safe and provided sufficiently high drug concentrations that exceeded the MIC of the infecting organism over the course of therapy. More data are required to determine the clinical utility of C/T in the setting of MDR PSA bacteremia. JF - Infectious Diseases and Therapy AU - Patel, Ursula C AU - Nicolau, David P AU - Sabzwari, Rabeeya K AD - Department of Pharmacy, Edward Hines, Jr. VA Medical Center, Hines, IL, 60141, USA, ursula.patel@va.gov Y1 - 2016/03// PY - 2016 DA - March 2016 SP - 73 EP - 79 PB - Springer Science & Business Media, Cheshire VL - 5 IS - 1 SN - 2193-8229, 2193-8229 KW - Microbiology Abstracts B: Bacteriology KW - Blood culture KW - High-performance liquid chromatography KW - Data processing KW - Amikacin KW - Kidney diseases KW - Bacteremia KW - Tazobactam KW - Antibiotics KW - Drug development KW - Urinary tract KW - Minimum inhibitory concentration KW - Colistin KW - Urine KW - Implants KW - Multidrug resistance KW - Pseudomonas aeruginosa KW - Nephrolithiasis KW - Drugs KW - Hospitals KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1785248255?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Infectious+Diseases+and+Therapy&rft.atitle=Successful+Treatment+of+Multi-Drug+Resistant+Pseudomonas+aeruginosa+Bacteremia+with+the+Recommended+Renally+Adjusted+Ceftolozane%2FTazobactam+Regimen&rft.au=Patel%2C+Ursula+C%3BNicolau%2C+David+P%3BSabzwari%2C+Rabeeya+K&rft.aulast=Patel&rft.aufirst=Ursula&rft.date=2016-03-01&rft.volume=5&rft.issue=1&rft.spage=73&rft.isbn=&rft.btitle=&rft.title=Infectious+Diseases+and+Therapy&rft.issn=21938229&rft_id=info:doi/10.1007%2Fs40121-016-0104-3 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-04-01 N1 - Number of references - 23 N1 - Last updated - 2016-07-07 N1 - SubjectsTermNotLitGenreText - High-performance liquid chromatography; Blood culture; Data processing; Amikacin; Kidney diseases; Bacteremia; Drug development; Antibiotics; Tazobactam; Urinary tract; Minimum inhibitory concentration; Colistin; Urine; Implants; Multidrug resistance; Drugs; Nephrolithiasis; Hospitals; Pseudomonas aeruginosa DO - http://dx.doi.org/10.1007/s40121-016-0104-3 ER - TY - JOUR T1 - Alcohol-Related Diagnoses and All-Cause Hospitalization Among HIV-Infected and Uninfected Patients: A Longitudinal Analysis of United States Veterans from 1997 to 2011 AN - 1776663748; PQ0002815375 AB - Individuals with HIV infection are living substantially longer on antiretroviral therapy, but hospitalization rates continue to be relatively high. We do not know how overall or diagnosis-specific hospitalization rates compare between HIV-infected and uninfected individuals or what conditions may drive hospitalization trends. Hospitalization rates among United States Veterans were calculated and stratified by HIV serostatus and principal diagnosis disease category. Because alcohol-related diagnoses (ARD) appeared to have a disproportional effect, we further stratified our calculations by ARD history. A multivariable Cox proportional hazards model was fitted to assess the relative risk of hospitalization controlling for demographic and other comorbidity variables. From 1997 to 2011, 46,428 HIV-infected and 93,997 uninfected patients were followed for 1,497,536 person-years. Overall hospitalization rates decreased among HIV-infected and uninfected patients. However, cardiovascular and renal insufficiency admissions increased for all groups while gastrointestinal and liver, endocrine, neurologic, and non-AIDS cancer admissions increased among those with an alcohol-related diagnosis. After multivariable adjustment, HIV-infected individuals with an ARD had the highest risk of hospitalization (hazard ratio 3.24, 95 % CI 3.00, 3.49) compared to those free of HIV infection and without an ARD. Still, HIV alone also conferred increased risk (HR 2.08, 95 % CI 2.04, 2.13). While decreasing overall, risk of all-cause hospitalization remains higher among HIV-infected than uninfected individuals and is strongly influenced by the presence of an ARD. JF - AIDS and Behavior AU - Rentsch, Christopher AU - Tate, Janet P AU - Akguen, Kathleen M AU - Crystal, Stephen AU - Wang, Karen H AU - Ryan Greysen, S AU - Wang, Emily A AU - Bryant, Kendall J AU - Fiellin, David A AU - Justice, Amy C AU - Rimland, David AD - Infectious Diseases, Atlanta VA Medical Center, Decatur, GA, USA, christopher.rentsch@va.gov Y1 - 2016/03// PY - 2016 DA - March 2016 SP - 555 EP - 564 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 20 IS - 3 SN - 1090-7165, 1090-7165 KW - Virology & AIDS Abstracts; Health & Safety Science Abstracts KW - Risk assessment KW - Historical account KW - Acquired immune deficiency syndrome KW - antiretroviral therapy KW - Infection KW - Antiretroviral agents KW - Morbidity KW - Cancer KW - Demography KW - Health risks KW - USA KW - Behavior KW - Human immunodeficiency virus KW - Risk factors KW - Kidney KW - Liver KW - Renal insufficiency KW - V 22360:AIDS and HIV KW - H 11000:Diseases/Injuries/Trauma UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1776663748?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=AIDS+and+Behavior&rft.atitle=Alcohol-Related+Diagnoses+and+All-Cause+Hospitalization+Among+HIV-Infected+and+Uninfected+Patients%3A+A+Longitudinal+Analysis+of+United+States+Veterans+from+1997+to+2011&rft.au=Rentsch%2C+Christopher%3BTate%2C+Janet+P%3BAkguen%2C+Kathleen+M%3BCrystal%2C+Stephen%3BWang%2C+Karen+H%3BRyan+Greysen%2C+S%3BWang%2C+Emily+A%3BBryant%2C+Kendall+J%3BFiellin%2C+David+A%3BJustice%2C+Amy+C%3BRimland%2C+David&rft.aulast=Rentsch&rft.aufirst=Christopher&rft.date=2016-03-01&rft.volume=20&rft.issue=3&rft.spage=555&rft.isbn=&rft.btitle=&rft.title=AIDS+and+Behavior&rft.issn=10907165&rft_id=info:doi/10.1007%2Fs10461-015-1025-y LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-03-01 N1 - Number of references - 52 N1 - Last updated - 2016-04-13 N1 - SubjectsTermNotLitGenreText - Risk assessment; Demography; Risk factors; antiretroviral therapy; Liver; Renal insufficiency; Infection; Cancer; Historical account; Acquired immune deficiency syndrome; Antiretroviral agents; Morbidity; Health risks; Behavior; Human immunodeficiency virus; Kidney; USA DO - http://dx.doi.org/10.1007/s10461-015-1025-y ER - TY - RPRT T1 - Ventricular Dysrhythmias from Loperamide Misuse. AN - 1767622595; 26794455 JF - The Journal of emergency medicine AU - Lasoff, Daniel R AU - Schneir, Aaron Y1 - 2016/03// PY - 2016 DA - March 2016 SP - 508 EP - 509 KW - Narcotic Antagonists KW - 0 KW - Loperamide KW - 6X9OC3H4II KW - Cimetidine KW - 80061L1WGD KW - Index Medicus KW - Young Adult KW - Tachycardia, Ventricular -- chemically induced KW - Heart Conduction System -- drug effects KW - Humans KW - Cimetidine -- administration & dosage KW - Male KW - Narcotic Antagonists -- poisoning KW - Arrhythmias, Cardiac -- chemically induced KW - Loperamide -- poisoning KW - Substance-Related Disorders -- complications UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1767622595?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=unknown&rft.jtitle=The+Journal+of+emergency+medicine&rft.atitle=Ventricular+Dysrhythmias+from+Loperamide+Misuse.&rft.au=Lasoff%2C+Daniel+R%3BSchneir%2C+Aaron&rft.aulast=Lasoff&rft.aufirst=Daniel&rft.date=2016-03-01&rft.volume=50&rft.issue=3&rft.spage=508&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+emergency+medicine&rft.issn=07364679&rft_id=info:doi/10.1016%2Fj.jemermed.2015.11.017 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-12-16 N1 - Date created - 2016-02-22 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.jemermed.2015.11.017 ER - TY - JOUR T1 - Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. AN - 1765109212; 26867889 AB - Hypofractionated radiation therapy (RT) has promising long-term biochemical relapse-free survival (bRFS) with comparable toxicity for definitive treatment of prostate cancer. However, data reporting outcomes after adjuvant and salvage postprostatectomy hypofractionated RT are sparse. Therefore, we report the toxicity and clinical outcomes after postprostatectomy hypofractionated RT. From a prospectively maintained database, men receiving image guided hypofractionated intensity modulated RT (HIMRT) with 2.5-Gy fractions constituted our study population. Androgen deprivation therapy was used at the discretion of the radiation oncologist. Acute toxicities were graded according to the Common Terminology Criteria for Adverse Events version 4.0. Late toxicities were scored using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Biochemical recurrence was defined as an increase of 0.1 in prostate-specific antigen (PSA) from posttreatment nadir or an increase in PSA despite treatment. The Kaplan-Meier method was used for the time-to-event outcomes. Between April 2008 and April 2012, 56 men received postoperative HIMRT. The median follow-up time was 48 months (range, 21-67 months). Thirty percent had pre-RT PSA <0.1; the median pre-RT detectable PSA was 0.32 ng/mL. The median RT dose was 65 Gy (range, 57.5-65 Gy). Ten patients received neoadjuvant and concurrent hormone therapy. Posttreatment acute urinary toxicity was limited. There was no acute grade 3 toxicity. Late genitourinary (GU) toxicity of any grade was noted in 52% of patients, 40% of whom had pre-RT urinary incontinence. The 4-year actuarial rate of late grade 3 GU toxicity (exclusively gross hematuria) was 28% (95% confidence interval [CI], 16%-41%). Most grade 3 GU toxicity resolved; only 7% had persistent grade ≥3 toxicity at the last follow-up visit. Fourteen patients experienced biochemical recurrence at a median of 20 months after radiation. The 4-year bPFS rate was 75% (95% CI, 63%-87%). The biochemical control in this series appears promising, although relatively short follow-up may lead to overestimation. Late grade 3 GU toxicity was higher than anticipated with hypofractionated radiation of 65 Gy to the prostate bed, although most resolved. Copyright © 2016 Elsevier Inc. All rights reserved. JF - International journal of radiation oncology, biology, physics AU - Lewis, Stephen L AU - Patel, Pretesh AU - Song, Haijun AU - Freedland, Stephen J AU - Bynum, Sigrun AU - Oh, Daniel AU - Palta, Manisha AU - Yoo, David AU - Oleson, James AU - Salama, Joseph K AD - Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. ; Surgery Section, Durham Veterans Administration, and Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California. ; Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. Electronic address: joseph.salama@duke.edu. Y1 - 2016/03/01/ PY - 2016 DA - 2016 Mar 01 SP - 605 EP - 611 VL - 94 IS - 3 KW - Prostate-Specific Antigen KW - EC 3.4.21.77 KW - Index Medicus KW - Prostatectomy KW - Postoperative Care KW - Humans KW - Prostate-Specific Antigen -- blood KW - Adult KW - Aged KW - Middle Aged KW - Follow-Up Studies KW - Time Factors KW - Male KW - Radiotherapy, Image-Guided -- methods KW - Radiotherapy, Intensity-Modulated -- methods KW - Radiotherapy, Image-Guided -- adverse effects KW - Prostatic Neoplasms -- surgery KW - Prostatic Neoplasms -- blood KW - Dose Hypofractionation KW - Radiotherapy, Intensity-Modulated -- adverse effects KW - Prostatic Neoplasms -- radiotherapy UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1765109212?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.atitle=Image+Guided+Hypofractionated+Postprostatectomy+Intensity+Modulated+Radiation+Therapy+for+Prostate+Cancer.&rft.au=Lewis%2C+Stephen+L%3BPatel%2C+Pretesh%3BSong%2C+Haijun%3BFreedland%2C+Stephen+J%3BBynum%2C+Sigrun%3BOh%2C+Daniel%3BPalta%2C+Manisha%3BYoo%2C+David%3BOleson%2C+James%3BSalama%2C+Joseph+K&rft.aulast=Lewis&rft.aufirst=Stephen&rft.date=2016-03-01&rft.volume=94&rft.issue=3&rft.spage=605&rft.isbn=&rft.btitle=&rft.title=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.issn=1879-355X&rft_id=info:doi/10.1016%2Fj.ijrobp.2015.11.025 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-06-16 N1 - Date created - 2016-02-12 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Comment In: Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):860-1 [26972661] Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):859-60 [26972660] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.ijrobp.2015.11.025 ER - TY - JOUR T1 - Analysis of the Structure and Function of FOX-4 Cephamycinase AN - 1768588190; PQ0002688441 AB - Class C beta -lactamases poorly hydrolyze cephamycins (e.g., cefoxitin, cefotetan, and moxalactam). In the past 2 decades, a new family of plasmid-based AmpC beta -lactamases conferring resistance to cefoxitin, the FOX family, has grown to include nine unique members descended from the Aeromonas caviae chromosomal AmpC. To understand the basis for the unique cephamycinase activity in the FOX family, we determined the first X-ray crystal structures of FOX-4, apo enzyme and the acyl-enzyme with its namesake compound, cefoxitin, using the Y150F deacylation-deficient variant. Notably, recombinant expression of N-terminally tagged FOX-4 also yielded an inactive adenylylated enzyme form not previously observed in beta -lactamases. The posttranslational modification (PTM), which occurs on the active site Ser64, would not seem to provide a selective advantage, yet might present an opportunity for the design of novel antibacterial drugs. Substantial ligand-induced changes in the enzyme are seen in the acyl-enzyme complex, particularly the R2 loop and helix H10 (P289 to N297), with movement of F293 by 10.3 Aa. Taken together, this study provides the first picture of this highly proficient class C cephamycinase, uncovers a novel PTM, and suggests a possible cephamycin resistance mechanism involving repositioning of the substrate due to the presence of S153P, N289P, and N346I substitutions in the ligand binding pocket. JF - Antimicrobial Agents & Chemotherapy AU - Lefurgy, S T AU - Malashkevich, V N AU - Aguilan, J T AU - Nieves, E AU - Mundorff, E C AU - Biju, B AU - Noel, M A AU - Toro, R AU - Baiwir, D AU - Papp-Wallace, K M AD - << + $0, robert.bonomo@va.gov. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 717 EP - 728 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 60 IS - 2 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Moxalactam KW - beta -Lactamase KW - New families KW - Enzymes KW - Drug development KW - Cefotetan KW - Aeromonas caviae KW - Cephamycins KW - Structure-function relationships KW - Ionizing radiation KW - Crystal structure KW - Cefoxitin KW - Drugs KW - A 01340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768588190?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Analysis+of+the+Structure+and+Function+of+FOX-4+Cephamycinase&rft.au=Lefurgy%2C+S+T%3BMalashkevich%2C+V+N%3BAguilan%2C+J+T%3BNieves%2C+E%3BMundorff%2C+E+C%3BBiju%2C+B%3BNoel%2C+M+A%3BToro%2C+R%3BBaiwir%2C+D%3BPapp-Wallace%2C+K+M&rft.aulast=Lefurgy&rft.aufirst=S&rft.date=2016-02-01&rft.volume=60&rft.issue=2&rft.spage=717&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.01887-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-02-01 N1 - Number of references - 41 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Moxalactam; Cephamycins; beta -Lactamase; New families; Structure-function relationships; Ionizing radiation; Crystal structure; Enzymes; Drug development; Drugs; Cefoxitin; Cefotetan; Aeromonas caviae DO - http://dx.doi.org/10.1128/AAC.01887-15 ER - TY - JOUR T1 - Biomechanical effects of anterior capsular plication and rotator interval closure in simulated anterior shoulder instability AN - 1768577507; PQ0002649475 AB - Purpose: The purpose of this study was to determine the effect of a stepwise arthroscopic anterior plication and arthroscopic-equivalent rotator interval (RI) closure on glenohumeral range of motion, kinematics, and translation in the setting of anterior instability. Methods: Six cadaveric shoulders were stretched to 10 % beyond maximum external rotation (ER) to create an anterior shoulder instability model. Range of motion, kinematics, and glenohumeral translations were recorded for the following conditions: (1) intact, (2) stretched, (3) after anterior capsular plication, and (4) after RI closure. Results: The total range of motion after capsular stretching increased significantly in the 60 degree abduction position (p = 0.037). Average ER and total rotation were significantly decreased from the intact and stretched conditions by both repair conditions at 60 degree and 0 degree of glenohumeral abduction (p < 0.05), with no significant difference between plication and additional RI closure. At 0 degree abduction and 0 degree ER, glenohumeral translation decreased significantly from the stretched condition after RI closure with 10 and 15 N anterior and 10 N posterior loads (p < 0.05). At 30 degree ER, translation after RI closure was significantly less than both the intact and stretched conditions with 10 N anterior loads (p = 0.009; p = 0.004). These changes in translational stability were not seen with plication alone. Conclusions: Anterior capsular plication reduced glenohumeral range of motion back to the intact state, and often tighter. RI closure did not contribute significantly to the reduction in the range of motion, but had implications regarding glenohumeral translation. Caution should be taken when performing anterior plication and combined repairs to avoid overtightening. Intraoperative translations could be useful when debating RI closure in patients with unidirectional anterior glenohumeral instability. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Sodl, Jeffrey F AU - McGarry, Michelle H AU - Campbell, Sean T AU - Tibone, James E AU - Lee, Thay Q AD - Orthopaedic Biomechanics Laboratory, VA Long Beach Healthcare System (09/151), 5901 East 7th. Street, Long Beach, CA, 90822, USA, tqlee@va.gov Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 365 EP - 373 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 2 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Kinematics KW - Flexibility KW - Surgery KW - Shoulders KW - Work load KW - Sports KW - Stability KW - Biomechanics KW - Stretching KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768577507?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=Biomechanical+effects+of+anterior+capsular+plication+and+rotator+interval+closure+in+simulated+anterior+shoulder+instability&rft.au=Sodl%2C+Jeffrey+F%3BMcGarry%2C+Michelle+H%3BCampbell%2C+Sean+T%3BTibone%2C+James+E%3BLee%2C+Thay+Q&rft.aulast=Sodl&rft.aufirst=Jeffrey&rft.date=2016-02-01&rft.volume=24&rft.issue=2&rft.spage=365&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-014-2878-8 LA - English DB - Physical Education Index N1 - Date revised - 2016-02-01 N1 - Number of references - 39 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Kinematics; Surgery; Flexibility; Work load; Shoulders; Stability; Sports; Biomechanics; Stretching DO - http://dx.doi.org/10.1007/s00167-014-2878-8 ER - TY - JOUR T1 - The biomechanical effect of shoulder remplissage combined with Bankart repair for the treatment of engaging Hill-Sachs lesions AN - 1768577497; PQ0002649479 AB - Purpose: The purpose of this study was to determine the biomechanical effects of the remplissage repair combined with Bankart repair for engaging Hill-Sachs lesions on range of motion (ROM), translation, and glenohumeral kinematics. Methods: Six cadaveric shoulders were tested using a custom shoulder testing system. ROM, kinematics, and anterior-posterior (AP) and superior-inferior glenohumeral translations were quantified at 0 degree and 60 degree glenohumeral abduction. Six conditions were tested: intact, Bankart lesion, Bankart with 40 % Hill-Sachs lesion, Bankart repair, Bankart repair with remplissage, and remplissage repair alone. Results: Humeral external rotation (ER) and total range of motion increased significantly after the creation of the Bankart lesion at both 0 degree and 60 degree abduction. The Bankart repair restored ER to intact values at 0 degree and 60 degree abduction, and the addition of the remplissage repair did not significantly alter range of motion from the Bankart repair alone. AP translation increased following the creation of the Bankart and Hill-Sachs lesions and was restored with the Bankart repair; the remplissage did not alter translation from the Bankart repair alone. At maximum ER at 60 degree abduction, the apex of the humeral head shifted posteriorly and inferiorly with remplissage repair. Conclusions: The addition of the remplissage procedure combined with Bankart repair for treatment of large Hill-Sachs lesions had no statistically significant effect on ROM or translation, but altered the kinematics of the glenohumeral joint. Thus, by addressing the humeral bone defect following an anterior shoulder dislocation, the remplissage technique with concurrent Bankart repair may be a relatively minimally invasive option for converting engaging Hill-Sachs lesions to non-engaging and promoting shoulder stability, though further biomechanical and clinical studies are warranted. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Argintar, Evan AU - Heckmann, Nathanael AU - Wang, Lawrence AU - Tibone, James E AU - Lee, Thay Q AD - Department of Orthopaedic Surgery, The University of Southern California, Los Angeles, CA, USA, tqlee@va.gov Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 585 EP - 592 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 2 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Kinematics KW - Statistics KW - Bones KW - Flexibility KW - Surgery KW - Shoulders KW - Sports KW - Biomechanics (sports techniques) KW - Biomechanics KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768577497?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=The+biomechanical+effect+of+shoulder+remplissage+combined+with+Bankart+repair+for+the+treatment+of+engaging+Hill-Sachs+lesions&rft.au=Argintar%2C+Evan%3BHeckmann%2C+Nathanael%3BWang%2C+Lawrence%3BTibone%2C+James+E%3BLee%2C+Thay+Q&rft.aulast=Argintar&rft.aufirst=Evan&rft.date=2016-02-01&rft.volume=24&rft.issue=2&rft.spage=585&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-014-3092-4 LA - English DB - Physical Education Index N1 - Date revised - 2016-02-01 N1 - Number of references - 32 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Kinematics; Bones; Statistics; Surgery; Flexibility; Shoulders; Biomechanics (sports techniques); Sports; Biomechanics DO - http://dx.doi.org/10.1007/s00167-014-3092-4 ER - TY - JOUR T1 - Biomechanical comparison of the Latarjet procedure with and without a coracoid bone block AN - 1768576351; PQ0002649512 AB - Purpose: The aim of this study was to biomechanically evaluate the Latarjet procedure, with and without a bone block, on glenohumeral range of motion, translation, and kinematics after creation of a bony Bankart lesion. Methods: Eight cadaveric shoulders were tested for range of motion, translation, and kinematics in 90 degree shoulder abduction in both the scapular and coronal planes with the following conditions: intact, Bankart lesion with 20 % glenoid bone loss, Latarjet procedure and soft tissue only conjoined tendon transfer. Results: There was a significant increase in range of motion in both the scapular and coronal planes with both the Latarjet and conjoined tendon transfer compared to the intact state. The Latarjet procedure restored anterior and inferior translation in both planes. The conjoined tendon transfer restored anterior and inferior translation at lower translational loads, but not with higher loads. Both reconstructions shifted the humeral head apex posteriorly in external rotation. Conclusions: The increase in range of motion suggests that the Latarjet procedure does not initially over-constrain the joint. At higher loads, there was improved stability with the Latarjet procedure compared to the conjoint tendon transfer. Both Latarjet and conjoined tendon transfer procedures alter normal joint kinematics by shifting the humeral head apex posteriorly in external rotation. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Barrett Payne, W AU - Kleiner, Matthew T AU - McGarry, Michelle H AU - Tibone, James E AU - Lee, Thay Q AD - Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, tqlee@med.va.gov Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 513 EP - 520 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 2 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Kinematics KW - Bones KW - Flexibility KW - Surgery KW - Work load KW - Shoulders KW - Sports KW - Tendons KW - Joints KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768576351?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=Biomechanical+comparison+of+the+Latarjet+procedure+with+and+without+a+coracoid+bone+block&rft.au=Barrett+Payne%2C+W%3BKleiner%2C+Matthew+T%3BMcGarry%2C+Michelle+H%3BTibone%2C+James+E%3BLee%2C+Thay+Q&rft.aulast=Barrett+Payne&rft.aufirst=W&rft.date=2016-02-01&rft.volume=24&rft.issue=2&rft.spage=513&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-015-3885-0 LA - English DB - Physical Education Index N1 - Date revised - 2016-02-01 N1 - Number of references - 35 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Kinematics; Bones; Surgery; Flexibility; Shoulders; Work load; Sports; Tendons; Joints DO - http://dx.doi.org/10.1007/s00167-015-3885-0 ER - TY - JOUR T1 - Exposing a beta -Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI beta -Lactamase AN - 1768571872; PQ0002688452 AB - Around the world, Burkholderia spp. are emerging as pathogens highly resistant to beta -lactam antibiotics, especially ceftazidime. Clinical variants of Burkholderia pseudomallei possessing the class A beta -lactamase PenI with substitutions at positions C69 and P167 are known to demonstrate ceftazidime resistance. However, the biochemical basis for ceftazidime resistance in class A beta -lactamases in B. pseudomallei is largely undefined. Here, we performed site saturation mutagenesis of the C69 position and investigated the kinetic properties of the C69F variant of PenI from B. pseudomallei that results in a high level of ceftazidime resistance (2 to 64 mg/liter) when expressed in Escherichia coli. Surprisingly, quantitative immunoblotting showed that the steady-state protein levels of the C69F variant beta -lactamase were similar to 4-fold lower than those of wild-type PenI (0.76 fg of protein/cell versus 4.1 fg of protein/cell, respectively). However, growth in the presence of ceftazidime increases the relative amount of the C69F variant to greater than wild-type PenI levels. The C69F variant exhibits a branched kinetic mechanism for ceftazidime hydrolysis, suggesting there are two different conformations of the enzyme. When incubated with an anti-PenI antibody, one conformation of the C69F variant rapidly hydrolyzes ceftazidime and most likely contributes to the higher levels of ceftazidime resistance observed in cell-based assays. Molecular dynamics simulations suggest that the electrostatic characteristics of the oxyanion hole are altered in the C69F variant. When ceftazidime was positioned in the active site, the C69F variant is predicted to form a greater number of hydrogen-bonding interactions than PenI with ceftazidime. In conclusion, we propose "a new twist" for enhanced ceftazidime resistance mediated by the C69F variant of the PenI beta -lactamase based on conformational changes in the C69F variant. Our findings explain the biochemical basis of ceftazidime resistance in B. pseudomallei, a pathogen of considerable importance, and suggest that the full repertoire of conformational states of a beta -lactamase profoundly affects beta -lactam resistance. JF - Antimicrobial Agents & Chemotherapy AU - Papp-Wallace, Krisztina M AU - Becka, Scott A AU - Taracila, Magdalena A AU - Winkler, Marisa L AU - Gatta, Julian A AU - Rholl, Drew A AU - Schweizer, Herbert P AU - Bonomo, Robert A AD - << + $0, robert.bonomo@va.gov. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 777 EP - 788 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 60 IS - 2 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Burkholderia pseudomallei KW - Immunoblotting KW - beta -Lactamase KW - Enzymes KW - Pathogens KW - Penis KW - Hydrolysis KW - Ceftazidime KW - Antibodies KW - saturation mutagenesis KW - Kinetics KW - beta -Lactam antibiotics KW - Escherichia coli KW - A 01340:Antibiotics & Antimicrobials KW - J 02320:Cell Biology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768571872?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Exposing+a+beta+-Lactamase+%22Twist%22%3A+the+Mechanistic+Basis+for+the+High+Level+of+Ceftazidime+Resistance+in+the+C69F+Variant+of+the+Burkholderia+pseudomallei+PenI+beta+-Lactamase&rft.au=Papp-Wallace%2C+Krisztina+M%3BBecka%2C+Scott+A%3BTaracila%2C+Magdalena+A%3BWinkler%2C+Marisa+L%3BGatta%2C+Julian+A%3BRholl%2C+Drew+A%3BSchweizer%2C+Herbert+P%3BBonomo%2C+Robert+A&rft.aulast=Papp-Wallace&rft.aufirst=Krisztina&rft.date=2016-02-01&rft.volume=60&rft.issue=2&rft.spage=777&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.02073-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-02-01 N1 - Number of references - 43 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Ceftazidime; Immunoblotting; saturation mutagenesis; Antibodies; beta -Lactamase; Kinetics; beta -Lactam antibiotics; Enzymes; Pathogens; Hydrolysis; Penis; Burkholderia pseudomallei; Escherichia coli DO - http://dx.doi.org/10.1128/AAC.02073-15 ER - TY - JOUR T1 - Biomechanical comparison of the modified Bristow procedure with and without capsular repair AN - 1768569532; PQ0002649501 AB - The Bristow procedure has become an effective surgical option for recurrent anterior instability of the shoulder; however, there is no consensus on whether a capsule repair following a Bristow procedure is necessary to restore glenohumeral stability. The purpose of this study was to evaluate whether capsular repair with a modified Bristow procedure affects rotational range of motion and glenohumeral stability. Rotational range of motion, glenohumeral translation and kinematics were measured in eight cadaveric shoulders in 90 degree shoulder abduction in the scapular and coronal planes for four conditions: intact, 20 % bony Bankart lesion, modified Bristow without capsular repair and modified Bristow with capsular repair. Creation of the bony Bankart led to a significant increase in total range of motion and anterior-inferior translation compared to the intact shoulder. The modified Bristow procedure significantly decreased anterior-inferior translation compared to the bony Bankart but did not decrease total range of motion. Capsular repair decreased total range of motion in the scapular and coronal planes and altered normal glenohumeral kinematics in external rotation positions. Repairing the capsule in a Bristow procedure decreases rotational range of motion yet does not offer any added anterior-inferior translational stability. Capsular repair also significantly alters normal glenohumeral kinematics. Capsule repair with a Bristow procedure may not add additional glenohumeral stability in positions of apprehension and may potentially over constrain the joint and cause altered kinematics. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Abdulian, Michael H AU - Kephart, Curtis J AU - McGarry, Michelle H AU - Tibone, James E AU - Lee, Thay Q AD - Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, tqlee@va.gov Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 489 EP - 495 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 2 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Kinematics KW - Measurement KW - Flexibility KW - Surgery KW - Shoulders KW - Stability KW - Sports KW - Biomechanics KW - Joints KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768569532?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=Biomechanical+comparison+of+the+modified+Bristow+procedure+with+and+without+capsular+repair&rft.au=Abdulian%2C+Michael+H%3BKephart%2C+Curtis+J%3BMcGarry%2C+Michelle+H%3BTibone%2C+James+E%3BLee%2C+Thay+Q&rft.aulast=Abdulian&rft.aufirst=Michael&rft.date=2016-02-01&rft.volume=24&rft.issue=2&rft.spage=489&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-015-3915-y LA - English DB - Physical Education Index N1 - Date revised - 2016-02-01 N1 - Number of references - 18 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Measurement; Kinematics; Surgery; Flexibility; Shoulders; Sports; Stability; Biomechanics; Joints DO - http://dx.doi.org/10.1007/s00167-015-3915-y ER - TY - JOUR T1 - The effect of defect orientation and size on glenohumeral instability: a biomechanical analysis AN - 1768569345; PQ0002649504 AB - The purpose of this study was to determine the relationship between bony stability and percentage of anterior glenoid bone loss and the effect of bone loss orientation. Twelve cadaveric shoulders were studied. Glenoid bone defects were simulated in two different osteotomy angles: 0 degree and 45 degree to the superoinferior (SI) axis of the glenoid. The force and displacement required for dislocation were measured under two compressive forces of 40 and 60N. Testing was performed for the intact glenoid and glenoid defects of 2, 4, 6, 8, and 10 mm from the anterior margin. The maximum force for dislocation with the 2-mm glenoid defect was significantly decreased compared with intact glenoid (p = 0.01), and this force also significantly decreased with each increase in defect size (p < 0.05). The dislocation force for 45 degree osteotomy was significantly higher than that for 0 degree osteotomy for all defect widths up to 8 mm with 40N compression and 6 mm with 60N compression (p < 0.001). The displacement at dislocation did not significantly decrease until the 8-mm defect with the 45 degree osteotomy but significantly decreased with the 4-mm defect with the 0 degree osteotomy. The required force for dislocation with 60N compression was significantly higher than that with 40N compression for all osteotomy sizes and orientations. The decrease in stability even with glenoid bone loss as small as 2 mm or 7.5 % of the glenoid width suggests that bony restoration is recommended whenever any bone loss exists. Bone defects parallel to SI axis may be more susceptible to recurrent instability, and shoulder muscle strengthening exercises may increase glenohumeral compressive force and thus improve glenohumeral stability. Bony restoration is recommended whenever bone loss exists even with small bone fragments particularly those in line with the superior-inferior axis of the glenoid. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Shin, Sang-Jin AU - Ko, Young Won AU - Scott, Jonathan AU - McGarry, Michelle H AU - Lee, Thay Q AD - Department of Orthopaedic Surgery, Ewha Womans University, Seoul, Korea, tqlee@va.gov Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 533 EP - 539 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 24 IS - 2 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Measurement KW - Bones KW - Dislocations KW - Surgery KW - Analysis KW - Muscles KW - Shoulders KW - Stability KW - Sports KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1768569345?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=The+effect+of+defect+orientation+and+size+on+glenohumeral+instability%3A+a+biomechanical+analysis&rft.au=Shin%2C+Sang-Jin%3BKo%2C+Young+Won%3BScott%2C+Jonathan%3BMcGarry%2C+Michelle+H%3BLee%2C+Thay+Q&rft.aulast=Shin&rft.aufirst=Sang-Jin&rft.date=2016-02-01&rft.volume=24&rft.issue=2&rft.spage=533&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-015-3943-7 LA - English DB - Physical Education Index N1 - Date revised - 2016-02-01 N1 - Number of references - 30 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Measurement; Bones; Dislocations; Analysis; Surgery; Muscles; Shoulders; Sports; Stability DO - http://dx.doi.org/10.1007/s00167-015-3943-7 ER - TY - JOUR T1 - Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. AN - 1761472208; 26694547 AB - We tested the hypothesis that intra-arterial (IA) infusion of temozolomide into the internal carotid artery would safely improve drug delivery to brain and enhance chemotherapy efficacy in a chemosensitive rat brain tumor model. Quantitative autoradiography after 25 µCi (14)C-temozolomide was given by oral, intravenous, or IA route of administration, or IA with osmotic blood-brain barrier disruption (BBBD) (n = 5-7 per group) showed that both IA and IA/BBBD administration increased drug delivery in tumor by over threefold compared to normal brain (P < 0.02), and also significantly elevated delivery throughout the infused right hemisphere. Temozolomide (20 mg/kg; ~150 mg/m(2)) increased median survival when given by oral (25.5 days), intravenous (25.5 days), or IA (33 days) route of administration, compared to 17.5 days in untreated controls (n = 8 per group; overall P < 0.0001). Survival time after IA temozolomide was significantly longer than all other groups (P < 0.01 for all comparisons). BBBD temozolomide was toxic in the efficacy study, but there was no evidence of symptomatic neurotoxicity in rats given IA temozolomide. After these promising animal results, a 49 year old male with glioblastoma multiforme who failed all standard therapy received temozolomide 100 mg/m(2) IA. Upon initiation of the second course of IA infusion the patient had increased heart rate, blood pressure, and rash, and the procedure was terminated without sequelae. Follow up IA infusion of temozolomide diluent in normal rats showed damaged cerebrovasculature as determined by dye leakage. These results demonstrate that IA infusion of temozolomide was toxic, with or without BBBD. We conclude that under the current formulation temozolomide is not safe for IA infusion in patients. JF - Journal of neuro-oncology AU - Muldoon, Leslie L AU - Pagel, Michael A AU - Netto, Joao Prola AU - Neuwelt, Edward A AD - Department of Neurology, Oregon Health & Sciences University, L603; 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. ; Veterans Administration Medical Center, Portland, OR, 97239, USA. ; Department of Neurology, Oregon Health & Sciences University, L603; 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. neuwelte@ohsu.edu. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 447 EP - 454 VL - 126 IS - 3 KW - Antineoplastic Agents, Alkylating KW - 0 KW - Dacarbazine KW - 7GR28W0FJI KW - temozolomide KW - YF1K15M17Y KW - Index Medicus KW - Case study KW - Chemotherapy KW - Intra-arterial infusion KW - Animal model KW - Rats KW - Animals KW - Tumor Cells, Cultured KW - Rats, Nude KW - Injections, Intra-Arterial KW - Humans KW - Xenograft Model Antitumor Assays KW - Antineoplastic Agents, Alkylating -- adverse effects KW - Middle Aged KW - Antineoplastic Agents, Alkylating -- administration & dosage KW - Male KW - Drug Delivery Systems KW - Small Cell Lung Carcinoma -- drug therapy KW - Lung Neoplasms -- drug therapy KW - Neurotoxicity Syndromes -- etiology KW - Dacarbazine -- adverse effects KW - Brain Neoplasms -- secondary KW - Blood-Brain Barrier -- drug effects KW - Brain Neoplasms -- drug therapy KW - Small Cell Lung Carcinoma -- pathology KW - Dacarbazine -- analogs & derivatives KW - Dacarbazine -- administration & dosage KW - Neurotoxicity Syndromes -- pathology KW - Lung Neoplasms -- pathology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1761472208?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+neuro-oncology&rft.atitle=Intra-arterial+administration+improves+temozolomide+delivery+and+efficacy+in+a+model+of+intracerebral+metastasis%2C+but+has+unexpected+brain+toxicity.&rft.au=Muldoon%2C+Leslie+L%3BPagel%2C+Michael+A%3BNetto%2C+Joao+Prola%3BNeuwelt%2C+Edward+A&rft.aulast=Muldoon&rft.aufirst=Leslie&rft.date=2016-02-01&rft.volume=126&rft.issue=3&rft.spage=447&rft.isbn=&rft.btitle=&rft.title=Journal+of+neuro-oncology&rft.issn=1573-7373&rft_id=info:doi/10.1007%2Fs11060-015-2000-1 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-11-01 N1 - Date created - 2016-01-30 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1007/s11060-015-2000-1 ER - TY - JOUR T1 - Counseling patients with asthma and allergy about electronic cigarettes: an evidence-based approach. AN - 1761460132; 26522253 AB - To provide an evidence-based review of common safety concerns and emerging potential benefits deriving from the regular use of electronic cigarettes (ECs) and thus improve counseling between physicians and their patients with asthma and allergy using or intending to use ECs. Peer-reviewed articles from the National Center for Biotechnology Information's PubMed about ECs, risk reduction, and harm reversal were appraised. Keywords used in the search were smoking cessation, electronic cigarette, counseling, asthma, allergy, nicotine, tobacco harm reduction, and harm reversal. Vapor toxicology is far less problematic compared with combustible cigarettes, with exclusive EC users having substantial lower risk of exposure to tobacco smoke toxicants and carcinogens compared with cigarette smokers. Moreover, there is emerging evidence that switching to regular EC use could produce significant respiratory health gains. Inaccurate and inconsistent information about EC safety and efficacy, tobacco harm reduction, and nicotine toxicity is being offered to smokers and EC users. In particular, most health care professionals cannot communicate a clear and consistent message to their patients with respiratory problems and allergy who use or intend to use ECs. Therefore, it is important for the medical community to take an active role in considering all the pathways available to a smoking patient and recommend those that provide the greatest probability of eliminating exposure to tobacco smoke, including ECs. Copyright © 2016 American College of Allergy, Asthma & Immunology. All rights reserved. JF - Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology AU - Polosa, Riccardo AU - Campagna, Davide AU - Sands, Mark F AD - Centro per la Prevenzione e Cura del Tabagismo, Azienda Ospedaliero-Universitaria "Policlinico V. Emanuele", Catania, Italy; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy; UOC di Medicina Interna e d'Urgenza, Azienda Ospedaliero-Universitaria "Policlinico V. Emanuele", Catania, Italy. Electronic address: polosa@unict.it. ; Centro per la Prevenzione e Cura del Tabagismo, Azienda Ospedaliero-Universitaria "Policlinico V. Emanuele", Catania, Italy; Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy; UOC di Medicina Interna e d'Urgenza, Azienda Ospedaliero-Universitaria "Policlinico V. Emanuele", Catania, Italy. ; Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York; The Veterans Administration Healthcare System of Western New York, Buffalo, New York. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 106 EP - 111 VL - 116 IS - 2 KW - Index Medicus KW - Evidence-Based Medicine KW - Humans KW - Smoking Cessation KW - Smoking -- adverse effects KW - Counseling KW - Hypersensitivity KW - Electronic Cigarettes -- adverse effects KW - Physician-Patient Relations UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1761460132?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Annals+of+allergy%2C+asthma+%26+immunology+%3A+official+publication+of+the+American+College+of+Allergy%2C+Asthma%2C+%26+Immunology&rft.atitle=Counseling+patients+with+asthma+and+allergy+about+electronic+cigarettes%3A+an+evidence-based+approach.&rft.au=Polosa%2C+Riccardo%3BCampagna%2C+Davide%3BSands%2C+Mark+F&rft.aulast=Polosa&rft.aufirst=Riccardo&rft.date=2016-02-01&rft.volume=116&rft.issue=2&rft.spage=106&rft.isbn=&rft.btitle=&rft.title=Annals+of+allergy%2C+asthma+%26+immunology+%3A+official+publication+of+the+American+College+of+Allergy%2C+Asthma%2C+%26+Immunology&rft.issn=1534-4436&rft_id=info:doi/10.1016%2Fj.anai.2015.10.012 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-06-02 N1 - Date created - 2016-01-28 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Comment In: Ann Allergy Asthma Immunol. 2016 Feb;116(2):89-90 [26815701] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.anai.2015.10.012 ER - TY - JOUR T1 - Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma. AN - 1760886762; 26423690 AB - Bladder cancer (BC) accounts for ∼14,680 deaths annually in the U.S. The prognosis of advanced disease remains dismal with current therapies. A phase III intergroup trial for metastatic BC adding bevacizumab to first-line cisplatin-gemcitabine chemotherapy (GCB regimen) is currently ongoing. We report the clinical-pathologic findings of a patient who developed fatal acute cardiac microvascular toxicity while receiving this regimen. A 66 year old man consulted for epigastric pain, nausea, intermittent diarrhea and lightheadedness two weeks after receiving the first cycle of GCB chemotherapy for metastatic BC. Physical evaluation, laboratory studies and electrocardiogram (EKG) were within normal limits except for marked thrombocytopenia that was attributed to his recent chemotherapy. The patient was admitted for observation, rehydrated and started on a proton pump inhibitor. The following day, however, he experienced sudden severe chest and right upper quadrant pain. EKG showed tachycardia, ST elevations in leads V2 and V3, laboratory analyses revealed marked elevation of cardiac troponin I, and an echocardiogram showed a markedly reduced ejection fraction of 10-20%, consistent with rapidly progressive cardiogenic shock. Emergent cardiac catheterization showed no significant coronary artery disease. Sepsis work-up was negative. He became progressively hypotensive, developed multi-organ failure, and died 48 h after admission. Postmortem examination showed diffuse microvasculopathy and changes due to global hypoperfusion of 12-48 h evolution. We present the first case of acute, fatal cardiac failure due to microvasculopathy most consistent with bevacizumab-associated toxicity. The findings are discussed in light of the existing literature. Published by Elsevier Ltd. JF - Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy AU - Gruenberg, Jessica AU - Manivel, J Carlos AU - Gupta, Pankaj AU - Dykoski, Richard AU - Mesa, Hector AD - Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, USA. Electronic address: grue0048@umn.edu. ; Department of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, USA; Department of Pathology, Minneapolis VA Health Care System, One Veterans Drive, Minneapolis, MN 55417, USA. Electronic address: Juan.Manivel@va.gov. ; Department of Hematology & Oncology, University of Minnesota School of Medicine, 420 Delaware St. SE, Minneapolis, MN 55455, USA; Department of Hematology & Oncology, Minneapolis VA Health Care System, One Veterans Drive, Minneapolis, MN 55417, USA. Electronic address: Pankaj.Gupta@va.gov. ; Department of Pathology, Minneapolis VA Health Care System, One Veterans Drive, Minneapolis, MN 55417, USA. Electronic address: Richard.Dykoski@va.gov. ; Department of Pathology, Minneapolis VA Health Care System, One Veterans Drive, Minneapolis, MN 55417, USA. Electronic address: Hector.Mesa@va.gov. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 112 EP - 116 VL - 22 IS - 2 KW - Deoxycytidine KW - 0W860991D6 KW - Bevacizumab KW - 2S9ZZM9Q9V KW - gemcitabine KW - B76N6SBZ8R KW - Cisplatin KW - Q20Q21Q62J KW - Index Medicus KW - Bladder cancer KW - Chemotherapy KW - Cardiotoxicity KW - Gemcitabine KW - Acute Disease KW - Bevacizumab -- adverse effects KW - Deoxycytidine -- adverse effects KW - Humans KW - Deoxycytidine -- analogs & derivatives KW - Deoxycytidine -- administration & dosage KW - Aged KW - Cisplatin -- adverse effects KW - Bevacizumab -- administration & dosage KW - Male KW - Cisplatin -- administration & dosage KW - Urothelium -- drug effects KW - Heart Diseases -- chemically induced KW - Carcinoma -- drug therapy KW - Urologic Neoplasms -- drug therapy KW - Heart Diseases -- mortality KW - Urologic Neoplasms -- mortality KW - Antineoplastic Combined Chemotherapy Protocols -- adverse effects KW - Carcinoma -- mortality KW - Antineoplastic Combined Chemotherapy Protocols -- therapeutic use UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1760886762?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.atitle=Fatal+acute+cardiac+vasculopathy+during+cisplatin-gemcitabine-bevacizumab+%28CGB%29+chemotherapy+for+advanced+urothelial+carcinoma.&rft.au=Gruenberg%2C+Jessica%3BManivel%2C+J+Carlos%3BGupta%2C+Pankaj%3BDykoski%2C+Richard%3BMesa%2C+Hector&rft.aulast=Gruenberg&rft.aufirst=Jessica&rft.date=2016-02-01&rft.volume=22&rft.issue=2&rft.spage=112&rft.isbn=&rft.btitle=&rft.title=Journal+of+infection+and+chemotherapy+%3A+official+journal+of+the+Japan+Society+of+Chemotherapy&rft.issn=1437-7780&rft_id=info:doi/10.1016%2Fj.jiac.2015.08.015 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-10-20 N1 - Date created - 2016-01-18 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.jiac.2015.08.015 ER - TY - JOUR T1 - BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. AN - 1754523526; 26731560 AB - Selective BRAF inhibitors (BRAFi) yield objective responses in 50% of patients with metastatic BRAF V600E mutant melanoma. Adding an MEK inhibitor increases this response rate to 70%. Limited data are available on the outcomes of unresectable stage III patients, and it remains unclear whether BRAF-targeted therapy can be utilized as a neoadjuvant strategy. Data on patients with advanced locoregional BRAF V600E mutant melanoma treated with BRAF-targeted therapy at Moffitt Cancer Center were analyzed to determine response rates, subsequent resection rates after tumor downsizing, pathologic responses, and patient survival. Fifteen patients with locoregional disease treated with BRAF-targeted therapy, either BRAFi alone (vemurafenib; 11 patients) or a combination of BRAFi and an MEK inhibitor (dabrafenib plus trametinib or placebo; four patients), were identified. The median age was 50 years; the median follow-up was 25.4 months. The median BRAF-targeted therapy treatment duration was 6.0 months (range 1.2-29.4 months). Response Evaluation Criteria In Solid Tumors-based evaluation demonstrated objective response in 11 patients (73.3%). Six patients underwent resection of the remaining disease after therapy. Pathological analysis showed complete pathologic response (n=2), partial pathologic response (n=2), or no pathologic response (n=2). Four of six patients undergoing surgery have been alive for more than 2 years, including three patients currently free from active disease. No complications attributable to BRAF-targeted therapy were observed in the perioperative period. Dose reduction or discontinuation because of toxicities occurred in 10/15 patients. Neoadjuvant BRAF-targeted therapy may be effective in advanced locoregional BRAF V600E mutant melanoma patients in increasing resectability, yielding pathological responses, and achieving prolonged survival. JF - Melanoma research AU - Sloot, Sarah AU - Zager, Jonathan S AU - Kudchadkar, Ragini R AU - Messina, Jane L AU - Benedict, Jacob J AU - Gonzalez, Ricardo J AU - DeConti, Ronald AU - Turner, Leslie M AU - McCardle, Timothy AU - Smalley, Keiran S M AU - Weber, Jeffrey S AU - Sondak, Vernon K AU - Gibney, Geoffrey T AD - Departments of aCutaneous Oncology bAnatomic Pathology, Moffitt Cancer Center Departments of cOncologic Sciences dSurgery, University of South Florida Morsani College of Medicine eDepartment of Pathology, Veterans Administration, Tampa, Florida fDepartment of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia gGeorgetown-Lombardi Comprehensive Cancer Center and Department of Medicine, Medstar-Georgetown University Hospital, Washington, DC, USA hUniversity of Groningen, Department of Surgical Oncology, University Medical Center Groningen, The Netherlands. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 83 EP - 87 VL - 26 IS - 1 KW - Imidazoles KW - 0 KW - Indoles KW - Oximes KW - Protein Kinase Inhibitors KW - Pyridones KW - Pyrimidinones KW - Sulfonamides KW - vemurafenib KW - 207SMY3FQT KW - trametinib KW - 33E86K87QN KW - Glutamic Acid KW - 3KX376GY7L KW - BRAF protein, human KW - EC 2.7.11.1 KW - Proto-Oncogene Proteins B-raf KW - Valine KW - HG18B9YRS7 KW - dabrafenib KW - QGP4HA4G1B KW - Index Medicus KW - Pyrimidinones -- administration & dosage KW - Oximes -- administration & dosage KW - Humans KW - Imidazoles -- administration & dosage KW - Protein Kinase Inhibitors -- administration & dosage KW - Neoadjuvant Therapy KW - Retrospective Studies KW - Disease Progression KW - Molecular Targeted Therapy KW - Valine -- genetics KW - Sulfonamides -- administration & dosage KW - Mutation, Missense KW - Glutamic Acid -- genetics KW - Pyridones -- administration & dosage KW - Treatment Outcome KW - Indoles -- administration & dosage KW - Follow-Up Studies KW - Middle Aged KW - Amino Acid Substitution KW - Female KW - Male KW - Skin Neoplasms -- genetics KW - Skin Neoplasms -- drug therapy KW - Melanoma -- pathology KW - Melanoma -- genetics KW - Melanoma -- mortality KW - Proto-Oncogene Proteins B-raf -- antagonists & inhibitors KW - Melanoma -- drug therapy KW - Antineoplastic Combined Chemotherapy Protocols -- therapeutic use KW - Skin Neoplasms -- mortality KW - Proto-Oncogene Proteins B-raf -- genetics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1754523526?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Melanoma+research&rft.atitle=BRAF+inhibition+for+advanced+locoregional+BRAF+V600E+mutant+melanoma%3A+a+potential+neoadjuvant+strategy.&rft.au=Sloot%2C+Sarah%3BZager%2C+Jonathan+S%3BKudchadkar%2C+Ragini+R%3BMessina%2C+Jane+L%3BBenedict%2C+Jacob+J%3BGonzalez%2C+Ricardo+J%3BDeConti%2C+Ronald%3BTurner%2C+Leslie+M%3BMcCardle%2C+Timothy%3BSmalley%2C+Keiran+S+M%3BWeber%2C+Jeffrey+S%3BSondak%2C+Vernon+K%3BGibney%2C+Geoffrey+T&rft.aulast=Sloot&rft.aufirst=Sarah&rft.date=2016-02-01&rft.volume=26&rft.issue=1&rft.spage=83&rft.isbn=&rft.btitle=&rft.title=Melanoma+research&rft.issn=1473-5636&rft_id=info:doi/10.1097%2FCMR.0000000000000214 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-10-19 N1 - Date created - 2016-01-06 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1097/CMR.0000000000000214 ER - TY - JOUR T1 - Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine. AN - 1750000796; 26362360 AB - Depression is a common co-morbid condition most often observed in subjects with mild cognitive impairment (MCI) and during the early stages of Alzheimer's disease (AD). Dysfunction of the central noradrenergic nervous system is an important component in depression. In AD, locus coeruleus (LC) noradrenergic neurons are significantly reduced pathologically and the reduction of LC neurons is hypothesized to begin very early in the progression of the disorder; however, it is not known if dysfunction of the noradrenergic system due to early LC neuronal loss is involved in mediating depression in early AD. Therefore, the purpose of this study was to determine in an animal model if a loss of noradrenergic LC neurons results in depressive-like behavior. The LC noradrenergic neuronal population was reduced by the bilateral administration of the neurotoxin 6-hydroxydopamine (6-OHDA) directly into the LC. Forced swim test (FST) was performed three weeks after the administration of 6-OHDA (5, 10 and 14 μg/μl), animals administered the 5 μg/μl of 6-OHDA demonstrated a significant increase in immobility, indicating depressive-like behavior. This increase in immobility at the 5 μg/μl dose was observed with a minimal loss of LC noradrenergic neurons as compared to LC neuronal loss observed at 10 and 14 μg/μl dose. A significant positive correlation between the number of surviving LC neurons after 6-OHDA and FST immobile time was observed, suggesting that in animals with a minimal loss of LC neurons (or a greater number of surviving LC neurons) following 6-OHDA demonstrated depressive-like behavior. As the 6-OHDA-induced loss of LC neurons is increased, the time spent immobile is reduced. Depressive-like behavior was also observed with the 5 μg/μl dose of 6-OHDA with a second behavior test, sucrose consumption. FST increased immobility following 6-OHDA (5 μg/μl) was reversed by the administration of a single dose of L-1-3-4-dihydroxyphenylalanine (DOPA) or l-threo-3,4-dihydroxyphenylserine (DOPS) prior to behavioral assessment. Surviving LC neurons 3 weeks after 6-OHDA (5 μg/μl) demonstrated compensatory changes of increased firing frequency, a more irregular firing pattern, and a higher percentage of cells firing in bursts. These results indicate that depressive-like behavior in mice is observed following the administration of 6-OHDA and the loss of LC noradrenergic neurons; however, the depressive-like behavior correlates positively with the number of surviving LC neurons with 6-OHDA administration. This data suggests the depression observed in MCI subjects and in the early stages of AD may due to the hypothesized early, minimal loss of LC neurons with remaining LC neurons being more active than normal. Published by Elsevier Ltd. JF - Neuropharmacology AU - Szot, Patricia AU - Franklin, Allyn AU - Miguelez, Cristina AU - Wang, Yangqing AU - Vidaurrazaga, Igor AU - Ugedo, Luisa AU - Sikkema, Carl AU - Wilkinson, Charles W AU - Raskind, Murray A AD - Mental Illness Research, Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, WA, USA; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA. Electronic address: szot@uw.edu. ; Mental Illness Research, Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, WA, USA. ; Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain; Department of Pharmacology, University of the Basque Country, UPV/EHU, Vitoria-Gasteiz, Spain. ; Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain. ; Geriatric Research, Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, WA, USA. ; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA; Geriatric Research, Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, WA, USA. ; Mental Illness Research, Education and Clinical Center, Veterans Administration Puget Sound Health Care System, Seattle, WA, USA; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA. Y1 - 2016/02// PY - 2016 DA - February 2016 SP - 76 EP - 86 VL - 101 KW - Adrenergic Agents KW - 0 KW - Catecholamines KW - Dopamine Agents KW - Phenazines KW - dihydroxyphenoxazine KW - Levodopa KW - 46627O600J KW - Sucrose KW - 57-50-1 KW - Oxidopamine KW - 8HW4YBZ748 KW - Index Medicus KW - Depression KW - Locus coeruleus KW - 6-Hydroxydopamine KW - Forced swim test KW - Electrophysiology KW - Levodopa -- pharmacology KW - Swimming -- psychology KW - Animals KW - Phenazines -- pharmacology KW - Food Preferences KW - Dose-Response Relationship, Drug KW - Dopamine Agents -- pharmacology KW - Mice, Inbred C57BL KW - Disease Models, Animal KW - Mice KW - Sucrose -- administration & dosage KW - Time Factors KW - Male KW - Locus Coeruleus -- pathology KW - Adrenergic Agents -- toxicity KW - Depression -- pathology KW - Catecholamines -- metabolism KW - Oxidopamine -- toxicity KW - Neurons -- drug effects KW - Neurons -- physiology KW - Action Potentials -- drug effects KW - Depression -- chemically induced UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1750000796?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Neuropharmacology&rft.atitle=Depressive-like+behavior+observed+with+a+minimal+loss+of+locus+coeruleus+%28LC%29+neurons+following+administration+of+6-hydroxydopamine+is+associated+with+electrophysiological+changes+and+reversed+with+precursors+of+norepinephrine.&rft.au=Szot%2C+Patricia%3BFranklin%2C+Allyn%3BMiguelez%2C+Cristina%3BWang%2C+Yangqing%3BVidaurrazaga%2C+Igor%3BUgedo%2C+Luisa%3BSikkema%2C+Carl%3BWilkinson%2C+Charles+W%3BRaskind%2C+Murray+A&rft.aulast=Szot&rft.aufirst=Patricia&rft.date=2016-02-01&rft.volume=101&rft.issue=&rft.spage=76&rft.isbn=&rft.btitle=&rft.title=Neuropharmacology&rft.issn=1873-7064&rft_id=info:doi/10.1016%2Fj.neuropharm.2015.09.003 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-09-22 N1 - Date created - 2015-12-16 N1 - Date revised - 2017-02-02 N1 - SuppNotes - Cited By: Eur J Pharmacol. 1978 Oct 1;51(3):291-4 [568552] Proc Natl Acad Sci U S A. 2004 May 25;101(21):8186-91 [15148402] J Neurol Sci. 1981 Mar;49(3):419-28 [7217992] Neurology. 1982 Feb;32(2):164-8 [7198741] Neurosci Lett. 1986 Mar 14;64(3):247-52 [3960404] Neuropharmacology. 1986 Apr;25(4):385-9 [3012399] Neuroscience. 1986 Jun;18(2):291-306 [3736860] Neuroscience. 1986 Jun;18(2):307-19 [3736861] Psychopharmacol Bull. 1986;22(3):943-9 [3797595] Ciba Found Symp. 1986;123:191-215 [3028724] Adv Exp Med Biol. 1988;245:425-40 [2906520] Neuropsychopharmacology. 1988 Dec;1(4):287-95 [2908021] Neuropharmacology. 1989 Jul;28(7):651-60 [2569689] J Comp Neurol. 1989 Sep 15;287(3):373-92 [2570794] Ann Neurol. 1992 Nov;32(5):667-76 [1449247] Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):267-72 [9050022] Eur J Pharmacol. 1997 Oct 22;337(2-3):115-23 [9430405] Psychopharmacology (Berl). 1998 Apr;136(3):299-303 [9566816] J Neurochem. 1998 Jun;70(6):2468-76 [9603211] J Neurosci. 2006 Jan 11;26(2):467-78 [16407544] Int Psychogeriatr. 2007 Feb;19(1):125-35 [16834811] Eur Neuropsychopharmacol. 2007 Apr;17(5):328-38 [16950604] J Affect Disord. 2008 Feb;106(1-2):169-72 [17698206] Am J Geriatr Psychiatry. 2009 Apr;17(4):308-16 [19307859] Int J Neuropsychopharmacol. 2009 Jun;12(5):627-41 [18950545] Acta Neuropathol. 2011 Feb;121(2):171-81 [21170538] Brain Res. 2011 Feb 10;1373:240-52 [21147074] Int J Neuropsychopharmacol. 2011 Mar;14(2):187-200 [20426885] Neurobiol Dis. 2011 Jun;42(3):327-40 [21310234] Acta Neuropathol. 2011 May;121(5):589-95 [21516512] Brain Res Rev. 2011 Jun 24;67(1-2):193-208 [21315760] Alzheimers Dement. 2011 Sep;7(5):532-9 [21889116] J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9 [22002422] Biol Psychiatry. 2012 May 1;71(9):814-21 [22322105] Epilepsia. 2012 Jun;53 Suppl 1:61-6 [22612810] Neuroscience. 2012 Aug 2;216:143-57 [22542679] Arch Neurol. 2004 Aug;61(8):1290-3 [15313849] N Engl J Med. 1969 Feb 13;280(7):337-45 [4178641] Psychol Med. 1973 Aug;3(3):333-6 [4729193] Am J Geriatr Psychiatry. 2012 Aug;20(8):653-63 [22157280] J Alzheimers Dis. 2012;31(2):325-34 [22543849] Neurobiol Aging. 2013 Jan;34(1):286-97 [22503003] Curr Opin Neurol. 2012 Dec;25(6):708-14 [23160422] Int J Neuropsychopharmacol. 2013 Jun;16(5):1093-104 [23040084] J Alzheimers Dis. 2014;38(2):319-29 [23963290] Am J Geriatr Psychiatry. 2014 Jan;22(1):4-13.e1 [23880336] Am J Psychiatry. 2014 May;171(5):572-81 [24700290] Eur Neuropsychopharmacol. 2014 Jul;24(7):1112-22 [24582527] J Neurosci. 1999 Dec 15;19(24):10985-92 [10594079] Biol Psychiatry. 1999 Nov 1;46(9):1167-80 [10560023] Neurobiol Aging. 2015 Jan;36(1):1-11 [25444609] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):325-30 [10618417] Neuropsychopharmacology. 2000 Feb;22(2):191-9 [10649831] Biol Psychiatry. 2001 Jan 15;49(2):117-29 [11164758] J Pharmacol Exp Ther. 2001 Aug;298(2):651-7 [11454927] Eur J Pharmacol. 2002 Feb 2;436(3):197-205 [11858799] Arch Neurol. 2003 Mar;60(3):337-41 [12633144] J Affect Disord. 2003 Apr;74(2):185-9 [12706520] Am J Psychiatry. 2003 May;160(5):857-66 [12727688] Psychopharmacology (Berl). 1979 Jun 28;64(1):95-7 [113840] N1 - Last updated - 2017-02-02 DO - http://dx.doi.org/10.1016/j.neuropharm.2015.09.003 ER - TY - JOUR T1 - Lamotrigine Induced Whole Body Tics: A Case Report and Literature Review. AN - 1790457977; 26537524 AB - Lamotrigine is an anticonvulsant medication that also has utility in the treatment of bipolar disorder. It has been associated with many side effects, including rashes that can progress to Stevens-Johnson syndrome or toxic epidermal necrolysis. It has also been associated with the development of motor tics, most commonly in the head, neck, and shoulders. We will now present the case of a 45-year-old woman who developed tics that involved the entire left side of her body after her dose of lamotrigine was increased from 200 mg daily (2.0 mg/kg/day) to 225 mg daily (2.3 mg/kg/day). We will review the prior cases of lamotrigine induced tics, and compare them to the circumstances surrounding our patient. We will also discuss the neurobiology of tics and make suggestions to improve the tics, based on the reported cases. JF - Current drug safety AU - Centorino, Michael B AU - Catalano, Glenn AU - Catalano, Maria C AD - Mental Health and Behavioral Sciences Service, James A. Haley Veterans Hospital, 13000 Bruce B. Downs Boulevard #116A, Tampa, Florida, FL 33612, USA. glenn.catalano@va.gov. Y1 - 2016 PY - 2016 DA - 2016 SP - 189 EP - 191 VL - 11 IS - 2 KW - Index Medicus UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1790457977?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Current+drug+safety&rft.atitle=Lamotrigine+Induced+Whole+Body+Tics%3A+A+Case+Report+and+Literature+Review.&rft.au=Centorino%2C+Michael+B%3BCatalano%2C+Glenn%3BCatalano%2C+Maria+C&rft.aulast=Centorino&rft.aufirst=Michael&rft.date=2016-01-01&rft.volume=11&rft.issue=2&rft.spage=189&rft.isbn=&rft.btitle=&rft.title=Current+drug+safety&rft.issn=2212-3911&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date created - 2016-05-19 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 ER - TY - JOUR T1 - Stress Reactivity in Insomnia AN - 1789436230 AB - This study examined whether individuals with primary insomnia (PI) are more reactive to stress than good sleepers (GS). PI and GS (n = 20 per group), matched on gender and age, completed three nights of polysomnography. On the stress night, participants received a mild electric shock and were told they could receive additional shocks during the night. Saliva samples were obtained for analysis of cortisol and alpha amylase along with self-report and visual analog scales (VAS). There was very little evidence of increased stress on the stress night, compared to the baseline night. There was also no evidence of greater stress reactivity in the PI group for any sleep or for salivary measures. In the GS group, stress reactivity measured by VAS scales was positively associated with an increase in sleep latency in the experimental night on exploratory analyses. Individuals with PI did not show greater stress reactivity compared to GS. JF - Behavioral Sleep Medicine AU - Gehrman, Philip R AU - Hall, Martica AU - Barilla, Holly AU - Buysse, Daniel AU - Perlis, Michael AU - Gooneratne, Nalaka AU - Ross, Richard J AD - Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania; Philadelphia Veterans Administration Medical Center ; Sleep Medicine Institute and Department of Psychiatry, University of Pittsburgh School of Medicine ; Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania ; Division of Geriatric Medicine Perelman School of Medicine at the University of Pennsylvania ; Philadelphia Veterans Administration Medical Center; Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania Y1 - 2016///Jan/Feb PY - 2016 DA - Jan/Feb 2016 SP - 23 EP - 33 CY - Mahwah PB - Taylor & Francis Ltd. VL - 14 IS - 1 SN - 1540-2002 KW - Psychology KW - Insomnia KW - Cortisol KW - Electric shock KW - Polysomnography KW - Reactivity KW - Stress KW - Sleep UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1789436230?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Behavioral+Sleep+Medicine&rft.atitle=Stress+Reactivity+in+Insomnia&rft.au=Gehrman%2C+Philip+R%3BHall%2C+Martica%3BBarilla%2C+Holly%3BBuysse%2C+Daniel%3BPerlis%2C+Michael%3BGooneratne%2C+Nalaka%3BRoss%2C+Richard+J&rft.aulast=Gehrman&rft.aufirst=Philip&rft.date=2016-01-01&rft.volume=14&rft.issue=1&rft.spage=23&rft.isbn=&rft.btitle=&rft.title=Behavioral+Sleep+Medicine&rft.issn=15402002&rft_id=info:doi/10.1080%2F15402002.2014.940112 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Copyright © Taylor & Francis Group, LLC N1 - Last updated - 2016-05-19 DO - http://dx.doi.org/10.1080/15402002.2014.940112 ER - TY - JOUR T1 - Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027 AN - 1758247329; PQ0002452947 AB - Antibiotics have been shown to influence the risk of infection with specific Clostridium difficile strains as well as the risk of C. difficile infection (CDI). We performed a retrospective case-control study of patients infected with the epidemic BI/NAP1/027 strain in a U.S. hospital following recognition of increased CDI severity and culture of stools positive by C. difficile toxin immunoassay. Between 2005 and 2007, 72% (103/143) of patients with first-episode CDIs were infected with the BI strain by restriction endonuclease analysis (REA) typing. Most patients received multiple antibiotics within 6 weeks of CDI onset (median of 3 antibiotic classes). By multivariate analysis, fluoroquinolone and macrolide exposure was more frequent among BI cases than among non-BI-infected controls (odds ratio [OR] for fluoroquinolones, 3.2; 95% confidence interval [CI], 1.3 to 7.5; (P < 0.001; OR for macrolides, 5.2; 95% CI, 1.1 to 24.0; P = 0.04)). In contrast, clindamycin use was less frequent among the BI cases than among the controls (OR, 0.1; 95% CI, 0.03 to 0.4; P = 0.001). High-level resistance to moxifloxacin and azithromycin was more frequent among BI strains (moxifloxacin, 49/102 [48%] BI versus 0/40 non-BI, P = 0.0001; azithromycin, 100/102 [98%] BI versus 22/40 [55%] non-BI, P = 0.0001). High-level resistance to clindamycin was more frequent among non-BI strains (22/40 [55%] non-BI versus 7/102 [7%] BI, P = 0.0001). Fluoroquinolone use, macrolide use, and C. difficile resistance to these antibiotic classes were associated with infection by the epidemic BI strain of C. difficile in a U.S. hospital during a time when CDI rates were increasing nationally due to the highly fluoroquinolone-resistant BI/NAP1/027 strain. JF - Antimicrobial Agents & Chemotherapy AU - Wieczorkiewicz, Jeffrey T AU - Lopansri, Bert K AU - Cheknis, Adam AU - Osmolski, James R AU - Hecht, David W AU - Gerding, Dale N AU - Johnson, Stuart AD - << + $0, stuart.johnson2@va.gov. Y1 - 2016/01// PY - 2016 DA - January 2016 SP - 418 EP - 423 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 60 IS - 1 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Health & Safety Science Abstracts; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Clindamycin KW - Epidemics KW - Fluoroquinolones KW - Chemotherapy KW - Antibiotics KW - Infection KW - Toxins KW - Antimicrobial agents KW - Health risks KW - Typing KW - Multivariate analysis KW - Moxifloxacin KW - Azithromycin KW - Clostridium difficile KW - Endonuclease KW - Feces KW - Immunoassays KW - Hospitals KW - A 01340:Antibiotics & Antimicrobials KW - H 13000:Medical Safety KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1758247329?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Fluoroquinolone+and+Macrolide+Exposure+Predict+Clostridium+difficile+Infection+with+the+Highly+Fluoroquinolone-+and+Macrolide-Resistant+Epidemic+C.+difficile+Strain+BI%2FNAP1%2F027&rft.au=Wieczorkiewicz%2C+Jeffrey+T%3BLopansri%2C+Bert+K%3BCheknis%2C+Adam%3BOsmolski%2C+James+R%3BHecht%2C+David+W%3BGerding%2C+Dale+N%3BJohnson%2C+Stuart&rft.aulast=Wieczorkiewicz&rft.aufirst=Jeffrey&rft.date=2016-01-01&rft.volume=60&rft.issue=1&rft.spage=418&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.01820-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-01-01 N1 - Number of references - 23 N1 - Last updated - 2016-02-29 N1 - SubjectsTermNotLitGenreText - Clindamycin; Epidemics; Fluoroquinolones; Antibiotics; Infection; Toxins; Typing; Moxifloxacin; Multivariate analysis; Azithromycin; Feces; Endonuclease; Immunoassays; Hospitals; Health risks; Chemotherapy; Antimicrobial agents; Clostridium difficile DO - http://dx.doi.org/10.1128/AAC.01820-15 ER - TY - JOUR T1 - Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection. AN - 1750425194; 26433782 AB - The aim of this study was to evaluate the susceptibilities of Clostridium difficile isolates to cadazolid, a novel antibiotic for the treatment of C. difficile infection. Ribotyping and susceptibilities were determined for C. difficile isolates from a multicentre, double-blind, Phase 2 study of oral cadazolid in patients with C. difficile infection (NCT01222702, ClinicalTrials.gov; EudraCT 2010-020941-29, European Clinical Trials Database). Patients were randomized to receive 250, 500 or 1000 mg of cadazolid twice daily or 125 mg of vancomycin four times daily, for 10 days. MICs of cadazolid, vancomycin, fidaxomicin, linezolid and moxifloxacin were determined at baseline for all patients and post-baseline for patients with clinical failure or recurrence, using the agar dilution method. Seventy-eight of 84 patients had an evaluable toxigenic C. difficile isolate at baseline. The most frequent PCR ribotype was 027 (15.4%). Cadazolid MICs for baseline isolates (including epidemic strain 027) ranged from 0.06 to 0.25 mg/L. Baseline cadazolid MICs were similar to those of fidaxomicin and lower than those of vancomycin, linezolid and moxifloxacin. For each clinical outcome group (clinical cure, clinical failure, sustained clinical response and clinical failure or recurrence), the baseline cadazolid MIC range was 0.06-0.25 mg/L. Mean (min-max) cadazolid faecal concentration (μg/g) on day 5 was 884 (101-2710), 1706 (204-4230) and 3226 (1481-12 600) for the doses 250, 500 and 1000 mg, respectively. For all cadazolid doses, the faecal concentration was in excess of several thousand-fold the MIC90 for C. difficile. The MIC of cadazolid for all C. difficile isolates, including epidemic strains, was low and in the same narrow range regardless of treatment outcome. © The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. JF - The Journal of antimicrobial chemotherapy AU - Gerding, D N AU - Hecht, D W AU - Louie, T AU - Nord, C E AU - Talbot, G H AU - Cornely, O A AU - Buitrago, M AU - Best, E AU - Sambol, S AU - Osmolski, J R AU - Kracker, H AU - Locher, H H AU - Charef, P AU - Wilcox, M AD - Loyola University, Maywood, IL, USA Edward Hines Jr VA Hospital, Hines, IL, USA dale.gerding2@va.gov. ; Loyola University, Maywood, IL, USA Edward Hines Jr VA Hospital, Hines, IL, USA. ; University of Calgary, Calgary, Alberta, Canada. ; Karolinska Institute, Stockholm, Sweden. ; Talbot Advisors, Anna Maria, FL, USA. ; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany Clinical Trials Centre Cologne, University of Cologne, Cologne, Germany Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. ; Idaho Falls Infectious Diseases, Idaho Falls, ID, USA. ; Leeds General Infirmary, Leeds, UK. ; Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. Y1 - 2016/01// PY - 2016 DA - January 2016 SP - 213 EP - 219 VL - 71 IS - 1 KW - Anti-Bacterial Agents KW - 0 KW - Oxazolidinones KW - cadazolid KW - 2OEA2UN10Y KW - Vancomycin KW - 6Q205EH1VU KW - Index Medicus KW - Young Adult KW - Ribotyping KW - Double-Blind Method KW - Aged, 80 and over KW - Humans KW - Adult KW - Aged KW - Middle Aged KW - Adolescent KW - Microbial Sensitivity Tests KW - Male KW - Female KW - Clostridium Infections -- drug therapy KW - Vancomycin -- pharmacology KW - Vancomycin -- administration & dosage KW - Clostridium difficile -- isolation & purification KW - Oxazolidinones -- administration & dosage KW - Anti-Bacterial Agents -- pharmacology KW - Clostridium difficile -- classification KW - Anti-Bacterial Agents -- administration & dosage KW - Oxazolidinones -- pharmacology KW - Clostridium difficile -- genetics KW - Clostridium Infections -- microbiology KW - Clostridium difficile -- drug effects UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1750425194?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+antimicrobial+chemotherapy&rft.atitle=Susceptibility+of+Clostridium+difficile+isolates+from+a+Phase+2+clinical+trial+of+cadazolid+and+vancomycin+in+C.+difficile+infection.&rft.au=Gerding%2C+D+N%3BHecht%2C+D+W%3BLouie%2C+T%3BNord%2C+C+E%3BTalbot%2C+G+H%3BCornely%2C+O+A%3BBuitrago%2C+M%3BBest%2C+E%3BSambol%2C+S%3BOsmolski%2C+J+R%3BKracker%2C+H%3BLocher%2C+H+H%3BCharef%2C+P%3BWilcox%2C+M&rft.aulast=Gerding&rft.aufirst=D&rft.date=2016-01-01&rft.volume=71&rft.issue=1&rft.spage=213&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+antimicrobial+chemotherapy&rft.issn=1460-2091&rft_id=info:doi/10.1093%2Fjac%2Fdkv300 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-10-05 N1 - Date created - 2015-12-17 N1 - Date revised - 2017-01-14 N1 - Genetic sequence - NCT01222702; ClinicalTrials.gov; 2010-020941-29; EudraCT N1 - SuppNotes - Cited By: Clin Infect Dis. 2009 Mar 1;48(5):568-76 [19191641] Nat Rev Microbiol. 2009 Jul;7(7):526-36 [19528959] Expert Rev Anti Infect Ther. 2010 May;8(5):555-64 [20455684] Nat Rev Gastroenterol Hepatol. 2011 Jan;8(1):17-26 [21119612] N Engl J Med. 2011 Feb 3;364(5):422-31 [21288078] Gut. 1986 Oct;27(10):1169-72 [3781329] Ann Intern Med. 1992 Aug 15;117(4):297-302 [1322075] J Clin Microbiol. 1993 Jul;31(7):1870-5 [8394378] J Clin Microbiol. 1999 Feb;37(2):461-3 [9889244] J Med Microbiol. 2005 Feb;54(Pt 2):101-11 [15673502] N Engl J Med. 2005 Dec 8;353(23):2433-41 [16322603] South Med J. 2006 May;99(5):518-20 [16711316] Clin Infect Dis. 2007 Jan 15;44(2):238-44 [17173224] Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9 [17517836] Clin Infect Dis. 2008 Nov 1;47(9):1162-70 [18808358] J Med Microbiol. 2008 Nov;57(Pt 11):1377-82 [18927415] Euro Surveill. 2008 Dec 4;13(49). pii: 19057 [19081002] Lancet Infect Dis. 2012 Apr;12(4):281-9 [22321770] Clin Infect Dis. 2012 Aug;55 Suppl 2:S65-70 [22752867] J Infect. 2013 Feb;66(2):115-28 [23103666] Anaerobe. 2013 Apr;20:32-5 [23454525] N Z Med J. 2013 Aug 16;126(1380):9-14 [24126745] Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26 [24118601] Antimicrob Agents Chemother. 2014;58(2):892-900 [24277020] Antimicrob Agents Chemother. 2014;58(2):901-8 [24277035] Gut Liver. 2014 Jan;8(1):1-6 [24516694] J Antimicrob Chemother. 2014 Mar;69(3):706-14 [24106141] J Antimicrob Chemother. 2014 Mar;69(3):697-705 [24128668] Antimicrob Agents Chemother. 2015 Oct;59(10):6266-73 [26248357] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1093/jac/dkv300 ER - TY - JOUR T1 - A Chemical Mutagenesis Screen Identifies Mouse Models with ERG Defects. AN - 1718905304; 26427409 AB - Mouse models provide important resources for many areas of vision research, pertaining to retinal development, retinal function and retinal disease. The Translational Vision Research Models (TVRM) program uses chemical mutagenesis to generate new mouse models for vision research. In this chapter, we report the identification of mouse models for Grm1, Grk1 and Lrit3. Each of these is characterized by a primary defect in the electroretinogram. All are available without restriction to the research community. JF - Advances in experimental medicine and biology AU - Charette, Jeremy R AU - Samuels, Ivy S AU - Yu, Minzhong AU - Stone, Lisa AU - Hicks, Wanda AU - Shi, Lan Ying AU - Krebs, Mark P AU - Naggert, Jürgen K AU - Nishina, Patsy M AU - Peachey, Neal S AD - The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Jeremy.Charette@jax.org. ; Louis Stokes Cleveland VA Medical Center, 44106, Cleveland, OH, USA. Ivy.Samuels@va.gov. ; Cole Eye Institute, Cleveland Clinic, 44195, Cleveland, OH, USA. YUM@ccf.org. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Lisa.Stone@jax.org. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Wanda.jordan@jax.org. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. lanying_shi1234@163.com. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Mark.Krebs@jax.org. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Juergen.Naggert@jax.org. ; The Jackson Laboratory, 04609, Bar Harbor, ME, USA. Nishina@jax.org. ; Louis Stokes Cleveland VA Medical Center, 44106, Cleveland, OH, USA. peachen@ccf.org. Y1 - 2016 PY - 2016 DA - 2016 SP - 177 EP - 183 VL - 854 SN - 0065-2598, 0065-2598 KW - Lrit3 protein, mouse KW - 0 KW - Membrane Proteins KW - Receptors, Metabotropic Glutamate KW - metabotropic glutamate receptor type 1 KW - G-Protein-Coupled Receptor Kinase 1 KW - EC 2.7.11.14 KW - Grk1 protein, mouse KW - Index Medicus KW - Retina KW - Mice KW - Electroretinogram KW - Photoreceptor KW - Mutagenesis KW - Animals KW - G-Protein-Coupled Receptor Kinase 1 -- genetics KW - Genetic Testing -- methods KW - Receptors, Metabotropic Glutamate -- genetics KW - Humans KW - Eye Diseases -- physiopathology KW - Vision, Ocular -- genetics KW - Disease Models, Animal KW - Translational Medical Research -- methods KW - Membrane Proteins -- genetics KW - Eye Diseases -- genetics KW - Mice, Inbred DBA KW - Alleles KW - Mice, Inbred C57BL KW - Eye Diseases -- diagnosis KW - Vision, Ocular -- physiology KW - Male KW - Electroretinography KW - Retina -- metabolism KW - Retinal Diseases -- diagnosis KW - Genetic Predisposition to Disease -- genetics KW - Retina -- physiopathology KW - Retina -- pathology KW - Retinal Diseases -- genetics KW - Mutation UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1718905304?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Advances+in+experimental+medicine+and+biology&rft.atitle=A+Chemical+Mutagenesis+Screen+Identifies+Mouse+Models+with+ERG+Defects.&rft.au=Charette%2C+Jeremy+R%3BSamuels%2C+Ivy+S%3BYu%2C+Minzhong%3BStone%2C+Lisa%3BHicks%2C+Wanda%3BShi%2C+Lan+Ying%3BKrebs%2C+Mark+P%3BNaggert%2C+J%C3%BCrgen+K%3BNishina%2C+Patsy+M%3BPeachey%2C+Neal+S&rft.aulast=Charette&rft.aufirst=Jeremy&rft.date=2016-01-01&rft.volume=854&rft.issue=&rft.spage=177&rft.isbn=&rft.btitle=&rft.title=Advances+in+experimental+medicine+and+biology&rft.issn=00652598&rft_id=info:doi/10.1007%2F978-3-319-17121-0_24 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-04-18 N1 - Date created - 2015-10-02 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1007/978-3-319-17121-0_24 ER - TY - JOUR T1 - Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy AN - 1832245252; PQ0002380877 AB - An increase in fluoroquinolone resistance and transrectal ultrasound-guided prostate (TRUS) biopsy infections has prompted the need for alternative effective antibiotic prophylaxis. We aimed to compare ciprofloxacin and other single-agent therapies to combination therapy for efficacy and adverse effects. Men who underwent a TRUS biopsy within the VA Boston health care system with documented receipt of prophylactic antibiotics periprocedure were eligible for inclusion. Postprocedure infections within 30 days were ascertained by chart review from electronic records, including any inpatient, outpatient, or urgent-care visits. Among 455 evaluable men over a 3-year period, there were 25 infections (5.49%), with sepsis occurring in 2.4%, urinary tract infections (UTI) in 1.54%, and bacteremia in 0.44% of patients. Escherichia coli was the most common urine (89%) and blood (92%) pathogen, with fluoroquinolone resistance rates of 88% and 91%, respectively. Ciprofloxacin alone was associated with significantly more infections than ciprofloxacin plus an additional agent (P = 0.014). Intramuscular gentamicin alone was also significantly associated with a higher infection rate obtained with all other regimens (P = 0.004). Any single-agent regimen, including ciprofloxacin, ceftriaxone, or gentamicin, was associated with significantly higher infection rates than any combination regimen (odds ratio [OR], 4; 95% confidence interval [CI], 1.47, 10.85; P = 0.004). Diabetes, immunosuppressive condition or medication, hospitalization within the previous year, and UTI within the previous 6 months were not associated with infection risk. Clostridium difficile infections were similar. These findings suggest that ciprofloxacin, ceftriaxone, and gentamicin alone are inferior to a combination regimen. Institutions with high failure rates of prophylaxis for TRUS biopsies should consider combination regimens derived from their local data. JF - Antimicrobial Agents & Chemotherapy AU - Marino, Kaylee AU - Parlee, Anne AU - Orlando, Ralph AU - Lerner, Lori AU - Strymish, Judith AU - Gupta, Kalpana AD - << + $0, kalpana.gupta@va.gov. Y1 - 2015/12// PY - 2015 DA - December 2015 SP - 7273 EP - 7275 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 59 IS - 12 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Data processing KW - Fluoroquinolones KW - Bacteremia KW - Antibiotics KW - Biopsy KW - Urinary tract KW - Ceftriaxone KW - Pathogens KW - Infection KW - Diabetes mellitus KW - Gentamicin KW - Ciprofloxacin KW - Blood KW - Sepsis KW - Urine KW - Escherichia coli KW - Prophylaxis KW - Clostridium difficile KW - Prostate KW - Side effects KW - A 01340:Antibiotics & Antimicrobials KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1832245252?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Comparative+Effectiveness+of+Single+versus+Combination+Antibiotic+Prophylaxis+for+Infections+after+Transrectal+Prostate+Biopsy&rft.au=Marino%2C+Kaylee%3BParlee%2C+Anne%3BOrlando%2C+Ralph%3BLerner%2C+Lori%3BStrymish%2C+Judith%3BGupta%2C+Kalpana&rft.aulast=Marino&rft.aufirst=Kaylee&rft.date=2015-12-01&rft.volume=59&rft.issue=12&rft.spage=7273&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.01457-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-10-01 N1 - Number of references - 9 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Data processing; Fluoroquinolones; Bacteremia; Biopsy; Antibiotics; Pathogens; Ceftriaxone; Urinary tract; Infection; Gentamicin; Diabetes mellitus; Blood; Ciprofloxacin; Sepsis; Urine; Prophylaxis; Prostate; Side effects; Escherichia coli; Clostridium difficile DO - http://dx.doi.org/10.1128/AAC.01457-15 ER - TY - JOUR T1 - A multi-targeted approach to suppress tumor-promoting inflammation. AN - 1736411274; 25951989 AB - Cancers harbor significant genetic heterogeneity and patterns of relapse following many therapies are due to evolved resistance to treatment. While efforts have been made to combine targeted therapies, significant levels of toxicity have stymied efforts to effectively treat cancer with multi-drug combinations using currently approved therapeutics. We discuss the relationship between tumor-promoting inflammation and cancer as part of a larger effort to develop a broad-spectrum therapeutic approach aimed at a wide range of targets to address this heterogeneity. Specifically, macrophage migration inhibitory factor, cyclooxygenase-2, transcription factor nuclear factor-κB, tumor necrosis factor alpha, inducible nitric oxide synthase, protein kinase B, and CXC chemokines are reviewed as important antiinflammatory targets while curcumin, resveratrol, epigallocatechin gallate, genistein, lycopene, and anthocyanins are reviewed as low-cost, low toxicity means by which these targets might all be reached simultaneously. Future translational work will need to assess the resulting synergies of rationally designed antiinflammatory mixtures (employing low-toxicity constituents), and then combine this with similar approaches targeting the most important pathways across the range of cancer hallmark phenotypes. Copyright © 2015 Elsevier Ltd. All rights reserved. JF - Seminars in cancer biology AU - Samadi, Abbas K AU - Bilsland, Alan AU - Georgakilas, Alexandros G AU - Amedei, Amedeo AU - Amin, Amr AU - Bishayee, Anupam AU - Azmi, Asfar S AU - Lokeshwar, Bal L AU - Grue, Brendan AU - Panis, Carolina AU - Boosani, Chandra S AU - Poudyal, Deepak AU - Stafforini, Diana M AU - Bhakta, Dipita AU - Niccolai, Elena AU - Guha, Gunjan AU - Vasantha Rupasinghe, H P AU - Fujii, Hiromasa AU - Honoki, Kanya AU - Mehta, Kapil AU - Aquilano, Katia AU - Lowe, Leroy AU - Hofseth, Lorne J AU - Ricciardiello, Luigi AU - Ciriolo, Maria Rosa AU - Singh, Neetu AU - Whelan, Richard L AU - Chaturvedi, Rupesh AU - Ashraf, S Salman AU - Shantha Kumara, H M C AU - Nowsheen, Somaira AU - Mohammed, Sulma I AU - Keith, W Nicol AU - Helferich, William G AU - Yang, Xujuan AD - Sanus Biosciences, San Diego, CA, United States. ; Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland, UK. ; Physics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece. ; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. ; Department of Biology, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates; Faculty of Science, Cairo University, Cairo, Egypt. ; Department of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, FL, United States. ; Department of Pathology, Wayne State Univeristy, Karmanos Cancer Center, Detroit, MI, USA. ; Department of Urology, University of Miami, Miller School of Medicine, Miami, FL, United States; Miami Veterans Administration Medical Center, Miami, FL, United States. ; Department of Environmental Science, Dalhousie University, Halifax, Nova Scotia, Canada; Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada. ; Laboratory of Inflammatory Mediators, State University of West Paraná, UNIOESTE, Paraná, Brazil. ; Department of BioMedical Sciences, School of Medicine, Creighton University, Omaha, NE, United States. ; Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, United States. ; Huntsman Cancer Institute and Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States. ; School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India. ; University of Florence, Florence, Italy. ; Department of Environmental Sciences, Faculty of Agriculture and Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. ; Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan. ; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States. ; Department of Biology, University of Rome "Tor Vergata", Rome, Italy. ; Getting to Know Cancer, Truro, Nova Scotia, Canada. Electronic address: leroy.lowe@gettingtoknowcancer.org. ; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ; Advanced Molecular Science Research Centre (Centre for Advanced Research), King George's Medical University, Lucknow, Uttar Pradesh, India. ; Department of Surgery, St. Luke's Roosevelt Hospital, New York, NY, United States. ; School of Biotechnology, Jawaharlal Nehru University, New Delhi, India. ; Department of Chemistry, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates. ; Medical Scientist Training Program, Mayo Graduate School, Mayo Medical School, Mayo Clinic, Rochester, MN, United States. ; Department of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN, United States. ; University of Illinois at Urbana Champaign, Champaign, IL, United States. Y1 - 2015/12// PY - 2015 DA - December 2015 SP - S151 EP - S184 VL - 35 Suppl KW - Antineoplastic Agents KW - 0 KW - Neoplasm Proteins KW - Index Medicus KW - Tumor KW - Phytochemicals KW - Hallmarks KW - Cancer KW - Inflammation KW - Genetic Heterogeneity -- drug effects KW - Humans KW - Signal Transduction -- drug effects KW - Molecular Targeted Therapy KW - Cell Transformation, Neoplastic -- drug effects KW - Neoplasms -- drug therapy KW - Neoplasms -- pathology KW - Neoplasm Proteins -- antagonists & inhibitors KW - Inflammation -- genetics KW - Inflammation -- drug therapy KW - Antineoplastic Agents -- therapeutic use KW - Neoplasms -- genetics KW - Inflammation -- pathology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1736411274?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Seminars+in+cancer+biology&rft.atitle=A+multi-targeted+approach+to+suppress+tumor-promoting+inflammation.&rft.au=Samadi%2C+Abbas+K%3BBilsland%2C+Alan%3BGeorgakilas%2C+Alexandros+G%3BAmedei%2C+Amedeo%3BAmin%2C+Amr%3BBishayee%2C+Anupam%3BAzmi%2C+Asfar+S%3BLokeshwar%2C+Bal+L%3BGrue%2C+Brendan%3BPanis%2C+Carolina%3BBoosani%2C+Chandra+S%3BPoudyal%2C+Deepak%3BStafforini%2C+Diana+M%3BBhakta%2C+Dipita%3BNiccolai%2C+Elena%3BGuha%2C+Gunjan%3BVasantha+Rupasinghe%2C+H+P%3BFujii%2C+Hiromasa%3BHonoki%2C+Kanya%3BMehta%2C+Kapil%3BAquilano%2C+Katia%3BLowe%2C+Leroy%3BHofseth%2C+Lorne+J%3BRicciardiello%2C+Luigi%3BCiriolo%2C+Maria+Rosa%3BSingh%2C+Neetu%3BWhelan%2C+Richard+L%3BChaturvedi%2C+Rupesh%3BAshraf%2C+S+Salman%3BShantha+Kumara%2C+H+M+C%3BNowsheen%2C+Somaira%3BMohammed%2C+Sulma+I%3BKeith%2C+W+Nicol%3BHelferich%2C+William+G%3BYang%2C+Xujuan&rft.aulast=Samadi&rft.aufirst=Abbas&rft.date=2015-12-01&rft.volume=35+Suppl&rft.issue=&rft.spage=S151&rft.isbn=&rft.btitle=&rft.title=Seminars+in+cancer+biology&rft.issn=1096-3650&rft_id=info:doi/10.1016%2Fj.semcancer.2015.03.006 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-09-07 N1 - Date created - 2015-11-23 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5419-24 [17369354] Curr Opin Genet Dev. 2007 Apr;17(2):145-50 [17317150] In Vivo. 2007 Mar-Apr;21(2):365-70 [17436589] Science. 2007 Apr 27;316(5824):604-8 [17463289] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372] Cancer Chemother Pharmacol. 2007 Jul;60(2):171-7 [17051370] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):962-8 [17507623] Cancer Res. 2007 May 15;67(10):4725-31 [17510400] J Nutr Biochem. 2007 Jul;18(7):449-56 [17049831] Cancer Res. 2007 Jun 15;67(12):5940-8 [17575164] Braz J Med Biol Res. 2007 Aug;40(8):1071-8 [17665043] Cancer Res. 2007 Aug 1;67(15):7518-24 [17671223] Blood. 2007 Aug 15;110(4):1168-77 [17426256] Blood. 2007 Aug 15;110(4):1330-3 [17496199] Gastroenterology. 2007 Aug;133(2):647-58 [17681183] Chest. 2007 Aug;132(2):581-8 [17550932] Anticancer Drugs. 2007 Jul;18(6):649-57 [17762393] Cell. 2007 Sep 7;130(5):918-31 [17803913] Hum Reprod. 2007 Oct;22(10):2623-31 [17725991] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866] J Immunol. 2007 Oct 15;179(8):5082-9 [17911593] Inflamm Bowel Dis. 2007 Nov;13(11):1323-32 [17636564] J Agric Food Chem. 1999 Mar;47(3):1083-91 [10552420] Oncogene. 1999 Oct 28;18(44):6013-20 [10557090] J Exp Med. 1999 Nov 15;190(10):1417-26 [10562317] Breast Cancer Res Treat. 1999 Jul;56(2):145-51 [10573107] Clin Cancer Res. 1999 Nov;5(11):3711-21 [10589791] J Exp Clin Cancer Res. 1999 Sep;18(3):433-7 [10606191] Lab Invest. 1999 Dec;79(12):1703-12 [10616218] J Ethnopharmacol. 1999 Oct;67(1):1-6 [10616954] J Clin Immunol. 1999 Nov;19(6):350-64 [10634209] Cancer. 2000 Feb 1;88(3):577-83 [10649250] Mol Cell Biol. 2000 Feb;20(4):1382-93 [10648623] Cancer Lett. 1999 Nov 15;146(2):173-80 [10656623] Ann Clin Lab Sci. 2000 Jan;30(1):3-21 [10678579] Hum Gene Ther. 2000 Jan 20;11(2):247-61 [10680839] Am J Pathol. 2000 Mar;156(3):831-7 [10702399] J Immunol. 2000 Mar 15;164(6):3112-22 [10706701] Eur J Cancer. 2000 Feb;36(3):314-29 [10708932] Mol Med. 1998 Jun;4(6):376-83 [10780880] Nat Med. 2000 May;6(5):573-7 [10802715] J Biol Chem. 2000 May 19;275(20):14838-45 [10809726] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062] Br J Cancer. 2000 Oct;83(7):880-6 [10970689] Annu Rev Biochem. 2000;69:145-82 [10966456] Cell. 2008 Feb 8;132(3):344-62 [18267068] Eur J Cancer Prev. 2008 Apr;17(2):169-77 [18287875] Int Immunopharmacol. 2008 Apr;8(4):542-7 [18328445] Carcinogenesis. 2008 Mar;29(3):519-27 [18174244] Cytokine Growth Factor Rev. 2008 Apr;19(2):157-65 [18308615] Int J Cancer. 2008 May 15;122(10):2330-6 [18092323] Antiviral Res. 2008 Jun;78(3):242-9 [18313149] Carcinogenesis. 2008 Apr;29(4):779-89 [17999991] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323] Clin Exp Dermatol. 2008 May;33(3):312-5 [18419608] Arthritis Rheum. 2008 Apr;58(4):1001-9 [18383392] BMC Cancer. 2008;8:132 [18471323] J Surg Res. 2008 Jun 15;147(2):240-6 [18498876] Arthritis Rheum. 2008 May;58(5):1284-92 [18438844] J Biol Chem. 2008 Jun 6;283(23):15878-83 [18417479] Gastroenterology. 2008 Jun;134(7):1972-80 [18549879] PLoS One. 2008;3(6):e2436 [18560586] Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S18-27 [18504707] Mol Nutr Food Res. 2008 Jun;52 Suppl 1:S62-70 [18551458] Virchows Arch. 2008 Mar;452(3):347-8 [18214534] Biomed Pharmacother. 2008 Jul-Aug;62(6):366-72 [17988825] Int Immunopharmacol. 2008 Sep;8(9):1172-82 [18602062] Cancer Biol Ther. 2008 Feb;7(2):255-64 [18059191] J Invest Dermatol. 2008 Aug;128(8):2069-77 [18273051] Clin Cancer Res. 2008 Jul 15;14(14):4491-9 [18628464] Hum Reprod. 2008 Aug;23(8):1873-83 [18492705] Nature. 2008 Jul 24;454(7203):436-44 [18650914] Cancer Lett. 2008 Aug 28;267(2):226-44 [18579287] Mutat Res. 2008 Jul-Aug;659(1-2):15-30 [18485806] Biochem Biophys Res Commun. 2008 Oct 10;375(1):162-7 [18692479] J Exp Med. 2008 Sep 1;205(9):2099-110 [18710929] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):12885-90 [18728182] Cancer Lett. 2008 Oct 8;269(2):226-42 [18492603] Cancer Lett. 2008 Oct 8;269(2):281-90 [18571839] Cell Death Differ. 2008 Oct;15(10):1533-41 [18794887] J Med Invest. 2008 Aug;55(3-4):167-73 [18797128] Nat Clin Pract Rheumatol. 2008 Oct;4(10):534-41 [18728632] Cancer Res. 2008 Oct 1;68(19):8164-72 [18829576] Endocrinology. 2008 Nov;149(11):5366-73 [18669594] Planta Med. 2008 Oct;74(13):1540-7 [18937168] RNA. 2008 Nov;14(11):2348-60 [18812439] Oncogene. 2008 Nov 6;27(52):6667-78 [18663355] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3020-5 [18990744] Nat Med. 2008 Nov;14(11):1271-7 [18931683] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401] Br J Pharmacol. 2001 Apr;132(8):1631-8 [11309233] Clin Cancer Res. 2001 May;7(5):1325-32 [11350902] Int J Oncol. 2001 Jul;19(1):83-8 [11408926] Gynecol Oncol. 2001 Jul;82(1):172-6 [11426981] Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1041-50 [11429232] Cancer Res. 2001 Jul 1;61(13):5045-50 [11431339] Clin Cancer Res. 2001 Jul;7(7):1894-900 [11448902] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8638-43 [11438703] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775] Cancer Metastasis Rev. 2006 Sep;25(3):409-16 [16951987] Genes Dev. 2006 Dec 15;20(24):3366-71 [17142669] Cancer Res. 2007 Jan 15;67(2):585-92 [17234767] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803] Nat Rev Cancer. 2007 Feb;7(2):79-94 [17251915] Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9 [17242365] Int J Cancer. 2007 Mar 15;120(6):1344-50 [17149697] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750] Mol Cell Biol. 2007 Mar;27(6):2240-52 [17242205] Gynecol Oncol. 2007 Apr;105(1):97-103 [17174383] Cancer. 2014 Jan 15;120(2):181-9 [24127364] Neoplasia. 2013 Dec;15(12):1330-46 [24403855] Dig Dis Sci. 2014 Jan;59(1):89-97 [24096876] Expert Opin Ther Targets. 2014 Feb;18(2):121-35 [24325753] Int J Oncol. 2014 Mar;44(3):791-6 [24402647] Gynecol Oncol. 2014 Jan;132(1):241-7 [24183727] J Biomed Sci. 2014;21:1 [24397824] Tumour Biol. 2014 Jan;35(1):195-204 [23922175] J Clin Invest. 2013 Nov;123(11):4821-35 [24084740] BMC Urol. 2014;14:12 [24472670] Cancer Res. 2014 Feb 15;74(4):1067-78 [24398473] Diab Vasc Dis Res. 2014 Mar;11(2):92-102 [24464099] Nutr Cancer. 2014;66(2):315-24 [24447094] World J Gastroenterol. 2014 Feb 21;20(7):1681-93 [24587647] J Cell Biochem. 2014 May;115(5):949-58 [24375531] Mol Carcinog. 2014 Feb;53 Suppl 1:E107-18 [23761018] Int J Cancer. 2014 May 15;134(10):2373-82 [24249671] Mol Cell Biochem. 2014 Feb;387(1-2):217-25 [24234420] PLoS One. 2014;9(3):e91406 [24614867] J Biomed Sci. 2014;21:17 [24589238] Pharmacol Ther. 2014 May;142(2):164-75 [24333502] Cancer Lett. 2014 May 1;346(2):197-205 [24463298] Mol Nutr Food Res. 2014 Apr;58(4):665-76 [24249144] J Huazhong Univ Sci Technolog Med Sci. 2014 Apr;34(2):234-40 [24710938] Tumour Biol. 2014 May;35(5):4637-44 [24408020] Sci Rep. 2014;4:4885 [24810584] Adv Exp Med Biol. 2014;816:53-73 [24818719] Adv Exp Med Biol. 2014;816:401-35 [24818732] Adv Exp Med Biol. 2014;816:437-69 [24818733] Curr Pharm Des. 2014;20(15):2619-26 [23859617] J Pharmacol Exp Ther. 2014 Jul;350(1):99-109 [24817032] PLoS One. 2014;9(6):e98656 [24887129] Cancer Prev Res (Phila). 2014 Jun;7(6):574-84 [24667581] J Neurosci. 2014 Jun 4;34(23):7862-70 [24899709] Cancer Treat Rev. 2014 Aug;40(7):862-71 [24774538] J Transl Med. 2014;12:158 [24893845] Angiogenesis. 2014 Jul;17(3):631-40 [24469069] Oncogene. 2014 Jun 19;33(25):3217-24 [23851506] Mediators Inflamm. 2014;2014:170381 [24966464] J Nutr Biochem. 2014 Aug;25(8):843-50 [24835302] PLoS One. 2014;9(7):e99943 [25000190] Oncogene. 2014 Jul 17;33(29):3820-9 [23975421] Semin Cancer Biol. 2014 Aug;27:46-51 [24607282] Cancer Treat Rev. 2014 Sep;40(8):980-9 [25037117] Biochem Soc Trans. 2014 Aug;42(4):798-803 [25109960] J Biol Chem. 2000 Oct 13;275(41):32357-62 [10934206] Cancer Res. 2001 Feb 1;61(3):1058-64 [11221833] Lancet. 2001 Feb 17;357(9255):539-45 [11229684] Biofactors. 2000;13(1-4):49-54 [11237198] Cell. 2001 Feb 23;104(4):487-501 [11239407] Mol Cell. 2001 Feb;7(2):401-9 [11239468] Cancer Res. 2001 Feb 15;61(4):1604-10 [11245472] Int J Cancer. 2001 Mar 15;91(6):894-9 [11275997] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264] Methods Enzymol. 2007;435:355-69 [17998063] Mol Cancer. 2007;6:60 [17894887] Carcinogenesis. 2007 Dec;28(12):2560-6 [17916904] Mol Pharm. 2007 Nov-Dec;4(6):807-18 [17999464] Eur J Pharmacol. 2008 Jan 28;579(1-3):411-7 [18022615] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133] Nat Rev Immunol. 2008 Feb;8(2):120-30 [18204468] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003] Oncology. 2007;72(5-6):397-402 [18196926] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):387-92 [18268122] Lancet Oncol. 2013 May;14(6):e218-28 [23639322] Anticancer Res. 2013 May;33(5):1861-6 [23645731] Biochimie. 2013 Jun;95(6):1336-43 [23454376] J Immunol. 2013 May 15;190(10):5102-9 [23589616] Oral Oncol. 2013 Jun;49(6):502-6 [23541947] J Biol Chem. 2013 May 10;288(19):13378-86 [23548906] J Surg Res. 2013 Jun 15;182(2):250-6 [23117118] PLoS One. 2013;8(5):e62773 [23667519] Microbiol Immunol. 2013 May;57(5):366-73 [23668609] Cancer Lett. 2013 Jul 10;335(1):81-92 [23403077] Br J Nutr. 2013 Jun 28;109(12):2117-25 [23069328] J Pathol. 2013 Jul;230(3):241-8 [23460481] Oncogene. 2013 Jun 13;32(24):2992-3000 [22797073] Mini Rev Med Chem. 2013 Jul;13(9):1272-94 [22512570] Curr Cancer Drug Targets. 2013 Jun;13(5):542-57 [23597198] Chin J Cancer. 2013 Jul;32(7):376-9 [23668928] Mol Cancer Ther. 2013 Jul;12(7):1223-34 [23619302] Ann N Y Acad Sci. 2013 Jul;1290:12-20 [23855461] Inflamm Bowel Dis. 2013 Aug;19(9):1904-12 [23846486] Mol Cancer. 2013;12:78 [23866118] Biochemistry. 2013 Jul 30;52(30):5075-83 [23829535] PLoS One. 2013;8(7):e68923 [23922669] Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2997-3006 [23882081] Oxid Med Cell Longev. 2013;2013:574029 [23936610] Oral Oncol. 2013 Sep;49(9):887-92 [23910564] Prostate. 2013 Oct;73(14):1538-46 [23818177] In Vivo. 2013 Sep-Oct;27(5):627-34 [23988898] Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):189-96 [23994796] Int J Cancer. 2013 Nov 15;133(10):2504-10 [23661584] PLoS One. 2013;8(8):e73038 [24023668] Mol Cell Biochem. 2013 Oct;382(1-2):137-43 [23793554] Clin Immunol. 2013 Oct;149(1):156-68 [23994769] Inflamm Allergy Drug Targets. 2013 Oct;12(5):349-61 [23876224] Curr Med Chem. 2013;20(33):4185-94 [23992306] Eur J Med Chem. 2012 Jul;53:235-45 [22551677] Diabet Med. 2013 Oct;30(10):1214-8 [23663119] J Immunol. 2013 Oct 15;191(8):4141-51 [24043896] Biochem Biophys Res Commun. 2013 Oct 11;440(1):137-42 [24051093] Toxicol Appl Pharmacol. 2013 Nov 1;272(3):637-46 [23933164] Hum Exp Toxicol. 2013 Oct;32(10):1067-80 [23536519] Leuk Res. 2013 Nov;37(11):1461-7 [23993427] Biochim Biophys Acta. 2013 Dec;1832(12):2085-96 [23911347] Eur J Cancer. 2013 Nov;49(17):3708-17 [23932230] Eur J Pharmacol. 2013 Oct 15;718(1-3):34-40 [24055188] Nutr Cancer. 2013;65(7):1076-85 [24053141] Trends Cell Biol. 2006 Sep;16(9):461-6 [16870447] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167] J Immunol. 2006 Oct 1;177(7):4818-25 [16982923] Chem Biol Interact. 2006 Nov 7;163(3):218-29 [16970933] J Immunol. 2006 Nov 1;177(9):6317-24 [17056562] Curr Drug Metab. 2006 Oct;7(7):755-809 [17073579] Biochem Pharmacol. 2006 Nov 30;72(11):1605-21 [16889756] Food Chem Toxicol. 2007 Jan;45(1):64-9 [16987575] Ann Otol Rhinol Laryngol. 2013 Oct;122(10):632-41 [24294686] Am J Gastroenterol. 2013 Dec;108(12):1835-42, quiz 1843 [24042192] Curr Opin Oncol. 2014 Jan;26(1):108-13 [24225413] PLoS One. 2013;8(11):e81767 [24312352] Cell Death Differ. 2014 Jan;21(1):124-35 [24096870] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Aug;33(8):1102-6 [24325063] Food Chem Toxicol. 2014 Jan;63:166-73 [23978414] Oncol Rep. 2014 Feb;31(2):573-80 [24337632] Oxid Med Cell Longev. 2013;2013:387014 [24382987] Cancer Immunol Immunother. 2014 Jan;63(1):11-20 [23990173] Mol Nutr Food Res. 2014 Jan;58(1):7-21 [23740855] Anticancer Agents Med Chem. 2012 Jun;12(5):554-63 [22263786] Mol Nutr Food Res. 2012 May;56(5):725-32 [22648619] J Surg Res. 2012 Jul;176(1):232-8 [22079843] J Pediatr Surg. 2012 Jun;47(6):1223-7 [22703797] Mol Nutr Food Res. 2012 Jun;56(6):889-99 [22707264] Iran J Immunol. 2012 Jun;9(2):119-27 [22735799] Breast Cancer Res Treat. 2012 Jun;133(3):881-8 [22048816] Mech Ageing Dev. 2012 Jun;133(6):444-55 [22613224] Free Radic Res. 2012 Aug;46(8):1051-7 [22571807] Mol Oncol. 2012 Aug;6(4):405-17 [22507634] Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64 [22376154] Genes Chromosomes Cancer. 2012 Oct;51(10):961-74 [22736505] J Nutr Biochem. 2012 Sep;23(9):1155-62 [22137263] Asian Pac J Cancer Prev. 2012;13(5):1737-44 [22901113] Biochem Biophys Res Commun. 2012 Aug 24;425(2):177-81 [22820192] Gastroenterology. 2012 Sep;143(3):741-53.e1-4 [22677195] J Exp Med. 2012 Aug 27;209(9):1655-70 [22891274] Invest New Drugs. 2012 Oct;30(5):1878-86 [21912888] Oncol Rep. 2012 Nov;28(5):1764-70 [22922827] Oncol Rep. 2012 Nov;28(5):1799-807 [22923287] Nucleic Acids Res. 2012 Sep;40(16):8048-58 [22684508] Mutat Res. 2012 Oct-Dec;751(2):287-303 [22683846] Breast Cancer Res. 2012;14(3):R77 [22583478] Free Radic Biol Med. 2012 Oct 1;53(7):1381-91 [22889596] Immunol Invest. 2012;41(6-7):635-57 [23017139] J Immunol. 2012 Oct 15;189(8):3905-13 [22972922] Oncol Rep. 2012 Dec;28(6):2049-56 [22992992] Trends Cell Biol. 2012 Nov;22(11):557-66 [22995730] Neurotherapeutics. 2012 Oct;9(4):827-43 [22996231] Carcinogenesis. 2012 Nov;33(11):2250-9 [22831955] Cancer Immunol Immunother. 2012 Nov;61(11):2193-201 [22618884] PLoS One. 2012;7(11):e48342 [23144866] Basic Res Cardiol. 2013 Jan;108(1):310 [23184390] PLoS One. 2012;7(11):e49321 [23185316] Cancer Res. 2012 Dec 15;72(24):6325-32 [23222302] Curr Pharm Des. 2013;19(1):115-25 [22950494] Curr Cancer Drug Targets. 2012 Nov 1;12(9):1244-57 [22873220] Curr Cancer Drug Targets. 2012 Nov 1;12(9):1191-232 [22873222] Oncogene. 2013 Jan 3;32(1):97-105 [22330139] Lung Cancer. 2013 Feb;79(2):111-7 [23199512] PLoS One. 2013;8(1):e53791 [23308284] Mol Cancer Ther. 2013 Jan;12(1):3-15 [23112250] Science. 2013 Jan 18;339(6117):286-91 [23329041] Int J Mol Med. 2013 Mar;31(3):621-7 [23314035] Biochem Biophys Res Commun. 2013 Feb 8;431(2):348-53 [23291179] Nutr Cancer. 2014;66(6):980-8 [25072980] Cancer Lett. 2014 Oct 10;353(1):1-7 [25079686] BMC Complement Altern Med. 2014;14:322 [25175005] Int J Oncol. 2014 Oct;45(4):1457-68 [25050663] Mol Med Rep. 2014 Oct;10(4):1697-702 [25050564] J Biol Chem. 2014 Sep 5;289(36):25088-100 [25056949] Cancer Invest. 2014 Oct;32(8):409-15 [25019211] Cancer Lett. 2014 Oct 28;353(2):248-57 [25069035] Immunol Rev. 2013 May;253(1):167-84 [23550646] Crit Rev Eukaryot Gene Expr. 2013;23(1):77-91 [23557339] Mol Vis. 2013;19:544-60 [23559849] J Transl Med. 2013;11:60 [23497377] Phytother Res. 2013 Apr;27(4):595-601 [22718574] Cancer Lett. 2013 May 28;332(2):313-24 [21345578] Skin Pharmacol Physiol. 2013;26(2):68-75 [23296023] J Biol Chem. 2013 Apr 19;288(16):10973-85 [23436656] Curr Med Chem. 2013;20(15):1923-45 [23410153] Asian Pac J Cancer Prev. 2013;14(2):835-40 [23621248] Cancer Prev Res (Phila). 2013 May;6(5):419-27 [23483004] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415] Cancer Cell. 2005 Mar;7(3):211-7 [15766659] Cell. 2005 Mar 11;120(5):635-47 [15766527] Int J Oncol. 2005 May;26(5):1419-28 [15809736] Clin Cancer Res. 2005 Apr 1;11(7):2735-46 [15814656] Microvasc Res. 2005 May;69(3):107-27 [15896353] Clin Cancer Res. 2005 Jun 1;11(11):4117-27 [15930347] Virchows Arch. 2005 May;446(5):475-82 [15856292] Nature. 2005 Jun 9;435(7043):828-33 [15944707] Clin Cancer Res. 2005 Jun 15;11(12):4627-33 [15958649] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784] Cancer Res. 2005 Jul 15;65(14):6354-63 [16024638] Carcinogenesis. 2005 Aug;26(8):1465-72 [15817611] Biomed Pharmacother. 2005 Aug;59(7):359-64 [16084059] Immunol Lett. 2005 Sep 15;100(2):159-63 [16154495] Clin Cancer Res. 2005 Sep 15;11(18):6738-44 [16166455] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180] Cell Mol Immunol. 2004 Feb;1(1):50-6 [16212921] Genes Chromosomes Cancer. 2006 Jan;45(1):103-6 [16175574] J Agric Food Chem. 2005 Nov 16;53(23):9268-73 [16277432] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762] Cancer Res. 2005 Nov 15;65(22):10623-31 [16288056] Mutat Res. 2005 Dec 11;591(1-2):123-46 [16102784] J Nutr. 2005 Dec;135(12):2767-73 [16317118] Biol Pharm Bull. 2005 Dec;28(12):2220-4 [16327153] Genes Chromosomes Cancer. 2006 Feb;45(2):211-2 [16252262] Cell. 2005 Dec 16;123(6):1133-46 [16337999] Mol Pharmacol. 2006 Jan;69(1):195-206 [16219905] Int J Mol Med. 2006 Feb;17(2):357-62 [16391837] J Exp Ther Oncol. 2005;5(1):69-78 [16416603] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):92-8 [16434593] Eur J Clin Invest. 2006 Feb;36(2):113-22 [16436093] Int J Oncol. 2006 Mar;28(3):641-8 [16465368] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460] Nutrition. 2006 Mar;22(3):259-65 [16413753] Cancer. 2006 Mar 15;106(6):1243-9 [16444744] Life Sci. 2006 Mar 27;78(18):2081-7 [16413584] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279] Food Chem Toxicol. 2006 May;44(5):636-50 [16387402] Eur J Pharmacol. 2006 Feb 17;532(1-2):187-93 [16499907] BMC Complement Altern Med. 2006;6:10 [16545122] Mol Carcinog. 2006 May;45(5):309-19 [16508969] J Invest Dermatol. 2006 May;126(5):998-1002 [16484987] Cell Death Differ. 2006 May;13(5):759-72 [16410803] Biochem Pharmacol. 2006 May 14;71(10):1397-421 [16563357] BMC Cancer. 2013;13:421 [24044575] Diagn Pathol. 2013;8:151 [24044375] PLoS One. 2013;8(11):e78700 [24244343] Cancer Lett. 2014 Jan 1;342(1):150-8 [24012639] Biochim Biophys Acta. 2013 Dec;1836(2):287-95 [23994549] J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):291-307 [24170420] Crit Rev Oncol Hematol. 2013 Dec;88(3):696-705 [24120239] Carcinogenesis. 2013 Dec;34(12):2891-9 [23825153] Carcinogenesis. 2006 Jul;27(7):1301-9 [16638787] Nutrition. 2006 Jul-Aug;22(7-8):802-9 [16815494] Med Sci Monit. 2006 May;12(5):RA79-84 [16641887] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8 [16757216] Ann Rheum Dis. 2006 Sep;65(9):1219-22 [16540548] Clin Exp Immunol. 2006 Sep;145(3):485-92 [16907918] Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6 [16885212] J Exp Clin Cancer Res. 2006 Jun;25(2):189-93 [16918129] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400] Cancer Res. 2006 Feb 15;66(4):2107-15 [16489011] Food Chem Toxicol. 2012 Jun;50(6):1826-33 [22429818] FEBS Lett. 1995 Sep 11;371(3):333-6 [7556623] Int J Cancer. 1995 Sep 15;62(6):743-8 [7558424] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):447-51 [7549798] J Gastroenterol Hepatol. 1995;10 Suppl 1:S68-71 [8589348] Cancer. 1996 Apr 15;77(8 Suppl):1598-604 [8608550] FASEB J. 1996 Apr;10(5):542-51 [8621054] Biochem Biophys Res Commun. 1996 Jul 5;224(1):153-8 [8694803] Neuroreport. 1996 Mar 22;7(4):853-6 [8724659] Neuroreport. 1995 Dec 29;7(1):294-6 [8742473] Science. 1996 Nov 1;274(5288):782-4 [8864118] Toxicol Lett. 1996 Nov;88(1-3):109-13 [8920724] Science. 1997 Jan 10;275(5297):200-3 [8985011] FASEB J. 1996 Dec;10(14):1607-13 [9002552] Nature. 1997 Feb 6;385(6616):540-4 [9020361] Crit Rev Immunol. 1997;17(1):77-88 [9034724] Adv Immunol. 1997;64:283-350 [9100984] J Cell Biochem Suppl. 1996;26:72-85 [9154169] FEBS Lett. 1997 May 12;408(1):33-8 [9180263] Mol Cell Biol. 1997 Jul;17(7):4015-23 [9199336] N Engl J Med. 1997 Jul 17;337(3):141-7 [9219699] Semin Cancer Biol. 1997 Apr;8(2):63-73 [9299584] J Exp Med. 1997 Oct 20;186(8):1383-8 [9334378] Am J Pathol. 1998 Jan;152(1):83-92 [9422526] Clin Cancer Res. 2004 Oct 15;10(20):6847-54 [15501961] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3537-42 [9520401] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3792-7 [9520446] Cancer Metastasis Rev. 1998 Mar;17(1):55-75 [9544423] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426] Cancer. 1998 May 15;82(10):1897-903 [9587122] Proc Soc Exp Biol Med. 1998 Jun;218(2):121-4 [9605209] Proc Soc Exp Biol Med. 1998 Jun;218(2):140-3 [9605212] Cancer Res. 1998 Jul 15;58(14):2929-34 [9679948] Blood. 1998 Aug 1;92(3):1031-43 [9680373] J Biol Chem. 1998 Aug 21;273(34):21875-82 [9705326] Br J Cancer. 1998 Aug;78(4):534-41 [9716040] Science. 1998 Aug 28;281(5381):1305-8 [9721089] FASEB J. 1998 Sep;12(12):1063-73 [9737710] Br J Cancer. 1998 Oct;78(7):841-9 [9764573] Am J Respir Crit Care Med. 1998 Dec;158(6):1825-30 [9847274] J Urol. 1999 Feb;161(2):630-4 [9915473] J Natl Cancer Inst. 1999 Feb 17;91(4):317-31 [10050865] Carcinogenesis. 1999 Feb;20(2):237-42 [10069459] Arch Surg. 1999 Mar;134(3):245-51 [10088562] Thyroid. 1999 Feb;9(2):113-7 [10090309] Br J Cancer. 1999 Mar;79(9-10):1609-12 [10188914] Biofactors. 2013 Jan-Feb;39(1):37-55 [22996381] Brain Behav Immun. 2013 Mar;30 Suppl:S26-31 [23164950] Thromb Haemost. 2013 Mar;109(3):391-8 [23329140] Phytother Res. 2013 Mar;27(3):422-30 [22628241] Int J Dermatol. 2013 Apr;52(4):471-4 [22928479] Mol Carcinog. 2013 Apr;52(4):304-17 [22213170] Science. 2013 Mar 29;339(6127):1546-58 [23539594] Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1291-300 [23509246] Int J Cancer. 1999 Jun 11;81(6):889-96 [10362135] Phytomedicine. 1999 May;6(2):79-84 [10374244] Clin Cancer Res. 1999 Jun;5(6):1411-5 [10389926] Surgery. 1999 Aug;126(2):438-42 [10455918] Biochem Pharmacol. 1999 Oct 1;58(7):1167-72 [10484074] Am J Pathol. 1999 Oct;155(4):1381-90 [10514420] Exp Cell Res. 1959 Feb;16(2):384-93 [13652999] Med Sci Monit. 2004 Nov;10(11):BR414-9 [15507846] Int J Cancer. 2005 Feb 10;113(4):660-9 [15455372] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5 [15668484] Photochem Photobiol. 2005 Jan-Feb;81(1):38-45 [15493960] J Pathol. 2012 Jan;226(2):148-57 [21989643] Hepatology. 2011 Dec;54(6):1947-55 [21837753] Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):345-58 [22000992] J Nutr Biochem. 2012 Jan;23(1):8-17 [21334870] Biochim Biophys Acta. 2012 Jan;1825(1):117-29 [22079531] Lancet. 2011 Dec 17;378(9809):2081-7 [22036019] Cancer Res. 2012 Jan 1;72(1):335-45 [22108826] J Agric Food Chem. 2011 Dec 28;59(24):13318-27 [22082235] J Cell Physiol. 2012 Apr;227(4):1493-500 [21678400] Mol Cancer Res. 2012 Jan;10(1):167-80 [22049153] Curr Mol Med. 2012 Feb;12(2):153-62 [22172099] Nutr Cancer. 2012;64(1):153-62 [22098108] Mol Endocrinol. 2012 Mar;26(3):360-71 [22301780] Cell Biochem Biophys. 2012 Mar;62(2):397-402 [22042732] J Cell Mol Med. 2012 Mar;16(3):496-506 [21545687] Carcinogenesis. 2012 Mar;33(3):652-60 [22219179] Mol Biol Rep. 2012 Apr;39(4):4971-9 [22160570] Mol Biosyst. 2012 Apr;8(4):1078-87 [22234583] BMC Cancer. 2012;12:44 [22280307] Mol Nutr Food Res. 2012 Feb;56(2):217-27 [22162208] Cell. 2012 Mar 16;148(6):1172-87 [22424228] Immunol Rev. 2012 Mar;246(1):379-400 [22435567] Mini Rev Med Chem. 2012 Apr;12(4):350-62 [22303948] Annu Rev Immunol. 2012;30:295-312 [22224773] Expert Rev Mol Med. 2012;14:e8 [22455872] Oncol Rep. 2012 Jun;27(6):2050-6 [22426504] Cancer Prev Res (Phila). 2012 Apr;5(4):621-30 [22293631] J Agric Food Chem. 2012 Apr 11;60(14):3686-92 [22404116] J Biol Chem. 2012 Apr 6;287(15):12132-41 [22337890] Mol Cancer Res. 2012 Apr;10(4):546-57 [22504913] Biochem Pharmacol. 2012 Jun 15;83(12):1591-601 [22342289] Brain Res. 2012 May 15;1454:1-13 [22498172] J Hematol Oncol. 2012;5:7 [22401860] Free Radic Biol Med. 2012 May 1;52(9):2013-37 [22391222] Ultrastruct Pathol. 2012 May;36(3):179-84 [22559045] Biochem Biophys Res Commun. 2012 May 11;421(3):462-7 [22507982] J Cancer Res Clin Oncol. 2012 Jun;138(6):999-1009 [22362301] Int J Food Sci Nutr. 2009;60 Suppl 6:1-13 [19306224] Adv Exp Med Biol. 2012;746:53-76 [22639159] J Immunother. 2010 May;33(4):335-51 [20386472] Recent Results Cancer Res. 1977;(60):97-109 [325611] Toxicology. 1980;16(3):259-65 [7423534] Nature. 1984 Dec 20-1985 Jan 2;312(5996):724-9 [6392892] Cell. 1986 Aug 29;46(5):705-16 [3091258] J Exp Med. 1988 Mar 1;167(3):1067-85 [3351434] Cancer Lett. 2006 Apr 28;235(2):248-59 [15975709] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092] Clin Immunol. 2006 Jun;119(3):229-40 [16540375] JAMA. 2006 May 17;295(19):2275-85 [16705109] Bioorg Med Chem Lett. 2006 Jul 1;16(13):3424-9 [16644221] Urology. 2006 Jun;67(6):1257-61 [16765186] Nutr Cancer. 2006;54(1):58-68 [16800773] Carcinogenesis. 2006 Jul;27(7):1465-74 [16474181] J Exp Med. 1993 May 1;177(5):1391-8 [8478614] J Neurochem. 1994 Feb;62(2):811-4 [7507517] J Natl Cancer Inst. 1994 Jun 1;86(11):855-8 [8182766] Biochem Biophys Res Commun. 1994 Oct 14;204(1):244-51 [7524498] J Neurochem. 1995 Jan;64(1):85-91 [7528267] J Neurosci Res. 1994 Nov 1;39(4):405-11 [7533844] J Exp Med. 1995 Apr 1;181(4):1333-43 [7535333] Alcohol Clin Exp Res. 1995 Feb;19(1):262-7 [7539602] Prostaglandins Leukot Essent Fatty Acids. 1995 Apr;52(4):223-7 [7784468] Nature. 1995 Sep 7;377(6544):68-71 [7659164] Cancer Res. 1995 Oct 1;55(19):4391-7 [7545539] J Cell Biochem. 2011 Jan;112(1):78-88 [20658545] Cancer Lett. 2011 Feb 1;301(1):75-84 [21078540] Cell Res. 2011 Jan;21(1):71-85 [21173796] Front Biosci (Landmark Ed). 2011;16:517-30 [21196185] Urology. 2011 Jan;77(1):248.e9-16 [21109292] Curr Cancer Drug Targets. 2010 Sep;10(6):593-9 [20482486] Basic Clin Pharmacol Toxicol. 2011 Feb;108(2):84-93 [21054790] Cancer Lett. 2011 Feb 28;301(2):168-76 [21168265] Nutr Cancer. 2011;63(1):139-50 [21161820] Mol Med. 2011 Jan-Feb;17(1-2):48-58 [20957335] Biosci Rep. 2011 Jun;31(3):185-97 [20815812] Ann N Y Acad Sci. 2011 Jan;1215:9-15 [21261636] Mol Nutr Food Res. 2011 Feb;55(2):259-67 [20848615] Expert Opin Ther Targets. 2011 Mar;15(3):237-51 [21208136] Cancer Invest. 2011 Mar;29(3):208-13 [21314329] Nat Genet. 2011 Mar;43(3):242-5 [21278745] Cancer Prev Res (Phila). 2011 Mar;4(3):354-64 [21372035] Mol Cancer. 2011;10:12 [21299897] Cell. 2011 Mar 4;144(5):646-74 [21376230] Biochim Biophys Acta. 2011 May;1812(5):581-91 [21320597] Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4908-13 [21383199] Oncogene. 2011 Mar 24;30(12):1402-12 [21076466] Oncogene. 2011 Mar 31;30(13):1577-85 [21119604] Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):638-46 [21335507] FASEB J. 2011 Apr;25(4):1198-207 [21177307] Cancer Lett. 2011 Jun 1;305(1):1-7 [21382660] PLoS One. 2011;6(3):e18286 [21464941] Pharm Res. 2011 May;28(5):1121-30 [21311958] PLoS One. 2011;6(3):e18108 [21483822] Mol Cancer Res. 2011 Apr;9(4):440-7 [21454377] Clin Cancer Res. 2011 Apr 15;17(8):2074-80 [21349998] Toxicol Appl Pharmacol. 2011 May 1;252(3):298-306 [21397623] Cancer Res. 2011 May 1;71(9):3268-77 [21398406] Cancer Prev Res (Phila). 2011 May;4(5):655-65 [21543343] BMC Cancer. 2011;11:144 [21501498] Genes Chromosomes Cancer. 2011 Jul;50(7):499-509 [21472816] PLoS One. 2011;6(5):e20034 [21603581] Cancer Chemother Pharmacol. 2011 Jun;67(6):1211-24 [21544630] Invest New Drugs. 2011 Aug;29(4):694-9 [20107864] PLoS One. 2011;6(5):e19652 [21625550] Proc Natl Acad Sci U S A. 2011 May 31;108(22):9184-9 [21576471] J Exp Med. 2011 Jun 6;208(6):1189-201 [21555486] Pharmacol Res. 2011 Aug;64(2):87-99 [21371557] Br J Cancer. 2011 Jun 28;105(1):146-53 [21629246] Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7 [21670304] Br J Pharmacol. 1999 Feb;126(3):673-80 [10188978] Drug Metab Dispos. 1999 Apr;27(4):486-94 [10101144] Aliment Pharmacol Ther. 1999 Feb;13(2):245-9 [10102956] Carcinogenesis. 1999 Mar;20(3):445-51 [10190560] J Surg Oncol. 1999 Apr;70(4):222-9 [10219017] J Biol Chem. 1999 May 7;274(19):13451-5 [10224110] Mol Cell. 1999 Apr;3(4):527-33 [10230406] Invest Ophthalmol Vis Sci. 1999 Jun;40(7):1624-9 [10359349] Cancer Prev Res (Phila). 2011 Sep;4(9):1419-25 [21680702] Acta Neuropathol. 2011 Sep;122(3):353-65 [21773885] Mol Cell. 2011 Sep 16;43(6):993-1004 [21925387] Clin Cancer Res. 2011 Oct 1;17(19):6125-9 [21685479] Expert Opin Biol Ther. 2011 Nov;11(11):1485-99 [21942554] J Cell Physiol. 2012 Jan;227(1):35-43 [21412767] Genome Biol. 2011;12(7):R70 [21801342] Biochem Pharmacol. 2011 Dec 15;82(12):1807-21 [21827739] Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):14-20 [21907301] DNA Repair (Amst). 2011 Dec 10;10(12):1282-93 [22041025] Carcinogenesis. 2011 Dec;32(12):1881-9 [21965273] Nat Cell Biol. 2004 Jan;6(1):45-51 [14688792] Urology. 2004 Feb;63(2):259-63 [14972467] Br J Cancer. 2004 Mar 8;90(5):1011-5 [14997198] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):340-5 [15006906] Am J Physiol Gastrointest Liver Physiol. 2004 Apr;286(4):G515-20 [15010360] Biochem Pharmacol. 2004 Apr 1;67(7):1399-410 [15013856] Oncogene. 2004 Mar 11;23(10):1845-53 [14661062] Inflamm Res. 2004 Jan;53(1):4-12 [15021975] Cancer Res. 2004 Mar 15;64(6):2030-8 [15026340] Trends Immunol. 2004 Apr;25(4):201-9 [15039047] In Vivo. 2004 Mar-Apr;18(2):237-44 [15113052] J Biol Chem. 2004 May 21;279(21):22727-37 [15020596] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):171-80 [15149738] Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17 [15194558] J Agric Food Chem. 2004 Jul 14;52(14):4571-6 [15237969] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966] Dig Dis Sci. 2004 Jun;49(6):948-53 [15309882] Drug Metab Dispos. 2004 Sep;32(9):906-8 [15319329] J Periodontal Res. 2004 Oct;39(5):300-7 [15324350] Immunology. 2004 Oct;113(2):203-11 [15379981] Prostaglandins Leukot Essent Fatty Acids. 2004 Nov;71(5):277-88 [15380814] J Med Food. 2004 Fall;7(3):284-9 [15383220] Oncogene. 2004 Sep 30;23(45):7507-16 [15326480] Wei Sheng Yan Jiu. 2004 Jul;33(4):456-7 [15461275] Int J Cancer. 2004 Dec 10;112(5):823-9 [15386368] Mutat Res. 2004 Nov 2;555(1-2):53-64 [15476851] J Immunol. 2004 Nov 1;173(9):5794-800 [15494532] Cancer Res. 2010 May 1;70(9):3606-17 [20388782] Cancer Metastasis Rev. 2010 Jun;29(2):309-16 [20405169] Mol Cancer Res. 2010 May;8(5):751-61 [20460401] Pharm Res. 2010 Jun;27(6):999-1013 [20354764] Pharm Res. 2010 Jun;27(6):1080-91 [20405173] Rheumatol Int. 2010 Jun;30(8):1063-70 [19707765] Oncol Rep. 2010 Jul;24(1):105-12 [20514450] Cell Res. 2010 Jun;20(6):603-4 [20502442] Drug News Perspect. 2010 May;23(4):257-64 [20520854] Cancer Prev Res (Phila). 2010 Jun;3(6):753-63 [20501860] Cell Mol Immunol. 2010 Jul;7(4):306-15 [20305684] Anticancer Res. 2010 Jun;30(6):2049-54 [20651350] Planta Med. 2010 Aug;76(11):1103-17 [20432202] Mol Cell. 2010 Aug 27;39(4):493-506 [20797623] BMC Cancer. 2010;10:437 [20716363] Carcinogenesis. 2010 Sep;31(9):1561-6 [20622002] Cancer Metastasis Rev. 2010 Sep;29(3):465-82 [20730632] Proc Natl Acad Sci U S A. 1991 May 15;88(10):4171-5 [1851997] Science. 1991 Oct 11;254(5029):274-7 [1833819] Eur J Biochem. 1991 Oct 15;201(2):475-81 [1718748] Am J Pathol. 1992 Mar;140(3):539-44 [1372154] Immunol Today. 1992 May;13(5):151-3 [1322675] J Nutr. 1992 Nov;122(11):2161-6 [1432255] Br J Cancer. 1993 Feb;67(2):290-6 [8381656] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2690-4 [7681986] Biochem Pharmacol. 2010 Dec 15;80(12):1801-15 [20615394] Toxicology. 2010 Dec 5;278(2):229-41 [19850100] Cancer Res. 2010 Nov 15;70(22):9003-11 [20935227] Lancet. 2010 Nov 20;376(9754):1741-50 [20970847] Phytother Res. 2010 Dec;24(12):1862-9 [20564502] Bull Exp Biol Med. 2010 Jul;149(1):78-81 [21113464] Anticancer Res. 2010 Nov;30(11):4587-93 [21115910] Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87 [20493977] Mol Cell. 2010 Dec 10;40(5):762-73 [21145484] J Invest Dermatol. 2011 Jan;131(1):195-202 [20720562] J Colloid Interface Sci. 2011 Feb 1;354(1):116-23 [21044788] Mol Pharmacol. 2001 Sep;60(3):528-33 [11502884] FASEB J. 2001 Sep;15(11):1953-62 [11532975] Cancer Lett. 2001 Oct 30;172(2):111-8 [11566484] Nat Genet. 2001 Oct;29(2):223-8 [11586304] Gene. 2001 Aug 22;274(1-2):157-67 [11675008] Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 [11712783] FASEB J. 2001 Dec;15(14):2742-4 [11606477] Life Sci. 2001 Nov 21;70(1):81-96 [11764009] Lung Cancer. 2002 Jan;35(1):23-8 [11750709] Oncogene. 2001 Nov 15;20(52):7597-609 [11753638] Cancer Res. 2002 Jan 1;62(1):165-70 [11782374] J Cardiovasc Pharmacol. 2002 Feb;39(2):271-7 [11791013] J Infect Dis. 2002 Jan 15;185(2):229-36 [11807697] Arch Biochem Biophys. 2002 Feb 1;398(1):125-31 [11811957] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):105-11 [11815407] Int J Exp Pathol. 2001 Dec;82(6):309-16 [11846837] Carcinogenesis. 2002 Mar;23(3):425-34 [11895857] Med Oncol. 2001;18(3):171-8 [11917941] Cancer Gene Ther. 2002 May;9(5):432-42 [11961666] Oncogene. 2002 May 30;21(24):3917-24 [12032830] Am J Epidemiol. 2002 Jun 1;155(11):1023-32 [12034581] J Environ Pathol Toxicol Oncol. 2002;21(2):113-20 [12086397] Clin Microbiol Rev. 2002 Jul;15(3):414-29 [12097249] J Leukoc Biol. 2002 Jul;72(1):9-18 [12101257] Biochem Pharmacol. 2002 Jul 15;64(2):229-37 [12123743] Trends Mol Med. 2002 Aug;8(8):385-9 [12127724] Pharmacol Ther. 2002 Feb-Mar;93(2-3):243-51 [12191616] Cancer Res. 2002 Sep 1;62(17):4945-54 [12208745] Cancer. 2002 Sep 15;95(6):1206-14 [12216086] Head Neck. 2002 Oct;24(10):925-32 [12369071] Free Radic Biol Med. 2002 Oct 15;33(8):1097-105 [12374621] Immunity. 2002 Oct;17(4):525-35 [12387745] Lancet Oncol. 2002 Nov;3(11):665-71 [12424068] Cell Immunol. 2002 May-Jun;217(1-2):78-86 [12426003] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020] Mol Cancer Ther. 2002 Sep;1(11):913-22 [12481412] Asia Pac J Clin Nutr. 2002;11(4):314-8 [12495265] Cancer Res. 2003 Jan 1;63(1):18-21 [12517770] J Biomed Sci. 2003 Mar-Apr;10(2):219-27 [12595758] Cancer Lett. 2003 Mar 10;191(2):125-35 [12618325] J Pathol. 2003 Apr;199(4):496-508 [12635141] Oncol Rep. 2001 Sep-Oct;8(5):955-64 [11496299] Semin Cancer Biol. 2003 Apr;13(2):107-14 [12654254] Genes Chromosomes Cancer. 2003 May;37(1):20-8 [12661002] FASEB J. 2003 Apr;17(6):702-4 [12586742] BMC Cancer. 2011;11:219 [21639915] Leuk Lymphoma. 2011 Aug;52(8):1446-54 [21417823] Nat Immunol. 2011 Aug;12(8):715-23 [21772280] Int J Cancer. 2011 Jul 15;129(2):476-86 [20839263] J Neurooncol. 2011 Aug;104(1):169-77 [21161674] Oncogene. 2011 Aug 11;30(32):3537-48 [21423202] J Immunol. 2011 Sep 1;187(5):2213-21 [21788439] Oncol Rep. 2011 Nov;26(5):1197-203 [21811763] Leukemia. 2003 Jul;17(7):1294-300 [12835717] Oncogene. 2003 Jul 24;22(30):4702-9 [12879015] FEBS Lett. 2003 Aug 28;550(1-3):79-83 [12935890] Nat Rev Immunol. 2003 Sep;3(9):745-56 [12949498] Carcinogenesis. 2003 Sep;24(9):1515-24 [12844482] J Pharmacol Exp Ther. 2003 Nov;307(2):745-52 [12970388] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012] Clin Exp Immunol. 2003 Dec;134(3):508-15 [14632759] Oncogene. 2003 Nov 24;22(53):8543-67 [14634618] Nat Genet. 2003 Dec;35(4):341-8 [14608356] Cancer Biol Ther. 2003 Nov-Dec;2(6):713-8 [14688483] Carcinogenesis. 2009 Jul;30(7):1073-81 [19468060] Cancer Res. 2009 Jul 1;69(13):5553-9 [19549910] Cell Res. 2009 Jul;19(7):828-37 [19546886] Arthritis Res Ther. 2009;11(3):R71 [19445683] Cell. 2009 Aug 7;138(3):592-603 [19665978] Cancer Res. 2009 Aug 15;69(16):6704-12 [19654291] Cancer Chemother Pharmacol. 2009 Nov;64(6):1261-8 [19363608] J Natl Cancer Inst. 2009 Aug 19;101(16):1141-55 [19638505] Mol Cancer. 2009;8:57 [19646263] Curr Opin Pharmacol. 2009 Aug;9(4):351-69 [19665429] Cell Signal. 2009 Nov;21(11):1541-7 [19298854] Ann N Y Acad Sci. 2009 Aug;1171:495-500 [19723095] Int J Cancer. 2009 Nov 1;125(9):2229-35 [19623653] Clin Cancer Res. 2009 Sep 15;15(18):5878-87 [19737943] Cell Biochem Biophys. 2009;55(2):55-79 [19672563] Nutr Res. 2009 Aug;29(8):568-78 [19761891] Mol Cancer Ther. 2009 Sep;8(9):2684-92 [19723889] Arch Pharm Res. 2009 Sep;32(9):1263-9 [19784583] Mol Cell. 2009 Sep 24;35(6):856-67 [19782034] Exp Cell Res. 2009 Oct 15;315(17):2941-52 [19591824] Nat Rev Immunol. 2009 Nov;9(11):811-6 [19809471] Cell. 2009 Nov 13;139(4):693-706 [19878981] Nitric Oxide. 2009 Nov-Dec;21(3-4):216-25 [19796704] Carcinogenesis. 2009 Nov;30(11):1949-56 [19793800] Mol Cancer. 2009;8:100 [19909554] BMB Rep. 2009 Nov 30;42(11):725-30 [19944013] Brain. 2009 Dec;132(Pt 12):3342-52 [19952055] Breast Cancer Res. 2009;11(5):209 [19818165] Genes Dev. 2009 Dec 15;23(24):2806-11 [20008931] Genes Dev. 2009 Dec 15;23(24):2839-49 [20008935] Front Biosci (Landmark Ed). 2010;15:213-25 [20036816] Mol Ther. 2010 Jan;18(1):181-7 [19738602] Carcinogenesis. 2010 Jan;31(1):37-49 [19955394] Indian J Cancer. 2010 Jan-Mar;47(1):53-8 [20071791] Nat Immunol. 2010 Feb;11(2):141-7 [19946272] Oncogene. 2008 Sep 18;27(42):5643-7 [18504431] Ann Rheum Dis. 2010 Feb;69(2):400-8 [19828563] Vaccine. 2010 Feb 3;28(5):1363-72 [19941994] J Clin Invest. 2010 Feb;120(2):485-97 [20051626] J Photochem Photobiol B. 2010 Jan 21;98(1):25-34 [19932626] Oncol Rep. 2010 Mar;23(3):725-32 [20127012] Anticancer Drugs. 2010 Mar;21(3):288-96 [20038829] Autoimmun Rev. 2010 Jan;9(3):175-80 [19647103] Cancer Cell. 2010 Jan 19;17(1):28-40 [20060366] Curr Opin Genet Dev. 2010 Feb;20(1):65-71 [20036794] Cancer Metastasis Rev. 2010 Sep;29(3):405-34 [20737283] Int J Oncol. 2010 Nov;37(5):1143-52 [20878062] Carcinogenesis. 2010 Oct;31(10):1813-21 [20699249] Curr Med Chem. 2010;17(29):3337-3352 [20712570] J Clin Oncol. 2010 Oct 10;28(29):4531-8 [20516428] QJM. 2010 Nov;103(11):831-6 [20805118] Immunity. 2010 Oct 29;33(4):607-19 [20888269] Oncol Rep. 2010 Dec;24(6):1471-7 [21042741] Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):104-12 [19808012] Clin Chem. 2010 Apr;56(4):603-12 [20093556] Nat Cell Biol. 2010 Apr;12(4):372-9 [20190740] Cancer Prev Res (Phila). 2010 Apr;3(4):549-59 [20332304] Cell. 2010 Apr 2;141(1):39-51 [20371344] Cancer Lett. 2010 Jun 1;292(1):54-63 [19959278] Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6976-81 [20308562] Oncology (Williston Park). 2010 Mar;24(3):296 [20394143] Cancer Res. 2010 Apr 15;70(8):3119-27 [20354188] Cancer Res. 2010 Apr 15;70(8):3299-308 [20388803] Gastroenterology. 2008 Nov;135(5):1624-1635.e24 [18835392] Osteoarthritis Cartilage. 2009 Apr;17(4):464-72 [19008124] Eur J Clin Pharmacol. 2009 Apr;65(4):331-41 [19198822] Immunol Rev. 2009 Mar;228(1):225-40 [19290931] Chem Biol Interact. 2009 May 15;179(2-3):131-44 [19073162] Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5282-7 [19289835] Clin Cancer Res. 2009 Apr 1;15(7):2380-6 [19293256] Br J Nutr. 2009 Apr;101(7):990-7 [18718045] Arthritis Rheum. 2009 Apr;60(4):1065-75 [19333922] Cancer Res. 2010 Feb 15;70(4):1486-95 [20124483] Nat Cell Biol. 2010 Mar;12(3):247-56 [20173740] Biochem Biophys Res Commun. 2010 Mar 5;393(2):319-24 [20138837] Cytokine Growth Factor Rev. 2010 Feb;21(1):27-39 [20004131] Trends Mol Med. 2010 Mar;16(3):133-44 [20163989] Cell. 2010 Mar 19;140(6):883-99 [20303878] Clin Pharmacol Ther. 2010 Apr;87(4):401-6 [20200512] J Cell Sci. 2010 Apr 1;123(Pt 7):1081-8 [20197403] Breast Cancer Res. 2014;16(4):410 [25060643] Carcinogenesis. 2014 Nov;35(11):2457-66 [25085901] Cancer Immunol Res. 2014 Nov;2(11):1080-9 [25080445] Arch Gynecol Obstet. 2014 Dec;290(6):1067-78 [25086744] J Agric Food Chem. 2014 Nov 12;62(45):10928-35 [25360711] Biochim Biophys Acta. 2014 Dec;1846(2):342-52 [25109892] Pharmacol Ther. 2015 Jan;145:1-18 [24929024] Basic Clin Pharmacol Toxicol. 2015 Jan;116(1):53-61 [24975165] Exp Dermatol. 2015 Feb;24(2):86-90 [25041143] Hum Immunol. 2014 Nov;75(11):1128-37 [25305034] Mol Carcinog. 2015 Apr;54(4):301-11 [24243709] Eur J Nutr. 2015 Jun;54(4):619-28 [25049110] In Vitro Cell Dev Biol Anim. 2014 Oct;50(9):840-50 [24938356] Cancer Res. 2009 Jan 1;69(1):338-48 [19118019] Nature. 2009 Jan 1;457(7225):36-7 [19122629] Nature. 2009 Jan 1;457(7225):102-6 [19122641] Curr Pharm Des. 2008;14(36):3790-801 [19128232] Cancer Prev Res (Phila). 2009 Jan;2(1):84-93 [19139022] Clin Cancer Res. 2009 Jan 15;15(2):425-30 [19147746] Cancer Cell. 2009 Feb 3;15(2):103-13 [19185845] J Biol Chem. 2009 Feb 6;284(6):3700-8 [19075017] Chest. 2009 Feb;135(2):353-67 [18719059] Mol Ther. 2009 Mar;17(3):439-47 [19107122] Ann N Y Acad Sci. 2009 Feb;1155:206-21 [19250206] Biomed Pharmacother. 2009 Mar;63(3):241-8 [18617357] Semin Cancer Biol. 2009 Apr;19(2):76-83 [19038343] Carcinogenesis. 2009 Mar;30(3):377-86 [19136477] Cancer Prev Res (Phila). 2009 Mar;2(3):200-8 [19258539] World J Gastroenterol. 2009 Mar 7;15(9):1065-71 [19266598] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666] J Altern Complement Med. 2003 Feb;9(1):161-8 [12676044] Carcinogenesis. 2003 Apr;24(4):637-42 [12727790] Mol Cell Biol. 2003 Jun;23(11):4026-33 [12748303] Regul Toxicol Pharmacol. 2003 Jun;37(3):396-406 [12758219] J Biol Chem. 2003 May 30;278(22):19852-60 [12657634] FEBS Lett. 2003 Jun 5;544(1-3):123-8 [12782301] FASEB J. 2003 Jul;17(10):1298-300 [12738811] Ann Rheum Dis. 2009 May;68(5):648-53 [18467516] Am J Pathol. 2009 May;174(5):1940-8 [19342367] Cancer. 2009 May 15;115(10):2031-40 [19326434] Cancer Prev Res (Phila). 2009 May;2(5):409-18 [19401532] Ann Rheum Dis. 2009 Jun;68(6):789-96 [19066176] Eur J Pharm Sci. 2009 Jun 28;37(3-4):223-30 [19491009] J Agric Food Chem. 2009 Jun 10;57(11):4467-77 [19489612] Mol Nutr Food Res. 2009 May;53 Suppl 1:S7-15 [19194969] Int J Exp Pathol. 2009 Jun;90(3):222-31 [19563607] Anticancer Drugs. 2009 Jul;20(6):437-43 [19398904] Nutr Rev. 2009 Jul;67(7):398-415 [19566600] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.semcancer.2015.03.006 ER - TY - JOUR T1 - Designing a broad-spectrum integrative approach for cancer prevention and treatment. AN - 1736411130; 26590477 AB - Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address stages and types of cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future research is offered. Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved. JF - Seminars in cancer biology AU - Block, Keith I AU - Gyllenhaal, Charlotte AU - Lowe, Leroy AU - Amedei, Amedeo AU - Amin, A R M Ruhul AU - Amin, Amr AU - Aquilano, Katia AU - Arbiser, Jack AU - Arreola, Alexandra AU - Arzumanyan, Alla AU - Ashraf, S Salman AU - Azmi, Asfar S AU - Benencia, Fabian AU - Bhakta, Dipita AU - Bilsland, Alan AU - Bishayee, Anupam AU - Blain, Stacy W AU - Block, Penny B AU - Boosani, Chandra S AU - Carey, Thomas E AU - Carnero, Amancio AU - Carotenuto, Marianeve AU - Casey, Stephanie C AU - Chakrabarti, Mrinmay AU - Chaturvedi, Rupesh AU - Chen, Georgia Zhuo AU - Chen, Helen AU - Chen, Sophie AU - Chen, Yi Charlie AU - Choi, Beom K AU - Ciriolo, Maria Rosa AU - Coley, Helen M AU - Collins, Andrew R AU - Connell, Marisa AU - Crawford, Sarah AU - Curran, Colleen S AU - Dabrosin, Charlotta AU - Damia, Giovanna AU - Dasgupta, Santanu AU - DeBerardinis, Ralph J AU - Decker, William K AU - Dhawan, Punita AU - Diehl, Anna Mae E AU - Dong, Jin-Tang AU - Dou, Q Ping AU - Drew, Janice E AU - Elkord, Eyad AU - El-Rayes, Bassel AU - Feitelson, Mark A AU - Felsher, Dean W AU - Ferguson, Lynnette R AU - Fimognari, Carmela AU - Firestone, Gary L AU - Frezza, Christian AU - Fujii, Hiromasa AU - Fuster, Mark M AU - Generali, Daniele AU - Georgakilas, Alexandros G AU - Gieseler, Frank AU - Gilbertson, Michael AU - Green, Michelle F AU - Grue, Brendan AU - Guha, Gunjan AU - Halicka, Dorota AU - Helferich, William G AU - Heneberg, Petr AU - Hentosh, Patricia AU - Hirschey, Matthew D AU - Hofseth, Lorne J AU - Holcombe, Randall F AU - Honoki, Kanya AU - Hsu, Hsue-Yin AU - Huang, Gloria S AU - Jensen, Lasse D AU - Jiang, Wen G AU - Jones, Lee W AU - Karpowicz, Phillip A AU - Keith, W Nicol AU - Kerkar, Sid P AU - Khan, Gazala N AU - Khatami, Mahin AU - Ko, Young H AU - Kucuk, Omer AU - Kulathinal, Rob J AU - Kumar, Nagi B AU - Kwon, Byoung S AU - Le, Anne AU - Lea, Michael A AU - Lee, Ho-Young AU - Lichtor, Terry AU - Lin, Liang-Tzung AU - Locasale, Jason W AU - Lokeshwar, Bal L AU - Longo, Valter D AU - Lyssiotis, Costas A AU - MacKenzie, Karen L AU - Malhotra, Meenakshi AU - Marino, Maria AU - Martinez-Chantar, Maria L AU - Matheu, Ander AU - Maxwell, Christopher AU - McDonnell, Eoin AU - Meeker, Alan K AU - Mehrmohamadi, Mahya AU - Mehta, Kapil AU - Michelotti, Gregory A AU - Mohammad, Ramzi M AU - Mohammed, Sulma I AU - Morre, D James AU - Muralidhar, Vinayak AU - Muqbil, Irfana AU - Murphy, Michael P AU - Nagaraju, Ganji Purnachandra AU - Nahta, Rita AU - Niccolai, Elena AU - Nowsheen, Somaira AU - Panis, Carolina AU - Pantano, Francesco AU - Parslow, Virginia R AU - Pawelec, Graham AU - Pedersen, Peter L AU - Poore, Brad AU - Poudyal, Deepak AU - Prakash, Satya AU - Prince, Mark AU - Raffaghello, Lizzia AU - Rathmell, Jeffrey C AU - Rathmell, W Kimryn AU - Ray, Swapan K AU - Reichrath, Jörg AU - Rezazadeh, Sarallah AU - Ribatti, Domenico AU - Ricciardiello, Luigi AU - Robey, R Brooks AU - Rodier, Francis AU - Rupasinghe, H P Vasantha AU - Russo, Gian Luigi AU - Ryan, Elizabeth P AU - Samadi, Abbas K AU - Sanchez-Garcia, Isidro AU - Sanders, Andrew J AU - Santini, Daniele AU - Sarkar, Malancha AU - Sasada, Tetsuro AU - Saxena, Neeraj K AU - Shackelford, Rodney E AU - Shantha Kumara, H M C AU - Sharma, Dipali AU - Shin, Dong M AU - Sidransky, David AU - Siegelin, Markus David AU - Signori, Emanuela AU - Singh, Neetu AU - Sivanand, Sharanya AU - Sliva, Daniel AU - Smythe, Carl AU - Spagnuolo, Carmela AU - Stafforini, Diana M AU - Stagg, John AU - Subbarayan, Pochi R AU - Sundin, Tabetha AU - Talib, Wamidh H AU - Thompson, Sarah K AU - Tran, Phuoc T AU - Ungefroren, Hendrik AU - Vander Heiden, Matthew G AU - Venkateswaran, Vasundara AU - Vinay, Dass S AU - Vlachostergios, Panagiotis J AU - Wang, Zongwei AU - Wellen, Kathryn E AU - Whelan, Richard L AU - Yang, Eddy S AU - Yang, Huanjie AU - Yang, Xujuan AU - Yaswen, Paul AU - Yedjou, Clement AU - Yin, Xin AU - Zhu, Jiyue AU - Zollo, Massimo AD - Block Center for Integrative Cancer Treatment, Skokie, IL, United States. Electronic address: drblock@blockmedical.com. ; Block Center for Integrative Cancer Treatment, Skokie, IL, United States. ; Getting to Know Cancer, Truro, Nova Scotia, Canada; Lancaster Environment Centre, Lancaster University, Bailrigg, Lancaster, United Kingdom. Electronic address: Leroy.lowe@gettingtoknowcancer.org. ; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. ; Winship Cancer Institute of Emory University, Atlanta, GA, United States. ; Department of Biology, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates. ; Department of Biology, University of Rome "Tor Vergata", Rome, Italy. ; Winship Cancer Institute of Emory University, Atlanta, GA, United States; Atlanta Veterans Administration Medical Center, Atlanta, GA, United States; Department of Dermatology, Emory University School of Medicine, Emory University, Atlanta, GA, United States. ; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, United States. ; Department of Biology, Temple University, Philadelphia, PA, United States. ; Department of Chemistry, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates. ; Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States. ; Department of Biomedical Sciences, Ohio University, Athens, OH, United States. ; School of Chemical and Bio Technology, SASTRA University, Thanjavur, Tamil Nadu, India. ; University of Glasgow, Glasgow, United Kingdom. ; Department of Pharmaceutical Sciences, College of Pharmacy, Larkin Health Sciences Institute, Miami, FL, United States. ; Department of Pediatrics, State University of New York, Downstate Medical Center, Brooklyn, NY, United States. ; Department of BioMedical Sciences, School of Medicine, Creighton University, Omaha, NE, United States. ; Head and Neck Cancer Biology Laboratory, University of Michigan, Ann Arbor, MI, United States. ; Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Cientificas, Seville, Spain. ; Centro di Ingegneria Genetica e Biotecnologia Avanzate, Naples, Italy; Department of Molecular Medicine and Medical Biotechnology, Federico II, Via Pansini 5, 80131 Naples, Italy. ; Stanford University, Division of Oncology, Department of Medicine and Pathology, Stanford, CA, United States. ; Department of Pathology, Microbiology, and Immunology, University of South Carolina, School of Medicine, Columbia, SC, United States. ; School of Biotechnology, Jawaharlal Nehru University, New Delhi, India. ; Department of Pediatrics, University of British Columbia, Michael Cuccione Childhood Cancer Research Program, Child and Family Research Institute, Vancouver, British Columbia, Canada. ; Ovarian and Prostate Cancer Research Laboratory, Guildford, Surrey, United Kingdom. ; Department of Biology, Alderson Broaddus University, Philippi, WV, United States. ; Cancer Immunology Branch, Division of Cancer Biology, National Cancer Center, Goyang, Gyeonggi, Republic of Korea. ; Faculty of Health and Medical Sciences, University of Surrey, Guildford, Surrey, United Kingdom. ; Department of Nutrition, Faculty of Medicine, University of Oslo, Oslo, Norway. ; Cancer Biology Research Laboratory, Southern Connecticut State University, New Haven, CT, United States. ; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, United States. ; Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden. ; Department of Oncology, Istituto Di Ricovero e Cura a Carattere Scientifico - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. ; Department of Cellular and Molecular Biology, the University of Texas Health Science Center at Tyler, Tyler, TX, United States. ; Children's Medical Center Research Institute, University of Texas - Southwestern Medical Center, Dallas, TX, United States. ; Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States. ; Department of Surgery and Cancer Biology, Division of Surgical Oncology, Vanderbilt University School of Medicine, Nashville, TN, United States. ; Department of Medicine, Duke University Medical Center, Durham, NC, United States. ; Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen, Scotland, United Kingdom. ; College of Medicine & Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. ; Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States. ; Discipline of Nutrition and Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand. ; Dipartimento di Scienze per la Qualità della Vita Alma Mater Studiorum-Università di Bologna, Rimini, Italy. ; Department of Molecular & Cell Biology, University of California Berkeley, Berkeley, CA, United States. ; Medical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, United Kingdom. ; Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan. ; Medicine and Research Services, Veterans Affairs San Diego Healthcare System & University of California, San Diego, CA, United States. ; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy; Molecular Therapy and Pharmacogenomics Unit, Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy. ; Physics Department, School of Applied Mathematics and Physical Sciences, National Technical University of Athens, Athens, Greece. ; First Department of Medicine, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany. ; Getting to Know Cancer, Guelph, Canada. ; Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, United States. ; Departments of Environmental Science, Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada. ; Department of Pathology, New York Medical College, Valhalla, NY, United States. ; University of Illinois at Urbana Champaign, Champaign, IL, United States. ; Charles University in Prague, Third Faculty of Medicine, Prague, Czech Republic. ; School of Medical Laboratory and Radiation Sciences, Old Dominion University, Norfolk, VA, United States. ; Department of Medicine, Duke University Medical Center, Durham, NC, United States; Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC, United States. ; College of Pharmacy, University of South Carolina, Columbia, SC, United States. ; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, United States. ; Department of Life Sciences, Tzu-Chi University, Hualien, Taiwan. ; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States. ; Department of Medical and Health Sciences, Linköping University, Linköping, Sweden; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. ; Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom. ; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States. ; University of Windsor, Windsor, Ontario, Canada. ; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. ; Henry Ford Hospital, Detroit, MI, United States. ; Inflammation and Cancer Research, National Cancer Institute (Retired), National Institutes of Health, Bethesda, MD, United States. ; University of Maryland BioPark, Innovation Center, KoDiscovery, Baltimore, MD, United States. ; Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, FL, United States. ; Cancer Immunology Branch, Division of Cancer Biology, National Cancer Center, Goyang, Gyeonggi, Republic of Korea; Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, United States. ; The Sol Goldman Pancreatic Cancer Research Center, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. ; New Jersey Medical School, Rutgers University, Newark, NJ, United States. ; College of Pharmacy, Seoul National University, South Korea. ; Department of Neurosurgery, Rush University Medical Center, Chicago, IL, United States. ; Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. ; Division of Nutritional Sciences, Cornell University, Ithaca, NY, United States. ; Department of Medicine, Georgia Regents University Cancer Center, Augusta, GA, United States. ; Andrus Gerontology Center, Division of Biogerontology, University of Southern California, Los Angeles, CA, United States. ; Department of Molecular and Integrative Physiology and Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI, United States. ; Children's Cancer Institute Australia, Kensington, New South Wales, Australia. ; Department of Biomedical Engineering, McGill University, Montréal, Canada. ; Department of Science, University Roma Tre, Rome, Italy. ; Metabolomic Unit, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Technology Park of Bizkaia, Bizkaia, Spain. ; Biodonostia Institute, Gipuzkoa, Spain. ; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. ; Field of Genetics, Genomics, and Development, Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, United States. ; Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, United States. ; Department of Comparative Pathobiology, Purdue University Center for Cancer Research, West Lafayette, IN, United States. ; Mor-NuCo, Inc, Purdue Research Park, West Lafayette, IN, United States. ; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, United States; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States. ; MRC Mitochondrial Biology Unit, Wellcome Trust-MRC Building, Hills Road, Cambridge, United Kingdom. ; University of Florence, Florence, Italy. ; Medical Scientist Training Program, Mayo Graduate School, Mayo Medical School, Mayo Clinic, Rochester, MN, United States. ; Laboratory of Inflammatory Mediators, State University of West Paraná, UNIOESTE, Paraná, Brazil. ; Medical Oncology Department, University Campus Bio-Medico, Rome, Italy. ; Center for Medical Research, University of Tübingen, Tübingen, Germany. ; Departments of Biological Chemistry and Oncology, Member at Large, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, United States. ; Department of Otolaryngology-Head and Neck, Medical School, University of Michigan, Ann Arbor, MI, United States. ; Laboratory of Oncology, Istituto Giannina Gaslini, Genoa, Italy. ; Center for Clinical and Experimental Photodermatology, Clinic for Dermatology, Venerology and Allergology, The Saarland University Hospital, Homburg, Germany. ; Department of Biology, University of Rochester, Rochester, NY, United States. ; Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy & National Cancer Institute Giovanni Paolo II, Bari, Italy. ; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ; White River Junction Veterans Affairs Medical Center, White River Junction, VT, United States; Geisel School of Medicine at Dartmouth, Hanover, NH, United States. ; Centre de Rechercher du Centre Hospitalier de l'Université de Montréal and Institut du Cancer de Montréal, Montréal, Quebec, Canada; Université de Montréal, Département de Radiologie, Radio-Oncologie et Médicine Nucléaire, Montréal, Quebec, Canada. ; Department of Environmental Sciences, Faculty of Agriculture and Department of Pathology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. ; Institute of Food Sciences National Research Council, Avellino, Italy. ; Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO, United States. ; Sanus Biosciences, San Diego, CA, United States. ; Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Salamanca, Spain. ; Department of Biology, University of Miami, Miami, FL, United States. ; Department of Immunology, Kurume University School of Medicine, Kurume, Fukuoka, Japan. ; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States. ; Department of Pathology, Louisiana State University, Health Shreveport, Shreveport, LA, United States. ; Department of Surgery, St. Luke's Roosevelt Hospital, New York, NY, United States. ; Department of Oncology, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States. ; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, United States. ; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, United States. ; National Research Council, Institute of Translational Pharmacology, Rome, Italy. ; Advanced Molecular Science Research Centre (Centre for Advanced Research), King George's Medical University, Lucknow, Uttar Pradesh, India. ; Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. ; DSTest Laboratories, Purdue Research Park, Indianapolis, IN, United States. ; Department of Biomedical Science, Sheffield Cancer Research Centre, University of Sheffield, Sheffield, United Kingdom. ; Huntsman Cancer Institute and Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States. ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Faculté de Pharmacie et Institut du Cancer de Montréal, Montréal, Quebec, Canada. ; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, United States. ; Department of Molecular Diagnostics, Sentara Healthcare, Norfolk, VA, United States. ; Department of Clinical Pharmacy and Therapeutics, Applied Science University, Amman, Jordan. ; Department of Surgery, Royal Adelaide Hospital, Adelaide, Australia. ; Departments of Radiation Oncology & Molecular Radiation Sciences, Oncology and Urology, Johns Hopkins School of Medicine, Baltimore, MD, United States. ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, United States. ; Department of Surgery, University of Toronto, Division of Urology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. ; Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA, United States. ; Department of Internal Medicine, New York University Lutheran Medical Center, Brooklyn, New York, NY, United States. ; Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. ; Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States. ; The School of Life Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang, China. ; Life Sciences Division, Lawrence Berkeley National Lab, Berkeley, CA, United States. ; Department of Biology, Jackson State University, Jackson, MS, United States. ; Washington State University College of Pharmacy, Spokane, WA, United States. Y1 - 2015/12// PY - 2015 DA - December 2015 SP - S276 EP - S304 VL - 35 Suppl KW - Antineoplastic Agents, Phytogenic KW - 0 KW - Index Medicus KW - Integrative medicine KW - Multi-targeted KW - Targeted therapy KW - Phytochemicals KW - Cancer hallmarks KW - Tumor Microenvironment -- genetics KW - Humans KW - Drug Resistance, Neoplasm -- genetics KW - Antineoplastic Agents, Phytogenic -- therapeutic use KW - Signal Transduction KW - Neoplasms -- pathology KW - Precision Medicine KW - Molecular Targeted Therapy KW - Neoplasms -- prevention & control KW - Neoplasms -- therapy KW - Neoplasms -- genetics KW - Genetic Heterogeneity UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1736411130?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Seminars+in+cancer+biology&rft.atitle=Designing+a+broad-spectrum+integrative+approach+for+cancer+prevention+and+treatment.&rft.au=Block%2C+Keith+I%3BGyllenhaal%2C+Charlotte%3BLowe%2C+Leroy%3BAmedei%2C+Amedeo%3BAmin%2C+A+R+M+Ruhul%3BAmin%2C+Amr%3BAquilano%2C+Katia%3BArbiser%2C+Jack%3BArreola%2C+Alexandra%3BArzumanyan%2C+Alla%3BAshraf%2C+S+Salman%3BAzmi%2C+Asfar+S%3BBenencia%2C+Fabian%3BBhakta%2C+Dipita%3BBilsland%2C+Alan%3BBishayee%2C+Anupam%3BBlain%2C+Stacy+W%3BBlock%2C+Penny+B%3BBoosani%2C+Chandra+S%3BCarey%2C+Thomas+E%3BCarnero%2C+Amancio%3BCarotenuto%2C+Marianeve%3BCasey%2C+Stephanie+C%3BChakrabarti%2C+Mrinmay%3BChaturvedi%2C+Rupesh%3BChen%2C+Georgia+Zhuo%3BChen%2C+Helen%3BChen%2C+Sophie%3BChen%2C+Yi+Charlie%3BChoi%2C+Beom+K%3BCiriolo%2C+Maria+Rosa%3BColey%2C+Helen+M%3BCollins%2C+Andrew+R%3BConnell%2C+Marisa%3BCrawford%2C+Sarah%3BCurran%2C+Colleen+S%3BDabrosin%2C+Charlotta%3BDamia%2C+Giovanna%3BDasgupta%2C+Santanu%3BDeBerardinis%2C+Ralph+J%3BDecker%2C+William+K%3BDhawan%2C+Punita%3BDiehl%2C+Anna+Mae+E%3BDong%2C+Jin-Tang%3BDou%2C+Q+Ping%3BDrew%2C+Janice+E%3BElkord%2C+Eyad%3BEl-Rayes%2C+Bassel%3BFeitelson%2C+Mark+A%3BFelsher%2C+Dean+W%3BFerguson%2C+Lynnette+R%3BFimognari%2C+Carmela%3BFirestone%2C+Gary+L%3BFrezza%2C+Christian%3BFujii%2C+Hiromasa%3BFuster%2C+Mark+M%3BGenerali%2C+Daniele%3BGeorgakilas%2C+Alexandros+G%3BGieseler%2C+Frank%3BGilbertson%2C+Michael%3BGreen%2C+Michelle+F%3BGrue%2C+Brendan%3BGuha%2C+Gunjan%3BHalicka%2C+Dorota%3BHelferich%2C+William+G%3BHeneberg%2C+Petr%3BHentosh%2C+Patricia%3BHirschey%2C+Matthew+D%3BHofseth%2C+Lorne+J%3BHolcombe%2C+Randall+F%3BHonoki%2C+Kanya%3BHsu%2C+Hsue-Yin%3BHuang%2C+Gloria+S%3BJensen%2C+Lasse+D%3BJiang%2C+Wen+G%3BJones%2C+Lee+W%3BKarpowicz%2C+Phillip+A%3BKeith%2C+W+Nicol%3BKerkar%2C+Sid+P%3BKhan%2C+Gazala+N%3BKhatami%2C+Mahin%3BKo%2C+Young+H%3BKucuk%2C+Omer%3BKulathinal%2C+Rob+J%3BKumar%2C+Nagi+B%3BKwon%2C+Byoung+S%3BLe%2C+Anne%3BLea%2C+Michael+A%3BLee%2C+Ho-Young%3BLichtor%2C+Terry%3BLin%2C+Liang-Tzung%3BLocasale%2C+Jason+W%3BLokeshwar%2C+Bal+L%3BLongo%2C+Valter+D%3BLyssiotis%2C+Costas+A%3BMacKenzie%2C+Karen+L%3BMalhotra%2C+Meenakshi%3BMarino%2C+Maria%3BMartinez-Chantar%2C+Maria+L%3BMatheu%2C+Ander%3BMaxwell%2C+Christopher%3BMcDonnell%2C+Eoin%3BMeeker%2C+Alan+K%3BMehrmohamadi%2C+Mahya%3BMehta%2C+Kapil%3BMichelotti%2C+Gregory+A%3BMohammad%2C+Ramzi+M%3BMohammed%2C+Sulma+I%3BMorre%2C+D+James%3BMuralidhar%2C+Vinayak%3BMuqbil%2C+Irfana%3BMurphy%2C+Michael+P%3BNagaraju%2C+Ganji+Purnachandra%3BNahta%2C+Rita%3BNiccolai%2C+Elena%3BNowsheen%2C+Somaira%3BPanis%2C+Carolina%3BPantano%2C+Francesco%3BParslow%2C+Virginia+R%3BPawelec%2C+Graham%3BPedersen%2C+Peter+L%3BPoore%2C+Brad%3BPoudyal%2C+Deepak%3BPrakash%2C+Satya%3BPrince%2C+Mark%3BRaffaghello%2C+Lizzia%3BRathmell%2C+Jeffrey+C%3BRathmell%2C+W+Kimryn%3BRay%2C+Swapan+K%3BReichrath%2C+J%C3%B6rg%3BRezazadeh%2C+Sarallah%3BRibatti%2C+Domenico%3BRicciardiello%2C+Luigi%3BRobey%2C+R+Brooks%3BRodier%2C+Francis%3BRupasinghe%2C+H+P+Vasantha%3BRusso%2C+Gian+Luigi%3BRyan%2C+Elizabeth+P%3BSamadi%2C+Abbas+K%3BSanchez-Garcia%2C+Isidro%3BSanders%2C+Andrew+J%3BSantini%2C+Daniele%3BSarkar%2C+Malancha%3BSasada%2C+Tetsuro%3BSaxena%2C+Neeraj+K%3BShackelford%2C+Rodney+E%3BShantha+Kumara%2C+H+M+C%3BSharma%2C+Dipali%3BShin%2C+Dong+M%3BSidransky%2C+David%3BSiegelin%2C+Markus+David%3BSignori%2C+Emanuela%3BSingh%2C+Neetu%3BSivanand%2C+Sharanya%3BSliva%2C+Daniel%3BSmythe%2C+Carl%3BSpagnuolo%2C+Carmela%3BStafforini%2C+Diana+M%3BStagg%2C+John%3BSubbarayan%2C+Pochi+R%3BSundin%2C+Tabetha%3BTalib%2C+Wamidh+H%3BThompson%2C+Sarah+K%3BTran%2C+Phuoc+T%3BUngefroren%2C+Hendrik%3BVander+Heiden%2C+Matthew+G%3BVenkateswaran%2C+Vasundara%3BVinay%2C+Dass+S%3BVlachostergios%2C+Panagiotis+J%3BWang%2C+Zongwei%3BWellen%2C+Kathryn+E%3BWhelan%2C+Richard+L%3BYang%2C+Eddy+S%3BYang%2C+Huanjie%3BYang%2C+Xujuan%3BYaswen%2C+Paul%3BYedjou%2C+Clement%3BYin%2C+Xin%3BZhu%2C+Jiyue%3BZollo%2C+Massimo&rft.aulast=Block&rft.aufirst=Casey&rft.date=2009-08-01&rft.volume=24&rft.issue=6&rft.spage=389&rft.isbn=&rft.btitle=&rft.title=Journal+of+Family+Violence&rft.issn=08857482&rft_id=info:doi/10.1007%2Fs10896-009-9241-8 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-09-07 N1 - Date created - 2015-11-23 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: World J Gastroenterol. 2013 Feb 21;19(7):1005-10 [23467420] Radiat Oncol. 2013;8:46 [23452621] Nutr Cancer. 2013;65(3):329-44 [23530632] Science. 2013 Mar 29;339(6127):1546-58 [23539594] Am J Chin Med. 2013;41(2):231-52 [23548116] Bioorg Med Chem Lett. 2009 Feb 1;19(3):706-9 [19112019] Breast. 2009 Feb;18(1):17-25 [19008099] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626] Nat Rev Cancer. 2009 Mar;9(3):153-66 [19238148] Am J Obstet Gynecol. 2009 Mar;200(3):233.e1-7 [19019336] Dis Model Mech. 2009 Mar-Apr;2(3-4):111 [19259381] Cancer Prev Res (Phila). 2009 Mar;2(3):187-94 [19258544] Nature. 2009 Apr 9;458(7239):719-24 [19360079] Cell Cycle. 2009 May 1;8(9):1314-8 [19279406] Science. 2009 May 22;324(5930):1029-33 [19460998] J Clin Oncol. 2009 Jun 1;27(16):2712-25 [19414669] J Soc Integr Oncol. 2009 Spring;7(2):43-51 [19476738] Ann Surg. 2009 Jun;249(6):973-7 [19474682] Breast J. 2009 Jul-Aug;15(4):357-66 [19470134] Mech Ageing Dev. 2009 Aug;130(8):528-37 [19559722] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381] J Exp Clin Cancer Res. 2009;28:112 [19674474] Cell Biochem Biophys. 2009;55(2):55-79 [19672563] PLoS Med. 2009 Oct;6(10):e1000161 [19823573] Mol Pharmacol. 2010 Jan;77(1):69-78 [19808995] BMC Cancer. 2009;9:444 [20015387] Breast Cancer Res Treat. 2010 Feb;120(1):111-8 [20054647] Eur J Cancer. 2014 Nov;50(16):2763-70 [25240289] Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):10-5 [25019993] Integr Cancer Ther. 2015 Mar;14(2):113-8 [25601968] Br J Nutr. 2015 Feb 28;113(4):665-71 [25639781] Cancer Causes Control. 2015 Mar;26(3):399-408 [25549833] Ann Rheum Dis. 2015 Jun;74(6):1078-86 [24733191] Nutr Rev. 2014 Jul;72(7):429-52 [24828476] Biomed Res Int. 2014;2014:409272 [25101278] Clin Cancer Res. 2014 Oct 1;20(19):4982-4 [24970841] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835] Nature. 2008 Jul 24;454(7203):436-44 [18650914] Mutat Res. 2008 Jul-Aug;659(1-2):15-30 [18485806] Cancer Lett. 2008 Oct 8;269(2):352-62 [18472213] Nature. 2009 Jan 1;457(7225):36-7 [19122629] Genes Dev. 2010 Jul 1;24(13):1329-33 [20551167] Methods Mol Biol. 2010;663:229-40 [20617421] Cancer Res. 2010 Jul 15;70(14):5649-69 [20610625] Am J Epidemiol. 2010 Sep 1;172(5):566-77 [20693267] Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1195-213 [20701553] Mol Biotechnol. 2010 Nov;46(3):308-16 [20717753] Brain Behav Immun. 2010 Nov;24(8):1231-40 [20600809] Nutr Cancer. 2010;62(7):919-30 [20924967] Mini Rev Med Chem. 2010 Dec;10(14):1385-92 [20937030] Am J Clin Nutr. 2011 Feb;93(2):234-42 [21147860] Cancer. 2011 Feb 15;117(4):677-87 [20945317] Cell. 2011 Mar 4;144(5):646-74 [21376230] Carcinogenesis. 2011 Apr;32(4):537-44 [21209038] Acta Clin Belg. 2011 Jan-Feb;66(1):2-9 [21485757] J Mol Med (Berl). 2011 Jun;89(6):595-602 [21331509] Surg Endosc. 2011 Jul;25(7):2153-8 [21184108] Food Funct. 2011 Feb;2(2):101-10 [21779554] Oncogene. 2011 Jul 28;30(30):3305-16 [21516129] Cancer Prev Res (Phila). 2011 Oct;4(10):1645-54 [21724580] Cancer Prev Res (Phila). 2011 Oct;4(10):1590-8 [21764858] Brain Behav Immun. 2011 Nov;25(8):1725-34 [21784145] Am J Clin Nutr. 2011 Nov;94(5):1284-94 [21955647] Toxins (Basel). 2010 Apr;2(4):517-51 [22069598] J Diabetes Complications. 2011 Nov-Dec;25(6):371-6 [22036100] Genes Dev. 2011 Dec 15;25(24):2559-72 [22190457] Mol Nutr Food Res. 2012 Jan;56(1):126-46 [22147677] Cancer Prev Res (Phila). 2012 Jan;5(1):41-50 [22135048] J Nutr. 2012 Feb;142(2):369-74 [22190020] Genet Med. 2015 Jul;17(7):519-32 [25474343] Epigenomics. 2015 Aug;7(5):847-62 [25689414] Integr Cancer Ther. 2014 May;13(3):201-10 [24165896] Surg Endosc. 2012 Mar;26(3):790-5 [22083320] Curr Pharm Biotechnol. 2012 Jan;13(1):191-9 [21466438] BMJ. 2001 Jan 20;322(7279):119-20 [11159553] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655] J Natl Cancer Inst. 2002 Sep 4;94(17):1275-81 [12208892] Annu Rev Med. 2003;54:17-28 [12359828] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666] Drug Resist Updat. 2003 Aug;6(4):169-72 [12962682] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667] Semin Cancer Biol. 2004 Apr;14(2):139-45 [15018898] Phytochemistry. 2004 Jul;65(13):1937-54 [15280001] Nat Genet. 2004 Sep;36(9):984-8 [15300252] Cancer. 1980 Mar 15;45(6):1498-506 [6153570] Nature. 1983 Aug 4-10;304(5925):451-3 [6877367] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198] Nihon Geka Gakkai Zasshi. 1989 Aug;90(8):1245-50 [2811843] Arch Surg. 1995 Jun;130(6):649-53 [7763175] Nat Med. 1995 Jan;1(1):27-31 [7584949] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13742-7 [8943005] Ann N Y Acad Sci. 1997 Dec 29;833:137-46 [9616746] Hum Pathol. 1998 Oct;29(10):1039-44 [9781638] Science. 2013 Jan 18;339(6117):286-91 [23329041] Eur J Nutr. 2013 Feb;52(1):337-45 [22426755] Integr Cancer Ther. 2013 Mar;12(2):145-52 [22532035] Cancer Immunol Immunother. 2013 Mar;62(3):405-10 [23423351] Curr Cancer Drug Targets. 2012 Nov 1;12(9):1191-232 [22873222] Open Biol. 2013 Jan;3(1):120144 [23303309] PLoS One. 2013;8(11):e81968 [24312387] J Immunother. 1999 Sep;22(5):431-40 [10546159] Cell. 2000 Jan 7;100(1):57-70 [10647931] Curr Opin Genet Dev. 2000 Feb;10(1):39-46 [10679392] Altern Med Rev. 2000 Jun;5(3):196-208 [10869101] J Nutr. 2000 Aug;130(8S Suppl):2073S-85S [10917926] Neoplasia. 2005 Sep;7(9):816-23 [16229804] J Am Diet Assoc. 2005 Nov;105(11):1735-44 [16256757] Integr Cancer Ther. 2005 Dec;4(4):301-14 [16282507] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76 [16172168] J Nutr. 2006 Mar;136(3 Suppl):816S-820S [16484572] Cancer Res. 2006 Mar 1;66(5):2500-5 [16510563] Ann Intern Med. 2006 Mar 7;144(5):364-7 [16520478] Eur J Clin Pharmacol. 2006 Mar;62(3):225-33 [16477470] J Nutr. 2006 Apr;136(4):981-6 [16549461] Integr Cancer Ther. 2006 Jun;5(2):150-71 [16685077] Surg Innov. 2006 Mar;13(1):41-7 [16708154] Cancer Lett. 2006 Jul 28;239(1):10-20 [16154256] J Clin Oncol. 2006 Aug 1;24(22):3535-41 [16822843] Int J Cancer. 2006 Sep 15;119(6):1249-53 [16642475] Biochem Pharmacol. 2006 Nov 30;72(11):1605-21 [16889756] Cell. 2006 Nov 17;127(4):679-95 [17110329] J Natl Cancer Inst. 2006 Dec 20;98(24):1767-76 [17179478] Int J Cancer. 2007 May 1;120(9):1971-6 [17266038] Nat Rev Genet. 2007 May;8(5):341-52 [17440531] Front Biosci. 2007;12:3468-74 [17485314] Br J Cancer. 2007 Jun 18;96(12):1788-95 [17519900] Pharmacogenet Genomics. 2007 Aug;17(8):571-9 [17622933] J Nutr. 2007 Aug;137(8):1951-4 [17634269] Oncologist. 2007 Jul;12(7):864-72 [17673617] Breast Cancer Res Treat. 2007 Sep;105(1):17-28 [17111207] JAMA. 2007 Aug 15;298(7):754-64 [17699009] Cancer Treat Rev. 2007 Aug;33(5):407-18 [17367938] Am J Clin Nutr. 2008 Feb;87(2):509S-13S [18258648] PLoS One. 2013;8(4):e60338 [23560092] Oncotarget. 2013 Apr;4(4):502-30 [23594434] Blood. 2013 May 30;121(22):4439-42 [23620577] Cancer Chemother Pharmacol. 2013 Jun;71(6):1521-30 [23543271] Integr Cancer Ther. 2013 Jul;12(4):336-46 [23241639] Oxid Med Cell Longev. 2013;2013:387014 [24382987] Cancer. 2014 Jan 15;120(2):181-9 [24127364] Anticancer Res. 2014 Jan;34(1):541-5 [24403514] CNS Drugs. 2014 Jan;28(1):45-61 [24327258] Cancer Chemother Pharmacol. 2014 Feb;73(2):373-80 [24297682] Cancer Lett. 2014 Mar 1;344(1):1-12 [24157811] Lancet. 2014 Feb 8;383(9916):558-63 [24351321] Integr Cancer Ther. 2014 Mar;13(2):152-60 [24105357] BMC Complement Altern Med. 2014;14:68 [24555771] Trends Genet. 2014 Mar;30(3):95-102 [24439457] Anticancer Res. 2014 Mar;34(3):1127-40 [24596350] Cancer Lett. 2014 Apr 28;346(1):6-16 [24333723] Cancer Immunol Immunother. 2014 Apr;63(4):407-18 [24514956] Cancer Cell. 2014 Mar 17;25(3):304-17 [24651012] BMB Rep. 2014 Mar;47(3):122-9 [24499671] J Nanosci Nanotechnol. 2014 Jan;14(1):803-14 [24730299] BMC Cancer. 2014;14:271 [24742042] Am J Gastroenterol. 2014 May;109(5):620-3 [24796999] Adv Exp Med Biol. 2014;816:401-35 [24818732] Mol Cell. 2014 Jun 5;54(5):716-27 [24905005] Int J Cancer. 2014 Jul 15;135(2):502-7 [24921086] AAPS J. 2014 Jul;16(4):705-13 [24821055] Biochem Pharmacol. 2012 Apr 15;83(8):1005-12 [22138445] J Bone Miner Res. 2007 Dec;22 Suppl 2:V74-80 [18290727] Nat Rev Cancer. 2008 Mar;8(3):167-79 [18256617] J Transl Med. 2008;6:14 [18348714] Obesity (Silver Spring). 2008 Jul;16(7):1573-8 [18451774] Int J Cancer. 2008 Sep 15;123(6):1227-39 [18623084] Clin Nutr. 2013 Aug;32(4):503-10 [23398953] Int J Clin Oncol. 2013 Jun;18(3):380-8 [22350026] Chin J Nat Med. 2013 Mar;11(2):110-20 [23787177] N Engl J Med. 2013 Jul 11;369(2):122-33 [23724867] Ann N Y Acad Sci. 2013 Jul;1290:12-20 [23855461] Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12018-23 [23818623] J Chromatogr A. 2013 Aug 23;1304:154-68 [23880467] Drug Metab Dispos. 2013 Sep;41(9):1679-85 [23835761] J Natl Cancer Inst. 2013 Aug 21;105(16):1230-8 [23853057] Nat Rev Mol Cell Biol. 2013 Sep;14(9):546 [23900393] Exerc Immunol Rev. 2013;19:120-43 [23977724] Carbohydr Polym. 2013 Oct 15;98(1):711-20 [23987403] Adv Exp Med Biol. 2013;792:109-31 [24014294] Anticancer Res. 2013 Sep;33(9):3603-9 [24023285] Sci Signal. 2013 Sep 24;6(294):eg5 [24065142] Sci Signal. 2013 Sep 24;6(294):pe32 [24065144] Cancer Treat Res. 2014;159:185-205 [24114481] Cancer Treat Res. 2014;159:311-23 [24114488] Cell Biochem Biophys. 2013 Nov;67(2):431-8 [22038302] PLoS One. 2013;8(10):e76438 [24204627] J Nutr. 2013 Dec;143(12):1966-73 [24132576] Food Chem Toxicol. 2013 Dec;62:707-21 [24080264] J Clin Oncol. 2013 Dec 1;31(34):4311-8 [24145345] Cancer Lett. 2010 Feb 1;288(1):36-41 [19616374] Nat Rev Drug Discov. 2010 Mar;9(3):203-14 [20168317] J Clin Oncol. 2010 Mar 20;28(9):1458-66 [20159820] Cell. 2010 Mar 19;140(6):883-99 [20303878] Integr Cancer Ther. 2010 Mar;9(1):50-8 [20308085] Curr Cancer Drug Targets. 2010 Mar;10(2):135-46 [20088800] J Biomed Sci. 2010;17(1):21 [20331869] J Immunother. 2010 May;33(4):335-51 [20386472] BMJ. 2012;344:e70 [22294757] Mol Cell Biol. 1999 Mar;19(3):2109-17 [10022898] Mol Cancer Ther. 2004 Nov;3(11):1427-38 [15542782] J Biol Chem. 2004 Dec 3;279(49):51163-71 [15383533] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9 [15980154] Cell. 2012 Feb 17;148(4):651-63 [22341440] J Ethnopharmacol. 2012 Apr 10;140(3):568-86 [22373513] Drug Discov Ther. 2012 Feb;6(1):1-8 [22460422] Curr Opin Immunol. 2012 Apr;24(2):207-12 [22236695] J Surg Res. 2012 May 15;174(2):284-90 [21324492] Carcinogenesis. 2012 Apr;33(4):895-901 [22266527] Am J Hematol. 2012 May;87(5):455-60 [22473809] Breast Cancer Res Treat. 2012 May;133(1):89-97 [21811816] Pharmacol Res. 2012 Jun;65(6):577-83 [22449789] Surg Endosc. 2012 Jun;26(6):1759-64 [22219007] Proc Natl Acad Sci U S A. 2012 May 15;109(20):7765-9 [22547799] PLoS One. 2012;7(5):e37113 [22606337] Semin Cell Dev Biol. 2012 Jun;23(4):352-61 [22406683] Surg Endosc. 2012 Jul;26(7):1856-64 [22258296] PLoS One. 2012;7(6):e39322 [22745732] Breast Cancer Res Treat. 2012 Jun;133(3):881-8 [22048816] CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74 [22539238] Curr Top Med Chem. 2012;12(12):1356-62 [22690682] Br J Clin Pharmacol. 2012 Sep;74(3):424-36 [22348323] J Clin Oncol. 2012 Aug 20;30(24):3012-9 [22802313] Int J Occup Environ Health. 2012 Jul-Sep;18(3):247-53 [23026008] ScientificWorldJournal. 2012;2012:637953 [23028251] Integr Cancer Ther. 2012 Dec;11(4):337-53 [21382962] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.semcancer.2015.09.007 ER - TY - JOUR T1 - Clinical Significance and Characterization of Streptococcus tigurinus Isolates in an Adult Population AN - 1751214286; PQ0002308812 AB - Streptococcus tigurinus is a newly described member of the Streptococcus mitis group. Due to the difficulty in distinguishing viridans group streptococci (VGS) by phenotype, analysis of 16S rRNA sequences is necessary for the accurate identification of most species. Through a laboratory policy of analyzing all clinically significant isolates from the VGS group by16S rRNA gene sequencing, we identified 14 S. tigurinus isolates from 11 patients. The Vitek 2 system most commonly gave an excellent rating to an incorrect identification (e.g., Streptococcus mitis), as did matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) (e.g., Streptococcus oralis). S. tigurinus strains were recovered from numerous body sites, including the blood, peritoneal fluid, bone, synovial fluid, a perianal abscess, and an arm wound. Retrospective chart review indicated that most isolates were clinically significant, with bacteremia (n = 5), soft tissue infections (n = 3) osteomyelitis (n = 2), infected joint prosthesis (n = 2), and peritonitis (n = 2) being the most common, thus expanding the spectrum of disease associated with S. tigurinus. JF - Journal of Clinical Microbiology AU - Bourassa, Lori AU - Clarridge, J E, III AD - << + $0, jill.clarridge@va.gov. Y1 - 2015/11// PY - 2015 DA - November 2015 SP - 3574 EP - 3579 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 53 IS - 11 SN - 0095-1137, 0095-1137 KW - Microbiology Abstracts B: Bacteriology KW - Streptococcus KW - Peritonitis KW - Bacteremia KW - Abscesses KW - Infection KW - Mass spectroscopy KW - Wounds KW - Joints KW - Blood KW - rRNA KW - Synovial fluid KW - Lasers KW - Streptococcus mitis KW - Soft tissues KW - rRNA 16S KW - Streptococcus oralis KW - peritoneal fluid KW - Osteomyelitis KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1751214286?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Clinical+Microbiology&rft.atitle=Clinical+Significance+and+Characterization+of+Streptococcus+tigurinus+Isolates+in+an+Adult+Population&rft.au=Bourassa%2C+Lori%3BClarridge%2C+J+E%2C+III&rft.aulast=Bourassa&rft.aufirst=Lori&rft.date=2015-11-01&rft.volume=53&rft.issue=11&rft.spage=3574&rft.isbn=&rft.btitle=&rft.title=Journal+of+Clinical+Microbiology&rft.issn=00951137&rft_id=info:doi/10.1128%2FJCM.01551-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-12-01 N1 - Number of references - 21 N1 - Last updated - 2016-07-20 N1 - SubjectsTermNotLitGenreText - Peritonitis; Bacteremia; Infection; Abscesses; Mass spectroscopy; Joints; Wounds; rRNA; Blood; Synovial fluid; Lasers; rRNA 16S; Soft tissues; Osteomyelitis; peritoneal fluid; Streptococcus; Streptococcus mitis; Streptococcus oralis DO - http://dx.doi.org/10.1128/JCM.01551-15 ER - TY - JOUR T1 - Elevated glutathione is not sufficient to protect against doxorubicin-induced nuclear damage in heart in multidrug resistance-associated protein 1 (Mrp1/Abcc1) null mice. AN - 1722186201; 26354996 AB - Cardiotoxicity is a major dose-limiting adverse effect of doxorubicin (DOX), mediated in part by overproduction of reactive oxygen species and oxidative stress. Abcc1 (Mrp1) mediates the efflux of reduced and oxidized glutathione (GSH, GSSG) and is also a major transporter that effluxes the GSH conjugate of 4-hydroxy-2-nonenal (HNE; GS-HNE), a toxic product of lipid peroxidation formed during oxidative stress. To assess the role of Mrp1 in protecting the heart from DOX-induced cardiac injury, wild-type (WT) and Mrp1 null (Mrp1(-/-)) C57BL/6 littermate mice were administered DOX (15 mg/kg) or saline (7.5 ml/kg) i.v., and heart ventricles were examined at 72 hours. Morphometric analysis by electron microscopy revealed extensive injuries in cytosol, mitochondria, and nuclei of DOX-treated mice in both genotypes. Significantly more severely injured nuclei were observed in Mrp1(-/-) versus WT mice (P = 0.031). GSH and the GSH/GSSG ratio were significantly increased in treatment-naïve Mrp1(-/-) versus WT mice; GSH remained significantly higher in Mrp1(-/-) versus WT mice after saline and DOX treatment, with no changes in GSSG or GSH/GSSG. GS-HNE, measured by mass spectrometry, was lower in the hearts of treatment-naïve Mrp1(-/-) versus WT mice (P < 0.05). DOX treatment decreased GS-HNE in WT but not Mrp1(-/-) mice, so that GS-HNE was modestly but significantly higher in Mrp1(-/-) versus WT hearts after DOX. Expression of enzymes mediating GSH synthesis and antioxidant proteins did not differ between genotypes. Thus, despite elevated GSH levels in Mrp1(-/-) hearts, DOX induced significantly more injury in the nuclei of Mrp1(-/-) versus WT hearts. Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics. JF - The Journal of pharmacology and experimental therapeutics AU - Deng, Jun AU - Coy, Donna AU - Zhang, Wei AU - Sunkara, Manjula AU - Morris, Andrew J AU - Wang, Chi AU - Chaiswing, Luksana AU - St Clair, Daret AU - Vore, Mary AU - Jungsuwadee, Paiboon AD - Department of Toxicology and Cancer Biology (J.D., D.C., L.C., W.Z., D.St.C., M.V.), Division of Cardiovascular Medicine (M.S., A.J.M.), Markey Cancer Center (C.W.) University of Kentucky, Lexington, Kentucky; Department of Pathology and Laboratory Medicine, William S. Middleton Memorial Veterans Administration Hospital and University of Wisconsin Medical School, Madison Wisconsin (L.C.); and School of Pharmacy, Fairleigh Dickinson University, Florham Park, New Jersey (P.J.). ; Department of Toxicology and Cancer Biology (J.D., D.C., L.C., W.Z., D.St.C., M.V.), Division of Cardiovascular Medicine (M.S., A.J.M.), Markey Cancer Center (C.W.) University of Kentucky, Lexington, Kentucky; Department of Pathology and Laboratory Medicine, William S. Middleton Memorial Veterans Administration Hospital and University of Wisconsin Medical School, Madison Wisconsin (L.C.); and School of Pharmacy, Fairleigh Dickinson University, Florham Park, New Jersey (P.J.) maryv@email.uky.edu paiboon@fdu.edu. Y1 - 2015/11// PY - 2015 DA - November 2015 SP - 272 EP - 279 VL - 355 IS - 2 KW - Antibiotics, Antineoplastic KW - 0 KW - Multidrug Resistance-Associated Proteins KW - glutathionyl 4-hydroxy-2-nonenal conjugate KW - Doxorubicin KW - 80168379AG KW - Glutathione KW - GAN16C9B8O KW - Glutathione Disulfide KW - ULW86O013H KW - multidrug resistance-associated protein 1 KW - Y49M64GZ4Q KW - Index Medicus KW - Animals KW - Glutathione Disulfide -- metabolism KW - Oxidative Stress KW - Mice, Inbred C57BL KW - Lipid Peroxidation KW - Cardiotoxicity -- metabolism KW - Mice, Knockout KW - Glutathione -- metabolism KW - Multidrug Resistance-Associated Proteins -- genetics KW - Myocardium -- ultrastructure KW - Doxorubicin -- toxicity KW - Cell Nucleus -- drug effects KW - Myocardium -- metabolism KW - Glutathione -- analogs & derivatives KW - Antibiotics, Antineoplastic -- toxicity UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1722186201?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.atitle=Elevated+glutathione+is+not+sufficient+to+protect+against+doxorubicin-induced+nuclear+damage+in+heart+in+multidrug+resistance-associated+protein+1+%28Mrp1%2FAbcc1%29+null+mice.&rft.au=Deng%2C+Jun%3BCoy%2C+Donna%3BZhang%2C+Wei%3BSunkara%2C+Manjula%3BMorris%2C+Andrew+J%3BWang%2C+Chi%3BChaiswing%2C+Luksana%3BSt+Clair%2C+Daret%3BVore%2C+Mary%3BJungsuwadee%2C+Paiboon&rft.aulast=Deng&rft.aufirst=Jun&rft.date=2015-11-01&rft.volume=355&rft.issue=2&rft.spage=272&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+pharmacology+and+experimental+therapeutics&rft.issn=1521-0103&rft_id=info:doi/10.1124%2Fjpet.115.225490 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-01-04 N1 - Date created - 2015-10-10 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H761-7 [18567705] Mol Cancer Ther. 2006 Nov;5(11):2851-60 [17121932] Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H829-35 [19561313] J Biol Chem. 2010 Apr 16;285(16):12416-25 [20159984] Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1282-90 [21297025] Chem Rev. 2011 Oct 12;111(10):5973-96 [21848345] Biochem Pharmacol. 2012 Apr 15;83(8):1005-12 [22138445] Pharmacogenet Genomics. 2012 Apr;22(4):273-84 [22293538] Am J Physiol Heart Circ Physiol. 2012 Apr 1;302(7):H1387-93 [22268115] J Mol Cell Cardiol. 2012 Jun;52(6):1213-25 [22465037] Cardiovasc Res. 2013 Feb 1;97(2):282-92 [23129588] Toxicol Sci. 2013 Mar;132(1):235-49 [23152189] Antioxid Redox Signal. 2014 Feb 1;20(4):621-39 [23879289] Free Radic Biol Med. 2014 Sep;74:188-99 [24973647] Mol Med. 2014;20:390-9 [25105301] Br J Pharmacol. 2014 Dec;171(24):5845-57 [25164592] J Pharmacol Exp Ther. 2015 Nov;355(2):280-7 [26354995] Anal Biochem. 2000 Apr 10;280(1):80-6 [10805524] Biochem J. 2000 Sep 1;350 Pt 2:555-61 [10947971] Circulation. 2000 Oct 24;102(17):2105-10 [11044428] J Biol Chem. 2001 Apr 20;276(16):13231-9 [11278596] Mol Aspects Med. 2003 Aug-Oct;24(4-5):177-87 [12892995] J Biol Chem. 1986 Feb 5;261(4):1576-81 [3753704] FASEB J. 1990 Oct;4(13):3076-86 [2210154] Science. 1992 Dec 4;258(5088):1650-4 [1360704] Mutat Res. 1993 Dec;290(2):183-92 [7694109] J Clin Invest. 1996 Sep 1;98(5):1253-60 [8787689] Biochim Biophys Acta. 1997 Feb 27;1360(1):45-52 [9061039] Cancer Res. 1997 Dec 1;57(23):5238-42 [9393741] Toxicol Appl Pharmacol. 1999 Jun 1;157(2):85-93 [10366541] Toxicol Pathol. 2004 Sep-Oct;32(5):536-47 [15605432] Free Radic Biol Med. 2005 Jun 1;38(11):1526-36 [15890627] Circulation. 2005 Dec 13;112(24):3754-62 [16330681] Mol Aspects Med. 2009 Feb-Apr;30(1-2):86-98 [18812186] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1124/jpet.115.225490 ER - TY - CPAPER T1 - Overview of Veterans Health Administration (VHA) Public Health Reporting to State and Territorial Public Health Authorities (PHA) T2 - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AN - 1731769187; 6365014 JF - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AU - Oda, Gina AU - Akaka, Loren Y1 - 2015/10/31/ PY - 2015 DA - 2015 Oct 31 KW - Reviews KW - Public health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1731769187?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.atitle=Overview+of+Veterans+Health+Administration+%28VHA%29+Public+Health+Reporting+to+State+and+Territorial+Public+Health+Authorities+%28PHA%29&rft.au=Oda%2C+Gina%3BAkaka%2C+Loren&rft.aulast=Oda&rft.aufirst=Gina&rft.date=2015-10-31&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.issn=&rft_id=info:doi/ L2 - https://apha.confex.com/apha/143am/webprogram/meeting.html LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-11-06 N1 - Last updated - 2015-11-09 ER - TY - CPAPER T1 - Improving the health of our nation's veterans by implementing healthy food service guidelines T2 - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AN - 1731766819; 6367365 JF - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AU - Bosley, Ellen AU - Ulin, Brigette AU - Lowry, Amy AU - Kimmons, Joel Y1 - 2015/10/31/ PY - 2015 DA - 2015 Oct 31 KW - Food KW - Guidelines UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1731766819?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.atitle=Improving+the+health+of+our+nation%27s+veterans+by+implementing+healthy+food+service+guidelines&rft.au=Bosley%2C+Ellen%3BUlin%2C+Brigette%3BLowry%2C+Amy%3BKimmons%2C+Joel&rft.aulast=Bosley&rft.aufirst=Ellen&rft.date=2015-10-31&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.issn=&rft_id=info:doi/ L2 - https://apha.confex.com/apha/143am/webprogram/meeting.html LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-11-06 N1 - Last updated - 2015-11-09 ER - TY - CPAPER T1 - Veterans Health Administration's Public Health Reporting Toolkit; Reducing the Complexity of Public Health Reporting to State, Local and Territory Public Health Departments T2 - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AN - 1731765245; 6365015 JF - 143rd American Public Health Association Annual Meeting and Exposition (APHA 2015) AU - Akaka, Loren AU - Medina-Martinez, Gisela AU - Rivera-Colon, Alessandra AU - Wu, Melody Y1 - 2015/10/31/ PY - 2015 DA - 2015 Oct 31 KW - Home range KW - Territory KW - Public health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1731765245?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.atitle=Veterans+Health+Administration%27s+Public+Health+Reporting+Toolkit%3B+Reducing+the+Complexity+of+Public+Health+Reporting+to+State%2C+Local+and+Territory+Public+Health+Departments&rft.au=Akaka%2C+Loren%3BMedina-Martinez%2C+Gisela%3BRivera-Colon%2C+Alessandra%3BWu%2C+Melody&rft.aulast=Akaka&rft.aufirst=Loren&rft.date=2015-10-31&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=143rd+American+Public+Health+Association+Annual+Meeting+and+Exposition+%28APHA+2015%29&rft.issn=&rft_id=info:doi/ L2 - https://apha.confex.com/apha/143am/webprogram/meeting.html LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-11-06 N1 - Last updated - 2015-11-09 ER - TY - JOUR T1 - "Respect the way I need to communicate with you": Healthcare experiences of adults on the autism spectrum AN - 1865906282 AB - Our objective was to obtain an in-depth understanding of autistic adults' experiences with healthcare and their recommendations for improving care. Our academic-community partnership used a community-based participatory research approach to conduct semi-structured, open-ended interviews with 39 autistic adults and 16 people who had experience supporting autistic adults in healthcare settings. Participants identified patient-level, autism-related factors that impact healthcare interactions, including verbal communication skills, sensory sensitivities, challenges with body awareness, slow processing speed, atypical non-verbal communication, and challenges with organization. However, the success of healthcare interactions largely depended on the interplay between patient- and provider-level factors, as well as the larger context in which patients were receiving care. Provider-level factors included providers' knowledge about autism in adults, incorrect assumptions about individual patients, willingness to allow written communication, use of accessible language, openness to providing other accommodations, and skill in appropriately incorporating supporters. System-level factors included the availability of supporters, complexity of the healthcare system, accessibility of healthcare facilities, and stigma about autism. Further efforts are needed to empower patients, adequately train providers, increase the accessibility of the healthcare system, and decrease discrimination. JF - Autism AU - Nicolaidis, Christina AU - Raymaker, Dora M AU - Ashkenazy, Elesia AU - McDonald, Katherine E AU - Dern, Sebastian AU - Baggs, Amelia EV AU - Kapp, Steven K AU - Weiner, Michael AU - Boisclair, W Cody AD - Portland State University, USA; Oregon Health & Science University, USA; Academic Autistic Spectrum Partnership in Research and Education, USA ; Portland State University, USA; Academic Autistic Spectrum Partnership in Research and Education, USA ; Academic Autistic Spectrum Partnership in Research and Education, USA ; Academic Autistic Spectrum Partnership in Research and Education, USA; Syracuse University, USA ; Academic Autistic Spectrum Partnership in Research and Education, USA; Indiana University Center for Health Services and Outcomes Research and Regenstrief Institute, Inc., USA; U.S. Department of Veterans Affairs, USA Y1 - 2015/10// PY - 2015 DA - Oct 2015 SP - 824 EP - 831 CY - London PB - SAGE PUBLICATIONS, INC. VL - 19 IS - 7 SN - 1362-3613 KW - Psychology KW - adults KW - autism spectrum disorders KW - community-based participatory research KW - health services KW - qualitative research KW - Accessibility KW - Adults KW - Autistic children KW - Autistic spectrum disorders KW - Communication skills KW - Community based action research KW - Discrimination KW - Health care KW - Nonverbal communication KW - Openness KW - Participatory research KW - Patient care KW - Quality of care KW - Sensory stimulation KW - Stigmatization KW - Supporters KW - Verbal communication skills UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1865906282?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Autism&rft.atitle=%22Respect+the+way+I+need+to+communicate+with+you%22%3A+Healthcare+experiences+of+adults+on+the+autism+spectrum&rft.au=Nicolaidis%2C+Christina%3BRaymaker%2C+Dora+M%3BAshkenazy%2C+Elesia%3BMcDonald%2C+Katherine+E%3BDern%2C+Sebastian%3BBaggs%2C+Amelia+EV%3BKapp%2C+Steven+K%3BWeiner%2C+Michael%3BBoisclair%2C+W+Cody&rft.aulast=Nicolaidis&rft.aufirst=Christina&rft.date=2015-10-01&rft.volume=19&rft.issue=7&rft.spage=824&rft.isbn=&rft.btitle=&rft.title=Autism&rft.issn=13623613&rft_id=info:doi/10.1177%2F1362361315576221 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - © The Author(s) 2015 N1 - Last updated - 2017-02-08 DO - http://dx.doi.org/10.1177/1362361315576221 ER - TY - JOUR T1 - Children's liver chemistries vary with age and gender and require customized pediatric reference ranges. AN - 1712523163; 26190302 AB - Used to detect liver disease and injury, baseline liver chemistry distributions were evaluated by age and gender in children without known liver disease. Baseline liver chemistries [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL)] were analyzed from 24 randomized controlled pediatric clinical trials. Using quantile regression, liver chemistry distributions were examined by age and gender; upper limit normal (ULN) ranges were compared to the 97.5th percentiles of the distributions for the specified ages and genders. 5410 subjects without known liver disease (0-18 years; 60% male) were studied. The median ALT varied little with age. In males age 5-18, the ALT 97.5th percentile increased from 34 to 63 IU/L. In both genders, the median and 97.5th percentile AST decreased with age. After age 9, ALP decreased. TBIL increased with age. Despite most liver chemistry 97.5th percentiles changing substantively with age and gender, the reference lab ULN generally changed minimally and did not correlate with the 97.5th percentile. Gender and age specific 97.5th percentile data should therefore be considered for the reference laboratory ULN in children to more accurately detect liver injury and disease. Copyright © 2015 Elsevier Inc. All rights reserved. JF - Regulatory toxicology and pharmacology : RTP AU - Stirnadel-Farrant, Heide A AU - Galwey, Nicholas AU - Bains, Chanchal AU - Yancey, Caroline AU - Hunt, Christine M AD - Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, UK. Electronic address: heide.a.stirnadel@gsk.com. ; Worldwide Epidemiology, GlaxoSmithKline, Stockley Park, UK. ; Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, USA. ; Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA; Durham Veterans Administration Medical Center, Durham, NC, USA. Y1 - 2015/10// PY - 2015 DA - October 2015 SP - 349 EP - 355 VL - 73 IS - 1 KW - Aspartate Aminotransferases KW - EC 2.6.1.1 KW - Alanine Transaminase KW - EC 2.6.1.2 KW - Alkaline Phosphatase KW - EC 3.1.3.1 KW - Bilirubin KW - RFM9X3LJ49 KW - Index Medicus KW - Alkaline phosphatase KW - Laboratory reference ranges KW - Pediatric clinical trials KW - Liver chemistries KW - Alanine aminotransferase KW - Young Adult KW - Liver Diseases -- physiopathology KW - Reference Values KW - Alanine Transaminase -- metabolism KW - Humans KW - Infant, Newborn KW - Alkaline Phosphatase -- metabolism KW - Child KW - Liver Diseases -- metabolism KW - Child, Preschool KW - Infant KW - Aspartate Aminotransferases -- metabolism KW - Bilirubin -- metabolism KW - Adult KW - Adolescent KW - Liver Function Tests -- methods KW - Male KW - Female KW - Liver -- metabolism KW - Liver -- physiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1712523163?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.atitle=Children%27s+liver+chemistries+vary+with+age+and+gender+and+require+customized+pediatric+reference+ranges.&rft.au=Stirnadel-Farrant%2C+Heide+A%3BGalwey%2C+Nicholas%3BBains%2C+Chanchal%3BYancey%2C+Caroline%3BHunt%2C+Christine+M&rft.aulast=Stirnadel-Farrant&rft.aufirst=Heide&rft.date=2015-10-01&rft.volume=73&rft.issue=1&rft.spage=349&rft.isbn=&rft.btitle=&rft.title=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.issn=1096-0295&rft_id=info:doi/10.1016%2Fj.yrtph.2015.07.013 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-06-28 N1 - Date created - 2015-09-14 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.yrtph.2015.07.013 ER - TY - JOUR T1 - Targeting glutamine metabolism in myeloproliferative neoplasms. AN - 1701345628; 26227854 AB - JAK2(V617F) mutation can be detected in the majority of myeloproliferative neoplasm (MPN) patients. The JAK2 inhibitor Ruxolitinib is the first FDA-approved treatment for MPNs. However, its use is limited by various dose related toxicities. Here, we studied the metabolic state and glutamine metabolism of BaF3-hEPOR-JAK2V617F and BaF3-hEPOR-JAK2WT cells. We found that the JAK2(V617F)-mutant cells were associated with increased oxygen consumption rate and extracellular acidification rate than the JAK2(WT) cells and there was an increased glutamine metabolism in JAK2(V617F)-mutant cells compared to wild-type cells. Glutaminase (GLS), the key enzyme in glutamine metabolism, was upregulated in the JAK2(V617F)-mutant BaF3 cells compared to the JAK2(WT) BaF3 cells. In MPN patient peripheral blood CD34+ cells, GLS expression was increased in JAK2(V617F)-mutant progenitor cells compared to JAK2 wild-type progenitor cells from the same patients and GLS levels were increased at the time of disease progression compared to at earlier time points. Moreover, GLS inhibitor increased the growth inhibitory effect of Ruxolitinib in both JAK2(V617F)-mutant cell lines and peripheral blood CD34+ cells from MPN patients. Therefore, GLS inhibitor should be further explored to enhance the therapeutic effectiveness of JAK2 inhibitor and allow the administration of lower doses of the drug to avoid its toxicity. Copyright © 2015. Published by Elsevier Inc. JF - Blood cells, molecules & diseases AU - Zhan, Huichun AU - Ciano, Kristen AU - Dong, Katherine AU - Zucker, Stanley AD - Northport VA Medical Center, Northport, NY, USA; Department of Medicine, Stony Brook University, Stony Brook, NY, USA. Electronic address: Huichun.Zhan@va.gov. ; Northport VA Medical Center, Northport, NY, USA. ; Rice University and Baylor College of Medicine, Houston, TX, USA. ; Northport VA Medical Center, Northport, NY, USA; Department of Medicine, Stony Brook University, Stony Brook, NY, USA. Y1 - 2015/10// PY - 2015 DA - October 2015 SP - 241 EP - 247 VL - 55 IS - 3 KW - INCB018424 KW - 0 KW - Pyrazoles KW - Glutamine KW - 0RH81L854J KW - JAK2 protein, human KW - EC 2.7.10.2 KW - Janus Kinase 2 KW - Index Medicus KW - Myeloproliferative neoplasm KW - Glutaminase inhibitor KW - Cancer metabolism KW - JAK2 inhibitor KW - Pyrazoles -- pharmacology KW - Humans KW - Cell Line, Tumor KW - Up-Regulation KW - Mutation KW - Janus Kinase 2 -- antagonists & inhibitors KW - Glutamine -- metabolism KW - Janus Kinase 2 -- metabolism KW - Janus Kinase 2 -- genetics KW - Myeloproliferative Disorders -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701345628?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Blood+cells%2C+molecules+%26+diseases&rft.atitle=Targeting+glutamine+metabolism+in+myeloproliferative+neoplasms.&rft.au=Zhan%2C+Huichun%3BCiano%2C+Kristen%3BDong%2C+Katherine%3BZucker%2C+Stanley&rft.aulast=Zhan&rft.aufirst=Huichun&rft.date=2015-10-01&rft.volume=55&rft.issue=3&rft.spage=241&rft.isbn=&rft.btitle=&rft.title=Blood+cells%2C+molecules+%26+diseases&rft.issn=1096-0961&rft_id=info:doi/10.1016%2Fj.bcmd.2015.07.007 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-13 N1 - Date created - 2015-08-03 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.bcmd.2015.07.007 ER - TY - JOUR T1 - Dual use of VA and non-VA hospitals by Veterans with multiple hospitalizations. AN - 1718077507; 26416176 AB - Veterans who are hospitalized in both VA and non-VA hospitals within a short timespan may be at risk for fragmented or conflicting care. To determine the characteristics of these "dual users," we analyzed administrative hospital discharge data for VA-enrolled veterans of any age in seven states, including any VA or non-VA hospitalizations they had in 2004-2007. For VA enrollees in Arizona, Iowa, Louisiana, Florida, South Carolina, Pennsylvania, or New York in 2007, we merged 2004-2007 discharge data for all VA hospitalizations and all non-VA hospitalizations listed in state health department or hospital association databases. For patients hospitalized in 2007, we compared those younger or older than 65 years who had one or multiple hospitalizations during the year, split into users of VA hospitals, non-VA hospitals, or both ("dual users"), on demographics, priority for VA care, travel times, principal diagnoses, co-morbidities, lengths of stay, and prior (2004-2006) hospitalizations, using chi-square analysis or ANOVA. Multiply hospitalized patients were compared with multinomial logistic regressions to predict non-VA and dual use. Payers for non-VA hospitalizations also were compared across groups. Of unique inpatients in 2007, 38 % of those 65 or older were hospitalized more than once during the year, as were 32 % of younger patients; 3 and 8 %, respectively, were dual users. Dual users averaged the most index-year (3.7) and prior (1.5) hospitalizations, split evenly between VA and non-VA. They also had higher rates of admission for circulatory diseases, symptoms/signs/ill-defined conditions, and injury and poisoning, and more admissions for multiple diagnostic categories; among younger patients they had the highest rate of mental disorders admissions. Higher income, non-rural residence, greater time to VA care, lower VA priority, prior non-VA hospitalization, no prior VA hospitalization, and several medical categories predicted greater non-VA use. Among younger patients, however, mental disorders predicted more dual use but less exclusively non-VA use. Dual users' non-VA admissions were more likely than others' to be covered by payers other than Medicare or commercial insurance. Younger dual users require more medical and psychiatric treatment, and rely more on government funding sources. Effective care coordination for these inpatients might improve outcomes while reducing taxpayer burden. JF - BMC health services research AU - West, Alan N AU - Charlton, Mary E AU - Vaughan-Sarrazin, Mary AD - Research Service, VA Medical Center (10A5A), 215 N. Main St., White River Junction, Vermont, 05009, USA. alan.west@va.gov. ; Iowa City VA Health Care System, Comprehensive Access and Delivery Research and Evaluation (CADRE) Center, Iowa City, Iowa, USA. mary-charlton@uiowa.edu. ; Iowa City VA Health Care System, Comprehensive Access and Delivery Research and Evaluation (CADRE) Center, Iowa City, Iowa, USA. mary-vaughan-sarrazin@uiowa.edu. Y1 - 2015/09/29/ PY - 2015 DA - 2015 Sep 29 SP - 431 VL - 15 KW - Index Medicus KW - United States KW - Humans KW - Aged KW - Medicare -- economics KW - Travel -- economics KW - Aged, 80 and over KW - Logistic Models KW - United States Department of Veterans Affairs KW - Patient Discharge -- trends KW - Databases, Factual KW - Middle Aged KW - Inpatients KW - Female KW - Male KW - Mental Disorders -- economics KW - Veterans KW - Hospitals, Veterans -- utilization KW - Hospitalization -- trends UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1718077507?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=BMC+health+services+research&rft.atitle=Dual+use+of+VA+and+non-VA+hospitals+by+Veterans+with+multiple+hospitalizations.&rft.au=West%2C+Alan+N%3BCharlton%2C+Mary+E%3BVaughan-Sarrazin%2C+Mary&rft.aulast=West&rft.aufirst=Alan&rft.date=2015-09-29&rft.volume=15&rft.issue=&rft.spage=431&rft.isbn=&rft.btitle=&rft.title=BMC+health+services+research&rft.issn=1472-6963&rft_id=info:doi/10.1186%2Fs12913-015-1069-8 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-08-10 N1 - Date created - 2015-09-29 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: J Rural Health. 2009 Summer;25(3):259-66 [19566611] Health Serv Res. 2009 Oct;44(5 Pt 1):1718-34 [19500162] Gen Hosp Psychiatry. 2009 Nov-Dec;31(6):589-91 [19892220] Health Serv Res. 2010 Jun;45(3):762-91 [20403056] Home Health Care Serv Q. 2010 Apr;29(2):91-104 [20635273] Psychiatr Serv. 2010 Oct;61(10):1035-8 [20889645] Med Care. 2011 Oct;49(10):911-7 [21685810] JAMA. 2012 Feb 22;307(8):789-90 [22357828] Mil Med. 2014 Nov;179(11):1236-43 [25373047] J Gen Intern Med. 1999 May;14(5):274-80 [10337036] Am J Med Qual. 1999 Jan-Feb;14(1):28-38 [10446661] J Healthc Manag. 2005 Mar-Apr;50(2):95-106; discussion 106-7 [15839324] Am J Public Health. 2005 Jul;95(7):1149-55 [15983270] BMC Health Serv Res. 2006;6:131 [17029643] Stroke. 2007 Feb;38(2):355-60 [17194888] Med Care. 2007 Mar;45(3):214-23 [17304078] BMC Health Serv Res. 2007;7:70 [17490488] Med Care. 2008 Mar;46(3):309-16 [18388846] J Gen Intern Med. 2009 Mar;24(3):305-11 [19101777] Soc Sci Med. 2000 Jun;50(12):1743-55 [10798329] Soc Sci Med. 1994 Jul;39(1):95-104 [8066492] Health Aff (Millwood). 1997 Jul-Aug;16(4):200-4 [9248165] Med Care. 1998 Jan;36(1):8-27 [9431328] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1186/s12913-015-1069-8 ER - TY - JOUR T1 - Human Engineered Heart Muscles Engraft and Survive Long Term in a Rodent Myocardial Infarction Model. AN - 1716934775; 26291556 AB - Tissue engineering approaches may improve survival and functional benefits from human embryonic stem cell-derived cardiomyocyte transplantation, thereby potentially preventing dilative remodeling and progression to heart failure. Assessment of transport stability, long-term survival, structural organization, functional benefits, and teratoma risk of engineered heart muscle (EHM) in a chronic myocardial infarction model. We constructed EHMs from human embryonic stem cell-derived cardiomyocytes and released them for transatlantic shipping following predefined quality control criteria. Two days of shipment did not lead to adverse effects on cell viability or contractile performance of EHMs (n=3, P=0.83, P=0.87). One month after ischemia/reperfusion injury, EHMs were implanted onto immunocompromised rat hearts to simulate chronic ischemia. Bioluminescence imaging showed stable engraftment with no significant cell loss between week 2 and 12 (n=6, P=0.67), preserving ≤25% of the transplanted cells. Despite high engraftment rates and attenuated disease progression (change in ejection fraction for EHMs, -6.7±1.4% versus control, -10.9±1.5%; n>12; P=0.05), we observed no difference between EHMs containing viable and nonviable human cardiomyocytes in this chronic xenotransplantation model (n>12; P=0.41). Grafted cardiomyocytes showed enhanced sarcomere alignment and increased connexin 43 expression at 220 days after transplantation. No teratomas or tumors were found in any of the animals (n=14) used for long-term monitoring. EHM transplantation led to high engraftment rates, long-term survival, and progressive maturation of human cardiomyocytes. However, cell engraftment was not correlated with functional improvements in this chronic myocardial infarction model. Most importantly, the safety of this approach was demonstrated by the lack of tumor or teratoma formation. © 2015 American Heart Association, Inc. JF - Circulation research AU - Riegler, Johannes AU - Tiburcy, Malte AU - Ebert, Antje AU - Tzatzalos, Evangeline AU - Raaz, Uwe AU - Abilez, Oscar J AU - Shen, Qi AU - Kooreman, Nigel G AU - Neofytou, Evgenios AU - Chen, Vincent C AU - Wang, Mouer AU - Meyer, Tim AU - Tsao, Philip S AU - Connolly, Andrew J AU - Couture, Larry A AU - Gold, Joseph D AU - Zimmermann, Wolfram H AU - Wu, Joseph C AD - From the Division of Cardiology, Department of Medicine, Stanford Cardiovascular Institute (J.R., A.E., E.T., U.R., O.J.A., O.S., N.G.K., E.N., M.W., P.S.T., J.D.G., J.C.W.) and Department of Pathology (A.J.C.), Stanford University School of Medicine, CA; Department for Research and Development, Veterans Administration Palo Alto Health Care System, CA (P.S.T.); Institute of Pharmacology, Heart Research Center, University Medical Center, Georg-August-University and German Center for Cardiovascular Research, Göttingen, Germany (M.T., T.M., W.H.Z.); and Center for Biomedicine and Genetics (V.C.C., L.A.C.) and Center for Applied Technology Development, Beckman Research Institute (A.J.C.), City of Hope, Duarte, CA. ; From the Division of Cardiology, Department of Medicine, Stanford Cardiovascular Institute (J.R., A.E., E.T., U.R., O.J.A., O.S., N.G.K., E.N., M.W., P.S.T., J.D.G., J.C.W.) and Department of Pathology (A.J.C.), Stanford University School of Medicine, CA; Department for Research and Development, Veterans Administration Palo Alto Health Care System, CA (P.S.T.); Institute of Pharmacology, Heart Research Center, University Medical Center, Georg-August-University and German Center for Cardiovascular Research, Göttingen, Germany (M.T., T.M., W.H.Z.); and Center for Biomedicine and Genetics (V.C.C., L.A.C.) and Center for Applied Technology Development, Beckman Research Institute (A.J.C.), City of Hope, Duarte, CA. joewu@stanford.edu w.zimmermann@med.uni-goettingen.de. Y1 - 2015/09/25/ PY - 2015 DA - 2015 Sep 25 SP - 720 EP - 730 VL - 117 IS - 8 KW - Biomarkers KW - 0 KW - Connexin 43 KW - GJA1 protein, human KW - Immunosuppressive Agents KW - Index Medicus KW - tissue engineering KW - cardiac function tests KW - myocardial infarction KW - myocardial ischemia KW - cell survival KW - cardiac MRI KW - transplantation KW - Heterografts KW - Animals KW - Humans KW - Cell Differentiation KW - Disease Models, Animal KW - Cell Survival KW - Immunosuppressive Agents -- pharmacology KW - Rats, Sprague-Dawley KW - Transfection KW - Rats, Nude KW - Myocardial Contraction KW - Biomarkers -- metabolism KW - Connexin 43 -- metabolism KW - Time Factors KW - Cell Line KW - Male KW - Stroke Volume KW - Papillary Muscles -- transplantation KW - Myocardial Infarction -- pathology KW - Myocardial Infarction -- surgery KW - Myocytes, Cardiac -- immunology KW - Papillary Muscles -- metabolism KW - Heart Transplantation -- methods KW - Papillary Muscles -- immunology KW - Myocytes, Cardiac -- pathology KW - Tissue Engineering -- methods KW - Myocardial Infarction -- physiopathology KW - Myocytes, Cardiac -- transplantation KW - Heart Transplantation -- adverse effects KW - Myocardial Infarction -- metabolism KW - Embryonic Stem Cells -- metabolism KW - Myocardial Infarction -- immunology KW - Embryonic Stem Cells -- transplantation KW - Papillary Muscles -- physiopathology KW - Embryonic Stem Cells -- immunology KW - Graft Survival KW - Papillary Muscles -- pathology KW - Myocytes, Cardiac -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1716934775?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Circulation+research&rft.atitle=Human+Engineered+Heart+Muscles+Engraft+and+Survive+Long+Term+in+a+Rodent+Myocardial+Infarction+Model.&rft.au=Riegler%2C+Johannes%3BTiburcy%2C+Malte%3BEbert%2C+Antje%3BTzatzalos%2C+Evangeline%3BRaaz%2C+Uwe%3BAbilez%2C+Oscar+J%3BShen%2C+Qi%3BKooreman%2C+Nigel+G%3BNeofytou%2C+Evgenios%3BChen%2C+Vincent+C%3BWang%2C+Mouer%3BMeyer%2C+Tim%3BTsao%2C+Philip+S%3BConnolly%2C+Andrew+J%3BCouture%2C+Larry+A%3BGold%2C+Joseph+D%3BZimmermann%2C+Wolfram+H%3BWu%2C+Joseph+C&rft.aulast=Riegler&rft.aufirst=Johannes&rft.date=2015-09-25&rft.volume=117&rft.issue=8&rft.spage=720&rft.isbn=&rft.btitle=&rft.title=Circulation+research&rft.issn=1524-4571&rft_id=info:doi/10.1161%2FCIRCRESAHA.115.306985 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-12-31 N1 - Date created - 2015-09-25 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Biotechnol Bioeng. 2000 Apr 5;68(1):106-14 [10699878] N Engl J Med. 2003 May 15;348(20):2007-18 [12748317] Am J Cardiol. 1991 Apr 15;67(9):897-9 [2011993] Circulation. 2006 Feb 21;113(7):1005-14 [16476845] Nat Med. 2006 Apr;12(4):452-8 [16582915] Nat Med. 2006 Apr;12(4):459-65 [16582917] Circ Res. 2007 Feb 2;100(2):263-72 [17218605] Nat Biotechnol. 2007 Sep;25(9):1015-24 [17721512] Heart. 2007 Oct;93(10):1278-84 [17566061] J Am Coll Cardiol. 2007 Nov 6;50(19):1884-93 [17980256] Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2604-13 [18408133] Circulation. 2008 Sep 30;118(14 Suppl):S121-9 [18824743] Circulation. 2008 Sep 30;118(14 Suppl):S145-52 [18824746] Toxicol Pathol. 2009 Apr;37(3):348-50 [19380844] Stem Cell Res. 2007 Oct;1(1):9-24 [19383383] Tissue Eng Part A. 2009 Jun;15(6):1211-22 [19063661] Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16568-73 [19805339] PLoS One. 2009;4(12):e8443 [20046878] J Magn Reson Imaging. 2010 Oct;32(4):869-77 [20882617] J Mol Cell Cardiol. 2010 Dec;49(6):941-9 [20854826] Nature. 2011 May 19;473(7347):326-35 [21593865] Circ Res. 2011 Jun 24;109(1):47-59 [21597009] Circulation. 2011 Nov 15;124(20):2275-7 [22083149] Cell Stem Cell. 2012 Jan 6;10(1):16-28 [22226352] Stem Cell Res. 2012 May;8(3):388-402 [22459095] Nature. 2012 Sep 13;489(7415):322-5 [22864415] Eur J Heart Fail. 2013 Jan;15(1):23-35 [23243122] J Clin Invest. 2013 Mar;123(3):1285-98 [23434590] Eur Heart J. 2013 Apr;34(15):1134-46 [23103664] Biomaterials. 2013 Jul;34(23):5813-20 [23642535] Lancet. 2013 Aug 17;382(9892):644-57 [23953388] Circ Res. 2013 Sep 13;113(7):922-32 [24030022] Stem Cells. 2013 Nov;31(11):2354-63 [24038578] Stem Cell Reports. 2013;1(5):387-96 [24286027] Circ Res. 2014 Jan 3;114(1):21-7 [24385505] FASEB J. 2014 Feb;28(2):644-54 [24174427] PLoS One. 2014;9(4):e94722 [24733085] Nature. 2014 Jun 12;510(7504):273-7 [24776797] Methods Mol Biol. 2014;1181:167-76 [25070336] Circulation. 2014 Sep 9;130(11 Suppl 1):S77-86 [25200059] Sci Rep. 2014;4:6716 [25336194] Eur Heart J. 2015 Mar 21;36(12):743-50 [24835485] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1161/CIRCRESAHA.115.306985 ER - TY - JOUR T1 - A rare case of immune reconstitution inflammatory syndrome presenting as secondary syphilis AN - 1765978956; PQ0002584109 AB - Immune reconstitution syndrome has rarely been reported in the context of syphilis infection. We report a patient with AIDS (CD4 42 cells/mm 3 , viral load 344,000 cp/ml), treated previously for secondary syphilis and started on an integrase inhibitor-based single-tablet antiretroviral treatment regimen. After four weeks of antiretroviral treatment, he presented with non-tender, non-blanching erythematous nodules on his chest, an elevated rapid plasma reagin (1:1024) and immune reconstitution (CD4 154 cells/mm 3 , HIV-RNA 130 cp/ml). A detailed workup to exclude opportunistic infections including secondary and neurosyphilis was performed. The patient was continued on antiretroviral treatment and treated empirically for neurosyphilis given cerebrospinal lymphocytosis and dermatopathology suggesting treponemal antigen-driven B-cell hyperplasia. We favour a diagnosis of immune reconstitution in association with prior syphilis infection attributable to rapid and potent immune restoration afforded by integrase inhibitors. JF - International Journal of STD & AIDS AU - Khatri, Asma AU - Skalweit, Marion J AD - 1 .Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA, marion.skalweit@va.gov Y1 - 2015/09// PY - 2015 DA - September 2015 SP - 749 EP - 751 PB - Sage Publications, Inc., 2455 Teller Road Thousand Oaks CA 91320 United States VL - 26 IS - 10 SN - 0956-4624, 0956-4624 KW - Microbiology Abstracts B: Bacteriology; Immunology Abstracts; Health & Safety Science Abstracts; Virology & AIDS Abstracts KW - Human immunodeficiency virus KW - AIDS KW - immune reconstitution syndrome KW - IRIS KW - syphilis KW - Treponema pallidum KW - antiretroviral therapy KW - HIV integrase inhibitors KW - Acquired immune deficiency syndrome KW - Lymphocytes B KW - Infection KW - Chest KW - Antiretroviral agents KW - Nodules KW - Inflammation KW - Opportunist infection KW - Immune reconstitution KW - Hyperplasia KW - CD4 antigen KW - Lymphocytosis KW - Antiviral agents KW - Reagin KW - Neurosyphilis KW - Syphilis KW - Sexually transmitted diseases KW - Integrase KW - V 22360:AIDS and HIV KW - H 11000:Diseases/Injuries/Trauma KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1765978956?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+Journal+of+STD+%26+AIDS&rft.atitle=A+rare+case+of+immune+reconstitution+inflammatory+syndrome+presenting+as+secondary+syphilis&rft.au=Khatri%2C+Asma%3BSkalweit%2C+Marion+J&rft.aulast=Khatri&rft.aufirst=Asma&rft.date=2015-09-01&rft.volume=26&rft.issue=10&rft.spage=749&rft.isbn=&rft.btitle=&rft.title=International+Journal+of+STD+%26+AIDS&rft.issn=09564624&rft_id=info:doi/10.1177%2F0956462414553013 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-02-01 N1 - Number of references - 8 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Acquired immune deficiency syndrome; Lymphocytes B; Chest; Nodules; Opportunist infection; Inflammation; Immune reconstitution; CD4 antigen; Hyperplasia; Lymphocytosis; Antiviral agents; Reagin; Neurosyphilis; Syphilis; Integrase; Infection; Antiretroviral agents; Sexually transmitted diseases; Human immunodeficiency virus; Treponema pallidum DO - http://dx.doi.org/10.1177/0956462414553013 ER - TY - JOUR T1 - Trajectories of Lifetime Comorbid Alcohol and Other Drug Use Disorders Through Midlife AN - 1761674707; 201603922 AB - Objective: Very few studies have examined the developmental nature of comorbid alcohol use disorders and drug use disorders (AUD-DUD). The current study sought to extend our understanding of the nature of AUD-DUD comorbidity by characterizing the developmental course of AUD-DUD comorbidity, determining the degree to which the two disorders occur during the same period, and eliciting differences in AUD-DUD trajectories over the life course. Method: Vietnam-era male veterans and matched civilians provided retrospective accounts of alcohol- and other drug-related experiences spanning 25 years. Concurrent growth mixture modeling was used to describe the course of AUD-DUD lifetime comorbidity. Results: Five trajectories were identified based on the probabilities of diagnosing with AUD-DUD: substance switching (increasing AUD, decreasing DUD); young adult (both AUD and DUD decreasing rapidly after young adulthood); severe nonchronic (both AUD and DUD decreasing slowly in the third decade of life); severe chronic alcohol-severe nonchronic drug (AUD remains high and DUD decreases in the fourth decade); and young adult alcohol-severe chronic drug (decreasing AUD in the second decade and DUD remains high). Conclusions: For the majority of this sample, substance use disorders continued or worsened through adulthood, indicating a problem that extends far beyond young adulthood. Demographic characteristics differed among the trajectories; however, psychiatric diagnoses did not differ except for the number of years with diagnoses of antisocial personality disorder. Subthreshold symptoms in adulthood may be present for a significant period before diagnosis, making this period important for intervention and prevention. Integration of efforts into healthcare, employment, and public policy will help target those at highest risk. Adapted from the source document. JF - Journal of Studies on Alcohol and Drugs AU - Upah, Roxanne AU - Jacob, Theodore AU - Price, Rumi Kato AD - Family Research Center, Veterans Affairs Palo Alto Healthcare System, Menlo Park, California roxanne.upah@va.gov Y1 - 2015/09// PY - 2015 DA - September 2015 SP - 721 EP - 732 PB - Center of Alcohol Studies, Rutgers, The State University of New Jersey, Piscataway VL - 76 IS - 5 SN - 1937-1888, 1937-1888 KW - Veterans KW - Symptoms KW - Alcohol Abuse KW - Males KW - Intervention KW - Young Adults KW - Comorbidity KW - Health Care Services KW - Drug Abuse KW - article KW - 2079: sociology of health and medicine; substance use/abuse & compulsive behaviors (drug abuse, addiction, alcoholism, gambling, eating disorders, etc.) UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1761674707?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocabs&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Studies+on+Alcohol+and+Drugs&rft.atitle=Trajectories+of+Lifetime+Comorbid+Alcohol+and+Other+Drug+Use+Disorders+Through+Midlife&rft.au=Upah%2C+Roxanne%3BJacob%2C+Theodore%3BPrice%2C+Rumi+Kato&rft.aulast=Upah&rft.aufirst=Roxanne&rft.date=2015-09-01&rft.volume=76&rft.issue=5&rft.spage=721&rft.isbn=&rft.btitle=&rft.title=Journal+of+Studies+on+Alcohol+and+Drugs&rft.issn=19371888&rft_id=info:doi/ LA - English DB - Sociological Abstracts N1 - Date revised - 2016-02-01 N1 - Last updated - 2016-09-28 N1 - SubjectsTermNotLitGenreText - Comorbidity; Drug Abuse; Young Adults; Health Care Services; Symptoms; Intervention; Veterans; Alcohol Abuse; Males ER - TY - JOUR T1 - Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain AN - 1707758382 AB - Background and Objectives Cannabis use is common among patients taking prescription opioids, although rates of concomitant cannabis use disorder (CUD) have been largely unexamined. CUD may increase safety risks in those taking opioid pain medications but it is unknown whether cannabis and opioids function as substitutes (cannabis use is associated with less prescription opioid use), or rather as complements (cannabis is associated with increased use of prescription opioids). Methods We examined rates of CUD in a national sample of Veterans Health Administration (VHA) patients ( n=1,316,464) with non-cancer pain diagnoses receiving opioid medications in fiscal year 2012. Using bivariate analysis to identify potentially confounding variables associated with CUD (eg, psychotropic medication, other substance use disorders) in this population, we then utilized logistic regression to examine rates of cannabis use disorder among individuals receiving different numbers of opioid prescriptions (0, 1–2, 3–10, 11–19, 20+). Results Descriptive analysis, largely confirmed by logistic regression, demonstrated that greater numbers of prescription opioid fills were associated with greater likelihood of CUD. This relationship was reduced somewhat for those receiving the most opioid prescriptions (20+) in the logistic regression, which controlled for potentially confounding variables. Discussion and Conclusions These results warrant increased attention to CUDs among patients receiving numerous opioid prescriptions. Increasing legalization of cannabis is likely to further increase use and abuse of cannabis in patients prescribed opioids. Scientific Significance These findings suggest that clinicians should be alert to concomitant CUD and prescription opioid use, as these substances appear to complement each other. (Am J Addict 2015;24:538–545) JF - The American Journal on Addictions AU - Hefner, Kathryn AU - Sofuoglu, Mehmet AU - Rosenheck, Robert AD - Veterans Health Administration Mental Illness Research, Education and Clinical Center (MIRECC), West Haven, Connecticut., Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. ; Veterans Health Administration Mental Illness Research, Education and Clinical Center (MIRECC), West Haven, Connecticut.; Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Y1 - 2015/09// PY - 2015 DA - Sep 2015 SP - 538 EP - 545 CY - Hoboken PB - Wiley Subscription Services, Inc. VL - 24 IS - 6 SN - 1055-0496 KW - Medical Sciences--Psychiatry And Neurology KW - Addicts KW - Prescribed KW - Prescriptions KW - Psychotropic drugs KW - Safety KW - Substance abuse disorders KW - Veterans KW - Canabis KW - Cancer KW - Cannabis KW - Drug dependency KW - Drugs KW - Legalization KW - Military hospitals KW - Opioids KW - Pain UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1707758382?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Child+and+Adolescent+Social+Work+Journal&rft.atitle=Attachment+Representations+and+Parental+Memories+of+Incarcerated+Fathers&rft.au=Fairchild%2C+Sherry+R&rft.aulast=Fairchild&rft.aufirst=Sherry&rft.date=2009-08-01&rft.volume=26&rft.issue=4&rft.spage=361&rft.isbn=&rft.btitle=&rft.title=Child+and+Adolescent+Social+Work+Journal&rft.issn=07380151&rft_id=info:doi/10.1007%2Fs10560-009-0180-2 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Name - Veterans Health Administration N1 - Date revised - 2015-09-22 N1 - Last updated - 2016-05-16 DO - http://dx.doi.org/10.1111/ajad.12260 ER - TY - JOUR T1 - Deliberate Microbial Infection Research Reveals Limitations to Current Safety Protections of Healthy Human Subjects AN - 1827923271; PQ0001877941 AB - Here we identify approximately 40,000 healthy human volunteers who were intentionally exposed to infectious pathogens in clinical research studies dating from late World War II to the early 2000s. Microbial challenge experiments continue today under contemporary human subject research requirements. In fact, we estimated 4,000 additional volunteers who were experimentally infected between 2010 and the present day. We examine the risks and benefits of these experiments and present areas for improvement in protections of participants with respect to safety. These are the absence of maximum limits to risk and the potential for institutional review boards to include questionable benefits to subjects and society when weighing the risks and benefits of research protocols. The lack of a duty of medical care by physician-investigators to research subjects is likewise of concern. The transparency of microbial challenge experiments and the safety concerns raised in this work may stimulate further dialogue on the risks to participants of human experimentation. JF - Science and Engineering Ethics AU - Evers, David L AU - Fowler, Carol B AU - Mason, Jeffrey T AU - Mimnall, Rebecca K AD - Veterans Affairs Maryland Health Care System, Research Service, 10 North Greene Street, Baltimore, MD, 21201, USA, david.evers2@va.gov Y1 - 2015/08// PY - 2015 DA - August 2015 SP - 1049 EP - 1064 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 21 IS - 4 SN - 1353-3452, 1353-3452 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Cost-benefit analysis KW - Dating KW - Ethics KW - Pathogens KW - Infection KW - A 01300:Methods UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1827923271?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Science+and+Engineering+Ethics&rft.atitle=Deliberate+Microbial+Infection+Research+Reveals+Limitations+to+Current+Safety+Protections+of+Healthy+Human+Subjects&rft.au=Evers%2C+David+L%3BFowler%2C+Carol+B%3BMason%2C+Jeffrey+T%3BMimnall%2C+Rebecca+K&rft.aulast=Evers&rft.aufirst=David&rft.date=2015-08-01&rft.volume=21&rft.issue=4&rft.spage=1049&rft.isbn=&rft.btitle=&rft.title=Science+and+Engineering+Ethics&rft.issn=13533452&rft_id=info:doi/10.1007%2Fs11948-014-9579-z LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-10-01 N1 - Number of references - 67 N1 - Last updated - 2016-10-26 N1 - SubjectsTermNotLitGenreText - Cost-benefit analysis; Ethics; Dating; Pathogens; Infection DO - http://dx.doi.org/10.1007/s11948-014-9579-z ER - TY - JOUR T1 - Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta -lactamases with single amino acid substitutions in the Omega -loop AN - 1712569374; PQ0001944540 AB - Objectives The objective of this study was to explore the activity of ceftazidime and ceftazidime/avibactam against a collection of isogenic strains of Escherichia coli DH10B possessing SHV and KPC beta -lactamases containing single amino acid substitutions in the Omega -loop (residues 164-179). Methods Ceftazidime and ceftazidime/avibactam MICs were determined by the agar dilution method for a panel of isogenic E. coli strains expressing SHV-1 and KPC-2 with amino acid substitutions at positions 164, 167, 169 or 179. Two KPC-2 beta -lactamase variants that possessed elevated MICs of ceftazidime/avibactam were selected for further biochemical analyses. Results Avibactam restored susceptibility to ceftazidime for all Omega -loop variants of SHV-1 with MICs 8 mg/L. beta -Lactamase kinetics showed that the Asp179Asn variant of KPC-2 demonstrated enhanced kinetic properties against ceftazidime. The K sub(i app), k sub(2)/K and k sub(off) of the Arg164Ala and Asp179Asn variant KPC-2 beta -lactamases indicated that avibactam effectively inhibited these enzymes. Conclusions Several KPC-2 variants demonstrating ceftazidime resistance as a result of single amino acid substitutions in the Omega -loop were not susceptible to ceftazidime/avibactam (MICs >8 mg/L). We hypothesize that this observation is due to the stabilizing interactions (e.g. hydrogen bonds) of ceftazidime within the active site of variant beta -lactamases that prevent avibactam from binding to and inhibiting the beta -lactamase. As ceftazidime/avibactam is introduced into the clinic, monitoring for new KPC-2 variants that may exhibit increased ceftazidime kinetics as well as resistance to this novel antibiotic combination will be important. JF - Journal of Antimicrobial Chemotherapy AU - Winkler, Marisa L AU - Papp-Wallace, Krisztina M AU - Bonomo, Robert A AD - Corresponding author. Tel: +1-216-791-3800, ext. 4801; , robert.bonomo@va.gov Y1 - 2015/08// PY - 2015 DA - Aug 2015 SP - 2279 EP - 2286 PB - Oxford University Press, Great Clarendon Street Oxford OX2 6DP United Kingdom VL - 70 IS - 8 SN - 0305-7453, 0305-7453 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - beta -lactamase inhibitors KW - extended-spectrum beta -lactamases KW - ESBLs KW - antibiotic resistance KW - Ceftazidime KW - Agar KW - beta -Lactamase KW - Amino acid substitution KW - Hydrogen bonding KW - Kinetics KW - Escherichia coli KW - Enzymes KW - Antibiotics KW - Minimum inhibitory concentration KW - A 01340:Antibiotics & Antimicrobials KW - J 02340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1712569374?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Antimicrobial+Chemotherapy&rft.atitle=Activity+of+ceftazidime%2Favibactam+against+isogenic+strains+of+Escherichia+coli+containing+KPC+and+SHV+beta+-lactamases+with+single+amino+acid+substitutions+in+the+Omega+-loop&rft.au=Winkler%2C+Marisa+L%3BPapp-Wallace%2C+Krisztina+M%3BBonomo%2C+Robert+A&rft.aulast=Winkler&rft.aufirst=Marisa&rft.date=2015-08-01&rft.volume=70&rft.issue=8&rft.spage=2279&rft.isbn=&rft.btitle=&rft.title=Journal+of+Antimicrobial+Chemotherapy&rft.issn=03057453&rft_id=info:doi/10.1093%2Fjac%2Fdkv094 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-09-01 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Ceftazidime; Agar; Amino acid substitution; beta -Lactamase; Hydrogen bonding; Kinetics; Enzymes; Antibiotics; Minimum inhibitory concentration; Escherichia coli DO - http://dx.doi.org/10.1093/jac/dkv094 ER - TY - JOUR T1 - Aerobactin, but Not Yersiniabactin, Salmochelin, or Enterobactin, Enables the Growth/Survival of Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae Ex Vivo and In Vivo AN - 1709184170; PQ0001900848 AB - The siderophore aerobactin is the dominant siderophore produced by hypervirulent Klebsiella pneumoniae (hvKP) and was previously shown to be a major virulence factor in systemic infection. However, strains of hvKP commonly produce the additional siderophores yersiniabactin, salmochelin, and enterobactin. The roles of these siderophores in hvKP infection have not been optimally defined. To that end, site-specific gene disruptions were created in hvKP1 (wild type), resulting in the generation of hvKP1 Delta iucA (aerobactin deficient), hvKP1 Delta iroB (salmochelin deficient), hvKP1 Delta entB (enterobactin and salmochelin deficient), hvKP1 Delta irp2 (yersiniabactin deficient), and hvKP1 Delta entB Delta irp2 (enterobactin, salmochelin, and yersiniabactin deficient). The growth/survival of these constructs was compared to that of their wild-type parent hvKP1 ex vivo in human ascites fluid, human serum, and human urine and in vivo in mouse systemic infection and pulmonary challenge models. Interestingly, in contrast to aerobactin, the inability to produce enterobactin, salmochelin, or yersiniabactin individually or in combination did not decrease the ex vivo growth/survival in human ascites or serum or decrease virulence in the in vivo infection models. Surprisingly, none of the siderophores increased growth in human urine. In human ascites fluid supplemented with exogenous siderophores, siderophores increased the growth of hvKP1 Delta iucA, with the relative activity being enterobactin > aerobactin > yersiniabactin > salmochelin, suggesting that the contribution of aerobactin to virulence is dependent on both innate biologic activity and quantity produced. Taken together, these data confirm and extend a role for aerobactin as a critical virulence factor for hvKP. Since it appears that aerobactin production is a defining trait of hvKP strains, this factor is a potential antivirulence target. JF - Infection and Immunity AU - Russo, Thomas A AU - Olson, Ruth AU - MacDonald, Ulrike AU - Beanan, Janet AU - Davidson, Bruce A AD - Veterans Administration Western New York Healthcare System, Buffalo, New York, USA, trusso@acsu.buffalo.edu. Y1 - 2015/08// PY - 2015 DA - Aug 2015 SP - 3325 EP - 3333 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 83 IS - 8 SN - 0019-9567, 0019-9567 KW - Microbiology Abstracts B: Bacteriology; Immunology Abstracts KW - Data processing KW - Gene disruption KW - virulence factors KW - aerobactin KW - Disseminated infection KW - Animal models KW - Survival KW - Models KW - Siderophores KW - Lung KW - Urine KW - Ascites KW - Enterobactin KW - Klebsiella pneumoniae KW - J 02410:Animal Diseases KW - F 06910:Microorganisms & Parasites UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1709184170?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Infection+and+Immunity&rft.atitle=Aerobactin%2C+but+Not+Yersiniabactin%2C+Salmochelin%2C+or+Enterobactin%2C+Enables+the+Growth%2FSurvival+of+Hypervirulent+%28Hypermucoviscous%29+Klebsiella+pneumoniae+Ex+Vivo+and+In+Vivo&rft.au=Russo%2C+Thomas+A%3BOlson%2C+Ruth%3BMacDonald%2C+Ulrike%3BBeanan%2C+Janet%3BDavidson%2C+Bruce+A&rft.aulast=Russo&rft.aufirst=Thomas&rft.date=2015-08-01&rft.volume=83&rft.issue=8&rft.spage=3325&rft.isbn=&rft.btitle=&rft.title=Infection+and+Immunity&rft.issn=00199567&rft_id=info:doi/10.1128%2FIAI.00430-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-09-01 N1 - Number of references - 47 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Data processing; aerobactin; virulence factors; Gene disruption; Disseminated infection; Animal models; Survival; Siderophores; Models; Ascites; Urine; Lung; Enterobactin; Klebsiella pneumoniae DO - http://dx.doi.org/10.1128/IAI.00430-15 ER - TY - JOUR T1 - Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. AN - 1701405838; 25988394 AB - Polypharmacy is common, and may modify mechanisms of drug-induced liver injury. We examined the effect of these drug-drug interactions on liver safety reports of four drugs highly associated with hepatotoxicity. In the WHO VigiBase™, liver event reports were examined for acetaminophen, isoniazid, valproic acid, and amoxicillin/clavulanic acid. Then, we evaluated the liver event reporting frequency of these 4 drugs in the presence of co-reported medications. Each of the 4 primary drugs was reported as having more than 2000 liver events, and co-reported with more than 600 different medications. Overall, the effect of 2275 co-reported drugs (316 drug classes) on the reporting frequency was analyzed. Decreased liver event reporting frequency was associated with 245 drugs/122 drug classes, including anti-TNFα, opioids, and folic acid. Increased liver event reporting frequency was associated with 170 drugs/82 drug classes; in particular, halogenated hydrocarbons, carboxamides, and bile acid sequestrants. After adjusting for age, gender, and other co-reported drug classes, multiple co-reported drug classes were significantly associated with decreased/increased liver event reporting frequency in a drug-specific/unspecific manner. In conclusion, co-reported medications were associated with changes in the liver event reporting frequency of drugs commonly associated with hepatotoxicity, suggesting that comedications may modify drug hepatic safety. Copyright © 2015 Elsevier Inc. All rights reserved. JF - Regulatory toxicology and pharmacology : RTP AU - Suzuki, Ayako AU - Yuen, Nancy A AU - Ilic, Katarina AU - Miller, Richard T AU - Reese, Melinda J AU - Brown, H Roger AU - Ambroso, Jeffrey I AU - Falls, J Gregory AU - Hunt, Christine M AD - Gastroenterology, Central Arkansas Veterans Healthcare System and Gastroenterology and Hepatology, Univ. of Arkansas for Med. Sciences, Little Rock, AR, United States. Electronic address: asuzuki@uams.edu. ; Clinical Safety, GlaxoSmithKline, Research Triangle Park, NC, United States. ; Pharmacovigilance and Risk Management, Raptor Pharmaceuticals, CA, United States. ; Safety Assessment, GlaxoSmithKline, Research Triangle Park, NC, United States. ; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Research Triangle Park, NC, United States. ; Gastroenterology, Duke University Medical Center and Durham Veterans Administration Medical Center, Durham, NC, United States. Electronic address: Christine.Hunt@va.gov. Y1 - 2015/08// PY - 2015 DA - August 2015 SP - 481 EP - 490 VL - 72 IS - 3 KW - Acetaminophen KW - 362O9ITL9D KW - Valproic Acid KW - 614OI1Z5WI KW - Amoxicillin-Potassium Clavulanate Combination KW - 74469-00-4 KW - Isoniazid KW - V83O1VOZ8L KW - Index Medicus KW - Quantitative signal detection methods KW - Concomitant medications KW - Hepatotoxicity KW - Spontaneous adverse event reporting system KW - Drug-induced liver injury KW - World Health Organization KW - Data Mining KW - Acetaminophen -- adverse effects KW - Databases, Factual KW - Valproic Acid -- adverse effects KW - Isoniazid -- adverse effects KW - Amoxicillin-Potassium Clavulanate Combination -- adverse effects KW - Drug Interactions KW - Chemical and Drug Induced Liver Injury -- etiology KW - Adverse Drug Reaction Reporting Systems -- statistics & numerical data UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701405838?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.atitle=Comedications+alter+drug-induced+liver+injury+reporting+frequency%3A+Data+mining+in+the+WHO+VigiBase%E2%84%A2.&rft.au=Suzuki%2C+Ayako%3BYuen%2C+Nancy+A%3BIlic%2C+Katarina%3BMiller%2C+Richard+T%3BReese%2C+Melinda+J%3BBrown%2C+H+Roger%3BAmbroso%2C+Jeffrey+I%3BFalls%2C+J+Gregory%3BHunt%2C+Christine+M&rft.aulast=Suzuki&rft.aufirst=Ayako&rft.date=2015-08-01&rft.volume=72&rft.issue=3&rft.spage=481&rft.isbn=&rft.btitle=&rft.title=Regulatory+toxicology+and+pharmacology+%3A+RTP&rft.issn=1096-0295&rft_id=info:doi/10.1016%2Fj.yrtph.2015.05.004 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-24 N1 - Date created - 2015-08-03 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Hepatology. 2014 Sep;60(3):1015-22 [24799086] Hepatology. 2014 Oct;60(4):1399-408 [25043597] Gastroenterology. 2000 Feb;118(2):422-30 [10648470] Hepatology. 2000 Mar;31(3):562-71 [10706543] Pharmacoepidemiol Drug Saf. 2003 Sep;12(6):517-21 [14513665] Br J Clin Pharmacol. 2004 Jul;58(1):71-80 [15206996] BMJ. 2004 Jul 3;329(7456):15-9 [15231615] J Am Soc Nephrol. 2004 Aug;15(8):2152-60 [15284300] J Perinatol. 1992 Jun;12(2):107-11 [1522425] Toxicol Appl Pharmacol. 1993 Feb;118(2):159-68 [8382844] J Hepatol. 1994 Jun;20(6):792-6 [7930480] Blood. 1996 Apr 15;87(8):3170-8 [8605331] Hepatology. 2000 Dec;32(6):1309-16 [11093738] J Nutr. 2001 Jan;131(1):33-8 [11208935] Hepatology. 2002 Aug;36(2):451-5 [12143055] JAMA. 2003 Mar 5;289(9):1107-16 [12622580] Life Sci. 1996;59(14):1141-7 [8831801] Neurochem Res. 1996 Nov;21(11):1375-86 [8947928] J Neuroimmunol. 1998 Mar 15;83(1-2):63-9 [9610674] Cell Physiol Biochem. 2005;15(1-4):69-76 [15665517] Arch Intern Med. 2005 Mar 14;165(5):567-73 [15767534] Drug Saf. 2005;28(11):981-1007 [16231953] Dig Liver Dis. 2006 Jan;38(1):33-8 [16054882] JAMA. 2006 Jul 5;296(1):87-93 [16820551] Hepatology. 2006 Oct;44(4):850-6 [17006920] J Hepatol. 2007 Feb;46(2):322-9 [17156885] Clin Liver Dis. 2007 Aug;11(3):507-24, vi [17723917] Arch Intern Med. 2007 Sep 10;167(16):1752-9 [17846394] Biochem Pharmacol. 2007 Dec 3;74(11):1665-76 [17897632] J Altern Complement Med. 2007 Nov;13(9):997-1006 [18047447] Dig Dis Sci. 2008 Jul;53(7):1977-82 [18392678] Hepatology. 2008 Jun;47(6):2003-9 [18454504] Drug Metab Dispos. 2009 Jan;37(1):229-36 [18838507] JAMA. 2008 Dec 24;300(24):2867-78 [19109115] World J Gastroenterol. 2009 Apr 14;15(14):1677-89 [19360911] Clin Gastroenterol Hepatol. 2009 Aug;7(8):882-8 [19362607] Clin Exp Immunol. 2009 Jul;157(1):27-34 [19659767] Acta Pharmacol Sin. 2009 Nov;30(11):1522-8 [19890360] Semin Liver Dis. 2010 May;30(2):134-46 [20422496] Drug Saf. 2010 Jun 1;33(6):503-22 [20486732] Mol Med. 2010 Jul-Aug;16(7-8):254-61 [20379612] Toxicol Pathol. 2010 Aug;38(5):715-29 [20551477] Toxicol Sci. 2010 Dec;118(2):485-500 [20829430] Hepatology. 2010 Dec;52(6):2065-76 [20949552] Respir Res. 2011;12:24 [21352583] Nat Rev Genet. 2011 Jun;12(6):417-28 [21587298] Clin Pharmacol Ther. 2011 Jun;89(6):902-7 [21508940] Thyroid. 2011 Jun;21(6):655-62 [21563917] Clin Pharmacol Ther. 2011 Jul;90(1):133-42 [21613990] Gastroenterology. 2011 Jul;141(1):338-47 [21570397] Toxicol Sci. 2012 Jan;125(1):126-33 [21984482] Drug Metab Rev. 2012 Feb;44(1):34-87 [21892896] Chem Res Toxicol. 2012 Oct 15;25(10):2067-82 [22931300] Clin Exp Allergy. 2013 Mar;43(3):344-52 [23414543] Pharmacol Rev. 2013 Apr;65(2):779-808 [23476052] Trends Pharmacol Sci. 2013 Apr;34(4):243-53 [23453390] Crit Rev Oncol Hematol. 2013 Nov;88(2):404-15 [23786843] Toxicol Sci. 2013 Nov;136(1):216-41 [23956101] Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7 [24203711] Eur J Clin Pharmacol. 2014 Apr;70(4):501-3 [24384565] Drug Metab Dispos. 2014 Apr;42(4):744-50 [24464804] Ann Pharmacother. 2003 Jul-Aug;37(7-8):1117-23 [12841826] Arch Surg. 2003 Aug;138(8):852-8 [12912743] Hepatology. 2003 Sep;38(3):664-73 [12939593] Gastroenterology. 2014 Jul;147(1):96-108.e4 [24681128] Arch Toxicol. 2014 Jul;88(7):1439-49 [24958025] Am J Gastroenterol. 2014 Jul;109(7):950-66; quiz 967 [24935270] Erratum In: Regul Toxicol Pharmacol. 2015 Oct;73(1):348 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.yrtph.2015.05.004 ER - TY - JOUR T1 - FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice. AN - 1700685795; 26092866 AB - Alcohol consumption leads to adipose tissue lipoatrophy and mobilization of FFAs, which contributes to hepatic fat accumulation in alcoholic liver disease. This study aimed to investigate the role of fibroblast growth factor (FGF)21, a metabolic regulator, in the regulation of chronic-binge alcohol-induced adipose tissue lipolysis. FGF21 KO mice were subjected to chronic-binge alcohol exposure, and epididymal white adipose tissue lipolysis and liver steatosis were investigated. Alcohol exposure caused adipose intracellular cAMP elevation and activation of lipolytic enzymes, leading to FFA mobilization in both WT and FGF21 KO mice. However, alcohol-induced systemic elevation of catecholamine, which is known to be a major player in adipose lipolysis by binding to the β-adrenergic receptor, was markedly inhibited in KO mice. Supplementation with recombinant human FGF21 to alcohol-exposed FGF21 KO mice resulted in an increase in fat loss in parallel with an increase of circulating norepinephrine concentration. Furthermore, alcohol consumption-induced fatty liver was blunted in the KO mice, indicating an inhibition of fatty acid reverse transport from adipose to the liver in the KO mice. Taken together, our studies demonstrate that FGF21 KO mice are protected from alcohol-induced adipose tissue excess-lipolysis through a mechanism involving systemic catecholamine release. JF - Journal of lipid research AU - Zhao, Cuiqing AU - Liu, Yanlong AU - Xiao, Jian AU - Liu, Liming AU - Chen, Shaoyu AU - Mohammadi, Moosa AU - McClain, Craig J AU - Li, Xiaokun AU - Feng, Wenke AD - College of Basic Medical Sciences, Jilin University, Changchun, China Departments of Medicine University of Louisville School of Medicine, Louisville, KY Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. ; Departments of Medicine University of Louisville School of Medicine, Louisville, KY Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. ; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. ; Departments of Medicine University of Louisville School of Medicine, Louisville, KY Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY. ; Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY. ; Department of Pharmacology, New York University School of Medicine, New York, NY. ; Departments of Medicine University of Louisville School of Medicine, Louisville, KY Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY Robley Rex Veterans Administration Medical Center, Louisville, KY. ; College of Basic Medical Sciences, Jilin University, Changchun, China School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. Y1 - 2015/08// PY - 2015 DA - August 2015 SP - 1481 EP - 1491 VL - 56 IS - 8 KW - Catecholamines KW - 0 KW - Insulin KW - fibroblast growth factor 21 KW - Ethanol KW - 3K9958V90M KW - Fibroblast Growth Factors KW - 62031-54-3 KW - Index Medicus KW - lipolysis and fatty acid metabolism KW - adipose tissue KW - cell signaling KW - liver KW - alcoholic liver disease KW - Animals KW - Epididymis KW - Fatty Liver, Alcoholic -- metabolism KW - Humans KW - Insulin -- metabolism KW - Mice KW - Binge Drinking -- pathology KW - Adipose Tissue, White -- drug effects KW - Gene Knockout Techniques KW - Adipose Tissue, White -- metabolism KW - Binge Drinking -- metabolism KW - Signal Transduction -- drug effects KW - Mice, Inbred C57BL KW - Fatty Liver, Alcoholic -- pathology KW - Gene Expression Regulation -- drug effects KW - Fatty Liver, Alcoholic -- genetics KW - Male KW - Fibroblast Growth Factors -- deficiency KW - Ethanol -- adverse effects KW - Adipose Tissue -- secretion KW - Adipose Tissue -- metabolism KW - Catecholamines -- secretion KW - Adipose Tissue -- drug effects KW - Lipolysis -- drug effects KW - Fibroblast Growth Factors -- pharmacology KW - Fibroblast Growth Factors -- metabolism KW - Fibroblast Growth Factors -- genetics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1700685795?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+lipid+research&rft.atitle=FGF21+mediates+alcohol-induced+adipose+tissue+lipolysis+by+activation+of+systemic+release+of+catecholamine+in+mice.&rft.au=Zhao%2C+Cuiqing%3BLiu%2C+Yanlong%3BXiao%2C+Jian%3BLiu%2C+Liming%3BChen%2C+Shaoyu%3BMohammadi%2C+Moosa%3BMcClain%2C+Craig+J%3BLi%2C+Xiaokun%3BFeng%2C+Wenke&rft.aulast=Zhao&rft.aufirst=Cuiqing&rft.date=2015-08-01&rft.volume=56&rft.issue=8&rft.spage=1481&rft.isbn=&rft.btitle=&rft.title=Journal+of+lipid+research&rft.issn=1539-7262&rft_id=info:doi/10.1194%2Fjlr.M058610 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-04-26 N1 - Date created - 2015-07-30 N1 - Date revised - 2017-02-06 N1 - SuppNotes - Cited By: Science. 1989 Sep 8;245(4922):1118-21 [2570461] J Lipid Res. 1995 Oct;36(10):2164-73 [8576642] J Lipid Res. 1996 Sep;37(9):1842-8 [8895050] Biochem Biophys Res Commun. 1960 Dec;3:635-40 [13715909] Diabetes Metab. 2004 Sep;30(4):294-309 [15525872] Science. 2004 Nov 19;306(5700):1383-6 [15550674] Alcohol. 2004 Aug;34(1):35-8 [15670663] Am J Pathol. 2005 Jun;166(6):1681-90 [15920153] J Clin Invest. 2005 Jun;115(6):1627-35 [15902306] J Biol Chem. 2005 Dec 30;280(52):43109-20 [16243839] Science. 2006 May 5;312(5774):734-7 [16675698] J Biol Chem. 2006 Jun 9;281(23):15837-44 [16595669] J Hepatol. 2006 Nov;45(5):717-24 [16879892] J Biol Chem. 2007 Jan 12;282(2):996-1002 [17114792] Cell Metab. 2007 Jun;5(6):415-25 [17550777] Cell Metab. 2007 Jun;5(6):426-37 [17550778] J Biol Chem. 2007 Sep 14;282(37):26687-95 [17623664] J Biol Chem. 2007 Sep 28;282(39):28465-73 [17686776] Sports Med. 2008;38(5):401-23 [18416594] FEBS Lett. 2008 May 28;582(12):1725-30 [18460341] Cell Metab. 2008 Jul;8(1):77-83 [18585098] Mol Pharmacol. 2008 Aug;74(2):403-12 [18467542] Diabetes. 2009 Jan;58(1):250-9 [18840786] Semin Liver Dis. 2009 May;29(2):178-87 [19387917] Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10853-8 [19541642] Endocrinology. 2009 Oct;150(10):4625-33 [19589869] Endocrinology. 2009 Nov;150(11):4931-40 [19819944] Am J Clin Nutr. 2010 Jan;91(1):254S-257S [19906798] Diabetes. 2010 Jan;59(1):61-70 [19808894] Mol Cell Endocrinol. 2010 Apr 29;318(1-2):34-43 [19747957] Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):377-81 [20531174] Nat Rev Endocrinol. 2011 Mar;7(3):137-50 [21079616] Nephrol Ther. 2011 Apr;7(2):69-79 [21156355] Am J Pathol. 2011 Dec;179(6):2866-75 [22093263] Cell. 2012 Feb 3;148(3):556-67 [22304921] Am J Pathol. 2012 Mar;180(3):998-1007 [22234172] J Clin Endocrinol Metab. 2012 Apr;97(4):1375-82 [22344195] Horm Metab Res. 2001 Feb;33(2):89-95 [11294499] J Lipid Res. 2012 Nov;53(11):2296-306 [22941773] Cell Metab. 2013 May 7;17(5):779-89 [23663741] Endocrinology. 2013 Sep;154(9):3099-109 [23766126] Br J Pharmacol. 2014 Sep;171(17):4073-86 [24819676] Cell Metab. 2014 Oct 7;20(4):670-7 [25130400] Am J Clin Nutr. 1999 Nov;70(5):928-36 [10539756] Cell. 2000 May 12;101(4):413-24 [10830168] Ann N Y Acad Sci. 1999 Nov 18;892:155-68 [10842661] Diabetes. 2002 Oct;51(10):2929-35 [12351429] J Biol Chem. 2003 Oct 31;278(44):43615-9 [12832420] Biochem Soc Trans. 2003 Dec;31(Pt 6):1120-4 [14641008] Cell. 2004 Jan 23;116(2 Suppl):S89-92, 1 p following S96 [15055592] Mol Pharmacol. 1965 Nov;1(3):280-96 [5842826] Comp Biochem Physiol. 1965 Dec;16(4):367-81 [5881746] Comp Biochem Physiol B. 1971 May 15;39(1):69-82 [5570026] Clin Sci (Lond). 1984 Jun;66(6):643-8 [6723203] Nature. 1986 May 1-7;321(6065):75-9 [3010132] Proc Natl Acad Sci U S A. 1987 Nov;84(22):7920-4 [2825170] J Lipid Res. 1993 Jul;34(7):1057-91 [8371057] Cell Signal. 1994 May;6(4):363-92 [7946963] N1 - Last updated - 2017-02-07 DO - http://dx.doi.org/10.1194/jlr.M058610 ER - TY - JOUR T1 - Assessment of ToxCast Phase II for Mitochondrial Liabilities Using a High-Throughput Respirometric Assay. AN - 1700334475; 25926417 AB - Previous high-throughput screens to identify mitochondrial toxicants used immortalized cell lines and focused on changes in mitochondrial membrane potential, which may not be sufficient and do not identify different types of mitochondrial dysfunction. Primary cultures of renal proximal tubule cells (RPTC) were examined with the Seahorse Extracellular Flux Analyzer to screen 676 compounds (5 μM; 1 h) from the ToxCast Phase II library for mitochondrial toxicants. Of the 676 compounds, 19 were classified as cytotoxicants, 376 were electron transport chain (ETC) inhibitors, and 5 were uncouplers. The remaining 276 compounds were examined after a 5-h exposure to identify slower acting mitochondrial toxicants. This experiment identified 3 cytotoxicants, 110 ETC inhibitors, and 163 compounds with no effect. A subset of the ToxCast Phase II library was also examined in immortalized human renal cells (HK2) to determine differences in susceptibility to mitochondrial toxicity. Of the 131 RPTC ETC inhibitors tested, only 14 were ETC inhibitors in HK2 cells. Of the 5 RPTC uncouplers, 1 compound was an uncoupler in HK2 cells. These results demonstrate that 73% (491/676) of the compounds in the ToxCast Phase II library compounds exhibit RPTC mitochondrial toxicity, overwhelmingly ETC inhibition. In contrast, renal HK2 cells are markedly less sensitive and only identified 6% of the compounds as mitochondrial toxicants. We suggest caution is needed when studying mitochondrial toxicity in immortalized cell lines. This information will provide mechanisms and chemical-based criteria for assessing and predicting mitochondrial liabilities of new drugs, consumer products, and environmental agents. © The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. JF - Toxicological sciences : an official journal of the Society of Toxicology AU - Wills, Lauren P AU - Beeson, Gyda C AU - Hoover, Douglas B AU - Schnellmann, Rick G AU - Beeson, Craig C AD - *MitoHealth Inc., Charleston, South Carolina. ; *MitoHealth Inc., Charleston, South Carolina, Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and. ; Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and. ; Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina. ; *MitoHealth Inc., Charleston, South Carolina, Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425 and beesonc@musc.edu. Y1 - 2015/08// PY - 2015 DA - August 2015 SP - 226 EP - 234 VL - 146 IS - 2 KW - Index Medicus KW - cell culture KW - systems toxicology KW - in vitro and alternatives, kidney KW - safety evaluation KW - Animals KW - Humans KW - Rabbits KW - Female KW - Cell Line KW - Electron Transport -- drug effects KW - High-Throughput Screening Assays KW - Cell Respiration -- drug effects KW - Mitochondria -- drug effects KW - Toxicity Tests UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1700334475?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Toxicological+sciences+%3A+an+official+journal+of+the+Society+of+Toxicology&rft.atitle=Assessment+of+ToxCast+Phase+II+for+Mitochondrial+Liabilities+Using+a+High-Throughput+Respirometric+Assay.&rft.au=Wills%2C+Lauren+P%3BBeeson%2C+Gyda+C%3BHoover%2C+Douglas+B%3BSchnellmann%2C+Rick+G%3BBeeson%2C+Craig+C&rft.aulast=Wills&rft.aufirst=Lauren&rft.date=2015-08-01&rft.volume=146&rft.issue=2&rft.spage=226&rft.isbn=&rft.btitle=&rft.title=Toxicological+sciences+%3A+an+official+journal+of+the+Society+of+Toxicology&rft.issn=1096-0929&rft_id=info:doi/10.1093%2Ftoxsci%2Fkfv085 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-31 N1 - Date created - 2015-07-29 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1093/toxsci/kfv085 ER - TY - JOUR T1 - Upregulation of autophagy decreases chlorine-induced mitochondrial injury and lung inflammation. AN - 1697759688; 25881550 AB - The mechanisms of toxicity during exposure of the airways to chlorinated biomolecules generated during the course of inflammation and to chlorine (Cl2) gas are poorly understood. We hypothesized that lung epithelial cell mitochondria are damaged by Cl2 exposure and activation of autophagy mitigates this injury. To address this, NCI-H441 (human lung adenocarcinoma epithelial) cells were exposed to Cl2 (100 ppm/15 min) and bioenergetics were assessed. One hour after Cl2, cellular bioenergetic function and mitochondrial membrane potential were decreased. These changes were associated with increased MitoSOX signal, and treatment with the mitochondrial redox modulator MitoQ attenuated these bioenergetic defects. At 6h postexposure, there was significant increase in autophagy, which was associated with an improvement of mitochondrial function. Pretreatment of H441 cells with trehalose (an autophagy activator) improved bioenergetic function, whereas 3-methyladenine (an autophagy inhibitor) resulted in increased bioenergetic dysfunction 1h after Cl2 exposure. These data indicate that Cl2 induces bioenergetic dysfunction, and autophagy plays a protective role in vitro. Addition of trehalose (2 vol%) to the drinking water of C57BL/6 mice for 6 weeks, but not 1 week, before Cl2 (400 ppm/30 min) decreased white blood cells in the bronchoalveolar lavage fluid at 6h after Cl2 by 70%. Acute administration of trehalose delivered through inhalation 24 and 1h before the exposure decreased alveolar permeability but not cell infiltration. These data indicate that Cl2 induces bioenergetic dysfunction associated with lung inflammation and suggests that autophagy plays a protective role. Published by Elsevier Inc. JF - Free radical biology & medicine AU - Jurkuvenaite, Asta AU - Benavides, Gloria A AU - Komarova, Svetlana AU - Doran, Stephen F AU - Johnson, Michelle AU - Aggarwal, Saurabh AU - Zhang, Jianhua AU - Darley-Usmar, Victor M AU - Matalon, Sadis AD - Department of Anesthesiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Pulmonary Injury and Repair Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294,USA; Center for Free Radical Biology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ; Department of Anesthesiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ; Department of Anesthesiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Pulmonary Injury and Repair Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Center for Free Radical Biology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294,USA; Center for Free Radical Biology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Veterans Administration Medical Center, Birmingham, AL 35233, USA. ; Department of Anesthesiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Pulmonary Injury and Repair Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA; Center for Free Radical Biology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Electronic address: sadis@uab.edu. Y1 - 2015/08// PY - 2015 DA - August 2015 SP - 83 EP - 94 VL - 85 KW - Chlorine KW - 4R7X1O2820 KW - Index Medicus KW - Lung injury KW - Bioenergetics KW - Autophagy KW - Free radicals KW - MitoQ KW - Trehalose KW - 3-Methyladenine KW - Mitochondrial dysfunction KW - Animals KW - Humans KW - Bronchoalveolar Lavage Fluid KW - Mice KW - Energy Metabolism KW - Cell Line KW - Chlorine -- toxicity KW - Mitochondria -- drug effects KW - Inflammation -- chemically induced KW - Lung -- drug effects KW - Mitochondria -- metabolism KW - Up-Regulation UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1697759688?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Free+radical+biology+%26+medicine&rft.atitle=Upregulation+of+autophagy+decreases+chlorine-induced+mitochondrial+injury+and+lung+inflammation.&rft.au=Jurkuvenaite%2C+Asta%3BBenavides%2C+Gloria+A%3BKomarova%2C+Svetlana%3BDoran%2C+Stephen+F%3BJohnson%2C+Michelle%3BAggarwal%2C+Saurabh%3BZhang%2C+Jianhua%3BDarley-Usmar%2C+Victor+M%3BMatalon%2C+Sadis&rft.aulast=Najavits&rft.aufirst=Lisa&rft.date=2009-07-01&rft.volume=10&rft.issue=3&rft.spage=290&rft.isbn=&rft.btitle=&rft.title=Trauma%2C+Violence%2C+%26+Abuse%3A+A+Review+Journal&rft.issn=15248380&rft_id=info:doi/10.1177%2F1524838009334455 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-26 N1 - Date created - 2015-07-20 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: News Physiol Sci. 2001 Aug;16:185-90 [11479370] Biol Chem. 2002 Mar-Apr;383(3-4):709-13 [12033460] Amino Acids. 2003 Dec;25(3-4):259-74 [14661089] Inhal Toxicol. 2004 Feb;16(2):87-91 [15204781] J Clin Invest. 1982 Sep;70(3):598-607 [6286728] N Engl J Med. 1989 Feb 9;320(6):365-76 [2536474] J Biol Chem. 1992 Nov 25;267(33):23937-41 [1385428] J Clin Invest. 1996 Sep 15;98(6):1283-9 [8823292] J Clin Invest. 1997 May 1;99(9):2075-81 [9151778] Methods Enzymol. 1999;301:151-60 [9919563] J Biol Chem. 2005 Jun 3;280(22):21346-52 [15799967] Arch Biochem Biophys. 2006 Jan 15;445(2):225-34 [16111649] Autophagy. 2005 Jul;1(2):84-91 [16874052] J Biol Chem. 2007 Feb 23;282(8):5641-52 [17182613] Pharmacol Ther. 2007 Sep;115(3):400-9 [17658610] Hepatology. 2008 May;47(5):1725-36 [18311843] PLoS One. 2008;3(10):e3316 [18830406] Am J Physiol Lung Cell Mol Physiol. 2008 Nov;295(5):L733-43 [18708632] Am J Emerg Med. 2009 Jan;27(1):1-7 [19041527] Biochem J. 2009 Jan 1;417(1):1-13 [19061483] Biochem J. 2009 Nov 15;424(1):99-107 [19740075] J Biol Chem. 2010 Mar 26;285(13):9716-28 [20106988] Mitochondrion. 2010 Jun;10(4):309-15 [20083234] Proc Am Thorac Soc. 2010 Jul;7(4):278-83 [20601632] Neurobiol Dis. 2010 Sep;39(3):423-38 [20546895] Mov Disord. 2010 Aug 15;25(11):1670-4 [20568096] Am J Physiol Lung Cell Mol Physiol. 2010 Sep;299(3):L289-300 [20525917] J Biol Chem. 2010 Nov 5;285(45):34447-59 [20805228] Am J Physiol Lung Cell Mol Physiol. 2011 Mar;300(3):L362-9 [21148791] Am J Respir Crit Care Med. 2011 Mar 1;183(5):649-58 [20889906] Hepatology. 2011 Jul;54(1):153-63 [21520201] Am J Respir Cell Mol Biol. 2011 Jul;45(1):88-94 [20855648] Am J Respir Cell Mol Biol. 2011 Aug;45(2):386-92 [21131440] Am J Respir Cell Mol Biol. 2011 Aug;45(2):419-25 [21131444] Am J Respir Cell Mol Biol. 2011 Oct;45(4):867-73 [21441382] Free Radic Biol Med. 2011 Nov 1;51(9):1621-35 [21872656] Biochem J. 2012 Jan 15;441(2):523-40 [22187934] Free Radic Biol Med. 2012 Jan 1;52(1):1-6 [22027063] Am J Respir Cell Mol Biol. 2012 Mar;46(3):342-54 [21997487] Life Sci. 2012 Mar 10;90(11-12):440-5 [22269828] Am J Physiol Heart Circ Physiol. 2012 Apr 1;302(7):H1394-409 [22245770] Am J Respir Cell Mol Biol. 2012 May;46(5):599-606 [22162906] J Physiol. 2012 Jul 15;590(14):3305-16 [22570377] Free Radic Biol Med. 2012 Oct 1;53(7):1431-9 [22917977] Chest. 2012 Nov;142(5):1289-99 [23131937] Am J Physiol Lung Cell Mol Physiol. 2013 Jan 1;304(1):L56-69 [23087019] Biol Chem. 2012 Dec;393(12):1485-1512 [23092819] Am J Physiol Lung Cell Mol Physiol. 2013 May 1;304(9):L582-92 [23457187] Am J Physiol Lung Cell Mol Physiol. 2013 Jun 1;304(11):L765-73 [23564508] Free Radic Biol Med. 2013 Oct;63:207-21 [23702245] Free Radic Biol Med. 2013 Dec;65:1215-28 [24056030] Antioxid Redox Signal. 2014 Jan 20;20(3):474-94 [23879400] Nat Protoc. 2014 Feb;9(2):421-38 [24457333] Biochem J. 2010 Nov 15;432(1):9-19 [20825366] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.freeradbiomed.2015.03.039 ER - TY - JOUR T1 - RAN translation at CGG repeats induces ubiquitin proteasome system impairment in models of fragile X-associated tremor ataxia syndrome. AN - 1694962601; 25954027 AB - Fragile X-associated tremor ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by a CGG trinucleotide repeat expansion in the 5' UTR of the Fragile X gene, FMR1. FXTAS is thought to arise primarily from an RNA gain-of-function toxicity mechanism. However, recent studies demonstrate that the repeat also elicits production of a toxic polyglycine protein, FMRpolyG, via repeat-associated non-AUG (RAN)-initiated translation. Pathologically, FXTAS is characterized by ubiquitin-positive intranuclear neuronal inclusions, raising the possibility that failure of protein quality control pathways could contribute to disease pathogenesis. To test this hypothesis, we used Drosophila- and cell-based models of CGG-repeat-associated toxicity. In Drosophila, ubiquitin proteasome system (UPS) impairment led to enhancement of CGG-repeat-induced degeneration, whereas overexpression of the chaperone protein HSP70 suppressed this toxicity. In transfected mammalian cells, CGG repeat expression triggered accumulation of a UPS reporter in a length-dependent fashion. To delineate the contributions from CGG repeats as RNA from RAN translation-associated toxicity, we enhanced or impaired the production of FMRpolyG in these models. Driving expression of FMRpolyG enhanced induction of UPS impairment in cell models, while prevention of RAN translation attenuated UPS impairment in cells and suppressed the genetic interaction with UPS manipulation in Drosophila. Taken together, these findings suggest that CGG repeats induce UPS impairment at least in part through activation of RAN translation. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US. JF - Human molecular genetics AU - Oh, Seok Yoon AU - He, Fang AU - Krans, Amy AU - Frazer, Michelle AU - Taylor, J Paul AU - Paulson, Henry L AU - Todd, Peter K AD - Department of Neurology, University of Michigan, Ann Arbor, MI, USA. ; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA and. ; Department of Neurology, University of Michigan, Ann Arbor, MI, USA, Neurology, U.S. Department of Veterans Affairs Medical Center, Ann Arbor, MI, USA petertod@umich.edu. Y1 - 2015/08/01/ PY - 2015 DA - 2015 Aug 01 SP - 4317 EP - 4326 VL - 24 IS - 15 KW - Drosophila Proteins KW - 0 KW - FMR1 protein, Drosophila KW - FMR1 protein, human KW - Ubiquitin KW - Fragile X Mental Retardation Protein KW - 139135-51-6 KW - Proteasome Endopeptidase Complex KW - EC 3.4.25.1 KW - Index Medicus KW - Trinucleotide Repeat Expansion -- genetics KW - Animals KW - Proteasome Endopeptidase Complex -- metabolism KW - Humans KW - Drosophila melanogaster KW - Disease Models, Animal KW - Mice KW - Proteasome Endopeptidase Complex -- genetics KW - Animals, Genetically Modified KW - Neurodegenerative Diseases KW - Tremor -- genetics KW - Ubiquitin -- metabolism KW - Ubiquitin -- genetics KW - Tremor -- pathology KW - Fragile X Syndrome -- genetics KW - Ataxia -- genetics KW - Fragile X Mental Retardation Protein -- genetics KW - Drosophila Proteins -- genetics KW - Fragile X Syndrome -- pathology KW - Ataxia -- pathology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1694962601?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Human+molecular+genetics&rft.atitle=RAN+translation+at+CGG+repeats+induces+ubiquitin+proteasome+system+impairment+in+models+of+fragile+X-associated+tremor+ataxia+syndrome.&rft.au=Oh%2C+Seok+Yoon%3BHe%2C+Fang%3BKrans%2C+Amy%3BFrazer%2C+Michelle%3BTaylor%2C+J+Paul%3BPaulson%2C+Henry+L%3BTodd%2C+Peter+K&rft.aulast=Oh&rft.aufirst=Seok&rft.date=2015-08-01&rft.volume=24&rft.issue=15&rft.spage=4317&rft.isbn=&rft.btitle=&rft.title=Human+molecular+genetics&rft.issn=1460-2083&rft_id=info:doi/10.1093%2Fhmg%2Fddv165 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-17 N1 - Date created - 2015-07-07 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Nat Genet. 1999 Dec;23(4):425-8 [10581028] Am J Hum Genet. 2000 Jan;66(1):6-15 [10631132] Nat Biotechnol. 2000 May;18(5):538-43 [10802622] Nature. 2000 Nov 2;408(6808):101-6 [11081516] Neurology. 2001 Jul 10;57(1):127-30 [11445641] Science. 2002 Feb 1;295(5556):865-8 [11823645] Hum Mol Genet. 2002 May 1;11(9):1107-17 [11978769] Hum Mol Genet. 2002 Nov 1;11(23):2895-904 [12393801] Am J Hum Genet. 2003 Apr;72(4):869-78 [12638084] Hum Mol Genet. 2003 May 1;12(9):985-94 [12700167] Neuron. 2003 Aug 28;39(5):739-47 [12948442] Genetics. 2003 Nov;165(3):1233-42 [14668378] JAMA. 2004 Jan 28;291(4):460-9 [14747503] Hum Mol Genet. 2004 Sep 15;13(18):2011-8 [15254017] Science. 2004 Aug 27;305(5688):1292-5 [15333840] Nature. 1991 Feb 14;349(6310):624-6 [1672039] Science. 1991 May 24;252(5009):1179-81 [2031189] Cell. 1991 May 31;65(5):905-14 [1710175] Science. 1991 Jun 21;252(5013):1711-4 [1675488] Cell. 1991 Aug 23;66(4):817-22 [1878973] Arch Biochem Biophys. 1999 Aug 1;368(1):85-97 [10415115] Trends Cell Biol. 2004 Dec;14(12):703-11 [15564047] Mol Cell. 2005 Apr 1;18(1):37-48 [15808507] FEBS Lett. 2005 May 9;579(12):2702-8 [15862312] Mov Disord. 2007 Oct 31;22(14):2018-30, quiz 2140 [17618523] J Clin Invest. 2008 Jun;118(6):2190-9 [18497889] Hum Mol Genet. 2011 Jun 15;20(12):2308-21 [21441568] Hum Mol Genet. 2011 Dec 15;20(24):4810-21 [21933837] Neurobiol Aging. 2012 May;33(5):1008.e1-15 [22118902] PLoS One. 2012;7(11):e47452 [23139745] Neuron. 2013 Feb 20;77(4):639-46 [23415312] Science. 2013 Mar 15;339(6125):1335-8 [23393093] Cell Rep. 2013 Mar 28;3(3):869-80 [23478018] PLoS One. 2013;8(4):e62572 [23626835] Science. 2014 Sep 5;345(6201):1192-4 [25103406] Acta Neuropathol. 2014 Oct;128(4):485-503 [25120191] Acta Neuropathol. 2014 Oct;128(4):505-24 [25173361] Brain Res. 2014 Oct 10;1584:3-14 [24709120] Neurotherapeutics. 2014 Oct;11(4):721-31 [25005000] Trends Neurosci. 2008 Oct;31(10):521-8 [18778858] Biochim Biophys Acta. 2008 Dec;1782(12):691-9 [18930136] Cell. 2009 Feb 20;136(4):777-93 [19239895] Hum Mol Genet. 2010 Jan 15;19(2):299-312 [19864489] Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5018-23 [20194754] PLoS Genet. 2010;6(12):e1001240 [21170301] Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):260-5 [21173221] Annu Rev Med. 2011;62:411-29 [21090964] Hum Mol Genet. 2011 May 1;20(9):1738-50 [21300695] Ann Neurol. 2010 Mar;67(3):291-300 [20373340] EMBO J. 2010 Apr 7;29(7):1248-61 [20186122] Genetics. 2010 Apr;184(4):927-45 [20065067] Mol Biol Cell. 2010 Jul 1;21(13):2128-37 [20444973] Hum Mol Genet. 2005 Dec 1;14(23):3661-71 [16239243] Brain. 2006 Jan;129(Pt 1):256-71 [16246864] Hum Mol Genet. 2006 Feb 1;15(3):433-42 [16368705] EMBO J. 2006 May 17;25(10):2253-62 [16642034] Hum Mol Genet. 2006 Jul 1;15(13):2138-45 [16723374] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11748-53 [16864772] RNA Biol. 2004 Jul;1(2):103-5 [17179750] J Biol Chem. 2007 Feb 23;282(8):5641-52 [17182613] RNA. 2007 Apr;13(4):555-62 [17283214] Nature. 2007 Jun 14;447(7146):859-63 [17568747] Neuron. 2007 Aug 16;55(4):556-64 [17698009] Neuron. 2007 Aug 16;55(4):565-71 [17698010] Neuron. 2013 May 8;78(3):440-55 [23602499] Acta Neuropathol. 2013 Jul;126(1):1-19 [23793382] Acta Neuropathol. 2013 Dec;126(6):829-44 [24129584] Acta Neuropathol. 2013 Dec;126(6):881-93 [24132570] Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4968-77 [24248382] Curr Opin Cell Biol. 2014 Feb;26:139-46 [24463332] Neurol Clin. 2014 Aug;32(3):705-19, viii [25037086] Neuron. 2014 Sep 3;83(5):1043-50 [25132468] Science. 2014 Sep 5;345(6201):1139-45 [25081482] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1093/hmg/ddv165 ER - TY - RPRT T1 - SAN FRANCISCO VETERAN AFFAIRS MEDICAL CENTER (SFVAMC) LONG RANGE DEVELOPMENT PLAN. AN - 16384969; 16559 AB - PURPOSE: This EIS evaluates potential environmental impacts resulting from implementation of the Veteran Affairs (VA) Proposed Action. VA's Proposed Action is a Long Range Development Plan (LRDP) that supports the mission of San Francisco Veteran Affairs Medical Center (SFVAMC) to provide for the health care needs of Bay Area and North Coast Veterans by providing for the renovation, expansion, and operation of the SFVAMC Fort Miley Campus within San Francisco County. The purpose of the Proposed Action is to meet the Veterans Health Administration mission of providing comprehensive, high-quality health care services that improve the health and well-being of Veterans and other eligible persons in the San Francisco Bay Area and Northern California. VA's need for the Proposed Action is to address the areas current and future capacity issues brought about by the growing Veteran population, to better serve the ever-changing health care needs of the growing Veteran population, and to provide safe and appropriate facilities for providing health care services and conducting research. This EIS analyzes three action alternatives that would involve implementation of an LRDP. All three action alternatives would include seismic retrofit, demolition, new construction, and operation of VA clinical, research, administrative, and parking structures. Also evaluated is the No Action Alternative, in which VA would continue operation and maintenance of the existing medical center at Fort Miley. Alternative 1 has been identified by VA as the Preferred Alternative. JF - EPA number: 150182, Final EIS, July 10, 2015 Y1 - 2015/07/10/ PY - 2015 DA - 2015 Jul 10 KW - Land Use KW - Air Quality KW - Air Quality Assessments KW - Archaeological Sites KW - Buildings KW - Cultural Resources Assessments KW - Demolition KW - Historic Districts KW - Hospitals KW - Parking KW - Research Facilities KW - Section 105 Statements KW - Traffic Analyses KW - California UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/16384969?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/Environmental+Impact+Statements%3A+Digests&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=report&rft.jtitle=&rft.atitle=&rft.au=&rft.aulast=&rft.aufirst=&rft.date=2015-07-10&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=SAN+FRANCISCO+VETERAN+AFFAIRS+MEDICAL+CENTER+%28SFVAMC%29+LONG+RANGE+DEVELOPMENT+PLAN.&rft.title=SAN+FRANCISCO+VETERAN+AFFAIRS+MEDICAL+CENTER+%28SFVAMC%29+LONG+RANGE+DEVELOPMENT+PLAN.&rft.issn=&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Name - Department of Veteran Affairs, Veterans Health Administration, San Francisco, California N1 - Date revised - 2017-01-26 N1 - SuppNotes - Final. Preparation date: July 10, 2015 N1 - Last updated - 2017-01-27 ER - TY - JOUR T1 - Early Life Development in a Multiethnic Sample and the Relation to Late Life Cognition AN - 1761683251; 201600661 AB - Objectives. Poor quality of early life conditions has been associated with poorer late life cognition and increased risk of dementia. Early life physical development can be captured using adult measures of height and head circumference. Availability of resources may be reflected by socioeconomic indicators, such as parental education and family size. We sought to determine the association between early life development and experience and late life semantic memory, episodic memory, and executive functioning abilities, as well as rate of cognitive decline. Method. This study was conducted using the UC Davis Aging Diversity cohort, an ethnically diverse sample of Caucasian, African American, and Hispanic individuals from northern California. We used latent variable modeling to measure growth and childhood socioeconomic environment (SES) and examine their associations with longitudinal cognitive outcomes using mixed effects modeling. Results. Growth was positively related to higher childhood SES. Higher childhood SES was associated with better semantic memory. Both low growth and low SES were associated with increased rate of cognitive decline. Discussion. These findings demonstrate that early life experiences influence the trajectory of cognitive aging. Early life development and experience appears to provide a distal basis upon which additional risk and protective factors interact in the development of dementia. Adapted from the source document. JF - Journals of Gerontology Series B: Psychological Sciences and Social Sciences AU - Melrose, Rebecca J AU - Brewster, Paul AU - Marquine, Maria J AU - MacKay-Brandt, Anna AU - Reed, Bruce AU - Farias, Sarah T AU - Mungas, Dan AD - VA Greater Los Angeles Healthcare System, California rebecca.melrose@va.gov Y1 - 2015/07// PY - 2015 DA - July 2015 SP - 519 EP - 531 PB - Oxford University Press VL - 70 IS - 4 SN - 1079-5014, 1079-5014 KW - Cognition Longitudinal change Minority and diverse populations KW - Socioeconomic Factors KW - Risk KW - Cultural Pluralism KW - Memory KW - Cognitive Development KW - Childhood KW - Socioeconomic Status KW - Cognition KW - Semantics KW - article KW - 6127: social gerontology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1761683251?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journals+of+Gerontology+Series+B%3A+Psychological+Sciences+and+Social+Sciences&rft.atitle=Early+Life+Development+in+a+Multiethnic+Sample+and+the+Relation+to+Late+Life+Cognition&rft.au=Melrose%2C+Rebecca+J%3BBrewster%2C+Paul%3BMarquine%2C+Maria+J%3BMacKay-Brandt%2C+Anna%3BReed%2C+Bruce%3BFarias%2C+Sarah+T%3BMungas%2C+Dan&rft.aulast=Melrose&rft.aufirst=Rebecca&rft.date=2015-07-01&rft.volume=70&rft.issue=4&rft.spage=519&rft.isbn=&rft.btitle=&rft.title=Journals+of+Gerontology+Series+B%3A+Psychological+Sciences+and+Social+Sciences&rft.issn=10795014&rft_id=info:doi/10.1093%2Fgeronb%2Fgbt126 LA - English DB - Social Services Abstracts N1 - Date revised - 2016-02-01 N1 - Last updated - 2016-09-28 N1 - CODEN - JGBSF3 N1 - SubjectsTermNotLitGenreText - Cognitive Development; Cognition; Socioeconomic Status; Memory; Childhood; Cultural Pluralism; Semantics; Risk; Socioeconomic Factors DO - http://dx.doi.org/10.1093/geronb/gbt126 ER - TY - JOUR T1 - Posttraumatic stress disorder and cancer risk: a nationwide cohort study AN - 1717501636; PQ0001939854 AB - The association between stress and cancer incidence has been studied for more than seven decades. Despite plausible biological mechanisms and evidence from laboratory studies, findings from clinical research are conflicting. The objective of this study was to examine the association between PTSD and various cancer outcomes. This nation-wide cohort study included all Danish-born residents of Denmark from 1995 to 2011. The exposure was PTSD diagnoses (n = 4131). The main outcomes were cancer diagnoses including: (1) all malignant neoplasms; (2) hematologic malignancies; (3) immune-related cancers; (4) smoking- and alcohol-related cancers; (5) cancers at all other sites. Standardized incidence ratios (SIR) were calculated. Null associations were found between PTSD and nearly all cancer diagnoses examined, both overall [SIR for all cancers = 1.0, 95 % confidence interval (CI) = 0.88, 1.2] and in analyses stratified by gender, age, substance abuse history and time since PTSD diagnosis. This study is the most comprehensive examination to date of PTSD as a predictor of many cancer types. Our data show no evidence of an association between PTSD and cancer in this nationwide cohort. JF - European Journal of Epidemiology AU - Gradus, Jaimie L AU - Farkas, Dora Kormendine AU - Svensson, Elisabeth AU - Ehrenstein, Vera AU - Lash, Timothy L AU - Milstein, Arnold AU - Adler, Nancy AU - Soerensen, Henrik Toft AD - National Center for PTSD, VA Boston Healthcare System, 150 S. Huntington Ave (116B-3), Boston, MA, 02130, USA, Jaimie.gradus@va.gov PY - 2015 SP - 563 EP - 568 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 30 IS - 7 SN - 0393-2990, 0393-2990 KW - Health & Safety Science Abstracts; Risk Abstracts KW - Historical account KW - Age KW - Psychology KW - Stress KW - Clinical trials KW - Cancer KW - Health risks KW - Posttraumatic stress disorder KW - Gender KW - Denmark KW - Standards KW - Substance abuse KW - H 4000:Food and Drugs KW - R2 23110:Psychological aspects UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1717501636?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ariskabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=European+Journal+of+Epidemiology&rft.atitle=Posttraumatic+stress+disorder+and+cancer+risk%3A+a+nationwide+cohort+study&rft.au=Gradus%2C+Jaimie+L%3BFarkas%2C+Dora+Kormendine%3BSvensson%2C+Elisabeth%3BEhrenstein%2C+Vera%3BLash%2C+Timothy+L%3BMilstein%2C+Arnold%3BAdler%2C+Nancy%3BSoerensen%2C+Henrik+Toft&rft.aulast=Gradus&rft.aufirst=Jaimie&rft.date=2015-07-01&rft.volume=30&rft.issue=7&rft.spage=563&rft.isbn=&rft.btitle=&rft.title=European+Journal+of+Epidemiology&rft.issn=03932990&rft_id=info:doi/10.1007%2Fs10654-015-0032-7 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-09-01 N1 - Number of references - 25 N1 - Last updated - 2015-12-23 N1 - SubjectsTermNotLitGenreText - Historical account; Health risks; Age; Posttraumatic stress disorder; Psychology; Gender; Stress; Standards; Clinical trials; Substance abuse; Cancer; Denmark DO - http://dx.doi.org/10.1007/s10654-015-0032-7 ER - TY - JOUR T1 - Avibactam and Inhibitor-Resistant SHV beta -Lactamases AN - 1701496792; PQ0001784609 AB - beta -Lactamase enzymes (EC 3.5.2.6) are a significant threat to the continued use of beta -lactam antibiotics to treat infections. A novel non- beta -lactam beta -lactamase inhibitor with activity against many class A and C and some class D beta -lactamase variants, avibactam, is now available in the clinic in partnership with ceftazidime. Here, we explored the activity of avibactam against a variety of characterized isogenic laboratory constructs of beta -lactamase inhibitor-resistant variants of the class A enzyme SHV (M69I/L/V, S130G, K234R, R244S, and N276D). We discovered that the S130G variant of SHV-1 shows the most significant resistance to inhibition by avibactam, based on both microbiological and biochemical characterizations. Using a constant concentration of 4 mg/liter of avibactam as a beta -lactamase inhibitor in combination with ampicillin, the MIC increased from 1 mg/liter for blaSHV-1 to 256 mg/liter for blaSHV S130G expressed in Escherichia coli DH10B. At steady state, the k2/K value of the S130G variant when inactivated by avibactam was 1.3 M-1 s-1, versus 60,300 M-1 s-1 for the SHV-1 beta -lactamase. Under timed inactivation conditions, we found that an approximately 1,700-fold-higher avibactam concentration was required to inhibit SHV S130G than the concentration that inhibited SHV-1. Molecular modeling suggested that the positioning of amino acids in the active site of SHV may result in an alternative pathway of inactivation when complexed with avibactam, compared to the structure of CTX-M-15-avibactam, and that S130 plays a role in the acylation of avibactam as a general acid/base. In addition, S130 may play a role in recyclization. As a result, we advance that the lack of a hydroxyl group at position 130 in the S130G variant of SHV-1 substantially slows carbamylation of the beta -lactamase by avibactam by (i) removing an important proton acceptor and donator in catalysis and (ii) decreasing the number of H bonds. In addition, recyclization is most likely also slow due to the lack of a general base to initiate the process. Considering other inhibitor-resistant mechanisms among class A beta -lactamases, S130 may be the most important amino acid for the inhibition of class A beta -lactamases, perhaps even for the novel diazabicyclooctane class of beta -lactamase inhibitors. JF - Antimicrobial Agents & Chemotherapy AU - Winkler, Marisa L AU - Papp-Wallace, Krisztina M AU - Taracila, Magdalena A AU - Bonomo, Robert A AD - Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA, robert.bonomo@va.gov. Y1 - 2015/07// PY - 2015 DA - Jul 2015 SP - 3700 EP - 3709 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 59 IS - 7 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Molecular modelling KW - Amino acids KW - beta -Lactamase KW - Protons KW - Ampicillin KW - Enzymes KW - Acylation KW - Carbamylation KW - Infection KW - Minimum inhibitory concentration KW - Ceftazidime KW - beta -Lactam antibiotics KW - Escherichia coli KW - Catalysis KW - A 01340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701496792?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Avibactam+and+Inhibitor-Resistant+SHV+beta+-Lactamases&rft.au=Winkler%2C+Marisa+L%3BPapp-Wallace%2C+Krisztina+M%3BTaracila%2C+Magdalena+A%3BBonomo%2C+Robert+A&rft.aulast=Winkler&rft.aufirst=Marisa&rft.date=2015-07-01&rft.volume=59&rft.issue=7&rft.spage=3700&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.04405-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-08-01 N1 - Number of references - 34 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Molecular modelling; beta -Lactamase; Amino acids; Protons; Enzymes; Ampicillin; Acylation; Infection; Carbamylation; Minimum inhibitory concentration; Ceftazidime; beta -Lactam antibiotics; Catalysis; Escherichia coli DO - http://dx.doi.org/10.1128/AAC.04405-14 ER - TY - JOUR T1 - Factors Associated with Antibiotic Misuse in Outpatient Treatment for Upper Respiratory Tract Infections AN - 1701496028; PQ0001784595 AB - The Centers for Disease Control and Prevention has promoted the appropriate use of antibiotics since 1995 when it initiated the National Campaign for Appropriate Antibiotic Use in the Community. This study examined upper respiratory tract infections included in the campaign to determine the degree to which antibiotics were appropriately prescribed and subsequent admission rates in a veteran population. This study was a retrospective chart review conducted among outpatients with a diagnosis of a respiratory tract infection, including bronchitis, pharyngitis, sinusitis, or nonspecific upper respiratory tract infection, between January 2009 and December 2011. The study found that 595 (35.8%) patients were treated appropriately, and 1,067 (64.2%) patients received therapy considered inappropriate based on the Get Smart Campaign criteria. Overall the subsequent readmission rate was 1.5%. The majority (77.5%) of patients were prescribed an antibiotic. The most common antibiotics prescribed were azithromycin (39.0%), amoxicillin-clavulanate (13.2%), and moxifloxacin (7.5%). A multivariate regression analysis demonstrated significant predictors of appropriate treatment, including the presence of tonsillar exudates (odds ratio [OR], 0.6; confidence interval [CI], 0.3 to 0.9), fever (OR, 0.6; CI, 0.4 to 0.9), and lymphadenopathy (OR, 0.4; CI, 0.3 to 0.6), while penicillin allergy (OR, 2.9; CI, 1.7 to 4.7) and cough (OR, 1.6; CI, 1.1 to 2.2) were significant predictors for inappropriate treatment. Poor compliance with the Get Smart Campaign was found in outpatients for respiratory infections. Results from this study demonstrate the overprescribing of antibiotics, while providing a focused view of improper prescribing. This article provides evidence that current efforts are insufficient for curtailing inappropriate antibiotic use. JF - Antimicrobial Agents & Chemotherapy AU - Schroeck, Jennifer L AU - Ruh, Christine A AU - Sellick, John A, Jr AU - Ott, Michael C AU - Mattappallil, Arun AU - Mergenhagen, Kari A AD - VA Western New York Healthcare System, Infectious Diseases and Pharmacy Departments, Buffalo, New York, USA, kari.mergenhagen@va.gov. Y1 - 2015/07// PY - 2015 DA - Jul 2015 SP - 3848 EP - 3852 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 59 IS - 7 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Disease control KW - Cough KW - Antibiotics KW - Pharyngitis KW - Sinusitis KW - Infection KW - Penicillin KW - Fever KW - Respiratory tract diseases KW - Exudates KW - Hypersensitivity KW - Lymphadenopathy KW - Tonsil KW - Moxifloxacin KW - Azithromycin KW - Regression analysis KW - Bronchitis KW - A 01380:Plant Protection, Fungicides & Seed Treatments UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701496028?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Factors+Associated+with+Antibiotic+Misuse+in+Outpatient+Treatment+for+Upper+Respiratory+Tract+Infections&rft.au=Schroeck%2C+Jennifer+L%3BRuh%2C+Christine+A%3BSellick%2C+John+A%2C+Jr%3BOtt%2C+Michael+C%3BMattappallil%2C+Arun%3BMergenhagen%2C+Kari+A&rft.aulast=Schroeck&rft.aufirst=Jennifer&rft.date=2015-07-01&rft.volume=59&rft.issue=7&rft.spage=3848&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.00652-15 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-08-01 N1 - Number of references - 20 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Disease control; Cough; Antibiotics; Sinusitis; Pharyngitis; Infection; Penicillin; Fever; Respiratory tract diseases; Lymphadenopathy; Hypersensitivity; Exudates; Tonsil; Moxifloxacin; Azithromycin; Regression analysis; Bronchitis DO - http://dx.doi.org/10.1128/AAC.00652-15 ER - TY - JOUR T1 - Variants of beta -Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam AN - 1701494887; PQ0001784610 AB - KPC-2 is the most prevalent class A carbapenemase in the world. Previously, KPC-2 was shown to hydrolyze the beta -lactamase inhibitors clavulanic acid, sulbactam, and tazobactam. In addition, substitutions at amino acid position R220 in the KPC-2 beta -lactamase increased resistance to clavulanic acid. A novel bridged diazabicyclooctane (DBO) non- beta -lactam beta -lactamase inhibitor, avibactam, was shown to inactivate the KPC-2 beta -lactamase. To better understand the mechanistic basis for inhibition of KPC-2 by avibactam, we tested the potency of ampicillin-avibactam and ceftazidime-avibactam against engineered variants of the KPC-2 beta -lactamase that possessed single amino acid substitutions at important sites (i.e., Ambler positions 69, 130, 234, 220, and 276) that were previously shown to confer inhibitor resistance in TEM and SHV beta -lactamases. To this end, we performed susceptibility testing, biochemical assays, and molecular modeling. Escherichia coli DH10B carrying KPC-2 beta -lactamase variants with the substitutions S130G, K234R, and R220M demonstrated elevated MICs for only the ampicillin-avibactam combinations (e.g., 512, 64, and 32 mg/liter, respectively, versus the MICs for wild-type KPC-2 at 2 to 8 mg/liter). Steady-state kinetics revealed that the S130G variant of KPC-2 resisted inactivation by avibactam; the k2/K ratio was significantly lowered 4 logs for the S130G variant from the ratio for the wild-type enzyme (21,580 M-1 s-1 to 1.2 M-1 s-1). Molecular modeling and molecular dynamics simulations suggested that the mobility of K73 and its ability to activate S70 (i.e., function as a general base) may be impaired in the S130G variant of KPC-2, thereby explaining the slowed acylation. Moreover, we also advance the idea that the protonation of the sulfate nitrogen of avibactam may be slowed in the S130G variant, as S130 is the likely proton donor and another residue, possibly K234, must compensate. Our findings show that residues S130 as well as K234 and R220 contribute significantly to the mechanism of avibactam inactivation of KPC-2. Fortunately, the emergence of S130G, K234R, and R220M variants of KPC in the clinic should not result in failure of ceftazidime-avibactam, as the ceftazidime partner is potent against E. coli DH10B strains possessing all of these variants. JF - Antimicrobial Agents & Chemotherapy AU - Papp-Wallace, Krisztina M AU - Winkler, Marisa L AU - Taracila, Magdalena A AU - Bonomo, Robert A AD - Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA, robert.bonomo@va.gov. Y1 - 2015/07// PY - 2015 DA - Jul 2015 SP - 3710 EP - 3717 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 59 IS - 7 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - Molecular modelling KW - Amino acid substitution KW - beta -Lactamase KW - Mobility KW - Protons KW - Enzymes KW - Tazobactam KW - carbapenemase KW - Acylation KW - Minimum inhibitory concentration KW - Sulfate KW - Sulbactam KW - Ceftazidime KW - Kinetics KW - Clavulanic acid KW - Escherichia coli KW - Nitrogen KW - A 01340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701494887?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Variants+of+beta+-Lactamase+KPC-2+That+Are+Resistant+to+Inhibition+by+Avibactam&rft.au=Papp-Wallace%2C+Krisztina+M%3BWinkler%2C+Marisa+L%3BTaracila%2C+Magdalena+A%3BBonomo%2C+Robert+A&rft.aulast=Papp-Wallace&rft.aufirst=Krisztina&rft.date=2015-07-01&rft.volume=59&rft.issue=7&rft.spage=3710&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.04406-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-08-01 N1 - Number of references - 26 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Molecular modelling; beta -Lactamase; Amino acid substitution; Mobility; Protons; Enzymes; carbapenemase; Tazobactam; Acylation; Minimum inhibitory concentration; Sulbactam; Sulfate; Ceftazidime; Clavulanic acid; Kinetics; Nitrogen; Escherichia coli DO - http://dx.doi.org/10.1128/AAC.04406-14 ER - TY - JOUR T1 - Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial AN - 1722169297; PQ0001911235 AB - Background. Pneumococcal vaccination is recommended for human immunodeficiency virus-infected (HIV+) persons; the best timing for immunization with respect to initiation of antiretroviral therapy (ART) is unknown. Methods. Double-blind, placebo-controlled trial in HIV+ with CD4 super(+) T cells/[mu]L (CD4) > or = 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo at enrollment, followed by placebo or PPV23, respectively, 9-12 months later (after > or =6 months of ART). Capsular polysaccharide-specific immunoglobin (Ig) G and IgM levels to serotypes 1, 3, 4, 6B, and 23F, and opsonophagocytic killing activity (OPA) to serotypes 6B and 23F were evaluated 1 month postvaccination. Results. One hundred seven subjects were enrolled, 72 (67.3%) were evaluable (36/group). Both groups had significant increases in pre- to 1-month postvaccination IgG levels, but negligible to IgM, and significant increases in OPA titers to serotype 6B but not to 23F. There were no significant differences between groups in serotype-specific IgM or IgG levels or OPA titers. For the combined groups, there was a significant correlation between serotype-specific IgG and OPA titers to 23F but not to 6B. There was no correlation between CD4, viral load and IgG responses. Conclusions. In HIV+ with CD4 > or = 200, delaying PPV23 until > or =6 months of ART does not improve responses and may lead to missed opportunities for immunization. JF - Journal of Infectious Diseases AU - Rodriguez-Barradas, Maria C AU - Serpa, Jose A AU - Munjal, Iona AU - Mendoza, Daniel AU - Rueda, Adriana M AU - Mushtaq, Mahwish AU - Pirofski, Liise-anne AD - Medical Care Line, Infectious Disease Section, maria.rodriguez-barradas2@va.gov Y1 - 2015/06/01/ PY - 2015 DA - 2015 Jun 01 SP - 1703 EP - 1711 PB - Oxford University Press, Oxford Journals, Great Clarendon Street Oxford OX2 6DP United Kingdom VL - 211 IS - 11 SN - 0022-1899, 0022-1899 KW - Virology & AIDS Abstracts; Immunology Abstracts; Microbiology Abstracts B: Bacteriology KW - antibody KW - HIV KW - pneumococcal vaccine KW - pneumococcal capsular polysaccharides KW - antiretroviral treatment KW - Serotypes KW - antiretroviral therapy KW - Immunodeficiency KW - Polysaccharides KW - Clinical trials KW - Vaccination KW - Streptococcus pneumoniae KW - CD4 antigen KW - Antiviral agents KW - Human immunodeficiency virus KW - Immunoglobulin G KW - Lymphocytes T KW - Vaccines KW - Immunoglobulin M KW - V 22360:AIDS and HIV KW - J 02350:Immunology KW - F 06910:Microorganisms & Parasites UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1722169297?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Infectious+Diseases&rft.atitle=Quantitative+and+Qualitative+Antibody+Responses+to+Immunization+With+the+Pneumococcal+Polysaccharide+Vaccine+in+HIV-Infected+Patients+After+Initiation+of+Antiretroviral+Treatment%3A+Results+From+a+Randomized+Clinical+Trial&rft.au=Rodriguez-Barradas%2C+Maria+C%3BSerpa%2C+Jose+A%3BMunjal%2C+Iona%3BMendoza%2C+Daniel%3BRueda%2C+Adriana+M%3BMushtaq%2C+Mahwish%3BPirofski%2C+Liise-anne&rft.aulast=Rodriguez-Barradas&rft.aufirst=Maria&rft.date=2015-06-01&rft.volume=211&rft.issue=11&rft.spage=1703&rft.isbn=&rft.btitle=&rft.title=Journal+of+Infectious+Diseases&rft.issn=00221899&rft_id=info:doi/10.1093%2Finfdis%2Fjiu819 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-10-01 N1 - Last updated - 2016-04-13 N1 - SubjectsTermNotLitGenreText - CD4 antigen; Serotypes; Antiviral agents; antiretroviral therapy; Lymphocytes T; Immunodeficiency; Immunoglobulin G; Vaccines; Polysaccharides; Vaccination; Clinical trials; Immunoglobulin M; Streptococcus pneumoniae; Human immunodeficiency virus DO - http://dx.doi.org/10.1093/infdis/jiu819 ER - TY - JOUR T1 - Knee Joint Loading During Lineman-Specific Movements in American Football Players AN - 1717497694; PQ0001991824 AB - Linemen are at high risk for knee cartilage injuries and osteoarthritis. High-intensity movements from squatting positions (eg, 3-point stance) may produce high joint loads, increasing the risk for cartilage damage. We hypothesized that knee moments and joint reaction forces during lineman-specific activities would be greater than during walking or jogging. Data were collected using standard motion analysis techniques. Fifteen NCAA linemen (mean + or - SD: height = 1.86 + or -0.07 m, mass= 121.45 + or - 12.78 kg) walked, jogged, and performed 3 unloaded lineman-specific blocking movements from a 3-point stance. External 3-dimen-sional knee moments and joint reaction forces were calculated using inverse dynamics equations. MANOVA with subsequent univariate ANOVA and post hoc Tukey comparisons were used to determine differences in peak kinetic variables and the flexion angles at which they occurred. All peak moments and joint reaction forces were significantly higher during jogging than during all blocking drills (all P 70[degrees] during blocking versus < 44[degrees] in walking or jogging. The magnitude of moments and joint reaction forces when initiating movement from a 3-point stance do not appear to increase risk for cartilage damage, but the high flexion angles at which they occur may increase risk on the posterior femoral condyles. JF - Journal of Applied Biomechanics AU - Lambach, Rebecca L AU - Young, Jay W AU - Flanigan, David C AU - Siston, Robert A AU - Chaudhari, Ajit MW AD - Ohio State University, Rebecca.lambach@va.gov Y1 - 2015/06// PY - 2015 DA - Jun 2015 SP - 142 EP - 148 PB - Human Kinetics Publishers, P.O. Box 5076 Champaign IL 61825-5076 United States VL - 31 IS - 3 SN - 1065-8483, 1065-8483 KW - Physical Education Index KW - joint moments KW - joint reaction forces KW - motion capture KW - cartilage KW - Running KW - Cartilage KW - Analysis KW - Arthritis KW - Knees KW - Walking KW - Work load KW - Movement KW - Joints KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1717497694?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Applied+Biomechanics&rft.atitle=Knee+Joint+Loading+During+Lineman-Specific+Movements+in+American+Football+Players&rft.au=Lambach%2C+Rebecca+L%3BYoung%2C+Jay+W%3BFlanigan%2C+David+C%3BSiston%2C+Robert+A%3BChaudhari%2C+Ajit+MW&rft.aulast=Lambach&rft.aufirst=Rebecca&rft.date=2015-06-01&rft.volume=31&rft.issue=3&rft.spage=142&rft.isbn=&rft.btitle=&rft.title=Journal+of+Applied+Biomechanics&rft.issn=10658483&rft_id=info:doi/10.1123%2FJAB.2014-0123 LA - English DB - Physical Education Index N1 - Date revised - 2015-09-01 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Arthritis; Analysis; Cartilage; Running; Knees; Walking; Work load; Movement; Joints DO - http://dx.doi.org/10.1123/JAB.2014-0123 ER - TY - JOUR T1 - Chronic pain and comorbid mental health conditions: independent associations of posttraumatic stress disorder and depression with pain, disability, and quality of life AN - 1698867774 AB - Both posttraumatic stress disorder (PTSD) and depression are highly comorbid with chronic pain and have deleterious effects on pain and treatment outcomes, but the nature of the relationships among chronic pain, PTSD, and depression has not been fully elucidated. This study examined 250 Veterans Affairs primary care patients with moderate to severe chronic musculoskeletal pain who participated in a randomized controlled pain treatment trial. Baseline data were analyzed to examine the independent associations of PTSD and major depression with multiple domains of pain, psychological status, quality of life, and disability. PTSD was strongly associated with these variables and in multivariate models, PTSD and major depression each had strong independent associations with these domains. PTSD demonstrated similar relationships as major depression with psychological, quality of life, and disability outcomes and significant but somewhat smaller associations with pain. Because PTSD and major depression have independent negative associations with pain, psychological status, quality of life, and disability, it is important for clinicians to recognize and treat both mental disorders in patients with chronic pain. JF - Journal of Behavioral Medicine AU - Kroenke, Kurt AU - Krebs, Erin E AU - Chumbler, Neale R AU - Wu, Jingwei AU - Yu, Zhangsheng AU - Bair, Matthew J AD - Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service CIN 13-416, Center for Health Information and Communication, Indianapolis, IN, USA, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA ; Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, USA, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA ; Department of Health Policy and Management, College of Public Health, University of Georgia, Athens, GA, USA ; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA ; Outcalt, Samantha D; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service CIN 13-416, Center for Health Information and Communication, Indianapolis, IN, USA; Roudebush VA Medical Center, 1481 W. 10th St. (11H), Indianapolis, IN, 46202, USA Y1 - 2015/06// PY - 2015 DA - Jun 2015 SP - 535 EP - 543 CY - New York PB - Springer Science & Business Media VL - 38 IS - 3 SN - 0160-7715 KW - Psychology KW - Associations KW - Chronic posttraumatic stress disorder KW - Patient care KW - Primary health care KW - Psychiatric disorders KW - Psychological status KW - Quality of life KW - Veterans KW - Chronic pain KW - Clinical outcomes KW - Comorbidity KW - Depression KW - Disability KW - Life stress KW - Mental health KW - Musculoskeletal pain KW - Pain UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1698867774?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Behavioral+Medicine&rft.atitle=Chronic+pain+and+comorbid+mental+health+conditions%3A+independent+associations+of+posttraumatic+stress+disorder+and+depression+with+pain%2C+disability%2C+and+quality+of+life&rft.au=Outcalt%2C+Samantha+D%3BKroenke%2C+Kurt%3BKrebs%2C+Erin+E%3BChumbler%2C+Neale+R%3BWu%2C+Jingwei%3BYu%2C+Zhangsheng%3BBair%2C+Matthew+J&rft.aulast=Outcalt&rft.aufirst=Samantha&rft.date=2015-06-01&rft.volume=38&rft.issue=3&rft.spage=535&rft.isbn=&rft.btitle=&rft.title=Journal+of+Behavioral+Medicine&rft.issn=01607715&rft_id=info:doi/10.1007%2Fs10865-015-9628-3 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-07-07 N1 - Last updated - 2016-05-12 DO - http://dx.doi.org/10.1007/s10865-015-9628-3 ER - TY - CONF T1 - Medications and the Culture of Safety : Conference Title: At the Precipice of Quality Health Care: The Role of the Toxicologist in Enhancing Patient and Medication Safety Venue ACMT Pre-Meeting Symposium, 2014 North American Congress of Clinical Toxicology, New Orleans, LA. AN - 1689844231; 25804671 AB - Medication mishaps are a common cause of morbidity and mortality both within and outside of hospitals. While the use of a variety of technologies and techniques have promised to improve these statistics, instead of eliminating errors, new ones have appeared as quickly as old ones have been improved. To truly improve safety across the entire enterprise, we must ensure that we create a culture that is willing to accept that errors occur in normal course of operation to the best of people. Focus must not be on punishment and shame, but rather building a fault tolerant system that maintains safety of both staff and patients. JF - Journal of medical toxicology : official journal of the American College of Medical Toxicology AU - Hemphill, Robin R Y1 - 2015/06// PY - 2015 DA - June 2015 SP - 253 EP - 256 VL - 11 IS - 2 KW - Index Medicus KW - Humans KW - Quality of Health Care -- trends KW - Organizational Culture KW - Medical Errors -- prevention & control KW - Toxicology KW - Leadership KW - Patient Safety KW - Culture KW - Drug-Related Side Effects and Adverse Reactions -- prevention & control UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1689844231?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=Journal+of+medical+toxicology+%3A+official+journal+of+the+American+College+of+Medical+Toxicology&rft.atitle=Medications+and+the+Culture+of+Safety+%3A+Conference+Title%3A+At+the+Precipice+of+Quality+Health+Care%3A+The+Role+of+the+Toxicologist+in+Enhancing+Patient+and+Medication+Safety+Venue+ACMT+Pre-Meeting+Symposium%2C+2014+North+American+Congress+of+Clinical+Toxicology%2C+New+Orleans%2C+LA.&rft.au=Hemphill%2C+Robin+R&rft.aulast=Hemphill&rft.aufirst=Robin&rft.date=2015-06-01&rft.volume=11&rft.issue=2&rft.spage=253&rft.isbn=&rft.btitle=&rft.title=Journal+of+medical+toxicology+%3A+official+journal+of+the+American+College+of+Medical+Toxicology&rft.issn=1937-6995&rft_id=info:doi/10.1007%2Fs13181-015-0474-z LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-03-22 N1 - Date created - 2015-06-17 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Health Serv Res. 2006 Aug;41(4 Pt 2):1690-709 [16898986] J Am Med Inform Assoc. 2013 May 1;20(3):470-6 [23425440] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1007/s13181-015-0474-z ER - TY - JOUR T1 - Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. AN - 1682891487; 25896164 AB - Dysfunction of the mesocorticolimbic system has a critical role in clinical features of addiction. Despite evidence suggesting that midbrain dopamine receptors influence amphetamine-induced dopamine release and that dopamine is involved in methamphetamine-induced neurotoxicity, associations between dopamine receptors and gray-matter volume have been unexplored in methamphetamine users. Here we used magnetic resonance imaging and [(18)F]fallypride positron emission tomography, respectively, to measure gray-matter volume (in 58 methamphetamine users) and dopamine D2/D3 receptor availability (binding potential relative to nondisplaceable uptake of the radiotracer, BPnd) (in 31 methamphetamine users and 37 control participants). Relationships between these measures and self-reported drug craving were examined. Although no difference in midbrain D2/D3 BPnd was detected between methamphetamine and control groups, midbrain D2/D3 BPnd was positively correlated with gray-matter volume in the striatum, prefrontal cortex, insula, hippocampus and temporal cortex in methamphetamine users, but not in control participants (group-by-midbrain D2/D3 BPnd interaction, P<0.05 corrected for multiple comparisons). Craving for methamphetamine was negatively associated with gray-matter volume in the insula, prefrontal cortex, amygdala, temporal cortex, occipital cortex, cerebellum and thalamus (P<0.05 corrected for multiple comparisons). A relationship between midbrain D2/D3 BPnd and methamphetamine craving was not detected. Lower midbrain D2/D3 BPnd may increase vulnerability to deficits in gray-matter volume in mesocorticolimbic circuitry in methamphetamine users, possibly reflecting greater dopamine-induced toxicity. Identifying factors that influence prefrontal and limbic volume, such as midbrain BPnd, may be important for understanding the basis of drug craving, a key factor in the maintenance of substance-use disorders. JF - Molecular psychiatry AU - Morales, A M AU - Kohno, M AU - Robertson, C L AU - Dean, A C AU - Mandelkern, M A AU - London, E D AD - Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA. ; 1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA [2] Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA. ; 1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA [2] Departments of Brain Research Institute, University of California, Los Angeles, CA, USA. ; 1] Department of Physics, University of California Irvine, Irvine, CA, USA [2] Veterans Administration of Greater Los Angeles Health System, Los Angeles, CA, USA. ; 1] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA [2] Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA [3] Departments of Brain Research Institute, University of California, Los Angeles, CA, USA [4] Veterans Administration of Greater Los Angeles Health System, Los Angeles, CA, USA. Y1 - 2015/06// PY - 2015 DA - June 2015 SP - 764 EP - 771 VL - 20 IS - 6 KW - Benzamides KW - 0 KW - Dopamine Antagonists KW - Receptors, Dopamine D2 KW - fallypride KW - Fluorodeoxyglucose F18 KW - 0Z5B2CJX4D KW - Methamphetamine KW - 44RAL3456C KW - Index Medicus KW - Magnetic Resonance Imaging KW - Regression Analysis KW - Fluorodeoxyglucose F18 -- pharmacokinetics KW - Positron-Emission Tomography KW - Protein Binding -- drug effects KW - Humans KW - Benzamides -- pharmacokinetics KW - Dopamine Antagonists -- pharmacokinetics KW - Time Factors KW - Image Processing, Computer-Assisted KW - Male KW - Female KW - Substance-Related Disorders -- physiopathology KW - Mesencephalon -- drug effects KW - Gray Matter -- drug effects KW - Mesencephalon -- pathology KW - Substance-Related Disorders -- pathology KW - Methamphetamine -- pharmacology KW - Mesencephalon -- diagnostic imaging KW - Gray Matter -- pathology KW - Substance-Related Disorders -- psychology KW - Receptors, Dopamine D2 -- metabolism KW - Drug-Seeking Behavior -- physiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1682891487?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Molecular+psychiatry&rft.atitle=Gray-matter+volume%2C+midbrain+dopamine+D2%2FD3+receptors+and+drug+craving+in+methamphetamine+users.&rft.au=Morales%2C+A+M%3BKohno%2C+M%3BRobertson%2C+C+L%3BDean%2C+A+C%3BMandelkern%2C+M+A%3BLondon%2C+E+D&rft.aulast=Morales&rft.aufirst=A&rft.date=2015-06-01&rft.volume=20&rft.issue=6&rft.spage=764&rft.isbn=&rft.btitle=&rft.title=Molecular+psychiatry&rft.issn=1476-5578&rft_id=info:doi/10.1038%2Fmp.2015.47 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-02-09 N1 - Date created - 2015-05-21 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Nat Med. 1996 Jun;2(6):699-703 [8640565] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12040-5 [8876259] IEEE Trans Med Imaging. 1997 Apr;16(2):176-86 [9101327] Neuron. 1997 Sep;19(3):591-611 [9331351] Nucl Med Biol. 1999 Jul;26(5):519-27 [10473190] Synapse. 2005 Nov;58(2):110-21 [16088948] IEEE Trans Med Imaging. 2005 Dec;24(12):1548-65 [16350916] Trends Neurosci. 2006 Mar;29(3):167-74 [16443286] J Neurosci. 2006 Jun 14;26(24):6583-8 [16775146] AAPS J. 2006;8(2):E413-8 [16808044] Crit Rev Neurobiol. 2005;17(2):87-117 [16808729] Neuropsychopharmacology. 2006 Dec;31(12):2716-27 [16971900] Med Image Comput Comput Assist Interv. 2006;9(Pt 2):33-40 [17354753] Neuroimage. 2007 Oct 15;38(1):95-113 [17761438] Neuroimage. 2008 Feb 1;39(3):1266-73 [18024160] Magn Reson Med. 2008 Apr;59(4):866-73 [18383286] Am J Psychiatry. 2008 Sep;165(9):1179-84 [18593776] J Neurosci. 2008 Dec 31;28(53):14372-8 [19118170] Neuroimage. 2009 Mar;45(1 Suppl):S173-86 [19059349] Biol Psychiatry. 2009 Apr 15;65(8):706-9 [19136097] Pharmacol Biochem Behav. 2009 Sep;93(3):343-8 [19490925] Int Rev Neurobiol. 2009;88:101-19 [19897076] J Neurosci. 2009 Nov 25;29(47):14734-40 [19940168] Neuropsychopharmacology. 2010 Jan;35(1):217-38 [19710631] Neuroimage. 2010 May 1;50(4):1392-401 [20096794] Neuroimage. 2010 May 15;51(1):53-62 [20149883] Science. 2010 Jul 30;329(5991):532 [20671181] Addiction. 2010 Oct;105(10):1809-18 [20840201] Neuropsychopharmacology. 2011 Feb;36(3):569-79 [20980989] J Neurosci. 2011 Mar 30;31(13):4805-10 [21451018] Addiction. 2011 Aug;106(8):1474-83 [21438934] Nat Neurosci. 2011 Aug;14(8):1033-8 [21743470] Neuroimage. 2000 Jun;11(6 Pt 1):805-21 [10860804] Alcohol Res Health. 1999;23(3):187-96 [10890814] Am J Psychiatry. 2000 Nov;157(11):1789-98 [11058476] Addiction. 2001 Jan;96(1):33-46 [11177518] Am J Psychiatry. 2001 Mar;158(3):377-82 [11229977] Schizophr Res. 2011 Nov;132(2-3):183-9 [21784619] Psychiatry Res. 2011 Dec 30;194(3):287-95 [22047731] J Neurosci. 2012 Jan 25;32(4):1353-9 [22279219] J Neurosci. 2012 Apr 25;32(17):5843-52 [22539846] Pharmacol Biochem Behav. 2012 Jul;102(1):124-32 [22507913] Mol Psychiatry. 2012 Sep;17(9):918-25 [21747399] Drug Alcohol Depend. 2012 Oct 1;125(3):230-8 [22445480] J Intern Med. 2013 May;273(5):437-53 [23600399] Psychopharmacology (Berl). 2013 Oct;229(3):527-38 [23748383] Neuropsychopharmacology. 2014 Jul;39(8):1833-42 [24513972] Neuropsychopharmacology. 2014 Jul;39(8):1816-22 [24584328] Am J Psychiatry. 2001 Dec;158(12):2015-21 [11729018] Neuropsychopharmacology. 2002 Mar;26(3):376-86 [11850152] Synapse. 2002 Dec 1;46(3):170-88 [12325044] Neuroimage. 1996 Dec;4(3 Pt 1):153-8 [9345505] Am J Psychiatry. 1998 Jan;155(1):124-6 [9433350] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7731-6 [9636219] Neuropsychopharmacology. 1999 Jan;20(1):60-80 [9885786] Am J Psychiatry. 1999 Jan;156(1):11-8 [9892292] Am J Psychiatry. 1999 Jan;156(1):19-26 [9892293] JAMA Psychiatry. 2014 Jul 1;71(7):812-20 [24850532] J Cereb Blood Flow Metab. 2002 Dec;22(12):1440-52 [12468889] J Neurosci. 2003 Apr 15;23(8):3531-7 [12716962] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):11035-40 [12958210] Drug Alcohol Depend. 2004 Feb 7;73(2):121-32 [14725951] J Neurosci. 2004 Feb 18;24(7):1551-60 [14973230] J Neurosci. 2004 Jun 30;24(26):6028-36 [15229250] Life Sci. 1979 Oct 15;25(16):1373-8 [42834] Ann N Y Acad Sci. 1990;604:323-43 [2171398] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):615-23 [7622696] Nucl Med Biol. 1995 Apr;22(3):283-96 [7627142] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1038/mp.2015.47 ER - TY - JOUR T1 - Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. AN - 1683574764; 26001631 AB - We evaluated the safety of current treatment regimens for patients with RA and HBV in a large US cohort. We identified biologic and nonbiologic treatment episodes of RA patients using 1997 to 2011 national data from the US Veterans Health Administration. Eligible episodes had evidence of HBV infection (HBV surface antigen, HBV core antibody, HBV e-antibody and/or HBV DNA) and had a baseline alanine aminotransferase (ALT) 100 IU/mL. Results were reported as the cumulative incidence of treatment episodes achieving hepatotoxicity at 3, 6 and 12 months post biologic exposure. Five hundred sixty-six unique RA patients with HBV contributed 959 treatment episodes. Mean age was 62.1 ± 10.3 years; 91.8% were male. Hepatotoxicity was uncommon, with 26 events identified among 959 episodes (2.7%) within 12 months. Hepatotoxicity was comparable between biologic and nonbiologic DMARDs (2.6% vs. 2.8%, P = 0.87). The median time between HBV screening and starting a new RA drug was 504 days (IQR 144, 1,163). Follow-up HBV testing occurred among 14 hepatotoxicity episodes (53.8%) at a median of 202 days (IQR 82, 716) from the date of ALT elevation. A total of 146 (15.2%) treatment episodes received at least one test for HBV DNA at any point in the observation period. Among US veterans with RA and HBV the risk of hepatotoxicity is low (2.7%), and comparable between biologic and nonbiologic DMARDS (2.8% vs. 2.6%, P = 0.87). HBV testing associated with DMARD initiation or hepatotoxicity was infrequent. JF - Arthritis research & therapy AU - Burton, Mary Jane AU - Curtis, Jeffrey R AU - Yang, Shuo AU - Chen, Lang AU - Singh, Jasvinder A AU - Mikuls, Ted R AU - Winthrop, Kevin L AU - Baddley, John W AD - G.V. Sonny Montgomery VA Medical Center, 1500 E Woodrow Wilson Avenue, Jackson, MS, 39216, USA. Mary.burton2@va.gov. ; Birmingham VAMC, 700 19th Street S, Birmingham, AL, 35233, USA. jcurtis@uab.edu. ; Birmingham VAMC, 700 19th Street S, Birmingham, AL, 35233, USA. shouyang@uab.edu. ; Birmingham VAMC, 700 19th Street S, Birmingham, AL, 35233, USA. langchen@uab.edu. ; Birmingham VAMC, 700 19th Street S, Birmingham, AL, 35233, USA. jassingh@uab.edu. ; Omaha VAMC; UNMC, 4101 Woolworth Avenue, Omaha, NE, 68105, USA. tmikuls@unmc.edu. ; Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. winthrop@ohsu.edu. ; Birmingham VAMC, 700 19th Street S, Birmingham, AL, 35233, USA. jbaddley@uab.edu. Y1 - 2015/05/22/ PY - 2015 DA - 2015 May 22 SP - 136 VL - 17 KW - Antirheumatic Agents KW - 0 KW - Index Medicus KW - Veterans KW - Humans KW - Cohort Studies KW - Retrospective Studies KW - Incidence KW - Aged KW - Middle Aged KW - Male KW - Female KW - Arthritis, Rheumatoid -- drug therapy KW - Hepatitis B -- complications KW - Chemical and Drug Induced Liver Injury -- etiology KW - Chemical and Drug Induced Liver Injury -- epidemiology KW - Antirheumatic Agents -- adverse effects KW - Arthritis, Rheumatoid -- complications UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1683574764?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychiatric+services+%28Washington%2C+D.C.%29&rft.atitle=VA+intensive+mental+health+case+management+in+urban+and+rural+areas%3A+veteran+characteristics+and+service+delivery.&rft.au=Mohamed%2C+Somaia%3BNeale%2C+Michael%3BRosenheck%2C+Robert+A&rft.aulast=Mohamed&rft.aufirst=Somaia&rft.date=2009-07-01&rft.volume=60&rft.issue=7&rft.spage=914&rft.isbn=&rft.btitle=&rft.title=Psychiatric+services+%28Washington%2C+D.C.%29&rft.issn=1557-9700&rft_id=info:doi/10.1176%2Fappi.ps.60.7.914 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-03-25 N1 - Date created - 2015-05-24 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: AIDS. 2000 Dec 22;14(18):2895-902 [11153671] Ann Rheum Dis. 2011 Oct;70(10):1719-25 [21719446] Ann Rheum Dis. 2011 Oct;70(10):1701-3 [21893581] Hepatology. 2012 Feb;55(2):447-54 [21987480] Arthritis Care Res (Hoboken). 2012 May;64(5):625-39 [22473917] Arthritis Care Res (Hoboken). 2012 Aug;64(8):1265-8 [22392695] Clin Rheumatol. 2012 Aug;31(8):1169-75 [22544263] Clin Mol Hepatol. 2012 Jun;18(2):225-8 [22893874] Ann Rheum Dis. 2013 Feb;72(2):308-10 [22930597] Arthritis Rheum. 2001 Feb;44(2):339-42 [11229464] Gastroenterology. 1987 Jun;92(6):1839-43 [3569757] Hepatology. 1998 May;27(5):1213-9 [9581673] Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241-3 [16552790] Ann Rheum Dis. 2006 Aug;65(8):983-9 [16627542] Arthritis Rheum. 2008 Jun 15;59(6):762-84 [18512708] MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20 [18802412] Hepatology. 2009 May;49(5 Suppl):S156-65 [19399803] Ann Rheum Dis. 2009 Jul;68(7):1086-93 [19033291] Hepatology. 2009 Sep;50(3):661-2 [19714720] Arthritis Res Ther. 2009;11(6):R179 [19941642] Arthritis Care Res (Hoboken). 2013 Sep;65(9):1504-14 [23436730] Int J Rheum Dis. 2013 Oct;16(5):527-31 [24164839] Clin Rheumatol. 2014 Apr;33(4):577-86 [24343455] Eur J Intern Med. 2014 Jun;25(5):482-4 [24495663] J Rheumatol. 2010 Feb;37(2):346-50 [20008922] Clin Exp Rheumatol. 2009 Nov-Dec;27(6):1017-25 [20149325] Arthritis Care Res (Hoboken). 2010 May;62(5):704-11 [20461789] Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54 [20535784] Ann Rheum Dis. 2010 Jul;69(7):1352-5 [20472596] Clin Rheumatol. 2010 Sep;29(9):1021-9 [20556450] Mod Rheumatol. 2011 Feb;21(1):16-23 [20668905] Nat Rev Rheumatol. 2011 Mar;7(3):139-50 [21263458] Mod Rheumatol. 2013 Jul;23(4):694-704 [22802011] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1186/s13075-015-0628-z ER - TY - CPAPER T1 - Listening Effort and the Division of Auditory Processing Resources T2 - 169th Meeting of the Acoustical Society of America AN - 1669822995; 6341386 JF - 169th Meeting of the Acoustical Society of America AU - Gallun, Frederick Y1 - 2015/05/18/ PY - 2015 DA - 2015 May 18 KW - Information processing UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1669822995?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=169th+Meeting+of+the+Acoustical+Society+of+America&rft.atitle=Listening+Effort+and+the+Division+of+Auditory+Processing+Resources&rft.au=Gallun%2C+Frederick&rft.aulast=Gallun&rft.aufirst=Frederick&rft.date=2015-05-18&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=169th+Meeting+of+the+Acoustical+Society+of+America&rft.issn=&rft_id=info:doi/ L2 - https://asa2015spring.abstractcentral.com/planner.jsp LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-03-31 N1 - Last updated - 2015-04-06 ER - TY - CPAPER T1 - Effects of Hospital Noise on Speech Intelligibility T2 - 169th Meeting of the Acoustical Society of America AN - 1669822542; 6341499 JF - 169th Meeting of the Acoustical Society of America AU - Gallun, Frederick Y1 - 2015/05/18/ PY - 2015 DA - 2015 May 18 KW - speech KW - Noise KW - Noise levels KW - Hospitals UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1669822542?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=169th+Meeting+of+the+Acoustical+Society+of+America&rft.atitle=Effects+of+Hospital+Noise+on+Speech+Intelligibility&rft.au=Gallun%2C+Frederick&rft.aulast=Gallun&rft.aufirst=Frederick&rft.date=2015-05-18&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=169th+Meeting+of+the+Acoustical+Society+of+America&rft.issn=&rft_id=info:doi/ L2 - https://asa2015spring.abstractcentral.com/planner.jsp LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-03-31 N1 - Last updated - 2015-04-06 ER - TY - JOUR T1 - Using a Spiritual Distress Scale to Assess Suicide Risk in Veterans: An Exploratory Study AN - 1683501085 AB - This exploratory study (1) examined the ability of a spiritual distress scale used by chaplains to identify Veterans with certain suicide risk factors and (2) provided an initial assessment of the reliability and validity of this scale to screen for Veterans at increased risk of suicide based on the presence of these risk factors. The scale consisted of five questions examining the presence or absence of guilt, sadness or grief, anger or resentment, despair or hopelessness, and feeling that life has no meaning or purpose. The scale was analyzed using Chronbach’s α-coefficient, factor analysis, Student’s t-tests, and logistic regression. Cut-off values were determined using the maximum Youden statistic. The five questions had a high level of internal consistency (α =0.88). Factor analysis suggested the presence of a common underlying factor, with correlations ranging from 0.42 to 0.78. Those identified with a suicide risk factor had significantly higher mean composite scores on this scale. Further, scores were significantly associated with increased odds of being identified with a suicide risk factor. A score ≥10 may be best suited for differentiating between individuals with and without certain suicide risk factors. This scale shows promise for identifying Veterans who may be at increased risk of suicide. JF - Pastoral Psychology AU - Kopacz, Marek S AU - Hoffmire, Claire A AU - Morley, Sybil W AU - Vance, C Garland AD - U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, 400 Fort Hill Avenue, Canandaigua, NY, 14424, USA marek.kopacz@va.gov marek.kopacz@va.gov marek.kopacz@va.gov; U.S. Department of Veterans Affairs, Charles George VA Medical Center, 1100 Tunnel Road, Asheville, NC, 28805, USA ; U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, 400 Fort Hill Avenue, Canandaigua, NY, 14424, USA Y1 - 2015/05// PY - 2015 DA - May 2015 SP - 381 EP - 390 CY - New York PB - Springer Science & Business Media VL - 64 IS - 3 SN - 0031-2789 KW - Religions And Theology KW - Anger KW - Psychological distress KW - Reliability KW - Resentment KW - Risk assessment KW - Risk factors KW - Sadness KW - Suicide KW - Veterans KW - Chaplains KW - Clinical assessment KW - Despair KW - Factor analysis KW - Grief KW - Guilt KW - Hopelessness KW - Life meaning KW - Meaning UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1683501085?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Pastoral+Psychology&rft.atitle=Using+a+Spiritual+Distress+Scale+to+Assess+Suicide+Risk+in+Veterans%3A+An+Exploratory+Study&rft.au=Kopacz%2C+Marek+S%3BHoffmire%2C+Claire+A%3BMorley%2C+Sybil+W%3BVance%2C+C+Garland&rft.aulast=Kopacz&rft.aufirst=Marek&rft.date=2015-05-01&rft.volume=64&rft.issue=3&rft.spage=381&rft.isbn=&rft.btitle=&rft.title=Pastoral+Psychology&rft.issn=00312789&rft_id=info:doi/10.1007%2Fs11089-014-0633-1 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-04-15 N1 - Last updated - 2016-05-18 DO - http://dx.doi.org/10.1007/s11089-014-0633-1 ER - TY - JOUR T1 - Urinary ATP Synthase Subunit β Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury. AN - 1676339963; 25666834 AB - Although the importance of mitochondrial dysfunction in acute kidney injury (AKI) has been documented, noninvasive early biomarkers of mitochondrial damage are needed. We examined urinary ATP synthase subunit β (ATPSβ) as a biomarker of renal mitochondrial dysfunction during AKI. Mice underwent sham surgery or varying degrees (5, 10, or 15 min ischemia) of ischemia/reperfusion (I/R)-induced AKI. Serum creatinine, BUN, and neutrophil gelatinase-associated lipocalin were elevated only in the 15 min I/R group at 24 h. Immunoblot analysis of urinary ATPSβ revealed two bands (full length ∼52 kDa and cleaved ∼25 kDa), both confirmed as ATPSβ by LC-MS/MS, that increased at 24 h in 10- and 15-min I/R groups. These changes were associated with mitochondrial dysfunction evidenced by reduced renal cortical expression of mitochondrial proteins, ATPSβ and COX1, proximal tubular oxygen consumption, and ATP. Furthermore, in the 15-min I/R group, urinary ATPSβ was elevated until 72 h before returning to baseline 144 h after reperfusion with recovery of renal function. Evaluation of urinary ATPSβ in a nonalcoholic steatohepatitis model of liver injury only revealed cleaved ATPSβ, suggesting specificity of full-length ATPSβ for renal injury. Immunoblot analyses of patient urine samples collected 36 h after cardiac surgery revealed increased urinary ATPSβ levels in patients with postcardiac surgery-induced AKI. LC-MS/MS urinalysis in human subjects with AKI confirmed increased ATPSβ. These translational studies provide evidence that ATPSβ may be a novel and sensitive urinary biomarker of renal mitochondrial dysfunction and could serve as valuable tool for the testing of potential therapies for AKI and chemical-induced nephrotoxicity. Published by Oxford University Press on behalf of the Society of Toxicology 2015. This work is written by US Government employees and is in the public domain in the US. JF - Toxicological sciences : an official journal of the Society of Toxicology AU - Whitaker, Ryan M AU - Korrapati, Midhun C AU - Stallons, Lindsey J AU - Jesinkey, Sean R AU - Arthur, John M AU - Beeson, Craig C AU - Zhong, Zhi AU - Schnellmann, Rick G AD - *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425 schnell@musc.edu. ; *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425. ; *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425 *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425. ; *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425 *Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina 29425, Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina 29425 and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina 29425 schnell@musc.edu. Y1 - 2015/05// PY - 2015 DA - May 2015 SP - 108 EP - 117 VL - 145 IS - 1 KW - Biomarkers KW - 0 KW - F1F0-ATP synthase KW - EC 3.6.1.- KW - Mitochondrial Proton-Translocating ATPases KW - EC 3.6.3.- KW - Index Medicus KW - mitochondria KW - acute kidney injury KW - biomarker KW - ischemia-reperfusion KW - ATP synthase β KW - Animals KW - Humans KW - Mice, Inbred C57BL KW - Aged KW - Male KW - Female KW - Mitochondria -- physiology KW - Acute Kidney Injury -- physiopathology KW - Biomarkers -- urine KW - Acute Kidney Injury -- enzymology KW - Mitochondrial Proton-Translocating ATPases -- urine UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1676339963?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Toxicological+sciences+%3A+an+official+journal+of+the+Society+of+Toxicology&rft.atitle=Urinary+ATP+Synthase+Subunit+%CE%B2+Is+a+Novel+Biomarker+of+Renal+Mitochondrial+Dysfunction+in+Acute+Kidney+Injury.&rft.au=Whitaker%2C+Ryan+M%3BKorrapati%2C+Midhun+C%3BStallons%2C+Lindsey+J%3BJesinkey%2C+Sean+R%3BArthur%2C+John+M%3BBeeson%2C+Craig+C%3BZhong%2C+Zhi%3BSchnellmann%2C+Rick+G&rft.aulast=Whitaker&rft.aufirst=Ryan&rft.date=2015-05-01&rft.volume=145&rft.issue=1&rft.spage=108&rft.isbn=&rft.btitle=&rft.title=Toxicological+sciences+%3A+an+official+journal+of+the+Society+of+Toxicology&rft.issn=1096-0929&rft_id=info:doi/10.1093%2Ftoxsci%2Fkfv038 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-05-16 N1 - Date created - 2015-04-27 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Nat Rev Neurol. 2013 Aug;9(8):474-81 [23817350] J Am Soc Nephrol. 2014 Jun;25(6):1157-62 [24511124] J Pharmacol Exp Ther. 2013 Dec;347(3):626-34 [24042162] Toxicol Appl Pharmacol. 2013 Dec 1;273(2):345-54 [24096033] Toxicol Lett. 2014 Jan 30;224(3):326-32 [24275386] Am J Physiol Renal Physiol. 2014 Feb 15;306(4):F367-78 [24305473] Clin J Am Soc Nephrol. 2014 Mar;9(3):435-6 [24526743] Nat Rev Nephrol. 2014 Apr;10(4):193-207 [24445744] J Am Soc Nephrol. 2003 Aug;14(8):2199-210 [12874476] Kidney Int. 1998 Jan;53(1):100-11 [9453005] Am J Physiol Renal Physiol. 2005 Jun;288(6):F1092-102 [15625081] Mol Cell Proteomics. 2006 Feb;5(2):313-23 [16244361] Nephron Physiol. 2007;105(1):p1-10 [17095876] J Clin Invest. 2009 May;119(5):1275-85 [19349686] Oxid Med Cell Longev. 2008 Oct-Dec;1(1):33-8 [19794906] Contrib Nephrol. 2010;165:9-17 [20427950] Anal Biochem. 2010 Sep 1;404(1):75-81 [20465991] Am J Physiol Renal Physiol. 2012 Apr 1;302(7):F853-64 [22160772] Anal Chim Acta. 2012 May 21;727:8-12 [22541816] Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):655-64 [22475359] J Pharmacol Exp Ther. 2012 Oct;343(1):34-43 [22736507] Clin J Am Soc Nephrol. 2013 Feb;8(2):184-93 [23143504] Transplantation. 2002 Feb 27;73(4):493-9 [11889418] PLoS One. 2013;8(9):e73655 [24040012] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1093/toxsci/kfv038 ER - TY - JOUR T1 - Bleeding risk, physical functioning and non-use of anticoagulation among patients with stroke and atrial fibrillation AN - 1811909380; PQ0003424252 AB - Background: Atrial fibrillation (AF) is common among people with stroke. Anticoagulation medications can be used to manage the deleterious impact of AF after stroke, however, may not be prescribed due to concerns about post-stroke falls and decreased functioning. Thus, the purpose of this study was to identify, among people with stroke and AF, predictors of anticoagulation prescription at hospital discharge.Methods: This is a secondary analysis of a retrospective cohort study of data retrieved via medical records, including National Institutes of Health Stroke Scale score, Functional Independence Measure (FIM) motor score (motor or physical function), ambulation on second day of hospitalization, Morse Falls Scale (fall risk) and HAS-BLED score (Hypertension; Abnormal renal and liver function; Stroke; Bleeding; Labile INRs; Elderly >65; and Drugs or alcohol). Data analyses included bivariate comparisons between people with and without anticoagulation at discharge. Logistic-regression modeling was used to assess predictors of discharge anticoagulation.Results: There were 334 subjects included in the analyses, whose average age was 75 years old. Anticoagulation was prescribed at discharge for 235 (70%) of patients. In the adjusted regression analyses, only the FIM motor score (adjusted OR = 1.015, 95% CI 1.001-1.028) and the HAS-BLED score (adjusted OR = 0.36, 95% CI 0.22-0.58) were significantly associated with anticoagulation prescription at discharge.Conclusion: It appears that in this sample, post-stroke anticoagulation decisions appear to be made based on clinical factors associated with bleed risk and motor deficits or physical functioning. However, opportunities may exist for improving clinician documentation of specific reasoning for non-anticoagulation prescription. JF - QJM: An International Journal of Medicine AU - Schmid, A A AU - Ofner, S AU - Shorr, R I AU - Williams, L S AU - Bravata, D M AD - From the Department of Occupational Therapy, College of Health and Human Sciences, Colorado State University, Fort Collins, CO, VA HSR&D Stroke Quality Enhancement Research Initiative (QUERI), Indianapolis, IN, Department of Biostatistics, Indiana University, Indianapolis, IN, GRECC (182), Malcom Randall VAMC, Gainesville, FL, Department of Epidemiology, University of Florida, Gainesville, FL, Roudebush Veterans Administration (VA) Medical Center, Health Services Research and Development (HSR&D) Center for Health Information and Communication, Indianapolis, IN, Indiana University Center for Aging Research, Indianapolis, IN, Regenstrief Institute, Inc., Indianapolis, IN, Department of Neurology, Indiana University, School of Medicine and Department of Medicine, Indiana University, School of Medicine, Indianapolis, IN, USA Y1 - 2015/03/29/ PY - 2015 DA - 2015 Mar 29 SP - 189 EP - 196 PB - Oxford University Press, Great Clarendon Street Oxford OX2 6DP United Kingdom VL - 108 IS - 3 SN - 1460-2725, 1460-2725 KW - Physical Education Index KW - Alcohol KW - Analysis KW - Stroke KW - Liver KW - Patients KW - Kidneys KW - Modeling KW - Hypertension KW - Hospitals KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1811909380?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=QJM%3A+An+International+Journal+of+Medicine&rft.atitle=Bleeding+risk%2C+physical+functioning+and+non-use+of+anticoagulation+among+patients+with+stroke+and+atrial+fibrillation&rft.au=Schmid%2C+A+A%3BOfner%2C+S%3BShorr%2C+R+I%3BWilliams%2C+L+S%3BBravata%2C+D+M&rft.aulast=Schmid&rft.aufirst=A&rft.date=2015-03-29&rft.volume=108&rft.issue=3&rft.spage=189&rft.isbn=&rft.btitle=&rft.title=QJM%3A+An+International+Journal+of+Medicine&rft.issn=14602725&rft_id=info:doi/10.1093%2Fqjmed%2Fhcu176 LA - English DB - Physical Education Index N1 - Date revised - 2016-08-01 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Alcohol; Analysis; Stroke; Liver; Patients; Kidneys; Modeling; Hospitals; Hypertension DO - http://dx.doi.org/10.1093/qjmed/hcu176 ER - TY - RPRT T1 - SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER (SFVAMC) LONG RANGE DEVELOPMENT PLAN, FORT MILEY, SAN FRANCISCO, CALIFORNIA (DRAFT SUPPLEMENT TO THE DRAFT ENVIRONMENTAL IMPACT STATEMENT OF AUGUST 2012) . AN - 16390501; 16443 AB - PURPOSE: This Supplemental Draft EIS evaluates potential environmental impacts resulting from implementation of the VA Proposed Action. VAs Proposed Action is an LRDP that supports the mission of SFVAMC to provide for the health care needs of Bay Area and North Coast Veterans by providing for the renovation, expansion, and operation of the SFVAMC Fort Miley Campus within San Francisco County. The purpose of the Proposed Action is to meet the Veterans Health Administration mission of providing comprehensive, high quality health care services that improve the health and well-being of Veterans and other eligible persons in the San Francisco Bay Area and Northern California. VAs need for the Proposed Action is to address the areas current and future capacity issues brought about by the growing Veteran population, to better serve the ever-changing health care needs of the growing Veteran population, and to provide safe and appropriate facilities for providing health care services and conducting research. This Supplemental Draft EIS analyzes three action alternatives that would involve implementation of an LRDP. All three action alternatives would include seismic retrofit, demolition, new construction, and operation of VA clinical, research, administrative, and parking structures. Also evaluated is the No Action Alternative, in which VA would continue operation and maintenance of the existing medical center at Fort Miley. Alternative 1 has been identified by VA as the Preferred Alternative. JF - EPA number: 150066, Draft Supplement EIS, March 20, 2015 Y1 - 2015/03/20/ PY - 2015 DA - 2015 Mar 20 KW - Land Use KW - Air Quality KW - Air Quality Assessments KW - Archaeological Sites KW - Buildings KW - Cultural Resources Assessments KW - Demolition KW - Historic Districts KW - Hospitals KW - Parking KW - Research Facilities KW - Section 106 Statements KW - Traffic Analyses KW - California UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/16390501?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/Environmental+Impact+Statements%3A+Digests&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=report&rft.jtitle=&rft.atitle=&rft.au=&rft.aulast=&rft.aufirst=Leeyup&rft.date=2009-07-01&rft.volume=102&rft.issue=1&rft.spage=272&rft.isbn=&rft.btitle=&rft.title=Journal+of+neurophysiology&rft.issn=00223077&rft_id=info:doi/10.1152%2Fjn.90769.2008 LA - English DB - ProQuest Environmental Science Collection N1 - Name - Department of Veteran Affairs, Veterans Health Administration, San Francisco, California N1 - Date revised - 2016-04-22 N1 - SuppNotes - Draft. Preparation date: March 20, 2015 N1 - Last updated - 2016-04-25 ER - TY - JOUR T1 - Neural correlates of adherence to extended-release naltrexone pharmacotherapy in heroin dependence. AN - 1664779142; 25781230 AB - Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid addiction, however its utility could be hampered by poor adherence. To gain a better insight into this phenomenon, we utilized blood oxygenation level-dependent functional magnetic resonance imaging (fMRI) in conjunction with a validated cue-induced craving procedure to examine neural correlates of XRNTX adherence. We operationalized treatment adherence as the number of monthly XRNTX injections (range: 0-3) administered to a group of fully detoxified heroin-dependent subjects (n=32). Additional outcomes included urine toxicology screening and self-reported tobacco use. The presented heroin-related visual cues reliably elicited heroin craving in all tested subjects. Nine, five, three and 15 of the participants, respectively, received zero, one, two and three XRNTX injections, predicted by the individual baseline fMRI signal change in response to the cues in the medial prefrontal cortex, a brain region involved in inhibitory self-control and emotional appraisal. The incidence of opioid-positive urines during the XRNTX therapy was low and remained about half the pre-treatment rate after the XRNTX ended. During the treatment, cigarette smoking behaviors followed patterns of opioid use, while cocaine consumption was increased with reductions in opioid use. The present data support the hypothesis that medial prefrontal cortex functions are involved in adherence to opioid antagonist therapy. A potential role of concurrent non-opioid addictive substances consumption during the XRNTX pharmacotherapy warrants further investigation. Our findings set the stage for further bio-behavioral investigations of the mechanisms of relapse prevention in opioid dependence. JF - Translational psychiatry AU - Wang, A-L AU - Elman, I AU - Lowen, S B AU - Blady, S J AU - Lynch, K G AU - Hyatt, J M AU - O'Brien, C P AU - Langleben, D D AD - Annenberg Public Policy Center, University of Pennsylvania, Philadelphia, PA, USA. ; Cambridge Health Alliance, Department of Psychiatry, Harvard Medical School, Cambridge, MA, USA. ; Brain Imaging Center, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, USA. ; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ; Department of Criminology, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA. ; 1] Annenberg Public Policy Center, University of Pennsylvania, Philadelphia, PA, USA [2] Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA [3] Behavioral Health Service, Veterans Administration Medical Center, Philadelphia, PA, USA. Y1 - 2015/03/17/ PY - 2015 DA - 2015 Mar 17 SP - 1 VL - 5 KW - Narcotic Antagonists KW - 0 KW - Naltrexone KW - 5S6W795CQM KW - Index Medicus KW - Magnetic Resonance Imaging KW - Craving KW - Narcotic Antagonists -- administration & dosage KW - Narcotic Antagonists -- therapeutic use KW - Humans KW - Adult KW - Cues KW - Male KW - Female KW - Brain -- physiopathology KW - Naltrexone -- administration & dosage KW - Patient Compliance -- statistics & numerical data KW - Patient Compliance -- psychology KW - Heroin Dependence -- physiopathology KW - Heroin Dependence -- drug therapy KW - Heroin Dependence -- psychology KW - Naltrexone -- therapeutic use UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1664779142?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Translational+psychiatry&rft.atitle=Neural+correlates+of+adherence+to+extended-release+naltrexone+pharmacotherapy+in+heroin+dependence.&rft.au=Wang%2C+A-L%3BElman%2C+I%3BLowen%2C+S+B%3BBlady%2C+S+J%3BLynch%2C+K+G%3BHyatt%2C+J+M%3BO%27Brien%2C+C+P%3BLangleben%2C+D+D&rft.aulast=Wang&rft.aufirst=A-L&rft.date=2015-03-17&rft.volume=5&rft.issue=&rft.spage=e531&rft.isbn=&rft.btitle=&rft.title=Translational+psychiatry&rft.issn=2158-3188&rft_id=info:doi/10.1038%2Ftp.2015.20 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-01-20 N1 - Date created - 2015-03-18 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Neuroimage. 2001 Dec;14(6):1370-86 [11707093] Drug Alcohol Depend. 2012 Jul 1;124(1-2):113-20 [22265192] Int J Environ Res Public Health. 2012 Mar;9(3):932-42 [22690174] Neuroradiology. 2012 Sep;54(9):1015-25 [22744798] J Clin Psychiatry. 2012 Aug;73(8):e1056-61 [22967782] Lancet. 2012 Dec 15;380(9859):2095-128 [23245604] Psychopharmacology (Berl). 2013 Jan;225(1):127-40 [22829433] J Neurosci. 2013 Mar 6;33(10):4584-93 [23467374] Subst Abus. 2013;34(2):94-6 [23577900] Curr Drug Abuse Rev. 2013 Mar;6(1):77-84 [23506370] Life Sci. 2013 Sep 17;93(9-11):373-9 [23891777] Nicotine Tob Res. 2013 Oct;15(10):1705-13 [23572466] Drug Alcohol Depend. 2013 Nov 1;133(1):80-5 [23827259] J Anal Toxicol. 2007 Oct;31(8):453-61 [17988459] Eur Psychiatry. 2007 Nov;22(8):540-8 [17596918] Eur J Pharmacol. 2008 Jan 28;579(1-3):160-6 [17977528] Am J Psychiatry. 2008 Mar;165(3):390-4 [18056224] JAMA. 2009 Jan 14;301(2):183-90 [19141766] Alcohol Clin Exp Res. 2009 Mar;33(3):383-93 [19053977] Brain Res. 2009 Oct 13;1293:61-75 [19332030] Epilepsy Behav. 2009 Oct;16(2):288-97 [19733509] Br J Psychiatry Suppl. 2009 Nov;52:S37-42 [19880915] Soc Cogn Affect Neurosci. 2009 Dec;4(4):423-8 [20035017] J Opioid Manag. 2010 Jul-Aug;6(4):300-3 [20862910] Nat Neurosci. 2011 Apr;14(4):426-7 [21358641] Mayo Clin Proc. 2011 Apr;86(4):304-14 [21389250] JAMA. 2011 Apr 6;305(13):1346-7 [21467287] Neuropharmacology. 2011 Jun;60(7-8):1209-20 [21108953] Lancet. 2011 Apr 30;377(9776):1506-13 [21529928] Eur Radiol. 2011 Nov;21(11):2369-87 [21710268] Nat Rev Neurosci. 2011 Nov;12(11):652-69 [22011681] J Stud Alcohol Drugs. 2011 Nov;72(6):1012-8 [22051215] Psychopharmacology (Berl). 2012 Apr;220(3):559-64 [21960180] J Neurosci. 2012 Apr 4;32(14):4982-91 [22492053] Emerg Med J. 2002 May;19(3):264-5 [11971848] Am J Psychiatry. 2002 Oct;159(10):1642-52 [12359667] Neuroimage. 2002 Oct;17(2):825-41 [12377157] Hum Brain Mapp. 2002 Nov;17(3):143-55 [12391568] Indian J Med Sci. 2002 Oct;56(10):495-500 [12712760] Stat Methods Med Res. 2003 Oct;12(5):401-18 [14599003] Neuropsychologia. 1971 Mar;9(1):97-113 [5146491] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5675-9 [1608978] Prog Neurobiol. 2013 Oct;109:1-27 [23827972] J Sex Med. 2014 Jan;11(1):22-32 [24344738] Acad Emerg Med. 2014 Jan;21(1):31-9 [24552522] Addict Biol. 2014 Mar;19(2):262-71 [22747521] BMJ Open. 2014;4(3):e004393 [24633528] Contemp Clin Trials. 2014 Mar;37(2):209-18 [24384538] N Engl J Med. 2014 May 29;370(22):2063-6 [24758595] Addict Biol. 2014 Jul;19(4):733-42 [23252742] Hum Brain Mapp. 2000 Jul;10(3):120-31 [10912591] Addiction. 2000 Aug;95 Suppl 2:S177-87 [11002913] Drug Alcohol Depend. 2001 Jan 1;61(2):163-72 [11137281] Arch Gen Psychiatry. 2001 May;58(5):503-8 [11343531] Med Image Anal. 2001 Jun;5(2):143-56 [11516708] Arch Gen Psychiatry. 2006 Feb;63(2):210-8 [16461865] Arch Intern Med. 2006 Jun 26;166(12):1280-7 [16801510] Hum Brain Mapp. 2006 Aug;27(8):652-61 [16281289] Addict Behav. 2006 Dec;31(12):2304-8 [16564643] Addict Behav. 2007 May;32(5):938-49 [16887281] J Addict Dis. 2007;26(1):61-70 [17439869] Exp Clin Psychopharmacol. 2007 Apr;15(2):134-43 [17469937] Drug Alcohol Depend. 2007 Dec 1;91(2-3):289-92 [17681716] J Pharmacol Exp Ther. 2011 Feb;336(2):488-95 [21051498] Am J Addict. 2011 Mar-Apr;20(2):106-12 [21314752] Cochrane Database Syst Rev. 2011;(2):CD001333 [21328250] Neuroimage. 2011 Apr 15;55(4):1825-35 [21272655] Magn Reson Med. 1992 Jun;25(2):390-7 [1614324] J Subst Abuse Treat. 1992;9(3):199-213 [1334156] Am J Emerg Med. 1993 Jan;11(1):96-7 [8447884] NIDA Res Monogr. 1993;137:73-95 [8289929] Magn Reson Med. 1995 May;33(5):636-47 [7596267] J Toxicol Clin Toxicol. 1996;34(4):409-16 [8699555] Neuroimage. 1996 Dec;4(3 Pt 1):223-35 [9345513] IEEE Trans Med Imaging. 2004 Feb;23(2):137-52 [14964560] Neuron. 2004 Sep 16;43(6):897-905 [15363399] N Engl J Med. 2014 Sep 4;371(10):932-43 [25184865] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1038/tp.2015.20 ER - TY - JOUR T1 - The Dynamics of Psychiatric Bed Use in General Hospitals AN - 1708525163; 201506197 AB - This study examines general hospitals' adjustments in psychiatric bed utilization practices in response to increases in psychiatric inpatient admissions. Using panel data from 439 hospitals, monthly observations (N = 7,831) between 2007 and 2010 on psychiatric admissions, psychiatric bed occupancy rates, and average length-of-stay were created for psychiatric inpatients. In fixed-effects regressions, an increase in psychiatric admissions was associated with an increase in the probability of psychiatric bed use exceeding 100 % occupancy and with a reduction of mean length-of-stay. These results were confirmed in instrumental variables models. General hospitals may dynamically adjust bed utilization practices in response to changing psychiatric bed needs. An implication of this dynamic adjustment model is that bed shortages are likely to be local, transitory events. Adapted from the source document. JF - Administration and Policy in Mental Health AND Mental Health Services Research AU - Slade, Eric P AU - Goldman, Howard H AD - U.S. Department of Veterans Affairs, VA Capitol Healthcare Network Mental Illness Research, Education, and Clinical Center, 10 N. Greene Street, Baltimore, MD, 21201, USA eslade@psych.umaryland.edu Y1 - 2015/03// PY - 2015 DA - March 2015 SP - 139 EP - 146 PB - Springer, Dordrecht The Netherlands VL - 42 IS - 2 SN - 0894-587X, 0894-587X KW - Scarcity KW - Mental Hospitals KW - Adjustment KW - Psychiatry KW - Hospitals KW - article KW - 6120: social work practice UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1708525163?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Administration+and+Policy+in+Mental+Health+AND+Mental+Health+Services+Research&rft.atitle=The+Dynamics+of+Psychiatric+Bed+Use+in+General+Hospitals&rft.au=Slade%2C+Eric+P%3BGoldman%2C+Howard+H&rft.aulast=Slade&rft.aufirst=Eric&rft.date=2015-03-01&rft.volume=42&rft.issue=2&rft.spage=139&rft.isbn=&rft.btitle=&rft.title=Administration+and+Policy+in+Mental+Health+AND+Mental+Health+Services+Research&rft.issn=0894587X&rft_id=info:doi/10.1007%2Fs10488-014-0554-4 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-09-01 N1 - Number of references - 18 N1 - Last updated - 2016-09-28 N1 - CODEN - APMHEM N1 - SubjectsTermNotLitGenreText - Psychiatry; Hospitals; Adjustment; Mental Hospitals; Scarcity DO - http://dx.doi.org/10.1007/s10488-014-0554-4 ER - TY - JOUR T1 - Quality Management and Federal Workers' Compensation: The Veterans Health Administration Workers' Compensation Program Model AN - 1680447972; PQ0001516826 AB - Objective: The federal workers' compensation program includes under a single employer five commonly encountered roles and responsibilities-injured patient, clinical provider, third-party administrator, adjudicator, and insurer. Data within the Veterans Health Administration (VHA) provide a unique opportunity to apply a simple model of health care quality improvement, exploring interactions between structures, processes, and outcomes. Methods: A facility survey identified reporting structures, levels of education and training, policies and processes, tool availability and use, and perceptions of role adherence. Administrative data included process and outcome metrics, including short-term disability, long-term disability, and lost time cases. Results: Improved collaboration between clinical and administrative staff within VHA and with the Department of Labor was associated with improved performance. Conclusions: Applying a clinical quality improvement model clarifies roles, expectations, and likely relationships for improved program management. JF - Journal of Occupational and Environmental Medicine AU - Hodgson, Michael J AU - Mohr, David C AU - Lipkowitz-Eaton, Jennifer AU - Rodrigues, Dianne AU - Moreau, Sarah AU - McPhaul, Kate AD - War-Related Illness and Injury Study Center, Office of Public Health, Veterans Health Administration; Occupational Health Strategic Health Care Group, Office of Public Health, michael.hodgson@va.gov PY - 2015 SP - S36 EP - S42 PB - Williams & Wilkins, 351 W. Camden St. Baltimore MD 21201 United States VL - 57 IS - 3S SN - 1076-2752, 1076-2752 KW - Health & Safety Science Abstracts KW - Workers' compensation KW - Education KW - Health care KW - Training KW - Perception KW - Disabilities KW - H 1000:Occupational Safety and Health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680447972?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Occupational+and+Environmental+Medicine&rft.atitle=Quality+Management+and+Federal+Workers%27+Compensation%3A+The+Veterans+Health+Administration+Workers%27+Compensation+Program+Model&rft.au=Hodgson%2C+Michael+J%3BMohr%2C+David+C%3BLipkowitz-Eaton%2C+Jennifer%3BRodrigues%2C+Dianne%3BMoreau%2C+Sarah%3BMcPhaul%2C+Kate&rft.aulast=Hodgson&rft.aufirst=Michael&rft.date=2015-03-01&rft.volume=57&rft.issue=3S&rft.spage=S36&rft.isbn=&rft.btitle=&rft.title=Journal+of+Occupational+and+Environmental+Medicine&rft.issn=10762752&rft_id=info:doi/10.1097%2FJOM.0000000000000375 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-05-01 N1 - Last updated - 2015-12-23 N1 - SubjectsTermNotLitGenreText - Workers' compensation; Education; Health care; Perception; Training; Disabilities DO - http://dx.doi.org/10.1097/JOM.0000000000000375 ER - TY - JOUR T1 - A Brief Summary of Workers' Compensation Performance Improvement Projects 2008 to 2012 in the Veterans Health Administration AN - 1680446679; PQ0001516828 AB - Background: The Veterans Health Administration undertook a series of performance improvement projects (PIP) using local initiatives identified through a national committee of regional workers' compensation representatives. Methods: A steering committee identified five types of risks and interventions that were considered worthwhile. They defined performance metrics as outcome measures and distinguished short-term from long-term disability management success. Results: Eight specific PIPs were implemented. No statistically significant differences in the planned outcome metrics were identified, although cost-benefit evaluations did identify a benefit. Conclusions: Conducting quantitative PIPs in a large system requires top management commitment, sequestration of funds, and mature systems. JF - Journal of Occupational and Environmental Medicine AU - Hodgson, Michael J AD - War-Related Illness and Injury Study Center, Washington DC VAMC, 50 Irving Street NW, Washington DC 20422, michael.hodgson@va.gov PY - 2015 SP - S43 EP - S46 PB - Williams & Wilkins, 351 W. Camden St. Baltimore MD 21201 United States VL - 57 IS - 3S SN - 1076-2752, 1076-2752 KW - Risk Abstracts; Health & Safety Science Abstracts KW - Workers' compensation KW - Funds KW - Committees KW - Disabilities KW - Intervention KW - R2 23080:Industrial and labor KW - H 1000:Occupational Safety and Health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680446679?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ariskabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Occupational+and+Environmental+Medicine&rft.atitle=A+Brief+Summary+of+Workers%27+Compensation+Performance+Improvement+Projects+2008+to+2012+in+the+Veterans+Health+Administration&rft.au=Hodgson%2C+Michael+J&rft.aulast=Hodgson&rft.aufirst=Michael&rft.date=2015-03-01&rft.volume=57&rft.issue=3S&rft.spage=S43&rft.isbn=&rft.btitle=&rft.title=Journal+of+Occupational+and+Environmental+Medicine&rft.issn=10762752&rft_id=info:doi/10.1097%2FJOM.0000000000000403 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-05-01 N1 - Last updated - 2015-12-23 N1 - SubjectsTermNotLitGenreText - Workers' compensation; Funds; Disabilities; Committees; Intervention DO - http://dx.doi.org/10.1097/JOM.0000000000000403 ER - TY - JOUR T1 - Impact of Clinical Quality on Employee Choice of Providers for Workers' Compensation-Related Medical Care AN - 1680445046; PQ0001516825 AB - Objective: The study examined the relationship between onsite occupational health practice characteristics, provider choice, and workers' compensation outcome metrics. Methods: Cross-sectional survey of 140 medical center occupational health clinics within the Department of Veterans Affairs. Multivariate regression models examined how specific clinical quality factors influenced provider choice and workers' compensation measures. Results: Several practice characteristics were associated with higher rates of in-house care selection-longer hours of operation, greater availability of workers' compensation-related medical services, clinic administration by a board certified physician, physician tenure, and adherence to clinical practice guidelines. Access to onsite, occupational and environmental medicine certified physician-directed care was associated with reductions in disability duration among injured healthcare workers. Conclusions: These findings suggest that occupational medicine board certification can positively impact provider choice among fully insured patients, which may have implications for other healthcare systems. JF - Journal of Occupational and Environmental Medicine AU - Eaton, Jennifer L AU - Mohr, David C AU - Gallarde, Sheryl AU - Hodgson, Michael J AD - Occupational Health Group, Office of Public Health, Veterans Health Administration, 1717 H St NW Rm 504, Washington, DC 20006; War Related Illness and Injury Study Center, VA Medical Center, Washington, DC, Jennifer.Lipkowitz-Eaton@va.gov PY - 2015 SP - S31 EP - S35 PB - Williams & Wilkins, 351 W. Camden St. Baltimore MD 21201 United States VL - 57 IS - 3S SN - 1076-2752, 1076-2752 KW - Health & Safety Science Abstracts KW - Workers' compensation KW - Health care KW - Disabilities KW - Guidelines KW - Certification KW - Medical personnel KW - Occupational health KW - H 1000:Occupational Safety and Health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680445046?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Occupational+and+Environmental+Medicine&rft.atitle=Impact+of+Clinical+Quality+on+Employee+Choice+of+Providers+for+Workers%27+Compensation-Related+Medical+Care&rft.au=Eaton%2C+Jennifer+L%3BMohr%2C+David+C%3BGallarde%2C+Sheryl%3BHodgson%2C+Michael+J&rft.aulast=Eaton&rft.aufirst=Jennifer&rft.date=2015-03-01&rft.volume=57&rft.issue=3S&rft.spage=S31&rft.isbn=&rft.btitle=&rft.title=Journal+of+Occupational+and+Environmental+Medicine&rft.issn=10762752&rft_id=info:doi/10.1097%2FJOM.0000000000000387 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-05-01 N1 - Last updated - 2015-12-23 N1 - SubjectsTermNotLitGenreText - Workers' compensation; Health care; Disabilities; Guidelines; Certification; Medical personnel; Occupational health DO - http://dx.doi.org/10.1097/JOM.0000000000000387 ER - TY - JOUR T1 - Reviewing Manuscripts for the Journal of Genetic Counseling: Practical Suggestions AN - 1673613764 AB - The Journal of Genetic Counseling is the literary voice of our profession and our scholarship is only as good as the articles that are accepted. A quality review assists the editor in making publication decisions and enhances the manuscripts that are published, ultimately benefitting our profession and the public. Perhaps you are new to the reviewing process and/or you wonder about the sorts of things that make for a good review. The purpose of this article is to provide general guidance to enhance your experience of peer review. While the focus is research manuscripts, many of the guidelines will be similar for case reports, reviews, or professional issues papers. JF - Journal of Genetic Counseling AU - Venne, Vickie AD - Genomic Medicine Service, Salt Lake City, UT, USA Vickie.Venne@va.gov; Genomic Medicine Service, Salt Lake City, UT, USA Y1 - 2015/03// PY - 2015 DA - Mar 2015 SP - 189 EP - 192 CY - New York PB - Springer Science & Business Media VL - 24 IS - 2 SN - 1059-7700 KW - Psychology KW - Counselling KW - Genetic counselling KW - Guidance KW - Manuscripts KW - Professional issues UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1673613764?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Genetic+Counseling&rft.atitle=Reviewing+Manuscripts+for+the+Journal+of+Genetic+Counseling%3A+Practical+Suggestions&rft.au=Venne%2C+Vickie&rft.aulast=Venne&rft.aufirst=Vickie&rft.date=2015-03-01&rft.volume=24&rft.issue=2&rft.spage=189&rft.isbn=&rft.btitle=&rft.title=Journal+of+Genetic+Counseling&rft.issn=10597700&rft_id=info:doi/10.1007%2Fs10897-014-9802-8 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-03-31 N1 - Last updated - 2016-05-12 DO - http://dx.doi.org/10.1007/s10897-014-9802-8 ER - TY - JOUR T1 - Smiling in a Job Interview: When Less Is More AN - 1665168164 AB - Two studies examined the effect of applicants’ smiling on hireability. In a pre-test study, participants were asked to rate the expected behavior for four types of applicants. Newspaper reporter applicants were expected to be more serious than applicants for other jobs. In Study 1, participants were randomly assigned to be an applicant or interviewer for a newspaper reporting job. Smiling was negatively related to hiring, and smiling mediated the relation between applicants’ motivation to make a good impression and hiring. Hiring was maximized when applicants smiled less in the middle of the interview relative to the start and end. In Study 2, participants watched Study 1 clips and were randomly assigned to believe the applicants were applying to one of four jobs. Participants rated more suitability when applicants smiled less, especially for jobs associated with a serious demeanor. This research shows that job type is an important moderator of the impact of smiling on hiring. JF - The Journal of Social Psychology AU - Ruben, Mollie A AU - Hall, Judith A AU - Schmid Mast, Marianne AD - U.S. Department of Veterans Affairs, Northeastern University, University of Lausanne ; U.S. Department of Veterans Affairs; Northeastern University; University of Lausanne Y1 - 2015/03// PY - 2015 DA - Mar 2015 SP - 107 EP - 126 CY - Philadelphia PB - Taylor & Francis Ltd. VL - 155 IS - 2 SN - 0022-4545 KW - Psychology KW - Applicants KW - Hiring KW - Job applicants KW - Motivation KW - Suitability KW - Nonverbal Communication KW - Job Search KW - 0312:social psychology; personality & social roles (individual traits, social identity, adjustment, conformism, & deviance) UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665168164?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+Social+Psychology&rft.atitle=Smiling+in+a+Job+Interview%3A+When+Less+Is+More&rft.au=Ruben%2C+Mollie+A%3BHall%2C+Judith+A%3BSchmid+Mast%2C+Marianne&rft.aulast=Ruben&rft.aufirst=Mollie&rft.date=2015-03-01&rft.volume=155&rft.issue=2&rft.spage=107&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+Social+Psychology&rft.issn=00224545&rft_id=info:doi/10.1080%2F00224545.2014.972312 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA); Sociological Abstracts N1 - Date revised - 2015-02-26 N1 - Last updated - 2016-09-05 DO - http://dx.doi.org/10.1080/00224545.2014.972312 ER - TY - JOUR T1 - Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. AN - 1660662110; 25580725 AB - Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberculosis infection is safe and effective for persons 12 years or older. Published data for children are limited. To compare treatment safety and assess noninferiority treatment effectiveness of combination therapy with rifapentine and isoniazid vs 9 months of isoniazid treatment for latent tuberculosis infection in children. A pediatric cohort nested within a randomized, open-label clinical trial conducted from June 11, 2001, through December 17, 2010, with follow-up through September 5, 2013, in 29 study sites in the United States, Canada, Brazil, Hong Kong (China), and Spain. Participants were children (aged 2-17 years) who were eligible for treatment of latent tuberculosis infection. Twelve once-weekly doses of the combination drugs, given with supervision by a health care professional, for 3 months vs 270 daily doses of isoniazid, without supervision by a health care professional, for 9 months. We compared rates of treatment discontinuation because of adverse events (AEs), toxicity grades 1 to 4, and deaths from any cause. The equivalence margin for the comparison of AE-related discontinuation rates was 5%. Tuberculosis disease diagnosed within 33 months of enrollment was the main end point for testing effectiveness. The noninferiority margin was 0.75%. Of 1058 children enrolled, 905 were eligible for evaluation of effectiveness. Of 471 in the combination-therapy group, 415 (88.1%) completed treatment vs 351 of 434 (80.9%) in the isoniazid-only group (P = .003). The 95% CI for the difference in rates of discontinuation attributed to an AE was -2.6 to 0.1, which was within the equivalence range. In the safety population, 3 of 539 participants (0.6%) who took the combination drugs had a grade 3 AE vs 1 of 493 (0.2%) who received isoniazid only. Neither arm had any hepatotoxicity, grade 4 AEs, or treatment-attributed death. None of the 471 in the combination-therapy group developed tuberculosis vs 3 of 434 (cumulative rate, 0.74%) in the isoniazid-only group, for a difference of -0.74% and an upper bound of the 95% CI of the difference of +0.32%, which met the noninferiority criterion. Treatment with the combination of rifapentine and isoniazid was as effective as isoniazid-only treatment for the prevention of tuberculosis in children aged 2 to 17 years. The combination-therapy group had a higher treatment completion rate than did the isoniazid-only group and was safe. clinicaltrials.gov Identifier: NCT00023452. JF - JAMA pediatrics AU - Villarino, M Elsa AU - Scott, Nigel A AU - Weis, Stephen E AU - Weiner, Marc AU - Conde, Marcus B AU - Jones, Brenda AU - Nachman, Sharon AU - Oliveira, Ricardo AU - Moro, Ruth N AU - Shang, Nong AU - Goldberg, Stefan V AU - Sterling, Timothy R AU - International Maternal Pediatric and Adolescents AIDS Clinical Trials Group AU - Tuberculosis Trials Consortium AD - Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. ; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia2CDC Foundation, Atlanta, Georgia. ; Department of Medicine, University of North Texas Health Science Center at Ft Worth. ; Department of Medicine, Audie L. Murphy San Antonio Veterans Administration Medical Center, San Antonio, Texas. ; Department of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. ; Department of Medicine, University of Southern California, Los Angeles. ; Department of Pediatrics, State University of New York at Stony Brook. ; Department of Pediatrics, Pediatric Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. ; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. ; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group ; Tuberculosis Trials Consortium Y1 - 2015/03// PY - 2015 DA - March 2015 SP - 247 EP - 255 VL - 169 IS - 3 KW - Antitubercular Agents KW - 0 KW - Isoniazid KW - V83O1VOZ8L KW - Rifampin KW - VJT6J7R4TR KW - rifapentine KW - XJM390A33U KW - Abridged Index Medicus KW - Index Medicus KW - Drug Therapy, Combination KW - Humans KW - Treatment Outcome KW - Child KW - Adolescent KW - Male KW - Female KW - Child, Preschool KW - Isoniazid -- therapeutic use KW - Rifampin -- analogs & derivatives KW - Rifampin -- adverse effects KW - Antitubercular Agents -- administration & dosage KW - Rifampin -- therapeutic use KW - Isoniazid -- adverse effects KW - Rifampin -- administration & dosage KW - Latent Tuberculosis -- prevention & control KW - Antitubercular Agents -- adverse effects KW - Isoniazid -- administration & dosage KW - Antitubercular Agents -- therapeutic use UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1660662110?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=JAMA+pediatrics&rft.atitle=Treatment+for+preventing+tuberculosis+in+children+and+adolescents%3A+a+randomized+clinical+trial+of+a+3-month%2C+12-dose+regimen+of+a+combination+of+rifapentine+and+isoniazid.&rft.au=Villarino%2C+M+Elsa%3BScott%2C+Nigel+A%3BWeis%2C+Stephen+E%3BWeiner%2C+Marc%3BConde%2C+Marcus+B%3BJones%2C+Brenda%3BNachman%2C+Sharon%3BOliveira%2C+Ricardo%3BMoro%2C+Ruth+N%3BShang%2C+Nong%3BGoldberg%2C+Stefan+V%3BSterling%2C+Timothy+R%3BInternational+Maternal+Pediatric+and+Adolescents+AIDS+Clinical+Trials+Group%3BTuberculosis+Trials+Consortium&rft.aulast=Villarino&rft.aufirst=M&rft.date=2015-03-01&rft.volume=169&rft.issue=3&rft.spage=247&rft.isbn=&rft.btitle=&rft.title=JAMA+pediatrics&rft.issn=2168-6211&rft_id=info:doi/10.1001%2Fjamapediatrics.2014.3158 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-04-30 N1 - Date created - 2015-03-03 N1 - Date revised - 2017-01-14 N1 - Genetic sequence - NCT00023452; ClinicalTrials.gov N1 - SuppNotes - Comment In: Indian Pediatr. 2015 May;52(5):421-5 [26061929] JAMA Pediatr. 2015 Mar;169(3):208-10 [25581905] Erratum In: JAMA Pediatr. 2015 Sep;169(9):878 [26348861] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1001/jamapediatrics.2014.3158 ER - TY - JOUR T1 - Health Care Employee Perceptions of Patient-Centered Care AN - 1660419597; PQ0001025656 AB - Given the importance of health care employees in the delivery of patient-centered care, understanding their unique perspectives is essential for quality improvement. The purpose of this study was to use photovoice to evaluate perceptions and experiences around patient-centered care among U.S. Veterans Affairs (VA) health care employees. We asked participants to take photographs of salient features in their environment related to patient-centered care. We used the photographs to facilitate dialogue during follow-up interviews. Twelve VA health care employees across two VA sites participated in the project. Although most participants felt satisfied with their work environment and experiences at the VA, they identified several areas for improvement. These included a need for more employee health and wellness initiatives and a need for enhanced opportunities for training and professional growth. Application of photovoice enabled us to learn about employees' unique perspectives around patient-centered care while engaging them in an evaluation of care delivery. JF - Qualitative Health Research AU - Balbale, Salva Najib AU - Turcios, Stephanie AU - LaVela, Sherri L AD - United States Department of Veterans Affairs, Hines, Illinois, USA Y1 - 2015/03// PY - 2015 DA - Mar 2015 SP - 417 EP - 425 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 25 IS - 3 SN - 1049-7323, 1049-7323 KW - Health & Safety Science Abstracts KW - health care KW - health care professionals KW - photography / photovoice KW - quality improvement KW - research, qualitative KW - Health care KW - Perception KW - Training KW - Occupational health KW - H 0500:General UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1660419597?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Qualitative+Health+Research&rft.atitle=Health+Care+Employee+Perceptions+of+Patient-Centered+Care&rft.au=Balbale%2C+Salva+Najib%3BTurcios%2C+Stephanie%3BLaVela%2C+Sherri+L&rft.aulast=Balbale&rft.aufirst=Salva&rft.date=2015-03-01&rft.volume=25&rft.issue=3&rft.spage=417&rft.isbn=&rft.btitle=&rft.title=Qualitative+Health+Research&rft.issn=10497323&rft_id=info:doi/10.1177%2F1049732314553011 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-03-01 N1 - Number of references - 34 N1 - Last updated - 2015-04-16 N1 - SubjectsTermNotLitGenreText - Health care; Training; Perception; Occupational health DO - http://dx.doi.org/10.1177/1049732314553011 ER - TY - JOUR T1 - Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study AN - 1808699310; PQ0003460396 AB - ObjectiveTo examine the association of body mass index (BMI), waist circumference (WC) and waist hip ratio (WHR) with sudden cardiac death (SCD) in community dwelling individuals.MethodsData from a multicentre, prospective, cohort study of 14941 men and women (African American, and white), aged 45-64years, participating in the Atherosclerosis Risk in Communities study was analysed. Obesity measures were assessed at baseline (1987-1989). SCD was adjudicated by a committee.ResultsAt enrolment mean plus or minus SD age of the participants was 54 plus or minus 6 years (55% female; 26% African American). During 12.6 plus or minus 2.5 years of follow-up, 253 SCD occurred (incidence rate 1.34/100 person-years). The association between obesity and SCD differed by smoking status (interaction p less than or equal to 0.01). In models adjusting for age, sex, race, study centre and education level, SCD risk was positively associated (p0.95 in women; >1.01 in men) had double the risk of SCD (HR 2.03, 95% CI 1.19 to 3.46; incidence rate 1.43/1000 person-years) versus those with normal WHR.ConclusionsGeneral obesity is associated with increased risk of SCD in middle-aged, non-smoking individuals, mediated by traditional cardiovascular risk factors. Central obesity, however, is independently associated with SCD by pathways that remain to be elucidated. JF - Heart AU - Adabag, Selcuk AU - Huxley, Rachel R AU - Lopez, Faye L AU - Chen, Lin Y AU - Sotoodehnia, Nona AU - Siscovick, David AU - Deo, Rajat AU - Konety, Suma AU - Alonso, Alvaro AU - Folsom, Aaron R AD - Division of Cardiology, Veterans Administration Medical Center, , Minneapolis, Minnesota, USA Y1 - 2015/02/01/ PY - 2015 DA - 2015 Feb 01 SP - 215 EP - 221 PB - British Medical Association, BMA House Square London WC1H 9JP United Kingdom VL - 101 IS - 3 SN - 1355-6037, 1355-6037 KW - Physical Education Index; Biotechnology and Bioengineering Abstracts KW - Age KW - Death KW - Blacks KW - Lipids KW - Body mass KW - Women KW - Arteriosclerosis KW - Models KW - Smoking KW - Risk factors KW - Races KW - Sex KW - Heart diseases KW - Heart KW - Obesity KW - Men KW - Blood diseases KW - Coronary heart disease KW - Diabetes mellitus KW - Hypertrophy KW - Waist KW - Cardiovascular diseases KW - Body mass index KW - Hip KW - Hypertension KW - W 30965:Miscellaneous, Reviews KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1808699310?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+Journal+of+Orthopsychiatry&rft.atitle=Effects+of+Social+Support+and+Conflict+on+Parenting+Among+Homeless+Mothers&rft.au=Marra%2C+Jaime+V%3BMcCarthy%2C+Elissa%3BLin%2C+Hsiu-Ju%3BFord%2C+Julian%3BRodis%2C+Eleni%3BFrisman%2C+Linda+K&rft.aulast=Marra&rft.aufirst=Jaime&rft.date=2009-07-01&rft.volume=79&rft.issue=3&rft.spage=348&rft.isbn=&rft.btitle=&rft.title=American+Journal+of+Orthopsychiatry&rft.issn=00029432&rft_id=info:doi/10.1037%2Fa0017241 LA - English DB - Physical Education Index; ProQuest Environmental Science Collection N1 - Date revised - 2016-07-01 N1 - Last updated - 2016-09-01 N1 - SubjectsTermNotLitGenreText - Obesity; Death; Waist; Men; Blacks; Body mass; Women; Blood diseases; Heart diseases; Heart; Age; Lipids; Arteriosclerosis; Coronary heart disease; Models; Diabetes mellitus; Smoking; Hypertrophy; Risk factors; Cardiovascular diseases; Body mass index; Races; Hypertension; Hip; Sex DO - http://dx.doi.org/10.1136/heartjnl-2014-306238 ER - TY - JOUR T1 - Typologies of positive psychotic symptoms in methamphetamine dependence AN - 1683503519 AB - Background and Objectives Understanding methamphetamine associated psychotic (MAP) symptom typologies could aid in identifying individuals at risk of progressing to schizophrenia and guide early intervention. Methods Latent class analysis (LCA) of psychotic symptoms collected from 40 ( n=40) methamphetamine dependent individuals with a history of psychotic symptoms but no history of a primary psychotic disorder. Results Three typologies were identified. In one, persecutory delusions dominated (Type 1), in another persecutory delusions were accompanied by hallucinations (Type 2), and in the third a high frequency of all the assessed hallucinatory and delusional symptoms was observed (Type 3). Discussion and Conclusion MAP is a heterogeneous syndrome with positive symptom typologies. Scientific Significance This study represents the first attempt at identifying typologies of MAP and highlights the potential utility of LCA in future large-scale studies. (Am J Addict 2015;24:94–97) JF - The American Journal on Addictions AU - Bousman, Chad A AU - McKetin, Rebecca AU - Burns, Richard AU - Woods, Steven Paul AU - Morgan, Erin E AU - Atkinson, J Hampton AU - Everall, Ian P AU - Grant, Igor AD - Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia., Department of General Practice, University of Melbourne, Parkville, VIC, Australia., Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorne, VIC, Australia., Florey Institute for Neuroscience and Mental Health, Parkville, VIC, Australia. ; Centre for Research on Ageing, Health and Wellbeing, Australia National University, Canberra, ACT, Australia. ; Department of Psychiatry, University of California, San Diego, San Diego, California. ; Department of Psychiatry, University of California, San Diego, San Diego, California., Veterans Administration San Diego Healthcare System, San Diego, California. ; Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia., Florey Institute for Neuroscience and Mental Health, Parkville, VIC, Australia., NorthWestern Mental Health, Melbourne, VIC, Australia. ; Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia.; Department of General Practice, University of Melbourne, Parkville, VIC, Australia.; Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorne, VIC, Australia.; Florey Institute for Neuroscience and Mental Health, Parkville, VIC, Australia. Y1 - 2015/02// PY - 2015 DA - Feb 2015 SP - 94 EP - 97 CY - Hoboken PB - Wiley Subscription Services, Inc. VL - 24 IS - 2 SN - 1055-0496 KW - Medical Sciences--Psychiatry And Neurology KW - At risk KW - Addicts KW - Delusions KW - Early intervention programmes KW - Hallucinations KW - Latent class analysis KW - Methamphetamine KW - Persecutory ideation KW - Psychoses KW - Psychotic symptoms KW - Schizophrenia UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1683503519?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+American+Journal+on+Addictions&rft.atitle=Typologies+of+positive+psychotic+symptoms+in+methamphetamine+dependence&rft.au=Bousman%2C+Chad+A%3BMcKetin%2C+Rebecca%3BBurns%2C+Richard%3BWoods%2C+Steven+Paul%3BMorgan%2C+Erin+E%3BAtkinson%2C+J+Hampton%3BEverall%2C+Ian+P%3BGrant%2C+Igor&rft.aulast=Bousman&rft.aufirst=Chad&rft.date=2015-02-01&rft.volume=24&rft.issue=2&rft.spage=94&rft.isbn=&rft.btitle=&rft.title=The+American+Journal+on+Addictions&rft.issn=10550496&rft_id=info:doi/10.1111%2Fajad.12160 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-04-15 N1 - Last updated - 2016-05-13 DO - http://dx.doi.org/10.1111/ajad.12160 ER - TY - JOUR T1 - Mental Health System Historians: Adults with Schizophrenia Describe Changes in Community Mental Health Care Over Time AN - 1673612714 AB - This qualitative study examined changes in community mental health care as described by adults diagnosed with schizophrenia with long-term involvement in the mental health system to situate their experiences within the context of mental health reform movements in the United States. A sample of 14 adults with schizophrenia who had been consumers of mental health services from 12 to 40 years completed interviews about their hospital and outpatient experiences over time and factors that contributed most to their mental health. Overall, adults noted gradual changes in mental health care over time that included higher quality of care, more humane treatment, increased partnership with providers, shorter hospital stays, and better conditions in inpatient settings. Regardless of the mental health reform era in which they were hospitalized, participants described negative hospitalization experiences resulting in considerable personal distress, powerlessness, and trauma. Adults with less than 27 years involvement in the system reported relationships with friends and family as most important to their mental health, while adults with more than 27 years involvement reported mental health services and relationships with professionals as the most important factors in their mental health. The sample did not differ in self-reported use of services during their initial and most recent hospitalization experiences, but differences were found in participants’ reported use of outpatient services over time. Findings underscore the importance of the lived experience of adults with schizophrenia in grounding current discourse on mental health care reform. JF - Psychiatric Quarterly AU - Stein, Catherine H AU - Leith, Jaclyn E AU - Osborn, Lawrence A AU - Greenberg, Sarah AU - Petrowski, Catherine E AU - Jesse, Samantha AU - Kraus, Shane W AU - May, Michael C AD - Department of Psychology, Bowling Green State University, Bowling Green, Ohio, 43403, USA cstein@bgsu.edu cstein@bgsu.edu cstein@bgsu.edu cstein@bgsu.edu cstein@bgsu.edu; Durham North Carolina Veterans Administration Medical Center, Durham, NC, 27705, USA ; New England Mental Illness Research Education and Clinical Centers, VA Connecticut Healthcare System, and Yale School of Medicine, New Haven, CT, 06516, USA ; Metropolitan Family Services, Chicago, IL, 60602, USA ; Department of Psychology, Bowling Green State University, Bowling Green, Ohio, 43403, USA Y1 - 2015/02// PY - 2015 DA - Feb 2015 SP - 33 EP - 48 CY - New York PB - Springer Science & Business Media VL - 86 IS - 1 SN - 0033-2720 KW - Medical Sciences--Psychiatry And Neurology KW - Community mental health services KW - Adults KW - Change agents KW - Service provision KW - Consumers KW - Discourse KW - Friends KW - Health care KW - Health services KW - Historians KW - Hospitalization KW - Hospitalized KW - Mental health care KW - Mental health services KW - Powerlessness KW - Psychological distress KW - Quality of care KW - Schizophrenia KW - United States--US UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1673612714?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychiatric+Quarterly&rft.atitle=Mental+Health+System+Historians%3A+Adults+with+Schizophrenia+Describe+Changes+in+Community+Mental+Health+Care+Over+Time&rft.au=Stein%2C+Catherine+H%3BLeith%2C+Jaclyn+E%3BOsborn%2C+Lawrence+A%3BGreenberg%2C+Sarah%3BPetrowski%2C+Catherine+E%3BJesse%2C+Samantha%3BKraus%2C+Shane+W%3BMay%2C+Michael+C&rft.aulast=Stein&rft.aufirst=Catherine&rft.date=2015-02-01&rft.volume=86&rft.issue=1&rft.spage=33&rft.isbn=&rft.btitle=&rft.title=Psychiatric+Quarterly&rft.issn=00332720&rft_id=info:doi/10.1007%2Fs11126-014-9325-3 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-03-24 N1 - Last updated - 2016-05-13 N1 - SubjectsTermNotLitGenreText - United States--US DO - http://dx.doi.org/10.1007/s11126-014-9325-3 ER - TY - JOUR T1 - Implementation of a Novel Occupational and Environmental Medicine Specialty Teleconsultation Service: The VHA Experience AN - 1668270281; PQ0001261238 AB - Objective: Occupational and environmental medicine (OEM) physician specialty practices continue to grow in scope and intensity across the Veterans Health Administration. This study characterizes the implementation of a novel, nationwide telemedicine program that provides OEM specialty consultation to providers across the Veterans Health Administration. Methods: We examined provider requests and specialist responses for a 6-month pilot from May to October 2013. Characteristics of consult users, determinants of case complexity, and specific applications of OEM specialty expertise were identified. Results: Over a 6-month period, employee occupational health providers consulted the OEM telemedicine pilot a total of 65 times. Employee occupational health providers without formal training repeatedly identified complex cases related to work and disability. Conclusions: The program has created a new system management solution to deliver expert, in-depth consultation and real-time provider education in OEM. JF - Journal of Occupational and Environmental Medicine AU - Eaton, Jennifer L AU - Mohr, David C AU - Mohammad, Amir AU - Kirkhorn, Steven AU - Gerstel-Santucci, Christina AU - McPhaul, Kathleen AU - Hodgson, Michael J AD - Occupational Health Group, Office of Public Health, Veterans Health Administration; War Related illness and Injury Study Center, Washington DC VA Medical Center; Occupational Health Group, VHA, 1717 H St NW Rm 504, Washington, DC 20006, Jennifer.Lipkowitz-Eaton@va.gov PY - 2015 SP - 173 EP - 177 PB - Williams & Wilkins, 351 W. Camden St. Baltimore MD 21201 United States VL - 57 IS - 2 SN - 1076-2752, 1076-2752 KW - Health & Safety Science Abstracts KW - Education KW - Training KW - Disabilities KW - Occupational health KW - H 1000:Occupational Safety and Health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1668270281?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ahealthsafetyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Occupational+and+Environmental+Medicine&rft.atitle=Implementation+of+a+Novel+Occupational+and+Environmental+Medicine+Specialty+Teleconsultation+Service%3A+The+VHA+Experience&rft.au=Eaton%2C+Jennifer+L%3BMohr%2C+David+C%3BMohammad%2C+Amir%3BKirkhorn%2C+Steven%3BGerstel-Santucci%2C+Christina%3BMcPhaul%2C+Kathleen%3BHodgson%2C+Michael+J&rft.aulast=Eaton&rft.aufirst=Jennifer&rft.date=2015-02-01&rft.volume=57&rft.issue=2&rft.spage=173&rft.isbn=&rft.btitle=&rft.title=Journal+of+Occupational+and+Environmental+Medicine&rft.issn=10762752&rft_id=info:doi/10.1097%2FJOM.0000000000000330 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-03-01 N1 - Last updated - 2015-12-23 N1 - SubjectsTermNotLitGenreText - Education; Training; Disabilities; Occupational health DO - http://dx.doi.org/10.1097/JOM.0000000000000330 ER - TY - JOUR T1 - Health Care Employee Perceptions of Patient-Centered Care AN - 1665159658 AB - Given the importance of health care employees in the delivery of patient-centered care, understanding their unique perspectives is essential for quality improvement. The purpose of this study was to use photovoice to evaluate perceptions and experiences around patient-centered care among U.S. Veterans Affairs (VA) health care employees. We asked participants to take photographs of salient features in their environment related to patient-centered care. We used the photographs to facilitate dialogue during follow-up interviews. Twelve VA health care employees across two VA sites participated in the project. Although most participants felt satisfied with their work environment and experiences at the VA, they identified several areas for improvement. These included a need for more employee health and wellness initiatives and a need for enhanced opportunities for training and professional growth. Application of photovoice enabled us to learn about employees’ unique perspectives around patient-centered care while engaging them in an evaluation of care delivery. JF - Qualitative Health Research AU - Balbale, Salva Najib AU - Turcios, Stephanie AU - LaVela, Sherri L AD - United States Department of Veterans Affairs, Hines, Illinois, USA ; United States Department of Veterans Affairs, Hines, Illinois, USA Y1 - 2015/02// PY - 2015 DA - Feb 2015 SP - 417 EP - 425 CY - Thousand Oaks PB - SAGE PUBLICATIONS, INC. VL - 25 IS - 3 SN - 1049-7323 KW - Medical Sciences KW - health care KW - health care professionals KW - photography / photovoice KW - quality improvement KW - research, qualitative KW - Care delivery KW - Health care KW - Health initiatives KW - Health professionals KW - Medical research KW - Patient care KW - Patient centredness KW - Perceptions KW - Photographs KW - Photography KW - Quality management KW - Service delivery KW - Veterans KW - Work environment KW - United States--US UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665159658?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Qualitative+Health+Research&rft.atitle=Health+Care+Employee+Perceptions+of+Patient-Centered+Care&rft.au=Balbale%2C+Salva+Najib%3BTurcios%2C+Stephanie%3BLaVela%2C+Sherri+L&rft.aulast=Balbale&rft.aufirst=Salva&rft.date=2015-02-01&rft.volume=25&rft.issue=3&rft.spage=417&rft.isbn=&rft.btitle=&rft.title=Qualitative+Health+Research&rft.issn=10497323&rft_id=info:doi/10.1177%2F1049732314553011 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-02-05 N1 - Last updated - 2016-05-12 N1 - SubjectsTermNotLitGenreText - United States--US DO - http://dx.doi.org/10.1177/1049732314553011 ER - TY - JOUR T1 - The Dynamics of Psychiatric Bed Use in General Hospitals AN - 1665153216 AB - This study examines general hospitals’ adjustments in psychiatric bed utilization practices in response to increases in psychiatric inpatient admissions. Using panel data from 439 hospitals, monthly observations ( N = 7,831) between 2007 and 2010 on psychiatric admissions, psychiatric bed occupancy rates, and average length-of-stay were created for psychiatric inpatients. In fixed-effects regressions, an increase in psychiatric admissions was associated with an increase in the probability of psychiatric bed use exceeding 100 % occupancy and with a reduction of mean length-of-stay. These results were confirmed in instrumental variables models. General hospitals may dynamically adjust bed utilization practices in response to changing psychiatric bed needs. An implication of this dynamic adjustment model is that bed shortages are likely to be local, transitory events. JF - Administration and Policy in Mental Health and Mental Health Services Research AU - Slade, Eric P AU - Goldman, Howard H AD - U.S. Department of Veterans Affairs, VA Capitol Healthcare Network Mental Illness Research, Education, and Clinical Center, 10 N. Greene Street, Baltimore, MD, 21201, USA, Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, Baltimore, MD, 21227, USA ; Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, Baltimore, MD, 21227, USA ; U.S. Department of Veterans Affairs, VA Capitol Healthcare Network Mental Illness Research, Education, and Clinical Center, 10 N. Greene Street, Baltimore, MD, 21201, USA; Department of Psychiatry, University of Maryland School of Medicine, 737 W. Lombard Street, Baltimore, MD, 21227, USA Y1 - 2015/02// PY - 2015 DA - Feb 2015 SP - 139 EP - 146 CY - New York PB - Springer Science & Business Media VL - 42 IS - 2 SN - 0894-587X KW - Public Health And Safety KW - Admissions KW - Adjustment KW - Hospitalization KW - Hospitals KW - Length of stay KW - Mentally ill people KW - Occupancy KW - Panel data KW - Psychiatric hospitals KW - Shortages UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665153216?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Administration+and+policy+in+mental+health&rft.atitle=Access+to+primary+care+for+homeless+veterans+with+serious+mental+illness+or+substance+abuse%3A+a+follow-up+evaluation+of+co-located+primary+care+and+homeless+social+services.&rft.au=McGuire%2C+James%3BGelberg%2C+Lillian%3BBlue-Howells%2C+Jessica%3BRosenheck%2C+Robert+A&rft.aulast=McGuire&rft.aufirst=James&rft.date=2009-07-01&rft.volume=36&rft.issue=4&rft.spage=255&rft.isbn=&rft.btitle=&rft.title=Administration+and+policy+in+mental+health&rft.issn=1573-3289&rft_id=info:doi/10.1007%2Fs10488-009-0210-6 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-03-05 N1 - Last updated - 2016-05-13 DO - http://dx.doi.org/10.1007/s10488-014-0554-4 ER - TY - JOUR T1 - Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa AN - 1660435225; PQ0001092211 AB - Pseudomonas aeruginosa is a notoriously difficult-to-treat pathogen that is a common cause of severe nosocomial infections. Investigating a collection of beta -lactam-resistant P. aeruginosa clinical isolates from a decade ago, we uncovered resistance to ceftazidime-avibactam, a novel beta -lactam/ beta -lactamase inhibitor combination. The isolates were systematically analyzed through a variety of genetic, biochemical, genomic, and microbiological methods to understand how resistance manifests to a unique drug combination that is not yet clinically released. We discovered that avibactam was able to inactivate different AmpC beta -lactamase enzymes and that blaPDC regulatory elements and penicillin-binding protein differences did not contribute in a major way to resistance. By using carefully selected combinations of antimicrobial agents, we deduced that the greatest barrier to ceftazidime-avibactam is membrane permeability and drug efflux. To overcome the constellation of resistance determinants, we show that a combination of antimicrobial agents (ceftazidime/avibactam/fosfomycin) targeting multiple cell wall synthetic pathways can restore susceptibility. In P. aeruginosa, efflux, as a general mechanism of resistance, may pose the greatest challenge to future antibiotic development. Our unexpected findings create concern that even the development of antimicrobial agents targeted for the treatment of multidrug-resistant bacteria may encounter clinically important resistance. Antibiotic therapy in the future must consider these factors. JF - Antimicrobial Agents & Chemotherapy AU - Winkler, Marisa L AU - Papp-Wallace, Krisztina M AU - Hujer, Andrea M AU - Domitrovic, T Nicholas AU - Hujer, Kristine M AU - Hurless, Kelly N AU - Tuohy, Marion AU - Hall, Geraldine AU - Bonomo, Robert A AD - Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA, robert.bonomo@va.gov. Y1 - 2015/02// PY - 2015 DA - Feb 2015 SP - 1020 EP - 1029 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 59 IS - 2 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Clinical isolates KW - fosfomycin KW - Bacteria KW - beta -Lactamase KW - Regulatory sequences KW - Drug resistance KW - Enzymes KW - Membrane permeability KW - penicillin-binding protein KW - Antibiotics KW - Pathogens KW - Antimicrobial agents KW - Ceftazidime KW - Gram-negative bacteria KW - beta -Lactam antibiotics KW - Nosocomial infection KW - genomics KW - Pseudomonas aeruginosa KW - Cell walls KW - J 02310:Genetics & Taxonomy KW - A 01340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1660435225?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Unexpected+Challenges+in+Treating+Multidrug-Resistant+Gram-Negative+Bacteria%3A+Resistance+to+Ceftazidime-Avibactam+in+Archived+Isolates+of+Pseudomonas+aeruginosa&rft.au=Winkler%2C+Marisa+L%3BPapp-Wallace%2C+Krisztina+M%3BHujer%2C+Andrea+M%3BDomitrovic%2C+T+Nicholas%3BHujer%2C+Kristine+M%3BHurless%2C+Kelly+N%3BTuohy%2C+Marion%3BHall%2C+Geraldine%3BBonomo%2C+Robert+A&rft.aulast=Winkler&rft.aufirst=Marisa&rft.date=2015-02-01&rft.volume=59&rft.issue=2&rft.spage=1020&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.04238-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-03-01 N1 - Number of references - 67 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - fosfomycin; Clinical isolates; beta -Lactamase; Drug resistance; Regulatory sequences; Membrane permeability; Enzymes; Antibiotics; penicillin-binding protein; Pathogens; Antimicrobial agents; Ceftazidime; Gram-negative bacteria; Nosocomial infection; beta -Lactam antibiotics; genomics; Cell walls; Bacteria; Pseudomonas aeruginosa DO - http://dx.doi.org/10.1128/AAC.04238-14 ER - TY - JOUR T1 - Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. AN - 1652410542; 25339356 AB - The precise mechanism for reduced thrombosis in prekallikrein null mice (Klkb1(-/-)) is unknown. Klkb1(-/-) mice have delayed carotid artery occlusion times on the rose bengal and ferric chloride thrombosis models. Klkb1(-/-) plasmas have long-activated partial thromboplastin times and defective contact activation-induced thrombin generation that partially corrects upon prolonged incubation. However, in contact activation-induced pulmonary thromboembolism by collagen/epinephrine or long-chain polyphosphate, Klkb1(-/-) mice, unlike F12(-/-) mice, do not have survival advantage. Klkb1(-/-) mice have reduced plasma BK levels and renal B2R mRNA. They also have increased expression of the renal receptor Mas and plasma prostacyclin. Increased prostacyclin is associated with elevated aortic vasculoprotective transcription factors Sirt1 and KLF4. Treatment of Klkb1(-/-) mice with the Mas antagonist A-779, COX-2 inhibitor nimesulide, or Sirt1 inhibitor splitomicin lowers plasma prostacyclin and normalizes arterial thrombosis times. Treatment of normal mice with the Mas agonist AVE0991 reduces thrombosis. Klkb1(-/-) mice have reduced aortic tissue factor (TF) mRNA, antigen, and activity. In sum, Klkb1(-/-) mice have a novel mechanism for thrombosis protection in addition to reduced contact activation. This pathway arises when bradykinin delivery to vasculature is compromised and mediated by increased receptor Mas, prostacyclin, Sirt1, and KLF4, leading to reduced vascular TF. © 2015 by The American Society of Hematology. JF - Blood AU - Stavrou, Evi X AU - Fang, Chao AU - Merkulova, Alona AU - Alhalabi, Omar AU - Grobe, Nadja AU - Antoniak, Silvio AU - Mackman, Nigel AU - Schmaier, Alvin H AD - Divisions of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH; Department of Medicine, Louis Stokes Veterans Administration Hospital, Cleveland, OH; ; Divisions of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH; Department of Pathology, Case Western Reserve University, Cleveland, OH; ; Divisions of Hematology and Oncology, Department of Medicine, Case Western Reserve University, Cleveland, OH; ; Department of Pharmacology and Toxicology, Wright State University Boonshoft School of Medicine, Dayton OH; and. ; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Y1 - 2015/01/22/ PY - 2015 DA - 2015 Jan 22 SP - 710 EP - 719 VL - 125 IS - 4 KW - 7-Ala-angiotensin (1-7) KW - 0 KW - AVE 0991 KW - GKLF protein KW - Imidazoles KW - Kruppel-Like Transcription Factors KW - Naphthalenes KW - Nerve Tissue Proteins KW - Peptide Fragments KW - Proto-Oncogene Proteins KW - Pyrones KW - RNA, Messenger KW - Receptor, Bradykinin B2 KW - Receptors, G-Protein-Coupled KW - Sulfonamides KW - Syt17 protein, mouse KW - proto-oncogene proteins c-mas-1 KW - Angiotensin II KW - 11128-99-7 KW - Synaptotagmins KW - 134193-27-4 KW - splitomicin KW - 4707-36-2 KW - Thromboplastin KW - 9035-58-9 KW - Prekallikrein KW - 9055-02-1 KW - Epoprostenol KW - DCR9Z582X0 KW - Sirt1 protein, mouse KW - EC 3.5.1.- KW - Sirtuin 1 KW - nimesulide KW - V4TKW1454M KW - Abridged Index Medicus KW - Index Medicus KW - Synaptotagmins -- genetics KW - Naphthalenes -- pharmacology KW - Angiotensin II -- analogs & derivatives KW - Animals KW - Sirtuin 1 -- biosynthesis KW - Imidazoles -- pharmacology KW - Synaptotagmins -- biosynthesis KW - Mice KW - Nerve Tissue Proteins -- biosynthesis KW - Nerve Tissue Proteins -- genetics KW - Receptor, Bradykinin B2 -- biosynthesis KW - Angiotensin II -- pharmacology KW - Mice, Knockout KW - Partial Thromboplastin Time KW - Pyrones -- pharmacology KW - Sulfonamides -- pharmacology KW - Sirtuin 1 -- genetics KW - Receptor, Bradykinin B2 -- genetics KW - Peptide Fragments -- pharmacology KW - Sirtuin 1 -- antagonists & inhibitors KW - Kruppel-Like Transcription Factors -- antagonists & inhibitors KW - Thromboplastin -- antagonists & inhibitors KW - Proto-Oncogene Proteins -- metabolism KW - Carotid Artery Thrombosis -- genetics KW - Thromboplastin -- biosynthesis KW - Receptors, G-Protein-Coupled -- antagonists & inhibitors KW - Proto-Oncogene Proteins -- antagonists & inhibitors KW - Carotid Artery Thrombosis -- metabolism KW - Kruppel-Like Transcription Factors -- biosynthesis KW - Receptors, G-Protein-Coupled -- metabolism KW - Receptors, G-Protein-Coupled -- genetics KW - Carotid Artery Thrombosis -- chemically induced KW - Thromboplastin -- genetics KW - Carotid Artery Thrombosis -- pathology KW - Proto-Oncogene Proteins -- genetics KW - Epoprostenol -- biosynthesis KW - Epoprostenol -- genetics KW - Kruppel-Like Transcription Factors -- genetics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1652410542?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Blood&rft.atitle=Reduced+thrombosis+in+Klkb1-%2F-+mice+is+mediated+by+increased+Mas+receptor%2C+prostacyclin%2C+Sirt1%2C+and+KLF4+and+decreased+tissue+factor.&rft.au=Stavrou%2C+Evi+X%3BFang%2C+Chao%3BMerkulova%2C+Alona%3BAlhalabi%2C+Omar%3BGrobe%2C+Nadja%3BAntoniak%2C+Silvio%3BMackman%2C+Nigel%3BSchmaier%2C+Alvin+H&rft.aulast=Stavrou&rft.aufirst=Evi&rft.date=2015-01-22&rft.volume=125&rft.issue=4&rft.spage=710&rft.isbn=&rft.btitle=&rft.title=Blood&rft.issn=1528-0020&rft_id=info:doi/10.1182%2Fblood-2014-01-550285 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-03-24 N1 - Date created - 2015-01-23 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Blood. 1974 May;43(5):641-4 [4821398] J Biol Chem. 2007 May 4;282(18):13769-79 [17339326] J Clin Invest. 1980 Feb;65(2):413-21 [7356688] Thromb Res. 1980 Jun 15;18(6):787-95 [6774443] J Lab Clin Med. 1983 Oct;102(4):487-99 [6604770] J Lab Clin Med. 1984 Dec;104(6):882-92 [6209352] Blood. 1985 Oct;66(4):835-9 [3929859] Nature. 1987 Jun 11-17;327(6122):524-6 [3495737] Mol Med. 2008 Jan-Feb;14(1-2):28-35 [18026570] J Exp Med. 2007 Sep 3;204(9):2053-61 [17724132] J Biol Chem. 1992 Jan 5;267(1):303-9 [1309739] Blood. 2008 Feb 1;111(3):1274-81 [18000168] Cell. 2009 Dec 11;139(6):1143-56 [20005807] Circulation. 2010 Apr 6;121(13):1510-7 [20308613] Mol Med. 2010 May-Jun;16(5-6):210-5 [20111697] Cardiovasc Res. 2011 Feb 1;89(2):464-72 [20978007] Nat Med. 2011 Feb;17(2):206-10 [21258336] Am J Respir Cell Mol Biol. 2011 May;44(5):725-38 [21531958] Blood. 2011 Nov 10;118(19):5302-11 [21821705] Thromb Haemost. 2012 Jun;107(6):1141-50 [22398951] Circulation. 2012 Sep 11;126(11):1373-84 [22865892] J Clin Invest. 2012 Dec;122(12):4727-31 [23160196] Thromb Haemost. 2013 Mar;109(3):368-74 [23306453] Blood. 2013 Apr 11;121(15):3023-32 [23386129] Am J Physiol Cell Physiol. 2013 May 15;304(10):C945-53 [23392115] Nucleic Acid Ther. 2013 Jun;23(3):175-87 [23582057] J Biol Chem. 2013 Jun 28;288(26):18872-84 [23661707] J Exp Med. 1978 Mar 1;147(3):719-29 [632748] Circulation. 2000 May 9;101(18):2144-8 [10801753] Arthritis Rheum. 2000 Aug;43(8):1891-6 [10943882] Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1821-9 [11247797] J Clin Invest. 2002 Apr;109(8):1057-63 [11956243] J Biol Chem. 2002 May 17;277(20):17962-9 [11830581] Hypertension. 2002 Nov;40(5):774-9 [12411476] Am J Physiol Regul Integr Comp Physiol. 2003 Jul;285(1):R1-13 [12793984] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190] Blood. 1993 Jun 1;81(11):2936-46 [8388750] Circulation. 1996 Aug 1;94(3):517-28 [8759097] J Clin Invest. 1969 Jan;48(1):11-22 [4974623] Science. 1964 Sep 18;145(3638):1310-2 [14173416] Blood. 2005 Jan 1;105(1):192-8 [15339841] J Exp Med. 2005 Jul 18;202(2):271-81 [16009717] Thromb Haemost. 2006 Jun;95(6):1003-10 [16732380] Blood. 2006 Jul 1;108(1):192-9 [16514058] Comment In: Blood. 2015 Jan 22;125(4):589-90 [25614637] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1182/blood-2014-01-550285 ER - TY - JOUR T1 - Effect modification by vitamin D receptor genetic polymorphisms in the association between cumulative lead exposure and pulse pressure: a longitudinal study. AN - 1697216633; 25582168 AB - Although the association between lead and cardiovascular disease is well established, potential mechanisms are still poorly understood. Calcium metabolism plays a role in lead toxicity and thus, vitamin D receptor (VDR) polymorphisms have been suggested to modulate the association between lead and health outcomes. We investigated effect modification by VDR genetic polymorphisms in the association between cumulative lead exposure and pulse pressure, a marker of arterial stiffness. We examined 727 participants (3,100 observations from follow-ups from 1991 to 2011) from the Normative Aging Study (NAS), a longitudinal study of aging. Tibia and patella bone lead levels were measured using K-x-ray fluorescence. Four single nucleotide polymorphisms (SNPs) in the VDR gene, Bsm1, Taq1, Apa1, and Fok1, were genotyped. Linear mixed effects models with random intercepts were implemented to take into account repeated measurements. Adjusting for potential confounders, pulse pressure was 2.5 mmHg (95% CI: 0.4-4.7) and 1.9 mmHg (95% CI: 0.1-3.8) greater per interquartile range (IQR) increase in tibia lead (15 μg/g) and patella lead (20 μg/g), respectively, in those with at least one minor frequency allele in Bsm1 compared with those with major frequency allele homozygotes. The observed interaction effect between bone lead and the Bsm1 genotype persists over time during the follow-up. Similar results were observed in effect modification by Taq1. This study suggests that subjects with the minor frequency alleles of VDR Bsm1 or Taq1 may be more susceptible to cumulative lead exposure-related elevated pulse pressure. JF - Environmental health : a global access science source AU - Jhun, Min A AU - Hu, Howard AU - Schwartz, Joel AU - Weisskopf, Marc G AU - Nie, Linda H AU - Sparrow, David AU - Vokonas, Pantel S AU - Park, Sung Kyun AD - Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. minajhun@umich.edu. ; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. howard.hu@utoronto.ca. ; Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA. jschwrtz@hsph.harvard.edu. ; Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA. mweissko@hsph.harvard.edu. ; School of Health Sciences, Purdue University, West Lafayette, IN, USA. hnie@purdue.edu. ; Veterans Affairs Boston Healthcare System and Boston University School of Medicine & Public Health, Boston, MA, USA. david.sparrow@va.gov. ; Veterans Affairs Boston Healthcare System and Boston University School of Medicine & Public Health, Boston, MA, USA. pantel.vokonas@va.gov. ; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. sungkyun@umich.edu. Y1 - 2015/01/13/ PY - 2015 DA - 2015 Jan 13 SP - 5 VL - 14 KW - Receptors, Calcitriol KW - 0 KW - Vitamin D KW - 1406-16-2 KW - Lead KW - 2P299V784P KW - Calcium KW - SY7Q814VUP KW - Index Medicus KW - Young Adult KW - Polymorphism, Single Nucleotide KW - Blood Pressure -- physiology KW - Humans KW - Environmental Exposure -- analysis KW - Aged KW - Boston KW - Longitudinal Studies KW - Tibia -- chemistry KW - Aging -- physiology KW - Patella -- chemistry KW - Aged, 80 and over KW - Adult KW - Middle Aged KW - Gene Expression Regulation KW - Female KW - Male KW - Calcium -- metabolism KW - Cardiovascular Diseases -- etiology KW - Receptors, Calcitriol -- genetics KW - Lead -- toxicity KW - Vitamin D -- metabolism KW - Vitamin D -- genetics KW - Receptors, Calcitriol -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1697216633?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Microbial+Drug+Resistance&rft.atitle=Marked+Increase+in+Biofilm-Derived+Rough+Pneumococcal+Variants+and+Rifampin-Resistant+Strains+Not+Due+to+hex+Gene+Mutations&rft.au=McEllistrem%2C+M+C%3BScott%2C+J+R%3BZuniga-Castillo%2C+J%3BKhan%2C+SA&rft.aulast=McEllistrem&rft.aufirst=M&rft.date=2009-06-01&rft.volume=15&rft.issue=2&rft.spage=85&rft.isbn=&rft.btitle=&rft.title=Microbial+Drug+Resistance&rft.issn=10766294&rft_id=info:doi/10.1089%2Fmdr.2009.0866 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-04-04 N1 - Date created - 2015-07-16 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Epidemiology. 2006 Sep;17(5):531-7 [16878040] Gene. 2006 Oct 1;380(2):63-71 [16872759] Environ Health Perspect. 2007 Dec;115(12):1696-700 [18087585] Arch Toxicol. 2008 Jan;82(1):29-36 [17701399] Med Clin (Barc). 2008 Mar 22;130(10):361-5 [18381026] Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H454-65 [18567711] J Gerontol A Biol Sci Med Sci. 2009 Feb;64(2):215-22 [19196902] Epidemiology. 2009 Nov;20(6):831-9 [19752734] J Pathol. 2010 Jan;220(2):152-63 [19918805] Environ Health Perspect. 2009 Oct;117(10):1526-30 [20019901] Neurotoxicol Teratol. 2010 Mar-Apr;32(2):262-72 [20006704] Environ Health Perspect. 2010 Sep;118(9):1261-6 [20478760] Nature. 2010 Sep 2;467(7311):52-8 [20811451] Environ Health Perspect. 2011 May;119(5):664-9 [21292600] J Occup Environ Med. 2011 Aug;53(8):850-5 [21788910] J Clin Endocrinol Metab. 2012 Oct;97(10):3717-23 [22767638] Epidemiology. 2013 Jan;24(1):10-3 [23232608] Cell Immunol. 2012 Oct;279(2):160-6 [23246677] Environ Health Perspect. 2000 Mar;108(3):199-203 [10706524] Mol Endocrinol. 2014 Jan;28(1):53-64 [24284821] Environ Health Perspect. 2000 Mar;108 Suppl 1:23-8 [10698721] Environ Health Perspect. 2000 Oct;108(10):949-54 [11049814] Am J Epidemiol. 2001 Jan 15;153(2):164-71 [11159162] Environ Health Perspect. 2001 Apr;109(4):383-9 [11335187] Hypertension. 2001 Oct;38(4):793-7 [11641288] Environ Health Perspect. 2004 May;112(6):746-50 [15121519] Br J Ind Med. 1975 May;32(2):119-39 [1131339] J Nutr. 1981 Aug;111(8):1321-9 [6267235] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6494-8 [6947240] J Nutr. 1984 Apr;114(4):692-700 [6325646] Neurotoxicology. 1984 Fall;5(3):295-331 [6151637] Toxicol Appl Pharmacol. 1989 May;98(3):530-43 [2718179] Proc Soc Exp Biol Med. 1990 Jul;194(3):258-64 [2162539] Arch Environ Contam Toxicol. 1995 Feb;28(2):168-72 [7710289] Phys Med Biol. 1995 Sep;40(9):1475-85 [8532760] Eur Heart J. 2005 Oct;26(20):2120-6 [16141262] Am J Epidemiol. 2006 Mar 1;163(5):467-78 [16421242] J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C7-12 [16631513] Environ Res. 2006 Sep;102(1):61-9 [16487505] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1186/1476-069X-14-5 ER - TY - JOUR T1 - Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder AN - 1837332245; PQ0001000216 AB - Introduction: This study identified distinct tobacco use trajectories across 18 months in 943 veteran smokers with posttraumatic stress disorder (PTSD) in order to describe quit and relapse patterns, examine associations between trajectory groups on baseline characteristics and cessation service utilization, and explore group differences in mental health outcomes. Methods: Veterans who participated in a multisite, randomized trial of integrated smoking cessation care were grouped using k-means clustering based on reported daily tobacco use between baseline and 18 months. Four trajectory clusters were identified: no reduction (62%), temporary reduction (11%), late sustained reduction (9%) and early sustained reduction (18%). Results: Median quit times in the early, late, temporary, and no reduction groups were 451,141.5,97, and 2 days, respectively. Compared to the early reduction group, the temporary reduction group exhibited higher baseline depression (p < 0.01) and anxiety (p < 0.01), but did not differ in treatment received, with both groups attending significantly more cessation visits (p < 0.001) and more likely to receive recommended pharmacotherapy (p < 0.001) than the no reduction group between baseline and 6 months. The early reduction group exhibited lower depression relative to the no reduction (p < 0.01) and temporary reduction (p < 0.01) groups across all assessments between baseline and 18 months. Differences were not observed between groups in depressive or PTSD symptom change over time between baseline and 18 months. Conclusions: Tobacco use trajectories among treated smokers with PTSD vary distinctly. Characteristics of identified subgroups may lead to targeted interventions among smokers with PTSD and potentially other psychiatric disorders. JF - Addictive Behaviors AU - Malte, Carol A AU - Dennis, Paul A AU - Saxon, Andrew J AU - McFall, Miles AU - Carmody, Timothy P AU - Unger, William AU - Beckham, Jean C AD - Veterans Affairs Puget Sound Health Care System, Seattle, WA United States; Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System, 1660 S. Columbian Way, S-116 ATC, Seattle, WA 98108, United States, Carol.Malte@va.gov Y1 - 2015///0, PY - 2015 DA - 0, 2015 SP - 238 EP - 246 PB - Elsevier B.V., P.O. Box 800 Kidlington Oxford OX5 1DX United Kingdom VL - 41 SN - 0306-4603, 0306-4603 KW - Toxicology Abstracts KW - Smoking cessation KW - Posttraumatic stress disorder KW - Veterans KW - Major depressive disorder KW - Relapse KW - Smoking KW - Mental disorders KW - Depression KW - Anxiety KW - Tobacco KW - Drug addiction KW - Post-traumatic stress disorder KW - X 24380:Social Poisons & Drug Abuse UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837332245?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Addictive+Behaviors&rft.atitle=Tobacco+use+trajectories+among+a+large+cohort+of+treated+smokers+with+posttraumatic+stress+disorder&rft.au=Malte%2C+Carol+A%3BDennis%2C+Paul+A%3BSaxon%2C+Andrew+J%3BMcFall%2C+Miles%3BCarmody%2C+Timothy+P%3BUnger%2C+William%3BBeckham%2C+Jean+C&rft.aulast=Malte&rft.aufirst=Carol&rft.date=2015-01-01&rft.volume=41&rft.issue=&rft.spage=238&rft.isbn=&rft.btitle=&rft.title=Addictive+Behaviors&rft.issn=03064603&rft_id=info:doi/10.1016%2Fj.addbeh.2014.10.034 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Smoking; Mental disorders; Depression; Anxiety; Tobacco; Drug addiction; Post-traumatic stress disorder DO - http://dx.doi.org/10.1016/j.addbeh.2014.10.034 ER - TY - JOUR T1 - Characteristics of substance use disorder treatment patients using medical cannabis for pain AN - 1837325652; PQ0001285144 AB - Background: This study was designed to assess the prevalence and correlates of self-reported medical cannabis use for pain in a substance use disorder (SUD) treatment program. Method: Participants (n = 433) aged 18 years and older were recruited from February 2012 to July 2014 at a large residential SUD treatment program. They completed a battery of questionnaires to assess demographics, usual pain level in the past three months (using the 11-point Numeric Rating Scale for pain), depression (using the Beck Depression Inventory), previous types of pain treatments, and lifetime and past-year use of substances (using the Addiction Severity Index). Using both adjusted and unadjusted logistic regression models, we compared those who reported medical cannabis use for pain with those who did not report it. Results: Overall, 15% of the sample (n = 63) reported using medical cannabis for pain in the past year. After adjusting for age, medical cannabis use for pain was significantly associated with past-year use of alcohol, cocaine, heroin, other opioids, and sedatives, but was not associated with usual pain level or depression. It was also associated with past year treatment of pain using prescription pain relievers without prescriptions. Conclusions: These results indicate that medical cannabis use for pain is relatively common and is associated with more extensive substance use among SUD patients. Future work is needed to develop and evaluate strategies to assess and treat individuals who report medical cannabis for pain in SUD treatment settings. JF - Addictive Behaviors AU - Ashrafioun, Lisham AU - Bohnert, Kipling M AU - Jannausch, Mary AU - Ilgen, Mark A AD - Bowling Green Srate University, Department of Psychology, 207 Psychology Building, Bowling Green, OH 43403, USA; VISN 2 Center of Excellence in Suicide Prevention, Canandaigua VA Medical Center, 400 Fort Hill Avenue, Canandaigua, NY 14424, USA, Lisham.ashrafion@va.gov Y1 - 2015///0, PY - 2015 DA - 0, 2015 SP - 185 EP - 188 PB - Elsevier B.V., P.O. Box 800 Kidlington Oxford OX5 1DX United Kingdom VL - 42 SN - 0306-4603, 0306-4603 KW - Toxicology Abstracts KW - Cannabis KW - Substance use disorders KW - Pain KW - Inventories KW - Age KW - Depression KW - Heroin KW - Models KW - Demography KW - Sedatives KW - Regression analysis KW - alcohols KW - Opioids KW - Addiction KW - Cocaine KW - X 24380:Social Poisons & Drug Abuse UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837325652?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Addictive+Behaviors&rft.atitle=Characteristics+of+substance+use+disorder+treatment+patients+using+medical+cannabis+for+pain&rft.au=Ashrafioun%2C+Lisham%3BBohnert%2C+Kipling+M%3BJannausch%2C+Mary%3BIlgen%2C+Mark+A&rft.aulast=Ashrafioun&rft.aufirst=Lisham&rft.date=2015-01-01&rft.volume=42&rft.issue=&rft.spage=185&rft.isbn=&rft.btitle=&rft.title=Addictive+Behaviors&rft.issn=03064603&rft_id=info:doi/10.1016%2Fj.addbeh.2014.11.024 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Inventories; Age; Depression; Heroin; Pain; Models; Demography; Sedatives; Cannabis; alcohols; Regression analysis; Opioids; Addiction; Cocaine DO - http://dx.doi.org/10.1016/j.addbeh.2014.11.024 ER - TY - JOUR T1 - Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer. AN - 1760902416; 26793618 AB - Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation, and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets IGF-1R. Pemetrexed (P) has higher activity in non-squamous lung cancer (NSQL). We initiated a randomized phase II trial to test the combination of P and Cisplatin (C) ± D in NSQL. Eligibility criteria were untreated NSQL stage IV, ECOG 0 or 1, measurable disease, adequate renal, hepatic and hematologic function, and no other intercurrent illness. P at 500 mg/m(2) and C at 75 mg/m(2) IV were given every 3 weeks. D was given at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle in the experimental group. The patients had a radiographic assessment after every two cycles and were treated for a maximum of six cycles if there was a response or stable disease. The primary objective of the study was to compare the clinical response rates of PC vs. PC + D. From 1/2009 to 2/2011, the study accrued 26 subjects: 16 male and 10 female, with a median age of 59; 14 were treated with PC and 12 were treated with PC + D. We observed two partial responses (PR), seven stable disease (SD), three progressive disease (PD), and two not evaluable (NE) in the PC arm. In comparison, for the PC + D arm, there were three PR, four SD, four PD, and one NE. The hematologic toxicity was similar in both groups. There was higher incidence of hyperglycemia in the experimental group; four cases with grade 3 and one case with grade 4. PC + D had a similar response rate compared to PC, with a higher rate of hyperglycemia. Identification of responders using predictive markers would be key to continuing the study of D in NSQL. NCT00799240, clinicaltrials.gov. JF - Frontiers in oncology AU - Huang, Chao H AU - Williamson, Stephen K AU - Neupane, Prakash AU - Taylor, Sarah A AU - Allen, Ace AU - Smart, Nora J AU - Uypeckcuat, Adelina M AU - Spencer, Sarah AU - Wick, Jo AU - Smith, Holly AU - Van Veldhuizen, Peter J AU - Kelly, Karen AD - Kansas City Veterans Administration Medical Center, Kansas City, MO, USA; University of Kansas Cancer Center, Westwood, KS, USA. ; University of Kansas Cancer Center , Westwood, KS , USA. ; Kansas City Veterans Administration Medical Center , Kansas City, MO , USA. ; Department of Biostatistics, University of Kansas , Kansas City, KS , USA. ; University of California Davis Comprehensive Cancer Center , Sacramento, CA , USA. Y1 - 2015 PY - 2015 DA - 2015 SP - 301 VL - 5 KW - non-squamous cell lung cancer KW - treatment KW - metastatic KW - IGF-1R KW - pemetrexed KW - dalotuzumab UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1760902416?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Frontiers+in+oncology&rft.atitle=Impact+Study%3A+MK-0646+%28Dalotuzumab%29%2C+Insulin+Growth+Factor+1+Receptor+Antibody+Combined+with+Pemetrexed+and+Cisplatin+in+Stage+IV+Metastatic+Non-squamous+Lung+Cancer.&rft.au=Huang%2C+Chao+H%3BWilliamson%2C+Stephen+K%3BNeupane%2C+Prakash%3BTaylor%2C+Sarah+A%3BAllen%2C+Ace%3BSmart%2C+Nora+J%3BUypeckcuat%2C+Adelina+M%3BSpencer%2C+Sarah%3BWick%2C+Jo%3BSmith%2C+Holly%3BVan+Veldhuizen%2C+Peter+J%3BKelly%2C+Karen&rft.aulast=Huang&rft.aufirst=Chao&rft.date=2015-01-01&rft.volume=5&rft.issue=&rft.spage=301&rft.isbn=&rft.btitle=&rft.title=Frontiers+in+oncology&rft.issn=&rft_id=info:doi/10.3389%2Ffonc.2015.00301 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2016-01-21 N1 - Date created - 2016-01-21 N1 - Date revised - 2017-02-06 N1 - Genetic sequence - NCT00799240; ClinicalTrials.gov N1 - Last updated - 2017-02-07 DO - http://dx.doi.org/10.3389/fonc.2015.00301 ER - TY - JOUR T1 - Caregivers of Veterans with 'Invisible' Injuries: What We Know and Implications for Social Work Practice AN - 1735650788; 201507000 AB - Today, as a result of the longest volunteer-fought conflict in U.S. history, there are many wounded coming home not only with posttraumatic stress disorder (PTSD), but also with traumatic brain injury (TBI), which together have been called the 'signature' or 'invisible' injuries of the Iraq and Afghanistan wars. Caregivers are an important part of their recovery, yet little is known about them, as previous research on caregivers mostly focused on geriatric populations. According to one estimate 275,000 to 1 million people are currently caring or have cared for loved ones who have returned from Iraq and Afghanistan. These caregivers are unique in that they are younger, some with children, and they are caring for a unique understudied population for longer periods of time. This article summarizes literature on caregivers of veterans who suffer from PTSD, TBI, or both; provides a theoretical framework; and discusses implications for social workers in assisting caregivers and their families. Adapted from the source document. JF - Social Work AU - Patel, Bina R AD - Caregiver Support Coordinator, Social Work, U.S. Department of Veterans Affairs, 1601 SW Archer Road, Mail Code 116A-4, Gainesville, FL beepat617@hotmail.com Y1 - 2015/01// PY - 2015 DA - January 2015 SP - 9 EP - 17 PB - Oxford University Press, Oxford Journals VL - 60 IS - 1 SN - 0037-8046, 0037-8046 KW - caregivers, Iraq/Afghanistan caregivers, military caregivers, Operation Iraqi Freedom and Operation Enduring Freedom caregivers, veteran caregivers KW - Veterans KW - Caregivers KW - War KW - Geriatrics KW - Brain KW - Afghanistan KW - Conflict KW - Posttraumatic Stress Disorder KW - Iraq KW - article KW - 6142: mental & emotional health problems KW - 6140: illness & health care UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1735650788?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Social+Work&rft.atitle=Caregivers+of+Veterans+with+%27Invisible%27+Injuries%3A+What+We+Know+and+Implications+for+Social+Work+Practice&rft.au=Patel%2C+Bina+R&rft.aulast=Patel&rft.aufirst=Bina&rft.date=2015-01-01&rft.volume=60&rft.issue=1&rft.spage=9&rft.isbn=&rft.btitle=&rft.title=Social+Work&rft.issn=00378046&rft_id=info:doi/10.1093%2Fsw%2Fswu043 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-12-01 N1 - Last updated - 2016-09-28 N1 - CODEN - SOWOA8 N1 - SubjectsTermNotLitGenreText - Caregivers; Posttraumatic Stress Disorder; Iraq; Veterans; Afghanistan; Conflict; War; Brain; Geriatrics DO - http://dx.doi.org/10.1093/sw/swu043 ER - TY - JOUR T1 - Diagnosis of toxic alcohols: limitations of present methods. AN - 1700334033; 26114345 AB - Methanol, ethylene glycol, diethylene glycol, and propylene glycol intoxications are associated with cellular dysfunction and an increased risk of death. Adverse effects can develop quickly; thus, there is a need for methods for rapidly detecting their presence. To examine the value and limitations of present methods to diagnose patients with possible toxic alcohol exposure. I searched MEDLINE for articles published between 1969 and 2014 using the terms: toxic alcohols, serum osmolality, serum osmol gap, serum anion gap, metabolic acidosis, methanol, ethylene glycol, diethylene glycol, propylene glycol, and fomepizole. Each article was reviewed for additional references. The diagnosis of toxic alcohol exposure is often made on the basis of this history and physical findings along with an increase in the serum osmol and anion gaps. However, an increase in the osmol and/or anion gaps is not always present. Definitive detection in blood requires gas or liquid chromatography, laborious and expensive procedures which are not always available. Newer methods including a qualitative colorimetric test for detection of all alcohols or enzymatic tests for a specific alcohol might allow for more rapid diagnosis. Exposure to toxic alcohols is associated with cellular dysfunction and increased risk of death. Treatment, if initiated early, can markedly improve outcome, but present methods of diagnosis including changes in serum osmol and anion gap, and use of gas or liquid chromatography have important limitations. Development of more rapid and effective tests for detection of these intoxications is essential for optimal care of patients. JF - Clinical toxicology (Philadelphia, Pa.) AU - Kraut, Jeffrey A AD - Medical and Research Services Veterans Administration Greater Los Angeles Healthcare System, UCLA Membrane Biology Laboratory, and Division of Nephrology, Veterans Administration Greater Los Angeles Healthcare System, and David Geffen School of Medicine , Los Angeles , California. Y1 - 2015 PY - 2015 DA - 2015 SP - 589 EP - 595 VL - 53 IS - 7 KW - Alcohols KW - 0 KW - Ethylene Glycols KW - Pyrazoles KW - diethylene glycol KW - 61BR964293 KW - Propylene Glycol KW - 6DC9Q167V3 KW - fomepizole KW - 83LCM6L2BY KW - Ethylene Glycol KW - FC72KVT52F KW - Methanol KW - Y4S76JWI15 KW - Abridged Index Medicus KW - Index Medicus KW - Propylene glycol KW - Serum osmolal gap KW - Fomepizole KW - Serum anion gap KW - Ethylene glycol KW - Toxic alcohols KW - Osmolar Concentration KW - Acid-Base Equilibrium KW - Humans KW - Acidosis -- blood KW - Pyrazoles -- blood KW - Propylene Glycol -- blood KW - Methanol -- blood KW - Ethylene Glycols -- blood KW - Ethylene Glycol -- blood KW - Alcohols -- poisoning UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1700334033?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.atitle=Diagnosis+of+toxic+alcohols%3A+limitations+of+present+methods.&rft.au=Kraut%2C+Jeffrey+A&rft.aulast=Kraut&rft.aufirst=Jeffrey&rft.date=2015-01-01&rft.volume=53&rft.issue=7&rft.spage=589&rft.isbn=&rft.btitle=&rft.title=Clinical+toxicology+%28Philadelphia%2C+Pa.%29&rft.issn=1556-9519&rft_id=info:doi/10.3109%2F15563650.2015.1056880 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-10-16 N1 - Date created - 2015-07-29 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.3109/15563650.2015.1056880 ER - TY - JOUR T1 - Progesterone and Src Family Inhibitor PP1 Synergistically Inhibit Cell Migration and Invasion of Human Basal Phenotype Breast Cancer Cells AN - 1691292124; PQ0001645787 AB - Basal phenotype breast cancer is one of the most aggressive breast cancers that frequently metastasize to brain. The role of sex hormones and their receptors in development of this disease is largely unclear. We demonstrated that mPR alpha was expressed at a moderate level in a brain metastatic BPBC cell line MB231Br, which was derived from the parent mPR alpha undetectable MB231 cells. It functioned as an essential mediator for progesterone induced inhibitory effects on cell migration of MB231Br and, when coincubated with PP1, synergistically enhanced the progesterone's inhibitory effect on cell migration and invasion in vitro . Progesterone and PP1 cotreatment induced a cascade of molecular signaling events, such as dephosphorylation of FAK, downregulation of MMP9, VEGF, and KCNMA1 expressions. Our in vitro study demonstrated that mPR alpha was expressed and functioned as an essential mediator for progesterone induced inhibitory effects on cell migration and invasion in BPBC cells. This inhibitory effect was enhanced by PP1 via FAK dephosphorylation, MMP9, VEGF, and KCNMA1 downregulation mechanisms. Our study provides a new clue toward the development of novel promising agents and pathways for inhibiting nuclear hormonal receptor-negative and endocrine-resistant breast cancers. JF - BioMed Research International AU - Xie, Mingxuan AU - Zhou, Li AU - Chen, Xi AU - Gainey, Lindsey O AU - Xiao, Jian AU - Nanes, Mark S AU - Hou, Anji AU - You, Shaojin AU - Chen, Qiong AD - Department of Geriatrics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China, shaojin.you@va.gov Y1 - 2015/01// PY - 2015 DA - Jan 2015 PB - Hindawi Publishing Corporation, P.O. Box 3079 Cuyahoga Falls OH 44223 United States VL - 2015 SN - 2314-6133, 2314-6133 KW - Biotechnology and Bioengineering Abstracts KW - Vascular endothelial growth factor KW - Progesterone KW - Dephosphorylation KW - Brain KW - Sex hormones KW - Metastases KW - Focal adhesion kinase KW - Src protein KW - Breast cancer KW - Cell migration KW - Gelatinase B KW - Signal transduction KW - W 30915:Pharmaceuticals & Vaccines UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1691292124?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=BioMed+Research+International&rft.atitle=Progesterone+and+Src+Family+Inhibitor+PP1+Synergistically+Inhibit+Cell+Migration+and+Invasion+of+Human+Basal+Phenotype+Breast+Cancer+Cells&rft.au=Xie%2C+Mingxuan%3BZhou%2C+Li%3BChen%2C+Xi%3BGainey%2C+Lindsey+O%3BXiao%2C+Jian%3BNanes%2C+Mark+S%3BHou%2C+Anji%3BYou%2C+Shaojin%3BChen%2C+Qiong&rft.aulast=Friedlander&rft.aufirst=Arthur&rft.date=2009-06-01&rft.volume=140&rft.issue=6&rft.spage=658&rft.isbn=&rft.btitle=&rft.title=Journal+of+the+American+Dental+Association+%281939%29&rft.issn=1943-4723&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-06-01 N1 - Number of references - 1 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Metastases; Vascular endothelial growth factor; Focal adhesion kinase; Progesterone; Dephosphorylation; Src protein; Brain; Breast cancer; Gelatinase B; Cell migration; Signal transduction; Sex hormones DO - http://dx.doi.org/10.1155/2015/426429 ER - TY - JOUR T1 - Changes in Sexual Behavior of HIV-Infected Older Adults Enrolled in a Clinical Trial of Standalone Group Psychotherapies Targeting Depression AN - 1680149582; 201502996 AB - By 2015, one-half of all HIV-positive persons in the U.S. will be 50-plus years of age, and as many as 30 % of older adults living with HIV/AIDS continue to engage in unprotected sexual intercourse. Contemporary positive prevention models often include mental health treatment as a key component of HIV prevention interventions. This secondary data analysis characterized longitudinal patterns of sexual behavior in HIV-positive older adults enrolled in a randomized controlled trial of group mental health interventions and assessed the efficacy of psychosocial treatments that targeted depression to reduce sexual risk behavior. Participants were 295 HIV-positive adults >=50 years of age experiencing mild to severe depressive symptoms, randomized to one of three study conditions: a 12-session coping improvement group intervention, a 12-session interpersonal support group intervention, or individual therapy upon request. Approximately one-fifth of participants reported one or more occasions of unprotected anal or vaginal intercourse with HIV-negative sexual partners or persons of unknown HIV serostatus over the study period. Changes in sexual behavior did not vary by intervention condition, indicating that standalone treatments that target and reduce depression may be insufficient to reduce sexual risk behavior in depressed HIV-positive older adults. Adapted from the source document. JF - AIDS and Behavior AU - Lovejoy, Travis I AU - Heckman, Timothy G AU - Sikkema, Kathleen J AU - Hansen, Nathan B AU - Kochman, Arlene AD - Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA travis.lovejoy@va.gov Y1 - 2015/01// PY - 2015 DA - January 2015 SP - 1 EP - 8 PB - Springer, Dordrecht, The Netherlands VL - 19 IS - 1 SN - 1090-7165, 1090-7165 KW - Risk KW - Sexual Behavior KW - Prevention KW - Depression (Psychology) KW - Acquired Immune Deficiency Syndrome KW - Elderly KW - Medical Research KW - Intervention KW - Sexual Intercourse KW - article KW - 6126: acquired immune deficiency syndrome (AIDS) UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680149582?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=AIDS+and+Behavior&rft.atitle=Changes+in+Sexual+Behavior+of+HIV-Infected+Older+Adults+Enrolled+in+a+Clinical+Trial+of+Standalone+Group+Psychotherapies+Targeting+Depression&rft.au=Lovejoy%2C+Travis+I%3BHeckman%2C+Timothy+G%3BSikkema%2C+Kathleen+J%3BHansen%2C+Nathan+B%3BKochman%2C+Arlene&rft.aulast=Lovejoy&rft.aufirst=Travis&rft.date=2015-01-01&rft.volume=19&rft.issue=1&rft.spage=1&rft.isbn=&rft.btitle=&rft.title=AIDS+and+Behavior&rft.issn=10907165&rft_id=info:doi/10.1007%2Fs10461-014-0746-7 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-05-01 N1 - Number of references - 29 N1 - Last updated - 2016-09-28 N1 - CODEN - AIBEFC N1 - SubjectsTermNotLitGenreText - Elderly; Intervention; Acquired Immune Deficiency Syndrome; Sexual Behavior; Depression (Psychology); Prevention; Medical Research; Risk; Sexual Intercourse DO - http://dx.doi.org/10.1007/s10461-014-0746-7 ER - TY - JOUR T1 - Active Injection Drug-Abuse Offsets Healthcare Engagement in HIV-Infected Patients AN - 1680149467; 201502992 AB - Active injection drug use (IDU) is a behavior with the potential to offset healthcare engagement for those with HIV. At the Washington DC Veterans Affairs Medical Center, we identified 316 patients with a history of addiction during an 11-year period while actively engaged in routine visits to our HIV-primary care clinic. Among all IDU, active-abuse was determined in 141/316 (45 %). There were 120 clinically relevant blood stream infection (BSI) episodes. HIV/HCV co-infection (95 %) and use of antiretroviral therapy (76 %) were common at the time of BSI. The majority of BSIs occurred among those with active-IDU (72/120, 60 %). Active-IDU behavior was associated with more thrombotic disease (12 vs. 2 %, P = 0.001) and more frequent hospitalization (1.1/year +/- 1.2 vs. 0.8/year +/- 1.1, P = 0.03). When compared to drug-users with no active injection practices or those with remote IDU, active-IDU was associated with an increase in all-cause mortality (43 vs. 27 %, P = 0.003) and a decrease in age-adjusted survival (HR 1.7, CI 1.16-2.51, P = 0.007). Addressing addiction has the potential to impact avoidable medical complications and contribute to the continued, overall health of patients linked to HIV-care. Adapted from the source document. JF - AIDS and Behavior AU - Liappis, Angelike P AU - Laake, Ann M AU - Delman, Mark AD - Medical Service, Section of Infectious Diseases, Veterans Affairs Medical Center, 50 Irving Street, NW, Washington, DC, 20422, USA angelike.liappis@va.gov Y1 - 2015/01// PY - 2015 DA - January 2015 SP - 81 EP - 84 PB - Springer, Dordrecht, The Netherlands VL - 19 IS - 1 SN - 1090-7165, 1090-7165 KW - Veterans KW - Mortality Rates KW - Drug Injection KW - Acquired Immune Deficiency Syndrome KW - Clinics KW - Medicine KW - Patients KW - Addiction KW - Health Care Services KW - article KW - 6126: acquired immune deficiency syndrome (AIDS) UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680149467?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=AIDS+and+Behavior&rft.atitle=Active+Injection+Drug-Abuse+Offsets+Healthcare+Engagement+in+HIV-Infected+Patients&rft.au=Liappis%2C+Angelike+P%3BLaake%2C+Ann+M%3BDelman%2C+Mark&rft.aulast=Liappis&rft.aufirst=Angelike&rft.date=2015-01-01&rft.volume=19&rft.issue=1&rft.spage=81&rft.isbn=&rft.btitle=&rft.title=AIDS+and+Behavior&rft.issn=10907165&rft_id=info:doi/10.1007%2Fs10461-014-0757-4 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-05-01 N1 - Number of references - 11 N1 - Last updated - 2016-09-28 N1 - CODEN - AIBEFC N1 - SubjectsTermNotLitGenreText - Patients; Health Care Services; Addiction; Acquired Immune Deficiency Syndrome; Medicine; Clinics; Drug Injection; Mortality Rates; Veterans DO - http://dx.doi.org/10.1007/s10461-014-0757-4 ER - TY - JOUR T1 - Delivering Chaplaincy Services to Veterans at Increased Risk of Suicide AN - 1665159012 AB - The present study quantitatively examines the delivery of chaplaincy services to Veterans at increased risk of suicide as well as how chaplains collaborate with other healthcare providers. An on-line survey was distributed to the nationwide network of U.S. Department of Veterans Affairs chaplains, yielding a response rate of 11.91% ( N = 118). Most chaplains reported some form of training in suicide prevention, approximately half were involved in safety planning, and the majority reported not engaging in firearm safety counseling. Chaplaincy services were usually delivered through in-person, group, and phone consultations. Respondents were generally satisfied with their collaboration with other healthcare providers, most often collaborating with psychologists, social workers, and counselors. As a descriptive study, the findings serve to inform the delivery of chaplaincy services to at-risk Veterans. Recommendations include expanding service delivery options, developing competency in safety planning and counseling, as well as increasing institutional awareness of chaplaincy services. JF - Journal of Health Care Chaplaincy AU - Kopacz, Marek S AU - Pollitt, Michael J AD - U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, New York, USA ; U.S. Department of Veterans Affairs, National Chaplain Center, Hampton, Virginia, USA ; U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, New York, USA Y1 - 2015/01// PY - 2015 DA - Jan 2015 SP - 1 EP - 13 CY - Philadelphia PB - Taylor & Francis Ltd. VL - 21 IS - 1 SN - 0885-4726 KW - Religions And Theology KW - At risk KW - Chaplains KW - Counselling KW - Counselling services KW - Health care KW - Internet KW - Preventive programmes KW - Psychologists KW - Response rate KW - Safety KW - Service delivery KW - Social workers KW - Suicide KW - Veterans KW - United States--US UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665159012?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Health+Care+Chaplaincy&rft.atitle=Delivering+Chaplaincy+Services+to+Veterans+at+Increased+Risk+of+Suicide&rft.au=Kopacz%2C+Marek+S%3BPollitt%2C+Michael+J&rft.aulast=Kopacz&rft.aufirst=Marek&rft.date=2015-01-01&rft.volume=21&rft.issue=1&rft.spage=1&rft.isbn=&rft.btitle=&rft.title=Journal+of+Health+Care+Chaplaincy&rft.issn=08854726&rft_id=info:doi/10.1080%2F08854726.2014.967525 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Name - Department of Veterans Affairs N1 - Date revised - 2015-02-05 N1 - Last updated - 2016-05-12 N1 - SubjectsTermNotLitGenreText - United States--US DO - http://dx.doi.org/10.1080/08854726.2014.967525 ER - TY - JOUR T1 - Lowered Humidity Produces Human Epidermal Equivalents with Enhanced Barrier Properties AN - 1647009725; 21327046 AB - Multilayered human keratinocyte cultures increasingly are used to model human epidermis. Until now, studies utilizing human epidermal equivalents (HEEs) have been limited because previous preparations do not establish a normal epidermal permeability barrier. In this report, we show that reducing environmental humidity to 50% relative humidity yields HEEs that closely match human postnatal epidermis and have enhanced repair of the permeability barrier. These cultures display low transepidermal water loss and possess a calcium and pH gradient that resembles those seen in human epidermis. These cultures upregulate glucosylceramide synthase and make normal-appearing lipid lamellar bilayers. The epidermal permeability barrier of these cultures can be perturbed, using the identical tools previously described for human skin, and recover in the same time course seen during in vivo barrier recovery. These cultures will be useful for basic and applied studies on epidermal barrier function. JF - Tissue Engineering, Part C: Methods AU - Sun, Richard AU - Celli, Anna AU - Crumrine, Debra AU - Hupe, Melanie AU - Adame, Lillian C AU - Pennypacker, Sally D AU - Park, Kyungho AU - Uchida, Yoshikazu AU - Feingold, Kenneth R AU - Elias, Peter M AU - Ilic, Dusko AU - Mauro, Theodora M AD - Department of Dermatology, San Francisco Veterans Administration Medical Center, San Francisco, California. Y1 - 2015/01// PY - 2015 DA - Jan 2015 SP - 15 EP - 22 PB - Mary Ann Liebert, Inc., 140 Huguenot St 3rd Fl New Rochelle NY 10801 United States VL - 21 IS - 1 SN - 1937-3384, 1937-3384 KW - Biotechnology and Bioengineering Abstracts KW - Relative humidity KW - Skin KW - Calcium KW - Lipids KW - Humidity KW - Tissue engineering KW - Permeability KW - Epidermis KW - Water loss KW - Ceramide glucosyltransferase KW - Keratinocytes KW - pH effects KW - W 30920:Tissue Engineering UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1647009725?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Tissue+Engineering%2C+Part+C%3A+Methods&rft.atitle=Lowered+Humidity+Produces+Human+Epidermal+Equivalents+with+Enhanced+Barrier+Properties&rft.au=Sun%2C+Richard%3BCelli%2C+Anna%3BCrumrine%2C+Debra%3BHupe%2C+Melanie%3BAdame%2C+Lillian+C%3BPennypacker%2C+Sally+D%3BPark%2C+Kyungho%3BUchida%2C+Yoshikazu%3BFeingold%2C+Kenneth+R%3BElias%2C+Peter+M%3BIlic%2C+Dusko%3BMauro%2C+Theodora+M&rft.aulast=Sun&rft.aufirst=Richard&rft.date=2015-01-01&rft.volume=21&rft.issue=1&rft.spage=15&rft.isbn=&rft.btitle=&rft.title=Tissue+Engineering%2C+Part+C%3A+Methods&rft.issn=19373384&rft_id=info:doi/10.1089%2Ften.tec.2014.0065 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-01-01 N1 - Number of references - 53 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Relative humidity; Epidermis; Permeability; Calcium; Skin; Lipids; Ceramide glucosyltransferase; Water loss; Humidity; Keratinocytes; Tissue engineering; pH effects DO - http://dx.doi.org/10.1089/ten.tec.2014.0065 ER - TY - JOUR T1 - Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells. AN - 1640331453; 25283348 AB - Angiogenesis is regulated by hyperglycemic conditions, which can induce cellular stress responses, reactive oxygen species (ROS), and anti-oxidant defenses that modulate intracellular signaling to prevent oxidative damage. The RUNX2 DNA-binding transcription factor is activated by a glucose-mediated intracellular pathway, plays an important role in endothelial cell (EC) function and angiogenesis, and is a target of oxidative stress. RUNX2 DNA-binding and EC differentiation in response to glucose were conserved in ECs from different tissues and inhibited by hyperglycemia, which stimulated ROS production through the aldose reductase glucose-utilization pathway. Furthermore, the redox status of cysteine and methionine residues regulated RUNX2 DNA-binding and reversal of oxidative inhibition was consistent with an endogenous Methionine sulfoxide reductase-A (MsrA) activity. Low molecular weight MsrA substrates and sulfoxide scavengers were potent inhibitors of RUNX2 DNA binding in the absence of oxidative stress, but acted as antioxidants to increase DNA binding in the presence of oxidants. MsrA was associated with RUNX2:DNA complexes, as measured by a sensitive, quantitative DNA-binding ELISA. The related RUNX2 protein family member, RUNX1, which contains an identical DNA-binding domain, was a catalytic substrate of recombinant MsrA. These findings define novel redox pathways involving aldose reductase and MsrA that regulate RUNX2 transcription factor activity and biological function in ECs. Targeting of these pathways could result in more effective strategies to alleviate the vascular dysfunction associated with diabetes or cancer. Copyright © 2014 Elsevier Inc. All rights reserved. JF - Microvascular research AU - Mochin, Maria T AU - Underwood, Karen F AU - Cooper, Brandon AU - McLenithan, John C AU - Pierce, Adam D AU - Nalvarte, Cesar AU - Arbiser, Jack AU - Karlsson, Anna I AU - Moise, Alexander R AU - Moskovitz, Jackob AU - Passaniti, Antonino AD - Department of Pathology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Biochemistry & Molecular Biology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Medicine, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Marlene & Stewart Greenebaum Cancer Center, The University of Maryland School of Medicine, Baltimore, MD 21201, USA. ; Department of Dermatology, Emory University, Atlanta, GA, USA; Atlanta Veterans Administration Medical Center, Atlanta, GA, USA. ; Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045, USA. ; Department of Pathology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Biochemistry & Molecular Biology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Department of Medicine, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; Marlene & Stewart Greenebaum Cancer Center, The University of Maryland School of Medicine, Baltimore, MD 21201, USA; The Veteran's Health Administration Research & Development Service, Baltimore, MD, USA. Electronic address: apass001@umaryland.edu. Y1 - 2015/01// PY - 2015 DA - January 2015 SP - 55 EP - 64 VL - 97 KW - Angiogenesis Inhibitors KW - 0 KW - Antioxidants KW - Core Binding Factor Alpha 1 Subunit KW - Core Binding Factor Alpha 2 Subunit KW - Oxidants KW - RUNX1 protein, human KW - RUNX2 protein, human KW - DNA KW - 9007-49-2 KW - Aldehyde Reductase KW - EC 1.1.1.21 KW - Methionine Sulfoxide Reductases KW - EC 1.8.4.- KW - methionine sulfoxide reductase KW - EC 1.8.4.11 KW - Glucose KW - IY9XDZ35W2 KW - Index Medicus KW - Endothelial cell differentiation KW - Oxidative stress KW - Angiogenesis KW - Transcriptional factors KW - Antioxidant enzymes KW - Human Umbilical Vein Endothelial Cells -- metabolism KW - Oxidants -- pharmacology KW - Dose-Response Relationship, Drug KW - Humans KW - Methionine Sulfoxide Reductases -- metabolism KW - Aldehyde Reductase -- metabolism KW - Binding Sites KW - Phenotype KW - Oxidation-Reduction KW - Angiogenesis Inhibitors -- pharmacology KW - Antioxidants -- pharmacology KW - Cells, Cultured KW - Oxidative Stress KW - Core Binding Factor Alpha 2 Subunit -- metabolism KW - Substrate Specificity KW - Time Factors KW - Signal Transduction KW - Core Binding Factor Alpha 1 Subunit -- metabolism KW - Endothelial Cells -- drug effects KW - Hyperglycemia -- metabolism KW - Glucose -- metabolism KW - DNA -- metabolism KW - Neovascularization, Pathologic KW - Endothelial Cells -- pathology KW - Hyperglycemia -- pathology KW - Hyperglycemia -- physiopathology KW - Endothelial Cells -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1640331453?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Microvascular+research&rft.atitle=Hyperglycemia+and+redox+status+regulate+RUNX2+DNA-binding+and+an+angiogenic+phenotype+in+endothelial+cells.&rft.au=Mochin%2C+Maria+T%3BUnderwood%2C+Karen+F%3BCooper%2C+Brandon%3BMcLenithan%2C+John+C%3BPierce%2C+Adam+D%3BNalvarte%2C+Cesar%3BArbiser%2C+Jack%3BKarlsson%2C+Anna+I%3BMoise%2C+Alexander+R%3BMoskovitz%2C+Jackob%3BPassaniti%2C+Antonino&rft.aulast=Mochin&rft.aufirst=Maria&rft.date=2015-01-01&rft.volume=97&rft.issue=&rft.spage=55&rft.isbn=&rft.btitle=&rft.title=Microvascular+research&rft.issn=1095-9319&rft_id=info:doi/10.1016%2Fj.mvr.2014.09.008 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-08-25 N1 - Date created - 2014-12-22 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Adv Cardiol. 2008;45:1-16 [18230953] Dev Biol. 2008 Mar 15;315(2):459-73 [18262513] Trends Biochem Sci. 2010 Sep;35(9):505-13 [20430626] Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18628-33 [20937881] Endocrinology. 2008 Apr;149(4):1697-704 [18162513] Free Radic Biol Med. 2008 Jul 15;45(2):193-200 [18466776] Mol Cell Biol. 2008 Aug;28(16):5106-19 [18559422] Free Radic Biol Med. 2008 Sep 1;45(5):549-61 [18544350] Am J Physiol Cell Physiol. 2008 Oct;295(4):C849-68 [18684987] Biopolymers. 2009 Jan;91(1):78-84 [18781628] J Biol Chem. 2009 Feb 27;284(9):5986-93 [18990697] Arch Biochem Biophys. 2009 May 1;485(1):35-40 [19388147] J Biol Chem. 2009 Jul 3;284(27):17947-55 [19383984] J Mol Neurosci. 2009 Nov;39(3):323-32 [19653131] Neurosci Lett. 2010 Jan 1;468(1):38-41 [19854239] Sci Transl Med. 2010 Jan 20;2(15):15ps3 [20371469] Neuroscience. 2011 Mar 17;177:223-9 [21219974] Cell. 2011 Sep 16;146(6):873-87 [21925313] J Cell Biochem. 2012 Jan;113(1):282-92 [21913213] Sci Transl Med. 2011 Dec 21;3(114):114rv3 [22190240] J Biochem. 2012 Mar;151(3):255-61 [22287686] J Bone Miner Res. 2012 Apr;27(4):913-25 [22189971] J Vis Exp. 2013;(78). doi: 10.3791/50512 [24022461] Cell Metab. 2013 Oct 1;18(4):478-89 [24035587] Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20057-62 [24277839] Nat Rev Endocrinol. 2014 Sep;10(9):530-9 [25048037] Oncogene. 2000 Jan 6;19(1):106-14 [10644985] J Biol Chem. 2000 May 12;275(19):14167-72 [10799493] Nucleic Acids Res. 2001 Feb 15;29(4):E21 [11160941] Cell. 2001 Mar 9;104(5):755-67 [11257229] Cancer Res. 2001 Jul 1;61(13):4994-5001 [11431332] Mech Dev. 2001 Aug;106(1-2):97-106 [11472838] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12920-5 [11606777] Nature. 2001 Dec 13;414(6865):813-20 [11742414] Biochem Biophys Res Commun. 2002 Jan 11;290(1):62-5 [11779133] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):13969-71 [12391310] Endocrinology. 2003 Jan;144(1):346-52 [12488363] Toxicol Pathol. 2002 Nov-Dec;30(6):620-50 [12512863] Eur Respir J. 2003 Jan;21(1):177-86 [12570126] Int J Clin Oncol. 2003 Aug;8(4):200-6 [12955574] Antioxid Redox Signal. 2003 Oct;5(5):577-82 [14580313] Oncogene. 2004 Jun 10;23(27):4722-34 [15107836] J Bone Miner Res. 2004 Sep;19(9):1481-9 [15312248] J Biol Chem. 2004 Oct 8;279(41):42709-18 [15304489] J Nutr. 2004 Nov;134(11):3213S-3214S [15514312] J Natl Cancer Inst. 1994 Sep 7;86(17):1303-14 [7520508] J Bacteriol. 1995 Feb;177(3):502-7 [7836279] J Biol Chem. 1996 Jul 12;271(28):16870-6 [8663420] Biochem J. 1996 Sep 1;318 ( Pt 2):379-82 [8809022] Gene. 1997 Jan 31;185(1):111-7 [9034321] Cell. 1997 May 30;89(5):755-64 [9182763] Oncogene. 1998 Mar 5;16(9):1217-22 [9528864] Aging (Milano). 1998 Apr;10(2):149-51 [9666202] Free Radic Biol Med. 1998 Dec;25(9):1089-97 [9870563] Biochim Biophys Acta. 2005 Jan 17;1703(2):135-40 [15680221] Biochim Biophys Acta. 2005 Jan 17;1703(2):203-12 [15680228] Biochim Biophys Acta. 2005 Jan 17;1703(2):213-9 [15680229] Oncogene. 2005 Feb 24;24(9):1641-7 [15674341] J Bone Miner Res. 2005 Mar;20(3):428-37 [15746987] Nat Rev Cancer. 2005 May;5(5):376-87 [15864279] Endocr Rev. 2005 May;26(3):380-92 [15814847] J Biol Chem. 2006 Mar 17;281(11):7118-28 [16407259] Circulation. 2006 Apr 18;113(15):1888-904 [16618833] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1549-61 [16987010] Bone. 2007 Jul;41(1):25-32 [17475575] BMC Cancer. 2007;7:172 [17784942] Curr Top Dev Biol. 2008;80:93-133 [17950373] Cancer Biol Ther. 2007 Jun;6(6):856-63 [17438369] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.mvr.2014.09.008 ER - TY - JOUR T1 - Shared genetic factors influence amygdala volumes and risk for alcoholism. AN - 1637552821; 25079289 AB - Alcohol abuse and dependence (alcohol use disorders, AUDs) are associated with brain shrinkage. Subcortical structures including the amygdala, hippocampus, ventral striatum, dorsal striatum, and thalamus subserve reward functioning and may be particularly vulnerable to alcohol-related damage. These structures may also show pre-existing deficits impacting the development and maintenance of AUD. It remains unclear whether there are common genetic features underlying both subcortical volumes and AUD. In this study, structural brain images were acquired from 872 Mexican-American individuals from extended pedigrees. Subcortical volumes were obtained using FreeSurfer, and quantitative genetic analyses were performed in SOLAR. We hypothesized the following: (1) reduced subcortical volumes in individuals with lifetime AUD relative to unrelated controls; (2) reduced subcortical volumes in individuals with current relative to past AUD; (3) in non-AUD individuals, reduced subcortical volumes in those with a family history of AUD compared to those without; and (4) evidence for common genetic underpinnings (pleiotropy) between AUD risk and subcortical volumes. Results showed that individuals with lifetime AUD showed larger ventricular and smaller amygdala volumes compared to non-AUD individuals. For the amygdala, there were no differences in volume between current vs past AUD, and non-AUD individuals with a family history of AUD demonstrated reductions compared to those with no such family history. Finally, amygdala volume was genetically correlated with the risk for AUD. Together, these results suggest that reduced amygdala volume reflects a pre-existing difference rather than alcohol-induced neurotoxic damage. Our genetic correlation analysis provides evidence for a common genetic factor underlying both reduced amygdala volumes and AUD risk. JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology AU - Dager, Alecia D AU - McKay, D Reese AU - Kent, Jack W AU - Curran, Joanne E AU - Knowles, Emma AU - Sprooten, Emma AU - Göring, Harald H H AU - Dyer, Thomas D AU - Pearlson, Godfrey D AU - Olvera, Rene L AU - Fox, Peter T AU - Lovallo, William R AU - Duggirala, Ravi AU - Almasy, Laura AU - Blangero, John AU - Glahn, David C AD - 1] Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA [2] Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. ; Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA. ; Department of Psychiatry, University of Texas Health Science Center San Antonio, San Antonio, TX, USA. ; 1] Research Imaging Institute, University of Texas Health Science Center San Antonio, San Antonio, TX, USA [2] South Texas Veterans Health System, San Antonio, TX, USA. ; Department of Psychiatry, Oklahoma University Heath Science Center and Veterans Administration Medical Center, Oklahoma City, OK, USA. Y1 - 2015/01// PY - 2015 DA - January 2015 SP - 412 EP - 420 VL - 40 IS - 2 KW - Index Medicus KW - Magnetic Resonance Imaging KW - Young Adult KW - Humans KW - Aged KW - Organ Size KW - Risk KW - Mexican Americans -- genetics KW - Aged, 80 and over KW - Adult KW - Family KW - Middle Aged KW - Adolescent KW - Female KW - Male KW - Genetic Pleiotropy KW - Alcohol-Related Disorders -- genetics KW - Genetic Predisposition to Disease KW - Amygdala -- pathology KW - Alcohol-Related Disorders -- pathology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1637552821?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Neuropsychopharmacology+%3A+official+publication+of+the+American+College+of+Neuropsychopharmacology&rft.atitle=Shared+genetic+factors+influence+amygdala+volumes+and+risk+for+alcoholism.&rft.au=Dager%2C+Alecia+D%3BMcKay%2C+D+Reese%3BKent%2C+Jack+W%3BCurran%2C+Joanne+E%3BKnowles%2C+Emma%3BSprooten%2C+Emma%3BG%C3%B6ring%2C+Harald+H+H%3BDyer%2C+Thomas+D%3BPearlson%2C+Godfrey+D%3BOlvera%2C+Rene+L%3BFox%2C+Peter+T%3BLovallo%2C+William+R%3BDuggirala%2C+Ravi%3BAlmasy%2C+Laura%3BBlangero%2C+John%3BGlahn%2C+David+C&rft.aulast=Dager&rft.aufirst=Alecia&rft.date=2015-01-01&rft.volume=40&rft.issue=2&rft.spage=412&rft.isbn=&rft.btitle=&rft.title=Neuropsychopharmacology+%3A+official+publication+of+the+American+College+of+Neuropsychopharmacology&rft.issn=1740-634X&rft_id=info:doi/10.1038%2Fnpp.2014.187 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-12-18 N1 - Date created - 2014-12-16 N1 - Date revised - 2017-01-24 N1 - SuppNotes - Cited By: Am J Med Genet B Neuropsychiatr Genet. 2011 Jul;156B(5):561-8 [21557468] Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15037-42 [21402948] Alcohol Clin Exp Res. 2011 Oct;35(10):1771-93 [21777260] Biol Psychiatry. 2012 Jan 1;71(1):6-14 [21982424] Twin Res Hum Genet. 2012 Jun;15(3):351-71 [22856370] Arch Gen Psychiatry. 2012 Aug;69(8):842-52 [22868938] Alcohol Clin Exp Res. 2013 Jan;37 Suppl 1:E161-71 [23078363] Alcohol Res Health. 2008;31(3):215-30 [20041042] Psychopharmacology (Berl). 2014 Apr;231(8):1731-42 [24553579] Biol Psychiatry. 2014 May 15;75(10):790-7 [24314346] Brain Imaging Behav. 2014 Jun;8(2):143-52 [24297733] Neuron. 2002 Jan 31;33(3):341-55 [11832223] Neurology. 2002 Mar 12;58(5):695-701 [11889230] Neuroimage. 2002 Oct;17(2):825-41 [12377157] Neuroimage. 2002 Oct;17(2):922-7 [12377166] J Stud Alcohol. 2003 Jan;64(1):98-104 [12608489] Arch Gen Psychiatry. 2003 Jul;60(7):727-35 [12860777] Arch Gen Psychiatry. 2003 Sep;60(9):878-88 [12963669] Cereb Cortex. 2004 Jul;14(7):721-30 [15054051] Psychiatr Dev. 1985 Spring;3(1):31-63 [3889898] Neuropsychopharmacology. 1991 May;4(3):175-86 [2064717] Brain Res. 1997 Jun 20;760(1-2):94-101 [9237523] Genet Epidemiol. 1997;14(6):953-8 [9433606] Am J Hum Genet. 1998 May;62(5):1198-211 [9545414] Adv Genet. 2001;42:151-81 [11037320] Biol Psychiatry. 2001 Jun 1;49(11):894-905 [11377407] Am J Psychiatry. 2001 Jul;158(7):1075-83 [11431229] Alcohol Clin Exp Res. 1998 Apr;22(2):534-8 [9581665] Neuroimage. 1999 Feb;9(2):195-207 [9931269] Ann N Y Acad Sci. 1999 Jun 29;877:445-60 [10415664] Nat Rev Genet. 2005 Jul;6(7):521-32 [15995696] Neuroimage. 2006 Aug 1;32(1):180-94 [16651008] Neuroimage. 2006 Sep;32(3):1465-71 [16872844] Hum Brain Mapp. 2006 Dec;27(12):957-62 [16628607] Neuroimage. 2007 Feb 1;34(3):879-87 [17127079] Addict Biol. 2007 Mar;12(1):122-32 [17407506] Biol Psychiatry. 2008 Aug 1;64(3):192-202 [18374900] Am J Psychiatry. 2008 Sep;165(9):1179-84 [18593776] Neuropsychol Rev. 2010 Mar;20(1):1-20 [19685291] Am J Drug Alcohol Abuse. 2010 May;36(3):161-7 [20465374] Neuroimage. 2010 Nov 15;53(3):1135-46 [20006715] Arch Gen Psychiatry. 1998 Oct;55(10):905-12 [9783561] J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 [9881538] Neuroimage. 1999 Feb;9(2):179-94 [9931268] Alcohol Clin Exp Res. 2011 Jun;35(6):1187-200 [21410483] N1 - Last updated - 2017-01-25 DO - http://dx.doi.org/10.1038/npp.2014.187 ER - TY - JOUR T1 - Does universal active MRSA surveillance influence anti-MRSA antibiotic use? A retrospective analysis of the treatment of patients admitted with suspicion of infection at Veterans Affairs Medical Centers between 2005 and 2010 AN - 1701492861; PQ0001800725 AB - Objectives After the implementation of an active surveillance programme for MRSA in US Veterans Affairs (VA) Medical Centers, there was an increase in vancomycin use. We investigated whether positive MRSA admission surveillance tests were associated with MRSA-positive clinical admission cultures and whether the availability of surveillance tests influenced prescribers' ability to match initial anti-MRSA antibiotic use with anticipated MRSA results from clinical admission cultures. Methods Analyses were based on barcode medication administration data, microbiology data and laboratory data from 129 hospitals between January 2005 and September 2010. Hospitalized patient admissions were included if clinical cultures were obtained and antibiotics started within 2 days of admission. Mixed-effects logistic regression was used to examine associations between positive MRSA admission cultures and (i) admission MRSA surveillance test results and (ii) initial anti-MRSA therapy. Results Among 569815 included admissions, positive MRSA surveillance tests were strong predictors of MRSA-positive admission cultures (OR 8.5; 95% CI 8.2-8.8). The negative predictive value of MRSA surveillance tests was 97.6% (95% CI 97.5%-97.6%). The diagnostic OR between initial anti-MRSA antibiotics and MRSA-positive admission cultures was 3.2 (95% CI 3.1-3.4) for patients without surveillance tests and was not significantly different for admissions with surveillance tests. Conclusions The availability of nasal MRSA surveillance tests in VA hospitals did not seem to improve the ability of prescribers to predict the necessity of initial anti-MRSA treatment despite the high negative predictive value of MRSA surveillance tests. Prospective trials are needed to establish the safety and effectiveness of using MRSA surveillance tests to guide antibiotic therapy. JF - Journal of Antimicrobial Chemotherapy AU - Jones, Makoto AU - Huttner, Benedikt AU - Leecaster, Molly AU - Huttner, Angela AU - Damal, Kavitha AU - Tanner, Windy AU - Nielson, Christopher AU - Rubin, Michael A AU - Goetz, Matthew Bidwell AU - Madaras-Kelly, Karl AU - Samore, Matthew H AD - Corresponding author. VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148, USA. Tel: +1-801-582-1565, ext. 4474; Fax: +; , makoto.jones@va.gov Y1 - 2014/12// PY - 2014 DA - Dec 2014 SP - 3401 EP - 3408 PB - Oxford University Press, Great Clarendon Street Oxford OX2 6DP United Kingdom VL - 69 IS - 12 SN - 0305-7453, 0305-7453 KW - Microbiology Abstracts A: Industrial & Applied Microbiology KW - vancomycin KW - empirical treatment KW - definitive treatment KW - Data processing KW - Drug resistance KW - Vancomycin KW - Antibiotics KW - Infection KW - Clinical trials KW - Hospitals KW - A 01340:Antibiotics & Antimicrobials UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1701492861?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologya&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Antimicrobial+Chemotherapy&rft.atitle=Does+universal+active+MRSA+surveillance+influence+anti-MRSA+antibiotic+use%3F+A+retrospective+analysis+of+the+treatment+of+patients+admitted+with+suspicion+of+infection+at+Veterans+Affairs+Medical+Centers+between+2005+and+2010&rft.au=Jones%2C+Makoto%3BHuttner%2C+Benedikt%3BLeecaster%2C+Molly%3BHuttner%2C+Angela%3BDamal%2C+Kavitha%3BTanner%2C+Windy%3BNielson%2C+Christopher%3BRubin%2C+Michael+A%3BGoetz%2C+Matthew+Bidwell%3BMadaras-Kelly%2C+Karl%3BSamore%2C+Matthew+H&rft.aulast=Jones&rft.aufirst=Makoto&rft.date=2014-12-01&rft.volume=69&rft.issue=12&rft.spage=3401&rft.isbn=&rft.btitle=&rft.title=Journal+of+Antimicrobial+Chemotherapy&rft.issn=03057453&rft_id=info:doi/10.1093%2Fjac%2Fdku299 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-08-01 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Data processing; Drug resistance; Vancomycin; Antibiotics; Infection; Clinical trials; Hospitals DO - http://dx.doi.org/10.1093/jac/dku299 ER - TY - JOUR T1 - Vancomycin Nephrotoxicity: A Review AN - 1691295208; PQ0001584889 AB - Vancomycin earned notoriety for its tendency to cause nephrotoxicity shortly after it was introduced into practice, though the impurities responsible for historically significant rates of nephrotoxicity are of minimal concern today. Increasing usage of vancomycin has provided evidence that the drug itself can be nephrotoxic, but the exact mechanism by which this occurs has not been determined. Various studies have identified risk factors associated with development of vancomycin-associated nephrotoxicity, including total daily dose > 4 grams, trough levels > 20 mg/L, therapy exceeding 6 days, concurrent use of other nephrotoxic agents, preexisting renal disease, obesity, hypotensive episodes, and increasing severity of illness. Preventative strategies beyond risk assessment and therapeutic drug monitoring have shown little promise. Most cases of nephrotoxicity are reversible with discontinuation of vancomycin, but permanent renal damage can occur. This article is intended to serve as a practical review of vancomycin-associated nephrotoxicity, including historical context, risk factors, and common methods to evaluate and define renal dysfunction. JF - Journal of Pharmacy Practice AU - Mergenhagen, Kari A AU - Borton, Angela R AD - Department of Pharmacy, Veterans Affairs Western New York Healthcare System, Buffalo, NY, USA, kari.mergenhagen@va.gov Y1 - 2014/12// PY - 2014 DA - Dec 2014 SP - 545 EP - 553 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 27 IS - 6 SN - 0897-1900, 0897-1900 KW - Toxicology Abstracts; Risk Abstracts KW - vancomycin KW - nephrotoxicity KW - therapeutic drug monitoring KW - Risk assessment KW - Historical account KW - Obesity KW - Impurities KW - Kidney diseases KW - Drug screening KW - Renal KW - Renal function KW - Reviews KW - Risk factors KW - Vancomycin KW - Drugs KW - X 24310:Pharmaceuticals KW - R2 23060:Medical and environmental health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1691295208?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ariskabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Pharmacy+Practice&rft.atitle=Vancomycin+Nephrotoxicity%3A+A+Review&rft.au=Mergenhagen%2C+Kari+A%3BBorton%2C+Angela+R&rft.aulast=Mergenhagen&rft.aufirst=Kari&rft.date=2014-12-01&rft.volume=27&rft.issue=6&rft.spage=545&rft.isbn=&rft.btitle=&rft.title=Journal+of+Pharmacy+Practice&rft.issn=08971900&rft_id=info:doi/10.1177%2F0897190014546114 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-06-01 N1 - Number of references - 39 N1 - Last updated - 2015-11-16 N1 - SubjectsTermNotLitGenreText - Risk assessment; Obesity; Renal function; Risk factors; Impurities; Kidney diseases; Vancomycin; Drug screening; Drugs; Renal; Historical account; Reviews DO - http://dx.doi.org/10.1177/0897190014546114 ER - TY - JOUR T1 - Post-traumatic growth among veterans in the USA: results from the National Health and Resilience in Veterans Study AN - 1665171705 AB - There is increasing recognition that, in addition to negative psychological consequences of trauma such as post-traumatic stress disorder (PTSD), some individuals may develop post-traumatic growth (PTG) following such experiences. To date, however, data regarding the prevalence, correlates and functional significance of PTG in population-based samples are lacking. Data were analysed from the National Health and Resilience in Veterans Study, a contemporary, nationally representative survey of 3157 US veterans. Veterans completed a survey containing measures of sociodemographic, military, health and psychosocial characteristics, and the Posttraumatic Growth Inventory-Short Form. We found that 50.1% of all veterans and 72.0% of veterans who screened positive for PTSD reported at least ‘moderate’ PTG in relation to their worst traumatic event. An inverted U-shaped relationship was found to best explain the relationship between PTSD symptoms and PTG. Among veterans with PTSD, those with PTSD reported better mental functioning and general health than those without PTG. Experiencing a life-threatening illness or injury and re-experiencing symptoms were most strongly associated with PTG. In multivariable analysis, greater social connectedness, intrinsic religiosity and purpose in life were independently associated with greater PTG. PTG is prevalent among US veterans, particularly among those who screen positive for PTSD. These results suggest that there may be a ‘positive legacy’ of trauma that has functional significance for veterans. They further suggest that interventions geared toward helping trauma-exposed US veterans process their re-experiencing symptoms, and to develop greater social connections, sense of purpose and intrinsic religiosity may help promote PTG in this population. JF - Psychological Medicine AU - Tsai, J AU - El-Gabalawy, R AU - Sledge, W H AU - Southwick, S M AU - Pietrzak, R H AD - United States Department of Veterans Affairs, New England Mental Illness Research, Education, and Clinical Center, West Haven, CT, USA, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA ; Department of Psychology, University of Manitoba, Winnipeg, Manitoba, Canada ; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA ; United States Department of Veterans Affairs, New England Mental Illness Research, Education, and Clinical Center, West Haven, CT, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Y1 - 2014/12// PY - 2014 DA - Dec 2014 SP - 165 EP - 179 CY - Cambridge PB - Cambridge University Press VL - 45 IS - 1 SN - 0033-2917 KW - Psychology KW - Threatening KW - Traumatic life events KW - Traumatic stress KW - Veterans KW - Injuries KW - Interventions KW - Life threatening KW - Mental health KW - Personal growth KW - Posttraumatic stress disorder KW - Psychological trauma KW - Psychosocial factors KW - Purpose in life KW - Religiosity KW - Resilience KW - Sense of purpose KW - Sociodemographic aspects KW - Symptoms KW - United States--US UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665171705?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychological+Medicine&rft.atitle=Post-traumatic+growth+among+veterans+in+the+USA%3A+results+from+the+National+Health+and+Resilience+in+Veterans+Study&rft.au=Tsai%2C+J%3BEl-Gabalawy%2C+R%3BSledge%2C+W+H%3BSouthwick%2C+S+M%3BPietrzak%2C+R+H&rft.aulast=Tsai&rft.aufirst=J&rft.date=2014-12-01&rft.volume=45&rft.issue=1&rft.spage=165&rft.isbn=&rft.btitle=&rft.title=Psychological+Medicine&rft.issn=00332917&rft_id=info:doi/10.1017%2FS0033291714001202 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-03-05 N1 - Last updated - 2016-08-16 N1 - SubjectsTermNotLitGenreText - United States--US DO - http://dx.doi.org/10.1017/S0033291714001202 ER - TY - JOUR T1 - Spouse health behavior outcomes from a randomized controlled trial of a spouse-assisted lifestyle change intervention to improve patient low-density lipoprotein cholesterol AN - 1665162030 AB - This study evaluated spouse health behavior outcomes from a randomized controlled trial of a spouse-assisted lifestyle intervention to reduce patient low-density lipoprotein cholesterol and improve patient health behaviors. Participants were 251 spouses of patients from the Durham Veterans Affairs Medical Center randomized to intervention or usual care. The intervention comprised 9 monthly telephone calls to patients and spouses. Outcomes were assessed at baseline, 6 and 11 months. At 11 months, there were no differences in spouse outcomes between intervention and usual care groups for moderate intensity physical activity (i.e., frequency, duration) or dietary intake (i.e., total calories, total fat, percentage of calories from total fat, saturated fat, percentage of calories from saturated fat, cholesterol, fiber). To improve spouse outcomes, couple interventions may need to include spouse behavior change goals and reciprocal support between patients and spouses and consider the need for improvement in spouse outcomes. JF - Journal of Behavioral Medicine AU - King, Heather A AU - Jeffreys, Amy S AU - McVay, Megan A AU - Coffman, Cynthia J AU - Voils, Corrine I AD - Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, HSR&D (152), 508 Fulton St., Durham, NC, 27705, USA heather.king2@va.gov heather.king2@va.gov; Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, HSR&D (152), 508 Fulton St., Durham, NC, 27705, USA, Department of Medicine, Duke University Medical Center, Durham, NC, USA ; Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, HSR&D (152), 508 Fulton St., Durham, NC, 27705, USA, Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA ; Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, HSR&D (152), 508 Fulton St., Durham, NC, 27705, USA Y1 - 2014/12// PY - 2014 DA - Dec 2014 SP - 1102 EP - 1107 CY - New York PB - Springer Science & Business Media VL - 37 IS - 6 SN - 0160-7715 KW - Psychology KW - Behavioural changes KW - Body fat KW - Cholesterol KW - Clinical outcomes KW - Density KW - Health behaviour KW - Health status KW - Interventions KW - Lifestyle KW - Physical activity KW - Spouses KW - Telephone calls KW - Veterans UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665162030?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Behavioral+Medicine&rft.atitle=Spouse+health+behavior+outcomes+from+a+randomized+controlled+trial+of+a+spouse-assisted+lifestyle+change+intervention+to+improve+patient+low-density+lipoprotein+cholesterol&rft.au=King%2C+Heather+A%3BJeffreys%2C+Amy+S%3BMcVay%2C+Megan+A%3BCoffman%2C+Cynthia+J%3BVoils%2C+Corrine+I&rft.aulast=King&rft.aufirst=Heather&rft.date=2014-12-01&rft.volume=37&rft.issue=6&rft.spage=1102&rft.isbn=&rft.btitle=&rft.title=Journal+of+Behavioral+Medicine&rft.issn=01607715&rft_id=info:doi/10.1007%2Fs10865-014-9559-4 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Name - Veterans Affairs Medical Center-Boston MA N1 - Copyright - Copyright Springer Science & Business Media Dec 2014 N1 - Date revised - 2015-01-09 N1 - Last updated - 2017-02-08 DO - http://dx.doi.org/10.1007/s10865-014-9559-4 ER - TY - JOUR T1 - Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections AN - 1639995259; 20983687 AB - Background Standard of care therapy (SOCT) for the treatment of methicillin susceptible staphylococcal aureus (MSSA) infections requires multiple daily infusions. Despite questionable efficacy due to high protein binding, ceftriaxone (CTX) is frequently used for treatment of MSSA at Hines VA Hospital. Objective The objective of this study was to determine clinical and microbiological outcomes in patients with MSSA bacteremia treated with CTX compared to SOCT. Setting This retrospective study was conducted at the Edward Hines, Jr. VA Hospital which is a comprehensive health care center serving the veteran population of the greater metropolitan Chicago and northwest Indiana regions and is institutionally affiliated with the Loyola University Medical Center. The Hines VA provides medical care to over 56,000 veterans and operates approximately 500 hospital beds, including acute care and nursing home beds. Method We conducted a retrospective cohort study of patients with MSSA bacteremia treated at Hines VA Hospital between January 2000 and September 2009. Patients who received either SOCT or CTX for >50 % of the treatment course and for the appropriate duration were included. Patients who were on multiple antibiotics concurrently or who received <14 days of therapy were excluded. Main outcome measure The primary outcome of this study is to compare clinical outcomes of patients with MSSA bacteremia who were treated with CTX compared to those who received standard of care agents. Results Ninety-three patients with MSSA bacteremia were included in the analysis. Fifty-one were treated with SOCT and 42 with CTX. There were no differences in microbiological cure between SOCT (94.1 %) and CTX (95.2 %) (p = 0.812). Clinical cure was similar between groups (74.5 % for SOCT, 83.3 % for CTX) (p = 0.303). CTX was used more often to treat Staphylococcus aureus bacteremia associated with osteomyelitis whereas endocarditis and central line associated infections were treated more frequently with SOCT (p = 0.01). More patients treated with CTX were managed in the ambulatory setting (64 vs. 24 %; p = <0.001). There was a trend toward a longer hospital stay with SOCT. Conclusion Clinical outcomes for MSSA bacteremia did not differ significantly between patients treated with CTX and SOCT. Findings suggest that CTX may be an alternative for outpatient management of MSSA bacteremia. JF - International Journal of Clinical Pharmacy AU - Patel, Ursula C AU - McKissic, Erin L AU - Kasper, Douglas AU - Lentino, Joseph R AU - Pachucki, Constance T AU - Lee, Todd AU - Lopansri, Bert K AD - Department of Pharmacy (119), Edward Hines, Jr. VA Hospital, 5000 S. Fifth Ave., Hines, IL, 60141, USA, ursula.patel@va.gov Y1 - 2014/12// PY - 2014 DA - Dec 2014 SP - 1282 EP - 1289 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 36 IS - 6 SN - 2210-7703, 2210-7703 KW - Microbiology Abstracts B: Bacteriology KW - Methicillin KW - Nursing KW - Bacteremia KW - Antibiotics KW - Ceftriaxone KW - Staphylococcus aureus KW - Infection KW - Hospitals KW - Endocarditis KW - Osteomyelitis KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1639995259?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=International+Journal+of+Clinical+Pharmacy&rft.atitle=Outcomes+of+ceftriaxone+use+compared+to+standard+of+therapy+in+methicillin+susceptible+staphylococcal+aureus+%28MSSA%29+bloodstream+infections&rft.au=Patel%2C+Ursula+C%3BMcKissic%2C+Erin+L%3BKasper%2C+Douglas%3BLentino%2C+Joseph+R%3BPachucki%2C+Constance+T%3BLee%2C+Todd%3BLopansri%2C+Bert+K&rft.aulast=Patel&rft.aufirst=Ursula&rft.date=2014-12-01&rft.volume=36&rft.issue=6&rft.spage=1282&rft.isbn=&rft.btitle=&rft.title=International+Journal+of+Clinical+Pharmacy&rft.issn=22107703&rft_id=info:doi/10.1007%2Fs11096-014-9999-5 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-12-01 N1 - Number of references - 19 N1 - Last updated - 2015-03-04 N1 - SubjectsTermNotLitGenreText - Methicillin; Nursing; Bacteremia; Antibiotics; Ceftriaxone; Infection; Osteomyelitis; Endocarditis; Hospitals; Staphylococcus aureus DO - http://dx.doi.org/10.1007/s11096-014-9999-5 ER - TY - JOUR T1 - Asbestos-induced disruption of calcium homeostasis induces endoplasmic reticulum stress in macrophages. AN - 1629334896; 25324550 AB - Although the mechanisms for fibrosis development remain largely unknown, recent evidence indicates that endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) may act as an important fibrotic stimulus in diseased lungs. ER stress is observed in lungs of patients with idiopathic pulmonary fibrosis. In this study we evaluated if ER stress and the UPR was present in macrophages exposed to chrysotile asbestos and if ER stress in macrophages was associated with asbestos-induced pulmonary fibrosis. Macrophages exposed to chrysotile had elevated transcript levels of several ER stress genes. Macrophages loaded with the Ca(2+)-sensitive dye Fura2-AM showed that cytosolic Ca(2+) increased significantly within minutes after chrysotile exposure and remained elevated for a prolonged time. Chrysotile-induced increases in cytosolic Ca(2+) were partially inhibited by either anisomycin, an inhibitor of passive Ca(2+) leak from the ER, or 1,2-bis(2-aminophenoxyl)ethane-N,N,N',N'-tetraacetic acid (BAPTA-AM), an intracellular Ca(2+) chelator known to deplete ER Ca(2+) stores. Anisomycin inhibited X-box-binding protein 1 (XBP1) mRNA splicing and reduced immunoglobulin-binding protein (BiP) levels, whereas BAPTA-AM increased XBP1 splicing and BiP expression, suggesting that ER calcium depletion may be one factor contributing to ER stress in cells exposed to chrysotile. To evaluate ER stress in vivo, asbestos-exposed mice showed fibrosis development, and alveolar macrophages from fibrotic mice showed increased expression of BiP. Bronchoalveolar macrophages from asbestosis patients showed increased expression of several ER stress genes compared with normal subjects. These findings suggest that alveolar macrophages undergo ER stress, which is associated with fibrosis development. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc. JF - The Journal of biological chemistry AU - Ryan, Alan J AU - Larson-Casey, Jennifer L AU - He, Chao AU - Murthy, Shuhba AU - Carter, A Brent AD - From the Departments of Internal Medicine. ; Radiation Oncology and Program in Free Radical and Radiation Biology, Carver College of Medicine. ; From the Departments of Internal Medicine, Radiation Oncology and Program in Free Radical and Radiation Biology, Carver College of Medicine, Human Toxicology, College of Public Health, University of Iowa, and Iowa City Veterans Administration Center, Iowa City, Iowa 52242 brent-carter@uiowa.edu. Y1 - 2014/11/28/ PY - 2014 DA - 2014 Nov 28 SP - 33391 EP - 33403 VL - 289 IS - 48 KW - Asbestos, Serpentine KW - 0 KW - DNA-Binding Proteins KW - Regulatory Factor X Transcription Factors KW - Transcription Factors KW - X-Box Binding Protein 1 KW - XBP1 protein, human KW - Xbp1 protein, mouse KW - Calcium KW - SY7Q814VUP KW - Index Medicus KW - Asbestos KW - Fibrosis KW - Lung Injury KW - Macrophage KW - Endoplasmic Reticulum Stress (ER Stress) KW - Pulmonary Fibrosis KW - Animals KW - RNA Splicing -- drug effects KW - Transcription Factors -- metabolism KW - Humans KW - Adult KW - Mice KW - Adolescent KW - Male KW - Female KW - DNA-Binding Proteins -- metabolism KW - Macrophages, Alveolar -- metabolism KW - Calcium -- metabolism KW - Pulmonary Fibrosis -- pathology KW - Pulmonary Fibrosis -- chemically induced KW - Asbestosis -- pathology KW - Asbestos, Serpentine -- toxicity KW - Asbestosis -- metabolism KW - Macrophages, Alveolar -- pathology KW - Pulmonary Fibrosis -- metabolism KW - Endoplasmic Reticulum Stress -- drug effects UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1629334896?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+biological+chemistry&rft.atitle=Asbestos-induced+disruption+of+calcium+homeostasis+induces+endoplasmic+reticulum+stress+in+macrophages.&rft.au=Ryan%2C+Alan+J%3BLarson-Casey%2C+Jennifer+L%3BHe%2C+Chao%3BMurthy%2C+Shuhba%3BCarter%2C+A+Brent&rft.aulast=Ryan&rft.aufirst=Alan&rft.date=2014-11-28&rft.volume=289&rft.issue=48&rft.spage=33391&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+biological+chemistry&rft.issn=1083-351X&rft_id=info:doi/10.1074%2Fjbc.M114.579870 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-02-10 N1 - Date created - 2014-11-29 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Immunity. 2013 Mar 21;38(3):555-69 [23477737] Curr Opin Rheumatol. 2012 Nov;24(6):663-8 [22918530] Biochim Biophys Acta. 2013 Jul;1833(7):1612-24 [23380704] J Biol Chem. 2013 Jul 12;288(28):20745-57 [23720777] Am J Respir Cell Mol Biol. 2013 Dec;49(6):892-901 [23885834] Science. 2000 Mar 3;287(5458):1647-51 [10698739] Mol Cell Biochem. 2003 Jun;248(1-2):41-7 [12870653] J Biol Chem. 2004 May 7;279(19):20108-17 [14978030] J Cell Sci. 2004 Aug 15;117(Pt 18):4135-42 [15280427] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2466-70 [2138778] Cell. 1998 Mar 20;92(6):747-58 [9529251] J Biol Chem. 1999 Oct 22;274(43):30858-63 [10521478] J Clin Invest. 2005 Jan;115(1):56-65 [15630444] J Biol Chem. 2005 Jun 10;280(23):21763-72 [15826936] J Clin Invest. 2005 Oct;115(10):2656-64 [16200199] Cardiovasc Res. 2006 Mar 1;69(4):908-15 [16376871] Neurochem Int. 2006 Jun;48(8):696-702 [16481070] FASEB J. 2006 Jun;20(8):1215-7 [16611832] Blood. 2006 Sep 1;108(5):1635-42 [16690965] Mol Cell Biol. 2006 Dec;26(24):9220-31 [17030611] Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 [17565364] Cell Metab. 2007 Aug;6(2):137-43 [17681149] Dev Cell. 2007 Sep;13(3):351-64 [17765679] Cell. 2007 Nov 2;131(3):596-610 [17981125] Cell Struct Funct. 2008;33(1):75-89 [18360008] Am J Physiol Lung Cell Mol Physiol. 2008 Jun;294(6):L1119-26 [18390830] Am J Respir Crit Care Med. 2008 Oct 15;178(8):838-46 [18635891] Nat Rev Drug Discov. 2008 Dec;7(12):1013-30 [19043451] J Cell Biol. 2009 Sep 21;186(6):783-92 [19752026] Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L846-55 [19684199] Biochem Pharmacol. 2010 May 1;79(9):1221-30 [20006589] J Biol Chem. 2010 Jul 16;285(29):22103-13 [20466729] Semin Liver Dis. 2010 Aug;30(3):245-57 [20665377] Clin Immunol. 2010 Oct;137(1):89-101 [20674506] Chem Biol Interact. 2010 Nov 5;188(2):309-18 [20380827] Methods Enzymol. 2011;490:31-51 [21266242] Am J Respir Cell Mol Biol. 2011 Mar;44(3):404-14 [20463293] Cold Spring Harb Perspect Biol. 2011 Jun;3(6). pii: a004317. doi: 10.1101/cshperspect.a004317 [21441595] Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10562-7 [21670280] J Exp Med. 2011 Jul 4;208(7):1339-50 [21727191] Nat Rev Mol Cell Biol. 2012 Feb;13(2):89-102 [22251901] J Biol Chem. 2012 Jan 27;287(5):3301-12 [22157762] J Biol Chem. 2012 Apr 6;287(15):11629-41 [22356914] Am J Physiol Lung Cell Mol Physiol. 2012 Apr 15;302(8):L721-9 [22287606] Am J Respir Cell Mol Biol. 2012 Jun;46(6):731-9 [21852685] Am J Respir Cell Mol Biol. 2012 Jun;46(6):748-56 [22227563] FASEB J. 2013 Apr;27(4):1600-9 [23322163] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1074/jbc.M114.579870 ER - TY - JOUR T1 - High serum iron is associated with increased cancer risk. AN - 1625344167; 25228650 AB - Epidemiologic studies linking high serum iron with cancer risks are limited and inconclusive, despite evidence implicating body iron in human carcinogenesis. A cohort of 309,443 adults in Taiwan who had no history of cancer had serum iron levels tested at the time of recruitment (1997-2008). Initially measured iron levels were associated with subsequent cancer risk by linking individuals with the National Cancer Registry and National Death File. HRs were calculated by the Cox model. One third of males (35%) and one fifth of females (18%) had high serum iron (≥120 μg/dL), which was associated with a 25% increase in risk for incidence of all cancers [HR, 1.25; 95% confidence interval (CI), 1.16-1.35] and with a 39% increase in risk for mortality from all cancers (HR, 1.39; 95% CI, 1.23-1.57). The relationship between serum iron and cancer risk was a J-shaped one, with higher cancer risk at both ends, either at lower than 60 μg/dL or higher than 120 μg/dL. At the higher end, cancer risk increased by 4% for every 10 μg/dL increment above 80 μg/dL, showing a dose-response relationship, with 60 to 79 μg/dL as a reference level. In a sensitivity analysis, the increases in risk were still observed after the first 5 years of cancer cases were excluded. Liver cancer risk was increased in HBV (-) non-hepatitis B carrier (3-fold) and HBV (+) hepatitis B carrier (24-fold). Lifestyle risks such as smoking, drinking, or inactivity interacted synergistically with high serum iron and significantly increased the cancer risks. The liver (HR, 2.49; 95% CI, 1.97-3.16) and the breast (HR, 1.31; 95% CI, 1.01-1.70) were the two major cancer sites where significant cancer risks were observed for serum iron either ≥120 μg/dL or ≥140 μg/dL, respectively. This study reveals that high serum iron is both a common disorder and a marker of increased risk for several cancers. ©2014 American Association for Cancer Research. JF - Cancer research AU - Wen, Chi Pang AU - Lee, June Han AU - Tai, Ya-Ping AU - Wen, Christopher AU - Wu, Shiuan Be AU - Tsai, Min Kuang AU - Hsieh, Dennis P H AU - Chiang, Hung-Che AU - Hsiung, Chao Agnes AU - Hsu, Chung Y AU - Wu, Xifeng AD - Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. China Medical University Hospital, Taichung, Taiwan. cwengood@nhri.org.tw. ; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. ; Long Beach Veterans Administration Hospital, University of Irvine, California. ; Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan. Department of Environmental Toxicology, University of California, Davis. ; National Environmental Health Center, National Health Research Institutes, Zhunan, Taiwan. ; Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. ; Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Y1 - 2014/11/15/ PY - 2014 DA - 2014 Nov 15 SP - 6589 EP - 6597 VL - 74 IS - 22 KW - Iron KW - E1UOL152H7 KW - Index Medicus KW - Life Style KW - Risk KW - Humans KW - Adult KW - Male KW - Female KW - Proportional Hazards Models KW - Neoplasms -- blood KW - Iron -- blood KW - Neoplasms -- etiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1625344167?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cancer+research&rft.atitle=High+serum+iron+is+associated+with+increased+cancer+risk.&rft.au=Wen%2C+Chi+Pang%3BLee%2C+June+Han%3BTai%2C+Ya-Ping%3BWen%2C+Christopher%3BWu%2C+Shiuan+Be%3BTsai%2C+Min+Kuang%3BHsieh%2C+Dennis+P+H%3BChiang%2C+Hung-Che%3BHsiung%2C+Chao+Agnes%3BHsu%2C+Chung+Y%3BWu%2C+Xifeng&rft.aulast=Wen&rft.aufirst=Chi&rft.date=2014-11-15&rft.volume=74&rft.issue=22&rft.spage=6589&rft.isbn=&rft.btitle=&rft.title=Cancer+research&rft.issn=1538-7445&rft_id=info:doi/10.1158%2F0008-5472.CAN-14-0360 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-07-08 N1 - Date created - 2014-11-15 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1158/0008-5472.CAN-14-0360 ER - TY - JOUR T1 - Transformer 2β homolog (Drosophila) (TRA2B) regulates protein kinase C δI (PKCδI) splice variant expression during 3T3L1 preadipocyte cell cycle. AN - 1625340816; 25261467 AB - Obesity is characterized by adipocyte hyperplasia and hypertrophy. We previously showed that PKCδ expression is dysregulated in obesity (Carter, G., Apostolatos, A., Patel, R., Mathur, A., Cooper, D., Murr, M., and Patel, N. A. (2013) ISRN Obes. 2013, 161345). Using 3T3L1 preadipocytes, we studied adipogenesis in vitro and showed that expression of PKCδ splice variants, PKCδI and PKCδII, have different expression patterns during adipogenesis (Patel, R., Apostolatos, A., Carter, G., Ajmo, J., Gali, M., Cooper, D. R., You, M., Bisht, K. S., and Patel, N. A. (2013) J. Biol. Chem. 288, 26834-26846). Here, we evaluated the role of PKCδI splice variant during adipogenesis. Our results indicate that PKCδI expression level is high in preadipocytes and decreasing PKCδI accelerated terminal differentiation. Our results indicate that PKCδI is required for mitotic clonal expansion of preadipocytes. We next evaluated the splice factor regulating the expression of PKCδI during 3T3L1 adipogenesis. Our results show TRA2B increased PKCδI expression. To investigate the molecular mechanism, we cloned a heterologous splicing PKCδ minigene and showed that inclusion of PKCδ exon 9 is increased by TRA2B. Using mutagenesis and a RNA-immunoprecipitation assay, we evaluated the binding of Tra2β on PKCδI exon 9 and show that its association is required for PKCδI splicing. These results provide a better understanding of the role of PKCδI in adipogenesis. Determination of this molecular mechanism of alternative splicing presents a novel therapeutic target in the management of obesity and its co-morbidities. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc. JF - The Journal of biological chemistry AU - Patel, Rekha S AU - Carter, Gay AU - Cooper, Denise R AU - Apostolatos, Hercules AU - Patel, Niketa A AD - Department of Molecular Medicine, University of South Florida, Tampa, Florida 33612. ; From the James A. Haley Veterans Hospital and. ; Department of Molecular Medicine, University of South Florida, Tampa, Florida 33612 From the James A. Haley Veterans Hospital and. ; Department of Molecular Medicine, University of South Florida, Tampa, Florida 33612 From the James A. Haley Veterans Hospital and Niketa.Patel@va.gov npatel@health.usf.edu. Y1 - 2014/11/14/ PY - 2014 DA - 2014 Nov 14 SP - 31662 EP - 31672 VL - 289 IS - 46 KW - Nuclear Proteins KW - 0 KW - RNA-Binding Proteins KW - Tra2b protein, mouse KW - Serine-Arginine Splicing Factors KW - 170974-22-8 KW - Protein Kinase C-delta KW - EC 2.7.11.13 KW - Index Medicus KW - Obesity KW - Adipogenesis KW - Alternative Splicing KW - TRA2B KW - Protein Kinase C (PKC) KW - PRKCD KW - Cell Cycle KW - Animals KW - Apoptosis KW - Cell Differentiation KW - Mice KW - 3T3-L1 Cells KW - Cell Proliferation KW - Mutation KW - Adipocytes -- cytology KW - RNA-Binding Proteins -- metabolism KW - Protein Kinase C-delta -- metabolism KW - Gene Expression Regulation KW - Nuclear Proteins -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1625340816?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+biological+chemistry&rft.atitle=Transformer+2%CE%B2+homolog+%28Drosophila%29+%28TRA2B%29+regulates+protein+kinase+C+%CE%B4I+%28PKC%CE%B4I%29+splice+variant+expression+during+3T3L1+preadipocyte+cell+cycle.&rft.au=Patel%2C+Rekha+S%3BCarter%2C+Gay%3BCooper%2C+Denise+R%3BApostolatos%2C+Hercules%3BPatel%2C+Niketa+A&rft.aulast=Patel&rft.aufirst=Rekha&rft.date=2014-11-14&rft.volume=289&rft.issue=46&rft.spage=31662&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+biological+chemistry&rft.issn=1083-351X&rft_id=info:doi/10.1074%2Fjbc.M114.592337 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-01-20 N1 - Date created - 2014-11-15 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Nat Rev Mol Cell Biol. 2006 Dec;7(12):885-96 [17139329] Gene Expr. 2006;13(2):73-84 [17017122] Am J Physiol Cell Physiol. 2007 Aug;293(2):C805-13 [17507429] Ann N Y Acad Sci. 2008 Oct;1139:197-205 [18991865] Mol Brain. 2008;1:12 [18945348] J Biol Chem. 2010 Jan 15;285(3):1879-87 [19917613] Genes Dev. 2010 Jun 1;24(11):1073-4 [20516191] J Biol Chem. 2010 Aug 20;285(34):25987-95 [20547768] Cell Metab. 2011 Aug 3;14(2):208-18 [21803291] PLoS Genet. 2011 Dec;7(12):e1002390 [22194695] J Biol Chem. 2012 Mar 16;287(12):9299-310 [22275369] J Biol Chem. 2012 May 11;287(20):16575-85 [22437831] J Endocrinol. 1997 Nov;155(2):217-8 [9415052] Biochem Soc Trans. 2012 Aug;40(4):784-8 [22817734] J Biol Chem. 2013 Sep 13;288(37):26834-46 [23902767] RNA Biol. 2014;11(4):351-9 [24658338] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9618-23 [10931943] Biochem J. 2002 Nov 15;368(Pt 1):349-55 [12207561] Hum Mol Genet. 2004 Mar 1;13(5):509-24 [14709600] Prog Nucleic Acid Res Mol Biol. 2004;78:37-88 [15210328] Cell. 1975 May;5(1):19-27 [165899] J Cell Physiol. 1979 Oct;101(1):169-71 [541350] Science. 1986 Jul 18;233(4761):305-12 [3014651] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9004-9 [8799144] J Biol Chem. 1997 May 23;272(21):13816-22 [9153238] DNA Cell Biol. 1997 Jun;16(6):679-90 [9212162] Int J Obes (Lond). 2005 Mar;29 Suppl 1:S13-6 [15711576] J Biol Chem. 2005 Sep 16;280(37):32107-14 [16051606] J Neurochem. 2006 Feb;96(3):635-44 [16371011] Int J Biochem Cell Biol. 2006;38(12):2151-63 [16950644] Mol Carcinog. 2007 May;46(5):381-90 [17219421] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1074/jbc.M114.592337 ER - TY - JOUR T1 - The effects of homelessness on Veterans' health care service use: an evaluation of independence from comorbidities AN - 1718059494; 2011-807975 AB - Objectives: This study evaluates the prevalence of Multiple Comorbid Chronic Disease (MCCD) within homeless and non-homeless Veterans and the association between MCCD and inpatient medical care. Methods: All individuals seen in the VA North Texas Health Care System between October 1, 2009 and September 30, 2010 (n = 102,034) were evaluated. Homelessness during the year and the number of common chronic diseases were evaluated for an association with likelihood of medical and psychiatric hospitalizations, bed days of care, inpatient substance treatment, rehabilitation admissions, and emergency department visits. Results: Homeless Veterans had higher all-cause mortality rates and rates of use of almost all resources after controlling for chronic disease burden using the Charlson Comorbidity Index, psychiatric illnesses, substance use disorders, and demographic variables. Conclusions: Homelessness Veterans are vulnerable to a high use of resources and mortality, independent of medical and psychiatric conditions. This finding should focus additional attention on reducing homelessness. [Copyright Elsevier B.V.] JF - Public Health AU - LePage, J P AU - Bradshaw, L D AU - Cipher, D J AU - Crawford, A M AU - Hoosyhar, D AD - VA North Texas Health Care System, USA James.lepage@va.gov Y1 - 2014/11// PY - 2014 DA - November 2014 SP - 985 EP - 992 PB - Elsevier Ltd, The Netherlands VL - 128 IS - 11 SN - 0033-3506, 0033-3506 KW - Social conditions and policy - Social conditions and problems KW - Military and defense policy - Military personnel and veterans KW - Health conditions and policy - Medicine and health care KW - Health conditions and policy - Diseases and disorders KW - Population groups, population policy, and demographics - Demography and census KW - Social conditions and policy - Associations and meetings KW - Education and education policy - Information services and sources KW - Homelessness Chronic medical diseases Veterans Hospitalization Emergency department treatment Bed days of care KW - Veterans KW - Indexes KW - Mortality KW - Rehabilitation KW - Associations KW - Admission KW - Texas KW - Diseases KW - Medical service KW - Demographics KW - Homelessness KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1718059494?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Apais&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Public+Health&rft.atitle=The+effects+of+homelessness+on+Veterans%27+health+care+service+use%3A+an+evaluation+of+independence+from+comorbidities&rft.au=LePage%2C+J+P%3BBradshaw%2C+L+D%3BCipher%2C+D+J%3BCrawford%2C+A+M%3BHoosyhar%2C+D&rft.aulast=LePage&rft.aufirst=J&rft.date=2014-11-01&rft.volume=128&rft.issue=11&rft.spage=985&rft.isbn=&rft.btitle=&rft.title=Public+Health&rft.issn=00333506&rft_id=info:doi/10.1016%2Fj.puhe.2014.07.004 LA - English DB - PAIS Index N1 - Date revised - 2015-10-01 N1 - Last updated - 2016-09-28 N1 - SubjectsTermNotLitGenreText - Homelessness; Veterans; Medical service; Diseases; Mortality; Associations; Rehabilitation; Indexes; Demographics; Texas; Admission DO - http://dx.doi.org/10.1016/j.puhe.2014.07.004 ER - TY - JOUR T1 - Clinician Perceptions of Using a Smartphone App with Prolonged Exposure Therapy AN - 1680150377; 201502747 AB - Clinician perceptions of clinical innovations affect their adoption and spread. This study investigated mental health clinicians' (n = 163) perceptions of a patient-facing smartphone application (app) for prolonged exposure (PE) therapy for posttraumatic stress disorder, before its public release. After reading a description of the app, participants rated perceptions of it based on diffusion of innovations theory constructs. Perceptions were generally favorable regarding the app's relative advantage over existing PE practices, compatibility with their values and needs, and complexity. Age (<40 years), smartphone ownership, and having used apps in care related to more favorable perceptions. Smartphone ownership, relative advantage, and complexity significantly predicted intention to use the app if it were available. These findings suggest that clinicians are receptive to using a PE app and that dissemination efforts should target sub-groups of PE clinicians to maximize adoption. Adapted from the source document. JF - Administration and Policy in Mental Health AND Mental Health Services Research AU - Kuhn, Eric AU - Eftekhari, Afsoon AU - Hoffman, Julia E AU - Crowley, Jill J AU - Ramsey, Kelly M AU - Reger, Greg M AU - Ruzek, Josef I AD - Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, 795 Willow Rd, Menlo Park, Palo Alto, CA, 94025, USA eric.kuhn@va.gov Y1 - 2014/11// PY - 2014 DA - November 2014 SP - 800 EP - 807 PB - Springer, Dordrecht The Netherlands VL - 41 IS - 6 SN - 0894-587X, 0894-587X KW - Values KW - Mental Health KW - Diffusion KW - Ownership KW - Posttraumatic Stress Disorder KW - Adoption of Innovations KW - Innovations KW - article KW - 6121: therapeutic interventions UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1680150377?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Administration+and+Policy+in+Mental+Health+AND+Mental+Health+Services+Research&rft.atitle=Clinician+Perceptions+of+Using+a+Smartphone+App+with+Prolonged+Exposure+Therapy&rft.au=Kuhn%2C+Eric%3BEftekhari%2C+Afsoon%3BHoffman%2C+Julia+E%3BCrowley%2C+Jill+J%3BRamsey%2C+Kelly+M%3BReger%2C+Greg+M%3BRuzek%2C+Josef+I&rft.aulast=Kuhn&rft.aufirst=Eric&rft.date=2014-11-01&rft.volume=41&rft.issue=6&rft.spage=800&rft.isbn=&rft.btitle=&rft.title=Administration+and+Policy+in+Mental+Health+AND+Mental+Health+Services+Research&rft.issn=0894587X&rft_id=info:doi/10.1007%2Fs10488-013-0532-2 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-05-01 N1 - Number of references - 24 N1 - Last updated - 2016-09-28 N1 - CODEN - APMHEM N1 - SubjectsTermNotLitGenreText - Ownership; Innovations; Values; Posttraumatic Stress Disorder; Diffusion; Adoption of Innovations; Mental Health DO - http://dx.doi.org/10.1007/s10488-013-0532-2 ER - TY - JOUR T1 - Clinician Perceptions of Using a Smartphone App with Prolonged Exposure Therapy AN - 1665156044 AB - Clinician perceptions of clinical innovations affect their adoption and spread. This study investigated mental health clinicians’ ( n = 163) perceptions of a patient-facing smartphone application (app) for prolonged exposure (PE) therapy for posttraumatic stress disorder, before its public release. After reading a description of the app, participants rated perceptions of it based on diffusion of innovations theory constructs. Perceptions were generally favorable regarding the app’s relative advantage over existing PE practices, compatibility with their values and needs, and complexity. Age (<40 years), smartphone ownership, and having used apps in care related to more favorable perceptions. Smartphone ownership, relative advantage, and complexity significantly predicted intention to use the app if it were available. These findings suggest that clinicians are receptive to using a PE app and that dissemination efforts should target sub-groups of PE clinicians to maximize adoption. JF - Administration and Policy in Mental Health and Mental Health Services Research AU - Kuhn, Eric AU - Eftekhari, Afsoon AU - Hoffman, Julia E AU - Crowley, Jill J AU - Ramsey, Kelly M AU - Reger, Greg M AU - Ruzek, Josef I AD - Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, 795 Willow Rd, Menlo Park, Palo Alto, CA, 94025, USA eric.kuhn@va.gov eric.kuhn@va.gov eric.kuhn@va.gov eric.kuhn@va.gov eric.kuhn@va.gov eric.kuhn@va.gov; National Center for Telehealth and Technology, Joint Base Lewis-McChord, Tacoma, WA, USA ; Dissemination and Training Division, National Center for PTSD, VA Palo Alto Health Care System, 795 Willow Rd, Menlo Park, Palo Alto, CA, 94025, USA Y1 - 2014/11// PY - 2014 DA - Nov 2014 SP - 800 EP - 807 CY - New York PB - Springer Science & Business Media VL - 41 IS - 6 SN - 0894-587X KW - Public Health And Safety KW - Compatibility KW - Mental health professionals KW - Dissemination KW - Exposure therapy KW - In care KW - Innovations KW - Mental health KW - Ownership KW - Perceptions KW - Posttraumatic stress disorder KW - Release UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665156044?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Administration+and+Policy+in+Mental+Health+and+Mental+Health+Services+Research&rft.atitle=Clinician+Perceptions+of+Using+a+Smartphone+App+with+Prolonged+Exposure+Therapy&rft.au=Kuhn%2C+Eric%3BEftekhari%2C+Afsoon%3BHoffman%2C+Julia+E%3BCrowley%2C+Jill+J%3BRamsey%2C+Kelly+M%3BReger%2C+Greg+M%3BRuzek%2C+Josef+I&rft.aulast=Kuhn&rft.aufirst=Eric&rft.date=2014-11-01&rft.volume=41&rft.issue=6&rft.spage=800&rft.isbn=&rft.btitle=&rft.title=Administration+and+Policy+in+Mental+Health+and+Mental+Health+Services+Research&rft.issn=0894587X&rft_id=info:doi/10.1007%2Fs10488-013-0532-2 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Copyright Springer Science & Business Media Nov 2014 N1 - Date revised - 2015-01-09 N1 - Last updated - 2017-02-08 DO - http://dx.doi.org/10.1007/s10488-013-0532-2 ER - TY - JOUR T1 - Managing Uncertainty in Complex Interventional Fluoroscopic Procedures AN - 1642618364; 21055615 AB - There was a concern for potential patient skin bums indicated by air kerma as recorded by fluoroscopy equipment during two interventional fluoroscopic procedures. Two sentinel events as defined by The Joint Commission were indicated. Dose reconstruction based on measurements of machine output showed the air kerma readings were high by approximately a factor of four and no patient injury or sentinel event occurred. The radiation safety program in effect at the time of the incidents allowed discovery of equipment problems before a serious patient injury occurred, but additional controls have been implemented as a result, including quality control checks performed by cardiology, additional training, a database for tracking equipment maintenance, and mandatory entry of patient dose into electronic health records with follow-up orders automatically generated by the electronic health records. Most unexpected injuries are a result of multiple failures, but there are also multiple opportunities to prevent the injury. This paper provides a comprehensive look at patient safety concerns during two interventional cardiology fluoroscopic procedures and offers ways to flirther reduce risks to patients. It focuses on lessons learned and a systems-based approach to improving and promoting radiation safety during complex interventional fluoroscopic procedures. JF - Health Physics AU - Leuenberger, Ronald AU - Meade, Jason A AD - Louis Stokes Cleveland VA Medical Center, 10701 East Blvd USA (W), Cleveland, OH 44106., ronald.leuenberxer@va.gov Y1 - 2014/11// PY - 2014 DA - Nov 2014 SP - S181 EP - S187 PB - Williams & Wilkins, 351 W. Camden St. Baltimore MD 21201 United States VL - 107 IS - 3 SN - 0017-9078, 0017-9078 KW - Risk Abstracts KW - operational topics KW - exposure KW - radiation KW - medical radiation KW - safety standards KW - Skin KW - Injuries KW - Training KW - Quality control KW - Commissions KW - Safety KW - Tracking equipment KW - Risk reduction KW - Maintenance KW - R2 23060:Medical and environmental health UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1642618364?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ariskabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Health+Physics&rft.atitle=Managing+Uncertainty+in+Complex+Interventional+Fluoroscopic+Procedures&rft.au=Leuenberger%2C+Ronald%3BMeade%2C+Jason+A&rft.aulast=Leuenberger&rft.aufirst=Ronald&rft.date=2014-11-01&rft.volume=107&rft.issue=3&rft.spage=S181&rft.isbn=&rft.btitle=&rft.title=Health+Physics&rft.issn=00179078&rft_id=info:doi/ LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2015-01-01 N1 - Last updated - 2015-05-27 N1 - SubjectsTermNotLitGenreText - Skin; Injuries; Training; Quality control; Safety; Commissions; Risk reduction; Tracking equipment; Maintenance ER - TY - JOUR T1 - Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. AN - 1559008780; 25050737 AB - The purpose of the study was to examine the molecular mechanisms by which rottlerin inhibited growth of human pancreatic tumors in Balb C nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice. AsPC-1 cells were injected subcutaneously into Balb c nude mice, and tumor-bearing mice were treated with rottlerin. Cell proliferation and apoptosis were measured by Ki67 and TUNEL staining, respectively. The expression of components of Akt, Notch, and Sonic Hedgehog (Shh) pathways were measured by the immunohistochemistry, Western blot analysis, and/or q-RT-PCR. The effects of rottlerin on pancreatic cancer cells isolated from Kras(G12D) mice were also examined. Rottlerin-treated mice showed a significant inhibition in tumor growth which was associated with suppression of cell proliferation, activation of capase-3 and cleavage of PARP. Rottlerin inhibited the expression of Bcl-2, cyclin D1, CDK2 and CDK6, and induced the expression of Bax in tumor tissues compared to untreated control. Rottlerin inhibited the markers of angiogenesis (Cox-2, VEGF, VEGFR, and IL-8), and metastasis (MMP-2 and MMP-9), thus blocking production of tumorigenic mediators in tumor microenvironment. Rottlerin also inhibited epithelial-mesenchymal transition by up-regulating E-cadherin and inhibiting the expression of Slug and Snail. Furthermore, rottlerin treatment of xenografted tumors or pancreatic cancer cells isolated from Kras(G12D) mice showed a significant inhibition in Akt, Shh and Notch pathways compared to control groups. These data suggest that rottlerin can inhibit pancreatic cancer growth by suppressing multiple signaling pathways which are constitutively active in pancreatic cancer. Taken together, our data show that the rottlerin induces apoptosis and inhibits pancreatic cancer growth by targeting Akt, Notch and Shh signaling pathways, and provide a new therapeutic approach with translational potential for humans. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. JF - Cancer letters AU - Huang, Minzhao AU - Tang, Su-Ni AU - Upadhyay, Ghanshyam AU - Marsh, Justin L AU - Jackman, Christopher P AU - Srivastava, Rakesh K AU - Shankar, Sharmila AD - Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. ; Department of Biochemistry, University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA. ; Department of Pharmacology, Toxicology and Therapeutics, and Medicine, The University of Kansas Cancer Center, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: rsrivastava.lab@gmail.com. ; Kansas City VA Medical Center, 4801 Linwood Boulevard, Kansas City, MO 64128, USA. Electronic address: sharmila.shankar@va.gov. Y1 - 2014/10/10/ PY - 2014 DA - 2014 Oct 10 SP - 32 EP - 40 VL - 353 IS - 1 KW - Acetophenones KW - 0 KW - Angiogenesis Inhibitors KW - Angiogenic Proteins KW - Apoptosis Regulatory Proteins KW - Benzopyrans KW - Hedgehog Proteins KW - Protein Kinase Inhibitors KW - Receptors, Notch KW - SHH protein, human KW - rottlerin KW - E29LP3ZMUH KW - Proto-Oncogene Proteins c-akt KW - EC 2.7.11.1 KW - Index Medicus KW - Rottlerin KW - Sonic Hedgehog KW - Notch KW - Cancer prevention KW - Pancreatic cancer KW - Akt KW - Proto-Oncogene Proteins c-akt -- metabolism KW - Animals KW - Humans KW - Tumor Microenvironment KW - Cell Line, Tumor KW - Epithelial-Mesenchymal Transition -- drug effects KW - Mice KW - Mice, Nude KW - Mice, Transgenic KW - Angiogenic Proteins -- metabolism KW - Mice, Inbred BALB C KW - Receptors, Notch -- metabolism KW - Hedgehog Proteins -- metabolism KW - Signal Transduction -- drug effects KW - Apoptosis -- drug effects KW - Apoptosis Regulatory Proteins -- metabolism KW - Xenograft Model Antitumor Assays KW - Neovascularization, Pathologic KW - Time Factors KW - Proto-Oncogene Proteins c-akt -- antagonists & inhibitors KW - Receptors, Notch -- antagonists & inhibitors KW - Hedgehog Proteins -- antagonists & inhibitors KW - Genes, ras KW - Cell Proliferation -- drug effects KW - Angiogenesis Inhibitors -- pharmacology KW - Pancreatic Neoplasms -- pathology KW - Pancreatic Neoplasms -- metabolism KW - Protein Kinase Inhibitors -- pharmacology KW - Acetophenones -- pharmacology KW - Tumor Burden -- drug effects KW - Benzopyrans -- pharmacology KW - Pancreatic Neoplasms -- genetics KW - Pancreatic Neoplasms -- drug therapy UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1559008780?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cancer+letters&rft.atitle=Rottlerin+suppresses+growth+of+human+pancreatic+tumors+in+nude+mice%2C+and+pancreatic+cancer+cells+isolated+from+Kras%28G12D%29+mice.&rft.au=Huang%2C+Minzhao%3BTang%2C+Su-Ni%3BUpadhyay%2C+Ghanshyam%3BMarsh%2C+Justin+L%3BJackman%2C+Christopher+P%3BSrivastava%2C+Rakesh+K%3BShankar%2C+Sharmila&rft.aulast=Huang&rft.aufirst=Minzhao&rft.date=2014-10-10&rft.volume=353&rft.issue=1&rft.spage=32&rft.isbn=&rft.btitle=&rft.title=Cancer+letters&rft.issn=1872-7980&rft_id=info:doi/10.1016%2Fj.canlet.2014.06.021 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-11-04 N1 - Date created - 2014-09-01 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.canlet.2014.06.021 ER - TY - JOUR T1 - Myocardial Atrophy and Chronic Mechanical Unloading of the Failing Human Heart: Implications for Cardiac Assist Device-Induced Myocardial Recovery AN - 1837304046; 21019592 AB - Background In animal models of heterotopic transplantation, mechanical unloading of the normal, nonhypertrophic heart results in atrophy. Primarily on the basis of these animal data, the notion that chronic left ventricular assist device (LVAD)-induced unloading will result in atrophy has dominated the clinical heart failure field, and anti-atrophic drugs have been used to enhance the cardiac recovery potential observed in some LVAD patients. However, whether unloading-induced atrophy in experimental normal heart models applies to failing and hypertrophic myocardium in heart failure patients unloaded by continuous-flow LVADs has not been studied. Objectives The study examined whether mechanical unloading by continuous-flow LVAD leads to myocardial atrophy. Methods We prospectively examined myocardial tissue and hemodynamic and echocardiographic data from 44 LVAD patients and 18 untransplanted normal donors. Results Cardiomyocyte size (cross-sectional area) decreased after LVAD unloading from 1,238 plus or minus 81 mu m2 to 1,011 plus or minus 68 mu m2 (p = 0.001), but not beyond that of normal donor hearts (682 plus or minus 56 mu m2). Electron microscopy ultrastructural evaluation, cardiomyocyte glycogen content, and echocardiographic assessment of myocardial mass and left ventricular function also did not suggest myocardial atrophy. Consistent with these findings, t-tubule morphology, cytoplasmic penetration, and distance from the ryanodine receptor were not indicative of ongoing atrophic remodeling during LVAD unloading. Molecular analysis revealed no up-regulation of proatrophic genes and proteins of the ubiquitin proteasome system. Conclusions Structural, ultrastructural, microstructural, metabolic, molecular, and clinical functional data indicated that prolonged continuous-flow LVAD unloading does not induce hypertrophy regression to the point of atrophy and degeneration. These findings may be useful in designing future investigations that combine LVAD unloading and pharmaceutical therapies as a bridge to recovery of the failing heart. JF - Journal of the American College of Cardiology AU - Diakos, Nikolaos A AU - Selzman, Craig H AU - Sachse, Frank B AU - Stehlik, Josef AU - Kfoury, Abdallah G AU - Wever-Pinzon, Omar AU - Catino, Anna AU - Alharethi, Rami AU - Reid, Bruce B AU - Miller, Dylan V AU - Salama, Mohamed AU - Zaitsev, Alexey V AU - Shibayama, Junko AU - Li, Hui AU - Fang, James C AU - Li, Dean Y AU - Drakos, Stavros G AD - Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program: Divisions of Cardiovascular Medicine and Cardiothoracic Surgery, University of Utah Health Sciences Center, Intermountain Medical Center, Veterans Administration Salt Lake City Health Care System, Salt Lake City, Utah Y1 - 2014/10// PY - 2014 DA - October 2014 SP - 1602 EP - 1612 PB - Elsevier Science Ltd., The Boulevard Kidlington Oxford OX5 1GB United Kingdom VL - 64 IS - 15 SN - 0735-1097, 0735-1097 KW - Toxicology Abstracts KW - left ventricular assist device KW - mechanical unloading KW - myocardial atrophy KW - ANP atrial natriuretic peptide KW - HF heart failure KW - LV left ventricular KW - LVAD left ventricular assist device KW - PAS periodic acid Schiff KW - PASD periodic acid Schiff with diastase KW - RyR ryanodine receptor KW - UBB ubiquitin KW - UBE2 ubiquitin-conjugating enzyme E2 KW - UPS ubiquitin proteasome system KW - Heart KW - Donors KW - Data processing KW - Mechanical unloading KW - Heart transplantation KW - Animal models KW - Hemodynamics KW - cardiomyocytes KW - Immunosuppressive agents KW - Glycogen KW - Ryanodine receptors KW - Ventricle KW - Allografts KW - Pharmaceuticals KW - Atrophy KW - Degeneration KW - Myocardium KW - Ubiquitin KW - Heart diseases KW - X 24310:Pharmaceuticals UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1837304046?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxicologyabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.atitle=Myocardial+Atrophy+and+Chronic+Mechanical+Unloading+of+the+Failing+Human+Heart%3A+Implications+for+Cardiac+Assist+Device-Induced+Myocardial+Recovery&rft.au=Diakos%2C+Nikolaos+A%3BSelzman%2C+Craig+H%3BSachse%2C+Frank+B%3BStehlik%2C+Josef%3BKfoury%2C+Abdallah+G%3BWever-Pinzon%2C+Omar%3BCatino%2C+Anna%3BAlharethi%2C+Rami%3BReid%2C+Bruce+B%3BMiller%2C+Dylan+V%3BSalama%2C+Mohamed%3BZaitsev%2C+Alexey+V%3BShibayama%2C+Junko%3BLi%2C+Hui%3BFang%2C+James+C%3BLi%2C+Dean+Y%3BDrakos%2C+Stavros+G&rft.aulast=Diakos&rft.aufirst=Nikolaos&rft.date=2014-10-01&rft.volume=64&rft.issue=15&rft.spage=1602&rft.isbn=&rft.btitle=&rft.title=Journal+of+the+American+College+of+Cardiology&rft.issn=07351097&rft_id=info:doi/10.1016%2Fj.jacc.2014.05.073 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2016-11-01 N1 - Last updated - 2016-12-22 N1 - SubjectsTermNotLitGenreText - Heart; Donors; Data processing; Mechanical unloading; Animal models; Heart transplantation; Hemodynamics; cardiomyocytes; Immunosuppressive agents; Glycogen; Ventricle; Ryanodine receptors; Allografts; Pharmaceuticals; Degeneration; Atrophy; Heart diseases; Ubiquitin; Myocardium DO - http://dx.doi.org/10.1016/j.jacc.2014.05.073 ER - TY - JOUR T1 - Classes of oppositional-defiant behavior: concurrent and predictive validity AN - 1627730983 AB - Background Oppositional defiant disorder (ODD) has components of both irritability and defiance. It remains unclear whether children with variation in these domains have different adult outcomes. This study examined the concurrent and predictive validity of classes of oppositional defiant behavior. Methods Latent class analysis was performed on the oppositional defiant problems scale of the Child Behavior Checklist in two samples, one in the US (the Achenbach Normative Sample, N = 2029) and one in the Netherlands (the Zuid-Holland Study, N = 2076). A third sample of American children (The Vermont Family Study, N = 399) was examined to determine concurrent validity with DSM diagnoses. Predictive validity over 14 years was assessed using the Zuid-Holland Study. Results Four classes of oppositional defiant problems were consistent in the two latent class analyses: No Symptoms, All Symptoms, Irritable, and Defiant. Individuals in the No Symptoms Class were rarely diagnosed concurrently with ODD or any future disorder. Individuals in the All Symptoms Class had an increased frequency of concurrent childhood diagnosis of ODD and of violence in adulthood. Subjects in the Irritable Class had low concurrent diagnosis of ODD, but increased odds of adult mood disorders. Individuals in the Defiant Class had low concurrent diagnosis of ODD, but had increased odds of violence as adults. Conclusions Only children in the All Symptoms class were likely to have a concurrent diagnosis of ODD. Although not diagnosed with ODD, children in the Irritable Class were more likely to have adult mood disorders and children in the Defiant Class were more likely to engage in violent behavior. JF - Journal of Child Psychology and Psychiatry and Allied Disciplines AU - Althoff, Robert R AU - Kuny-Slock, Ana V AU - Verhulst, Frank C AU - Hudziak, James J AU - Ende, Jan AD - Departments of Psychiatry and Pediatrics, College of Medicine, University of Vermont, Burlington, VT, USA., Department of Psychology, University of Vermont, Burlington, VT, USA., Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. ; New Mexico Veterans Administration Hospital, Albuquerque, NM, USA. ; Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. ; Departments of Psychiatry and Pediatrics, College of Medicine, University of Vermont, Burlington, VT, USA., Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands., Department of Medicine, College of Medicine, University of Vermont, Burlington, VT, USA. ; Departments of Psychiatry and Pediatrics, College of Medicine, University of Vermont, Burlington, VT, USA.; Department of Psychology, University of Vermont, Burlington, VT, USA.; Department of Child and Adolescent Psychiatry, Erasmus University Medical Center, Rotterdam, The Netherlands. Y1 - 2014/10// PY - 2014 DA - Oct 2014 SP - 1162 EP - 1171 CY - Cambridge PB - Blackwell Publishing Ltd. VL - 55 IS - 10 SN - 0021-9630 KW - Psychology KW - Adulthood KW - Adults KW - Behaviour KW - Child Behaviour Checklist KW - Affective disorders KW - Childhood KW - Children KW - Defiance KW - Diagnosis KW - Irritability KW - Latent class analysis KW - Only children KW - Oppositional defiant disorder KW - Predictive validity KW - Symptoms KW - Violence KW - United States--US KW - Netherlands KW - Vermont UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1627730983?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Child+Psychology+and+Psychiatry+and+Allied+Disciplines&rft.atitle=Classes+of+oppositional-defiant+behavior%3A+concurrent+and+predictive+validity&rft.au=Althoff%2C+Robert+R%3BKuny-Slock%2C+Ana+V%3BVerhulst%2C+Frank+C%3BHudziak%2C+James+J%3BEnde%2C+Jan&rft.aulast=Althoff&rft.aufirst=Robert&rft.date=2014-10-01&rft.volume=55&rft.issue=10&rft.spage=1162&rft.isbn=&rft.btitle=&rft.title=Journal+of+Child+Psychology+and+Psychiatry+and+Allied+Disciplines&rft.issn=00219630&rft_id=info:doi/10.1111%2Fjcpp.12233 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-11-10 N1 - Last updated - 2016-05-12 N1 - SubjectsTermNotLitGenreText - Netherlands; United States--US; Vermont DO - http://dx.doi.org/10.1111/jcpp.12233 ER - TY - JOUR T1 - Positive and negative religious coping, depressive symptoms, and quality of life in people with HIV AN - 1627730004 AB - The present study examined the relationships of positive and negative types of religious coping with depression and quality of life, and the mediating role of benefit finding in the link between religious coping and psychological outcomes among 198 individuals with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). The results of multiple hierarchical analyses revealed that negative religious coping was significantly associated with a high level of depressive symptoms and a low level of quality of life, controlling for demographic and clinical variables. On the other hand, positive religious coping was significantly associated with positive domains of outcome measures such as positive affect and life satisfaction, but not with overall depressive symptoms or quality of life. Tests of mediation analyses showed that benefit finding fully mediated the relationship between positive religious coping and the positive sub-domains of psychological outcomes. The importance of investigating both positive and negative types of religious coping in their relationships with psychological adaptation in people with HIV was discussed, as well as the significance of benefit finding in understanding the link between religious coping and psychological outcomes. JF - Journal of Behavioral Medicine AU - Lee, Minsun AU - Nezu, Arthur M AU - Nezu, Christine Maguth AD - Department of Psychology, Drexel University, Stratton Hall, 3141 Chestnut Street, Philadelphia, PA, 19104, USA minsunlee87@gmail.com; Department of Psychology, Drexel University, Stratton Hall, 3141 Chestnut Street, Philadelphia, PA, 19104, USA, Philadelphia Veterans Administration Medical Center, Philadelphia, PA, USA ; Department of Psychology, Drexel University, Stratton Hall, 3141 Chestnut Street, Philadelphia, PA, 19104, USA Y1 - 2014/10// PY - 2014 DA - Oct 2014 SP - 921 EP - 930 CY - New York PB - Springer Science & Business Media VL - 37 IS - 5 SN - 0160-7715 KW - Psychology KW - Adaptation KW - AIDS KW - Clinical variables KW - Coping KW - Depression KW - HIV KW - Immune disorders KW - Life satisfaction KW - Mediation KW - Positive affect KW - Quality of life KW - Religious aspects KW - Symptoms UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1627730004?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Behavioral+Medicine&rft.atitle=Positive+and+negative+religious+coping%2C+depressive+symptoms%2C+and+quality+of+life+in+people+with+HIV&rft.au=Lee%2C+Minsun%3BNezu%2C+Arthur+M%3BNezu%2C+Christine+Maguth&rft.aulast=Lee&rft.aufirst=Minsun&rft.date=2014-10-01&rft.volume=37&rft.issue=5&rft.spage=921&rft.isbn=&rft.btitle=&rft.title=Journal+of+Behavioral+Medicine&rft.issn=01607715&rft_id=info:doi/10.1007%2Fs10865-014-9552-y LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Copyright - Copyright Springer Science & Business Media Oct 2014 N1 - Date revised - 2014-11-10 N1 - Last updated - 2017-02-08 DO - http://dx.doi.org/10.1007/s10865-014-9552-y ER - TY - JOUR T1 - Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing blaVIM-2 and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio AN - 1622600568; 20856056 AB - Carbapenems are a mainstay of treatment for infections caused by Pseudomonas aeruginosa. Carbapenem resistance mediated by metallo- beta -lactamases (MBLs) remains uncommon in the United States, despite the worldwide emergence of this group of enzymes. Between March 2012 and May 2013, we detected MBL-producing P. aeruginosa in a university-affiliated health care system in northeast Ohio. We examined the clinical characteristics and outcomes of patients, defined the resistance determinants and structure of the genetic element harboring the blaMBL gene through genome sequencing, and typed MBL-producing P. aeruginosa isolates using pulsed-field gel electrophoresis (PFGE), repetitive sequence-based PCR (rep-PCR), and multilocus sequence typing (MLST). Seven patients were affected that were hospitalized at three community hospitals, a long-term-care facility, and a tertiary care center; one of the patients died as a result of infection. Isolates belonged to sequence type 233 (ST233) and were extensively drug resistant (XDR), including resistance to all fluoroquinolones, aminoglycosides, and beta -lactams; two isolates were nonsusceptible to colistin. The blaMBL gene was identified as blaVIM-2 contained within a class 1 integron (In559), similar to the cassette array previously detected in isolates from Norway, Russia, Taiwan, and Chicago, IL. Genomic sequencing and assembly revealed that In559 was part of a novel 35-kb region that also included a Tn501-like transposon and Salmonella genomic island 2 (SGI2)-homologous sequences. This analysis of XDR strains producing VIM-2 from northeast Ohio revealed a novel recombination event between Salmonella and P. aeruginosa, heralding a new antibiotic resistance threat in this region's health care system. JF - Antimicrobial Agents & Chemotherapy AU - Perez, Federico AU - Hujer, Andrea M AU - Marshall, Steven H AU - Ray, Amy J AU - Rather, Philip N AU - Suwantarat, Nuntra AU - Dumford, Donald III AU - O'Shea, Patrick AU - Domitrovic, T Nicholas J AU - Salata, Robert A AD - Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA, robert.bonomo@va.gov. Y1 - 2014/10// PY - 2014 DA - Oct 2014 SP - 5929 EP - 5935 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 58 IS - 10 SN - 0066-4804, 0066-4804 KW - Genetics Abstracts; Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Genomes KW - Metallo- beta -lactamase KW - Fluoroquinolones KW - Drug resistance KW - Enzymes KW - Carbapenems KW - Infection KW - Aminoglycoside antibiotics KW - multilocus sequence typing KW - Transposons KW - Colistin KW - Recombination KW - Islands KW - beta -Lactam antibiotics KW - Pulsed-field gel electrophoresis KW - Polymerase chain reaction KW - genomics KW - Pseudomonas aeruginosa KW - Salmonella KW - Antibiotic resistance KW - Hospitals KW - J 02400:Human Diseases KW - A 01350:Microbial Resistance KW - G 07770:Bacteria UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1622600568?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Extensively+Drug-Resistant+Pseudomonas+aeruginosa+Isolates+Containing+blaVIM-2+and+Elements+of+Salmonella+Genomic+Island+2%3A+a+New+Genetic+Resistance+Determinant+in+Northeast+Ohio&rft.au=Perez%2C+Federico%3BHujer%2C+Andrea+M%3BMarshall%2C+Steven+H%3BRay%2C+Amy+J%3BRather%2C+Philip+N%3BSuwantarat%2C+Nuntra%3BDumford%2C+Donald+III%3BO%27Shea%2C+Patrick%3BDomitrovic%2C+T+Nicholas+J%3BSalata%2C+Robert+A&rft.aulast=Perez&rft.aufirst=Federico&rft.date=2014-10-01&rft.volume=58&rft.issue=10&rft.spage=5929&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.02372-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-11-01 N1 - Number of references - 50 N1 - Last updated - 2015-06-26 N1 - SubjectsTermNotLitGenreText - Genomes; Metallo- beta -lactamase; Fluoroquinolones; Drug resistance; Carbapenems; Enzymes; Infection; Aminoglycoside antibiotics; multilocus sequence typing; Colistin; Transposons; Recombination; Islands; beta -Lactam antibiotics; Pulsed-field gel electrophoresis; Polymerase chain reaction; genomics; Antibiotic resistance; Hospitals; Pseudomonas aeruginosa; Salmonella DO - http://dx.doi.org/10.1128/AAC.02372-14 ER - TY - JOUR T1 - Cyclooxygenases: mediators of UV-induced skin cancer and potential targets for prevention. AN - 1618140029; 24804836 AB - Non-melanoma skin cancers (NMSCs) are among the most common human malignancies. Current methods for their prevention include avoidance of natural and artificial sources of UV radiation and using photoprotective clothing and sunscreens. However, these methods have proven to be inadequate in stemming the rise in skin cancer incidence over the past several years. There is accumulating evidence that cyclooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis, may be involved in the pathogenesis of NMSC. In preclinical studies, animals genetically deficient in the COX-2 enzyme or that have been treated with pharmacological inhibitors of COX-2 develop significantly fewer tumors when subjected to a UV-induced skin carcinogenesis protocol compared with control mice. Several epidemiological studies in humans support the concept that this enzyme is intimately involved in UV-induced skin cancer development, and UV radiation is known to augment COX-2 expression in human skin. Recent studies suggest that drugs that block COX-2 expression may prevent the development of NMSCs. Thus, pharmacologic agents that inhibit the enzyme COX-2 may be effective chemopreventive agents for NMSCs. JF - The Journal of investigative dermatology AU - Elmets, Craig A AU - Ledet, Johnathan J AU - Athar, Mohammad AD - 1] Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA [2] UAB Skin Diseases Research Center, University of Alabama at Birmingham, Birmingham, Alabama, USA [3] UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA [4] Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA. ; 1] Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA [2] Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA. ; 1] Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA [2] UAB Skin Diseases Research Center, University of Alabama at Birmingham, Birmingham, Alabama, USA [3] UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA. Y1 - 2014/10// PY - 2014 DA - October 2014 SP - 2497 EP - 2502 VL - 134 IS - 10 KW - Cyclooxygenase 2 Inhibitors KW - 0 KW - Sunscreening Agents KW - Prostaglandin-Endoperoxide Synthases KW - EC 1.14.99.1 KW - Index Medicus KW - Animals KW - Sunscreening Agents -- therapeutic use KW - Humans KW - Cyclooxygenase 2 Inhibitors -- therapeutic use KW - Cyclooxygenase 2 Inhibitors -- pharmacology KW - Disease Models, Animal KW - Mice KW - Skin Neoplasms -- physiopathology KW - Prostaglandin-Endoperoxide Synthases -- physiology KW - Neoplasms, Radiation-Induced -- physiopathology KW - Skin Neoplasms -- etiology KW - Ultraviolet Rays -- adverse effects KW - Neoplasms, Radiation-Induced -- prevention & control KW - Prostaglandin-Endoperoxide Synthases -- drug effects KW - Skin Neoplasms -- prevention & control UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1618140029?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+investigative+dermatology&rft.atitle=Cyclooxygenases%3A+mediators+of+UV-induced+skin+cancer+and+potential+targets+for+prevention.&rft.au=Elmets%2C+Craig+A%3BLedet%2C+Johnathan+J%3BAthar%2C+Mohammad&rft.aulast=Elmets&rft.aufirst=Craig&rft.date=2014-10-01&rft.volume=134&rft.issue=10&rft.spage=2497&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+investigative+dermatology&rft.issn=1523-1747&rft_id=info:doi/10.1038%2Fjid.2014.192 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-01-13 N1 - Date created - 2014-09-15 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Br J Dermatol. 2007 Apr;156(4):716-9 [17493070] Mol Carcinog. 2007 May;46(5):363-71 [17219415] Mol Carcinog. 2007 Aug;46(8):692-8 [17443745] Photochem Photobiol. 2008 Jan-Feb;84(1):10-8 [18173696] Photochem Photobiol. 2008 Mar-Apr;84(2):322-9 [18194346] Circulation. 2008 Apr 22;117(16):2104-13 [18378608] Cancer Prev Res (Phila). 2008 Jun;1(1):32-8 [18841250] Clin Pharmacol Ther. 2009 Feb;85(2):190-7 [18987620] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541] Cancer Prev Res (Phila). 2009 Nov;2(11):951-6 [19892664] Cancer Prev Res (Phila). 2010 Jan;3(1):25-34 [20051370] Arch Dermatol. 2010 Mar;146(3):283-7 [20231499] Arch Dermatol. 2010 Apr;146(4):388-95 [20157019] Pharm Res. 2010 Jun;27(6):1092-102 [20143255] J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44 [21115882] Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6668-73 [21460251] Pharmacoepidemiol Drug Saf. 2011 Sep;20(9):922-9 [21688346] Cancer Prev Res (Phila). 2011 Nov;4(11):1728-35 [21778329] Cancer Metastasis Rev. 2011 Dec;30(3-4):465-80 [22012553] PLoS One. 2012;7(4):e35196 [22496907] Cancer. 2012 Oct 1;118(19):4768-76 [22644960] Dermatol Surg. 2013 Jan;39(1 Pt 1):35-42 [23199014] CA Cancer J Clin. 2013 Jan;63(1):11-30 [23335087] Photodermatol Photoimmunol Photomed. 2013 Apr;29(2):57-64 [23458388] Toxicol Appl Pharmacol. 2013 May 1;268(3):249-55 [23274568] Neoplasia. 2013 Jul;15(7):795-804 [23814491] Cancer Prev Res (Phila). 2013 Jul;6(7):675-85 [23682071] Prostaglandins Other Lipid Mediat. 2000 Oct;62(4):367-84 [11060900] BMJ. 2000 Nov 11;321(7270):1183-7 [11073508] Lancet. 2002 Jan 12;359(9301):118-23 [11809254] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310] J Drugs Dermatol. 2002 Jul;1(1):44-7 [12847753] Mol Carcinog. 2003 Oct;38(2):49-58 [14502644] Toxicol Appl Pharmacol. 2004 Mar 15;195(3):370-8 [15020200] Cancer Res. 2004 Aug 15;64(16):5587-91 [15313895] J Natl Cancer Inst. 1974 Nov;53(5):1333-6 [4139281] J Immunol. 1986 Oct 15;137(8):2478-84 [3463622] N Engl J Med. 1993 Oct 14;329(16):1147-51 [8377777] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081] Br J Dermatol. 1998 Feb;138(2):301-3 [9602879] Carcinogenesis. 1998 May;19(5):723-9 [9635856] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029] Lancet. 1999 Aug 28;354(9180):723-9 [10475183] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944] JAMA. 2005 Aug 10;294(6):681-90 [16091570] J Am Acad Dermatol. 2005 Dec;53(6):966-72 [16310056] J Invest Dermatol. 2005 Dec;125(6):1317-20 [16354205] J Invest Dermatol. 2006 Jan;126(1):205-11 [16417238] Nat Rev Cancer. 2006 Feb;6(2):130-40 [16491072] Int J Cancer. 2006 Aug 1;119(3):682-6 [16496410] N Engl J Med. 2007 Jul 26;357(4):360-9 [17652651] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1038/jid.2014.192 ER - TY - JOUR T1 - Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. AN - 1566113653; 24953794 AB - To determine whether rituximab, a monoclonal antibody against the B-lymphocyte antigen CD20, is effective in the treatment of refractory noninfectious scleritis. Prospective, dose-ranging, randomized, double-masked phase I/II clinical trial. Twelve patients with noninfectious scleritis refractory to systemic corticosteroid and ≥1 other systemic immunosuppressive agent were enrolled from January 2007 to March 2010. Subjects were randomly assigned to 500 (n = 5) or 1000 mg (n = 7) dosing arms of rituximab intravenous infusions (500 or 1000 mg), given at study days 1 and 15. Initial responders with breakthrough inflammation after study week 24 were offered treatment with an additional cycle of 2 open-label rituximab 1000 mg infusions. Primary outcomes were reduction of inflammation, as measured with a validated scleritis disease grading scale (SGS) and reduction in corticosteroid dose by ≥50%. Patients were characterized as responders to study therapy if ≥1 of these endpoints showed improvement and neither showed evidence of worsening. Secondary outcomes were improvement in visual acuity, reduction in pain, and improvement in patient and physician-reported global health assessment. Of 12 enrolled patients, 9 met the SGS endpoint at or before week 24, and 4 additionally were able to reduce corticosteroid dose by ≥50%. With regard to secondary outcome measures, 11 and 9 patients showed improvement in patient and physician global health scores, respectively, and 7 patients had reduction in pain. Of 9 initial responders, 7 experienced breakthrough inflammation after 24 weeks and were treated with a second cycle of rituximab infusions. Four patients had significant objective or subjective worsening within 8 weeks of receiving rituximab; this event was averted in subsequent patients by treatment with peri-infusional oral corticosteroid. No other significant adverse events were noted. No differences in efficacy, toxicity, or likelihood of retreatment were noted between the dosing arms. Rituximab was effective treatment for 9 of 12 enrolled patients with refractory, noninfectious scleritis at 24 weeks, although 7 required reinfusion with rituximab to maintain inflammatory control. The treatment was well-tolerated, and peri-infusional inflammatory exacerbations were managed successfully with oral corticosteroids. Further long-term studies are warranted to determine the safety and efficacy of rituximab in treating noninfectious scleritis and other ocular inflammatory diseases. Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. JF - Ophthalmology AU - Suhler, Eric B AU - Lim, Lyndell L AU - Beardsley, Robert M AU - Giles, Tracy R AU - Pasadhika, Sirichai AU - Lee, Shelly T AU - de Saint Sardos, Alexandre AU - Butler, Nicholas J AU - Smith, Justine R AU - Rosenbaum, James T AD - Portland Veterans Administration Medical Center, Portland, Oregon; Oregon Health & Science University, Department of Ophthalmology/Casey Eye Institute, Portland, Oregon; Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon. Electronic address: suhlere@ohsu.edu. ; Oregon Health & Science University, Department of Ophthalmology/Casey Eye Institute, Portland, Oregon; Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia. ; Oregon Health & Science University, Department of Ophthalmology/Casey Eye Institute, Portland, Oregon. ; Oregon Health & Science University, Department of Ophthalmology/Casey Eye Institute, Portland, Oregon; Department of Developmental Biology, Oregon Health & Science University, Portland, Oregon; Clinical and Molecular Medicine, Flinders University, Adelaide, Australia. ; Oregon Health & Science University, Department of Ophthalmology/Casey Eye Institute, Portland, Oregon; Department of Medicine, and Cell and Developmental Biology, Oregon Health & Science University, Portland, Oregon; Department of Developmental Biology, Oregon Health & Science University, Portland, Oregon; Devers Eye Institute, Portland, Oregon. Y1 - 2014/10// PY - 2014 DA - October 2014 SP - 1885 EP - 1891 VL - 121 IS - 10 KW - Antibodies, Monoclonal, Murine-Derived KW - 0 KW - Immunologic Factors KW - Rituximab KW - 4F4X42SYQ6 KW - Index Medicus KW - Severity of Illness Index KW - Young Adult KW - Prospective Studies KW - Infusions, Intravenous KW - Dose-Response Relationship, Drug KW - Humans KW - Adult KW - Middle Aged KW - Male KW - Female KW - Immunologic Factors -- administration & dosage KW - Antibodies, Monoclonal, Murine-Derived -- administration & dosage KW - Scleritis -- drug therapy UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1566113653?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Ophthalmology&rft.atitle=Rituximab+therapy+for+refractory+scleritis%3A+results+of+a+phase+I%2FII+dose-ranging%2C+randomized%2C+clinical+trial.&rft.au=Suhler%2C+Eric+B%3BLim%2C+Lyndell+L%3BBeardsley%2C+Robert+M%3BGiles%2C+Tracy+R%3BPasadhika%2C+Sirichai%3BLee%2C+Shelly+T%3Bde+Saint+Sardos%2C+Alexandre%3BButler%2C+Nicholas+J%3BSmith%2C+Justine+R%3BRosenbaum%2C+James+T&rft.aulast=Suhler&rft.aufirst=Eric&rft.date=2014-10-01&rft.volume=121&rft.issue=10&rft.spage=1885&rft.isbn=&rft.btitle=&rft.title=Ophthalmology&rft.issn=1549-4713&rft_id=info:doi/10.1016%2Fj.ophtha.2014.04.044 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-11-18 N1 - Date created - 2014-09-27 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.ophtha.2014.04.044 ER - TY - JOUR T1 - Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin. AN - 1562427730; 24107515 AB - Hematopoietic cell transplant (HCT) is a life-saving therapy for many malignant and non-malignant bone marrow diseases. Associated morbidities are often due to transplant-related toxicities and infections, exacerbated by regimen-induced immune suppression and systemic incursion of bacterial products. Patients undergoing myeloablative conditioning for HCT become endotoxemic and display blood/plasma changes consistent with lipopolysaccharide (LPS)-induced systemic innate immune activation. Herein, we addressed whether patients scheduled for HCT display differences in recognition/response to LPS ex vivo traceable to specific single nucleotide polymorphisms (SNPs). Two SNPs of LPS binding protein (LBP) were associated with changes in plasma LBP levels, with one LBP SNP also associating with differences in efficiency of extraction and transfer of endotoxin to myeloid differentiation factor-2 (MD-2), a step needed for activation of TLR4. None of the examined SNPs of CD14, bactericidal/permeability-increasing protein (BPI), TLR4 or MD-2 were associated with corresponding protein plasma levels or endotoxin delivery to MD-2, but CD14 and BPI SNPs significantly associated with differences in LPS-induced TNF-α release ex vivo and infection frequency, respectively. These findings suggest that specific LBP, CD14 and BPI SNPs might be contributory assessments in studies where clinical outcome may be affected by host response to endotoxin and bacterial infection. © The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav. JF - Innate immunity AU - Guinan, Eva C AU - Palmer, Christine D AU - Mancuso, Christy J AU - Brennan, Lisa AU - Stoler-Barak, Liat AU - Kalish, Leslie A AU - Suter, Eugenie E AU - Gallington, Leighanne C AU - Huhtelin, David P AU - Mansilla, Maria AU - Schumann, Ralf R AU - Murray, Jeffrey C AU - Weiss, Jerrold AU - Levy, Ofer AD - Boston Children's Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA Dana-Farber Cancer Institute, Boston, MA, USA. ; Boston Children's Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, MA, USA. ; Boston Children's Hospital, Boston, MA, USA. ; Dana-Farber Cancer Institute, Boston, MA, USA. ; Boston Children's Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA. ; University of Iowa and Veterans' Administration Medical Center, Coralville, Iowa City, IA, USA. ; Department of Pediatrics, University of Iowa, IA, Iowa City, USA. ; Institute for Microbiology, Charité-University Medical Center, Berlin, Germany. ; Boston Children's Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA ofer.levy@childrens.harvard.edu. Y1 - 2014/10// PY - 2014 DA - October 2014 SP - 697 EP - 711 VL - 20 IS - 7 KW - Acute-Phase Proteins KW - 0 KW - Antigens, CD14 KW - Carrier Proteins KW - Chemokines KW - Endotoxins KW - Membrane Glycoproteins KW - Tumor Necrosis Factor-alpha KW - lipopolysaccharide-binding protein KW - Index Medicus KW - bactericidal/permeability-increasing protein (BPI) KW - TNF KW - bone marrow transplant KW - hematopoietic cell transplant (HCT) KW - LPS-binding protein (LBP) KW - lipopolysaccharide (LPS) KW - CD14 KW - Genotype KW - Chemokines -- metabolism KW - Acute-Phase Proteins -- genetics KW - Humans KW - Carrier Proteins -- genetics KW - Cohort Studies KW - Tumor Necrosis Factor-alpha -- metabolism KW - Membrane Glycoproteins -- genetics KW - Antigens, CD14 -- genetics KW - Bone Marrow Diseases -- genetics KW - Hematopoietic Stem Cell Transplantation KW - Bone Marrow Diseases -- therapy KW - Polymorphism, Single Nucleotide -- genetics KW - Endotoxins -- toxicity UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1562427730?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Innate+immunity&rft.atitle=Identification+of+single+nucleotide+polymorphisms+in+hematopoietic+cell+transplant+patients+affecting+early+recognition+of%2C+and+response+to%2C+endotoxin.&rft.au=Guinan%2C+Eva+C%3BPalmer%2C+Christine+D%3BMancuso%2C+Christy+J%3BBrennan%2C+Lisa%3BStoler-Barak%2C+Liat%3BKalish%2C+Leslie+A%3BSuter%2C+Eugenie+E%3BGallington%2C+Leighanne+C%3BHuhtelin%2C+David+P%3BMansilla%2C+Maria%3BSchumann%2C+Ralf+R%3BMurray%2C+Jeffrey+C%3BWeiss%2C+Jerrold%3BLevy%2C+Ofer&rft.aulast=Guinan&rft.aufirst=Eva&rft.date=2014-10-01&rft.volume=20&rft.issue=7&rft.spage=697&rft.isbn=&rft.btitle=&rft.title=Innate+immunity&rft.issn=1753-4267&rft_id=info:doi/10.1177%2F1753425913505122 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-05-22 N1 - Date created - 2014-09-15 N1 - Date revised - 2017-01-13 N1 - SuppNotes - Cited By: J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345] Gene. 2013 Jul 1;523(1):70-5 [23562783] J Biol Chem. 2001 Oct 12;276(41):38044-51 [11500507] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3902-7 [11891303] Transplantation. 2002 May 15;73(9):1522-6 [12023636] Annu Rev Med. 2003;54:29-52 [12359826] Biochem Soc Trans. 2003 Aug;31(Pt 4):785-90 [12887306] J Infect Dis. 2003 Sep 15;188(6):938-43 [12964127] Pediatr Infect Dis J. 2003 Nov;22(11):978-81 [14614371] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4186-91 [15010525] Mil Med. 2004 Mar;169(3):194-7 [15080238] J Endotoxin Res. 2004;10(2):71-84 [15119998] J Infect Dis. 2004 Aug 1;190(3):527-34 [15243928] Biol Blood Marrow Transplant. 2004 Sep;10(9):635-44 [15319775] Blood. 1992 Dec 15;80(12):2964-8 [1467511] Lancet. 1994 Aug 13;344(8920):429-31 [7520106] Mol Cell Biol. 1996 Jul;16(7):3490-503 [8668165] J Leukoc Biol. 2004 Nov;76(5):909-25 [15292276] J Endotoxin Res. 2005;11(2):69-84 [15949133] J Endotoxin Res. 2005;11(4):225-9 [16176659] Diabetes. 2006 Jan;55(1):216-24 [16380496] Cleft Palate Craniofac J. 2006 Jan;43(1):21-9 [16405370] Hybridoma (Larchmt). 2006 Dec;25(6):349-57 [17203997] J Biol Chem. 2007 Jan 12;282(2):1010-7 [17121827] Immunol Res. 2007;39(1-3):249-60 [17917069] Blood. 2008 Feb 15;111(4):2462-9 [18056482] J Allergy Clin Immunol. 2008 Feb;121(2):434-440.e1 [17949800] J Biol Chem. 2008 Aug 8;283(32):21881-9 [18519568] J Clin Oncol. 2008 Dec 10;26(35):5767-74 [19001324] Hepatology. 2009 Mar;49(3):960-8 [19085953] Expert Rev Anti Infect Ther. 2009 Jun;7(5):607-21 [19485800] J Mol Med (Berl). 2009 Aug;87(8):815-24 [19468702] Crit Care Med. 2009 Oct;37(10):2759-66 [19707138] Curr Opin Gastroenterol. 2010 Mar;26(2):88-94 [20040865] J Immunol. 2010 Apr 15;184(8):4362-7 [20212095] J Allergy Clin Immunol. 2010 Jun;125(6):1361-8 [20398919] Biol Blood Marrow Transplant. 2010 Dec;16(12):1718-27 [20541026] Int Immunol. 2011 Aug;23(8):503-10 [21712422] Biochem Soc Trans. 2011 Aug;39(4):994-9 [21787336] Occup Environ Med. 2011 Nov;68(11):826-31 [21389010] Sci Transl Med. 2011 Nov 23;3(110):110ra118 [22116933] Br J Anaesth. 2012 Mar;108(3):452-9 [22298243] COPD. 2012 Apr;9(2):197-202 [22409502] J Biol Chem. 2012 May 11;287(20):16346-55 [22433852] PLoS One. 2013;8(3):e58164 [23483986] J Biol Chem. 2001 Feb 23;276(8):5883-91 [11084043] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1177/1753425913505122 ER - TY - JOUR T1 - Occupational Therapy Use by Older Adults With Cancer AN - 1679030081 AB - Occupational therapy may significantly improve cancer survivorsʼ ability to participate in activities, thereby improving quality of life. Little is known, however, about the use of occupational therapy services by adults with cancer. The objective of this study was to understand what shapes patterns of occupational therapy use to help improve service delivery. We examined older (age >65 yr) adults diagnosed with breast, prostate, lung, or melanoma (skin) cancer between 2004 and 2007 ( N = 27,131) using North Carolina Central Cancer Registry data linked to Medicare billing claims. Survivors who used occupational therapy within 1 yr before their cancer diagnosis were more likely to use occupational therapy after diagnosis but also experienced the highest levels of comorbidities. Survivors with Stage 4 cancers or lung cancer were less likely to use occupational therapy. These findings suggest possible disparities in utilization of occupational therapy by older adults with cancer. JF - The American Journal of Occupational Therapy AU - Cutchin, Malcolm P AU - Weinberger, Morris AU - Meyer, Anne-Marie AD - Department of Health Care Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI ; Healthcare Quality Management, Department of Health Policy and Management, University of North Carolina at Chapel Hill; Durham Veterans Administration Medical Center, Center for Health Services Research, Durham, NC ; Department of Epidemiology, Gillings School of Global Pubic Health, University of North Carolina at Chapel Hill; Integrated Cancer Information and Surveillance System, University of North Carolina at Chapel Hill ; Pergolotti, Mackenzi; Cancer Care Quality Training Program, Department of Health Policy and Management, Gillings School of Global Public Health, CB#7411, 1102G McGavran-Greenberg Hall, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 Y1 - 2014///Sep/Oct PY - 2014 DA - Sep/Oct 2014 SP - 597 EP - 607 CY - Bethesda PB - American Occupational Therapy Association, Inc. VL - 68 IS - 5 SN - 0272-9490 KW - Medical Sciences KW - Breast cancer KW - Adults KW - Service delivery KW - Skin cancer KW - Skin melanoma KW - Survivors KW - Cancer KW - Charges KW - Diagnosis KW - Elderly people KW - Lung cancer KW - Medicare KW - Occupational therapy KW - Prostate KW - Quality of life KW - North Carolina UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1679030081?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+American+Journal+of+Occupational+Therapy&rft.atitle=Occupational+Therapy+Use+by+Older+Adults+With+Cancer&rft.au=Pergolotti%2C+Mackenzi%3BCutchin%2C+Malcolm+P%3BWeinberger%2C+Morris%3BMeyer%2C+Anne-Marie&rft.aulast=Pergolotti&rft.aufirst=Mackenzi&rft.date=2014-09-01&rft.volume=68&rft.issue=5&rft.spage=597&rft.isbn=&rft.btitle=&rft.title=The+American+Journal+of+Occupational+Therapy&rft.issn=02729490&rft_id=info:doi/10.5014%2Fajot.2014.011791 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-05-05 N1 - Last updated - 2016-05-12 N1 - SubjectsTermNotLitGenreText - North Carolina DO - http://dx.doi.org/10.5014/ajot.2014.011791 ER - TY - JOUR T1 - PARTNERSHIP AND EXTENDED FAMILY RELATIONSHIP QUALITY MODERATE ASSOCIATIONS BETWEEN LIFETIME PSYCHIATRIC DIAGNOSES AND CURRENT DEPRESSIVE SYMPTOMS IN MIDLIFE AN - 1665156385 AB - Adult close relationships, both in marriage and extended family, are hypothesized to be foremost among potential supports and influences on adult development, and the quality of these close relationships has been associated with symptoms of depression and anxiety. In a socioeconomically diverse sample of 182 midlife Black/African American and White/European American men and women, we examined whether close relationship quality moderated the association between lifetime diagnosis of mood and/or anxiety disorder and current symptoms of depression and anxiety. Results supported a buffering hypothesis, such that adults with these lifetime diagnoses and higher quality, supportive, and reciprocal extended family relationships had low depressive symptoms, comparable to those who had no lifetime history of mood/anxiety disorders. Further evidence for a buffering effect of close relationships was seen when both marital and extended family relationships were examined together. When the three risk factors were considered together, that is, lifetime diagnoses, extended family quality, and marital quality, they were additive with respect to predicting depressive symptoms. JF - Journal of Social and Clinical Psychology AU - CROWELL, JUDITH A AU - DEARING, ERIC AU - DAVIS, CYNTHIA R AU - MIRANDA-JULIAN, CLAUDIA AU - BARKAI, AYELET R AU - USHER, NICOLE AU - TRIFILETTI, SARAH AU - MANTZOROS, CHRISTOS AD - Stony Brook University and Judge Baker Childrenʼs Center, Harvard Medical School; Division of Child and Adolescent Psychiatry, Putnam Hall-South Campus, Stony Brook University, Stony Brook, NY 11794 ; Boston College ; Judge Baker Childrenʼs Center, Harvard Medical School ; Tufts University ; Beth Israel Deaconess Medical Center and Harvard Medical School; Boston Veteransʼ Administration Healthcare System ; Stony Brook University and Judge Baker Childrenʼs Center, Harvard Medical School; Division of Child and Adolescent Psychiatry, Putnam Hall-South Campus, Stony Brook University, Stony Brook, NY 11794 Y1 - 2014/09// PY - 2014 DA - Sep 2014 SP - 612 EP - 629 CY - New York PB - Guilford Publications, Inc. VL - 33 IS - 7 SN - 0736-7236 KW - Psychology KW - Anxiety disorders KW - Adults KW - Anxiety-Depression KW - Black American people KW - Buffering KW - Depression KW - Diagnosis KW - Family relationships KW - Interpersonal relationships KW - Marital quality KW - Marriage KW - Midlife KW - Moderated KW - Quality KW - Risk factors KW - Symptoms UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665156385?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Social+and+Clinical+Psychology&rft.atitle=PARTNERSHIP+AND+EXTENDED+FAMILY+RELATIONSHIP+QUALITY+MODERATE+ASSOCIATIONS+BETWEEN+LIFETIME+PSYCHIATRIC+DIAGNOSES+AND+CURRENT+DEPRESSIVE+SYMPTOMS+IN+MIDLIFE&rft.au=CROWELL%2C+JUDITH+A%3BDEARING%2C+ERIC%3BDAVIS%2C+CYNTHIA+R%3BMIRANDA-JULIAN%2C+CLAUDIA%3BBARKAI%2C+AYELET+R%3BUSHER%2C+NICOLE%3BTRIFILETTI%2C+SARAH%3BMANTZOROS%2C+CHRISTOS&rft.aulast=CROWELL&rft.aufirst=JUDITH&rft.date=2014-09-01&rft.volume=33&rft.issue=7&rft.spage=612&rft.isbn=&rft.btitle=&rft.title=Journal+of+Social+and+Clinical+Psychology&rft.issn=07367236&rft_id=info:doi/ LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-01-09 N1 - Last updated - 2016-05-13 ER - TY - JOUR T1 - Hepatitis C treatment eligibility among HIV–hepatitis C virus coinfected patients in Oregon: a population-based sample AN - 1627733768 AB - Approximately 287,000 individuals in the USA are coinfected with HIV and hepatitis C. Recently, new hepatitis C regimens have become available, increasing rates of sustained virologic response in the monoinfected, with studies evaluating their success in the coinfected under way. Previous investigators estimated eligibility for hepatitis C therapy among the coinfected patients, but all had significant methodological limitations. Our study is the first to use a multi-year, statewide, population-based sample to estimate treatment eligibility, and the first to estimate eligibility in the setting of an interferon-free regimen. In a population-based sample of 161 patients infected with HIV and hepatitis C living in Oregon during 2007–2010, 21% were eligible for hepatitis C therapy. Despite the anticipation surrounding an interferon-sparing regimen, eligibility assuming an interferon-free regimen increased only to 26%, largely due to multiple simultaneous contraindications. Obesity was described for the first time as being associated with decreased eligibility (OR: 0.11). Active alcohol abuse was the most common contraindication (24%); uncontrolled mental health (22%), recent injection drug use (21%), poor antiretroviral adherence (22%), and infection (21%) were also common excluding conditions. When active drug or alcohol abuse was excluded as contraindications to therapy, the eligibility rate was 34%, a 62% increase. Assuming an interferon-free regimen and the exclusion of active drug or alcohol abuse as contraindications to therapy, the eligibility rate increased to 42%. Despite the availability of direct-acting anti-viral regimens, eligibility rates in HIV–hepatitis C virus (HCV) coinfection are modest. Many factors precluding hepatitis C therapy are reversible, and targeted interventions could result in increased eligibility. JF - AIDS Care AU - Maier, Marissa M AU - He, Haiou AU - Schafer, Sean D AU - Ward, Thomas T AU - Zaman, Atif AD - Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Program Design and Evaluation Service, Oregon Health Authority, Portland, OR, USA, HIV/STD/TB Program, Oregon Health Authority, Portland, OR, USA, Section of Infectious Diseases, Portland Veterans Administration Medical Center, Portland, OR, USA, Division of Gastroenterology and Hepatology, Oregon Health and Sciences University, Portland, OR, USA ; Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA; Program Design and Evaluation Service, Oregon Health Authority, Portland, OR, USA; HIV/STD/TB Program, Oregon Health Authority, Portland, OR, USA; Section of Infectious Diseases, Portland Veterans Administration Medical Center, Portland, OR, USA; Division of Gastroenterology and Hepatology, Oregon Health and Sciences University, Portland, OR, USA Y1 - 2014/09// PY - 2014 DA - Sep 2014 SP - 1178 EP - 1185 CY - London PB - Taylor & Francis Ltd. VL - 26 IS - 9 SN - 0954-0121 KW - Medical Sciences--Psychiatry And Neurology KW - Eligibility KW - Drug abuse KW - Hepatitis KW - Interferon KW - Substance abuse KW - Hepatitis C KW - Alcohol abuse KW - HIV KW - First time KW - Anticipation KW - Adherence KW - Obesity KW - Intravenous drug addiction KW - Mental health KW - Infection KW - Antiretroviral therapy KW - Interventions KW - Reversible KW - Oregon UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1627733768?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=AIDS+Care&rft.atitle=Hepatitis+C+treatment+eligibility+among+HIV%E2%80%93hepatitis+C+virus+coinfected+patients+in+Oregon%3A+a+population-based+sample&rft.au=Maier%2C+Marissa+M%3BHe%2C+Haiou%3BSchafer%2C+Sean+D%3BWard%2C+Thomas+T%3BZaman%2C+Atif&rft.aulast=Maier&rft.aufirst=Marissa&rft.date=2014-09-01&rft.volume=26&rft.issue=9&rft.spage=1178&rft.isbn=&rft.btitle=&rft.title=AIDS+Care&rft.issn=09540121&rft_id=info:doi/10.1080%2F09540121.2014.892563 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-10-14 N1 - Last updated - 2016-05-12 N1 - SubjectsTermNotLitGenreText - Oregon DO - http://dx.doi.org/10.1080/09540121.2014.892563 ER - TY - JOUR T1 - Clinical correlates of attentional bias to drug cues associated with cocaine dependence AN - 1627733398 AB - Background and Objective Preoccupation (attentional bias) related to drug-related stimuli has been consistently observed for drug-dependent persons with several studies reporting an association of the magnitude of measured attentional bias with treatment outcomes. The major goal of the present study was to determine if pre-treatment attentional bias to personal drug use reminders in an addiction Stroop task predicts relapse in treatment-seeking, cocaine-dependent subjects. Methods We sought to maximize the potential of attentional bias as a marker of risk for relapse by incorporating individualized rather than generalized drug use cues to reflect the personal conditioned associations that form the incentive motivation properties of drug cues in a sample of cocaine-dependent subjects ( N=35). Results Although a significant group Stroop interference effect was present for drug versus neutral stimuli (ie, attentional bias), the level of attentional bias for cocaine-use words was not predictive of eventual relapse in this sample ( d=.56). A similar lack of prediction power was observed for a non-drug counting word Stroop task as a significant interference effect was detected but did not predict relapse outcomes ( d=.40). Conclusions and Scientific Significance The results of the present study do not provide clear support for the predictive value of individual variation in drug-related attentional bias to forecast probability of relapse in cocaine-dependent men. JF - The American Journal on Addictions AU - Kennedy, Ashley P AU - Gross, Robin E AU - Ely, Tim AU - Drexler, Karen PG AU - Kilts, Clinton D AD - Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia ; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, Atlanta Veteranʼs Administration Medical Center, Atlanta, Georgia ; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas ; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia Y1 - 2014/09// PY - 2014 DA - Sep 2014 SP - 478 EP - 484 CY - Hoboken PB - Wiley Subscription Services, Inc. VL - 23 IS - 5 SN - 1055-0496 KW - Medical Sciences--Psychiatry And Neurology KW - Addiction KW - Men KW - Motivation KW - Power KW - Preoccupation KW - Relapse KW - Reminders KW - Attentional bias KW - Bias KW - Clinical outcomes KW - Cocaine KW - Counting KW - Cues KW - Drug abuse KW - Drug addiction KW - Drug dependency KW - Goals KW - Helpseeking KW - Individualized KW - Interference KW - Magnitude UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1627733398?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+American+Journal+on+Addictions&rft.atitle=Clinical+correlates+of+attentional+bias+to+drug+cues+associated+with+cocaine+dependence&rft.au=Kennedy%2C+Ashley+P%3BGross%2C+Robin+E%3BEly%2C+Tim%3BDrexler%2C+Karen+PG%3BKilts%2C+Clinton+D&rft.aulast=Kennedy&rft.aufirst=Ashley&rft.date=2014-09-01&rft.volume=23&rft.issue=5&rft.spage=478&rft.isbn=&rft.btitle=&rft.title=The+American+Journal+on+Addictions&rft.issn=10550496&rft_id=info:doi/10.1111%2Fj.1521-0391.2014.12134.x LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-10-14 N1 - Last updated - 2016-05-16 DO - http://dx.doi.org/10.1111/j.1521-0391.2014.12134.x ER - TY - JOUR T1 - Bacterial infections in cirrhosis AN - 1566848098; 20759399 AB - Bacterial infections occur in 25-35 % of cirrhotics admitted to hospital. Health-care associated and hospital acquired (nosocomial) infections are the most common epidemiology, with community acquired infections less common (15-30 %). Spontaneous bacterial peritonitis and urinary infections are the most common sites, with spontaneous bacteremia, pneumonia, cellulitis and other sites being less common. The risk of infection is increased among subjects with more severe liver disease and an infection in the past 6 months. Bacteria are isolated from approximately half of patients with a clinical diagnosis of infection. Gram-negative enterobacteriaceae are the most common organisms among community acquired infections; Gram-positive cocci are the most common organisms isolated among subjects with nosocomial infections. Up to 30 % of hospital associated infections are with multidrug resistant bacteria. Consequently, empiric antibiotic therapy that is recommended for community acquired infections is often inadequate for nosocomial infections. Infections worsen liver function. In-hospital and 1-year mortality of cirrhotics with infections is significantly higher than among cirrhotics without infection. In-hospital complications of infections, such as severe sepsis and septic shock, and mortality, are increased among subjects with multidrug-resistant infections as compared with cirrhotics with susceptible bacteria. Short-term antibiotic prophylaxis of cirrhotics with upper gastrointestinal bleeding and long-term antibiotic prophylaxis of selected cirrhotics with spontaneous bacterial peritonitis reduces infections and improves survival. Albumin administration to cirrhotics with SBP and evidence of advanced liver disease improves survival. The benefit of albumin administration to cirrhotics with infections other than SBP is under investigation. JF - Hepatology International AU - Botwin, Gregory J AU - Morgan, Timothy R AD - Gastroenterology Services, VA Long Beach Healthcare Group-11 (GI), VA Long Beach Healthcare System, 5901 E. Seventh Street, Long Beach, CA, 90822, USA, timothy.morgan@va.gov Y1 - 2014/09// PY - 2014 DA - September 2014 SP - 467 EP - 474 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 8 IS - 2 SN - 1936-0533, 1936-0533 KW - Microbiology Abstracts A: Industrial & Applied Microbiology; Microbiology Abstracts B: Bacteriology KW - Bacteria KW - Mortality KW - Liver diseases KW - Cirrhosis KW - Drug resistance KW - Peritonitis KW - Survival KW - Bacteremia KW - Antibiotics KW - Septic shock KW - Cellulitis KW - Sepsis KW - Epidemiology KW - Albumin KW - Nosocomial infection KW - Prophylaxis KW - Bleeding KW - Gram-positive cocci KW - Multidrug resistance KW - Enterobacteriaceae KW - Pneumonia KW - Hospitals KW - A 01340:Antibiotics & Antimicrobials KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1566848098?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Hepatology+International&rft.atitle=Bacterial+infections+in+cirrhosis&rft.au=Botwin%2C+Gregory+J%3BMorgan%2C+Timothy+R&rft.aulast=Botwin&rft.aufirst=Gregory&rft.date=2014-09-01&rft.volume=8&rft.issue=2&rft.spage=467&rft.isbn=&rft.btitle=&rft.title=Hepatology+International&rft.issn=19360533&rft_id=info:doi/10.1007%2Fs12072-014-9522-z LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-09-01 N1 - Number of references - 29 N1 - Last updated - 2016-03-17 N1 - SubjectsTermNotLitGenreText - Mortality; Cirrhosis; Liver diseases; Peritonitis; Drug resistance; Bacteremia; Survival; Antibiotics; Septic shock; Sepsis; Cellulitis; Epidemiology; Nosocomial infection; Albumin; Bleeding; Prophylaxis; Gram-positive cocci; Multidrug resistance; Pneumonia; Hospitals; Bacteria; Enterobacteriaceae DO - http://dx.doi.org/10.1007/s12072-014-9522-z ER - TY - JOUR T1 - Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry AN - 1566847157; 20698460 AB - Anaerobic bacteria are often difficult to detect, especially after the initiation of antibiotics. We describe the application of PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) using a sample of cerebrospinal fluid to identify an anaerobic Gram-negative bacillus, Fusobacterium nucleatum, in a patient with "culture-negative" meningitis and cerebral abscesses. JF - Journal of Clinical Microbiology AU - Nagalingam, Sudha AU - Lisgaris, Michelle AU - Rodriguez, Benigno AU - Jacobs, Michael R AU - Lederman, Michael AU - Salata, Robert A AU - Hujer, Andrea M AU - Muehlenbachs, Atis AU - DeLeon-Carnes, Marlene AU - Farrell, John J AD - Department of Medicine, Division of Infectious Disease and HIV Medicine, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA, Robert.bonomo@va.gov. Y1 - 2014/09// PY - 2014 DA - September 2014 SP - 3462 EP - 3464 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 52 IS - 9 SN - 0095-1137, 0095-1137 KW - Microbiology Abstracts B: Bacteriology KW - Central nervous system KW - Cerebrospinal fluid KW - Polymerase chain reaction KW - Antibiotics KW - Abscesses KW - Infection KW - Bacillus KW - Fusobacterium nucleatum KW - Mass spectroscopy KW - Meningitis KW - Anaerobic bacteria KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1566847157?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Clinical+Microbiology&rft.atitle=Identification+of+Occult+Fusobacterium+nucleatum+Central+Nervous+System+Infection+by+Use+of+PCR-Electrospray+Ionization+Mass+Spectrometry&rft.au=Nagalingam%2C+Sudha%3BLisgaris%2C+Michelle%3BRodriguez%2C+Benigno%3BJacobs%2C+Michael+R%3BLederman%2C+Michael%3BSalata%2C+Robert+A%3BHujer%2C+Andrea+M%3BMuehlenbachs%2C+Atis%3BDeLeon-Carnes%2C+Marlene%3BFarrell%2C+John+J&rft.aulast=Nagalingam&rft.aufirst=Sudha&rft.date=2014-09-01&rft.volume=52&rft.issue=9&rft.spage=3462&rft.isbn=&rft.btitle=&rft.title=Journal+of+Clinical+Microbiology&rft.issn=00951137&rft_id=info:doi/10.1128%2FJCM.01082-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-09-01 N1 - Number of references - 8 N1 - Last updated - 2016-02-04 N1 - SubjectsTermNotLitGenreText - Central nervous system; Cerebrospinal fluid; Polymerase chain reaction; Antibiotics; Infection; Abscesses; Mass spectroscopy; Anaerobic bacteria; Meningitis; Bacillus; Fusobacterium nucleatum DO - http://dx.doi.org/10.1128/JCM.01082-14 ER - TY - JOUR T1 - Simultaneous anatomic reconstruction of the acromioclavicular and coracoclavicular ligaments using a single tendon graft AN - 1566831198; 20644130 AB - Purpose: The purpose of this study was to introduce a novel surgical technique for simultaneous anatomic reconstruction of the acromioclavicular and coracoclavicular ligaments using a single tendon graft and to compare its biomechanical characteristics to those of a coracoid cerclage reconstruction of the coracoclavicular ligaments. Methods: Six matched pairs of human acromioclavicular joints with an average age of 54.8 plus or minus 7.8 years were used. One shoulder from each pair received the single tendon acromioclavicular-coracoclavicular reconstruction; the contralateral shoulder received the coracoid cerclage reconstruction. Bovine extensor tendon was used for both techniques. The single tendon acromioclavicular-coracoclavicular reconstruction technique provided anatomic restoration of the two coracoclavicular ligaments and the superior and inferior acromioclavicular ligaments simultaneously using one coracoid hole, one acromion hole, and two clavicular holes with interference screws. Anterior-posterior and superior-inferior translations were quantified for all specimens before and after reconstruction, followed by load to failure testing. Results: Following coracoid cerclage reconstruction, total anterior-posterior translation was significantly greater than intact (10.0 plus or minus 5.7 mm; p = 0.008). Following single tendon acromioclavicular-coracoclavicular reconstruction, there was no significant difference in anterior-posterior translation compared to intact (-1.6 plus or minus 2.2 mm; n.s.). The coracoid cerclage technique demonstrated significantly greater anterior-posterior translation than the single tendon acromioclavicular-coracoclavicular technique (p = 0.007). Both techniques restored superior-inferior translation to the intact condition (n.s.). Ultimate load, deformation at ultimate load, and energy absorbed at ultimate load were significantly greater after acromioclavicular-coracoclavicular reconstruction than after coracoid cerclage reconstruction (p < 0.05). Conclusions: This novel single tendon anatomic acromioclavicular-coracoclavicular reconstruction provided greater stability and stronger load to failure characteristics than the isolated coracoid cerclage reconstruction. A simultaneous acromioclavicular-coracoclavicular reconstruction technique using a single free tendon graft provided anatomic reconstruction of the conoid, trapezoid, and superior and inferior acromioclavicular ligaments and may reduce postoperative subluxation. JF - Knee Surgery, Sports Traumatology, Arthroscopy AU - Shin, Sang-Jin AU - Campbell, Sean AU - Scott, Jonathan AU - McGarry, Michelle H AU - Lee, Thay Q AD - Orthopaedic Biomechanics Laboratory, VA Long Beach Healthcare System (09/151), 5901 East 7th Street, Long Beach, CA, 90822, USA, tqlee@med.va.gov Y1 - 2014/09// PY - 2014 DA - Sep 2014 SP - 2216 EP - 2222 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 22 IS - 9 SN - 0942-2056, 0942-2056 KW - Physical Education Index KW - Ligaments KW - Surgery KW - Techniques KW - Failure KW - Work load KW - Shoulders KW - Biomechanics (sports techniques) KW - Sports KW - Tendons KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1566831198?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.atitle=Simultaneous+anatomic+reconstruction+of+the+acromioclavicular+and+coracoclavicular+ligaments+using+a+single+tendon+graft&rft.au=Shin%2C+Sang-Jin%3BCampbell%2C+Sean%3BScott%2C+Jonathan%3BMcGarry%2C+Michelle+H%3BLee%2C+Thay+Q&rft.aulast=Shin&rft.aufirst=Sang-Jin&rft.date=2014-09-01&rft.volume=22&rft.issue=9&rft.spage=2216&rft.isbn=&rft.btitle=&rft.title=Knee+Surgery%2C+Sports+Traumatology%2C+Arthroscopy&rft.issn=09422056&rft_id=info:doi/10.1007%2Fs00167-013-2569-x LA - English DB - Physical Education Index N1 - Date revised - 2014-09-01 N1 - Number of references - 22 N1 - Last updated - 2014-10-15 N1 - SubjectsTermNotLitGenreText - Ligaments; Surgery; Failure; Techniques; Shoulders; Work load; Sports; Biomechanics (sports techniques); Tendons DO - http://dx.doi.org/10.1007/s00167-013-2569-x ER - TY - JOUR T1 - The neuroscience of free will: implications for psychiatry AN - 1558993124; 201431247 AB - Belief in free will has been a mainstay in philosophy throughout history, grounded in large part in our intuitive sense that we consciously control our actions and could have done otherwise. However, psychology and psychiatry have long sought to uncover mechanistic explanations for human behavior that challenge the notion of free will. In recent years, neuroscientific discoveries have produced a model of volitional behavior that is at odds with the notion of contra-causal free will and our sense of conscious agency. Volitional behavior instead appears to have antecedents in unconscious brain activity that is localizable to specific neuroanatomical structures. Updating notions of free will in favor of a continuous model of volitional self-control provides a useful paradigm to conceptualize and study some forms of psychopathology such as addiction and impulse control disorders. Similarly, thinking of specific symptoms of schizophrenia as disorders of agency may help to elucidate mechanisms of psychosis. Beyond clinical understanding and etiological research, a neuroscientific model of volitional behavior has the potential to modernize forensic notions of responsibility and criminal punishment in order to inform public policy. Ultimately, moving away from the language of free will towards the language of volitional control may result in an enhanced understanding of the very nature of ourselves. Adapted from the source document. JF - Psychological Medicine AU - Pierre, J M AD - 11301 Wilshire Boulevard, Building 210, Room 15, Los Angeles, CA 90073, USA joseph.pierre2@va.gov Y1 - 2014/09// PY - 2014 DA - September 2014 SP - 2465 EP - 2474 PB - Cambridge University Press, UK VL - 44 IS - 12 SN - 0033-2917, 0033-2917 KW - Schizophrenia KW - Offenders KW - Perception KW - Unconscious KW - Psychiatry KW - Free will KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1558993124?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychological+Medicine&rft.atitle=The+neuroscience+of+free+will%3A+implications+for+psychiatry&rft.au=Pierre%2C+J+M&rft.aulast=Pierre&rft.aufirst=J&rft.date=2014-09-01&rft.volume=44&rft.issue=12&rft.spage=2465&rft.isbn=&rft.btitle=&rft.title=Psychological+Medicine&rft.issn=00332917&rft_id=info:doi/10.1017%2FS0033291713002985 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-09-01 N1 - Number of references - 105 N1 - Last updated - 2016-09-27 N1 - CODEN - PSMDCO N1 - SubjectsTermNotLitGenreText - Free will; Perception; Psychiatry; Unconscious; Offenders; Schizophrenia DO - http://dx.doi.org/10.1017/S0033291713002985 ER - TY - JOUR T1 - Hepatitis C treatment eligibility among HIV-Hepatitis C virus coinfected patients in Oregon: a population-based sample AN - 1548776131; 4583139 AB - Approximately 287,000 individuals in the USA are coinfected with HIV and hepatitis C. Recently, new hepatitis C regimens have become available, increasing rates of sustained virologic response in the monoinfected, with studies evaluating their success in the coinfected under way. Previous investigators estimated eligibility for hepatitis C therapy among the coinfected patients, but all had significant methodological limitations. Our study is the first to use a multi-year, statewide, population-based sample to estimate treatment eligibility, and the first to estimate eligibility in the setting of an interferon-free regimen. In a population-based sample of 161 patients infected with HIV and hepatitis C living in Oregon during 2007-2010, 21% were eligible for hepatitis C therapy. Despite the anticipation surrounding an interferon-sparing regimen, eligibility assuming an interferon-free regimen increased only to 26%, largely due to multiple simultaneous contraindications. Obesity was described for the first time as being associated with decreased eligibility (OR: 0.11). Active alcohol abuse was the most common contraindication (24%); uncontrolled mental health (22%), recent injection drug use (21%), poor antiretroviral adherence (22%), and infection (21%) were also common excluding conditions. When active drug or alcohol abuse was excluded as contraindications to therapy, the eligibility rate was 34%, a 62% increase. Assuming an interferon-free regimen and the exclusion of active drug or alcohol abuse as contraindications to therapy, the eligibility rate increased to 42%. Despite the availability of direct- acting anti-viral regimens, eligibility rates in HIV-hepatitis C virus (HCV) coinfection are modest. Many factors precluding hepatitis C therapy are reversible, and targeted interventions could result in increased eligibility. Reprinted by permission of Routledge, Taylor & Francis Ltd. JF - AIDS care AU - Maier, Marissa M AU - He, Haiou AU - Schafer, Sean D AU - Ward, Thomas T AU - Zaman, Atif AD - Oregon Health & Sciences University ; Portland Veterans Administration Medical Center Y1 - 2014/09// PY - 2014 DA - Sep 2014 SP - 1178 EP - 1185 VL - 26 IS - 9 SN - 0954-0121, 0954-0121 KW - Sociology KW - Hepatitis KW - Oregon KW - Alcoholism KW - Mental health KW - Patients KW - Medical treatment KW - U.S.A. KW - HIV KW - Eligibility UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1548776131?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aibss&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=AIDS+care&rft.atitle=Hepatitis+C+treatment+eligibility+among+HIV-Hepatitis+C+virus+coinfected+patients+in+Oregon%3A+a+population-based+sample&rft.au=Maier%2C+Marissa+M%3BHe%2C+Haiou%3BSchafer%2C+Sean+D%3BWard%2C+Thomas+T%3BZaman%2C+Atif&rft.aulast=Maier&rft.aufirst=Marissa&rft.date=2014-09-01&rft.volume=26&rft.issue=9&rft.spage=1178&rft.isbn=&rft.btitle=&rft.title=AIDS+care&rft.issn=09540121&rft_id=info:doi/10.1080%2F09540121.2014.892563 LA - English DB - International Bibliography of the Social Sciences (IBSS) N1 - Date revised - 2014-07-28 N1 - Last updated - 2014-07-29 N1 - SubjectsTermNotLitGenreText - 4176; 5810 3617 6220; 5703 3617 6220; 7890 5792 10484; 9271 7890 5792 10484; 913 561 6220; 7947 5772 7954; 314 433 293 14; 433 293 14 DO - http://dx.doi.org/10.1080/09540121.2014.892563 ER - TY - JOUR T1 - Management of persistent pain in the older patient: a clinical review. AN - 1558525591; 25157726 AB - Persistent pain is highly prevalent, costly, and frequently disabling in later life. To describe barriers to the management of persistent pain among older adults, summarize current management approaches, including pharmacologic and nonpharmacologic modalities; present rehabilitative approaches; and highlight aspects of the patient-physician relationship that can help to improve treatment outcomes. This review is relevant for physicians who seek an age-appropriate approach to delivering pain care for the older adult. Search of MEDLINE and the Cochrane database from January 1990 through May 2014, using the search terms older adults, senior, ages 65 and above, elderly, and aged along with non-cancer pain, chronic pain, persistent pain, pain management, intractable pain, and refractory pain to identify English-language peer-reviewed systematic reviews, meta-analyses, Cochrane reviews, consensus statements, and guidelines relevant to the management of persistent pain in older adults. Of the 92 identified studies, 35 evaluated pharmacologic interventions, whereas 57 examined nonpharmacologic modalities; the majority (n = 50) focused on older adults with osteoarthritis. This evidence base supports a stepwise approach with acetaminophen as first-line therapy. If treatment goals are not met, a trial of a topical nonsteroidal anti-inflammatory drug, tramadol, or both is recommended. Oral nonsteroidal anti-inflammatory drugs are not recommended for long-term use. Careful surveillance to monitor for toxicity and efficacy is critical, given that advancing age increases risk for adverse effects. A multimodal approach is strongly recommended-emphasizing a combination of both pharmacologic and nonpharmacologic treatments to include physical and occupational rehabilitation, as well as cognitive-behavioral and movement-based interventions. An integrated pain management approach is ideally achieved by cultivating a strong therapeutic alliance between the older patient and the physician. Treatment planning for persistent pain in later life requires a clear understanding of the patient's treatment goals and expectations, comorbidities, and cognitive and functional status, as well as coordinating community resources and family support when available. A combination of pharmacologic, nonpharmacologic, and rehabilitative approaches in addition to a strong therapeutic alliance between the patient and physician is essential in setting, adjusting, and achieving realistic goals of therapy. JF - JAMA AU - Makris, Una E AU - Abrams, Robert C AU - Gurland, Barry AU - Reid, M Carrington AD - Department of Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, Texas2Department of Medicine, Division of Rheumatology, Veterans Administration Medical Center, Dallas, Texas. ; Department of Psychiatry, Weill Cornell Medical College, New York, New York4Division of Geriatrics and Palliative Medicine, Weill Cornell Medical College, New York, New York. ; Stroud Center, Columbia University, New York, New York. ; Division of Geriatrics and Palliative Medicine, Weill Cornell Medical College, New York, New York. Y1 - 2014/08/27/ PY - 2014 DA - 2014 Aug 27 SP - 825 EP - 836 VL - 312 IS - 8 KW - Analgesics KW - 0 KW - Anti-Inflammatory Agents, Non-Steroidal KW - Abridged Index Medicus KW - Index Medicus KW - Age Factors KW - Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use KW - Aged, 80 and over KW - Humans KW - Aged KW - Female KW - Pain Management KW - Chronic Pain -- drug therapy KW - Analgesics -- therapeutic use UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1558525591?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=JAMA&rft.atitle=Management+of+persistent+pain+in+the+older+patient%3A+a+clinical+review.&rft.au=Makris%2C+Una+E%3BAbrams%2C+Robert+C%3BGurland%2C+Barry%3BReid%2C+M+Carrington&rft.aulast=Makris&rft.aufirst=Una&rft.date=2014-08-27&rft.volume=312&rft.issue=8&rft.spage=825&rft.isbn=&rft.btitle=&rft.title=JAMA&rft.issn=1538-3598&rft_id=info:doi/10.1001%2Fjama.2014.9405 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-09-10 N1 - Date created - 2014-08-27 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Arch Intern Med. 2006 Dec 11-25;166(22):2533-8 [17159021] Clin J Pain. 2007 Jan;23(1 Suppl):S1-43 [17179836] Pain Med. 2007 Jan-Feb;8(1):25-35 [17244101] Pain. 2007 Mar;128(1-2):69-77 [17055167] J Am Geriatr Soc. 2007 May;55(5):780-91 [17493201] Ann Intern Med. 2007 Jun 19;146(12):868-77 [17577006] Ann Intern Med. 2007 Oct 2;147(7):478-91 [17909209] JAMA. 2008 Jan 2;299(1):89-91 [18167410] Phys Ther. 2008 Jan;88(1):123-36 [17986496] BMJ. 2008 Jan 19;336(7636):138-42 [18056743] Gerontologist. 2008 Jun;48(3):311-23 [18591356] Pain Pract. 2008 Jul-Aug;8(4):287-313 [18503626] JAMA. 2009 Mar 25;301(12):1242-52 [19318652] Pain Med. 2009 Apr;10(3):537-48 [19416440] Pain Med. 2009 Apr;10(3):521-30 [19207235] J Aging Phys Act. 2006 Apr;14(2):212-35 [19462551] J Clin Psychol Med Settings. 2009 Sep;16(3):254-62 [19424781] J Am Geriatr Soc. 2009 Aug;57(8):1331-46 [19573219] Pain Med. 2009 Sep;10(6):959-61 [19744206] Pain. 2009 Dec;146(3):253-60 [19625125] JAMA. 2009 Nov 25;302(20):2214-21 [19934422] Pain Med. 2009 Nov;10(8):1395-407 [20021599] Arthritis Care Res (Hoboken). 2010 Sep;62(9):1287-93 [20853470] J Am Geriatr Soc. 2010 Sep;58(9):1664-70 [20863326] J Gerontol A Biol Sci Med Sci. 2010 Dec;65(12):1325-31 [20675619] Arch Intern Med. 2010 Dec 13;170(22):1968-76 [21149752] Arch Intern Med. 2010 Dec 13;170(22):1979-86 [21149754] Arch Gen Psychiatry. 2011 Jan;68(1):33-41 [21199963] Sci Transl Med. 2011 Feb 16;3(70):70ra14 [21325618] J Am Geriatr Soc. 2011 Mar;59(3):430-8 [21391934] BMC Geriatr. 2011;11:35 [21752299] Pain Med. 2011 Sep;12(9):1336-57 [21834914] Holist Nurs Pract. 2011 Nov-Dec;25(6):316-26 [22015342] Arch Intern Med. 2011 Nov 14;171(20):1854-6 [21949032] J Am Geriatr Soc. 2012 Mar;60(3):555-68 [22288789] Pain Med. 2012 Mar;13(3):405-18 [22313547] Pain Med. 2012 Apr;13 Suppl 2:S57-66 [22497749] J Pain. 2012 Aug;13(8):715-24 [22607834] Disabil Health J. 2012 Oct;5(4):305-11 [23021743] JAMA. 2012 Nov 14;308(18):1863-4 [23150005] Diabetes Care. 2012 Dec;35(12):2451-8 [22991449] Am J Geriatr Pharmacother. 2012 Dec;10(6):331-42 [23036838] J Fam Pract. 2012 Nov;61(11):666-70 [23256096] J Geriatr Phys Ther. 2013 Jan-Mar;36(1):3-12 [22573005] Age Ageing. 2013 Mar;42 Suppl 1:i1-57 [23420266] Phys Ther. 2013 Apr;93(4):470-8 [23139428] Pain. 2013 Jun;154(6):824-35 [23522927] Breast Cancer Res Treat. 2013 Jun;139(2):515-27 [23657404] J Rehabil Med. 2013 Jun;45(6):580-6 [23532262] JAMA. 2013 Sep 18;310(11):1168-77 [24045741] J Clin Psychiatry. 2013 Sep;74(9):932-9 [24107767] Patient Educ Couns. 2005 Jun;57(3):300-7 [15893212] Pain. 2005 Jul;116(1-2):109-18 [15927394] J Gerontol A Biol Sci Med Sci. 2005 Jun;60(6):793-7 [15983185] BMC Musculoskelet Disord. 2005;6:44 [16086839] Ann Intern Med. 2005 Sep 20;143(6):427-38 [16172441] Cochrane Database Syst Rev. 2006;(1):CD004257 [16437479] J Bone Joint Surg Am. 2006 Apr;88 Suppl 2:21-4 [16595438] Geriatr Nurs. 2006 Sep-Oct;27(5):309-16 [17045130] Brain Inj. 2006 Nov;20(12):1271-82 [17132550] Mayo Clin Proc. 2010 Mar;85(3 Suppl):S3-14 [20194146] J Gen Intern Med. 2010 Apr;25(4):310-5 [20049546] Curr Med Res Opin. 2010 May;26(5):1231-45 [20337502] JAMA Intern Med. 2013 Aug 12;173(15):1468-9 [23780284] Pain. 2013 Dec;154(12):2649-57 [24287107] BMJ. 2014;348:g1393 [24553363] Pain Manag Nurs. 2014 Dec;15(4):760-7 [24144569] Hepatology. 2005 Dec;42(6):1364-72 [16317692] Geriatr Nurs. 1999 May-Jun;20(3):144-6 [10661104] BMJ. 2000 Nov 4;321(7269):1107-11 [11061730] Pain. 2001 Jan;89(2-3):127-34 [11166468] Clin Geriatr Med. 2001 Aug;17(3):417-31, v [11459713] Ann Intern Med. 2001 Dec 18;135(12):1038-46 [11747382] J Gerontol Nurs. 2001 May;27(5):35-41 [11915272] J Am Geriatr Soc. 2002 Jun;50(6 Suppl):S205-24 [12067390] Fam Pract. 2002 Oct;19(5):476-83 [12356698] J Gen Intern Med. 2002 Oct;17(10):766-73 [12390552] J Am Geriatr Soc. 2003 Aug;51(8):1092-8 [12890071] Arch Intern Med. 2003 Nov 10;163(20):2433-45 [14609780] JAMA. 2003 Nov 12;290(18):2428-9 [14612479] Osteoarthritis Cartilage. 2004 Mar;12(3):253-5 [14972343] Ann Rheum Dis. 2004 Aug;63(8):901-7 [15020311] Age Ageing. 2004 Sep;33(5):453-60 [15315918] Pain. 2004 Nov;112(1-2):65-75 [15494186] J Pers Soc Psychol. 1998 Mar;74(3):774-89 [9523419] Arthritis Rheum. 1998 May;41(5):778-99 [9588729] BMJ. 1999 Feb 27;318(7183):593-6 [10037645] Arch Intern Med. 1999 Sep 13;159(16):1931-7 [10493324] Lancet. 1999 Oct 9;354(9186):1248-52 [10520633] BMJ. 2004 Dec 4;329(7478):1317 [15561731] Clin Ther. 2004 Nov;26(11):1774-82 [15639689] Am Fam Physician. 2005 Feb 1;71(3):483-90 [15712623] N Engl J Med. 2005 Mar 31;352(13):1324-34 [15800228] J Clin Pharm Ther. 2005 Apr;30(2):113-20 [15811163] Gerontologist. 2010 Jun;50(3):382-92 [19917645] J Rheumatol. 2010 Jun;37(6):1236-43 [20360183] Pain Med. 2010 Jul;11(7):1063-71 [20642732] J Am Geriatr Soc. 2010 Jul;58(7):1353-69 [20533971] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1001/jama.2014.9405 ER - TY - JOUR T1 - Bile acid flux through portal but not peripheral veins inhibits CYP7A1 expression without involvement of ileal FGF19 in rabbits. AN - 1553708250; 24994853 AB - It was proposed that CYP7A1 expression is suppressed through the gut-hepatic signaling pathway fibroblast growth factor (FGF) 15/19-fibroblast growth factor receptor 4, which is initiated by activation of farnesoid X receptor in the intestine rather than in the liver. The present study tested whether portal bile acid flux alone without ileal FGF19 could downregulate CYP7A1 expression in rabbits. A rabbit model was developed by infusing glycodeoxycholic acid (GDCA) through the splenic vein to bypass ileal FGF19. Study was conducted in four groups of rabbits: control; bile fistula + bovine serum albumin solution perfusion (BF); BF + GDCA (by portal perfusion); and BF + GDCA-f (by femoral perfusion). Compared with only BF, BF + GDCA (6 h portal perfusion) suppressed CYP7A1 mRNA, whereas BF + GDCA-f (via femoral vein) with the same perfusion rate of GDCA did not show inhibitory effects. Meanwhile, there was a decrease in ileal FGF19 expression and portal FGF19 protein levels, but an equivalent increase in biliary bile acid outputs in both GDCA perfusion groups. This study demonstrated that portal bile acid flux alone downregulated CYP7A1 expression with diminished FGF19 expression and protein levels, whereas the same bile acid flux reaching the liver through the hepatic artery via femoral vein had no inhibitory effect on CYP7A1. We propose that bile acid flux through the portal venous system may be a kind of "intestinal factor" that suppresses CYP7A1 expression. Copyright © 2014 the American Physiological Society. JF - American journal of physiology. Gastrointestinal and liver physiology AU - Shang, Quan AU - Guo, Grace L AU - Honda, Akira AU - Shi, Daniel AU - Saumoy, Monica AU - Salen, Gerald AU - Xu, Guorong AD - Department of Medicine, Rutgers, New Jersey Medical School, Newark, New Jersey; Medical Research Service, Veterans Affairs Medical Center, East Orange, New Jersey; ; Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey; and. ; Department of Gastroenterology, Ibaraki Medical Center, Tokyo Medical University, Ibaraki, Japan. ; Medical Research Service, Veterans Affairs Medical Center, East Orange, New Jersey; ; Department of Medicine, Rutgers, New Jersey Medical School, Newark, New Jersey; ; Department of Medicine, Rutgers, New Jersey Medical School, Newark, New Jersey; Medical Research Service, Veterans Affairs Medical Center, East Orange, New Jersey; guorong.xu@va.gov. Y1 - 2014/08/15/ PY - 2014 DA - 2014 Aug 15 SP - G479 EP - G486 VL - 307 IS - 4 KW - Glycodeoxycholic Acid KW - 360-65-6 KW - Fibroblast Growth Factors KW - 62031-54-3 KW - Cholesterol 7-alpha-Hydroxylase KW - EC 1.14.14.23 KW - Index Medicus KW - fibroblast growth factor 19 KW - cholesterol 7α-hydroxylase KW - bile acid synthesis KW - Animals KW - Down-Regulation KW - Portal Vein KW - Rabbits KW - Biliary Fistula KW - Fibroblast Growth Factors -- metabolism KW - Glycodeoxycholic Acid -- pharmacology KW - Cholesterol 7-alpha-Hydroxylase -- biosynthesis KW - Ileum -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1553708250?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+journal+of+physiology.+Gastrointestinal+and+liver+physiology&rft.atitle=Bile+acid+flux+through+portal+but+not+peripheral+veins+inhibits+CYP7A1+expression+without+involvement+of+ileal+FGF19+in+rabbits.&rft.au=Shang%2C+Quan%3BGuo%2C+Grace+L%3BHonda%2C+Akira%3BShi%2C+Daniel%3BSaumoy%2C+Monica%3BSalen%2C+Gerald%3BXu%2C+Guorong&rft.aulast=Shang&rft.aufirst=Quan&rft.date=2014-08-15&rft.volume=307&rft.issue=4&rft.spage=G479&rft.isbn=&rft.btitle=&rft.title=American+journal+of+physiology.+Gastrointestinal+and+liver+physiology&rft.issn=1522-1547&rft_id=info:doi/10.1152%2Fajpgi.00062.2014 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-10-21 N1 - Date created - 2014-08-16 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1152/ajpgi.00062.2014 ER - TY - JOUR T1 - Endoplasmic reticulum stress and the unfolded protein responses in retinal degeneration. AN - 1562664991; 24792589 AB - The endoplasmic reticulum (ER) is the primary intracellular organelle responsible for protein and lipid biosynthesis, protein folding and trafficking, calcium homeostasis, and several other vital processes in cell physiology. Disturbance in ER function results in ER stress and subsequent activation of the unfolded protein response (UPR). The UPR up-regulates ER chaperones, reduces protein translation, and promotes clearance of cytotoxic misfolded proteins to restore ER homeostasis. If this vital process fails, the cell will be signaled to enter apoptosis, resulting in cell death. Sustained ER stress also can trigger an inflammatory response and exacerbate oxidative stress, both of which contribute synergistically to tissue damage. Studies performed over the past decade have implicated ER stress in a broad range of human diseases, including neurodegenerative diseases, cancer, diabetes, and vascular disorders. Several of these diseases also entail retinal dysfunction and degeneration caused by injury to retinal neurons and/or to the blood vessels that supply retinal cells with nutrients, trophic and homeostatic factors, oxygen, and other essential molecules, as well as serving as a conduit for removal of waste products and potentially toxic substances from the retina. Collectively, such injuries represent the leading cause of blindness world-wide in all age groups. Herein, we summarize recent progress on the study of ER stress and UPR signaling in retinal biology and discuss the molecular mechanisms and the potential clinical applications of targeting ER stress as a new therapeutic approach to prevent and treat neuronal degeneration in the retina. Copyright © 2014 Elsevier Ltd. All rights reserved. JF - Experimental eye research AU - Zhang, Sarah X AU - Sanders, Emily AU - Fliesler, Steven J AU - Wang, Joshua J AD - Departments of Ophthalmology and Biochemistry, University at Buffalo, The State University of New York, Buffalo, NY, USA; SUNY Eye Institute, Buffalo, NY, USA. Electronic address: xzhang38@buffalo.edu. ; Department of Medicine, Endocrinology and Diabetes, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. ; Departments of Ophthalmology and Biochemistry, University at Buffalo, The State University of New York, Buffalo, NY, USA; SUNY Eye Institute, Buffalo, NY, USA; Research Service, Veterans Administration Western New York Healthcare System, Buffalo, NY, USA. ; Departments of Ophthalmology and Biochemistry, University at Buffalo, The State University of New York, Buffalo, NY, USA; SUNY Eye Institute, Buffalo, NY, USA. Y1 - 2014/08// PY - 2014 DA - August 2014 SP - 30 EP - 40 VL - 125 KW - eIF-2 Kinase KW - EC 2.7.11.1 KW - Index Medicus KW - cell death KW - inflammation KW - retinal degeneration KW - unfolded protein response KW - apoptosis KW - endoplasmic reticulum stress KW - Signal Transduction -- physiology KW - Humans KW - eIF-2 Kinase -- physiology KW - Unfolded Protein Response -- physiology KW - Retinal Degeneration -- physiopathology KW - Oxidative Stress -- physiology KW - Endoplasmic Reticulum Stress -- physiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1562664991?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Experimental+eye+research&rft.atitle=Endoplasmic+reticulum+stress+and+the+unfolded+protein+responses+in+retinal+degeneration.&rft.au=Zhang%2C+Sarah+X%3BSanders%2C+Emily%3BFliesler%2C+Steven+J%3BWang%2C+Joshua+J&rft.aulast=Zhang&rft.aufirst=Sarah&rft.date=2014-08-01&rft.volume=125&rft.issue=&rft.spage=30&rft.isbn=&rft.btitle=&rft.title=Experimental+eye+research&rft.issn=1096-0007&rft_id=info:doi/10.1016%2Fj.exer.2014.04.015 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-09-26 N1 - Date created - 2014-08-04 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: J Exp Med. 2008 May 12;205(5):1227-42 [18458112] Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3224-30 [18378578] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3437-42 [19211803] FEBS Lett. 2009 May 6;583(9):1521-7 [19364508] EMBO J. 2009 May 6;28(9):1296-307 [19339992] Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3743-9 [19234343] J Cell Biol. 2009 Aug 10;186(3):323-31 [19651891] Int J Biochem Cell Biol. 2009 Oct;41(10):1817-27 [19389485] J Clin Invest. 2009 Oct;119(10):2925-41 [19741297] Antioxid Redox Signal. 2009 Nov;11(11):2807-50 [19476414] J Biol Chem. 2009 Nov 27;284(48):33333-42 [19801547] Brain Res. 2010 Jan 13;1308:158-66 [19853589] Ann Rheum Dis. 2010 Jan;69 Suppl 1:i67-71 [19995749] Prog Retin Eye Res. 2010 Mar;29(2):95-112 [19961953] Adv Exp Med Biol. 2010;664:115-21 [20238009] Adv Exp Med Biol. 2010;664:317-23 [20238031] Adv Exp Med Biol. 2010;664:403-9 [20238041] Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5961-6 [20231467] Prog Retin Eye Res. 2010 May;29(3):191-207 [20096366] J Lipid Res. 2010 Jul;51(7):1624-42 [20299492] Prog Retin Eye Res. 2010 Sep;29(5):398-427 [20399883] Mol Biol Cell. 2010 Sep 1;21(17):2975-86 [20631254] Prog Lipid Res. 2010 Oct;49(4):476-92 [20633576] Bioorg Med Chem. 2010 Oct 1;18(19):7022-8 [20805032] PLoS Genet. 2010 Aug;6(8). pii: e1001075. doi: 10.1371/journal.pgen.1001075 [20865169] Curr Gene Ther. 2010 Oct;10(5):381-8 [20712579] Diabetes Obes Metab. 2010 Oct;12 Suppl 2:108-15 [21029307] Mol Med. 2010 Nov-Dec;16(11-12):535-42 [20683548] Biochem J. 1999 Dec 1;344 Pt 2:281-92 [10567207] J Biol Chem. 2011 Feb 11;286(6):4912-21 [21138840] Prog Mol Biol Transl Sci. 2011;100:331-68 [21377630] J Biol Chem. 2011 Apr 1;286(13):10939-49 [21285359] Proc Natl Acad Sci U S A. 2011 May 24;108(21):8879-84 [21555576] Ophthalmology. 2011 Jul;118(7):1444-8 [21310491] Antioxid Redox Signal. 2011 Sep 1;15(5):1271-84 [21294655] Int J Biochem Cell Biol. 2011 Sep;43(9):1392-401 [21693198] Free Radic Res. 2011 Sep;45(9):1083-92 [21736484] Trends Mol Med. 2011 Aug;17(8):442-51 [21620769] J Clin Invest. 2011 Sep;121(9):3542-53 [21821918] Science. 2011 Sep 30;333(6051):1891-4 [21852455] Cold Spring Harb Perspect Biol. 2011 Nov;3(11):a007492 [21825021] PLoS One. 2012;7(3):e33266 [22432009] J Biol Chem. 2012 May 25;287(22):18018-29 [22493484] Invest Ophthalmol Vis Sci. 2012 Jun;53(7):3349-56 [22531707] PLoS One. 2012;7(6):e38616 [22715395] Invest Ophthalmol Vis Sci. 2012 Jun;53(7):3792-800 [22589437] Diabetologia. 2012 Sep;55(9):2533-45 [22660795] Science. 2012 Nov 9;338(6108):818-22 [23042294] Invest Ophthalmol Vis Sci. 2012 Nov;53(12):7590-9 [23074209] Stem Cells Transl Med. 2012 Jun;1(6):503-9 [23197854] Invest Ophthalmol Vis Sci. 2013 Aug;54(8):5712-9 [23975727] Cell Rep. 2013 Nov 14;5(3):791-801 [24183663] Exp Eye Res. 2013 Nov;116:433 [24021353] Exp Eye Res. 2014 Feb;119:115 [24472671] Eur J Immunol. 2014 Mar;44(3):867-76 [24242955] Antioxid Redox Signal. 2014 May 10;20(14):2091-106 [24053669] Circ Res. 2006 May 12;98(9):1186-93 [16601230] Invest Ophthalmol Vis Sci. 2006 Jun;47(6):2280-90 [16723435] Science. 2006 Jul 7;313(5783):104-7 [16825573] Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3234-41 [16877386] Lancet. 2006 Nov 18;368(9549):1795-809 [17113430] Science. 2011 Nov 25;334(6059):1081-6 [22116877] Science. 2007 Nov 9;318(5852):944-9 [17991856] Med Hypotheses. 2008;70(2):378-80 [17590524] Curr Opin Neurobiol. 2007 Oct;17(5):541-7 [17933512] Br J Ophthalmol. 2008 Apr;92(4):448-50 [18369057] Mol Vis. 2005;11:657-64 [16145543] Cell. 2006 Feb 10;124(3):587-99 [16469704] Adv Exp Med Biol. 2012;723:285-92 [22183344] Biochem J. 2012 Jan 15;441(2):685-96 [21992067] Front Biosci (Landmark Ed). 2012;17:1976-95 [22201850] Exp Diabetes Res. 2012;2012:589589 [22216020] Diabetes. 2012 Feb;61(2):492-504 [22228718] Biochim Biophys Acta. 2012 Apr;1821(4):637-46 [22342272] Science. 2000 Jan 28;287(5453):664-6 [10650002] Genes Dev. 2000 Jan 15;14(2):152-7 [10652269] Invest Ophthalmol Vis Sci. 2000 May;41(6):1546-53 [10798675] Nat Cell Biol. 2000 Jun;2(6):326-32 [10854322] Mol Cell. 2000 May;5(5):897-904 [10882126] Mol Vis. 2000 Jul 8;6:116-24 [10889272] Mol Cell Biol. 2000 Sep;20(18):6755-67 [10958673] Invest Ophthalmol Vis Sci. 2001 Jan;42(1):3-9 [11133841] Hum Mutat. 2001;17(1):42-51 [11139241] Mol Cell Biol. 2001 Feb;21(4):1249-59 [11158311] Biochem J. 2001 Apr 1;355(Pt 1):19-28 [11256944] Curr Opin Cell Biol. 2001 Jun;13(3):349-55 [11343907] Surv Ophthalmol. 2001 Sep-Oct;46(2):149-63 [11578648] J Neurochem. 2001 Nov;79(4):719-25 [11723164] Cell. 2001 Dec 28;107(7):881-91 [11779464] Blood. 2002 Feb 1;99(3):736-45 [11806972] Genes Dev. 2002 Feb 15;16(4):452-66 [11850408] J Biol Chem. 2002 Apr 12;277(15):13045-52 [11821395] Hum Mol Genet. 2002 May 15;11(10):1169-76 [12015276] Prog Retin Eye Res. 2002 Jul;21(4):395-428 [12150989] Mol Cell. 2003 Mar;11(3):619-33 [12667446] Ophthalmol Clin North Am. 2003 Dec;16(4):515-27, v-vi [14740993] Novartis Found Symp. 2004;255:195-202; discussion 202-7 [14750605] Cell Death Differ. 2004 Apr;11(4):372-80 [14765132] J Biol Chem. 2004 Apr 9;279(15):14844-52 [14747470] Arch Ophthalmol. 2004 Apr;122(4):532-8 [15078671] Arch Ophthalmol. 2004 Apr;122(4):564-72 [15078675] Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6617-22 [15090652] CRC Crit Rev Biochem. 1984;16(1):21-49 [6232113] Nature. 1984 Oct 11-17;311(5986):575-7 [6332991] DNA. 1988 May;7(4):275-86 [2840249] Surv Ophthalmol. 1988 May-Jun;32(6):375-413 [2457955] Mol Biol Cell. 1992 Feb;3(2):143-55 [1550958] Biochemistry. 1994 May 24;33(20):6121-8 [8193125] J Biol Chem. 1995 Mar 3;270(9):4697-704 [7876241] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4554-9 [8643442] Genes Dev. 1998 Jun 15;12(12):1812-24 [9637683] EMBO J. 1998 Oct 1;17(19):5708-17 [9755171] Nature. 1999 Jan 21;397(6716):271-4 [9930704] Vision Res. 1999 Jul;39(15):2537-44 [10396622] J Cell Biol. 2004 Nov 8;167(3):445-56 [15520230] Mol Cell Biol. 2004 Dec;24(23):10161-8 [15542827] Genes Dev. 2004 Dec 15;18(24):3066-77 [15601821] Annu Rev Biochem. 2005;74:739-89 [15952902] Mol Vis. 2006;12:1706-14 [17213800] Exp Eye Res. 2007 Mar;84(3):486-92 [17178414] Mol Vis. 2007;13:578-87 [17438523] Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29 [17565364] Pflugers Arch. 2007 Aug;454(5):821-47 [17487503] J Neurosci. 2007 Aug 22;27(34):9043-53 [17715341] Dev Cell. 2007 Sep;13(3):365-76 [17765680] Antioxid Redox Signal. 2007 Dec;9(12):2277-93 [17979528] Science. 2008 Jul 25;321(5888):569-72 [18653895] PLoS One. 2008;3(9):e3119 [18769672] Invest Ophthalmol Vis Sci. 2009 Jan;50(1):334-44 [18757512] Nat Rev Immunol. 2008 Sep;8(9):663-74 [18670423] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.exer.2014.04.015 ER - TY - JOUR T1 - Population Structure of KPC-Producing Klebsiella pneumoniae Isolates from Midwestern U.S. Hospitals AN - 1560107210; 20602484 AB - Genome sequencing of carbapenem-resistant Klebsiella pneumoniae isolates from regional U.S. hospitals was used to characterize strain diversity and the blaKPC genetic context. A phylogeny based on core single-nucleotide variants (SNVs) supports a division of sequence type 258 (ST258) into two distinct groups. The primary differences between the groups are in the capsular polysaccharide locus (cps) and their plasmid contents. A strict association between clade and KPC variant was found. The blaKPC gene was found on variants of two plasmid backbones. This study indicates that highly similar K. pneumoniae subpopulations coexist within the same hospitals over time. JF - Antimicrobial Agents & Chemotherapy AU - Wright, Meredith S AU - Perez, Federico AU - Brinkac, Lauren AU - Jacobs, Michael R AU - Kaye, Keith AU - Cober, Eric AU - Duin, David van AU - Marshall, Steven H AU - Hujer, Andrea M AU - Rudin, Susan D AD - J. Craig Venter Institute, La Jolla, California, USA, Robert.Bonomo@va.gov. Y1 - 2014/08// PY - 2014 DA - Aug 2014 SP - 4961 EP - 4965 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 58 IS - 8 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Genomes KW - Phylogeny KW - Subpopulations KW - Population structure KW - Plasmids KW - Capsular polysaccharides KW - Klebsiella pneumoniae KW - Hospitals KW - A 01340:Antibiotics & Antimicrobials KW - J 02400:Human Diseases UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1560107210?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Population+Structure+of+KPC-Producing+Klebsiella+pneumoniae+Isolates+from+Midwestern+U.S.+Hospitals&rft.au=Wright%2C+Meredith+S%3BPerez%2C+Federico%3BBrinkac%2C+Lauren%3BJacobs%2C+Michael+R%3BKaye%2C+Keith%3BCober%2C+Eric%3BDuin%2C+David+van%3BMarshall%2C+Steven+H%3BHujer%2C+Andrea+M%3BRudin%2C+Susan+D&rft.aulast=Wright&rft.aufirst=Meredith&rft.date=2014-08-01&rft.volume=58&rft.issue=8&rft.spage=4961&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.00125-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-09-01 N1 - Number of references - 31 N1 - Last updated - 2014-10-02 N1 - SubjectsTermNotLitGenreText - Phylogeny; Genomes; Subpopulations; Population structure; Plasmids; Capsular polysaccharides; Hospitals; Klebsiella pneumoniae DO - http://dx.doi.org/10.1128/AAC.00125-14 ER - TY - JOUR T1 - Reclaiming the Efficacy of beta -Lactam- beta -Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime AN - 1560107131; 20602521 AB - CMY-2 is a plasmid-encoded Ambler class C cephalosporinase that is widely disseminated in Enterobacteriaceae and is responsible for expanded-spectrum cephalosporin resistance. As a result of resistance to both ceftazidime and beta -lactamase inhibitors in strains carrying blaCMY, novel beta -lactam- beta -lactamase inhibitor combinations are sought to combat this significant threat to beta -lactam therapy. Avibactam is a bridged diazabicyclo [3.2.1]octanone non- beta -lactam beta -lactamase inhibitor in clinical development that reversibly inactivates serine beta -lactamases. To define the spectrum of activity of ceftazidime-avibactam, we tested the susceptibilities of Escherichia coli clinical isolates that carry blaCMY-2 or blaCMY-69 and investigated the inactivation kinetics of CMY-2. Our analysis showed that CMY-2-containing clinical isolates of E. coli were highly susceptible to ceftazidime-avibactam (MIC90, less than or equal to 0.5 mg/liter); in comparison, ceftazidime had a MIC90 of >128 mg/liter. More importantly, avibactam was an extremely potent inhibitor of CMY-2 beta -lactamase, as demonstrated by a second-order onset of acylation rate constant (k2/K) of (4.9 plus or minus 0.5) 104 M-1 s-1 and the off-rate constant (koff) of (3.7 plus or minus 0.4) 10-4 s-1. Analysis of the reaction of avibactam with CMY-2 using mass spectrometry to capture reaction intermediates revealed that the CMY-2-avibactam acyl-enzyme complex was stable for as long as 24 h. Molecular modeling studies raise the hypothesis that a series of successive hydrogen-bonding interactions occur as avibactam proceeds through the reaction coordinate with CMY-2 (e.g., T316, G317, S318, T319, S343, N346, and R349). Our findings support the microbiological and biochemical efficacy of ceftazidime-avibactam against E. coli containing plasmid-borne CMY-2 and CMY-69. JF - Antimicrobial Agents & Chemotherapy AU - Papp-Wallace, Krisztina M AU - Winkler, Marisa L AU - Gatta, Julian A AU - Taracila, Magdalena A AU - Chilakala, Sujatha AU - Xu, Yan AU - Johnson, J Kristie AU - Bonomo, Robert A AD - Research Service, Louis Stokes Cleveland Department of Veterans Affairs, Cleveland, Ohio, USA, robert.bonomo@va.gov. Y1 - 2014/08// PY - 2014 DA - Aug 2014 SP - 4290 EP - 4297 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 58 IS - 8 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Clinical isolates KW - Molecular modelling KW - Cephalosporins KW - beta -Lactamase KW - Development KW - Acylation KW - Mass spectroscopy KW - Ceftazidime KW - Cephalosporinase KW - Kinetics KW - beta -Lactam antibiotics KW - Escherichia coli KW - Enterobacteriaceae KW - Serine KW - A 01340:Antibiotics & Antimicrobials KW - J 02300:Methods UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1560107131?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Reclaiming+the+Efficacy+of+beta+-Lactam-+beta+-Lactamase+Inhibitor+Combinations%3A+Avibactam+Restores+the+Susceptibility+of+CMY-2-Producing+Escherichia+coli+to+Ceftazidime&rft.au=Papp-Wallace%2C+Krisztina+M%3BWinkler%2C+Marisa+L%3BGatta%2C+Julian+A%3BTaracila%2C+Magdalena+A%3BChilakala%2C+Sujatha%3BXu%2C+Yan%3BJohnson%2C+J+Kristie%3BBonomo%2C+Robert+A&rft.aulast=Papp-Wallace&rft.aufirst=Krisztina&rft.date=2014-08-01&rft.volume=58&rft.issue=8&rft.spage=4290&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.02625-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-09-01 N1 - Number of references - 49 N1 - Last updated - 2014-10-02 N1 - SubjectsTermNotLitGenreText - Clinical isolates; Ceftazidime; Cephalosporins; Molecular modelling; Cephalosporinase; beta -Lactamase; Kinetics; beta -Lactam antibiotics; Acylation; Development; Serine; Mass spectroscopy; Escherichia coli; Enterobacteriaceae DO - http://dx.doi.org/10.1128/AAC.02625-14 ER - TY - JOUR T1 - Recruitment of septin cytoskeletal proteins by botulinum toxin A protease determines its remarkable stability. AN - 1551026781; 24928902 AB - Proteolytic cleavage of synaptosomal-associated protein 25 by the light chain of botulinum neurotoxin type A (LCA) results in a blockade of neurotransmitter release that persists for several months in motor neurons. The L428A/L429A mutation in LCA is known to significantly shorten both the proteolytic and neuroparalytic effects of the neurotoxin in mice. To elucidate the cellular mechanism for LCA longevity, we studied the effects of L428A/L429A mutation on the interactome, localization and stability of LCA expressed in cultured neuronal cells. Mass spectrometry analysis of the LCA interactome showed that the mutation prevented the interaction of LCA with septins. The wild-type LCA was concentrated in plasma-membrane-associated clusters, colocalizing with septins-2 and septin-7, which accumulated in these clusters only in the presence of LCA. The L428A/L429A mutation decreased co-clustering of LCA and septins and accelerated proteasomal and non-proteasomal degradation of LCA. Similarly, the impairment of septin oligomerization by forchlorfenuron or silencing of septin-2 prevented LCA interaction and clustering with septins and increased LCA degradation. Therefore, the dileucine-mediated LCA-septin co-clustering is crucial for the long-lasting stabilization of LCA-related proteolytic and presumably neuroparalytic activity. © 2014. Published by The Company of Biologists Ltd. JF - Journal of cell science AU - Vagin, Olga AU - Tokhtaeva, Elmira AU - Garay, Patton E AU - Souda, Puneet AU - Bassilian, Sara AU - Whitelegge, Julian P AU - Lewis, Ramilla AU - Sachs, George AU - Wheeler, Larry AU - Aoki, Roger AU - Fernandez-Salas, Ester AD - Department of Physiology, School of Medicine, UCLA and Veterans Administration Greater Los Angeles Health Care System, Los Angeles, CA 91343, USA olgav@ucla.edu. ; Department of Physiology, School of Medicine, UCLA and Veterans Administration Greater Los Angeles Health Care System, Los Angeles, CA 91343, USA. ; Department of Biological Sciences, Allergan Inc., Irvine, CA 92612, USA. ; The NPI-Semel Institute, Pasarow Mass Spectrometry Laboratory, UCLA, Los Angeles, CA 90095, USA. Y1 - 2014/08/01/ PY - 2014 DA - 2014 Aug 01 SP - 3294 EP - 3308 VL - 127 KW - Cell Cycle Proteins KW - 0 KW - Phenylurea Compounds KW - Pyridines KW - RNA, Small Interfering KW - N-(2-chloro-4-pyridyl)-N'-phenylurea KW - 68157-60-8 KW - Botulinum Toxins, Type A KW - EC 3.4.24.69 KW - SEPT7 protein, human KW - EC 3.6.1.- KW - Septins KW - septin 2 protein, human KW - Index Medicus KW - Degradation KW - Botulinum toxin A protease KW - Protein stability KW - Ubiquitylation KW - Septin KW - Animals KW - Protein Transport -- drug effects KW - Humans KW - Protein Multimerization -- drug effects KW - RNA, Small Interfering -- genetics KW - Cell Line, Tumor KW - Mice KW - Cell Cycle Proteins -- metabolism KW - Phenylurea Compounds -- pharmacology KW - Protein Transport -- genetics KW - Cell Cycle Proteins -- genetics KW - Protein Binding -- drug effects KW - Protein Stability -- drug effects KW - Mutation -- genetics KW - Protein Binding -- genetics KW - Pyridines -- pharmacology KW - Septins -- metabolism KW - Neurons -- microbiology KW - Neurons -- physiology KW - Botulinum Toxins, Type A -- metabolism KW - Botulinum Toxins, Type A -- genetics KW - Neurotoxicity Syndromes -- metabolism KW - Cell Membrane -- metabolism KW - Neurotoxicity Syndromes -- microbiology KW - Septins -- genetics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1551026781?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+cell+science&rft.atitle=Recruitment+of+septin+cytoskeletal+proteins+by+botulinum+toxin+A+protease+determines+its+remarkable+stability.&rft.au=Vagin%2C+Olga%3BTokhtaeva%2C+Elmira%3BGaray%2C+Patton+E%3BSouda%2C+Puneet%3BBassilian%2C+Sara%3BWhitelegge%2C+Julian+P%3BLewis%2C+Ramilla%3BSachs%2C+George%3BWheeler%2C+Larry%3BAoki%2C+Roger%3BFernandez-Salas%2C+Ester&rft.aulast=Vagin&rft.aufirst=Olga&rft.date=2014-08-01&rft.volume=127&rft.issue=&rft.spage=3294&rft.isbn=&rft.btitle=&rft.title=Journal+of+cell+science&rft.issn=1477-9137&rft_id=info:doi/10.1242%2Fjcs.146324 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-10-23 N1 - Date created - 2014-08-01 N1 - Date revised - 2017-01-14 N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1242/jcs.146324 ER - TY - JOUR T1 - Myeloperoxidase in human neutrophil host defence. AN - 1549177421; 24844117 AB - Human neutrophils represent the predominant leucocyte in circulation and the first responder to infection. Concurrent with ingestion of microorganisms, neutrophils activate and assemble the NADPH oxidase at the phagosome, thereby generating superoxide anion and hydrogen peroxide. Concomitantly, granules release their contents into the phagosome, where the antimicrobial proteins and enzymes synergize with oxidants to create an environment toxic to the captured microbe. The most rapid and complete antimicrobial action by human neutrophils against many organisms relies on the combined efforts of the azurophilic granule protein myeloperoxidase and hydrogen peroxide from the NADPH oxidase to oxidize chloride, thereby generating hypochlorous acid and a host of downstream reaction products. Although individual components of the neutrophil antimicrobial response exhibit specific activities in isolation, the situation in the environment of the phagosome is far more complicated, a consequence of multiple and complex interactions among oxidants, proteins and their by-products. In most cases, the cooperative interactions among the phagosomal contents, both from the host and the microbe, culminate in loss of viability of the ingested organism. © 2014 John Wiley & Sons Ltd. JF - Cellular microbiology AU - Nauseef, William M AD - Inflammation Program, Department of Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Veterans Administration Medical Center, Iowa City, IA, 52242, USA. Y1 - 2014/08// PY - 2014 DA - August 2014 SP - 1146 EP - 1155 VL - 16 IS - 8 KW - Hypochlorous Acid KW - 712K4CDC10 KW - Hydrogen Peroxide KW - BBX060AN9V KW - Peroxidase KW - EC 1.11.1.7 KW - Index Medicus KW - Oxidation-Reduction KW - Cytoplasmic Granules -- enzymology KW - Hypochlorous Acid -- metabolism KW - Hydrogen Peroxide -- metabolism KW - Humans KW - Phagocytosis -- physiology KW - Neutrophils -- immunology KW - Phagosomes -- enzymology KW - Peroxidase -- metabolism KW - Neutrophils -- enzymology KW - Phagosomes -- microbiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1549177421?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Cellular+microbiology&rft.atitle=Myeloperoxidase+in+human+neutrophil+host+defence.&rft.au=Nauseef%2C+William+M&rft.aulast=Nauseef&rft.aufirst=William&rft.date=2014-08-01&rft.volume=16&rft.issue=8&rft.spage=1146&rft.isbn=&rft.btitle=&rft.title=Cellular+microbiology&rft.issn=1462-5822&rft_id=info:doi/10.1111%2Fcmi.12312 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-05-11 N1 - Date created - 2014-07-28 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Blood. 1975 Dec;46(6):913-9 [173439] J Biol Chem. 1976 Mar 10;251(5):1371-4 [176150] J Clin Invest. 1976 Jul;58(1):50-60 [180060] Infect Immun. 1976 Dec;14(6):1276-83 [12111] Proc Natl Acad Sci U S A. 1977 Oct;74(10):4214-8 [270665] J Clin Invest. 1978 May;61(5):1176-85 [207730] Infect Immun. 1979 Feb;23(2):522-31 [217834] Biochim Biophys Acta. 1979 Apr 12;567(2):309-14 [36154] Infect Immun. 1979 Jul;25(1):110-6 [39030] J Clin Invest. 1979 Oct;64(4):913-20 [225353] J Immunol. 1980 Apr;124(4):2020-6 [6245132] J Biol Chem. 1981 Apr 10;256(7):3348-53 [6162845] Blood. 1981 May;57(5):888-93 [6260268] J Clin Invest. 1981 May;67(5):1541-9 [7229038] FEBS Lett. 1982 Jul 19;144(1):157-61 [6286355] Blood. 1985 Feb;65(2):375-81 [2981586] Science. 1985 Feb 15;227(4688):747-9 [2982211] Methods Enzymol. 1986;132:585-93 [3547027] Crit Rev Biochem Mol Biol. 1989;24(4):271-328 [2548810] Biochim Biophys Acta. 1971 Jun 16;235(3):419-24 [4378090] Arch Biochem Biophys. 1991 Feb 15;285(1):53-9 [1846732] Infect Immun. 1992 Aug;60(8):3446-7 [1639513] Biochemistry. 1994 Feb 15;33(6):1447-54 [8312264] Chem Res Toxicol. 1995 Sep;8(6):833-40 [7492732] Infect Immun. 1996 Sep;64(9):3512-7 [8751892] Free Radic Biol Med. 1995 Mar;18(3):437-49 [9101234] Infect Immun. 1997 Oct;65(10):4173-8 [9317024] J Mol Med (Berl). 1998 Sep;76(10):669-75 [9766844] Biochemistry. 1998 Dec 22;37(51):17923-30 [9922160] Infect Immun. 1999 Apr;67(4):1828-36 [10085024] J Exp Med. 1950 Oct 1;92(4):337-47 [14778915] Arch Biochem Biophys. 1962 Mar;96:465-7 [13909511] J Immunol. 2005 Feb 1;174(3):1557-65 [15661916] J Leukoc Biol. 2005 May;77(5):598-625 [15689384] Biochemistry. 2005 May 10;44(18):6910-9 [15865436] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9317-22 [15967999] J Biol Chem. 2005 Aug 12;280(32):29311-21 [15967795] Free Radic Biol Med. 2005 Dec 1;39(11):1468-77 [16274882] J Leukoc Biol. 2006 Jan;79(1):87-94 [16244110] Kidney Int. 2003 Dec;64(6):1956-67 [14633118] Amino Acids. 2003 Dec;25(3-4):259-74 [14661089] Arch Biochem Biophys. 2006 Jan 15;445(2):269-77 [16098474] Chem Res Toxicol. 2005 Oct;18(10):1600-10 [16533025] J Biol Chem. 2006 May 5;281(18):12277-88 [16522634] J Med Microbiol. 2006 Sep;55(Pt 9):1291-9 [16914663] Biochemistry. 2006 Aug 29;45(34):10260-9 [16922501] Curr Med Chem. 2006;13(27):3271-90 [17168851] J Leukoc Biol. 2007 Jan;81(1):137-43 [17020929] J Biol Chem. 2006 Dec 29;281(52):39860-9 [17074761] Nat Prod Rep. 2007 Jun;24(3):571-84 [17534531] Immunol Rev. 2007 Oct;219:88-102 [17850484] J Leukoc Biol. 2008 Jun;83(6):1345-53 [18353929] Proteins. 2008 Aug;72(2):589-605 [18247411] Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L96-103 [18424617] Chem Res Toxicol. 2008 Sep;21(9):1832-40 [18698849] Cell. 2008 Nov 14;135(4):691-701 [19013278] J Lipid Res. 2009 Apr;50 Suppl:S346-51 [19091698] J Immunol. 2009 Jun 15;182(12):7990-6 [19494324] J Immunol. 2009 Aug 15;183(4):2632-41 [19620311] J Biol Chem. 2009 Nov 6;284(45):30825-35 [19726691] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18686-91 [19833874] J Leukoc Biol. 2010 May;87(5):933-42 [20089668] Inflamm Res. 2012 Mar;61(3):197-205 [22116298] J Biol Chem. 2012 Feb 24;287(9):6375-86 [22219194] J Physiol. 2012 Jul 15;590(Pt 14):3231-43 [22526882] Free Radic Biol Med. 2012 Aug 1;53(3):508-20 [22609248] Antioxid Redox Signal. 2013 Feb 20;18(6):692-713 [22823200] Antioxid Redox Signal. 2013 Feb 20;18(6):642-60 [22881869] Hematol Oncol Clin North Am. 2013 Feb;27(1):89-99, viii [23351990] J Leukoc Biol. 2013 Feb;93(2):185-98 [23066164] Physiol Rev. 2013 Apr;93(2):599-652 [23589829] J Innate Immun. 2013;5(3):219-30 [23486169] J Leukoc Biol. 2013 Oct;94(4):711-21 [23650620] Free Radic Biol Med. 2012 Dec 15;53(12):2308-17 [23089227] J Innate Immun. 2014;6(3):353-64 [24247266] J Clin Invest. 1982 Sep;70(3):598-607 [6286728] J Lab Clin Med. 1982 Dec;100(6):896-907 [6292313] Biochemistry. 1982 Nov 23;21(24):6299-308 [6295461] Blood. 1983 Mar;61(3):483-92 [6297637] Nature. 1983 Feb 24;301(5902):715-6 [6828155] J Clin Invest. 1983 Aug;72(2):441-54 [6308055] Science. 1970 Sep 11;169(3950):1095-7 [4988715] J Infect Dis. 2000 Oct;182(4):1276-9 [10979934] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):11961-6 [11593004] Chem Res Toxicol. 2001 Oct;14(10):1453-64 [11599938] J Biol Chem. 2001 Nov 2;276(44):41279-87 [11533038] J Biol Chem. 2002 Mar 22;277(12):9757-62 [11733505] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3481-6 [11904413] J Infect Dis. 2002 Jun 15;185(12):1833-7 [12085336] J Clin Invest. 2002 Oct;110(8):1151-63 [12393851] Med Mycol. 2002 Dec;40(6):557-63 [12521119] Biochem Biophys Res Commun. 2003 Feb 7;301(2):551-7 [12565898] J Biol Chem. 2003 Aug 1;278(31):28403-9 [12759346] Microbiol Immunol. 2003;47(7):527-31 [12953846] Annu Rev Microbiol. 2003;57:395-418 [14527285] J Immunol. 2004 Mar 1;172(5):2731-8 [14978070] Blut. 1966 Dec;14(3):129-36 [5957405] J Exp Med. 1967 Dec 1;126(6):1063-78 [4964565] Eur J Biochem. 1968 May;4(4):540-7 [5242086] J Bacteriol. 1968 Jun;95(6):2131-8 [4970226] Nature. 1969 Jul 5;223(5201):78-9 [4978299] J Clin Invest. 1969 Aug;48(8):1478-88 [5796360] J Clin Invest. 1971 Oct;50(10):2226-9 [5116211] J Reticuloendothel Soc. 1972 Aug;12(2):170-96 [5075520] Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Feb;82(1):127-35 [4275242] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1111/cmi.12312 ER - TY - JOUR T1 - Paranoid Personality Disorder in the United States: The Role of Race, Illicit Drug Use, and Income AN - 1660020443; 201500720 AB - Differential rates of schizophrenia and paranoia symptoms have been found for Black and White individuals. Paranoid personality disorder shares symptoms with schizophrenia, yet has received minimal attention with regard to potential racial differences. In a sample consisting of 180 substance use disorder treatment-seeking individuals, the association between the diagnosis of paranoid personality disorder and the variables of race, cannabis use disorder, and income were examined. Results extended previous findings to paranoid personality disorder, supporting the hypothesis that Black individuals would be diagnosed with higher rates of paranoid personality disorder. Cannabis use disorder status and income did not predict paranoid personality disorder diagnoses. Adapted from the source document. JF - Journal of Ethnicity in Substance Abuse AU - Raza, Gina T AU - DeMarce, Josephine M AU - Lash, Steven J AU - Parker, Jefferson D AD - Veterans Affairs Medical Center, Salem, Virginia gina.raza@va.gov Y1 - 2014/07// PY - 2014 DA - July 2014 SP - 247 EP - 257 PB - Taylor & Francis, Philadelphia PA VL - 13 IS - 3 SN - 1533-2640, 1533-2640 KW - Schizophrenia KW - Symptoms KW - Black White Relations KW - Paranoia KW - Race KW - Racial Differences KW - Marijuana KW - Income KW - Personality Disorders KW - article KW - 6129: addiction UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1660020443?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Asocialservices&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Ethnicity+in+Substance+Abuse&rft.atitle=Paranoid+Personality+Disorder+in+the+United+States%3A+The+Role+of+Race%2C+Illicit+Drug+Use%2C+and+Income&rft.au=Raza%2C+Gina+T%3BDeMarce%2C+Josephine+M%3BLash%2C+Steven+J%3BParker%2C+Jefferson+D&rft.aulast=Raza&rft.aufirst=Gina&rft.date=2014-07-01&rft.volume=13&rft.issue=3&rft.spage=247&rft.isbn=&rft.btitle=&rft.title=Journal+of+Ethnicity+in+Substance+Abuse&rft.issn=15332640&rft_id=info:doi/10.1080%2F15332640.2013.850463 LA - English DB - Social Services Abstracts N1 - Date revised - 2015-03-01 N1 - Last updated - 2016-09-28 N1 - SubjectsTermNotLitGenreText - Personality Disorders; Income; Symptoms; Marijuana; Schizophrenia; Race; Racial Differences; Black White Relations; Paranoia DO - http://dx.doi.org/10.1080/15332640.2013.850463 ER - TY - JOUR T1 - Community Fall Prevention Programs: Comparing Three InSTEP Models by Level of Intensity AN - 1560104345; 20555566 AB - The Fall Prevention Center of Excellence designed three progressive-intensity fall prevention program models, Increasing Stability Through Evaluation and Practice (InSTEP), to reduce risk in community-dwelling older adults. Each model included physical activity, medical risk, and home safety components and was implemented as a 12-week program for small class sizes (12-15 people) in community and senior centers. Change in fall rates and fall risk factors was assessed using a battery of performance tests, self-reports of function, and fall diaries in a 3-group within-subjects (N = 200) design measured at baseline, immediately postintervention, and at 3 and 9 months postintervention. Overall, participants experienced a reduction in falls, improved self-perception of gait and balance, and improved dynamic gait function. The medium-intensity InSTEP model significantly (p = .003) reduced self-reported falls in comparison with the other models. InSTEP is a feasible model for addressing fall risk reduction in community-dwelling older adults. JF - Journal of Aging and Physical Activity AU - Kramer, B Josea AU - Creekmur, Beth AU - Mitchell, Michael N AU - Rose, Debra J AU - Pynoos, Jon AU - Rubenstein, Laurence Z AD - Geriatric Research Education Clinical Center, VA Greater Los Angeles Healthcare System, Los Angeles, CA, josea.kramer@va.gov Y1 - 2014/07// PY - 2014 DA - Jul 2014 SP - 372 EP - 379 PB - Human Kinetics Publishers, P.O. Box 5076 Champaign IL 61825-5076 United States VL - 22 IS - 3 SN - 1063-8652, 1063-8652 KW - Physical Education Index KW - injury KW - risk reduction KW - older adults KW - Evaluation KW - Programs KW - Home KW - Preventive health KW - Gerontology KW - Exercise KW - Adults KW - Performance KW - Gait KW - PE 030:Exercise, Health & Physical Fitness UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1560104345?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Aging+and+Physical+Activity&rft.atitle=Community+Fall+Prevention+Programs%3A+Comparing+Three+InSTEP+Models+by+Level+of+Intensity&rft.au=Kramer%2C+B+Josea%3BCreekmur%2C+Beth%3BMitchell%2C+Michael+N%3BRose%2C+Debra+J%3BPynoos%2C+Jon%3BRubenstein%2C+Laurence+Z&rft.aulast=Kramer&rft.aufirst=B&rft.date=2014-07-01&rft.volume=22&rft.issue=3&rft.spage=372&rft.isbn=&rft.btitle=&rft.title=Journal+of+Aging+and+Physical+Activity&rft.issn=10638652&rft_id=info:doi/10.1123%2FJAPA.2012-0344 LA - English DB - Physical Education Index N1 - Date revised - 2014-09-01 N1 - Last updated - 2015-04-02 N1 - SubjectsTermNotLitGenreText - Evaluation; Programs; Home; Preventive health; Gerontology; Performance; Adults; Exercise; Gait DO - http://dx.doi.org/10.1123/JAPA.2012-0344 ER - TY - JOUR T1 - Effectiveness of a Psychosocial Weight Management Program for Individuals with Schizophrenia AN - 1558993499; 201430967 AB - The objective of this study was to examine the effectiveness of a weight loss program for individuals with schizophrenia in usual care. The study included 146 adults with schizophrenia from two mental health clinics of the Department of Veterans Affairs. The 109 individuals who were overweight or obese were offered a 16-week, psychosocial, weight management program. Weight and Body Mass Index (BMI) were assessed at baseline, 1 year later, and at each treatment session. Only 51% of those who were overweight or obese chose to enroll in the weight management program. Participants attended an average of 6.7 treatment sessions, lost an average of 2.4 pounds, and had an average BMI decrease of 0.3. There was no significant change in weight or BMI compared to the control group. Intervention strategies that both improve utilization and yield greater weight loss need to be developed. Adapted from the source document. JF - The Journal of Behavioral Health Services & Research AU - Niv, Noosha AU - Cohen, Amy N AU - Hamilton, Alison AU - Reist, Christopher AU - Young, Alexander S AD - VA Desert Pacific MIRECC and University of California Los Angeles, Department of Psychiatry and Biobehavioral Sciences, Los Angeles, CA, USA noosha.niv@va.gov Y1 - 2014/07// PY - 2014 DA - July 2014 SP - 370 EP - 380 PB - Springer, US VL - 41 IS - 3 SN - 1094-3412, 1094-3412 KW - Schizophrenia KW - Obesity KW - Weight loss KW - Clinics KW - Psychosocial factors KW - Body Mass Index KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1558993499?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+Behavioral+Health+Services+%26+Research&rft.atitle=Effectiveness+of+a+Psychosocial+Weight+Management+Program+for+Individuals+with+Schizophrenia&rft.au=Niv%2C+Noosha%3BCohen%2C+Amy+N%3BHamilton%2C+Alison%3BReist%2C+Christopher%3BYoung%2C+Alexander+S&rft.aulast=Niv&rft.aufirst=Noosha&rft.date=2014-07-01&rft.volume=41&rft.issue=3&rft.spage=370&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+Behavioral+Health+Services+%26+Research&rft.issn=10943412&rft_id=info:doi/10.1007%2Fs11414-012-9273-3 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-09-01 N1 - Number of references - 47 N1 - Last updated - 2016-09-27 N1 - SubjectsTermNotLitGenreText - Weight loss; Body Mass Index; Obesity; Schizophrenia; Psychosocial factors; Clinics DO - http://dx.doi.org/10.1007/s11414-012-9273-3 ER - TY - JOUR T1 - Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network AN - 1547865469; 20207811 AB - Carbapenem resistance in Gram-negative bacteria is on the rise in the United States. A regional network was established to study microbiological and genetic determinants of clinical outcomes in hospitalized patients with carbapenem-resistant (CR) Klebsiella pneumoniae in a prospective, multicenter, observational study. To this end, predefined clinical characteristics and outcomes were recorded and K. pneumoniae isolates were analyzed for strain typing and resistance mechanism determination. In a 14-month period, 251 patients were included. While most of the patients were admitted from long-term care settings, 28% of them were admitted from home. Hospitalizations were prolonged and complicated. Nonsusceptibility to colistin and tigecycline occurred in isolates from 7 and 45% of the patients, respectively. Most of the CR K. pneumoniae isolates belonged to repetitive extragenic palindromic PCR (rep-PCR) types A and B (both sequence type 258) and carried either blaKPC-2 (48%) or blaKPC-3 (51%). One isolate tested positive for blaNDM-1, a sentinel discovery in this region. Important differences between strain types were noted; rep-PCR type B strains were associated with blaKPC-3 (odds ratio [OR], 294; 95% confidence interval [CI], 58 to 2,552; P < 0.001), gentamicin nonsusceptibility (OR, 24; 95% CI, 8.39 to 79.38; P < 0.001), amikacin susceptibility (OR, 11.0; 95% CI, 3.21 to 42.42; P < 0.001), tigecycline nonsusceptibility (OR, 5.34; 95% CI, 1.30 to 36.41; P = 0.018), a shorter length of stay (OR, 0.98; 95% CI, 0.95 to 1.00; P = 0.043), and admission from a skilled-nursing facility (OR, 3.09; 95% CI, 1.26 to 8.08; P = 0.013). Our analysis shows that (i) CR K. pneumoniae is seen primarily in the elderly long-term care population and that (ii) regional monitoring of CR K. pneumoniae reveals insights into molecular characteristics. This work highlights the crucial role of ongoing surveillance of carbapenem resistance determinants. JF - Antimicrobial Agents & Chemotherapy AU - Duin, David van AU - Perez, Federico AU - Rudin, Susan D AU - Cober, Eric AU - Hanrahan, Jennifer AU - Ziegler, Julie AU - Webber, Raymond AU - Fox, Jacqueline AU - Mason, Pamela AU - Richter, Sandra S AD - Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA, robert.bonomo@va.gov. Y1 - 2014/07// PY - 2014 DA - Jul 2014 SP - 4035 EP - 4041 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 58 IS - 7 SN - 0066-4804, 0066-4804 KW - Microbiology Abstracts B: Bacteriology; Microbiology Abstracts A: Industrial & Applied Microbiology KW - Colistin KW - Gentamicin KW - Typing KW - Amikacin KW - Epidemiology KW - tigecycline KW - Gram-negative bacteria KW - Geriatrics KW - Carbapenems KW - Polymerase chain reaction KW - Klebsiella pneumoniae KW - J 02400:Human Diseases KW - A 01350:Microbial Resistance UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1547865469?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Antimicrobial+Agents+%26+Chemotherapy&rft.atitle=Surveillance+of+Carbapenem-Resistant+Klebsiella+pneumoniae%3A+Tracking+Molecular+Epidemiology+and+Outcomes+through+a+Regional+Network&rft.au=Duin%2C+David+van%3BPerez%2C+Federico%3BRudin%2C+Susan+D%3BCober%2C+Eric%3BHanrahan%2C+Jennifer%3BZiegler%2C+Julie%3BWebber%2C+Raymond%3BFox%2C+Jacqueline%3BMason%2C+Pamela%3BRichter%2C+Sandra+S&rft.aulast=Duin&rft.aufirst=David&rft.date=2014-07-01&rft.volume=58&rft.issue=7&rft.spage=4035&rft.isbn=&rft.btitle=&rft.title=Antimicrobial+Agents+%26+Chemotherapy&rft.issn=00664804&rft_id=info:doi/10.1128%2FAAC.02636-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-07-01 N1 - Number of references - 24 N1 - Last updated - 2014-10-02 N1 - SubjectsTermNotLitGenreText - Gentamicin; Colistin; Typing; Epidemiology; Amikacin; tigecycline; Gram-negative bacteria; Geriatrics; Polymerase chain reaction; Carbapenems; Klebsiella pneumoniae DO - http://dx.doi.org/10.1128/AAC.02636-14 ER - TY - JOUR T1 - Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer. AN - 1535630047; 24926542 AB - Cigarette smoke associated polycyclic aromatic hydrocarbons can induce key drug-metabolizing enzymes of cytochrome P450 and isoforms of the glucuronyl transferases families. These enzymes metabolize several systemic therapies for lung cancer. Induction of these enzymes may lead to accelerated clearance with resultant impact on systemic therapy efficacy and toxicity in smokers compared with nonsmokers. This article reviews published literature regarding the influence of smoking as it relates to alteration of metabolism of systemic therapy in lung cancer. A structured search of the National Library of Medicine's PubMed/MEDLINE identified relevant articles. Data were abstracted and analyzed to summarize the findings. Studies that analyzed pharmacokinetic data were prospective. Smokers receiving erlotinib exhibited rapid clearance, requiring a higher dose to reach equivalent systemic exposure compared with nonsmokers. Smokers receiving irinotecan also demonstrated increased clearance and lower systemic exposure. There was no difference in clearance of paclitaxel or docetaxel in smokers. Chemotherapy-associated neutropenia was worse in nonsmokers compared with smokers in patients treated with paclitaxel, docetaxel, irinotecan, and gemcitabine. Systemic therapy for lung cancer has a narrow therapeutic index such that small changes in plasma concentrations or exposure in smokers may result in suboptimal therapy and poor outcomes. Smoking cessation must be emphasized at each clinical visit. However, prospective trials should take into consideration the effects of smoking history on drug pharmacokinetics and efficacy. The metabolizing enzyme phenotype in smokers may require individualized dose algorithms for specific agents. JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer AU - O'Malley, Meaghan AU - King, Amanda N AU - Conte, Marisa AU - Ellingrod, Vicki L AU - Ramnath, Nithya AD - *Department of Medicine, Division of Hematology-Oncology; †Taubman Health Sciences Library; ‡College of Pharmacy, University of Michigan; and §The Ann Arbor Veterans Administration Medical Center, Ann Arbor, MI. Y1 - 2014/07// PY - 2014 DA - July 2014 SP - 917 EP - 926 VL - 9 IS - 7 KW - Antineoplastic Agents KW - 0 KW - Polycyclic Aromatic Hydrocarbons KW - Quinazolines KW - Taxoids KW - irinotecan KW - 0H43101T0J KW - Deoxycytidine KW - 0W860991D6 KW - docetaxel KW - 15H5577CQD KW - Nicotine KW - 6M3C89ZY6R KW - gemcitabine KW - B76N6SBZ8R KW - Erlotinib Hydrochloride KW - DA87705X9K KW - Cytochrome P-450 CYP1A1 KW - EC 1.14.14.1 KW - Cytochrome P-450 CYP1A2 KW - Cytochrome P-450 CYP2D6 KW - Cytochrome P-450 CYP3A KW - Paclitaxel KW - P88XT4IS4D KW - Camptothecin KW - XT3Z54Z28A KW - Index Medicus KW - Taxoids -- pharmacokinetics KW - Quinazolines -- pharmacokinetics KW - Cytochrome P-450 CYP2D6 -- metabolism KW - Paclitaxel -- pharmacokinetics KW - Neutropenia -- etiology KW - Deoxycytidine -- analogs & derivatives KW - Humans KW - Cytochrome P-450 CYP1A2 -- metabolism KW - Cytochrome P-450 CYP1A1 -- metabolism KW - Deoxycytidine -- therapeutic use KW - Paclitaxel -- therapeutic use KW - Taxoids -- therapeutic use KW - Camptothecin -- therapeutic use KW - Camptothecin -- pharmacokinetics KW - Deoxycytidine -- pharmacokinetics KW - Cytochrome P-450 CYP3A -- metabolism KW - Quinazolines -- therapeutic use KW - Camptothecin -- analogs & derivatives KW - Polycyclic Aromatic Hydrocarbons -- metabolism KW - Lung Neoplasms -- enzymology KW - Enzyme Induction -- drug effects KW - Nicotine -- metabolism KW - Antineoplastic Agents -- pharmacokinetics KW - Lung Neoplasms -- drug therapy KW - Smoking -- metabolism KW - Smoking -- adverse effects KW - Antineoplastic Agents -- therapeutic use UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1535630047?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.atitle=Effects+of+cigarette+smoking+on+metabolism+and+effectiveness+of+systemic+therapy+for+lung+cancer.&rft.au=O%27Malley%2C+Meaghan%3BKing%2C+Amanda+N%3BConte%2C+Marisa%3BEllingrod%2C+Vicki+L%3BRamnath%2C+Nithya&rft.aulast=O%27Malley&rft.aufirst=Meaghan&rft.date=2014-07-01&rft.volume=9&rft.issue=7&rft.spage=917&rft.isbn=&rft.btitle=&rft.title=Journal+of+thoracic+oncology+%3A+official+publication+of+the+International+Association+for+the+Study+of+Lung+Cancer&rft.issn=1556-1380&rft_id=info:doi/10.1097%2FJTO.0000000000000191 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2015-02-09 N1 - Date created - 2014-06-14 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Comment In: J Thorac Oncol. 2014 Jul;9(7):914-6 [24926541] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1097/JTO.0000000000000191 ER - TY - JOUR T1 - Arthroscopic Repair of Full-Thickness Rotator Cuff Tears With and Without Acromioplasty: Randomized Prospective Trial With 2-Year Follow-up AN - 1705062292; PQ0001815612 AB - Background: Acromioplasty is commonly performed during arthroscopic rotator cuff repair, but its effect on short-term outcomes is debated. Purpose: To report the short-term clinical outcomes of patients undergoing arthroscopic repair of full-thickness rotator cuff tears with and without acromioplasty. Study Design: Randomized controlled trial; Level of evidence, 2. Methods: Patients undergoing arthroscopic repair of full-thickness rotator cuff tears were randomized into acromioplasty or nonacromioplasty groups. The Simple Shoulder Test (SST), American Shoulder and Elbow Surgeons (ASES) score, Constant score, University of CaliforniaLos Angeles (UCLA) score, and Short Form12 (SF-12) health assessment were collected along with physical examination including range of motion and dynamometer strength testing. Intraoperative data including tear size, repair configuration, and concomitant procedures were recorded. Follow-up examination was performed at regular intervals up to 2 years. Preoperative imaging was reviewed to classify the acromial morphologic type, acromial angle, and lateral acromial angulation. Results: A total of 114 patients were initially enrolled in the study, and 95 (83%; 43 nonacromioplasty, 52 acromioplasty) were available for a minimum 2-year follow-up. There were no significant differences in baseline characteristics, including number of tendons torn, repair configuration, concomitant procedures, and acromion type and angles. Within groups, there was a significant (P < .001) improvement in all functional outcome scores from preoperatively to all follow-up time points, including 2 years, for the nonacromioplasty and acromioplasty groups (ASES score: 55.1-91.5, 48.8-89.0; Constant score: 48.3-75.0, 51.9-78.7, respectively). There were no significant differences in functional outcomes between nonacromioplasty and acromioplasty groups or between subjects with different acromial features at any time point. Conclusion: The results of this study demonstrate no difference in clinical outcomes after rotator cuff repair with or without acromioplasty at 2 years postoperatively. JF - American Journal of Sports Medicine AU - Abrams, Geoffrey D AU - Gupta, Anil K AU - Hussey, Kristen E AU - Tetteh, Elizabeth S AU - Karas, Vasili AU - Bach, Bernard R AU - Cole, Brian J AU - Romeo, Anthony A AU - Verma, Nikhil N AD - Department of Orthopedic Surgery, Stanford University, Stanford, CA, USA, Veterans Administration Palo Alto, Palo Alto, CA, USA,, gabrams@gmail.com Y1 - 2014/06// PY - 2014 DA - June 2014 SP - 1296 EP - 1303 PB - Sage Publications Ltd., 6 Bonhill St. London EC2A 4PU United Kingdom VL - 42 IS - 6 SN - 0363-5465, 0363-5465 KW - Physical Education Index KW - rotator cuff KW - acromioplasty KW - shoulder KW - acromion KW - repair KW - Rotator cuff KW - Sports medicine KW - PE 090:Sports Medicine & Exercise Sport Science UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1705062292?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aphysicaleducation&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=American+Journal+of+Sports+Medicine&rft.atitle=Arthroscopic+Repair+of+Full-Thickness+Rotator+Cuff+Tears+With+and+Without+Acromioplasty%3A+Randomized+Prospective+Trial+With+2-Year+Follow-up&rft.au=Abrams%2C+Geoffrey+D%3BGupta%2C+Anil+K%3BHussey%2C+Kristen+E%3BTetteh%2C+Elizabeth+S%3BKaras%2C+Vasili%3BBach%2C+Bernard+R%3BCole%2C+Brian+J%3BRomeo%2C+Anthony+A%3BVerma%2C+Nikhil+N&rft.aulast=Abrams&rft.aufirst=Geoffrey&rft.date=2014-06-01&rft.volume=42&rft.issue=6&rft.spage=1296&rft.isbn=&rft.btitle=&rft.title=American+Journal+of+Sports+Medicine&rft.issn=03635465&rft_id=info:doi/10.1177%2F0363546514529091 LA - English DB - Physical Education Index N1 - Date revised - 2015-08-01 N1 - Number of references - 22 N1 - Last updated - 2016-03-30 N1 - SubjectsTermNotLitGenreText - Rotator cuff; Sports medicine DO - http://dx.doi.org/10.1177/0363546514529091 ER - TY - JOUR T1 - Trauma-Informed Care: Keeping Mental Health Settings Safe for Veterans AN - 1665160943 AB - Veterans, as military personnel returning from wars in Afghanistan and Iraq, are frequently coping with various mental health problems. These veterans are at high risk for posttraumatic stress disorder (PTSD) and associated behavioral consequences, including self-harm, verbal and physical aggression, and violence. In this article, we highlight the physiological, physical, and emotional consequences of trauma. We focus on the unique experiences that affect veteransʼ mental health and associated behaviors and advocate for veterans to receive evidenced-based treatment using trauma-informed and recovery-oriented care. JF - Issues in Mental Health Nursing AU - Boyd, Mary Ann AU - Valente, Sharon M AU - Czekanski, Elizabeth AD - Atlanta VAMC, Nursing and Patient Care Services, Decatur, Georgia, and Emory University, Nell; Hodgson Woodruff School of Nursing, Atlanta, Georgia, USA; Veterans Administration, Office of Nursing Service, St. Louis, Missouri, USA; Department of Veterans Affairs, Nursing Research/Education, Los Angeles, California, USA; Veterans Administration, Office of Nursing Service, Washington, DC, and Carlow University,Pittsburgh, Pennsylvania, USA ; Kelly, Ursula; Atlanta VAMC, Nursing and Patient Care Services, Decatur, Georgia, and Emory University, Nell; Hodgson Woodruff School of Nursing, Atlanta, Georgia, USA; Veterans Administration, Office of Nursing Service, St. Louis, Missouri, USA; Department of Veterans Affairs, Nursing Research/Education, Los Angeles, California, USA; Veterans Administration, Office of Nursing Service, Washington, DC, and Carlow University,Pittsburgh, Pennsylvania, USA Y1 - 2014/06// PY - 2014 DA - Jun 2014 SP - 413 EP - 419 CY - Washington PB - Taylor & Francis Ltd. VL - 35 IS - 6 SN - 0161-2840 KW - Medical Sciences--Psychiatry And Neurology KW - Aggression KW - Posttraumatic stress disorder KW - Psychological trauma KW - Recovery KW - Selfinjury KW - Veterans KW - Violence KW - Wars KW - Coping KW - Health behaviour KW - Health care KW - Health problems KW - High risk KW - Mental health care KW - Mental illness KW - Military personnel KW - Personnel KW - Afghanistan KW - Iraq UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1665160943?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Issues+in+Mental+Health+Nursing&rft.atitle=Trauma-Informed+Care%3A+Keeping+Mental+Health+Settings+Safe+for+Veterans&rft.au=Kelly%2C+Ursula%3BBoyd%2C+Mary+Ann%3BValente%2C+Sharon+M%3BCzekanski%2C+Elizabeth&rft.aulast=Kelly&rft.aufirst=Ursula&rft.date=2014-06-01&rft.volume=35&rft.issue=6&rft.spage=413&rft.isbn=&rft.btitle=&rft.title=Issues+in+Mental+Health+Nursing&rft.issn=01612840&rft_id=info:doi/10.3109%2F01612840.2014.881941 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2015-09-22 N1 - Last updated - 2016-05-16 N1 - SubjectsTermNotLitGenreText - Afghanistan; Iraq DO - http://dx.doi.org/10.3109/01612840.2014.881941 ER - TY - JOUR T1 - Can Improved Intra- and Inter-team Communication Reduce Missed Delirium? AN - 1558988482; 201428718 AB - To assess the prevalence and the team interaction in cases of missed delirium in acute care veterans coded as not having a diagnosis of delirium in admission or discharge notes. In this retrospective study, the records of 183 hospitalized veterans admitted to the emergency department (ED), medicine, surgery and psychiatry services and coded as not having a diagnosis of delirium were analyzed. Clinical notes of each case were examined using DSM IV TR criteria for delirium. Of the 52 cases assessed to have delirium, 5 cases had been miscoded as not having delirium. In the remaining 47 cases the diagnosis of delirium had been missed. The rates of undiagnosed delirium were ED 46/160, medicine 39/132, surgery 4/17, psychiatry 4/29 and consult liaison (CL) 0/9. Of the 5 cases of delirium identified by the CL service, 2 consult diagnoses were accepted and 3 were rejected. Nursing notes had words suggesting delirium in 70.2 % of 47 cases compared to 41.3 and 43.6 % of the clinician case notes for these patients admitted to ED and medicine respectively. No delirium or cognitive screening scales were utilized in the work up of the 52 cases involving delirium. The study results suggest that continuing education by the CL service of all hospital personnel involved in patient care may improve the diagnosis of delirium. Also, increased clinician-nursing intra-team communication, in addition to careful scrutiny of the nursing and clinician notes may contribute to the reduced incidence of missed delirium. Adapted from the source document. JF - Psychiatric Quarterly AU - Detweiler, Mark B AU - Kenneth, Arline AU - Bader, Geoffrey AU - Sullivan, Kelly AU - Murphy, Pamela F AU - Halling, Mary AU - Kalafat, Naciye AU - Detweiler, Jonna G AD - Salem Veterans Affairs Medical Center, 1970 Roanoke Boulevard, Salem, VA, 24153, USA mark.detweiler1@va.gov Y1 - 2014/06// PY - 2014 DA - June 2014 SP - 211 EP - 224 PB - Springer. New York NY VL - 85 IS - 2 SN - 0033-2720, 0033-2720 KW - Veterans KW - Surgery KW - Nursing KW - Accident and emergency departments KW - Undiagnosed KW - Delirium KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1558988482?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychiatric+Quarterly&rft.atitle=Can+Improved+Intra-+and+Inter-team+Communication+Reduce+Missed+Delirium%3F&rft.au=Detweiler%2C+Mark+B%3BKenneth%2C+Arline%3BBader%2C+Geoffrey%3BSullivan%2C+Kelly%3BMurphy%2C+Pamela+F%3BHalling%2C+Mary%3BKalafat%2C+Naciye%3BDetweiler%2C+Jonna+G&rft.aulast=Detweiler&rft.aufirst=Mark&rft.date=2014-06-01&rft.volume=85&rft.issue=2&rft.spage=211&rft.isbn=&rft.btitle=&rft.title=Psychiatric+Quarterly&rft.issn=00332720&rft_id=info:doi/10.1007%2Fs11126-013-9284-0 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-09-01 N1 - Number of references - 49 N1 - Last updated - 2016-09-27 N1 - CODEN - PSQUAP N1 - SubjectsTermNotLitGenreText - Delirium; Undiagnosed; Accident and emergency departments; Nursing; Veterans; Surgery DO - http://dx.doi.org/10.1007/s11126-013-9284-0 ER - TY - JOUR T1 - Patient-specific finite element modeling of the Cardiokinetix Parachute super( registered ) device: effects on left ventricular wall stress and function AN - 1534849953; 19976089 AB - The Parachute super( registered ) (Cardiokinetix, Inc., Menlo Park, California) is a catheter-based device intended to reverse left ventricular (LV) remodeling after antero-apical myocardial infarction. When deployed, the device partitions the LV into upper and lower chambers. To simulate its mechanical effects, we created a finite element LV model based on computed tomography (CT) images from a patient before and 6 months after Parachute super( registered ) implantation. Acute mechanical effects were determined by in silico device implantation (VIRTUAL-Parachute). Chronic effects of the device were determined by adjusting the diastolic and systolic material parameters to better match the 6-month post-implantation CT data and LV pressure data at end-diastole (ED) (POST-OP). Regional myofiber stress and pump function were calculated in each case. The principal finding is that VIRTUAL-Parachute was associated with a 61.2 % reduction in the lower chamber myofiber stress at ED. The POST-OP model was associated with a decrease in LV diastolic stiffness and a larger reduction in myofiber stress at the upper (27.1 %) and lower chamber (78.4 %) at ED. Myofiber stress at end-systole and stroke volume was little changed in the POST-OP case. These results suggest that the primary mechanism of Parachute super( registered ) is a reduction in ED myofiber stress, which may reverse eccentric post-infarct LV hypertrophy. JF - Medical & Biological Engineering & Computing AU - Lee, Lik Chuan AU - Ge, Liang AU - Zhang, Zhihong AU - Pease, Matthew AU - Nikolic, Serjan D AU - Mishra, Rakesh AU - Ratcliffe, Mark B AU - Guccione, Julius M AD - Departments of Surgery, University of California, San Francisco, CA, USA, mark.ratcliffe@va.gov Y1 - 2014/06// PY - 2014 DA - Jun 2014 SP - 557 EP - 566 PB - Springer Science+Business Media, Van Godewijckstraat 30 Dordrecht 3311 GX Netherlands VL - 52 IS - 6 SN - 0140-0118, 0140-0118 KW - Biotechnology and Bioengineering Abstracts KW - Heart KW - Data processing KW - Mathematical models KW - Stroke KW - Stress KW - Myocardial infarction KW - Ventricle KW - Hypertrophy KW - Chronic effects KW - Computed tomography KW - Parks KW - Pressure KW - W 30910:Imaging UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1534849953?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Abiotechresearch&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Medical+%26+Biological+Engineering+%26+Computing&rft.atitle=Patient-specific+finite+element+modeling+of+the+Cardiokinetix+Parachute+super%28+registered+%29+device%3A+effects+on+left+ventricular+wall+stress+and+function&rft.au=Lee%2C+Lik+Chuan%3BGe%2C+Liang%3BZhang%2C+Zhihong%3BPease%2C+Matthew%3BNikolic%2C+Serjan+D%3BMishra%2C+Rakesh%3BRatcliffe%2C+Mark+B%3BGuccione%2C+Julius+M&rft.aulast=Lee&rft.aufirst=Lik&rft.date=2014-06-01&rft.volume=52&rft.issue=6&rft.spage=557&rft.isbn=&rft.btitle=&rft.title=Medical+%26+Biological+Engineering+%26+Computing&rft.issn=01400118&rft_id=info:doi/10.1007%2Fs11517-014-1159-5 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-06-01 N1 - Number of references - 24 N1 - Last updated - 2015-03-20 N1 - SubjectsTermNotLitGenreText - Heart; Hypertrophy; Ventricle; Mathematical models; Data processing; Chronic effects; Stroke; Computed tomography; Parks; Stress; Pressure; Myocardial infarction DO - http://dx.doi.org/10.1007/s11517-014-1159-5 ER - TY - JOUR T1 - Aerobactin Mediates Virulence and Accounts for Increased Siderophore Production under Iron-Limiting Conditions by Hypervirulent (Hypermucoviscous) Klebsiella pneumoniae AN - 1534835457; 19968475 AB - Hypervirulent (hypermucoviscous) Klebsiella pneumoniae (hvKP) strains are an emerging variant of "classical" K. pneumoniae (cKP) that cause organ and life-threatening infection in healthy individuals. An understanding of hvKP-specific virulence mechanisms that enabled evolution from cKP is limited. Observations by our group and previously published molecular epidemiologic data led us to hypothesize that hvKP strains produced more siderophores than cKP strains and that this trait enhanced hvKP virulence. Quantitative analysis of 12 hvKP strains in iron-poor minimal medium or human ascites fluid showed a significant and distinguishing 6- to 10-fold increase in siderophore production compared to that for 14 cKP strains. Surprisingly, high-pressure liquid chromatography (HPLC)-mass spectrometry and characterization of the hvKP strains hvKP1, A1142, and A1365 and their isogenic aerobactin-deficient ( Delta iucA) derivatives established that aerobactin accounted for the overwhelming majority of increased siderophore production and that this was not due to gene copy number. Further, aerobactin was the primary factor in conditioned medium that enhanced the growth/survival of hvKP1 in human ascites fluid. Importantly the ex vivo growth/survival of hvKP1 Delta iucA was significantly less than that of hvKP1 in human ascites fluid, and the survival of outbred CD1 mice challenged subcutaneously or intraperitoneally with hvKP1 was significantly less than that of mice challenged with hvKP1 Delta iucA. The lowest subcutaneous and intraperitoneal challenge inocula of 3 102 and 3.2 101 CFU, respectively, resulted in 100% mortality, demonstrating the virulence of hvKP1 and its ability to cause infection at a low dose. These data strongly support that aerobactin accounts for increased siderophore production in hvKP compared to cKP (a potential defining trait) and is an important virulence factor. JF - Infection and Immunity AU - Russo, Thomas A AU - Olson, Ruth AU - MacDonald, Ulrike AU - Metzger, Daniel AU - Maltese, Lauren M AU - Drake, Eric J AU - Gulick, Andrew M AD - Veterans Administration Western New York Healthcare System, Buffalo, New York, USA, trusso@acsu.buffalo.edu. Y1 - 2014/06// PY - 2014 DA - Jun 2014 SP - 2356 EP - 2367 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 82 IS - 6 SN - 0019-9567, 0019-9567 KW - Microbiology Abstracts B: Bacteriology; Immunology Abstracts KW - High-performance liquid chromatography KW - Mortality KW - Data processing KW - virulence factors KW - aerobactin KW - Survival KW - Infection KW - copy number KW - Spectrometry KW - Siderophores KW - Virulence KW - Ascites KW - Colony-forming cells KW - Evolution KW - Klebsiella pneumoniae KW - J 02350:Immunology KW - F 06910:Microorganisms & Parasites UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1534835457?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Infection+and+Immunity&rft.atitle=Aerobactin+Mediates+Virulence+and+Accounts+for+Increased+Siderophore+Production+under+Iron-Limiting+Conditions+by+Hypervirulent+%28Hypermucoviscous%29+Klebsiella+pneumoniae&rft.au=Russo%2C+Thomas+A%3BOlson%2C+Ruth%3BMacDonald%2C+Ulrike%3BMetzger%2C+Daniel%3BMaltese%2C+Lauren+M%3BDrake%2C+Eric+J%3BGulick%2C+Andrew+M&rft.aulast=Russo&rft.aufirst=Thomas&rft.date=2014-06-01&rft.volume=82&rft.issue=6&rft.spage=2356&rft.isbn=&rft.btitle=&rft.title=Infection+and+Immunity&rft.issn=00199567&rft_id=info:doi/10.1128%2FIAI.01667-13 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-06-01 N1 - Number of references - 55 N1 - Last updated - 2015-04-02 N1 - SubjectsTermNotLitGenreText - High-performance liquid chromatography; Mortality; Data processing; aerobactin; virulence factors; Survival; Infection; Siderophores; Spectrometry; copy number; Virulence; Ascites; Colony-forming cells; Evolution; Klebsiella pneumoniae DO - http://dx.doi.org/10.1128/IAI.01667-13 ER - TY - CPAPER T1 - Psychological and Physiological Acoustics: Investigating the auditory system and its responses to sound T2 - 167th Meeting of the Acoustical Society of America AN - 1548628468; 6291133 JF - 167th Meeting of the Acoustical Society of America AU - Gallun, Frederick Y1 - 2014/05/05/ PY - 2014 DA - 2014 May 05 KW - Auditory system KW - Psychology KW - Acoustics KW - Physiology UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1548628468?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=167th+Meeting+of+the+Acoustical+Society+of+America&rft.atitle=Psychological+and+Physiological+Acoustics%3A+Investigating+the+auditory+system+and+its+responses+to+sound&rft.au=Gallun%2C+Frederick&rft.aulast=Gallun&rft.aufirst=Frederick&rft.date=2014-05-05&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=167th+Meeting+of+the+Acoustical+Society+of+America&rft.issn=&rft_id=info:doi/ L2 - http://acousticalsociety.org/sites/default/files/docs/fullprogram.pdf LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-06-30 N1 - Last updated - 2014-07-28 ER - TY - CPAPER T1 - Future directions in psychoacoustic research facilities T2 - 167th Meeting of the Acoustical Society of America AN - 1548628164; 6291406 JF - 167th Meeting of the Acoustical Society of America AU - Gordon, Samuel AU - Ellingson, Roger Y1 - 2014/05/05/ PY - 2014 DA - 2014 May 05 KW - Acoustics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1548628164?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=167th+Meeting+of+the+Acoustical+Society+of+America&rft.atitle=Future+directions+in+psychoacoustic+research+facilities&rft.au=Gordon%2C+Samuel%3BEllingson%2C+Roger&rft.aulast=Gordon&rft.aufirst=Samuel&rft.date=2014-05-05&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=167th+Meeting+of+the+Acoustical+Society+of+America&rft.issn=&rft_id=info:doi/ L2 - http://acousticalsociety.org/sites/default/files/docs/fullprogram.pdf LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-06-30 N1 - Last updated - 2014-07-28 ER - TY - CPAPER T1 - A tutorial on psychoacoustical approaches relevant to listening in rooms T2 - 167th Meeting of the Acoustical Society of America AN - 1548628124; 6291623 JF - 167th Meeting of the Acoustical Society of America AU - Gallun, Frederick Y1 - 2014/05/05/ PY - 2014 DA - 2014 May 05 KW - Acoustics UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1548628124?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Acpi&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=conference&rft.jtitle=167th+Meeting+of+the+Acoustical+Society+of+America&rft.atitle=A+tutorial+on+psychoacoustical+approaches+relevant+to+listening+in+rooms&rft.au=Gallun%2C+Frederick&rft.aulast=Gallun&rft.aufirst=Frederick&rft.date=2014-05-05&rft.volume=&rft.issue=&rft.spage=&rft.isbn=&rft.btitle=&rft.title=167th+Meeting+of+the+Acoustical+Society+of+America&rft.issn=&rft_id=info:doi/ L2 - http://acousticalsociety.org/sites/default/files/docs/fullprogram.pdf LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-06-30 N1 - Last updated - 2014-07-28 ER - TY - JOUR T1 - Clinical Significance and Characterization of Haemophilus influenzae Type b Genogroup Isolates from Urine Samples in an Adult Male Population AN - 1529932075; 19798203 AB - The occurrence and significance of Haemophilus spp. isolated from the genitourinary tract are not well known. Herein, we describe the clinical significance and characteristics of Haemophilus influenzae type b genogroup strains isolated from genitourinary tract specimens from an adult male veteran patient population and, in particular, their associations with prostatitis and epididymitis. JF - Journal of Clinical Microbiology AU - Dingle, Tanis C AU - Clarridge, Jill E, III AD - Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA, jill.clarridge@va.gov. Y1 - 2014/05// PY - 2014 DA - May 2014 SP - 1745 EP - 1748 PB - American Society for Microbiology, 1752 N Street N.W. Washington, DC 20036 United States VL - 52 IS - 5 SN - 0095-1137, 0095-1137 KW - Microbiology Abstracts B: Bacteriology; Health & Safety Science Abstracts KW - Prostatitis KW - Haemophilus influenzae KW - Urine KW - Males KW - Epididymitis KW - Genitourinary tract KW - J 02400:Human Diseases KW - H 0500:General UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1529932075?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Amicrobiologyb&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Clinical+Microbiology&rft.atitle=Clinical+Significance+and+Characterization+of+Haemophilus+influenzae+Type+b+Genogroup+Isolates+from+Urine+Samples+in+an+Adult+Male+Population&rft.au=Dingle%2C+Tanis+C%3BClarridge%2C+Jill+E%2C+III&rft.aulast=Dingle&rft.aufirst=Tanis&rft.date=2014-05-01&rft.volume=52&rft.issue=5&rft.spage=1745&rft.isbn=&rft.btitle=&rft.title=Journal+of+Clinical+Microbiology&rft.issn=00951137&rft_id=info:doi/10.1128%2FJCM.00506-14 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-05-01 N1 - Number of references - 20 N1 - Last updated - 2015-04-02 N1 - SubjectsTermNotLitGenreText - Prostatitis; Urine; Epididymitis; Genitourinary tract; Males; Haemophilus influenzae DO - http://dx.doi.org/10.1128/JCM.00506-14 ER - TY - JOUR T1 - Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. AN - 1519846618; 24508063 AB - Epithelial-mesenchymal transition (EMT), a critical step in the acquisition of metastatic state, is an attractive target for therapeutic interventions directed against tumor metastasis. Honokiol (HNK) is a natural phenolic compound isolated from an extract of seed cones from Magnolia grandiflora. Recent studies from our lab show that HNK impedes breast carcinogenesis. Here, we provide molecular evidence that HNK inhibits EMT in breast cancer cells resulting in significant downregulation of mesenchymal marker proteins and concurrent upregulation of epithelial markers. Experimental EMT induced by exposure to TGFβ and TNFα in spontaneously immortalized nontumorigenic human mammary epithelial cells is also completely reversed by HNK as evidenced by morphological as well as molecular changes. Investigating the downstream mediator(s) that may direct EMT inhibition by HNK, we found functional interactions between HNK, Stat3, and EMT-signaling components. In vitro and in vivo analyses show that HNK inhibits Stat3 activation in breast cancer cells and tumors. Constitutive activation of Stat3 abrogates HNK-mediated activation of epithelial markers whereas inhibition of Stat3 using small molecule inhibitor, Stattic, potentiates HNK-mediated inhibition of EMT markers, invasion and migration of breast cancer cells. Mechanistically, HNK inhibits recruitment of Stat3 on mesenchymal transcription factor Zeb1 promoter resulting in decreased Zeb1 expression and nuclear translocation. We also discover that HNK increases E-cadherin expression via Stat3-mediated release of Zeb1 from E-cadherin promoter. Collectively, this study reports that HNK effectively inhibits EMT in breast cancer cells and provide evidence for a previously unrecognized cross-talk between HNK and Stat3/Zeb1/E-cadherin axis. Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. JF - Molecular oncology AU - Avtanski, Dimiter B AU - Nagalingam, Arumugam AU - Bonner, Michael Y AU - Arbiser, Jack L AU - Saxena, Neeraj K AU - Sharma, Dipali AD - Department of Oncology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. ; Department of Dermatology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA. ; Department of Dermatology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA 30322, USA; Atlanta Veterans Administration Medical Center, Atlanta, GA 30322, USA. ; Department of Medicine, University of Maryland School of Medicine, 660 W Redwood St., Howard Hall, Rm 301, Baltimore, MD 21201, USA. Electronic address: nsaxena@medicine.umaryland.edu. ; Department of Oncology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. Electronic address: dsharma7@jhmi.edu. Y1 - 2014/05// PY - 2014 DA - May 2014 SP - 565 EP - 580 VL - 8 IS - 3 KW - Antineoplastic Agents, Phytogenic KW - 0 KW - Biphenyl Compounds KW - Cadherins KW - Homeodomain Proteins KW - Lignans KW - STAT3 Transcription Factor KW - Transcription Factors KW - ZEB1 protein, human KW - Zinc Finger E-box-Binding Homeobox 1 KW - honokiol KW - 11513CCO0N KW - Index Medicus KW - Zeb1 KW - Honokiol KW - Breast cancer KW - Stat3 KW - EMT KW - E-cadherin KW - Humans KW - Signal Transduction -- drug effects KW - Breast -- drug effects KW - Magnolia -- chemistry KW - Cell Line, Tumor KW - Female KW - Breast -- metabolism KW - Breast Neoplasms -- drug therapy KW - Antineoplastic Agents, Phytogenic -- isolation & purification KW - STAT3 Transcription Factor -- antagonists & inhibitors KW - Cadherins -- metabolism KW - Transcription Factors -- metabolism KW - Lignans -- isolation & purification KW - Lignans -- pharmacology KW - Antineoplastic Agents, Phytogenic -- pharmacology KW - Biphenyl Compounds -- pharmacology KW - Breast Neoplasms -- metabolism KW - Epithelial-Mesenchymal Transition -- drug effects KW - Homeodomain Proteins -- metabolism KW - Biphenyl Compounds -- isolation & purification KW - STAT3 Transcription Factor -- metabolism UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1519846618?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Atoxline&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Molecular+oncology&rft.atitle=Honokiol+inhibits+epithelial-mesenchymal+transition+in+breast+cancer+cells+by+targeting+signal+transducer+and+activator+of+transcription+3%2FZeb1%2FE-cadherin+axis.&rft.au=Avtanski%2C+Dimiter+B%3BNagalingam%2C+Arumugam%3BBonner%2C+Michael+Y%3BArbiser%2C+Jack+L%3BSaxena%2C+Neeraj+K%3BSharma%2C+Dipali&rft.aulast=Avtanski&rft.aufirst=Dimiter&rft.date=2014-05-01&rft.volume=8&rft.issue=3&rft.spage=565&rft.isbn=&rft.btitle=&rft.title=Molecular+oncology&rft.issn=1878-0261&rft_id=info:doi/10.1016%2Fj.molonc.2014.01.004 LA - English DB - ProQuest Environmental Science Collection N1 - Date completed - 2014-12-17 N1 - Date created - 2014-04-28 N1 - Date revised - 2017-01-14 N1 - SuppNotes - Cited By: Free Radic Biol Med. 2008 Jun 15;44(12):2043-50 [18423412] Cell Stem Cell. 2008 Jun 5;2(6):511-2 [18522839] PLoS One. 2008;3(8):e2888 [18682804] Acta Pharmacol Sin. 2008 Sep;29(9):1060-8 [18718175] Lung Cancer. 2008 Oct;62(1):8-14 [18372076] Expert Opin Investig Drugs. 2009 Jan;18(1):45-56 [19053881] Int J Biochem Cell Biol. 2009 May;41(5):1034-45 [18930836] Cancer Metastasis Rev. 2009 Jun;28(1-2):151-66 [19153669] Cancer Res. 2009 Apr 1;69(7):2887-95 [19276366] Chem Biol Interact. 2009 Aug 14;180(3):506-14 [19539808] Oncogene. 2009 Jul 23;28(29):2621-33 [19483724] Cell. 2009 Aug 7;138(3):592-603 [19665978] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13820-5 [19666588] BMC Cancer. 2009;9:325 [19751508] Cell. 2009 Nov 25;139(5):871-90 [19945376] Antioxid Redox Signal. 2009 May;11(5):1139-48 [19203212] Breast Cancer Res. 2009;11(6):213 [19909494] Curr Med Chem. 2010;17(3):190-7 [20214562] J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):253-60 [20354771] J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):235-52 [20521089] Gastroenterology. 2010 Nov;139(5):1762-73, 1773.e1-5 [20637208] Hepatology. 2010 Nov;52(5):1713-22 [20941777] Carcinogenesis. 2011 Mar;32(3):359-67 [21163886] PLoS One. 2011;6(4):e18490 [21559510] PLoS One. 2011;6(6):e21573 [21720559] Cancer Prev Res (Phila). 2011 Jul;4(7):1107-17 [21464039] J Clin Invest. 2011 Jul;121(7):2723-35 [21633165] Brain Res Bull. 2012 Feb 10;87(2-3):144-53 [22155297] Hum Pathol. 2012 Mar;43(3):364-73 [21835433] J Biol Chem. 2012 Feb 17;287(8):5819-32 [22205702] Breast Cancer Res. 2012;14(1):202 [22264257] Breast Cancer Res. 2012;14(1):R35 [22353783] Epigenetics. 2013 Jan;8(1):54-65 [23221619] PLoS One. 2013;8(4):e60749 [23580348] Curr Mol Med. 2012 Dec;12(10):1244-52 [22834827] Oncogene. 2000 May 15;19(21):2474-88 [10851046] Oncogene. 2000 Nov 16;19(48):5419-27 [11114718] Oncogene. 2000 Dec 27;19(56):6613-26 [11426647] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584] Planta Med. 2001 Nov;67(8):705-8 [11731909] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098] Biochem Pharmacol. 2002 May 1;63(9):1641-51 [12007567] Mol Cancer Ther. 2002 Sep;1(11):893-9 [12481410] Mol Biol Cell. 2003 May;14(5):1790-800 [12802055] J Biol Chem. 2003 Sep 12;278(37):35501-7 [12816951] Nat Rev Cancer. 2004 Feb;4(2):97-105 [14964307] Mol Cancer Ther. 2004 Feb;3(2):149-59 [14985455] World J Gastroenterol. 2004 Aug 1;10(15):2205-8 [15259066] J Clin Invest. 2004 Aug;114(4):569-81 [15314694] Expert Opin Ther Targets. 2004 Oct;8(5):409-22 [15469392] Yakugaku Zasshi. 1973 Apr;93(4):429-34 [4738511] Biochem Pharmacol. 1994 Feb 9;47(3):549-53 [8117323] Life Sci. 1994;55(13):1061-9 [8084211] Nature. 1996 Feb 15;379(6566):645-8 [8628398] J Clin Invest. 1998 Oct 1;102(7):1385-92 [9769331] Int J Mol Med. 1998 Dec;2(6):671-3 [9850734] Immunity. 1999 Jan;10(1):105-15 [10023775] Cell. 1999 Aug 6;98(3):295-303 [10458605] Oncogene. 2005 Feb 3;24(6):970-9 [15592503] Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4700-5 [15781862] Am J Pathol. 2005 May;166(5):1321-32 [15855634] Planta Med. 2005 Apr;71(4):338-43 [15856410] Blood. 2005 Jul 15;106(2):690-7 [15802533] Blood. 2005 Sep 1;106(5):1794-800 [15870175] Neuropharmacology. 2005 Sep;49(4):542-50 [15921707] Biochem Pharmacol. 2005 Nov 15;70(10):1443-57 [16181613] Nat Clin Pract Oncol. 2005 Jun;2(6):315-24 [16264989] Cancer Res. 2006 Jun 15;66(12):6370-8 [16778215] Mol Cancer Res. 2006 Sep;4(9):621-33 [16966432] Carcinogenesis. 2006 Nov;27(11):2180-9 [16675472] Oncogene. 2007 Feb 1;26(5):711-24 [16862183] Cancer Res. 2007 Mar 15;67(6):2497-507 [17363567] Cancer. 2007 Apr 1;109(7):1279-89 [17326044] J Biol Chem. 2007 May 4;282(18):13316-25 [17344214] Cancer Res. 2007 Dec 15;67(24):11742-50 [18089804] Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):715-25 [18093712] Biochem Biophys Res Commun. 2008 May 16;369(4):1098-102 [18331824] Cell. 2008 May 16;133(4):704-15 [18485877] N1 - Last updated - 2017-01-19 DO - http://dx.doi.org/10.1016/j.molonc.2014.01.004 ER - TY - JOUR T1 - Combat exposure severity as a moderator of genetic and environmental liability to post-traumatic stress disorder AN - 1516740617; 19544395 AB - Twin studies of veterans and adults suggest that approximately 30-46% of the variance in post-traumatic stress disorder (PTSD) is attributable to genetic factors. The remaining variance is attributable to the non-shared environment, which, by definition, includes combat exposure. This study used a gene by measured environment twin design to determine whether the effects of genetic and environmental factors that contribute to the etiology of PTSD are dependent on the level of combat exposure. The sample was drawn from the Vietnam Era Twin Registry (VETR) and included 620 male-male twin pairs who served in the US Military in South East Asia during the Vietnam War era. Analyses were based on data from a clinical diagnostic interview of lifetime PTSD symptoms and a self-report measure of combat exposure. Biometric modeling revealed that the effects of genetic and non-shared environment factors on PTSD varied as a function of level of combat exposure such that the association between these factors and PTSD was stronger at higher levels of combat exposure. Combat exposure may act as a catalyst that augments the impact of hereditary and environmental contributions to PTSD. Individuals with the greatest exposure to combat trauma were at increased risk for PTSD as a function of both genetic and environmental factors. Additional work is needed to determine the biological and environmental mechanisms driving these associations. JF - Psychological Medicine AU - Wolf, E J AU - Mitchell, K S AU - Koenen, K C AU - Miller, M W AD - National Center for PTSD, VA Boston Healthcare System, Boston, MA, USA, Erika.Wolf@va.gov Y1 - 2014/05// PY - 2014 DA - May 2014 SP - 1499 EP - 1509 PB - Cambridge University Press, The Edinburgh Building, Cambridge CB2 2RU United Kingdom VL - 44 IS - 7 SN - 0033-2917, 0033-2917 KW - Genetics Abstracts; Risk Abstracts; CSA Neurosciences Abstracts KW - Genetic factors KW - Psychology KW - Environmental factors KW - Vietnam KW - War KW - Risk factors KW - Catalysts KW - Asia KW - Military KW - Etiology KW - Data processing KW - Biometrics KW - Liability KW - Post-traumatic stress disorder KW - Trauma KW - Posttraumatic stress disorder KW - Twins KW - Military personnel KW - N3 11001:Behavioral and Cognitive Neuroscience KW - G 07750:Ecological & Population Genetics KW - R2 23110:Psychological aspects UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1516740617?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Ariskabstracts&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Psychological+Medicine&rft.atitle=Combat+exposure+severity+as+a+moderator+of+genetic+and+environmental+liability+to+post-traumatic+stress+disorder&rft.au=Wolf%2C+E+J%3BMitchell%2C+K+S%3BKoenen%2C+K+C%3BMiller%2C+M+W&rft.aulast=Wolf&rft.aufirst=E&rft.date=2014-05-01&rft.volume=44&rft.issue=7&rft.spage=1499&rft.isbn=&rft.btitle=&rft.title=Psychological+Medicine&rft.issn=00332917&rft_id=info:doi/10.1017%2FS0033291713002286 LA - English DB - ProQuest Environmental Science Collection N1 - Date revised - 2014-04-01 N1 - Number of references - 54 N1 - Last updated - 2014-05-15 N1 - SubjectsTermNotLitGenreText - Etiology; Genetic factors; Data processing; Twins; War; Catalysts; Biometrics; Environmental factors; Post-traumatic stress disorder; Military personnel; Trauma; Posttraumatic stress disorder; Psychology; Risk factors; Liability; Military; Asia; Vietnam DO - http://dx.doi.org/10.1017/S0033291713002286 ER - TY - JOUR T1 - A Position Article for Applying Spirituality to Suicide Prevention AN - 1541982167; 201419270 AB - Suicide is a major public health concern in the United States. Halting the rising trend of suicides requires that new options be identified and implemented so as to achieve the overarching goal of reducing the total number of suicide deaths and attempts in America. The aim of this article is to review constructs and outline a proposed operational framework for incorporating spiritual well-being into suicide prevention efforts. By presenting conceptual, preventive, and theoretical arguments, the hope is to elicit empirical interest in finding practical applications for the protective potential of spirituality. Adapted from the source document. JF - Journal of Spirituality in Mental Health AU - Kopacz, Marek S AU - Silver, Eric AU - Bossarte, Robert M AD - U.S. Department of Veterans Affairs, VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, USA Y1 - 2014/04/03/ PY - 2014 DA - 2014 Apr 03 SP - 133 EP - 146 PB - Taylor & Francis, Philadelphia PA VL - 16 IS - 2 SN - 1934-9637, 1934-9637 KW - Goals KW - Spirituality KW - Hope KW - Suicide KW - Preventive programmes KW - Public health KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1541982167?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=Journal+of+Spirituality+in+Mental+Health&rft.atitle=A+Position+Article+for+Applying+Spirituality+to+Suicide+Prevention&rft.au=Kopacz%2C+Marek+S%3BSilver%2C+Eric%3BBossarte%2C+Robert+M&rft.aulast=Kopacz&rft.aufirst=Marek&rft.date=2014-04-03&rft.volume=16&rft.issue=2&rft.spage=133&rft.isbn=&rft.btitle=&rft.title=Journal+of+Spirituality+in+Mental+Health&rft.issn=19349637&rft_id=info:doi/10.1080%2F19349637.2014.896856 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-07-01 N1 - Last updated - 2016-09-27 N1 - SubjectsTermNotLitGenreText - Suicide; Preventive programmes; Spirituality; Hope; Goals; Public health DO - http://dx.doi.org/10.1080/19349637.2014.896856 ER - TY - JOUR T1 - Rates and Predictors of Referral for Individual Psychotherapy, Group Psychotherapy, and Medications among Iraq and Afghanistan Veterans with PTSD AN - 1558995902; 201430837 AB - This study examined rates of referral for medication, individual psychotherapy, and group psychotherapy within a Veterans Affairs (VA) posttraumatic stress disorder (PTSD) specialty mental health clinic. Participants were 388 Iraq and Afghanistan veterans who were referred for PTSD treatment following a mental health evaluation required for all new VA enrollees. The majority of the sample was referred for medication (79 %), with comparatively fewer referrals for individual (39 %) or group psychotherapy (24 %). Forty percent of participants were referred for combined medication and psychotherapy. Patient demographic and clinical characteristics were examined to determine whether these variables predicted referral type. Female veterans and those with lower clinician ratings of overall functioning were more likely to be referred for individual therapy. Group psychotherapy referrals were more common in veterans who were older, unemployed, identified as an ethnic minority, and had a comorbid anxiety disorder. There were no significant predictors of medication referral. Adapted from the source document. JF - The Journal of Behavioral Health Services & Research AU - Mott, Juliette M AU - Barrera, Terri L AU - Hernandez, Caitlin AU - Graham, David P AU - Teng, Ellen J AD - VA HSR&D Houston Center of Excellence, Houston, TX, USA juliette.mott@va.gov Y1 - 2014/04// PY - 2014 DA - April 2014 SP - 99 EP - 109 PB - Springer, US VL - 41 IS - 2 SN - 1094-3412, 1094-3412 KW - Veterans KW - Mental health services KW - Posttraumatic stress disorder KW - Referrals KW - Group psychotherapy KW - Iraq KW - article UR - http://libproxy.lib.unc.edu/login?url=http://search.proquest.com/docview/1558995902?accountid=14244 L2 - http://vb3lk7eb4t.search.serialssolutions.com/?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&rfr_id=info:sid/ProQ%3Aassia&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.jtitle=The+Journal+of+Behavioral+Health+Services+%26+Research&rft.atitle=Rates+and+Predictors+of+Referral+for+Individual+Psychotherapy%2C+Group+Psychotherapy%2C+and+Medications+among+Iraq+and+Afghanistan+Veterans+with+PTSD&rft.au=Mott%2C+Juliette+M%3BBarrera%2C+Terri+L%3BHernandez%2C+Caitlin%3BGraham%2C+David+P%3BTeng%2C+Ellen+J&rft.aulast=Mott&rft.aufirst=Juliette&rft.date=2014-04-01&rft.volume=41&rft.issue=2&rft.spage=99&rft.isbn=&rft.btitle=&rft.title=The+Journal+of+Behavioral+Health+Services+%26+Research&rft.issn=10943412&rft_id=info:doi/10.1007%2Fs11414-013-9352-0 LA - English DB - Applied Social Sciences Index & Abstracts (ASSIA) N1 - Date revised - 2014-09-01 N1 - Number of references - 37 N1 - Last updated - 2016-09-27 N1 - SubjectsTermNotLitGenreText - Referrals; Veterans; Posttraumatic stress disorder; Group psychotherapy; Iraq; Mental health services DO - http://dx.doi.org/10.1007/s11414-013-9352-0 ER -